FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Hamed, HA Yacoub, A Park, MA Eulitt, PJ Dash, R Sarkar, D Dmitriev, IP Lesniak, MS Shah, K Grant, S Curiel, DT Fisher, PB Dent, P AF Hamed, Hossein A. Yacoub, Adly Park, Margaret A. Eulitt, Patrick J. Dash, Rupesh Sarkar, Devanand Dmitriev, Igor P. Lesniak, Maciej S. Shah, Khalid Grant, Steven Curiel, David T. Fisher, Paul B. Dent, Paul TI Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma SO MOLECULAR THERAPY LA English DT Article ID CANCER-SPECIFIC APOPTOSIS; DIFFERENTIATION-ASSOCIATED GENE-7; RENAL-CARCINOMA CELLS; HUMAN-MELANOMA CELLS; GLIOBLASTOMA CELLS; BYSTANDER ACTIVITY; PANCREATIC-CANCER; MDA-7 EXPRESSION; SUPPRESSOR GENE; PHASE-I AB We have explored the mechanism by which inhibition of multiple cytoprotective cell-signaling pathways enhance melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) toxicity toward invasive primary human glioblastoma multiforme (GBM) cells, and whether improving adenoviral infectivity/delivery of mda-7/IL-24 enhances therapeutic outcome in animals containing orthotopic xenografted GBM cells. The toxicity of a serotype 5 recombinant adenovirus to express MDA-7/IL-24 (Ad.5-mda-7) was enhanced by combined molecular or small molecule inhibition of mitogen-activated extra-cellular regulated kinase (MEK) 1/2 and phosphatidyl inositol 3-kinase (PI3K) or AKT; inhibition of mammalian target of rapamycin (mTOR) and MEK1/2; and the HSP90 inhibitor 17AAG. Molecular inhibition of mTOR/PI3K/MEK1 signaling in vivo also enhanced Ad.5-mda-7 toxicity. In GBM cells of diverse genetic backgrounds, inhibition of cytoprotective cell-signaling pathways enhanced MDA-7/IL-24-induced autophagy, mitochondrial dysfunction and tumor cell death. Due partly to insufficient adenovirus serotype 5 gene delivery this therapeutic approach has shown limited success in GBM. To address this problem, we employed a recombinant adenovirus that comprises the tail and shaft domains of a serotype 5 virus and the knob domain of a serotype 3 virus expressing MDA-7/IL-24, Ad.5/3-mda-7. Ad.5/3-mda-7 more effectively infected and killed GBM cells in vitro and in vivo than Ad.5-mda-7. Future combinations of these approaches hold promise for developing an effective therapy for GBM. C1 [Dent, Paul] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Massey Canc Ctr, Sch Med, Richmond, VA 23298 USA. [Dash, Rupesh; Sarkar, Devanand; Fisher, Paul B.] Virginia Commonwealth Univ, Dept Human Mol Genet, Sch Med, Richmond, VA 23298 USA. [Sarkar, Devanand; Grant, Steven; Fisher, Paul B.; Dent, Paul] Virginia Commonwealth Univ, VCU Inst Mol Med, Sch Med, Richmond, VA 23298 USA. [Dmitriev, Igor P.; Curiel, David T.] Univ Alabama, Div Human Gene Therapy, Birmingham, AL USA. [Lesniak, Maciej S.] Univ Chicago, Brain Tumor Ctr, Chicago, IL 60637 USA. [Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA USA. [Grant, Steven] Virginia Commonwealth Univ, Dept Med, Sch Med, Richmond, VA 23298 USA. [Grant, Steven; Fisher, Paul B.; Dent, Paul] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, Richmond, VA 23298 USA. RP Dent, P (reprint author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Massey Canc Ctr, Sch Med, 401 Coll St,Box 980035, Richmond, VA 23298 USA. EM pdent@vcu.edu OI dash, rupesh/0000-0001-5740-7053 FU PHS [P01-CA104177, R01-CA108325, R01-DK52825, R01CA63753, R01CA77141, R01-CA097318, R01-CA134721, P01-NS031492]; Jim Valvano "V" foundation; Department of Defense [DAMD17-03-1-0262]; Leukemia Society of America [640597]; Samuel Waxman Cancer Research Foundation (SWCRF) FX Support for this study was provided to: P.D. from PHS grants (P01-CA104177, R01-CA108325, R01-DK52825), The Jim Valvano "V" foundation, and Department of Defense Award (DAMD17-03-1-0262); S. G. from PHS grants (R01CA63753, R01CA77141) and a Leukemia Society of America grant 640597; P. B. F. from PHS grants (P01-CA104177, R01-CA097318, R01-CA134721, P01-NS031492), and the Samuel Waxman Cancer Research Foundation (SWCRF); D. T. C. from PHS grant (P01-CA104177). P. D. is The Universal Inc. Professor in Signal Transduction Research. D. S. is a Harrison Scholar in Cancer Research in the Virginia Commonwealth University (VCU) Massey Cancer Center, VCU, School of Medicine. P. B. F. holds the Thelma Newmeyer Corman Chair in Cancer Research at the VCU Massey Cancer Center, VCU, School of Medicine and an SWCRF Investigator. NR 50 TC 29 Z9 29 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1525-0016 J9 MOL THER JI Mol. Ther. PD JUN PY 2010 VL 18 IS 6 BP 1130 EP 1142 DI 10.1038/mt.2010.29 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 607ZM UT WOS:000278545800011 PM 20179672 ER PT J AU Lovera, JF Frohman, E Brown, TR Bandari, D Nguyen, L Yadav, V Stuve, O Karman, J Bogardus, K Heimburger, G Cua, L Remingon, G Fowler, J Monahan, T Kilcup, S Courtney, Y McAleenan, J Butler, K Wild, K Whitham, R Bourdette, D AF Lovera, J. F. Frohman, E. Brown, T. R. Bandari, D. Nguyen, L. Yadav, V. Stuve, O. Karman, J. Bogardus, K. Heimburger, G. Cua, L. Remingon, G. Fowler, J. Monahan, T. Kilcup, S. Courtney, Y. McAleenan, J. Butler, K. Wild, K. Whitham, R. Bourdette, D. TI Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE attention; cognition disorders; memantine; memory; multiple sclerosis; neuropsychological tests; placebo; randomized controlled trial ID NEUROPSYCHIATRIC INVENTORY; MS PATIENTS; GLUTAMATE; DONEPEZIL; MODERATE; DISEASE; MEMORY; SCALE AB Background: Memantine, an NMDA antagonist, is effective for moderate to severe Alzheimer's disease. Objective: Determine whether memantine improves cognitive performance (CP) among subjects with multiple sclerosis (MS) and cognitive impairment (CI). Methods: This double-blind, randomized, placebo-controlled trial (Clinicaltrials.gov NCT00300716) compared memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose) with placebo. The primary outcome was the change from baseline to exit on the Paced Auditory Serial Addition Test (PASAT) and the California Verbal Learning Test-II (CVLT-II) Long Delay Free Recall (LDFR). Secondary outcomes included additional neuropsychological tests; self-report measures of quality of life, fatigue, and depression; and family/caregiver reports of subjects' CI and neuropsychiatric symptoms. Results: The differences between the groups on the change on the PASAT (placebo-memantine = 0.0 correct responses, 95% CI 3.4, 3.4; p = 0.9) and on CVLT-II LDFR (placebo-memantine = -0.6 words, 95% CI - 2.1, 0.8; p = 0.4) as well as on the other cognitive tests were not significant. Subjects on memantine had no serious adverse events (AEs) but had more fatigue and neurological AEs as well as, per family members' reports, less cognitive improvement and greater neuropsychiatric symptoms than subjects on placebo. Conclusion: Memantine 10 mg twice a day does not improve CP in subjects with MS, ages 18-65, without major depression, who have subjective cognitive complaints and perform worse than one SD below the mean on the PASAT or on the California Verbal Learning Test-II (total recall or delayed free recall). C1 [Lovera, J. F.] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70003 USA. [Frohman, E.; Stuve, O.; Remingon, G.; Fowler, J.] UT SW, Dallas, TX USA. [Brown, T. R.; Monahan, T.; Kilcup, S.; Courtney, Y.; McAleenan, J.; Butler, K.] Evergreen Neurosci Inst & Med Ctr, Kirkland, WA USA. [Bandari, D.; Cua, L.] Univ So Calif, Los Angeles, CA USA. [Nguyen, L.; Yadav, V.; Karman, J.; Bogardus, K.; Heimburger, G.; Wild, K.; Whitham, R.; Bourdette, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Whitham, R.; Bourdette, D.] Portland VA Med Ctr, Portland, OR USA. RP Lovera, JF (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, RM 718,1542 Tulane Ave, New Orleans, LA 70003 USA. EM jlover@lsuhsc.edu FU Forest Laboratories FX Special thanks to: Cynthia Morris, PhD for performing the randomization and Debbie Griffith, RN, Stacey Moultrie, RN, Lynn Tylkalsky, John Phillips for entering the data into the database. This study was supported by an investigator-initiated grant from Forest Laboratories. NR 27 TC 37 Z9 37 U1 0 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER J JI Mult. Scler. J. PD JUN PY 2010 VL 16 IS 6 BP 715 EP 723 DI 10.1177/1352458510367662 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 611OY UT WOS:000278829800010 PM 20483885 ER PT J AU Hugos, CL Copperman, LF Fuller, BE Yadav, V Lovera, J Bourdette, DN AF Hugos, C. L. Copperman, L. F. Fuller, B. E. Yadav, V. Lovera, J. Bourdette, D. N. TI Clinical trial of a formal group fatigue program in multiple sclerosis SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE energy conservation; exercise; fatigue; guideline; multiple sclerosis; quality of life; rehabilitation; self-efficacy; symptom management ID RANDOMIZED CONTROLLED-TRIAL; ENERGY-CONSERVATION COURSE; SELF-EFFICACY; IMPACT SCALE; VALIDATION; DISABILITY; THERAPY; MS AB Fatigue: Take Control is a novel program to teach fatigue management to people with multiple sclerosis (MS) following recommendations in the Fatigue and Multiple Sclerosis guideline. Fatigue: Take Control includes six 2-hour group sessions with DVD viewing, discussion and homework and accompanying participant and leader workbooks. While many people have participated in Fatigue: Take Control programs, its efficacy has not been determined. The objective of this study was to determine whether participation in Fatigue: Take Control reduces fatigue and increases self-efficacy in people with MS. Thirty participants were randomly assigned to a group who immediately participated in the program (FTC) or a wait-list group (WL). The primary outcome was the Modified Fatigue Impact Scale (MFIS) and secondary outcomes were the Multiple Sclerosis Self-Efficacy Scale (MSSE) and the Fatigue Severity Scale (FSS). The MFIS was administered on 10 occasions. Other measures were administered on four occasions. A mixed model tested the effects using all observations. Compared with the WL, the FTC group had significantly more improvement on the MFIS [F(1, 269) = 7.079, p = 0.008] and the MSSE [F(1, 111) = 5.636, p = 0.019]. No significant effect was found for the FSS. Across all visits, fatigue was significantly lower and self-efficacy was significantly higher for the FTC group compared with the WL group. This pilot study demonstrated significant effects in fatigue and self-efficacy among subjects taking the Fatigue: Take Control program, suggesting that this comprehensive program based on the Fatigue and Multiple Sclerosis guideline may be beneficial in MS. C1 [Hugos, C. L.] Oregon Hlth & Sci Univ, Dept Rehabil Serv, Dept Neurol, Portland, OR 97239 USA. [Fuller, B. E.] Portland VA Med Ctr, Div Mental Hlth, Portland, OR USA. [Lovera, J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA. [Lovera, J.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [Fuller, B. E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. RP Hugos, CL (reprint author), Oregon Hlth & Sci Univ, Dept Rehabil Serv, Dept Neurol, 3303 SW Bond Ave,CH3T, Portland, OR 97239 USA. EM hugosc@ohsu.edu FU National MS Society Pilot [1327]; NIH [K23 AT003258, UL1 RR024140]; Department of Veterans Affairs FX The PI would like to acknowledge Laura Mitchell, OTR, for her contribution as the 'trained substitute' leading two of the Fatigue: Take Control classes. This study was funded by National MS Society Pilot Grant 1327 (CLH), NIH K23 AT003258 (VY), the Department of Veterans Affairs (JL and DNB), Nancy Davis Center Without Walls, and Oregon Clinical and Translational Research Institute (OCTRI) NIH UL1 RR024140. NR 27 TC 23 Z9 23 U1 1 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER J JI Mult. Scler. J. PD JUN PY 2010 VL 16 IS 6 BP 724 EP 732 DI 10.1177/1352458510364536 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 611OY UT WOS:000278829800011 PM 20375125 ER PT J AU David, WS Goyal, N Henry, FP Baldassari, LE Redmond, RW AF David, William S. Goyal, Namita Henry, Francis P. Baldassari, Laura E. Redmond, Robert W. TI VALIDATION OF AN INCREMENTAL MOTOR UNIT NUMBER ESTIMATION TECHNIQUE IN RABBITS SO MUSCLE & NERVE LA English DT Article DE histomorphometry; incremental stimulation; motor unit number estimation; rabbit; summated single motor unit action potentials ID AMYOTROPHIC-LATERAL-SCLEROSIS; MULTIPLE POINT STIMULATION; CLINICAL-TRIAL; ALS; MUSCLE; REPRODUCIBILITY; MICE; MUNE; RELIABILITY; SURVIVAL AB Motor unit number estimation (MUNE) allows for quantitative assessment of functional motor units in a nerve. Several techniques have been applied to human studies. Although MUNE has been performed in animals to study neurological disorders, reproducibility has not been addressed. We analyzed the test-retest reproducibility of an incremental MUNE technique in rabbits and performed histological correlation. A peroneal MUNE was performed in 9 rabbits on two occasions separated by 30 days. MUNE was then performed on 18 rabbits prior to euthanize. A count of total fibers and a second count of large myelinated fibers were performed on nerve cross-sections. Test-retest reproducibility revealed an intraclass correlation coefficient (ICC) of 0.75. The average test-retest relative difference was 26.6%. Comparison of MUNE and histomorphometrical counts revealed a correlation coefficient (r) of 0.21 (total fiber counts) and 0.27 (large fibers). Although incremental MUNE has a high degree of reproducibility in rabbits, there is poor correlation with histological fiber counts. Muscle Nerve 41: 794-799, 2010 C1 [David, William S.; Goyal, Namita] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuromuscular Diagnost Ctr, Boston, MA 02114 USA. [Henry, Francis P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Plast Surg Res Lab, Boston, MA 02114 USA. [Henry, Francis P.; Redmond, Robert W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. [Baldassari, Laura E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Goyal, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuromuscular Diagnost Ctr, 165 Cambridge St,Suite 820, Boston, MA 02114 USA. EM nagoyal@partners.org OI Henry, Francis P./0000-0003-4170-7806 NR 29 TC 5 Z9 5 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD JUN PY 2010 VL 41 IS 6 BP 794 EP 799 DI 10.1002/mus.21590 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 604NI UT WOS:000278285300010 PM 20169589 ER PT J AU Huang, LY Terakawa, M Zhiyentayev, T Huang, YY Sawayama, Y Jahnke, A Tegos, GP Wharton, T Hamblin, MR AF Huang, Liyi Terakawa, Mitsuhiro Zhiyentayev, Timur Huang, Ying-Ying Sawayama, Yohei Jahnke, Ashlee Tegos, George P. Wharton, Tim Hamblin, Michael R. TI Innovative cationic fullerenes as broad-spectrum light-activated antimicrobials SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE LA English DT Article DE Photodynamic therapy; Functionalized fullerenes; Antimicrobial photoinactivation; Quantitative structure-function relationships; Broad-spectrum antimicrobials ID GRAM-NEGATIVE BACTERIA; PHOTODYNAMIC THERAPY; PSEUDOMONAS-AERUGINOSA; CANDIDA-ALBICANS; IN-VITRO; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; OUTER-MEMBRANE; INACTIVATION; C-60 AB Photodynamic inactivation is a rapidly developing antimicrobial technology that combines a nontoxic photoactivatable dye or photosensitizer in combination with harmless visible light of the correct wavelength to excite the dye to its reactive-triplet state that will then generate reactive oxygen species that are highly toxic to cells. Buckminsterfullerenes are closed-cage molecules entirely composed of sp2-hybridized carbon atoms, and although their main absorption is in the UV, they also absorb visible light and have a long-lived triplet state. When C-60 fullerene is derivatized with cationic functional groups it forms molecules that are more water-soluble and can mediate photodynamic therapy efficiently upon illumination; moreover, cationic fullerenes can selectively bind to microbial cells. In this report we describe the synthesis and characterization of several new cationic fullerenes. Their relative effectiveness as broad-spectrum antimicrobial photosensitizers against gram-positive and gram-negative bacteria, and a fungal yeast was determined by quantitative structure-function relationships. From the Clinical Editor: Photodynamic inactivation (PDI) is a rapidly developing antimicrobial technology in which a non-toxic photoactivatable dye or photosensitizer is excited with harmless visible light to its reactive state, where it will generate highly toxic reactive oxygen species. Buckminsterfullerenes derivatized with cationic functional groups form molecules that are water-soluble and mediate PDI efficiently. These fullerenes can also selectively bind to microbial cells. Several new cationic fullerenes are presented in this paper, and their efficacy against Gram-positive, Gram-negative bacteria, and a fungal yeast is also demonstrated. (C) 2010 Elsevier Inc. All rights reserved. C1 [Huang, Liyi; Terakawa, Mitsuhiro; Zhiyentayev, Timur; Huang, Ying-Ying; Sawayama, Yohei; Tegos, George P.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Huang, Liyi; Huang, Ying-Ying; Tegos, George P.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Huang, Liyi] Guangxi Med Univ, Dept Infect Dis, Affiliated Coll & Hosp 1, Nanning, Peoples R China. [Terakawa, Mitsuhiro] Keio Univ, Dept Elect & Elect Engn, Tokyo 108, Japan. [Zhiyentayev, Timur] MIT, Dept Chem, Cambridge, MA 02139 USA. [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China. [Sawayama, Yohei] Univ Tokyo, Grad Sch Engn, Tokyo 1138654, Japan. [Jahnke, Ashlee; Wharton, Tim] Lynntech Inc, College Stn, TX USA. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu RI Tegos, George/C-8830-2011; Huang, Ying-ying/G-3153-2011; Terakawa, Mitsuhiro/C-4912-2014; OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin, Michael/0000-0001-6431-4605 FU National Institutes of Health [R44AI068400, R44CA103177, R01AI050875] FX This work was supported by the National Institutes of Health (grants R44AI068400 and R44CA103177 to T.W. and R01AI050875 to M.R.H.). NR 48 TC 53 Z9 54 U1 1 U2 20 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1549-9634 EI 1549-9642 J9 NANOMED-NANOTECHNOL JI Nanomed.-Nanotechnol. Biol. Med. PD JUN PY 2010 VL 6 IS 3 BP 442 EP 452 DI 10.1016/j.nano.2009.10.005 PG 11 WC Nanoscience & Nanotechnology; Medicine, Research & Experimental SC Science & Technology - Other Topics; Research & Experimental Medicine GA 603MY UT WOS:000278213900006 PM 19914400 ER PT J AU Rodin, S Domogatskaya, A Strom, S Hansson, EM Chien, KR Inzunza, J Hovatta, O Tryggvason, K AF Rodin, Sergey Domogatskaya, Anna Strom, Susanne Hansson, Emil M. Chien, Kenneth R. Inzunza, Jose Hovatta, Outi Tryggvason, Karl TI Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511 SO NATURE BIOTECHNOLOGY LA English DT Article ID FEEDER CELLS; IN-VITRO; EXPRESSION; LINES; DERIVATION; CHAIN; PURIFICATION; FIBROBLASTS; INTEGRIN; CULTURE AB We describe a system for culturing human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells on a recombinant form of human laminin-511, a component of the natural hES cell niche. The system is devoid of animal products and feeder cells and contains only one undefined component, human albumin. The hES cells self-renewed with normal karyotype for at least 4 months (20 passages), after which the cells could produce teratomas containing cell lineages of all three germ layers. When plated on laminin-511 in small clumps, hES cells spread out in a monolayer, maintaining cellular homogeneity with approximately 97% OCT4-positive cells. Adhesion of hES cells was dependent on alpha 6 beta 1 integrin. The use of homogeneous monolayer hES or iPS cell cultures provides more controllable conditions for the design of differentiation methods. This xeno-free and feeder-free system may be useful for the development of cell lineages for therapeutic purposes. C1 [Rodin, Sergey; Domogatskaya, Anna; Tryggvason, Karl] Karolinska Inst, Div Matrix Biol, Dept Med Biochem & Biophys, Stockholm, Sweden. [Strom, Susanne; Hovatta, Outi] Karolinska Inst, Div Obstet & Gynecol, Dept Clin Sci Intervent & Technol, Stockholm, Sweden. [Strom, Susanne; Hovatta, Outi] Karolinska Univ Hosp, Stockholm, Sweden. [Hansson, Emil M.; Chien, Kenneth R.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Chien, Kenneth R.] Dept Stem Cell & Regenerat Biol, Cambridge, MA USA. [Inzunza, Jose] Karolinska Inst, Novum, Dept Biosci & Nutr, Huddinge, Sweden. [Inzunza, Jose] Karolinska Hosp, S-10401 Stockholm, Sweden. RP Tryggvason, K (reprint author), Karolinska Inst, Div Matrix Biol, Dept Med Biochem & Biophys, Stockholm, Sweden. EM karl.tryggvason@ki.se RI Domogatskaya, Anna/F-5794-2012; OI Domogatskaya, Anna/0000-0002-6468-1963; Rodin, Sergey/0000-0002-6954-1986 FU Knut and Alice Wallenberg Foundation; Novo Nordisk Foundation; Soderberg's Foundation; Swedish Research Council; Swedish Cancer Foundation; Harvard Stem Cell Institute; Leducq Foundation FX We thank A.-S. Nilsson and A.-M. Stromberg for excellent technical assistance, C. Cowan for collaboration in procuring the iPS cell lines, F. Holm and R. Bergstrom for their help with the cell cultures and D. Baker for carrying out karyotyping of hES cells. This work was supported in part by grants from the Knut and Alice Wallenberg Foundation (K. T.), the Novo Nordisk Foundation (K. T.), the Soderberg's Foundation (K. T.), the Swedish Research Council (K. T., O.H.), the Swedish Cancer Foundation (K. T.), the Harvard Stem Cell Institute (K. R. C.) and the Leducq Foundation (K. R. C.). E. M. H. is a Wenner-Gren Foundation fellow. EU: ESTOOLS (O.H.) has not been used for the derivation of new hES cell lines. NR 32 TC 234 Z9 239 U1 5 U2 46 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD JUN PY 2010 VL 28 IS 6 BP 611 EP U102 DI 10.1038/nbt.1620 PG 7 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 611MS UT WOS:000278820200026 PM 20512123 ER PT J AU Abu-Yousif, AO Hett, EC Skoczenski, AM Hasan, T AF Abu-Yousif, Adnan O. Hett, Erik C. Skoczenski, Ann M. Hasan, Tayyaba TI The ABC's of industry: a postdoc program provides a sneak peek into industry careers SO NATURE BIOTECHNOLOGY LA English DT Editorial Material C1 [Abu-Yousif, Adnan O.; Hett, Erik C.; Skoczenski, Ann M.; Hasan, Tayyaba] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Abu-Yousif, AO (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM aabu-yousif@partners.org NR 0 TC 1 Z9 1 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD JUN PY 2010 VL 28 IS 6 BP 625 EP 626 PG 2 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 611MS UT WOS:000278820200033 PM 20531344 ER PT J AU Castoreno, AB Smurnyy, Y Torres, AD Vokes, MS Jones, TR Carpenter, AE Eggert, US AF Castoreno, Adam B. Smurnyy, Yegor Torres, Angelica D. Vokes, Martha S. Jones, Thouis R. Carpenter, Anne E. Eggert, Ulrike S. TI Small molecules discovered in a pathway screen target the Rho pathway in cytokinesis SO NATURE CHEMICAL BIOLOGY LA English DT Article ID DROSOPHILA S2 CELLS; CONTRACTILE RING; MYOSIN-II; GTPASES; ANILLIN; MICROTUBULES; PROTEIN; INHIBITOR; SPINDLE; COMPLEX AB We report the discovery of small molecules that target the Rho pathway, which is a central regulator of cytokinesis-the final step in cell division. We have developed a way of targeting a small molecule screen toward a specific pathway, which should be widely applicable to the investigation of any signaling pathway. In a chemical genetic variant of a classical modifier screen, we used RNA interference (RNAi) to sensitize cells and identified small molecules that suppressed or enhanced the RNAi phenotype. We discovered promising candidate molecules, which we named Rhodblock 1-8, and we identified the target of Rhodblock 6 as Rho kinase. Several Rhodblocks inhibited one function of the Rho pathway in cells: the correct localization of phosphorylated myosin light chain during cytokinesis. Rhodblocks differentially perturb Rho pathway proteins in cells and can be used to dissect the mechanism of the Rho pathway during cytokinesis. C1 [Castoreno, Adam B.; Smurnyy, Yegor; Torres, Angelica D.; Eggert, Ulrike S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Castoreno, Adam B.; Smurnyy, Yegor; Torres, Angelica D.; Eggert, Ulrike S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Vokes, Martha S.; Jones, Thouis R.; Carpenter, Anne E.] Broad Inst Harvard & MIT, Cambridge, MA USA. RP Castoreno, AB (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM ulrike_eggert@dfci.harvard.edu RI Carpenter, Anne/C-4982-2008 OI Carpenter, Anne/0000-0003-1555-8261 FU Life Sciences Research Foundation (Novartis); L'Oreal for Women in Science; Society for Biomolecular Screening; US National Institutes of Health (NIH) [5 RL1 CA133834-03]; NIH [R01 GM082834]; Claudia Adams Barr Program; Dana-Farber Cancer Institute FX We thank the staff at ICCB-Longwood, the Nikon Imaging Center at Harvard Medical School and the Broad Institute's Imaging Platform for their assistance and F. Roth for helpful discussions. We thank C. Field (Harvard Medical School), R. Saint (Australian National University) and E. Griffis (University of California, San Francisco) for reagents. Funding for M.S.V., T.R.J. and A.E.C. was from the Life Sciences Research Foundation (Novartis), L'Oreal for Women in Science, the Society for Biomolecular Screening and the US National Institutes of Health (NIH) 5 RL1 CA133834-03. A.B.C., Y.S., A.D.T. and U.S.E. were supported by NIH grant R01 GM082834, the Claudia Adams Barr Program and the Dana-Farber Cancer Institute. NR 50 TC 31 Z9 31 U1 2 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1552-4450 J9 NAT CHEM BIOL JI Nat. Chem. Biol. PD JUN PY 2010 VL 6 IS 6 BP 457 EP 463 DI 10.1038/nchembio.363 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 597HS UT WOS:000277748100016 PM 20436488 ER PT J AU Stahl, EA Raychaudhuri, S Remmers, EF Xie, G Eyre, S Thomson, BP Li, YH Kurreeman, FAS Zhernakova, A Hinks, A Guiducci, C Chen, R Alfredsson, L Amos, CI Ardlie, KG Barton, A Bowes, J Brouwer, E Burtt, NP Catanese, JJ Coblyn, J Coenen, MJH Costenbader, KH Criswell, LA Crusius, JBA Cui, J de Bakker, PIW De Jager, PL Ding, B Emery, P Flynn, E Harrison, P Hocking, LJ Huizinga, TWJ Kastner, DL Ke, XY Lee, AT Liu, XD Martin, P Morgan, AW Padyukov, L Posthumus, MD Radstake, TRDJ Reid, DM Seielstad, M Seldin, MF Shadick, NA Steer, S Tak, PP Thomson, W van der Helm-van Mil, AHM van der Horst-Bruinsma, IE van der Schoot, CE van Riel, PLCM Weinblatt, ME Wilson, AG Wolbink, GJ Wordsworth, BP Wijmenga, C Karlson, EW Toes, REM de Vries, N Begovich, AB Worthington, J Siminovitch, KA Gregersen, PK Klareskog, L Plenge, RM AF Stahl, Eli A. Raychaudhuri, Soumya Remmers, Elaine F. Xie, Gang Eyre, Stephen Thomson, Brian P. Li, Yonghong Kurreeman, Fina A. S. Zhernakova, Alexandra Hinks, Anne Guiducci, Candace Chen, Robert Alfredsson, Lars Amos, Christopher I. Ardlie, Kristin G. Barton, Anne Bowes, John Brouwer, Elisabeth Burtt, Noel P. Catanese, Joseph J. Coblyn, Jonathan Coenen, Marieke J. H. Costenbader, Karen H. Criswell, Lindsey A. Crusius, J. Bart A. Cui, Jing de Bakker, Paul I. W. De Jager, Philip L. Ding, Bo Emery, Paul Flynn, Edward Harrison, Pille Hocking, Lynne J. Huizinga, Tom W. J. Kastner, Daniel L. Ke, Xiayi Lee, Annette T. Liu, Xiangdong Martin, Paul Morgan, Ann W. Padyukov, Leonid Posthumus, Marcel D. Radstake, Timothy R. D. J. Reid, David M. Seielstad, Mark Seldin, Michael F. Shadick, Nancy A. Steer, Sophia Tak, Paul P. Thomson, Wendy van der Helm-van Mil, Annette H. M. van der Horst-Bruinsma, Irene E. van der Schoot, C. Ellen van Riel, Piet L. C. M. Weinblatt, Michael E. Wilson, Anthony G. Wolbink, Gert Jan Wordsworth, B. Paul Wijmenga, Cisca Karlson, Elizabeth W. Toes, Rene E. M. de Vries, Niek Begovich, Ann B. Worthington, Jane Siminovitch, Katherine A. Gregersen, Peter K. Klareskog, Lars Plenge, Robert M. CA BIRAC Consortium YEAR Consortium TI Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci SO NATURE GENETICS LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; SUSCEPTIBILITY LOCI; CELIAC-DISEASE; VARIANTS; GENE; COMMON; REGION; POLYMORPHISMS; CONFIRMATION; REPLICATION AB To identify new genetic risk factors for rheumatoid arthritis, we conducted a genome-wide association study meta-analysis of 5,539 autoantibody-positive individuals with rheumatoid arthritis (cases) and 20,169 controls of European descent, followed by replication in an independent set of 6,768 rheumatoid arthritis cases and 8,806 controls. Of 34 SNPs selected for replication, 7 new rheumatoid arthritis risk alleles were identified at genome-wide significance (P < 5 x 10(-8)) in an analysis of all 41,282 samples. The associated SNPs are near genes of known immune function, including IL6ST, SPRED2, RBPJ, CCR6, IRF5 and PXK. We also refined associations at two established rheumatoid arthritis risk loci (IL2RA and CCL21) and confirmed the association at AFF3. These new associations bring the total number of confirmed rheumatoid arthritis risk loci to 31 among individuals of European ancestry. An additional 11 SNPs replicated at P < 0.05, many of which are validated autoimmune risk alleles, suggesting that most represent genuine rheumatoid arthritis risk alleles. C1 [Stahl, Eli A.; Raychaudhuri, Soumya; Kurreeman, Fina A. S.; Chen, Robert; Coblyn, Jonathan; Costenbader, Karen H.; Cui, Jing; Shadick, Nancy A.; Weinblatt, Michael E.; Karlson, Elizabeth W.; Plenge, Robert M.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Stahl, Eli A.; Raychaudhuri, Soumya; Thomson, Brian P.; Kurreeman, Fina A. S.; Guiducci, Candace; Ardlie, Kristin G.; Burtt, Noel P.; de Bakker, Paul I. W.; De Jager, Philip L.; Plenge, Robert M.] Broad Inst, Cambridge, MA USA. [Raychaudhuri, Soumya] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Remmers, Elaine F.; Kastner, Daniel L.] NIAMSD, Genet & Genom Branch, US NIH, Bethesda, MD 20892 USA. [Xie, Gang; Liu, Xiangdong; Siminovitch, Katherine A.] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada. [Xie, Gang; Liu, Xiangdong; Siminovitch, Katherine A.] Univ Hlth Network, Toronto, ON, Canada. [Eyre, Stephen; Hinks, Anne; Barton, Anne; Bowes, John; Flynn, Edward; Ke, Xiayi; Martin, Paul; Thomson, Wendy; Worthington, Jane] Univ Manchester, Arthrit Res UK Epidemiol Unit, Manchester, Lancs, England. [Li, Yonghong; Catanese, Joseph J.; Begovich, Ann B.] Celera, Alameda, CA USA. [Kurreeman, Fina A. S.; Huizinga, Tom W. J.; van der Helm-van Mil, Annette H. M.; Toes, Rene E. M.] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands. [Zhernakova, Alexandra; Wijmenga, Cisca] Univ Med Ctr Groningen, Dept Genet, NL-9713 AV Groningen, Netherlands. [Zhernakova, Alexandra; Brouwer, Elisabeth; Posthumus, Marcel D.; Wijmenga, Cisca] Univ Groningen, Groningen, Netherlands. [Alfredsson, Lars; Ding, Bo] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden. [Amos, Christopher I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Brouwer, Elisabeth; Posthumus, Marcel D.] Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, NL-9713 AV Groningen, Netherlands. [Coenen, Marieke J. H.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands. [Criswell, Lindsey A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA. [Crusius, J. Bart A.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Immunogenet Lab, Amsterdam, Netherlands. [de Bakker, Paul I. W.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [De Jager, Philip L.] Brigham & Womens Hosp, Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA. [Emery, Paul; Morgan, Ann W.] Univ Leeds, Leeds Inst Mol Med, Leeds Musculoskeletal Biomed Res Unit, Natl Inst Hlth Res, Leeds, W Yorkshire, England. [Harrison, Pille; Wordsworth, B. Paul] Univ Oxford, Inst Musculoskeletal Sci, Botnar Res Ctr, Oxford, England. [Hocking, Lynne J.; Reid, David M.] Univ Aberdeen, Div Appl Med, Musculoskeletal & Genet Sect, Aberdeen, Scotland. [Lee, Annette T.; Gregersen, Peter K.] N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA. [Padyukov, Leonid; Klareskog, Lars] Karolinska Inst, Dept Med, Rheumatol Unit, Stockholm, Sweden. [Padyukov, Leonid; Klareskog, Lars] Karolinska Univ Hosp Solna, Stockholm, Sweden. [Radstake, Timothy R. D. J.; van Riel, Piet L. C. M.] Radboud Univ Nijmegen, Med Ctr, Dept Rheumatol, NL-6525 ED Nijmegen, Netherlands. [Seielstad, Mark] Genome Inst Singapore, Singapore, Singapore. [Seldin, Michael F.] Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA. [Steer, Sophia] Kings Coll Hosp Natl Hlth Serv Fdn Trust, Clin & Acad Rheumatol, London, England. [van der Schoot, C. Ellen; Wolbink, Gert Jan] Univ Amsterdam, Acad Med Ctr, Sanquin Res Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands. [van der Horst-Bruinsma, Irene E.] Vrije Univ Amsterdam, Univ Med Ctr, Dept Rheumatol, Amsterdam, Netherlands. [Wilson, Anthony G.] Univ Sheffield, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England. [Wolbink, Gert Jan] Jan van Breemen Inst, Amsterdam, Netherlands. [Begovich, Ann B.] Roche Diagnost, Pleasanton, CA USA. RP Plenge, RM (reprint author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA. EM rplenge@partners.org RI Worthington, Jane/M-9770-2014; Barton, Anne/N-2053-2014; Bowes, John/B-3472-2015; Hinks, Anne/E-1853-2015; Brouwer, Elisabeth/A-3198-2015; Coenen, Marieke/A-2159-2010; de Vries, Niek/J-9348-2013; de Bakker, Paul/B-8730-2009; Wijmenga, Cisca/D-2173-2009; Siminovitch, Katherine/K-1475-2013; Riel, P.L.C.M./H-8082-2014; OI Hocking, Lynne J/0000-0002-2414-2826; Alfredsson, Lars/0000-0003-1688-6697; Seielstad, Mark/0000-0001-5783-1401; Martin, Paul/0000-0002-1016-6851; Wijmenga, Cisca/0000-0002-5635-1614; Klareskog, Lars/0000-0001-9601-6186; Thomson, Wendy/0000-0002-9022-5179; Eyre, Stephen/0000-0002-1251-6974; Worthington, Jane/0000-0003-0544-042X; Barton, Anne/0000-0003-3316-2527; Bowes, John/0000-0003-4659-031X; Hinks, Anne/0000-0001-8843-3967; de Vries, Niek/0000-0002-6257-8604; de Bakker, Paul/0000-0001-7735-7858; Zhernakova, Alexandra/0000-0002-4574-0841; Padyukov, Leonid/0000-0003-2950-5670 FU US National Institutes of Health (NIH) [R01-AR057108, R01-AR056768, U54 RR020278]; Fox Trot Fund; William Randolph Hearst Fund of Harvard University; Burroughs Wellcome Fund; NIH [1K08AR055688-01A1, NO1-AR-2-2263, RO1 AR44422, R01 AI065841, 5-M01-RR-00079, P01 CA87969, CA49449, CA67262, CA50385, AR049880-06, AR47782]; American College of Rheumatology Bridge Grant; EMBO-UNESCO L'Oreal Fellowship; National Center for Research Resources [U54 RR020278]; Crescendo; Swedish Medical Research council; Swedish Council for Working Life and Social Research; Swedish Rheumatism Foundation; Vinnova; AFA; National Institute of Arthritis; Musculoskeletal and Skin Diseases of the US National Institutes of Health; Canadian Institutes for Health Research [MOP79321, IIN-84042]; Ontario Research Fund [RE01061]; Canada Research Chair; Arthritis Research campaign arc [17552]; Manchester Biomedical Research Centre; Manchester Academy of Health Sciences; Netherlands Organization for Scientific Research (VICI) [918.66.620]; Existing Epidemiological Data (STAMPEED) genomics research program [R01HL087676]; National Center for Research Resources; Biogen-Idec; King Gustaf V's 80-year foundation; US National Institutes of Health and National Heart, Lung, and Blood Institute; Stockholm County Council FX R. M. P. is supported by grants from the US National Institutes of Health (NIH) (R01-AR057108, R01-AR056768 and U54 RR020278), a private donation from the Fox Trot Fund, the William Randolph Hearst Fund of Harvard University, the American College of Rheumatology 'Within Our Reach' campaign and a Career Award for Medical Scientists from the Burroughs Wellcome Fund. S. R. is supported by an NIH Career Development Award (1K08AR055688-01A1) and an American College of Rheumatology Bridge Grant. F. A. S. K. is supported by an EMBO-UNESCO L'Oreal Fellowship. The Broad Institute Center for Genotyping and Analysis is supported by grant U54 RR020278 from the National Center for Research Resources. The BRASS Registry is supported by a grant from Crescendo and Biogen-Idec. EIRA is supported by grants from the Swedish Medical Research council, the Swedish Council for Working Life and Social Research, King Gustaf V's 80-year foundation, the Swedish Rheumatism Foundation, Stockholm County Council, from Vinnova and the insurance company AFA. NARAC is supported by the NIH (NO1-AR-2-2263 and RO1 AR44422). L. A. C. is supported by the NIH (R01 AI065841 and). The Nurses Health Study is supported by NIH grants P01 CA87969, CA49449, CA67262, CA50385, AR049880-06 and AR47782. This research was also supported in part by the Intramural Research Program of the National Institute of Arthritis, Musculoskeletal and Skin Diseases of the US National Institutes of Health. This research was also supported in part by grants to K. A. S. from the Canadian Institutes for Health Research (MOP79321 and IIN-84042) and the Ontario Research Fund (RE01061) and by a Canada Research Chair. Genotyping of United Kingdom Rheumatoid Arthritis Genetics samples was supported by the Arthritis Research campaign arc grant reference number 17552 and by the Manchester Biomedical Research Centre and Manchester Academy of Health Sciences. C. W. was funded by the Netherlands Organization for Scientific Research (VICI grant 918.66.620). We acknowledge the help of B. A. C. Dijkmans, D. van Schaardenburg, A. Salvador Pena, P. L. Klarenbeek, Z. Zhang, M. T. Nurmohamed, W. F. Lems, R.R.J. van de Stadt, W. H. Bos, J. Ursum, M. G. M. Bartelds, D. M. Gerlag, M. G. H. van der Sande, C. A. Wijbrandts and M. M. J. Herenius in gathering Genetics Network Rheumatology Amsterdam subject samples and data. We thank the Myocardial Infarction Genetics Consortium (MIGen) study for the use of genotype data from their healthy controls in our study. The MIGen study was funded by the US National Institutes of Health and National Heart, Lung, and Blood Institute's SNP Typing for Association with Multiple Phenotypes from Existing Epidemiological Data (STAMPEED) genomics research program R01HL087676 and a grant from the National Center for Research Resources. We thank J. Seddon, Progression of AMD Study, Age-Related Macular Degeneration (AMD) Registry Study, Family Study of AMD, The US Twin Study of AMD and the Age-Related Eye Disease Study (AREDS) for use of genotype data from their healthy controls in our study. We thank D. Hafler and the Multiple Sclerosis Collaborative for use of genotype data from their healthy controls recruited at Brigham and Women's Hospital. NR 57 TC 600 Z9 609 U1 5 U2 69 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JUN PY 2010 VL 42 IS 6 BP 508 EP U56 DI 10.1038/ng.582 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 601RN UT WOS:000278081500016 PM 20453842 ER PT J AU Colvin, RA Means, TK Diefenbach, TJ Moita, LF Friday, RP Sever, S Campanella, GSV Abrazinski, T Manice, LA Moita, C Andrews, NW Wu, DQ Hacohen, N Luster, AD AF Colvin, Richard A. Means, Terry K. Diefenbach, Thomas J. Moita, Luis F. Friday, Robert P. Sever, Sanja Campanella, Gabriele S. V. Abrazinski, Tabitha Manice, Lindsay A. Moita, Catarina Andrews, Norma W. Wu, Dianqing Hacohen, Nir Luster, Andrew D. TI Synaptotagmin-mediated vesicle fusion regulates cell migration SO NATURE IMMUNOLOGY LA English DT Article ID CHEMOKINE RECEPTOR CXCR4; LENTIVIRAL RNAI LIBRARY; MYOSIN HEAVY-CHAIN; PHOSPHOINOSITIDE-3 KINASE; SIGNAL-TRANSDUCTION; NEUTROPHIL FUNCTION; LEADING LAMELLA; PLASMA-MEMBRANE; CHEMOTAXIS; FIBROBLASTS AB Chemokines and other chemoattractants direct leukocyte migration and are essential for the development and delivery of immune and inflammatory responses. To probe the molecular mechanisms that underlie chemoattractant-guided migration, we did an RNA-mediated interference screen that identified several members of the synaptotagmin family of calcium-sensing vesicle-fusion proteins as mediators of cell migration: SYT7 and SYTL5 were positive regulators of chemotaxis, whereas SYT2 was a negative regulator of chemotaxis. SYT7-deficient leukocytes showed less migration in vitro and in a gout model in vivo. Chemoattractant-induced calcium-dependent lysosomal fusion was impaired in SYT7-deficient neutrophils. In a chemokine gradient, SYT7-deficient lymphocytes accumulated lysosomes in their uropods and had impaired uropod release. Our data identify a molecular pathway required for chemotaxis that links chemoattractant-induced calcium flux to exocytosis and uropod release. C1 [Colvin, Richard A.; Means, Terry K.; Moita, Luis F.; Friday, Robert P.; Campanella, Gabriele S. V.; Abrazinski, Tabitha; Manice, Lindsay A.; Moita, Catarina; Hacohen, Nir; Luster, Andrew D.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. [Colvin, Richard A.; Means, Terry K.; Moita, Luis F.; Friday, Robert P.; Campanella, Gabriele S. V.; Abrazinski, Tabitha; Manice, Lindsay A.; Moita, Catarina; Hacohen, Nir; Luster, Andrew D.] Harvard Univ, Sch Med, Boston, MA USA. [Diefenbach, Thomas J.] MIT, Ragon Inst MGH, Boston, MA USA. [Moita, Luis F.; Moita, Catarina] Univ Lisbon, Fac Med, Inst Mol Med, Cell Biol Immune Syst Unit, P-1699 Lisbon, Portugal. [Sever, Sanja] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. [Andrews, Norma W.] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA. [Wu, Dianqing] Yale Univ, Sch Med, New Haven, CT USA. [Hacohen, Nir] Broad Inst, Cambridge, MA USA. RP Luster, AD (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. EM aluster@mgh.harvard.edu RI Moita, Luis/L-1296-2013; OI Moita, Luis/0000-0003-0707-315X; Ferreira Moita, Catarina/0000-0002-9910-2343 FU US National Institutes of Health [R01 DK074449, R01 GM064625]; Defense Advanced Research Projects Agency [W81XWH-04-C-0139]; Fundacao Luso-Americana para o Desenvolvimento; Fundacao para a Ciencia e a Tecnologia FX We thank the Immune Circuits and RNAi Platform groups of the Broad Institute and W. Xu for discussions and the Imaging Core of the Ragon Institute of MGH, MIT and Harvard. Supported by the US National Institutes of Health (R01 DK074449 to A. D. L. and R01 GM064625 to N.W.A.), the Defense Advanced Research Projects Agency (W81XWH-04-C-0139 to N.H.), Fundacao Luso-Americana para o Desenvolvimento (L. F. M.) and Fundacao para a Ciencia e a Tecnologia (L. F. M.). NR 59 TC 51 Z9 52 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD JUN PY 2010 VL 11 IS 6 BP 495 EP U60 DI 10.1038/ni.1878 PG 10 WC Immunology SC Immunology GA 598FV UT WOS:000277821300010 PM 20473299 ER PT J AU Fan, ZG Spencer, JA Lu, Y Pitsillides, CM Singh, G Kim, P Yun, SH Toxavidis, V Strom, TB Lin, CP Koulmanda, M AF Fan, Zhigang Spencer, Joel A. Lu, Yan Pitsillides, Costas M. Singh, Gurbakhshish Kim, Pilhan Yun, Seok H. Toxavidis, Vasilis Strom, Terry B. Lin, Charles P. Koulmanda, Maria TI In vivo tracking of 'color-coded' effector, natural and induced regulatory T cells in the allograft response SO NATURE MEDICINE LA English DT Article ID TRANSPLANTATION TOLERANCE; INDUCTION; REJECTION; GENERATION; AUTOIMMUNE; APOPTOSIS; BALANCE; FOXP3 AB Here we present methods to longitudinally track islet allograft-infiltrating T cells in live mice by endoscopic confocal microscopy and to analyze circulating T cells by in vivo flow cytometry. We developed a new reporter mouse whose T cell subsets express distinct, 'color-coded' proteins enabling in vivo detection and identification of effector T cells (T(eff) cells) and discrimination between natural and induced regulatory T cells (nT(reg) and iT(reg) cells). Using these tools, we observed marked differences in the T cell response in recipients receiving tolerance-inducing therapy (CD154-specific monoclonal antibody plus rapamycin) compared to untreated controls. These results establish real-time cell tracking as a powerful means to probe the dynamic cellular interplay mediating immunologic rejection or transplant tolerance. C1 [Fan, Zhigang; Lu, Yan; Singh, Gurbakhshish; Toxavidis, Vasilis; Strom, Terry B.; Koulmanda, Maria] Harvard Univ, Beth Israel Deaconess Med Ctr, Transplant Inst, Sch Med, Boston, MA 02215 USA. [Spencer, Joel A.; Pitsillides, Costas M.; Lin, Charles P.] Harvard Univ, Sch Med, Adv Microscopy Program, Ctr Syst Biol, Boston, MA 02215 USA. [Spencer, Joel A.] Tufts Univ, Dept Biomed Engn, Ctr Sci & Technol, Medford, MA 02155 USA. [Pitsillides, Costas M.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. [Kim, Pilhan; Yun, Seok H.] Harvard Univ, Sch Med,Adv Microscopy Program, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02215 USA. RP Strom, TB (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Transplant Inst, Sch Med, Boston, MA 02215 USA. EM tstrom@bidmc.harvard.edu; lin@helix.mgh.harvard.edu RI Kim, Pilhan/C-1836-2011; Spencer, Joel/A-4590-2013 OI Kim, Pilhan/0000-0001-8388-1840; FU US National Institutes of Health [R21 AI081010, R01 EY14106, P01-AI041521, P01-AI041521-S1]; Juvenile Diabetes Research Foundation (JDRF) [7-2005-1329] FX This work was supported by grants from the US National Institutes of Health (R21 AI081010 to S.H.Y. and R01 EY14106 to C.P.L. and P01-AI041521 and P01-AI041521-S1 to T.B.S.) and the Juvenile Diabetes Research Foundation (JDRF 7-2005-1329 to T.B.S. and M.K.). NR 29 TC 82 Z9 85 U1 0 U2 16 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JUN PY 2010 VL 16 IS 6 BP 718 EP U125 DI 10.1038/nm.2155 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 606BA UT WOS:000278394200040 PM 20495571 ER PT J AU Tseng, YH Cypess, AM Kahn, CR AF Tseng, Yu-Hua Cypess, Aaron M. Kahn, C. Ronald TI Cellular bioenergetics as a target for obesity therapy SO NATURE REVIEWS DRUG DISCOVERY LA English DT Review ID BROWN ADIPOSE-TISSUE; DIET-INDUCED OBESITY; BONE MORPHOGENETIC PROTEIN-7; BETA(3)-ADRENERGIC RECEPTOR AGONIST; NONEXERCISE ACTIVITY THERMOGENESIS; MITOCHONDRIAL UNCOUPLING PROTEIN; PLACEBO-CONTROLLED TRIAL; PPAR-GAMMA ACTIVATION; HUMAN SKELETAL-MUSCLE; GROWTH-FACTOR-BETA AB Obesity develops when energy intake exceeds energy expenditure. Although most current obesity therapies are focused on reducing calorific intake, recent data suggest that increasing cellular energy expenditure (bioenergetics) may be an attractive alternative approach. This is especially true for adaptive thermogenesis - the physiological process whereby energy is dissipated in mitochondria of brown fat and skeletal muscle in the form of heat in response to external stimuli. There have been significant recent advances in identifying the factors that control the development and function of these tissues, and in techniques to measure brown fat in human adults. In this article, we integrate these developments in relation to the classical understandings of cellular bioenergetics to explore the potential for developing novel anti-obesity therapies that target cellular energy expenditure. C1 [Tseng, Yu-Hua; Cypess, Aaron M.; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Tseng, YH (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM yu-hua.tseng@joslin.harvard.edu; c.ronald.kahn@joslin.harvard.edu FU National Institutes of Health (NIH) [DK077097, DK082659, DK046200, DK081604, RR025757]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [P30 DK036836]; Harvard Stem Cell Institute; Harvard Catalyst/Harvard Clinical and Translational Science Center [RR025758] FX We thank L. J. Goodyear for critical reading of the manuscript. This work was supported in part by National Institutes of Health (NIH) grants DK077097 (to Y.-H.T.); DK082659 (to C. R. K); and DK046200, DK081604 and RR025757 (to A. M. C.). And grants to the Joslin Diabetes Center's Diabetes and Endocrinology Research Center (P30 DK036836 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)). Work was also supported by funding from the Harvard Stem Cell Institute (to Y.-H.T.); the Harvard Catalyst/Harvard Clinical and Translational Science Center, RR025758 (to Y.-H.T. and A. M. C.). The content herein is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK or the NIH. NR 204 TC 202 Z9 212 U1 4 U2 37 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1776 J9 NAT REV DRUG DISCOV JI Nat. Rev. Drug Discov. PD JUN PY 2010 VL 9 IS 6 BP 465 EP 481 DI 10.1038/nrd3138 PG 17 WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA 603KQ UT WOS:000278207900023 PM 20514071 ER PT J AU Faustman, D Davis, M AF Faustman, Denise Davis, Miriam TI TNF receptor 2 pathway: drug target for autoimmune diseases SO NATURE REVIEWS DRUG DISCOVERY LA English DT Review ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; SYSTEMIC-LUPUS-ERYTHEMATOSUS; NONOBESE DIABETIC MICE; MONOCLONAL-ANTIBODY HOKT3-GAMMA-1(ALA-ALA); MAJOR HISTOCOMPATIBILITY COMPLEX; INFLAMMATORY-BOWEL-DISEASE; ALPHA-INDUCED APOPTOSIS; SIGNALS CELL-DEATH; CD8+ T-CELLS AB Although drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells. Targeted autoimmune therapies capable of eradicating the rare autoreactive immune cells that are responsible for the attack on the body's own cells are yet to be identified. This Review presents a new emerging approach aimed at selectively destroying autoreactive immune cells by specific activation of tumour necrosis factor receptor 2 (TNFR2), which is found on autoreactive and normal T lymphocytes, with the potential of avoiding or reducing the toxicity observed with existing therapies. C1 [Faustman, Denise] Massachusetts Gen Hosp, Immunobiol Lab, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Faustman, D (reprint author), Massachusetts Gen Hosp, Immunobiol Lab, Room 3602,Bldg 149,13th St, Charlestown, MA 02129 USA. EM faustman@helix.mgh.harvard.edu FU Iacocca Foundation FX We would like to thank the Iacocca Foundation for supporting this work. NR 147 TC 143 Z9 148 U1 3 U2 24 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1776 J9 NAT REV DRUG DISCOV JI Nat. Rev. Drug Discov. PD JUN PY 2010 VL 9 IS 6 BP 482 EP 493 DI 10.1038/nrd3030 PG 12 WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA 603KQ UT WOS:000278207900024 PM 20489699 ER PT J AU Jessen, N Goodyear, LJ AF Jessen, Niels Goodyear, Laurie J. TI DIABETES Exercise and type 2 diabetes mellitus-good for body and mind? SO NATURE REVIEWS ENDOCRINOLOGY LA English DT Editorial Material ID HEALTH C1 [Goodyear, Laurie J.] Harvard Univ, Sch Med, Sect Integrat Physiol & Metab, Joslin Diabet Ctr, Boston, MA 02215 USA. [Jessen, Niels] Aarhus Univ Hosp, Dept Clin Pharmacol, DK-8000 Aarhus, Denmark. RP Goodyear, LJ (reprint author), Harvard Univ, Sch Med, Sect Integrat Physiol & Metab, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM laurie.goodyear@joslin.harvard.edu RI Jessen, Niels/E-1731-2011; OI Jessen, Niels/0000-0001-5613-7274 NR 9 TC 2 Z9 3 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5029 J9 NAT REV ENDOCRINOL JI Nat. Rev. Endocrinol. PD JUN PY 2010 VL 6 IS 6 BP 303 EP 304 DI 10.1038/nrendo.2010.47 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 601RM UT WOS:000278081400002 PM 20502463 ER PT J AU Almandoz, JED Yoo, AJ Stone, MJ Schaefer, PW Goldstein, JN Rosand, J Oleinik, A Lev, MH Gonzalez, RG Romero, JM AF Almandoz, Josser E. Delgado Yoo, Albert J. Stone, Michael J. Schaefer, Pamela W. Goldstein, Joshua N. Rosand, Jonathan Oleinik, Alexandra Lev, Michael H. Gonzalez, R. Gilberto Romero, Javier M. TI Extended analysis of the spot sign score's performance SO NATURE REVIEWS NEUROLOGY LA English DT Letter ID PRIMARY INTRACEREBRAL HEMORRHAGE; PREDICTS HEMATOMA EXPANSION; CONTRAST EXTRAVASATION; HIGHEST RISK; IDENTIFIES PATIENTS; MORTALITY C1 [Almandoz, Josser E. Delgado] Washington Univ, Div Neuroradiol, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. [Yoo, Albert J.; Stone, Michael J.; Schaefer, Pamela W.; Lev, Michael H.; Gonzalez, R. Gilberto; Romero, Javier M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neuroradiol,Dept Radiol, Boston, MA 02114 USA. [Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02114 USA. [Rosand, Jonathan; Oleinik, Alexandra] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. RP Almandoz, JED (reprint author), Washington Univ, Div Neuroradiol, Mallinckrodt Inst Radiol, Campus Box 8131,510 S Kingshighway Blvd, St Louis, MO 63110 USA. EM delgadoj@mir.wustl.edu RI Goldstein, Joshua/H-8953-2016 NR 10 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4758 J9 NAT REV NEUROL JI Nat. Rev. Neurol. PD JUN PY 2010 VL 6 IS 6 BP 1 EP 1 DI 10.1038/nrneurol.2009.152-c1 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 608NK UT WOS:000278590800011 ER PT J AU Khurana, V Lindquist, S AF Khurana, Vikram Lindquist, Susan TI OPINION Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? SO NATURE REVIEWS NEUROSCIENCE LA English DT Article ID ENDOPLASMIC-RETICULUM STRESS; ALPHA-SYNUCLEIN TOXICITY; PRPSC-LIKE CONFORMATION; POLYGLUTAMINE AGGREGATION; HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; CELLULAR TOXICITY; EXPANDED POLYGLUTAMINE; MUTANT HUNTINGTIN; TRANSGENIC MOUSE AB In ageing populations, neurodegenerative diseases increase in prevalence, exacting an enormous toll on individuals and their communities. Multiple complementary experimental approaches are needed to elucidate the mechanisms underlying these complex diseases and to develop novel therapeutics. Here, we describe why the budding yeast Saccharomyces cerevisiae has a unique role in the neurodegeneration armamentarium. As the best-understood and most readily analysed eukaryotic organism, S. cerevisiae is delivering mechanistic insights into cell-autonomous mechanisms of neurodegeneration at an interactome-wide scale. C1 [Khurana, Vikram; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Lindquist, Susan] MIT, Dept Biol, Cambridge, MA USA. [Lindquist, Susan] Howard Hughes Med Inst, Chevy Chase, MD USA. [Khurana, Vikram] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Khurana, Vikram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA. RP Lindquist, S (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA. EM lindquist_admin@wi.mit.edu FU HHMI; US National Institutes of Health [NS038372]; Whitehead Institute Regenerative Biology Initiative FX We thank members of the Lindquist laboratory for their insightful comments on the manuscript, and particularly E. Nabieva for her assistance in the preparation of Table 2. S. L. is an Investigator at the Howard Hughes Medical Institute (HHMI). This work was supported by an HHMI Collaborative Innovation Award, US National Institutes of Health Udall program grant NS038372, and the Whitehead Institute Regenerative Biology Initiative. NR 92 TC 83 Z9 85 U1 2 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-0048 J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD JUN PY 2010 VL 11 IS 6 BP 436 EP 449 DI 10.1038/nrn2809 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 598ZN UT WOS:000277879400013 PM 20424620 ER PT J AU Bouwman, P Aly, A Escandell, JM Pieterse, M Bartkova, J van der Gulden, H Hiddingh, S Thanasoula, M Kulkarni, A Yang, QF Haffty, BG Tommiska, J Blomqvist, C Drapkin, R Adams, DJ Nevanlinna, H Bartek, J Tarsounas, M Ganesan, S Jonkers, J AF Bouwman, Peter Aly, Amal Escandell, Jose M. Pieterse, Mark Bartkova, Jirina van der Gulden, Hanneke Hiddingh, Sanne Thanasoula, Maria Kulkarni, Atul Yang, Qifeng Haffty, Bruce G. Tommiska, Johanna Blomqvist, Carl Drapkin, Ronny Adams, David J. Nevanlinna, Heli Bartek, Jiri Tarsounas, Madalena Ganesan, Shridar Jonkers, Jos TI 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers SO NATURE STRUCTURAL & MOLECULAR BIOLOGY LA English DT Article ID CONDITIONAL MOUSE MODEL; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; MAMMARY-TUMORS; CELL-CYCLE; GENOMIC INSTABILITY; OVARIAN-CANCER; STEM-CELLS; GENE BRCA1 AB Germ-line mutations in breast cancer 1, early onset (BRCA1) result in predisposition to breast and ovarian cancer. BRCA1-mutated tumors show genomic instability, mainly as a consequence of impaired recombinatorial DNA repair. Here we identify p53-binding protein 1 (53BP1) as an essential factor for sustaining the growth arrest induced by Brca1 deletion. Depletion of 53BP1 abrogates the ATM-dependent checkpoint response and G2 cell-cycle arrest triggered by the accumulation of DNA breaks in Brca1-deleted cells. This effect of 53BP1 is specific to BRCA1 function, as 53BP1 depletion did not alleviate proliferation arrest or checkpoint responses in Brca2-deleted cells. Notably, loss of 53BP1 partially restores the homologous-recombination defect of Brca1-deleted cells and reverts their hypersensitivity to DNA-damaging agents. We find reduced 53BP1 expression in subsets of sporadic triple-negative and BRCA-associated breast cancers, indicating the potential clinical implications of our findings. C1 [Bouwman, Peter; Pieterse, Mark; van der Gulden, Hanneke; Hiddingh, Sanne; Jonkers, Jos] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands. [Aly, Amal; Kulkarni, Atul; Yang, Qifeng; Haffty, Bruce G.; Ganesan, Shridar] Canc Inst New Jersey, New Brunswick, NJ USA. [Escandell, Jose M.; Thanasoula, Maria; Tarsounas, Madalena] Canc Res UK MRC Gray Inst Radiat Oncol & Biol, Telomere & Genome Stabil Grp, Oxford, England. [Bartkova, Jirina; Bartek, Jiri] Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark. [Bartkova, Jirina; Bartek, Jiri] Danish Canc Soc, Ctr Genotox Stress Res, Copenhagen, Denmark. [Tommiska, Johanna; Nevanlinna, Heli] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland. [Blomqvist, Carl] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland. [Drapkin, Ronny] Dana Farber Canc Inst, Dept Med Oncol, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Adams, David J.] Wellcome Trust Sanger Inst, Cambridge, England. [Bartek, Jiri] Palacky Univ, Inst Mol & Translat Med, CR-77147 Olomouc, Czech Republic. RP Jonkers, J (reprint author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands. EM madalena.tarsounas@rob.ox.ac.uk; ganesash@umdnj.edu; j.jonkers@nki.nl RI Bartek, Jiri/G-5870-2014; Drapkin, Ronny/E-9944-2016; OI Drapkin, Ronny/0000-0002-6912-6977; Jose Miguel, Escandell Planells/0000-0003-4857-9413; Tommiska, Johanna/0000-0001-7958-8262; Nevanlinna, Heli/0000-0002-0916-2976 FU Dutch Cancer Society; Netherlands Organization for Scientific Research; European Community; Cancer Research UK; Breast Cancer Campaign; US Department of Defense; US National Cancer Institute; Sidney Kimmel Foundation; Breast Cancer Research Foundation; Danish Cancer Society; Danish National Research Foundation; Vilhelm Pedersen and Hustrus Mindelegat; Czech Ministry of Education; Helsinki University Central Hospital Research Fund; Finnish Cancer Society; Academy of Finland [132473]; Sigrid Juselius Foundation; Wellcome Trust FX We wish to thank M. Treur-Mulder for her help with targeting of the Brca1SCo allele, W. Wang and P. Liu (Wellcome Trust Sanger Institute) for their kind gift of the piggyBac transposon MSCV 5'-LTR transposon and the mPB transposase, E. de Bruin, E. Cuppen and M. Koudijs for help with PCR amplification of the piggyBac insertions, J. Kong and D. Sie for mapping of piggyBac insertions, K, Szuhai for multicolor fluorescence in situ hybridization karyotyping, S. Philipsen (Erasmus Univ.) for providing shRNA vectors, H. te Riele and P. Borst for their comments on the manuscript, E. Bilal and G. Bhanot for their help with analysis of microarray data and P. Heikkil and K. Aittom ki for their help with the Finnish breast cancer data and sample collection. We are most grateful to the patients who provided clinical samples that were analyzed in this study. Work in the Jonkers laboratory is supported by the Dutch Cancer Society, the Netherlands Organization for Scientific Research and the European Community 7th Framework Program (EuroSyStem project). Work in the Tarsounas laboratory is supported by Cancer Research UK and Breast Cancer Campaign. Work in the Ganesan laboratory is supported by the US Department of Defense (A.A.), the US National Cancer Institute (S.G.), the Sidney Kimmel Foundation (S.G.) and the Breast Cancer Research Foundation (S.G.). B. G. H. is supported by the Breast Cancer Research Foundation and the US National Cancer Institute. Work in the Bartek laboratory is supported by the Danish Cancer Society, the Danish National Research Foundation, Vilhelm Pedersen and Hustrus Mindelegat, the Czech Ministry of Education and the European Community 7th Framework Program (projects GENICA and INFLA-CARE). Work in the Nevanlinna laboratory is supported by the Helsinki University Central Hospital Research Fund, the Finnish Cancer Society, the Academy of Finland (132473) and the Sigrid Juselius Foundation. D.J.A. is supported by Cancer Research UK and the Wellcome Trust. NR 54 TC 355 Z9 361 U1 3 U2 45 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1545-9985 J9 NAT STRUCT MOL BIOL JI Nat. Struct. Mol. Biol. PD JUN PY 2010 VL 17 IS 6 BP 688 EP U56 DI 10.1038/nsmb.1831 PG 9 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 606AU UT WOS:000278393400012 PM 20453858 ER PT J AU Chi, LY Yu, J Zhu, H Li, XG Zhu, SG Li, ZZ Pettigrew, LC Grass, D Hickman, JJ Kindy, MS AF Chi, Lingyi Yu, Jin Zhu, Hong Li, Xingang Zhu, Shugan Li, Zhenzhong Pettigrew, L. Creed Grass, David Hickman, James J. Kindy, Mark S. TI Dual neuronal response to tumor necrosis factor-alpha following spinal cord injury SO NEURAL REGENERATION RESEARCH LA English DT Article DE spinal cord injury; tumor necrosis factor-alpha; rats; inflammation; motor function; astrocytes; microglia; nerve growth factor; brain-derived neurotrophic factors ID NERVE GROWTH-FACTOR; BRAIN-INJURY; TRANSGENIC MICE; GENE-EXPRESSION; WORKING-MEMORY; CYTOKINES; RATS; APOPTOSIS; SYSTEM; INFLAMMATION AB BACKGROUND: Numerous studies have shown that tumor necrosis factor a (TNF-alpha) is closely correlated with spinal cord injury (SCI), but the mechanisms of TNF-alpha and therapeutic treatments for SCI are still poorly understood. OBJECTIVE: To determine the role of TNF-alpha in the pathogenesis of SCI. DESIGN, TIME AND SETTING: An in vivo experiment based on genetically engineered animals was performed at the Medical University of South Carolina, Charleston, South Carolina, USA, between June 2007 and October 2008. MATERIALS: TNF-alpha transgenic rats (Xenogen Biosciences in Cranbury, New Jersey, USA) were utilized in this study. METHODS: TNF-alpha transgenic (tg) and wild-type (WT) rats underwent a complete single-level laminectomy at the 10(th) thoracic vertebra (T(10)). MAIN OUTCOME MEASURES: Motor function of rat hindlimb was assessed using the Basso, Beattie, and Bresnahan hindlimb locomotor rating scale. Histological evaluation of spinal cord tissue loss was conducted. Immunohistochemistry for astrocytes, microglia/macrophages, and TNF receptors (TNFRs) was performed on spinal cord tissue sections. TNF-alpha mRNA expression was detected by real-time polymerase chain reaction. The concentrations of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the supernatant were determined using an enzyme-linked immunosorbent assay kit for rat NGF or BDNF, respectively. The rats were injected subcutaneously with etanercept to verify that TNF-alpha was the direct effect of the modulation of behavioral and neurodegenerative outcomes in the TNF-alpha tg rats. RESULTS: TNF-alpha tg rats showed higher expression of TNF-alpha mRNA in the spinal cord prior to SCI. TNF-alpha tg rats showed worse motor deficits than WT rats in the acute period (<3 days) after SCI (P < 0.01), while in the chronic period, TNF-alpha tg rats exhibited persistent elevated baseline levels of TNF-alpha mRNA and improved recovery in motor function and tissue healing compared to WT rats (P < 0.01). Following SCI, the number of microglia/macrophages in TNF-alpha tg rat was always greater than in WT rat (P < 0.01). There were no significant differences in NGF and BDNF levels in the supernatant of spinal cord homogenates. TNFR1 expression was significantly greater in the TNF-alpha tg rats compared to the WT rats (P < 0.01). However, TNFR2 expression did not reveal a significant increase in the TNF-alpha tg rats compared to the WT rats. Finally, treatment with etanercept reduced injury acutely, but exacerbated the injury chronically. CONCLUSION: Overexpression of TNF-alpha is deleterious in the acute phase, but beneficial in the chronic phase in the response to SCI. The role of TNF-alpha post-injury may depend on TNF-alpha expression in the spinal cord and its differential binding to TNFR1. Our observations may have clinical relevance that antagonists or inhibitors of TNF-alpha could be administered within the early time window post-injury, and appropriate amounts of TNF-alpha could be administered during the chronic stage, in order to improve the final neurological recovery in patients with SCI. C1 [Chi, Lingyi; Yu, Jin; Zhu, Hong; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Chi, Lingyi; Li, Xingang; Zhu, Shugan] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China. [Chi, Lingyi; Li, Xingang] Shandong Univ, Qilu Hosp, Lab Neurosurg, Jinan 250012, Shandong, Peoples R China. [Li, Zhenzhong; Kindy, Mark S.] Shandong Univ, Sch Med, Dept Anat, Jinan 250012, Shandong, Peoples R China. [Pettigrew, L. Creed] Univ Kentucky, Sanders Brown Ctr Aging, Stroke Program, Coll Med, Lexington, KY 40536 USA. [Pettigrew, L. Creed] Dept Vet Affairs Med Ctr, Lexington, KY 40536 USA. [Grass, David] Xenogen Corp, Cranbury, NJ 08512 USA. [Hickman, James J.] Univ Cent Florida, NanoSci Technol Ctr, Orlando, FL 32826 USA. [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. EM drlixingangneurosurgery@yahoo.com.cn; kindyms@musc.edu FU VA [ES016774-01A1]; National Science Foundation [EPS-0132573, EPS-0447660, NS050452-05] FX Supported by: the ES016774-01A1*, VA Merit Award and National Science Foundation EPSCoR grant, No. EPS-0132573* and EPS-0447660 (MSK)* and NS050452-05 (JJH)* NR 56 TC 2 Z9 2 U1 1 U2 7 PU SHENYANG EDITORIAL DEPT NEURAL REGENERATION RES PI SHENYANG PA PO BOX 1234, SHENYANG, LIAONING 110004, PEOPLES R CHINA SN 1673-5374 J9 NEURAL REGEN RES JI Neural Regen. Res. PD JUN PY 2010 VL 5 IS 12 BP 917 EP 926 DI 10.3969/j.issn.1673-5374.2010.12.007 PG 10 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA 625LC UT WOS:000279895700007 ER PT J AU Scott, BJ Quant, EC McNamara, MB Ryg, PA Batchelor, TT Wen, PY AF Scott, Brian J. Quant, Eudocia C. McNamara, Margaret B. Ryg, Peter A. Batchelor, Tracy T. Wen, Patrick Y. TI Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors SO NEURO-ONCOLOGY LA English DT Article DE bevacizumab; recurrent glioblastoma; tyrosine kinase inhibitor; vascular endothelial growth factor ID MALIGNANT GLIOMA; PLUS IRINOTECAN; RECURRENT GLIOBLASTOMA; ANTIANGIOGENIC THERAPY; TUMOR VASCULATURE; PHASE-II; ANGIOGENESIS; ANTITUMOR; EFFICACY; INVASION AB Agents targeting the vascular endothelial growth factor (VEGF) pathway are being used with increasing frequency in patients with recurrent high-grade glioma. The effect of more than one antiangiogenic therapy given in succession has not been established. We reviewed the efficacy of bevacizumab, a VEGF-A monoclonal antibody, in patients who progressed following prior therapy with VEGF receptor tyrosine kinase inhibitors (R-TKi). Seventy-three patients with recurrent high-grade gliomas received VEGF R-TKi (cediranib, sorafenib, pazopanib, or sunitinib) as part of phase I or II clinical trials. Twenty-four of these patients with glioblastoma progressed and received bevacizumab-containing regimens immediately after R-TKi. Those who stopped R-TKi therapy for reasons other than disease progression, or received a treatment that did not include bevacizumab, were excluded from the analysis. The efficacy of bevacizumab-containing regimens in these 24 patients was evaluated. During R-TKi therapy, 6 of 24 patients (25%) had a partial response (PR) to treatment. The 6-month progression-free survival (APF6) was 16.7% and median time-to-progression (TTP) was 14.3 weeks. Grade III/IV toxicities were seen in 13 of 24 patients (54%). Subsequently with bevacizumab salvage therapy, 5 of 24 patients (21%) had a PR, the APF6 was 12.5%, and the median TIP was 8 weeks. Five of 24 patients had grade III/IV toxicities (21%). The median overall survival (OS) from the start of R-TKi therapy was 9.2 months (range: 2.8-34.1+), whereas the median OS after bevacizumab was 5.2 months (range: 1.3-28.9+). Bevacizumab retains modest activity in high-grade glioma patients who progress on R-TKi. However, the APF6 of 12.5% in this cohort of patients indicates that durable tumor control is not achieved for most patients. C1 [Scott, Brian J.; Quant, Eudocia C.; Ryg, Peter A.; Batchelor, Tracy T.] Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Boston, MA 02114 USA. [Scott, Brian J.; Quant, Eudocia C.; McNamara, Margaret B.; Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. RP Scott, BJ (reprint author), Lahey Clin Med Ctr, Dept Neurol, 41 Mall Rd, Burlington, MA 01805 USA. EM brian.j.scott@lahey.org FU NIH [R21-CA117079, K24-CA125440, R01-CA129371]; Harvard Clinical and Translational Science Center, the National Center for Research Resources FX This work was supported by NIH grant R21-CA117079, and in part by NIH grants K24-CA125440 and R01-CA129371 and the Harvard Clinical and Translational Science Center, from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. NR 23 TC 36 Z9 37 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP 603 EP 607 DI 10.1093/neuonc/nop073 PG 5 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700010 PM 20156808 ER PT J AU Cho, Y Tamayo, P Tsherniak, A Greulich, H Lu, J Kool, M Zhou, T Eberhart, CG Olson, JM Lau, CC Meyerson, M Mesirov, JP Pomeroy, SL AF Cho, Y. Tamayo, P. Tsherniak, A. Greulich, H. Lu, J. Kool, M. Zhou, T. Eberhart, C. G. Olson, J. M. Lau, C. C. Meyerson, M. Mesirov, J. P. Pomeroy, S. L. TI INTEGRATIVE GENOMIC ANALYSIS OF MEDULLOBLASTOMA IDENTIFIES A MOLECULAR SUBGROUP THAT DRIVES POOR CLINICAL OUTCOME SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Cho, Y.; Pomeroy, S. L.] Childrens Hosp, Boston, MA 02115 USA. [Cho, Y.; Meyerson, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tamayo, P.; Tsherniak, A.; Greulich, H.; Meyerson, M.; Mesirov, J. P.] MIT, Broad Inst, Cambridge, MA 02139 USA. [Lu, J.] Yale Univ, Med Ctr, New Haven, CT USA. [Kool, M.] Acad Med Ctr, Amsterdam, Netherlands. [Zhou, T.] Childrens Oncol Grp, Acadia, CA USA. [Eberhart, C. G.] Johns Hopkins Med Ctr, Baltimore, MD USA. [Olson, J. M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Lau, C. C.] Texas Childrens Hosp, Houston, TX 77030 USA. RI Meyerson, Matthew/E-7123-2012; Kool, Marcel/H-2541-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II1 EP II1 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700015 ER PT J AU Chordas, C Zimmerman, M Kieran, MW Chi, SN Lee, M Robison, N Stratton, N Goumnerova, L Ullrich, NJ Marcus, KJ Manley, PE AF Chordas, C. Zimmerman, M. Kieran, M. W. Chi, S. N. Lee, M. Robison, N. Stratton, N. Goumnerova, L. Ullrich, N. J. Marcus, K. J. Manley, P. E. TI ECHOCARDIOGRAPHIC FINDINGS FOLLOWING TREATMENT FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER'S EXPERIENCE SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Chordas, C.; Zimmerman, M.; Kieran, M. W.; Chi, S. N.; Lee, M.; Robison, N.; Stratton, N.; Goumnerova, L.; Ullrich, N. J.; Marcus, K. J.; Manley, P. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kieran, M. W.; Chi, S. N.; Lee, M.; Robison, N.; Goumnerova, L.; Ullrich, N. J.; Marcus, K. J.; Manley, P. E.] Childrens Hosp Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II114 EP II114 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700527 ER PT J AU Chordas, C Liptak, C Delaney, B Barnes, J Chabot, J Northman, L Morris, M Gambhir, R Rey-Casserly, C Diver, T Manley, PE AF Chordas, C. Liptak, C. Delaney, B. Barnes, J. Chabot, J. Northman, L. Morris, M. Gambhir, R. Rey-Casserly, C. Diver, T. Manley, P. E. TI RESOURCE AND INFORMATION NEEDS OF BRAIN TUMOR SURVIVORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Chordas, C.; Liptak, C.; Delaney, B.; Barnes, J.; Chabot, J.; Northman, L.; Morris, M.; Gambhir, R.; Rey-Casserly, C.; Manley, P. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rey-Casserly, C.; Manley, P. E.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II110 EP II110 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700506 ER PT J AU Chordas, C Manley, P Medeiros-Nancarrow, C Merport, A Zwemer, E Liptak, C Recklitis, C AF Chordas, C. Manley, P. Medeiros-Nancarrow, C. Merport, A. Zwemer, E. Liptak, C. Recklitis, C. TI PREVALENCE OF AND FACTORS ASSOCIATED WITH POST-CANCER PAIN IN A COHORT OF CHILDHOOD BRAIN TUMOR SURVIVORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Chordas, C.; Manley, P.; Medeiros-Nancarrow, C.; Merport, A.; Zwemer, E.; Liptak, C.; Recklitis, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Manley, P.; Zwemer, E.; Liptak, C.; Recklitis, C.] Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II108 EP II108 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700497 ER PT J AU Diver, T Manley, P Kieran, MW Chi, S Goumnerova, L Scott, R Marcus, KJ Ullrich, N Liptak, C Chordas, C Zimmerman, M Delaney, B Rey-Casserly, C AF Diver, T. Manley, P. Kieran, M. W. Chi, S. Goumnerova, L. Scott, R. Marcus, K. J. Ullrich, N. Liptak, C. Chordas, C. Zimmerman, M. Delaney, B. Rey-Casserly, C. TI AGE AT DIAGNOSIS AND CRANIOSPINAL RADIATION DOSE EFFECTS ON INTELLECTUAL OUTCOME IN CHILDREN/ADOLESCENTS TREATED FOR MEDULLOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Diver, T.; Rey-Casserly, C.] Childrens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Diver, T.; Manley, P.; Kieran, M. W.; Chi, S.; Goumnerova, L.; Scott, R.; Marcus, K. J.; Ullrich, N.; Liptak, C.; Chordas, C.; Zimmerman, M.; Delaney, B.; Rey-Casserly, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II7 EP II8 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700040 ER PT J AU Gruber-Olipitz, M Dabral, SK Ligon, KL Segal, RA AF Gruber-Olipitz, M. Dabral, S. K. Ligon, K. L. Segal, R. A. TI DASATINIB ACTIVITY ON GLIOBLASTOMA CELLS IS DUE TO ANOIKIS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Gruber-Olipitz, M.; Dabral, S. K.; Segal, R. A.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA USA. [Ligon, K. L.] Dept Med Oncol, Boston, MA USA. [Ligon, K. L.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Ligon, K. L.] Childrens Hosp Boston, Dept Pathol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II88 EP II88 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700402 ER PT J AU Kieran, MW Rich, BE Santagata, S Chan, JA MacConaill, L Goff, D Stiles, C Garraway, L Golub, T Golub, T Ligon, KL AF Kieran, M. W. Rich, B. E. Santagata, S. Chan, J. A. MacConaill, L. Goff, D. Stiles, C. Garraway, L. Golub, T. Golub, T. Ligon, K. L. TI GANGLIOGLIOMAS AND V600E STATUS IDENTIFIED BY EXTENDED MUTATIONAL ANALYSIS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Kieran, M. W.; Rich, B. E.; MacConaill, L.; Goff, D.; Stiles, C.; Garraway, L.; Golub, T.; Golub, T.; Ligon, K. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA. [Santagata, S.; Chan, J. A.; MacConaill, L.; Garraway, L.; Golub, T.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Santagata, S.; Chan, J. A.; Ligon, K. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II92 EP II92 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700421 ER PT J AU Kieran, MW Rich, BE MacConaill, L Chan, JA Santagata, S Goff, D Stiles, C Golub, T Garraway, L Ligon, KL AF Kieran, M. W. Rich, B. E. MacConaill, L. Chan, J. A. Santagata, S. Goff, D. Stiles, C. Golub, T. Garraway, L. Ligon, K. L. TI MOLECULAR CHARACTERIZATION BY AGE OF PEDIATRIC PILOCYTIC ASTROCYTOMAS IN THE PRESENCE OR ABSENCE OF BRAF MUTATION OR DUPLICATION SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Kieran, M. W.; Rich, B. E.; MacConaill, L.; Goff, D.; Stiles, C.; Ligon, K. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA. [Rich, B. E.; Chan, J. A.; Santagata, S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [MacConaill, L.; Chan, J. A.; Santagata, S.; Golub, T.; Garraway, L.] MIT, Broad Inst, Cambridge, MA 02139 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II23 EP II23 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700109 ER PT J AU Kieran, MW Mehta, S Huillard, E Rowitch, DH Saad, A Stiles, CD Ligon, KL AF Kieran, M. W. Mehta, S. Huillard, E. Rowitch, D. H. Saad, A. Stiles, C. D. Ligon, K. L. TI REMISSION AND RELAPSE IN PEDIATRIC LOW GRADE ASTROCYTOMA: AN OPPOSITIONAL RELATIONSHIP BETWEEN STEMNESS AND P53? SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Kieran, M. W.; Mehta, S.; Stiles, C. D.; Ligon, K. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA. [Huillard, E.; Rowitch, D. H.] UCSF, San Francisco, CA USA. [Saad, A.; Ligon, K. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II24 EP II24 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700113 ER PT J AU Kieran, MW MacConaill, L Chan, JA Santagata, S Goff, D Stiles, C Garraway, L Ligon, KL AF Kieran, M. W. MacConaill, L. Chan, J. A. Santagata, S. Goff, D. Stiles, C. Garraway, L. Ligon, K. L. TI INTEGRATIVE MOLECULAR PROFILING OF PEDIATRIC LOW-GRADE ASTROCYTOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Kieran, M. W.; MacConaill, L.; Chan, J. A.; Goff, D.; Stiles, C.; Garraway, L.; Ligon, K. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA. [MacConaill, L.; Chan, J. A.; Santagata, S.; Garraway, L.] MIT, Broad Inst, Cambridge, MA USA. [Santagata, S.; Ligon, K. L.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II23 EP II24 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700111 ER PT J AU Kuhlthau, KA Pulsifer, M Delahaye, J MacDonald, SM Tarbell, NJ Yock, TI AF Kuhlthau, K. A. Pulsifer, M. Delahaye, J. MacDonald, S. M. Tarbell, N. J. Yock, T. I. TI HEALTH-RELATED QUALITY OF LIFE OF PEDIATRIC BRAIN TUMOR PATIENTS ON PROTON TREATMENT SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Kuhlthau, K. A.; Pulsifer, M.; Delahaye, J.; MacDonald, S. M.; Tarbell, N. J.; Yock, T. I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II111 EP II111 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700513 ER PT J AU Liptak, C Zwemer, E Merport, A Manley, P Recklitis, CJ AF Liptak, C. Zwemer, E. Merport, A. Manley, P. Recklitis, C. J. TI ASSESSMENT OF PSYCHOLOGICAL DISTRESS IN ADOLESCENT AND YOUNG ADULT BRAIN TUMOR SURVIVORS: THE VALUE OF PARENT AND SURVIVOR SELF-REPORT SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Liptak, C.; Zwemer, E.; Merport, A.; Manley, P.; Recklitis, C. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Liptak, C.; Zwemer, E.; Manley, P.; Recklitis, C. J.] Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II109 EP II109 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700500 ER PT J AU Liptak, C Brinkman, T Ing, J Chordas, C Delaney, B Manley, PE AF Liptak, C. Brinkman, T. Ing, J. Chordas, C. Delaney, B. Manley, P. E. TI QUALITATIVE ASSESSMENT OF A SOCIAL PROGRAM FOR ADOLESCENT AND YOUNG ADULT BRAIN TUMOR SURVIVORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Liptak, C.; Brinkman, T.; Ing, J.; Delaney, B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Manley, P. E.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II110 EP II110 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700508 ER PT J AU MacDonald, SM Lavally, B Yeap, BY Marcus, K Ebb, D Yock, TI Tarbell, NJ AF MacDonald, S. M. Lavally, B. Yeap, B. Y. Marcus, K. Ebb, D. Yock, T. I. Tarbell, N. J. TI PROTON THERAPY FOR CHILDHOOD CNS EPENDYMOMA: CLINICAL OUTCOMES IN A COHORT OF 49 PATIENTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [MacDonald, S. M.; Lavally, B.; Yeap, B. Y.; Ebb, D.; Yock, T. I.; Tarbell, N. J.] Massachusetts Gen Hosp, Boston, MA USA. [Marcus, K.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II27 EP II27 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700124 ER PT J AU Manley, PE Pietrantonio, J Chi, SN Lee, M Robison, N Ullrich, NJ Zimmerman, M Chordas, C Goumnerova, L Kieran, MW AF Manley, P. E. Pietrantonio, J. Chi, S. N. Lee, M. Robison, N. Ullrich, N. J. Zimmerman, M. Chordas, C. Goumnerova, L. Kieran, M. W. TI A PHASE II PILOT STUDY OF THALIDOMIDE AND TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR PROGRESSIVE BRAIN TUMORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Manley, P. E.; Pietrantonio, J.; Chi, S. N.; Lee, M.; Robison, N.; Ullrich, N. J.; Zimmerman, M.; Chordas, C.; Goumnerova, L.; Kieran, M. W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Manley, P. E.; Chi, S. N.; Lee, M.; Robison, N.; Ullrich, N. J.; Goumnerova, L.; Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II89 EP II90 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700410 ER PT J AU Manley, PE McKendrick, K Chi, SN Kieran, MW Marcus, KJ Cohen, LE Goumnerova, L Lee, M Robison, N Pomeroy, S Ullrich, NJ AF Manley, P. E. McKendrick, K. Chi, S. N. Kieran, M. W. Marcus, K. J. Cohen, L. E. Goumnerova, L. Lee, M. Robison, N. Pomeroy, S. Ullrich, N. J. TI SLEEP DYSFUNCTION IN LONG TERM SURVIVORS OF CRANIOPHARYNGIOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Manley, P. E.; McKendrick, K.; Chi, S. N.; Kieran, M. W.; Marcus, K. J.; Goumnerova, L.; Lee, M.; Robison, N.; Pomeroy, S.; Ullrich, N. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Manley, P. E.; Chi, S. N.; Kieran, M. W.; Marcus, K. J.; Cohen, L. E.; Goumnerova, L.; Lee, M.; Robison, N.; Pomeroy, S.; Ullrich, N. J.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II39 EP II39 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700177 ER PT J AU Manley, PE Jones, I Chordas, C Zimmerman, M Kieran, MV Chi, SN Lee, M Robison, N Stratton, N Goumnerova, L Ullrich, NJ Marcus, KJ Cohen, LE AF Manley, P. E. Jones, I. Chordas, C. Zimmerman, M. Kieran, M. V. Chi, S. N. Lee, M. Robison, N. Stratton, N. Goumnerova, L. Ullrich, N. J. Marcus, K. J. Cohen, L. E. TI ABNORMAL TIMING OF PUBERTAL ONSET IN FEMALE SURVIVORS OF MEDULLOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Manley, P. E.; Chordas, C.; Zimmerman, M.; Kieran, M. V.; Chi, S. N.; Lee, M.; Robison, N.; Stratton, N.; Goumnerova, L.; Ullrich, N. J.; Marcus, K. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Manley, P. E.; Jones, I.; Kieran, M. V.; Chi, S. N.; Lee, M.; Robison, N.; Goumnerova, L.; Ullrich, N. J.; Marcus, K. J.; Cohen, L. E.] Childrens Hosp Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II31 EP II31 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700143 ER PT J AU Paugh, BS Jones, C Qu, C Liu, Z Adamowicz-Brice, M Zhang, J Bax, DA Coyle, B Barrow, J Hargrave, D Lowe, J Zhao, W Geyer, JR Chi, S da Silva, NS Baker, J Gajjar, A Grundy, R Ellison, DW Broniscer, A Baker, SJ AF Paugh, B. S. Jones, C. Qu, C. Liu, Z. Adamowicz-Brice, M. Zhang, J. Bax, D. A. Coyle, B. Barrow, J. Hargrave, D. Lowe, J. Zhao, W. Geyer, J. R. Chi, S. da Silva, N. Saba Baker, J. Gajjar, A. Grundy, R. Ellison, D. W. Broniscer, A. Baker, S. J. TI INTEGRATED MOLECULAR GENETIC PROFILING OF PEDIATRIC HIGH-GRADE GLIOMAS AND DIFFUSE INTRINSIC PONTINE GLIOMAS REVEALS KEY DIFFERENCES WITH ADULT GLIOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Paugh, B. S.; Qu, C.; Liu, Z.; Zhang, J.; Zhao, W.; Baker, J.; Gajjar, A.; Ellison, D. W.; Broniscer, A.; Baker, S. J.] St Jude Childrens Hosp, Memphis, TN 38105 USA. [Jones, C.; Bax, D. A.] Inst Canc Res, Surrey, England. [Adamowicz-Brice, M.; Coyle, B.; Barrow, J.; Lowe, J.; Grundy, R.] Univ Nottingham, Nottingham NG7 2RD, England. [Hargrave, D.] Royal Marsden NHS Fdn Trust, Surrey, England. [Geyer, J. R.] Univ Washington, Seattle, WA 98195 USA. [Chi, S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [da Silva, N. Saba] Univ Fed Sao Paulo, Sao Paulo, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II10 EP II10 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700052 ER PT J AU Peyrl, A Heinrich, M Azizi, AA Reismueller, B Kieran, MV Woehrer, A Prayer, D Slavc, I AF Peyrl, A. Heinrich, M. Azizi, A. A. Reismueller, B. Kieran, M. V. Woehrer, A. Prayer, D. Slavc, I. TI OBJECTIVE RESPONSE TO ANTIANGIOGENIC METRONOMIC THERAPY INCLUDING BEVACIZUMAB AND IMATINIB IN TWO PATIENTS WITH MULTIPLY RECURRENT SECRETING INTRACRANIAL NONGERMINOMATOUS GERM CELL TUMORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Peyrl, A.; Heinrich, M.; Azizi, A. A.; Reismueller, B.; Slavc, I.] Med Univ Vienna, Dept Pediat, Vienna, Austria. [Kieran, M. V.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kieran, M. V.] Childrens Hosp, Boston, MA 02115 USA. [Woehrer, A.] Med Univ Vienna, Inst Neurol, Vienna, Austria. [Prayer, D.] Med Univ Vienna, Dept Radiol, Vienna, Austria. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II107 EP II107 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700492 ER PT J AU Peyrl, A Azizi, AA Reismueller, B Kieran, NV Heinrich, M Czech, T Dieckmann, K Slave, I AF Peyrl, A. Azizi, A. A. Reismueller, B. Kieran, N. V. Heinrich, M. Czech, T. Dieckmann, K. Slave, I. TI ANTIANGIOGENIC METRONOMIC CHEMOTHERAPY FOR PATIENTS WITH RECURRENT EMBRYONAL AND EPENDYMAL BRAIN TUMORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Peyrl, A.; Azizi, A. A.; Reismueller, B.; Heinrich, M.; Slave, I.] Med Univ Vienna, Dept Pediat, Vienna, Austria. [Kieran, N. V.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Czech, T.] Med Univ Vienna, Dept Neurosurg, Vienna, Austria. [Dieckmann, K.] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II44 EP II44 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700201 ER PT J AU Robison, NJ Chi, SN Kieran, MW Manley, P Cohen, LE Goumnerova, L Smith, E Scott, M Ullrich, NJ AF Robison, N. J. Chi, S. N. Kieran, M. W. Manley, P. Cohen, L. E. Goumnerova, L. Smith, E. Scott, M. Ullrich, N. J. TI EVALUATION OF PATIENTS WITH PITUITARY STALK ENLARGEMENT SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Robison, N. J.; Chi, S. N.; Kieran, M. W.; Manley, P.; Goumnerova, L.; Smith, E.; Scott, M.; Ullrich, N. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Robison, N. J.; Chi, S. N.; Kieran, M. W.; Manley, P.] Childrens Hosp Boston, Dept Hematol Oncol, Boston, MA USA. [Cohen, L. E.] Childrens Hosp Boston, Div Endocrinol, Boston, MA USA. [Goumnerova, L.; Smith, E.; Scott, M.] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Ullrich, N. J.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II29 EP II29 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700135 ER PT J AU Shiers, D Sheehan, K Gregory, M AF Shiers, D. Sheehan, K. Gregory, M. TI NURSING CARE OF THE CHILD AFTER CRANIOTOMY FOR BRAIN TUMOR RESECTION IN A STEP-UP UNIT SETTING SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Shiers, D.; Sheehan, K.; Gregory, M.] Childrens Hosp, Boston, MA 02115 USA. [Shiers, D.; Sheehan, K.; Gregory, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II82 EP II82 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700372 ER PT J AU Turner, CD Chi, SN Chordas, CA Zimmerman, MA Ullrich, N Goumnerova, L Kieran, MW AF Turner, C. D. Chi, S. N. Chordas, C. A. Zimmerman, M. A. Ullrich, N. Goumnerova, L. Kieran, M. W. TI INTRATHECAL LIPOSOMAL CYTARABINE IN COMBINATION WITH SYSTEMIC CHEMOTHERAPY IN CHILDREN WITH DISSEMINATED LEPTOMENINGEAL MEDULLOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Turner, C. D.; Chi, S. N.; Chordas, C. A.; Zimmerman, M. A.; Ullrich, N.; Goumnerova, L.; Kieran, M. W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Turner, C. D.; Chi, S. N.; Ullrich, N.; Goumnerova, L.; Kieran, M. W.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II60 EP II60 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700272 ER PT J AU Ullrich, NJ Pomeroy, SL Manley, P Chordas, C Looddenkemper, T AF Ullrich, N. J. Pomeroy, S. L. Manley, P. Chordas, C. Looddenkemper, T. TI OUTCOME OF AND PREDICTORS OF SEIZURES IN LONG-TERM SURVIVORS OF PEDIATRIC BRAIN TUMORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Ullrich, N. J.; Pomeroy, S. L.; Looddenkemper, T.] Childrens Hosp Boston, Dept Neurol, Boston, MA USA. [Ullrich, N. J.; Pomeroy, S. L.; Manley, P.; Chordas, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Manley, P.] Childrens Hosp Boston, Dept Hematol & Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II114 EP II114 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700524 ER PT J AU Ullrich, NJ Zimmerman, M Smith, E Irons, MB Marcus, KJ Kieran, MW AF Ullrich, N. J. Zimmerman, M. Smith, E. Irons, M. B. Marcus, K. J. Kieran, M. W. TI RAPID PROGRESSION OF NEUROFIBROMATOSIS-ASSOCIATED MOYAMOYA AFTER BEVACIZUMAB FOR GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Ullrich, N. J.] Childrens Hosp Boston, Dept Neurol, Boston, MA USA. [Ullrich, N. J.; Zimmerman, M.; Marcus, K. J.; Kieran, M. W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Smith, E.] Childrens Hosp Boston, Dept Neurosurg, Boston, MA USA. [Irons, M. B.] Childrens Hosp Boston, Dept Genet, Boston, MA USA. [Marcus, K. J.] Childrens Hosp Boston, Dept Radiat Oncol, Boston, MA USA. [Kieran, M. W.] Childrens Hosp Boston, Dept Hematol Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II85 EP II85 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700390 ER PT J AU Ullrich, NJ McGowan, C Porter, A Miller, D Kieran, M Korf, B Irons, MB AF Ullrich, N. J. McGowan, C. Porter, A. Miller, D. Kieran, M. Korf, B. Irons, M. B. TI DOES SURVEILLANCE NEUROIMAGING CHANGE MANAGEMENT OF OPTIC PATHWAY GLIOMAS IN NEUROFIBROMATOSIS TYPE 1? SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Ullrich, N. J.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. [Ullrich, N. J.; Kieran, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [McGowan, C.; Miller, D.] Childrens Hosp, Div Genet, Boston, MA 02115 USA. [Kieran, M.] Childrens Hosp, Dept Hematol Oncol, Boston, MA 02115 USA. [Korf, B.] Univ Alabama, Dept Genet, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II22 EP II22 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700103 ER PT J AU Van Vuurden, DG Hulleman, E Van der Stoop, PM Gupta, R Wedekind, LE Badr, CE Meijer, DH Noske, DP Wurdinger, T Kaspers, GJL Cloos, J AF Van Vuurden, D. G. Hulleman, E. Van der Stoop, P. M. Gupta, R. Wedekind, L. E. Badr, C. E. Meijer, D. H. Noske, D. P. Wurdinger, T. Kaspers, G. J. L. Cloos, J. TI DEREGULATION AND POTENTIAL THERAPEUTIC TARGETING OF THE NF-kappa B PATHWAY IN HIGH-GRADE CHILDHOOD BRAIN TUMORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Van Vuurden, D. G.; Kaspers, G. J. L.; Cloos, J.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat, Amsterdam, Netherlands. [Van Vuurden, D. G.; Hulleman, E.; Van der Stoop, P. M.; Gupta, R.; Wedekind, L. E.; Badr, C. E.; Meijer, D. H.; Noske, D. P.; Wurdinger, T.] Vrije Univ Amsterdam, Med Ctr, Ctr Canc, Neuro Oncol Res Grp, Amsterdam, Netherlands. [Hulleman, E.; Van der Stoop, P. M.; Wedekind, L. E.; Noske, D. P.] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, Amsterdam, Netherlands. [Badr, C. E.; Wurdinger, T.] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA. [Badr, C. E.; Wurdinger, T.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Badr, C. E.; Wurdinger, T.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Cloos, J.] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II50 EP II50 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700226 ER PT J AU Vanan, I Redner, AS Quinlan, A Mittler, M Schneider, S Leibsch, NJ Atlas, MP AF Vanan, I. Redner, A. S. Quinlan, A. Mittler, M. Schneider, S. Leibsch, N. J. Atlas, M. P. TI MULTI-MODALITY MANAGEMENT OF CLIVAL CHORDOMAS - EXPERIENCE FROM A TERTIARY CARE CENTER SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Vanan, I.; Redner, A. S.; Quinlan, A.; Mittler, M.; Schneider, S.; Atlas, M. P.] Schneider Childrens Hosp, New Hyde Pk, NY USA. [Leibsch, N. J.] Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr, Massachusetts, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II125 EP II125 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700578 ER PT J AU Winkfield, KM Tsai, HK Yao, X Neuberg, D Larson, E Pomeroy, SL Ullrich, N Cohen, LE Kieran, MW Scott, RM Goumnerova, LL Marcus, KS AF Winkfield, K. M. Tsai, H. K. Yao, X. Neuberg, D. Larson, E. Pomeroy, S. L. Ullrich, N. Cohen, L. E. Kieran, M. W. Scott, R. M. Goumnerova, L. L. Marcus, K. S. TI LONG-TERM CLINICAL OUTCOMES FOLLOWING TREATMENT OF CHILDHOOD CRANIOPHARYNGIOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Winkfield, K. M.; Tsai, H. K.] Harvard Radiat Oncol Program, Boston, MA USA. [Winkfield, K. M.; Tsai, H. K.; Marcus, K. S.] Childrens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Yao, X.; Neuberg, D.] Dana Farber Canc Inst, Dept Biostatist & Computat Biol, Boston, MA 02115 USA. [Larson, E.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Pomeroy, S. L.; Ullrich, N.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. [Cohen, L. E.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Kieran, M. W.] Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA. [Kieran, M. W.] Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA. [Scott, R. M.; Goumnerova, L. L.] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II38 EP II38 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700174 ER PT J AU Zimmerman, M Marcus, KJ Cohen, LE Chordas, C Chi, SN Lee, M Manley, PE Robison, N Ullrich, NJ Goumnerova, L Kieran, MW AF Zimmerman, M. Marcus, K. J. Cohen, L. E. Chordas, C. Chi, S. N. Lee, M. Manley, P. E. Robison, N. Ullrich, N. J. Goumnerova, L. Kieran, M. W. TI ENDOCRINOLOGIC ASSESSMENT IN PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 14th International Symposium on Pediatric Neuro-Oncology CY JUN 20-23, 2010 CL Vienna, AUSTRIA C1 [Zimmerman, M.; Marcus, K. J.; Chordas, C.; Chi, S. N.; Lee, M.; Manley, P. E.; Robison, N.; Ullrich, N. J.; Goumnerova, L.; Kieran, M. W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Marcus, K. J.; Cohen, L. E.; Chi, S. N.; Lee, M.; Manley, P. E.; Robison, N.; Ullrich, N. J.; Goumnerova, L.; Kieran, M. W.] Childrens Hosp Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2010 VL 12 IS 6 BP II123 EP II123 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 611LW UT WOS:000278817700566 ER PT J AU Coma, M Sereno, L Da Rocha-Souto, B Scotton, TC Espana, J Sanchez, MB Rodriguez, M Agullo, J Guardia-Laguarta, C Garcia-Alloza, M Borrelli, LA Clarimon, J Lleo, A Bacskai, BJ Saura, CA Hyman, BT Gomez-Isla, T AF Coma, M. Sereno, L. Da Rocha-Souto, B. Scotton, T. C. Espana, J. Sanchez, M. B. Rodriguez, M. Agullo, J. Guardia-Laguarta, C. Garcia-Alloza, M. Borrelli, L. A. Clarimon, J. Lleo, A. Bacskai, B. J. Saura, C. A. Hyman, B. T. Gomez-Isla, T. TI Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Alzheimer's disease; Transgenic mice; Triflusal; Amyloid; Neuroinflammation; Cytokines; Cognition; CREB; c-fos; BDNF ID FACTOR-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LONG-TERM-MEMORY; ANIMAL-MODEL; 4-TRIFLUOROMETHYL DERIVATIVES; AMYLOID PLAQUES; IN-VIVO; 2-HYDROXY-4-TRIFLUOROMETHYLBENZOIC ACID; MICROGLIAL PHAGOCYTOSIS; SYNAPTIC PLASTICITY AB Inflammation has been associated with the two classic lesions in the Alzheimer's (AD) brain, amyloid deposits and neurofibrillary tangles. Recent data suggest that Triflusal, a compound with potent anti-inflammatory effects in the central nervous system in vivo, might delay the conversion from amnestic mild cognitive impairment to a fully established clinical picture of dementia. In the present study, we investigated the effect of Triflusal on brain A beta accumulation, neuroinflammation, axonal curvature and cognition in an AD transgenic mouse model (Tg2576). Triflusal treatment did not alter the total brain A beta accumulation but significantly reduced dense-cored plaque load and associated glial cell proliferation, proinflammatory cytokine levels and abnormal axonal curvature, and rescued cognitive deficits in Tg2576 mice. Behavioral benefit was found to involve increased expression of c-fos and BDNF, two of the genes regulated by CREB, as part of the signal transduction cascade underlying the molecular basis of long-term potentiation. These results add preclinical evidence of a potentially beneficial effect of Triflusal in AD. (C) 2010 Elsevier Inc. All rights reserved. C1 [Coma, M.; Sereno, L.; Da Rocha-Souto, B.; Sanchez, M. B.; Rodriguez, M.; Agullo, J.; Guardia-Laguarta, C.; Clarimon, J.; Lleo, A.; Gomez-Isla, T.] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, Barcelona 08025, Spain. [Coma, M.; Da Rocha-Souto, B.; Scotton, T. C.; Garcia-Alloza, M.; Borrelli, L. A.; Bacskai, B. J.; Hyman, B. T.; Gomez-Isla, T.] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. [Espana, J.; Saura, C. A.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Inst Neurociencies, Barcelona 08025, Spain. RP Gomez-Isla, T (reprint author), Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, C St Antoni Ma Claret 167, Barcelona 08025, Spain. EM mgomezi@santpau.es RI Saura, Carlos/D-2727-2011; OI Saura, Carlos/0000-0003-3692-5657; Clarimon, Jordi/0000-0002-6824-6942; Guardia-Laguarta, Cristina/0000-0003-0811-9068; Garcia-Alloza, Monica/0000-0003-1610-4114 FU FIS [PI041887]; CIBERNED; NIH [AG020570]; Marato [072610] FX This project was funded in part by FIS PI041887, CIBERNED, NIH AG020570 and Marato 072610. NR 58 TC 21 Z9 21 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD JUN PY 2010 VL 38 IS 3 SI SI BP 482 EP 491 DI 10.1016/j.nbd.2010.01.019 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 595XU UT WOS:000277648200019 PM 20149872 ER PT J AU Klein, JC Rushworth, MFS Behrens, TEJ Mackay, CE de Crespigny, AJ D'Arceuil, H Johansen-Berg, H AF Klein, Johannes C. Rushworth, Matthew F. S. Behrens, Timothy E. J. Mackay, Clare E. de Crespigny, Alex J. D'Arceuil, Helen Johansen-Berg, Heidi TI Topography of connections between human prefrontal cortex and mediodorsal thalamus studied with diffusion tractography SO NEUROIMAGE LA English DT Article DE Anatomy; DTI; Human; Macaque; Thalamus ID COMPARATIVE CYTOARCHITECTONIC ANALYSIS; MACAQUE MONKEYS; CORTICAL PROJECTIONS; FRONTAL-CORTEX; ORBITOFRONTAL CORTEX; SOCIAL-BEHAVIOR; BRAIN IMAGES; FUNCTIONAL SPECIALIZATION; DIFFERENTIAL CONNECTIONS; LONGITUDINAL COLUMNS AB Studies in monkeys show clear anatomical and functional distinctions among networks connecting with subregions within the prefrontal cortex. Three such networks are centered on lateral orbitofrontal cortex, medial frontal and cingulate cortex, and lateral prefrontal cortex and all have been identified with distinct cognitive roles. Although these areas differ in a number of their cortical connections, some of the first anatomical evidence for these networks came from tracer studies demonstrating their distinct patterns of connectivity with the mediodorsal (MD) nucleus of the thalamus. Here, we present evidence for a similar topography of MD thalamus prefrontal connections, using non-invasive imaging and diffusion tractography (DWI-DT) in human and macaque. DWI-DT suggested that there was a high probability of interconnection between medial MD and lateral orbitofrontal cortex, between caudodorsal MD and medial frontal/cingulate cortex, and between lateral MD and lateral prefrontal cortex, in both species. Within the lateral prefrontal cortex a dorsolateral region (the principal sulcus in the macaque and middle frontal gyrus in the human) was found to have a high probability of interconnection with the MD region between the regions with a high probability of interconnection with other parts of the lateral prefrontal cortex and with the lateral orbitofrontal cortex. In addition to suggesting that the thalamic connectivity in the macaque is a good guide to human prefrontal cortex, and therefore that there are likely to be similarities in the cognitive roles played by the prefrontal areas in both species, the present results are also the first to provide insight into the topography of projections of an individual thalamic nucleus in the human brain. (C) 2010 Elsevier Inc. All rights reserved. C1 [Klein, Johannes C.; Rushworth, Matthew F. S.; Behrens, Timothy E. J.; Mackay, Clare E.; Johansen-Berg, Heidi] Univ Oxford, Ctr Funct MRI Brain, Oxford OX3 9DU, England. [Klein, Johannes C.] Goethe Univ Frankfurt, Dept Neurol, Frankfurt, Germany. [Rushworth, Matthew F. S.; Behrens, Timothy E. J.] Univ Oxford, Dept Expt Psychol, Oxford OX3 9DU, England. [Mackay, Clare E.] Univ Oxford, Dept Psychiat, Oxford OX3 9DU, England. [de Crespigny, Alex J.; D'Arceuil, Helen] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Johansen-Berg, H (reprint author), Univ Oxford, FMRIB Ctr, Oxford OX3 9DU, England. EM heidi@fmrib.ox.ac.uk OI Johansen-Berg, Heidi/0000-0002-4134-9730; Mackay, Clare/0000-0001-6111-8318 FU Biotechnology and Biological Sciences Research Council UK; Wellcome Trust; Medical Research Council UK; A. A. Martinos Center (NIH) [P41RR14075, 1S10RR016811-01] FX This work was supported by the Biotechnology and Biological Sciences Research Council UK (to JK, HJB, and TEJB). We are grateful for personal support from the Wellcome Trust (to HJB) and Medical Research Council UK (to TEJB, MFSR, and FMRIB core grant) and the A. A. Martinos Center (NIH: P41RR14075, 1S10RR016811-01). NR 80 TC 76 Z9 76 U1 1 U2 18 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD JUN PY 2010 VL 51 IS 2 BP 555 EP 564 DI 10.1016/j.neuroimage.2010.02.062 PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 589IT UT WOS:000277141200006 PM 20206702 ER PT J AU Wang, L LaViolette, P O'Keefe, K Putcha, D Bakkour, A Van Dijk, KRA Pihlajamaki, M Dickerson, BC Sperling, RA AF Wang, Liang LaViolette, Peter O'Keefe, Kelly Putcha, Deepti Bakkour, Akram Van Dijk, Koene R. A. Pihlajamaeki, Maija Dickerson, Bradford C. Sperling, Reisa A. TI Intrinsic connectivity between the hippocampus and posteromedial cortex predicts memory performance in cognitively intact older individuals SO NEUROIMAGE LA English DT Article ID MEDIAL TEMPORAL-LOBE; RESTING HUMAN BRAIN; FUNCTIONAL CONNECTIVITY; ALZHEIMERS-DISEASE; DEFAULT-MODE; PARIETAL DEACTIVATION; ACTIVITY FLUCTUATIONS; MOTOR CORTEX; NETWORK; MRI AB Coherent fluctuations of spontaneous brain activity are present in distinct functional-anatomic brain systems during undirected wakefulness. However, the behavioral significance of this spontaneous activity has only begun to be investigated. Our previous studies have demonstrated that successful memory formation requires coordinated neural activity in a distributed memory network including the hippocampus and posteromedial cortices, specifically the precuneus and posterior cingulate (PPC), thought to be integral nodes of the default network. In this study, we examined whether intrinsic connectivity during the resting state between the hippocampus and PPC can predict individual differences in the performance of an associative memory task among cognitively intact older individuals. The intrinsic connectivity, between regions within the hippocampus and PPC that were maximally engaged during a subsequent memory fMRI task, was measured during a period of rest prior to the performance of the memory paradigm. Stronger connectivity between the hippocampal and posteromedial regions during rest predicted better performance on the memory task. Furthermore, hippocampal-PPC intrinsic connectivity was also significantly correlated with episodic memory measures on neuropsychological tests, but not with performance in non-memory domains. Whole-brain exploratory analyses further confirmed the spatial specificity of the relationship between hippocampal-default network posteromedial cortical connectivity and memory performance in older subjects. Our findings provide support for the hypothesis that one of the functions of this large-scale brain network is to subserve episodic memory processes. Research is ongoing to determine if impaired connectivity between these regions may serve as a predictor of memory decline related to early Alzheimer's disease. (C) 2010 Elsevier Inc. All rights reserved. C1 [O'Keefe, Kelly; Putcha, Deepti; Pihlajamaeki, Maija; Sperling, Reisa A.] Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Dept Neurol, Boston, MA 02115 USA. [Wang, Liang; LaViolette, Peter] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. [Wang, Liang; LaViolette, Peter; Bakkour, Akram; Van Dijk, Koene R. A.; Dickerson, Bradford C.; Sperling, Reisa A.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Bakkour, Akram; Dickerson, Bradford C.; Sperling, Reisa A.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. [Van Dijk, Koene R. A.; Dickerson, Bradford C.; Sperling, Reisa A.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Sperling, RA (reprint author), Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Dept Neurol, 221 Longwood Ave, Boston, MA 02115 USA. EM reisa@rics.bwh.harvard.edu RI Wang, Liang/E-8652-2011; Van Dijk, Koene/G-3317-2012; OI Van Dijk, Koene/0000-0001-6137-4282; Bakkour, Akram/0000-0002-6070-4945 FU NIA NIH HHS [K24 AG035007, P50 AG005134, P50 AG005134-268381, R01 AG027435, R01 AG027435-04, R01 AG027435-05, R01 AG029411] NR 48 TC 97 Z9 98 U1 1 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD JUN PY 2010 VL 51 IS 2 BP 910 EP 917 DI 10.1016/j.neuroimage.2010.02.046 PG 8 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 589IT UT WOS:000277141200042 PM 20188183 ER PT J AU De Grauwe, S Swain, A Holcomb, PJ Ditman, T Kuperberg, GR AF De Grauwe, Sophie Swain, Abigail Holcomb, Phillip J. Ditman, Tali Kuperberg, Gina R. TI Electrophysiological insights into the processing of nominal metaphors SO NEUROPSYCHOLOGIA LA English DT Article DE Language; Semantic; Metaphor; ERP; N400; LPC; P600 ID EVENT-RELATED POTENTIALS; BRAIN POTENTIALS; RIGHT-HEMISPHERE; TIME-COURSE; LANGUAGE COMPREHENSION; SENTENCE COMPREHENSION; AMBIGUOUS WORDS; THEMATIC RELATIONSHIPS; INDIVIDUAL-DIFFERENCES; SYNTACTIC ANOMALIES AB We used event-related potentials (ERPs) to examine the time-course of processing metaphorical and literal sentences in the brain. ERPs were measured to sentence-final (Experiment 1) and mid-sentence (Experiment 2) critical words (CWs) as participants read and made plausibility judgments about familiar nominal metaphors ("A is a B") as well as literal and semantically anomalous sentences of the same form. Unlike the anomalous words, which evoked a robust N400 effect (on the CW in experiments 1 and 2 as well as on the sentence-final word in experiment 2), CWs in the metaphorical, relative to the literal, sentences only evoked an early, localized N400 effect that was over by 400 ms after CW onset, suggesting that, by this time, their metaphorical meaning had been accessed. CWs in the metaphorical sentences also evoked a significantly larger LPC (Late Positive Component) than in the literal sentences. We suggest that this LPC reflected additional analysis that resolved a conflict between the implausibility of the literal sentence interpretation and the match between the metaphorical meaning of the CW, the context and stored information within semantic memory, resulting from early access to both literal and figurative meanings of the CWs. (C) 2010 Elsevier Ltd. All rights reserved. C1 [De Grauwe, Sophie] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit, NL-6500 HE Nijmegen, Netherlands. [De Grauwe, Sophie; Swain, Abigail; Holcomb, Phillip J.; Ditman, Tali; Kuperberg, Gina R.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA. [Ditman, Tali; Kuperberg, Gina R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Ditman, Tali; Kuperberg, Gina R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [De Grauwe, Sophie] Katholieke Univ Leuven, Lab Cognit Neurol, Louvain, Belgium. [De Grauwe, Sophie] Univ Groningen, Groningen, Netherlands. RP De Grauwe, S (reprint author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit, POB 9104, NL-6500 HE Nijmegen, Netherlands. EM s.degrauwe@donders.ru.nl RI De Grauwe, Sophie/D-9450-2012 FU NIMH [R01 MH071635]; NARSAD (with the Sidney Baer Trust); NICHD [HD25889, HD043251]; Marco Polo grant; Groninger Universiteitsfonds grant FX We are very grateful to Laurie Stowe, Martin Paczynski, Courtney Brown, and Laura Davis for their help with design and to Mante Nieuwland and Herman Kolk for their helpful comments on the manuscript. This research was supported by NIMH (R01 MH071635), NARSAD (with the Sidney Baer Trust) to GRK, NICHD (HD25889 and HD043251) to PJH and a Marco Polo grant and a Groninger Universiteitsfonds grant to SDG. NR 92 TC 34 Z9 34 U1 2 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD JUN PY 2010 VL 48 IS 7 BP 1965 EP 1984 DI 10.1016/j.neuropsychologia.2010.03.017 PG 20 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 613ZD UT WOS:000279023100011 PM 20307557 ER PT J AU Filley, CM AF Filley, Christopher M. TI White Matter: Organization and Functional Relevance SO NEUROPSYCHOLOGY REVIEW LA English DT Review DE White matter; Geschwind; Disconnection; Distributed neural networks; White matter dementia ID CENTRAL-NERVOUS-SYSTEM; AIDS DEMENTIA COMPLEX; NORMAL-PRESSURE HYDROCEPHALUS; CHRONIC TOLUENE ABUSE; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; BINSWANGERS-DISEASE; VASCULAR DEMENTIA; DISCONNECTION SYNDROMES; LUPUS-ERYTHEMATOSUS AB Norman Geschwind's landmark paper in 1965, "Disconnexion Syndromes in Animals and Man," inspired a generation of investigators to consider the effects of focal brain lesions disrupting higher brain functions. Although Geschwind viewed disconnection as resulting from either white or gray matter lesions, his signature article drew upon the insights of 19th century neurologists and firmly established white matter within the vocabulary of behavioral neurology, neuropsychology, and cognitive neuroscience. This influence, and the advent of sensitive neuroimaging techniques later in the 20th century, led to white matter gradually gaining more attention as an essential component of distributed neural networks subserving cognition and emotion. Today, whereas focal white matter lesions remain central to the pathogenesis of classic neurobehavioral syndromes, diffuse white matter involvement is regarded as increasingly relevant to a wide variety of dementia syndromes and a host of neuropsychiatric disorders as well. In parallel, better understanding of the neurobiology of brain white matter at all ages has been achieved. While much remains to be explored, a general conceptual formulation is that white matter supports information transfer to complement the information processing carried out by gray matter. As knowledge of the organization and functional relevance of white matter continues to advance, improved understanding of the role of myelinated tracts in higher function can be anticipated, and with it many clinical benefits. C1 [Filley, Christopher M.] Behav Neurol Sect, Aurora, CO 80045 USA. [Filley, Christopher M.] Univ Colorado, Sch Med, Behav Neurol Sect, Denver, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Filley, CM (reprint author), Behav Neurol Sect, 12631 E 17th Ave,MS B185,POB 6511, Aurora, CO 80045 USA. EM christopher.filley@ucdenver.edu FU National Institutes of Health [R01 AR049152-02S1, R01 AR049152-01A2] FX Preparation of this article was supported by National Institutes of Health research grants R01 AR049152-02S1 and R01 AR049152-01A2. NR 119 TC 29 Z9 30 U1 0 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1040-7308 J9 NEUROPSYCHOL REV JI Neuropsychol. Rev. PD JUN PY 2010 VL 20 IS 2 SI SI BP 158 EP 173 DI 10.1007/s11065-010-9127-9 PG 16 WC Psychology, Clinical; Neurosciences SC Psychology; Neurosciences & Neurology GA 607AK UT WOS:000278470400005 PM 20352350 ER PT J AU Eygenov, OV AF Eygenov, Olee V. TI Soluble guanylate cyclase as a therapeutic target in pulmonary hypertension SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY LA English DT Meeting Abstract CT 6th Int Conf on Biol, Chemistry, and Therapeutic Applications of Nitric Oxide/2nd Int Conf NO and Cancer/10th Annual Meeting of the Nitric-Oxide-Soc-Japan CY JUN 14-18, 2010 CL Kyoto, JAPAN SP Nitr Oxide Soc Japan C1 [Eygenov, Olee V.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1089-8603 J9 NITRIC OXIDE-BIOL CH JI Nitric Oxide-Biol. Chem. PD JUN PY 2010 VL 22 SU S BP S32 EP S32 DI 10.1016/j.niox.2010.05.091 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 606PZ UT WOS:000278440700088 ER PT J AU Ichinose, F AF Ichinose, Fumito TI Surviving cardiac arrest with hydrogen sulfide SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY LA English DT Meeting Abstract CT 6th Int Conf on Biol, Chemistry, and Therapeutic Applications of Nitric Oxide/2nd Int Conf NO and Cancer/10th Annual Meeting of the Nitric-Oxide-Soc-Japan CY JUN 14-18, 2010 CL Kyoto, JAPAN SP Nitr Oxide Soc Japan C1 [Ichinose, Fumito] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1089-8603 J9 NITRIC OXIDE-BIOL CH JI Nitric Oxide-Biol. Chem. PD JUN PY 2010 VL 22 SU S BP S28 EP S28 DI 10.1016/j.niox.2010.05.078 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 606PZ UT WOS:000278440700075 ER PT J AU Rane, S Nair, G Duong, TQ AF Rane, Swati Nair, Govind Duong, Timothy Q. TI DTI at long diffusion time improves fiber tracking SO NMR IN BIOMEDICINE LA English DT Article DE diffusion tensor imaging; STEAM sequence; rhesus macaques; cross-terms; formalin fixation; fractional anisotropy; white matter tracking ID HUMAN BRAIN; SPIN-ECHO; SELF-DIFFUSION; TENSOR; MRI; TISSUE; WATER; NMR; COEFFICIENT; PRINCIPLES AB While diffusion-tensor-imaging tractography provides remarkable in vivo anatomical connectivity of the central nervous system, the majority of DTI studies to date are predominantly limited to tracking large white-matter fibers. This study investigated DTI tractography using long diffusion time (t(diff)) to improve tracking of thinner fibers in fixed rhesus monkey brains. Stimulated Echo Acquisition Mode (STEAM) sequence on a 3T Siemens TRIO was modified to include a diffusion module. DTI was acquired using STEAM with t(diff) of 48 and 192 ms with matched signal-to-noise ratios (SNR). Comparisons were also made with the conventional double-spin echo (DSE) at a short t(diff) of 45 ms. Not only did the fractional anisotropy increase significantly with the use of long diffusion time, but directional entropy measures indicated that there was an increased coherence amongst neighboring tensors. Further, the magnitude of the major eigenvector was larger at the t(diff) = 192 ms as compared to the short t(diff). Probabilistic connectivity maps at long t(diff) showed larger areas of connectivity with the use of long diffusion time, which traversed deeper into areas of low anisotropy. With tractography, it was found that the length of the fibers, increased by almost 10% in the callosal fibers that branch into the paracentral gyrus, the precentral gyrus and the post central gyrus. A similar increase of about 20% was observed in the fibers of the internal capsule. These findings offer encouraging data that DTI at long diffusion time could improve tract tracing of small fibers in areas of low fractional anisotropy (FA), such as at the interfaces of white matter and grey matter. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Radiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Physiol, San Antonio, TX 78229 USA. [Rane, Swati] Georgia Inst Technol, Atlanta, GA 30332 USA. [Rane, Swati; Nair, Govind] Emory Univ, Atlanta, GA 30322 USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008 FU NIH [R01NS45879]; Center for Behavioral Neuroscience, NSF [IBN-9876754] FX Contract/grant sponsor: NIH; contract/grant number: R01NS45879.; Contract/grant sponsor: The Center for Behavioral Neuroscience; contract/grant number: NSF, IBN-9876754. NR 38 TC 8 Z9 8 U1 0 U2 7 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0952-3480 J9 NMR BIOMED JI NMR Biomed. PD JUN PY 2010 VL 23 IS 5 BP 459 EP 465 DI 10.1002/nbm.1482 PG 7 WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy GA 620UQ UT WOS:000279526300003 PM 20175137 ER PT J AU Goren, A Kim, E Amit, M Vaknin, K Kfir, N Ram, O Ast, G AF Goren, Amir Kim, Eddo Amit, Maayan Vaknin, Keren Kfir, Nir Ram, Oren Ast, Gil TI Overlapping splicing regulatory motifs-combinatorial effects on splicing SO NUCLEIC ACIDS RESEARCH LA English DT Article ID BINDING-SITES; TRANSCRIPTION FACTORS; PROTEIN-COMPOSITION; SEQUENCE MOTIFS; GENE PROMOTER; HUMAN GENOME; ENHANCERS; IDENTIFICATION; RECOGNITION; SELECTION AB Regulation of splicing in eukaryotes occurs through the coordinated action of multiple splicing factors. Exons and introns contain numerous putative binding sites for splicing regulatory proteins. Regulation of splicing is presumably achieved by the combinatorial output of the binding of splicing factors to the corresponding binding sites. Although putative regulatory sites often overlap, no extensive study has examined whether overlapping regulatory sequences provide yet another dimension to splicing regulation. Here we analyzed experimentally-identified splicing regulatory sequences using a computational method based on the natural distribution of nucleotides and splicing regulatory sequences. We uncovered positive and negative interplay between overlapping regulatory sequences. Examination of these overlapping motifs revealed a unique spatial distribution, especially near splice donor sites of exons with weak splice donor sites. The positively selected overlapping splicing regulatory motifs were highly conserved among different species, implying functionality. Overall, these results suggest that overlap of two splicing regulatory binding sites is an evolutionary conserved widespread mechanism of splicing regulation. Finally, over-abundant motif overlaps were experimentally tested in a reporting minigene revealing that overlaps may facilitate a mode of splicing that did not occur in the presence of only one of the two regulatory sequences that comprise it. C1 [Goren, Amir; Kim, Eddo; Amit, Maayan; Vaknin, Keren; Kfir, Nir; Ram, Oren; Ast, Gil] Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel. [Ram, Oren] Massachusetts Gen Hosp, Pathol & Canc Ctr, Boston Harvard Med Sch, Boston Broad Inst, Cambridge, MA USA. RP Ast, G (reprint author), Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel. EM gilast@post.tau.ac.il FU Israel Science Foundation (ISF) [61/09]; Joint Germany-Israeli Research Program [ca-139]; Deutsche-Israel Project (DIP) [MI-1317]; European Alternative Splicing Network (EURASNET); Israel Academy of Sciences and Humanities FX FUNDING; Israel Science Foundation (ISF 61/09), Joint Germany-Israeli Research Program (ca-139), Deutsche-Israel Project (DIP MI-1317) and European Alternative Splicing Network (EURASNET). AG is supported by the Adams Fellowship Program of the Israel Academy of Sciences and Humanities and EK is a fellow of the Clore Scholars Program. Funding for open access charge: EURASNET. NR 45 TC 8 Z9 8 U1 1 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD JUN PY 2010 VL 38 IS 10 BP 3318 EP 3327 DI 10.1093/nar/gkq005 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 606QQ UT WOS:000278442600022 PM 20110253 ER PT J AU Henderson, GC Nadeau, D Horton, ES Nair, KS AF Henderson, Gregory C. Nadeau, Daniel Horton, Edward S. Nair, K. Sreekumaran TI Effects of Adiposity and 30 Days of Caloric Restriction Upon Protein Metabolism in Moderately vs. Severely Obese Women SO OBESITY LA English DT Article ID HEALTHY-HUMAN SUBJECTS; WHOLE-BODY; LEUCINE TURNOVER; WEIGHT-LOSS; INSULIN-SECRETION; AMINO-ACIDS; GLUCOSE; HUMANS; OXIDATION; KINETICS AB Protein metabolism adapts during caloric restriction (CR) to minimize protein loss, and it is unclear whether greater fat stores favorably affect this response. We sought to determine whether protein metabolism is related to degree of obesity and whether the response to CR is impacted by pre-CR adiposity level. Whole body protein metabolism was studied in 12 obese women over a wide range of BMI (30-53 kg/m(2)) as inpatients using [1-(13)C] leucine as a tracer following 5 days of a weight-maintaining diet and then after 30 days of CR (1,400 kcal deficit with maintained protein intake). When expressed as total rates, per body weight (BW) or per fat-free mass (FFM), leucine rate of appearance (Ra), and nonoxidative leucine disposal (NOLD) were significantly higher in the individuals with a greater degree of obesity (P < 0.05). Leucine oxidation (Rox) was also higher in more highly obese women when expressed as a total rate (P < 0.05) but not if expressed per BW or FFM. CR reduced BW, FFM, and fat mass (P < 0.001), and declines were relatively similar between individuals. CR reduced Ra (P < 0.001), NOLD (P < 0.01), and Rox (P < 0.05), and the relative decline was not affected by differences in fat mass. CR-induced declines were significant even when Ra and NOLD were normalized to BW or FFM. We conclude that fat mass, like FFM, is a key determinant of protein turnover. However, during CR, higher fat mass does not favorably alter the response of protein metabolism and does not mitigate the loss of FFM. C1 [Henderson, Gregory C.; Nair, K. Sreekumaran] Mayo Clin, Div Endocrinol, Rochester, MN 55905 USA. [Nadeau, Daniel] Univ Vermont, Dept Med, Burlington, VT USA. [Horton, Edward S.] Harvard Univ, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Nair, KS (reprint author), Mayo Clin, Div Endocrinol, Rochester, MN 55905 USA. EM nair.sree@mayo.edu RI Biguzzi, Felipe/E-4724-2015 FU Univite Corporation; NIH [RO1 DK412973, UL1 RR024150-01, GCRC RR109, T32 DK07352] FX We thank the study participants for their time and compliance with the protocol. We additionally thank Dr Basu, and members of the University of Vermont GCRC nursing and dietetic staff. This work was supported by funding from Univite Corporation, NIH grant RO1 DK412973 to K.S.N., NIH grants UL1 RR024150-01 and GCRC RR109, and G.C.H. was supported by NIH grant T32 DK07352. NR 42 TC 5 Z9 5 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD JUN PY 2010 VL 18 IS 6 BP 1135 EP 1142 DI 10.1038/oby.2009.505 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 600RQ UT WOS:000278005300012 PM 20134416 ER PT J AU Barth, WH AF Barth, William H., Jr. TI Familial Spontaneous Preterm Birth Further Evidence of a Complex Genetic Disease SO OBSTETRICS AND GYNECOLOGY LA English DT Editorial Material ID GENOMEWIDE ASSOCIATION; RISK C1 [Barth, William H., Jr.] Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02114 USA. [Barth, William H., Jr.] Harvard Univ, Sch Med, Boston, MA USA. RP Barth, WH (reprint author), Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02114 USA. EM wbarthjr@partners.org NR 12 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JUN PY 2010 VL 115 IS 6 BP 1114 EP 1115 DI 10.1097/AOG.0b013e3181e15e1f PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 603VD UT WOS:000278235300002 PM 20502278 ER PT J AU Wylie, BJ Gilbert, S Landon, MB Spong, CY Rouse, DJ Leveno, KJ Varner, MW Caritis, SN Meis, PJ Wapner, RJ Sorokin, Y Miodovnik, M O'Sullivan, MJ Sibai, BM Langer, O AF Wylie, Blair J. Gilbert, Sharon Landon, Mark B. Spong, Catherine Y. Rouse, Dwight J. Leveno, Kenneth J. Varner, Michael W. Caritis, Steve N. Meis, Paul J. Wapner, Ronald J. Sorokin, Yoram Miodovnik, Menachem O'Sullivan, Mary J. Sibai, Baha M. Langer, Oded CA Eunice Kennedy Shriver NICHD TI Comparison of Transverse and Vertical Skin Incision for Emergency Cesarean Delivery SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID OUTCOMES AB OBJECTIVE: To compare incision-to-delivery intervals and related maternal and neonatal outcomes by skin incision in primary and repeat emergent cesarean deliveries. METHODS: From 1999 to 2000, a prospective cohort study of all cesarean deliveries was conducted at 13 hospitals comprising the Eunice Kennedy Shriver National Institute of Child Health and Human Development's Maternal-Fetal Medicine Units Network. This secondary analysis was limited to emergent procedures, defined as those performed for cord prolapse, abruption, placenta previa with hemorrhage, nonreassuring fetal heart rate tracing, or uterine rupture. Incision-to-delivery intervals, incision-to-closure intervals, and maternal outcomes were compared by skin-incision type (transverse compared with vertical) after stratifying for primary compared with repeat singleton cesarean delivery. Neonatal outcomes were compared by skin-incision type. RESULTS: Of the 37,112 live singleton cesarean deliveries, 3,525 (9.5%) were performed for emergent indications of which 2,498 (70.9%) were performed by transverse and the remaining 1,027 (29.1%) by vertical incision. Vertical skin incision shortened median incision-to-delivery intervals by 1 minute (3 compared with 4 minutes, P<.001) in primary and 2 minutes (3 compared with 5 minutes, P<.001) in repeat cesarean deliveries. Total median operative time was longer after vertical skin incision by 3 minutes in primary (46 compared with 43 minutes, P<.001) and 4 minutes in repeat cesarean deliveries (56 compared with 52 minutes, P<.001). Neonates delivered through a vertical incision were more likely to have an umbilical artery pH of less than 7.0 (10% compared with 7%, P=.02), to be intubated in the delivery room (17% compared with 13%, P=.001), or to be diagnosed with hypoxic ischemic encephalopathy (3% compared with 1%, P<.001). CONCLUSION: In emergency cesarean deliveries, neonatal delivery occurred more quickly after a vertical skin incision, but this was not associated with improved neonatal outcomes. (Obstet Gynecol 2010; 115: 1134-40) C1 Columbia Univ, Dept Obstet & Gynecol, New York, NY USA. Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA. Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA. Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA. Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA. Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA. Wake Forest Univ Hlth Sci, Dept Obstet & Gynecol, Winston Salem, NC USA. Thomas Jefferson Univ, Dept Obstet & Gynecol, Philadelphia, PA 19107 USA. Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA. Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH USA. Univ Miami, Dept Obstet & Gynecol, Miami, FL USA. Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA. Univ Texas San Antonio, Dept Obstet & Gynecol, San Antonio, TX USA. George Washington Univ, Dept Obstet & Gynecol, Ctr Biostat, Washington, DC USA. Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. RP Wylie, BJ (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA. EM bwylie@partners.org RI Varner, Michael/K-9890-2013 OI caritis, steve/0000-0002-2169-0712; Varner, Michael/0000-0001-9455-3973 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [HD21410, HD21414, HD27860, HD27861, HD27869, HD27905, HD27915, HD27917, HD34116, HD34122, HD34136, HD34208, HD34210, HD36801]; National Institute of Child Health and Human Development (NICHD); NICHD Maternal-Fetal Medicine Units Network; NIH-NICHD [HD-27905-05]; National Heart, Lung and Blood Institute; National Institutes of Health FX Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD21410, HD21414, HD27860, HD27861, HD27869, HD27905, HD27915, HD27917, HD34116, HD34122, HD34136, HD34208, HD34210, HD36801).; Dr. Landon received honoraria for doing grand rounds at various institutions and travel and accommodation expenses covered or reimbursed for grand rounds. Dr. Leveno received royalties for the Williams Obstetrics textbook. Dr. Varner received grants or grants pending from the National Institute of Child Health and Human Development (NICHD) for research conducted with funding from the NICHD Maternal-Fetal Medicine Units Network. Dr. Miodovnik received a grant, NIH-NICHD HD-27905-05 (until 2003). Dr. O'Sullivan was reimbursed for travel expenses related to this study by the NICHD; participated in the data monitoring committee after no longer a member of the study group and the compensation for travel and hotel was reimbursed by the NICHD; received a grant or has grants pending from the National Heart, Lung and Blood Institute for The Women's Health Initiative (WHI; The National Children's Study, sponsored by the National Institutes of Health); travel and accommodation expenses were reimbursed by NHLBI for the WHI annual meeting. The other authors did not report any potential conflicts of interest. NR 9 TC 12 Z9 12 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JUN PY 2010 VL 115 IS 6 BP 1134 EP 1140 DI 10.1097/AOG.0b013e3181df937f PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 603VD UT WOS:000278235300006 PM 20502282 ER PT J AU Delaney, S Shaffer, BL Cheng, YW Vargas, J Sparks, TN Paul, K Caughey, AB AF Delaney, Shani Shaffer, Brian L. Cheng, Yvonne W. Vargas, Juan Sparks, Teresa N. Paul, Kathleen Caughey, Aaron B. TI Labor Induction With a Foley Balloon Inflated to 30 mL Compared With 60 mL A Randomized Controlled Trial SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID ORAL MISOPROSTOL; CATHETER; GEL; DINOPROSTONE; OXYTOCIN; 30-ML; RISK AB OBJECTIVE: To compare 30-mL and 60-mL Foley balloon inflation for labor induction and the effect on length of labor and mode of delivery. METHODS: Women with term, vertex, singleton pregnancies (n = 192) and a Bishop score less than 5 were assigned randomly to receive a transcervical Foley balloon inflated to either 30 mL or 60 mL. Exclusion criteria were painful, regular contractions on admission, ruptured membranes, low-lying placenta, or prior hysterotomy. Randomization was stratified by parity, and health care providers were blinded to Foley balloon size. Primary outcome was delivery within 24 hours of Foley balloon placement. Secondary outcomes included delivery within 12 hours, time from Foley balloon placement to expulsion, cervical dilation after Foley balloon expulsion, maximum oxytocin dose, method of delivery, wchorioamnionitis, meconium, cervical laceration, abruption, 5-minute Apgar score, and umbilical cord gases. RESULTS: A higher proportion of women randomly assigned to the 60-mL Foley balloon achieved delivery within 12 hours of placement compared with the 30-mL Foley balloon group (26% compared with 14%, P=.04). This difference was more pronounced among nulliparous women. There was no difference in median time interval to delivery or proportion of women who achieved delivery within 24 hours. Median cervical dilation after Foley balloon expulsion was higher in the 60-mL Foley balloon group (4 cm compared with 3 cm, P<.01). There were no differences in the frequencies of cesarean delivery, maternal morbidity, or neonatal outcomes. CONCLUSION: Labor induction using Foley balloons inflated to 60 mL was more likely to achieve delivery within 12 hours compared with 30-mL inflation. There were no differences in delivery within 24 hours, cesarean delivery, labor complications, or neonatal outcomes. C1 Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr Clin & Policy Perinatal Res, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Boston, MA 02114 USA. RP Delaney, S (reprint author), 1959 NE Pacific St,Box 356460, Seattle, WA 98195 USA. EM delaneys@u.washington.edu FU Robert Wood Johnson Physician Faculty Scholar [RWJF-61535] FX Dr. Caughey was funded as a Robert Wood Johnson Physician Faculty Scholar (RWJF-61535). The other authors did not report any potential conflicts of interest. NR 19 TC 32 Z9 35 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JUN PY 2010 VL 115 IS 6 BP 1239 EP 1245 DI 10.1097/AOG.0b013e3181dec6d0 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 603VD UT WOS:000278235300020 PM 20502296 ER PT J AU Panda, B Panda, A Riley, LE AF Panda, Britta Panda, Alexander Riley, Laura E. TI Selected Viral Infections in Pregnancy SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Influenza; Hepatitis A; Hepatitis B; Hepatitis C ID HEPATITIS-C VIRUS; IMMUNIZATION PRACTICES ACIP; TO-INFANT TRANSMISSION; VERTICAL TRANSMISSION; ADVISORY-COMMITTEE; MATERNAL INFLUENZA; H1N1 INFLUENZA; WOMEN; RISK; RECOMMENDATIONS AB This article reviews the impact of seasonal influenza on pregnancy with particular emphasis on the 2009 novel H1N1 pandemic. Antiviral therapy for influenza, as well as recommendations and safety data on vaccination are discussed. In addition, the impact of hepatitis A, B, and C in pregnancy is addressed with a focus on prevention and treatment strategies for hepatitis B and C. C1 [Riley, Laura E.] Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02114 USA. [Panda, Britta] Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02210 USA. [Panda, Alexander] Yale Univ, Div Pulm & Crit Care Med, New Haven, CT 06512 USA. [Panda, Alexander] Yale Univ, Div Infect Dis, New Haven, CT 06512 USA. RP Riley, LE (reprint author), Massachusetts Gen Hosp, Div Maternal Fetal Med, Founders 4-414, Boston, MA 02114 USA. EM lriley@partners.org NR 55 TC 4 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8545 J9 OBSTET GYN CLIN N AM JI Obstet. Gynecol. Clin. N. Am. PD JUN PY 2010 VL 37 IS 2 BP 321 EP + DI 10.1016/j.ogc.2010.02.009 PG 12 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 618DK UT WOS:000279331400014 PM 20685556 ER PT J AU Shin, H Sampat, MP Koomen, JM Markey, MK AF Shin, Hyunjin Sampat, Mehul P. Koomen, John M. Markey, Mia K. TI Wavelet-Based Adaptive Denoising and Baseline Correction for MALDI TOF MS SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY LA English DT Article ID MASS-SPECTROMETRY DATA; ENHANCED LASER-DESORPTION; IMPROVED PEAK DETECTION; DISEASE CLASSIFICATION; SERUM; QUANTIFICATION; IONIZATION; TRANSFORM; SHRINKAGE; SPECTRUM AB Proteomic profiling by MALDI TOF mass spectrometry (MS) is an effective method for identifying biomarkers from human serum/plasma, but the process is complicated by the presence of noise in the spectra. In MALDI TOF MS, the major noise source is chemical noise, which is defined as the interference from matrix material and its clusters. Because chemical noise is nonstationary and nonwhite, wavelet-based denoising is more effective than conventional noise reduction schemes based on Fourier analysis. However, current wavelet-based denoising methods for mass spectrometry do not fully consider the characteristics of chemical noise. In this article, we propose new wavelet-based high-frequency noise reduction and baseline correction methods that were designed based on the discrete stationary wavelet transform. The high-frequency noise reduction algorithm adaptively estimates the time-varying threshold for each frequency subband from multiple realizations of chemical noise and removes noise from mass spectra of samples using the estimated thresholds. The baseline correction algorithm computes the monotonically decreasing baseline in the highest approximation of the wavelet domain. The experimental results demonstrate that our algorithms effectively remove artifacts in mass spectra that are due to chemical noise while preserving informative features as compared to commonly used denoising methods. C1 [Markey, Mia K.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Shin, Hyunjin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol,Dept Biostat, Boston, MA 02115 USA. [Sampat, Mehul P.] Univ Calif San Francisco, Dept Neurol, Adv Imaging Multiple Sclerosis Lab, San Francisco, CA 94143 USA. [Koomen, John M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol Prote, Tampa, FL 33612 USA. RP Markey, MK (reprint author), Univ Texas Austin, Dept Biomed Engn, 1 Univ Stn C0800, Austin, TX 78712 USA. EM mia.markey@mail.utexas.edu RI Koomen, John/D-1844-2013; OI Markey, Mia/0000-0001-8186-4959 NR 27 TC 10 Z9 10 U1 0 U2 8 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1536-2310 J9 OMICS JI OMICS PD JUN PY 2010 VL 14 IS 3 BP 283 EP 295 DI 10.1089/omi.2009.0119 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 614HS UT WOS:000279046800007 PM 20455751 ER PT J AU Fingert, JH Roos, B Eyestone, ME Pham, JD Mellot, ML Stone, E AF Fingert, John H. Roos, Ben Eyestone, Mari E. Pham, Joshua D. Mellot, Mei L. Stone, Edwin TI Novel Intragenic FRMD7 Deletion in a Pedigree with Congenital X-Linked Nystagmus SO OPHTHALMIC GENETICS LA English DT Article DE Nystagmus; Genetics; Mutation ID MOTOR NYSTAGMUS; INFANTILE NYSTAGMUS; CHINESE FAMILIES; GENE; MUTATIONS; HEREDITARY; LINKAGE AB Objective: To identify the disease-causing mutation in a large 3 generation pedigree of X-linked congenital nystagmus. Methods: Twenty-three members of a single pedigree, including 7 affected males, 2 affected females, 5 obligate carriers, and 9 unaffected family members were tested for mutations in the FRMD7 gene using PCR-based DNA sequencing assays and multiplex PCR assays for deletions. Results: A hemizygous deletion of exons 2, 3, and 4 of FRMD7 was detected in all affected males in the family and was absent from 40 control subjects. Conclusions: A range of missense, nonsense, frameshift, and splicing mutations in FRMD7 have been shown to cause X-linked congenital nystagmus. Here we show for the first time that large intragenic deletions of FRMD7 can also cause this form of nystagmus. C1 [Fingert, John H.; Roos, Ben; Eyestone, Mari E.; Pham, Joshua D.; Stone, Edwin] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA. [Mellot, Mei L.] Massachusetts Eye & Ear Infirm, Cambridge, MA USA. [Stone, Edwin] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA. RP Fingert, JH (reprint author), Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA. EM john-fingert@uiowa.edu RI Fingert, John/F-8787-2012 OI Fingert, John/0000-0002-0377-0479 FU Research to Prevent Blindness FX Dr. Fingert is supported by a Research to Prevent Blindness Career Development Award. NR 22 TC 11 Z9 13 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1381-6810 J9 OPHTHALMIC GENET JI Ophthalmic Genet. PD JUN PY 2010 VL 31 IS 2 BP 77 EP 80 DI 10.3109/13816810903584989 PG 4 WC Genetics & Heredity; Ophthalmology SC Genetics & Heredity; Ophthalmology GA 613VA UT WOS:000279009200004 PM 20450309 ER PT J AU Jones-Jordan, LA Walline, JJ Mutti, DO Rah, MJ Nichols, KK Nichols, JJ Zadnik, K AF Jones-Jordan, Lisa A. Walline, Jeffrey J. Mutti, Donald O. Rah, Marjorie J. Nichols, Kelly K. Nichols, Jason J. Zadnik, Karla TI Gas Permeable and Soft Contact Lens Wear in Children SO OPTOMETRY AND VISION SCIENCE LA English DT Article DE pediatric; gas permeable contact lenses; soft contact lenses; myopia; refractive error; children ID MYOPIA PROGRESSION CLAMP; RANDOMIZED-TRIAL; SPECTACLES AB Purpose. To compare children's reports of comfort, vision, and contact lens-related issues in gas permeable (GP) and soft (SCL) contact lens wearers. Methods. Subjects were 116 8-to 11-year old children in the Contact Lenses and Myopia Progression Study. Aspects of contact lens wear were compared for children remaining in their original treatment group (either GPs or SCLs) for 3 years. Questionnaires were completed at every visit, as was visual acuity. Comparisons were made between the two groups using logistic regression or mixed linear models analyses as appropriate to examine the contact lens wearing experience. Additionally, children crossing over from GP wear to SCLs were compared with children remaining in GP lenses to determine the potential factors related to GP dissatisfaction. Results. Seventy percent of GP wearers and 93% of SCL wearers wore their assigned lenses every visit. GP wearers wore their lenses significantly fewer hours per week than the SCL wearers (76.2 h/week vs. 86.8 h/week, respectively, p = 0.003). GP wearers had statistically significantly better visual acuity though the difference was not clinically meaningful (p < 0.001). Comfort was poorer among the GP wearers using the Ocular Pain subscale (p < 0.001) but did not differ using a subjective question about comfort. Symptoms were more frequent in GP wearers than SCL wearers (p = 0.002) and were related to reports of discomfort. Significant factors relating to crossing over from GPs to SCLs were lower wearing time with GPs and itching. Conclusions. Children are able to successfully wear GP and soft contact lenses. Long-term adaptation occurred more frequently to SCLs than to GPs. The amount of time GP lens wearers are able to comfortably wear their contact lenses and the amount of itching may help determine whether they will remain in that modality. (Optom Vis Sci 2010; 87: 414-420) C1 [Jones-Jordan, Lisa A.; Walline, Jeffrey J.; Mutti, Donald O.; Nichols, Kelly K.; Nichols, Jason J.; Zadnik, Karla] Ohio State Univ, Coll Optometry, Columbus, OH 43210 USA. [Rah, Marjorie J.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Jones-Jordan, LA (reprint author), Ohio State Univ, Coll Optometry, 338 W 10Th Ave, Columbus, OH 43210 USA. EM ljordan@optometry.osu.edu OI Nichols, Jason/0000-0003-1519-7734 FU National Eye Institute, National Institutes of Health, Bethesda, MD [K23-EY00383, T35-EY07151, R21-EY12273, R24-014792]; Menicon Co, Ltd, Nagoya, Japan; CIBAVision Corporation, Duluth, GA; SOLA Optical, U.S., Petaluma, CA; American Optometric Foundation FX This study was supported by grants K23-EY00383, T35-EY07151, R21-EY12273, and R24-014792 from the National Eye Institute, National Institutes of Health, Bethesda, MD; Menicon Co, Ltd, Nagoya, Japan; CIBAVision Corporation, Duluth, GA; SOLA Optical, U.S., Petaluma, CA; and an American Optometric Foundation William C. Ezell Fellowship, sponsored by Essilor, Dallas, TX (to JJW). NR 32 TC 9 Z9 9 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-5488 J9 OPTOMETRY VISION SCI JI Optom. Vis. Sci. PD JUN PY 2010 VL 87 IS 6 BP 414 EP 420 DI 10.1097/OPX.0b013e3181dc9a04 PG 7 WC Ophthalmology SC Ophthalmology GA 622EC UT WOS:000279642200006 PM 20386349 ER PT J AU Eckstein, F Wirth, W Hunter, DJ Guermazi, A Kwoh, CK Nelson, DR Benichou, O AF Eckstein, F. Wirth, W. Hunter, D. J. Guermazi, A. Kwoh, C. K. Nelson, D. R. Benichou, O. CA OAI Investigators TI Magnitude and regional distribution of cartilage loss associated with grades of joint space narrowing in radiographic osteoarthritis - data from the Osteoarthritis Initiative (OAI) SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Joint space narrowing; Radiographic osteoarthritis; Cartilage loss; Magnetic resonance imaging; Side comparison ID KNEE-JOINT; ARTICULAR-CARTILAGE; SURFACE-AREA; STANDING ANTEROPOSTERIOR; TIBIOFEMORAL COMPARTMENT; 3 TESLA; RESONANCE; BONE; MORPHOLOGY; PRECISION AB Objective Clinically, radiographic joint space narrowing (JSN) is regarded a surrogate of cartilage loss in osteoarthritis (OA) Using magnetic resonance imaging (MRI), we explored the magnitude and regional distribution of differences in cartilage thickness and subchondral bone area associated with specific Osteoarthritis Research Society International (OARSI) JSN grades Method Seventy-three participants with unilateral medial JSN were selected from the first half (2678 cases) of the OA Initiative cohort (45, 21, and 7 with OARSI JSN grades 1, 2, and 3, respectively, no medial JSN in the contra-lateral knee) Bilateral sagittal baseline DESSwe MRIs were segmented by experienced operators Intra-person between-knee differences in cartilage thickness and subchondral bone areas were determined in medial femorotibial subregions Results Knees with medial OARSI JSN grades 1, 2, and 3 displayed a 190 mu m (5 2%), 630 mu m (18%), and 1560 mu m (44%) smaller cartilage thickness in weight-bearing medial femorotibial compartments compared to knees without JSN, respectively. The weight-bearing femoral condyle displayed relatively greater differences than the posterior femoral condyle or the medial tibia (MT) The central subregion within the weight-bearing medial femur (cMF) of the femoral condyle (30-75 degrees), and the external and central subregions within the tibia displayed relatively greater JSN-associated differences compared to other medial femorotibial subregions Knees with higher JSN grades also displayed larger than contralateral femorotibial subchondral bone areas Conclusions This study provides quantitative estimates of JSN-related cartilage loss, with the central part of the weight-bearing femoral condyle being most strongly affected Knees with higher JSN grades displayed larger subchondral bone areas, suggesting that an increase in subchondral bone area occurs in advanced OA (C) 2010 Osteoarthritis Research Society International Published by Elsevier Ltd All rights reserved C1 [Eckstein, F.; Wirth, W.] PMU, Inst Anat, A-5020 Salzburg, Austria. [Eckstein, F.; Wirth, W.] Chondrometrics GmbH, Ainring, Germany. [Hunter, D. J.] New England Baptist Hosp, Div Res, Boston, MA USA. [Guermazi, A.] Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA. [Kwoh, C. K.] Univ Pittsburgh, Div Clin Immunol & Rheumatol, Pittsburgh, PA USA. [Kwoh, C. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Nelson, D. R.; Benichou, O.] Eli Lilly & Co, Indianapolis, IN 46285 USA. RP Eckstein, F (reprint author), PMU, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria. RI Eckstein, Felix/E-1585-2011; Hunter, David/A-4622-2010; Wirth, Wolfgang/C-8724-2011 OI Hunter, David/0000-0003-3197-752X; Wirth, Wolfgang/0000-0002-2297-8283 FU Eli Lilly Co, IN; National Institute of Health, Department of Health and Human Services [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-22262]; OAI include Merck Research Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Pfizer, Inc. FX Funding sources The image analysis of this study was funded by Eli Lilly & Co, IN. The images were acquired by the OAI, a public private partnership comprised five contracts (N01-AR-2-2258, N01-AR-2-2259; N01-AR-2-2260, N01-AR-2-2261; N01-AR-22262) funded by the National Institute of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners of the OAI include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institute of Health This manuscript has received the approval of the OAI Publications Committee based on a review of its scientific content and data interpretation NR 43 TC 31 Z9 31 U1 0 U2 5 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD JUN PY 2010 VL 18 IS 6 BP 760 EP 768 DI 10.1016/j.joca.2009.12.009 PG 9 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 609FX UT WOS:000278642400005 PM 20171298 ER PT J AU Perkins, JA Manning, SC Tempero, RM Cunningham, MJ Edmonds, JL Hoffer, FA Egbert, MA AF Perkins, Jonathan A. Manning, Scott C. Tempero, Richard M. Cunningham, Michael J. Edmonds, Joseph L., Jr. Hoffer, Fredric A. Egbert, Mark A. TI Lymphatic malformations: Current cellular and clinical investigations SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article ID VASCULAR MALFORMATIONS; ENDOTHELIAL-CELLS; OUTCOMES RESEARCH; VEGF-C; LYMPHANGIOMAS; HEMANGIOMAS; INFANTS; DISEASE; SYSTEM; TUMORS AB OBJECTIVE: Summarize current knowledge of lymphatic malformation development, biology, and clinical outcome measures. METHODS: Panel presentation of lymphatic malformation biology and measurement of head and neck malformation treatment outcomes. RESULTS: Characterization of lymphatic malformation endothelial and stromal cells may lead to biologically based treatment. Traditionally, lymphatic malformation treatment outcomes have been measured according to reduction of malformation size. Currently, methods to measure functional outcomes following lymphatic malformation treatment are lacking. This is particularly apparent when the malformation directly involves the upper aero-digestive tract. CONCLUSIONS: The etiology and pathogenesis of head and neck lymphatic malformations are poorly understood, but understanding is improving through ongoing investigation. Reduction of lymphatic malformation size is generally possible, but further work is necessary to optimize methods for measuring therapeutic outcomes in problematic areas. (C) 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 [Perkins, Jonathan A.; Manning, Scott C.] Seattle Childrens Hosp, Div Pediat Otolaryngol Head & Neck Surg, Seattle, WA 98105 USA. [Perkins, Jonathan A.; Manning, Scott C.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Tempero, Richard M.] Boys Town Natl Res Hosp, Omaha, NE 68131 USA. [Cunningham, Michael J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol, Boston, MA USA. [Cunningham, Michael J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Edmonds, Joseph L., Jr.] Childrens ENT Houston, Houston, TX USA. [Hoffer, Fredric A.] Univ Washington, Dept Radiol, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Egbert, Mark A.] Univ Washington, Dept Oral & Maxillofacial Surg, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Edmonds, Joseph L., Jr.] Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA. [Edmonds, Joseph L., Jr.] Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. [Edmonds, Joseph L., Jr.] Weill Cornell Coll Med, Dept Otolaryngol, New York, NY USA. [Edmonds, Joseph L., Jr.] Univ Texas Houston, Sch Med, Dept Otolaryngol, Houston, TX USA. RP Perkins, JA (reprint author), Seattle Childrens Hosp, Div Otolaryngol Head & Neck Surg, 4800 Sand Point Way NE,Mailstop W-7729, Seattle, WA 98105 USA. EM jonathan.perkins@seattlechildrens.org FU Arthrocare FX Arthrocare: approval of manuscript. NR 32 TC 36 Z9 37 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JUN PY 2010 VL 142 IS 6 BP 789 EP 794 DI 10.1016/j.otohns.2010.02.025 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 601EQ UT WOS:000278041400003 PM 20493347 ER PT J AU Perkins, JA Manning, SC Tempero, RM Cunningham, MJ Edmonds, JL Hoffer, FA Egbert, MA AF Perkins, Jonathan A. Manning, Scott C. Tempero, Richard M. Cunningham, Michael J. Edmonds, Joseph L., Jr. Hoffer, Fredric A. Egbert, Mark A. TI Lymphatic malformations: Review of current treatment SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Review ID CYSTIC HYGROMA; PERCUTANEOUS SCLEROTHERAPY; VASCULAR MALFORMATIONS; CHILDREN; OK-432; LYMPHANGIOMAS; MANAGEMENT; INJECTION; HEAD; NECK AB OBJECTIVE: Summarize current knowledge of lymphatic malformation medical, sclerotherapy, and surgical treatment; and highlight areas of treatment controversy and treatment difficulty that need improvement. METHODS: Panel presentation of various aspects of lymphatic malformation treatment. RESULTS: The mainstay of lymphatic malformation treatment has been surgical resection, which has been refined through lesion staging and radiographic characterization. Intralesional sclerotherapy in macrocystic lymphatic malformations is effective. Suprahyoid microcystic lymphatic malformations are more difficult to treat than macrocystic lymphatic malformations in the infrahyoid and posterior cervical regions. Bilateral suprahyoid lymphatic malformations require staged treatment to prevent complications, Lymphatic malformation treatment planning is primarily determined by the presence or possibility of functional compromise. Problematic areas include chronic lymphatic malformation inflammation, dental health maintenance, macroglossia, airway obstruction, and dental malocclusion. CONCLUSIONS: Lymphatic malformation treatment improvements have been made through radiographic characterization and staging of lymphatic malformations. Direct malformation involvement of the upper aerodigestive tract can cause significant functional compromise that is difficult to treat. (C) 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 [Perkins, Jonathan A.; Manning, Scott C.] Seattle Childrens Hosp, Div Pediat Otolaryngol Head & Neck Surg, Seattle, WA 98105 USA. [Perkins, Jonathan A.; Manning, Scott C.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Tempero, Richard M.] Boys Town Natl Res Hosp, Omaha, NE 68131 USA. [Cunningham, Michael J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol, Boston, MA USA. [Cunningham, Michael J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Edmonds, Joseph L., Jr.] Childrens ENT Houston, Houston, TX USA. [Hoffer, Fredric A.] Univ Washington, Dept Radiol, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Egbert, Mark A.] Univ Washington, Dept Oral & Maxillofacial Surg, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Edmonds, Joseph L., Jr.] Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA. [Edmonds, Joseph L., Jr.] Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. [Edmonds, Joseph L., Jr.] Weill Cornell Coll Med, Dept Otolaryngol, New York, NY USA. [Edmonds, Joseph L., Jr.] Univ Texas Houston, Sch Med, Dept Otolaryngol, Houston, TX USA. RP Perkins, JA (reprint author), Seattle Childrens Hosp, Div Otolaryngol Head & Neck Surg, 4800 Sand Point Way NE,Mailstop W-7729, Seattle, WA 98105 USA. EM jonathan.perkins@seattlechildrens.org FU Arthrocare FX Arthrocare: approval of manuscript. NR 51 TC 62 Z9 69 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JUN PY 2010 VL 142 IS 6 BP 795 EP 803 DI 10.1016/j.otohns.2010.02.026 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 601EQ UT WOS:000278041400004 PM 20493348 ER PT J AU Miller, ME Makary, C Lopez, IA Ishiyama, A AF Miller, Mia E. Makary, Chadi Lopez, Ivan A. Ishiyama, Akira TI Endolymphatic Hydrops in Otologic Syphilis: A Temporal Bone Study SO OTOLOGY & NEUROTOLOGY LA English DT Article DE Endolymphatic hydrops; Gumma; Microgummata; Osteitis; Otologic syphilis; Otosyphilis; Syphilis ID HEARING-LOSS; SAC; OBLITERATION; DUCT AB Hypothesis: Endolymphatic hydrops in temporal bones with otologic syphilis directly relates to osteitis, new bone formation, and/or resorption along the course of the endolymphatic system. Background: Meniere's disease and otosyphilis both cause progressive endolymphatic hydrops, and the mechanism of hydrops formation in each disease process remains unclear. Traditionally, osteitic changes of the labyrinthine capsule were thought to lead to endolymphatic hydrops in syphilitic temporal bones. More recently, authors have suggested that microgummata and inflammatory change obliterating the endolymphatic duct and sac may cause endolymphatic hydrops in otosyphilis. Methods: This is a histopathologic study of 11 temporal bones from patients with otosyphilis. Gathered data include presence/absence of endolymphatic hydrops of the cochlea, saccule, and utricle; bony changes involving the endolymphatic duct and sac; a description of bony changes throughout the temporal bone; and the degree of atrophy of the organ of Corti, spiral ganglion, and stria vascularis. Results: The presence of osteitic changes surrounding the endolymphatic duct and sac and whether the endolymphatic system was obliterated did not directly correlate with the presence of endolymphatic hydrops in this study. Conclusion: We reject the hypothesis that otologic syphilis is directly related to osteitis, new bone formation, and/or resorption along the course of the endolymphatic duct and sac. Although a change in the endolymphatic system may contribute to the formation of endolymphatic hydrops in otologic syphilis, it is not the only cause. Whether otosyphilis and Meniere's disease share a common mechanism of endolymphatic hydrops formation remains unclear, and the relationship between these causes of hydrops should be investigated further. C1 [Miller, Mia E.; Lopez, Ivan A.; Ishiyama, Akira] Univ Calif Los Angeles, Div Head & Neck Surg, Los Angeles, CA 90095 USA. [Makary, Chadi] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Ishiyama, A (reprint author), Univ Calif Los Angeles, Div Head & Neck Surg, 10833 Le Conte Ave,CHS 62-158, Los Angeles, CA 90095 USA. EM ishiyama@ucla.edu OI Lopez, Ivan/0000-0001-5205-7293 FU National Institute on Deafness and Other Communication Disorders Temporal Bone, Hearing and Balance Pathology Resource Registry; National Institutes of Health [NIDCD R01 DC-06-001, DC 008635, DC 005028, DC 005187]; Temporal Bone Registry at the Massachusetts Eye and Ear Infirmary FX This work was supported in part by the Otopathology Mini-Travel Fellowship Program of the National Institute on Deafness and Other Communication Disorders Temporal Bone, Hearing and Balance Pathology Resource Registry. This also was funded in part by the National Institutes of Health Grants NIDCD R01 DC-06-001, DC 008635, DC 005028, and DC 005187.; The authors thank Dr. Saumil Merchant and the Temporal Bone Registry at the Massachusetts Eye and Ear Infirmary for help and support. NR 16 TC 8 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1531-7129 J9 OTOL NEUROTOL JI Otol. Neurotol. PD JUN PY 2010 VL 31 IS 4 BP 681 EP 686 DI 10.1097/MAO.0b013e3181dbb7e4 PG 6 WC Clinical Neurology; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 604CF UT WOS:000278254200023 PM 20431499 ER PT J AU Goebel, JR Sherbourne, CD Asch, SM Meredith, L Cohen, AB Hagenmaier, E Lanto, AB Simon, B Rubenstein, LV Shugarman, LR Lorenz, KA AF Goebel, Joy R. Sherbourne, Cathy D. Asch, Steven M. Meredith, Lisa Cohen, Angela B. Hagenmaier, Emily Lanto, Andy B. Simon, Barbara Rubenstein, Lisa V. Shugarman, Lisa R. Lorenz, Karl A. TI Addressing Patients' Concerns about Pain Management and Addiction Risks SO PAIN MANAGEMENT NURSING LA English DT Article ID NURSES; QUALITY; KNOWLEDGE; VIGNETTES; BARRIERS AB Fear of engendering addiction is frequently reported as both a provider and a patient barrier to effective pain management. In this study, a clinical scenario ascertained nursing staff members' usual practice in addressing addiction fears for patients with concerns about the addictive potential of pain medication. One hundred forty-five Veterans Health Administration nursing staff members from eight ambulatory care sites were queried to identify variables associated with proclivity to address patient fears about addiction risks in a population where pain is prevalent and the risk for substance abuse is high. Regarding addressing addiction concerns, 66% of nursing staff were very likely, 16% somewhat likely, 9% unsure, 6% somewhat unlikely, and 2% very unlikely to take action. Health technicians were less likely to address addiction concerns than registered or licensed vocational nurses (odds ratio [OR] 0.116; p=.004). Nursing staff with more years' experience (OR 1.070; p=.005) and higher levels of self-efficacy/confidence (OR 1.380; p=.001) were more likely to engage in discussions related to addiction risks. Targeted efforts to improve pain management activities should focus on retaining experienced nursing staff in initial assessment positions and improving the skills and confidence of less experienced and less skilled staff. (C) 2010 by the American Society for Pain Management Nursing C1 [Goebel, Joy R.] Calif State Univ Long Beach, Dept Nursing, Long Beach, CA 90840 USA. [Sherbourne, Cathy D.; Asch, Steven M.; Meredith, Lisa; Rubenstein, Lisa V.; Shugarman, Lisa R.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA. [Asch, Steven M.; Meredith, Lisa; Rubenstein, Lisa V.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Asch, Steven M.; Cohen, Angela B.; Hagenmaier, Emily; Lanto, Andy B.; Simon, Barbara; Rubenstein, Lisa V.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Goebel, JR (reprint author), Calif State Univ Long Beach, Dept Nursing, 1250 Bellflower Blvd, Long Beach, CA 90840 USA. NR 36 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1524-9042 EI 1532-8635 J9 PAIN MANAG NURS JI Pain Manag. Nurs. PD JUN PY 2010 VL 11 IS 2 BP 92 EP 98 DI 10.1016/j.pmn.2009.03.009 PG 7 WC Nursing SC Nursing GA 610QH UT WOS:000278748700005 PM 20510839 ER PT J AU Arnstein, P AF Arnstein, Paul TI Balancing Analgesic Efficacy with Safety Concerns in the Older Patient SO PAIN MANAGEMENT NURSING LA English DT Article ID LIDOCAINE PATCH 5-PERCENT; INAPPROPRIATE MEDICATION USE; ADVERSE DRUG EVENTS; OF-THE-LITERATURE; NEUROPATHIC PAIN; TOPICAL NSAIDS; DOUBLE-BLIND; EXPLICIT CRITERIA; HIGH-RISK; PREVENTION AB The rapidly expanding number of aged Americans and the increasing prevalence of persistent pain in older adults create an urgent need to unravel the complexities of chronic pain management in this population. This requires health professionals to understand both normal and pathologic changes that occur within the aging body and mind, as well as how those factors affect responses to pain and pain-relieving treatments. The medical management of pharmacologic treatment for pain in older adults is often suboptimal, ranging from failing to use analgesics for patients with considerable pain to exposing older adults to potentially life-threatening toxicities, overdoses, or drug interactions. Models for safe and effective approaches to treating pain in older adults exist, but treatments must still be tailored for each individual's needs. A growing array of targeted therapies are available for managing pain, yet two or three trials of different agents within the same drug class are often needed to optimize treatment because of the considerable variability in responses to the effects of particular medications. Older adults tend to be more vulnerable to side effects and drug interactions than their younger counterparts, owing to differences in drug distribution, metabolism, and elimination. This review delineates these vulnerabilities and informs clinicians of the strategies needed to promote safe and effective use of medications to treat pain in older adults. The goal of this paper was to review specific considerations for balancing efficacy and safety in the pharmacologic treatment of persistent pain in older adults. (C) 2010 by the American Society for Pain Management Nursing C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Arnstein, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM pmarnstein@partners.org NR 65 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1524-9042 EI 1532-8635 J9 PAIN MANAG NURS JI Pain Manag. Nurs. PD JUN PY 2010 VL 11 IS 2 SU 1 BP S11 EP S22 DI 10.1016/j.pmn.2010.03.003 PG 12 WC Nursing SC Nursing GA 610QJ UT WOS:000278748900002 PM 20510845 ER PT J AU Rodriguez, KL Bayliss, NK Jaffe, E Zickmund, S Sevick, MA AF Rodriguez, Keri L. Bayliss, Nichole K. Jaffe, Emily Zickmund, Susan Sevick, Mary Ann TI Factor analysis and internal consistency evaluation of the FAMCARE Scale for use in the long-term care setting SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Long-term care; Nursing homes; Consumer satisfaction; Family; Psychometrics AB Objective: The FAMCARE Scale was originally designed to measure family satisfaction with advanced cancer care. The current study evaluated the instrument's psychometric qualities when used in the long-term care (LTC) setting. Method: In a prospective cohort study in 2004, the 20-item instrument was administered via telephone to family members of 51 patients receiving LTC in Veterans Affairs facilities. Satisfaction scores on a 5-point Likert scale were used for factor analysis and internal consistency evaluation. Results: Although 16 patients were in geriatric palliative care and 35 were in nursing home care, scores of their family members did not vary based on care unit. The total satisfaction score was high, with a mean (SD) of 44.7 (11.9) and a Cronbach alpha of 0.94. Inter-item correlations were low for care availability items (range, 0.01-0.59). Two items-availability of a hospital bed and availability of nurses to the family-had low eigenvalues (0.26 and 0.18, respectively) and weak correlations with the total score (0.23 and 0.16, respectively). Significance of results: In the LTC setting, FAMCARE appears to have good internal consistency, but it may be preferable to exclude the two items with weak correlations and to use a 10-point visual analog scale. C1 [Rodriguez, Keri L.; Bayliss, Nichole K.; Zickmund, Susan; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Rodriguez, Keri L.; Zickmund, Susan; Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Rodriguez, Keri L.; Jaffe, Emily; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Bayliss, Nichole K.] Univ Pittsburgh, Sociol Dept, Pittsburgh, PA USA. [Jaffe, Emily] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Sevick, Mary Ann] Univ Pittsbsburg, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. RP Rodriguez, KL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Bldg 2,Room 4083E,151C-H, Pittsburgh, PA 15206 USA. EM keri.rodriguez@va.gov NR 25 TC 10 Z9 10 U1 1 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD JUN PY 2010 VL 8 IS 2 BP 169 EP 176 DI 10.1017/S1478951509990927 PG 8 WC Health Policy & Services SC Health Care Sciences & Services GA V25ON UT WOS:000208487400009 PM 20331914 ER PT J AU Lando, HA Hipple, BJ Muramoto, M Klein, JD Prokhorov, AV Ossip, DJ Winickoff, JP AF Lando, Harry A. Hipple, Bethany J. Muramoto, Myra Klein, Jonathan D. Prokhorov, Alexander V. Ossip, Deborah J. Winickoff, Jonathan P. TI Tobacco Control and Children: An International Perspective SO PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY LA English DT Article ID DEVELOPING-COUNTRIES; SMOKING; HEALTH; WORKING; YOUTH; TUBERCULOSIS; CARCINOGEN; EXPOSURE; IMPACT; HIV AB Tobacco use currently claims >5 million deaths per year worldwide and this number is projected to increase dramatically by 2030. The burden of death and disease is shifting to low- and middle-income countries. Tobacco control initiatives face numerous challenges including not being a high priority in many countries, government dependence upon immediate revenue from tobacco sales and production, and opposition of the tobacco industry. Tobacco leads to environmental harms, exploitation of workers in tobacco farming, and increased poverty. Children are especially vulnerable. Not only do they initiate tobacco use themselves, but also they are victimized by exposure to highly toxic secondhand smoke. Awareness of tobacco adverse health effects is often superficial even among health professionals. The tobacco industry continues to aggressively promote its products and recognizes that children are its future. The tools and knowledge exist, however, to dramatically reduce the global burden of tobacco. In 2003 the World Health Organization adopted the Framework Convention on Tobacco Control. Aggressive tobacco control initiatives have been undertaken not only in high-income countries but also in less-wealthy countries such as Uruguay and Thailand. Stakeholders must come together in coordinated efforts and there must be a broad and sustained investment in global tobacco control. C1 [Lando, Harry A.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA. [Hipple, Bethany J.; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA. [Hipple, Bethany J.] Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, Netherlands. [Muramoto, Myra] Univ Arizona, Tucson, AZ USA. [Klein, Jonathan D.] Amer Acad Pediat, Elk Grove Village, IL USA. [Prokhorov, Alexander V.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ossip, Deborah J.] Univ Rochester, Rochester, NY USA. RP Lando, HA (reprint author), Univ Minnesota, Div Epidemiol & Community Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA. EM lando001@umn.edu FU NIH [R01 CA132950] FX This article was written on behalf of the American Academy of Pediatrics Tobacco Consortium and the Julius B. Richmond Center of Excellence. Some content overlaps with an editorial in the Bulletin of the World Health Organization 4 by the current authors. Additional content was taken from a longer unpublished draft of that editorial. This study was supported in part by an NIH grant R01 CA132950 (Principal Investigator: Deborah J. Ossip). NR 42 TC 5 Z9 5 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2151-321X J9 PEDIAT ALLER IMM PUL JI Pediatr. Allergy Immunol. Pulmonol. PD JUN PY 2010 VL 23 IS 2 BP 99 EP 103 DI 10.1089/ped.2010.0012 PG 5 WC Allergy; Immunology; Pediatrics; Respiratory System SC Allergy; Immunology; Pediatrics; Respiratory System GA 645DX UT WOS:000281432200002 PM 22375275 ER PT J AU Gutierrez, A Grebliunaite, R Feng, H Den Hertog, J Prochownik, E Testa, J Kanki, J Look, T AF Gutierrez, Alejandro Grebliunaite, Ruta Feng, Hui Den Hertog, Jeroen Prochownik, Edward Testa, Joseph Kanki, John Look, Thomas TI Pten INACTIVATION PROMOTES LOSS OF MYC "ONCOGENE ADDICTION" IN A CONDITIONAL ZEBRAFISH MODEL OF T-ALL SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Gutierrez, Alejandro; Grebliunaite, Ruta; Feng, Hui; Den Hertog, Jeroen; Prochownik, Edward; Testa, Joseph; Kanki, John; Look, Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD JUN PY 2010 VL 54 IS 6 BP 787 EP 787 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 578JT UT WOS:000276290300003 ER PT J AU Gutierrez, A Dahlberg, S Neuberg, D Zhang, JH Grebliunaite, R Sanda, T Protopopov, A Kutok, J Winter, S Larson, R Borowitz, M Loh, M Silverman, L Chin, L Hunger, S Sallan, S Look, T AF Gutierrez, Alejandro Dahlberg, Suzanne Neuberg, Donna Zhang, Jianhua Grebliunaite, Ruta Sanda, Takaomi Protopopov, Alexei Kutok, Jeffrey Winter, Stuart Larson, Richard Borowitz, Michael Loh, Mignon Silverman, Lewis Chin, Lynda Hunger, Stephen Sallan, Stephen Look, Thomas TI ABSENCE OF BIALLELIC TCR gamma DELETIONS (ABGD) PREDICTS INDUCTION FAILURE IN PEDIATRIC T-ALL SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Gutierrez, Alejandro; Dahlberg, Suzanne; Neuberg, Donna; Zhang, Jianhua; Grebliunaite, Ruta; Sanda, Takaomi; Protopopov, Alexei; Kutok, Jeffrey; Winter, Stuart; Larson, Richard; Borowitz, Michael; Loh, Mignon; Silverman, Lewis; Chin, Lynda; Hunger, Stephen; Sallan, Stephen; Look, Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD JUN PY 2010 VL 54 IS 6 BP 812 EP 812 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 578JT UT WOS:000276290300090 ER PT J AU Narla, A Bernt, K Gordon, P Hettmer, S Hoffman, I Lee, M Billett, A AF Narla, Anu Bernt, Kathrin Gordon, Peter Hettmer, Simone Hoffman, Inga Lee, Michelle Billett, Amy TI MAXIMIZING THE USE OF TMP-SMZ FOR PCP PROPHYLAXIS IN PEDIATRIC ONCOLOGY PATIENTS SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Narla, Anu; Bernt, Kathrin; Gordon, Peter; Hettmer, Simone; Hoffman, Inga; Lee, Michelle; Billett, Amy] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 2 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD JUN PY 2010 VL 54 IS 6 BP 829 EP 829 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 578JT UT WOS:000276290300151 ER PT J AU Benor, S Russell, GH Silver, M Israel, EJ Yuan, Q Winter, HS AF Benor, Shira Russell, George H. Silver, Michael Israel, Esther J. Yuan, Qian Winter, Harland S. TI Shortcomings of the Inflammatory Bowel Disease Serology 7 Panel SO PEDIATRICS LA English DT Article DE inflammatory bowel disease; serological testing; Crohn disease; ulcerative colitis; indeterminate colitis; thrombocytosis; erythrocyte sedimentation rate; anemia ID CROHNS-DISEASE; ULCERATIVE-COLITIS; SACCHAROMYCES-CEREVISIAE; DIAGNOSTIC-ACCURACY; LABORATORY TESTS; CHILDREN; MARKERS; ANTIBODIES; ASCA; RESPONSES AB OBJECTIVE: The goal was to compare the predictive values of the Prometheus Inflammatory Bowel Disease (IBD) Serology 7 (IBD7) panel (Prometheus Laboratories, San Diego, CA) with the predictive values of routine blood tests in a population of children referred for initial evaluation of suspected IBD. METHODS: Medical records of pediatric patients referred for evaluation of IBD for whom IBD7 testing was performed at Prometheus Laboratories between January 2006 and November 2008 were reviewed. Patients underwent diagnosis by pediatric gastroenterologists on the basis of clinical, radiologic, endoscopic, and pathologic evaluations. RESULTS: A total of 394 records were identified. We excluded 90 records on the basis of age of >21 years, previous diagnosis of IBD, or unclear diagnosis. The prevalence of IBD in this cohort was 38%. The sensitivity, specificity, positive predictive value, negative predictive value, and kappa value for the serological panel were 67%, 76%, 63%, 79%, and 42%, respectively, compared with values for a combination of 3 abnormal routine laboratory test results of 72%, 94%, 85%, 79%, and 47%. The antiflagellin antibody assay, the newest assay added to the panel, had sensitivity of 50% and specificity of 53%. Repeat serological testing failed to produce consistent results for 4 of 10 patients. CONCLUSION: Despite its recent inclusion of the antiflagellin assay, the IBD7 panel has lower predictive values than routine laboratory tests in pediatric screening for IBD. Pediatrics 2010; 125: 1230-1236 C1 [Benor, Shira; Russell, George H.; Israel, Esther J.; Yuan, Qian; Winter, Harland S.] Massachusetts Gen Hosp Children, Dept Pediat Gastroenterol & Nutr, Boston, MA USA. [Silver, Michael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Biostat, Boston, MA USA. RP Benor, S (reprint author), Dana Hosp Children, Tel Aviv Sourasky Med Ctr, Dept Pediat, 6 Weizman St, IL-64239 Tel Aviv, Israel. EM shirabenor@yahoo.com FU Advanced IBD Fellowship FX This study was supported by an Advanced IBD Fellowship grant provided by Martin Schlaff. NR 29 TC 20 Z9 21 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD JUN PY 2010 VL 125 IS 6 BP 1230 EP 1236 DI 10.1542/peds.2009-1936 PG 7 WC Pediatrics SC Pediatrics GA 604GX UT WOS:000278268600018 PM 20439597 ER PT J AU Pekary, AE Stevens, SA Blood, JD Sattin, A AF Pekary, Albert Eugene Stevens, Schetema A. Blood, James D. Sattin, Albert TI Rapid modulation of TRH and TRH-like peptide release in rat brain, pancreas, and testis by a GSK-3 beta inhibitor SO PEPTIDES LA English DT Article DE GSK-3 beta; Thyrotropin-releasing hormone; Limbic system; Testis; HPLC; Radioimmunoassay ID GLYCOGEN-SYNTHASE KINASE-3-BETA; PGLU-GLU-PRO-NH2 EEP; TAU-PHOSPHORYLATION; PERIPHERAL-TISSUES; INSULIN-SECRETION; LIGHT-CHAIN; HORMONE TRH; IN-VITRO; KINESIN; GSK3 AB Antidepressants have been shown to be neuroprotective and able to reverse damage to glia and neurons. Thyrotropin-releasing hormone (TRH) is an endogenous antidepressant-like neuropeptide that reduces the expression of glycogen synthase kinase-3 beta (GSK-3 beta), an enzyme that hyperphosphorylates tau and is implicated in bipolar disorder, diabetes and Alzheimer's disease. In order to understand the potential role of GSK-3 beta in the modulation of depression by TRH and TRH-like peptides and the therapeutic potential of GSK-3 beta inhibitors for neuropsychiatric and metabolic diseases, young adult male Sprague-Dawley (SD) rats were (a) injected ip with 1.8 mg/kg of GSK-3 beta inhibitor VIII (GSKI) and sacrificed 0, 2, 4, 6, and 8 h later or (b) injected with 0, 0.018, 0.18 or 1.8 mg/kg GSKI and bled 4 h later. Levels of TRH and TRH-like peptides were measured in various brain regions involved in mood regulation, pancreas and reproductive tissues. Large, 3-15-fold, increases of TRH and TRH-like peptide levels in cerebellum, for example, as well as other brain regions were noted at 2 and 4 h. In contrast, a nearly complete loss of TRH and TRH-like peptides from testis within 2 h and pancreas by 4 h following GSKI injection was observed. We have previously reported similar acute effects of corticosterone in brain and peripheral tissues. Incubation of a decapsulated rat testis with either GSKI or corticosterone accelerated release of TRH, and TRH-like peptides. Glucocorticoids, via inhibition of GSK3-beta activity, may thus be involved in the inhibition of TRH and TRH-like peptide release in brain, thereby contributing to the depressogenic effect of this class of steroids. Corticosterone-induced acceleration of release of these peptides from testis may contribute to the decline in reproductive function and redirection of energy needed during life-threatening emergencies. These contrasting effects of glucocorticoid on peptide release appear to be mediated by GSK-3 beta. Published by Elsevier Inc. C1 [Pekary, Albert Eugene; Stevens, Schetema A.; Blood, James D.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. [Pekary, Albert Eugene] VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. [Pekary, Albert Eugene] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Eugene.Pekary@va.gov FU Veterans Administration Medical Research Funds; Pekary Family Trust FX This work was supported by Veterans Administration Medical Research Funds (AEP and AS) and the Pekary Family Trust. NR 63 TC 6 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JUN PY 2010 VL 31 IS 6 BP 1083 EP 1093 DI 10.1016/j.peptides.2010.03.020 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 676SN UT WOS:000283939000013 PM 20338209 ER PT J AU Peter, L Stengel, A Noetzel, S Inhoff, T Goebel, M Tache, Y Veh, RW Bannert, N Grotzinger, C Wiedenmann, B Klapp, BF Monnikes, H Kobelt, P AF Peter, Lisa Stengel, Andreas Noetzel, Steffen Inhoff, Tobias Goebel, Miriam Tache, Yvette Veh, Ruediger W. Bannert, Norbert Groetzinger, Carsten Wiedenmann, Bertram Klapp, Burghard F. Moennikes, Hubert Kobelt, Peter TI Peripherally injected CCK-8S activates CART positive neurons of the paraventricular nucleus in rats SO PEPTIDES LA English DT Article DE CCK; CART; c-Fos; Food intake; PVN ID C-FOS EXPRESSION; CORTICOTROPIN-RELEASING HORMONE; DORSAL VAGAL COMPLEX; FOOD-INTAKE; SOLITARY TRACT; HYPOTHALAMIC NEUROENDOCRINE; CHOLECYSTOKININ-OCTAPEPTIDE; GENE-EXPRESSION; BRAIN-STEM; PEPTIDE AB Cholecystokinin (CCK) plays a role in the short-term inhibition of food intake. Cocaine-and amphetamine-regulated transcript (CART) peptide has been observed in neurons of the paraventricular nucleus (PVN). It has been reported that intracerebroventricular injection of CART peptide inhibits food intake in rodents. The aim of the study was to determine whether intraperitoneally (ip) injected CCK-8S affects neuronal activity of PVN-CART neurons. Ad libitum fed male Sprague-Dawley rats received 6 or 10 mu g/kg CCK-8S or 0.15M NaCl ip (n = 4/group). The number of c-Fos-immunoreactive neurons was determined in the PVN, arcuate nucleus (ARC), and the nucleus of the solitary tract (NTS). CCK-8S dose-dependently increased the number of c-Fos-immunoreactive neurons in the PVN (mean +/- SEM: 102 +/- 6 vs. 150 +/- 5 neurons/section, p < 0.05) and compared to vehicle treated rats (18 +/- 7, p < 0.05 vs. 6 and 10 mu g/kg CCK-8S). CCK-8S at both doses induced an increase in the number of c-Fos-immunoreactive neurons in the NTS (65 +/- 13, p < 0.05, and 182 +/- 16, p < 0.05). No effect on the number of c-Fos neurons was observed in the ARC. Immunostaining for CART and c-Fos revealed a dose-dependent increase of activated CART neurons (19 +/- 3 vs. 29 +/- 7; p < 0.05), only few activated CART neuron were observed in the vehicle group (1 +/- 0). The present observation shows that CCK-8S injected ip induces an increase in neuronal activity in PVN-CART neurons and suggests that CART neurons in the PVN may play a role in the mediation of peripheral CCK-8S's anorexigenic effects. (C) 2010 Elsevier Inc. All rights reserved. C1 [Klapp, Burghard F.; Kobelt, Peter] Charite, Dept Med, Div Psychosomat Med & Psychotherapy, D-10117 Berlin, Germany. [Peter, Lisa; Noetzel, Steffen; Inhoff, Tobias; Groetzinger, Carsten; Wiedenmann, Bertram; Kobelt, Peter] Charite, Dept Med, Div Hepatol Gastroenterol & Endocrinol, D-10117 Berlin, Germany. [Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurobiol Stress, Los Angeles, CA USA. [Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Veh, Ruediger W.] Charite, Inst Integrat Neuroanat, D-10117 Berlin, Germany. [Bannert, Norbert] Robert Koch Inst, D-1000 Berlin, Germany. [Moennikes, Hubert] Martin Luther Hosp, Dept Med, Berlin, Germany. [Moennikes, Hubert] Martin Luther Hosp, Inst Neurogastroenterol, Berlin, Germany. RP Kobelt, P (reprint author), Charite, Dept Med, Div Psychosomat Med & Psychotherapy, Campus Mitte,Luisenstr 13 A, D-10117 Berlin, Germany. EM peter.kobelt@charite.de OI Grotzinger, Carsten/0000-0001-9872-3087 FU German Research Foundation [DFG KO 3864/2-1]; Charite-Universitatsmedizin Berlin [UFF 09/41730, 09/42458]; Veterans Administration; NIHDK [33061]; [DK-41301] FX This work was supported by grants from the German Research Foundation to P.K (DFG KO 3864/2-1), and from Charite-Universitatsmedizin Berlin to P.K (UFF 09/41730 and 09/42458) as well as Veterans Administration Research Career Scientist Award (Y.T), Veterans Administration Merit Award (Y.T), NIHDK 33061 (Y.T), Center Grant DK-41301 (Animal Core) (Y.T.). NR 44 TC 10 Z9 11 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JUN PY 2010 VL 31 IS 6 BP 1118 EP 1123 DI 10.1016/j.peptides.2010.03.013 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 676SN UT WOS:000283939000018 PM 20307613 ER PT J AU Sharma, SD Katiyar, SK AF Sharma, Som D. Katiyar, Santosh K. TI Dietary Grape Seed Proanthocyanidins Inhibit UVB-Induced Cyclooxygenase-2 Expression and Other Inflammatory Mediators in UVB-Exposed Skin and Skin Tumors of SKH-1 Hairless Mice SO PHARMACEUTICAL RESEARCH LA English DT Article DE chemoprevention; COX-2; grape seed proanthocyanidins; skin cancer; ultraviolet radiation ID INDUCED OXIDATIVE STRESS; NF-KAPPA-B; MOUSE SKIN; GREEN TEA; DNA-REPAIR; PREVENTS PHOTOCARCINOGENESIS; ULTRAVIOLET-LIGHT; COX-2 EXPRESSION; CARCINOMA-CELLS; IN-VIVO AB The purpose of this study was to determine the chemopreventive mechanism of dietary grape seed proanthocyanidins (GSPs) against ultraviolet (UV) radiation-induced skin tumor development in mice. Six-to-seven-week-old SKH-1 hairless mice were subjected to photocarcinogenesis protocol, and exposed to UVB radiation (180 mJ/cm(2)) three times/week for 24 weeks. Mice were fed a standard AIN76A control diet with or without supplementation with grape seed proanthocyanidins (GSPs; 0.2% or 0.5%, w/w). At the termination of the experiment, mice were sacrificed, and skin and skin tumor samples were harvested and subjected to the analysis of biomarkers related to inflammation using immunostaining, western blot analysis, ELISA and real-time PCR. Dietary GSPs inhibited UVB-induced infiltration of proinflammatory leukocytes and the levels of myeloperoxidase, cyclooxygenase-2 (COX-2), prostaglandin (PG) E-2, cyclin D1 and proliferating cell nuclear antigen (PCNA) in the skin and skin tumors compared to non-GSPs-treated UVB irradiated mouse skin and skin tumors. GSPs also significantly inhibited the levels of proinflammatory cytokines, tumor necrosis factor-alpha (P < 0.01), IL-1 beta (P < 0.001) and IL-6 (P < 0.001), in UVB-exposed skin and skin tumors. The results from this study clearly suggest that dietary GSPs inhibit photocarcinogenesis in mice through the inhibition of UVB-induced inflammation and mediators of inflammation in mouse skin. C1 [Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award FX This work was financially supported by the Veterans Administration Merit Review Award (S.K.K.). NR 42 TC 40 Z9 43 U1 1 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0724-8741 J9 PHARM RES-DORDR JI Pharm. Res. PD JUN PY 2010 VL 27 IS 6 BP 1092 EP 1102 DI 10.1007/s11095-010-0050-9 PG 11 WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA 597VW UT WOS:000277791300016 PM 20143255 ER PT J AU Luttrell, LM Gesty-Palmer, D AF Luttrell, Louis M. Gesty-Palmer, Diane TI Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling SO PHARMACOLOGICAL REVIEWS LA English DT Review ID PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; PARATHYROID-HORMONE PTH; CLATHRIN-MEDIATED ENDOCYTOSIS; ANGIOTENSIN-II RECEPTOR; GROWTH-FACTOR RECEPTOR; TERNARY COMPLEX MODEL; CHRONIC HEART-FAILURE; FAILING HUMAN HEART; BETA(2)-ADRENERGIC RECEPTOR AB Heptahelical G protein-coupled receptors are the most diverse and therapeutically important family of receptors in the human genome. Ligand binding activates heterotrimeric G proteins that transmit intracellular signals by regulating effector enzymes or ion channels. G protein signaling is terminated, in large part, by arrestin binding, which uncouples the receptor and G protein and targets the receptor for internalization. It is clear, however, that heptahelical receptor signaling does not end with desensitization. Arrestins bind a host of catalytically active proteins and serve as ligand-regulated scaffolds that recruit protein and lipid kinase, phosphatase, phosphodiesterase, and ubiquitin ligase activity into the receptor-arrestin complex. Although many of these arrestin-bound effectors serve to modulate G protein signaling, degrading second messengers and regulating endocytosis and trafficking, other signals seem to extend beyond the receptor-arrestin complex to regulate such processes as protein translation and gene transcription. Although these findings have led to a re-envisioning of heptahelical receptor signaling, little is known about the physiological roles of arrestin-dependent signaling. In vivo, the duality of arrestin function makes it difficult to dissociate the consequences of arrestin-dependent desensitization from those that might be ascribed to arrestin-mediated signaling. Nonetheless, recent evidence generated using arrestin knockouts, G protein-uncoupled receptor mutants, and arrestin pathway-selective "biased agonists" is beginning to reveal that arrestin signaling plays important roles in the retina, central nervous system, cardiovascular system, bone remodeling, immune system, and cancer. Understanding the signaling roles of arrestins may foster the development of pathway-selective drugs that exploit these pathways for therapeutic benefit. C1 [Gesty-Palmer, Diane] Duke Univ, Med Ctr, Div Endocrinol & Metab, Dept Med, Durham, NC 27710 USA. [Gesty-Palmer, Diane] Durham Vet Affairs Med Ctr, Durham, NC USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Gesty-Palmer, D (reprint author), Duke Univ, Med Ctr, Div Endocrinol & Metab, Dept Med, Box 103015, Durham, NC 27710 USA. EM gesty001@mc.duke.edu FU National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [DK64353, DK55524]; National Institutes of Health National Institute of Child Health & Human Development [HD043446]; Arthritis Foundation; Research Services of the Charleston, SC, and Durham, NC, Veterans Affairs Medical Centers FX This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grants DK64353, DK55524 (to L. M. L.)]; the National Institutes of Health National Institute of Child Health & Human Development [Grant HD043446 (to D.G.-P.)]; the Arthritis Foundation (to D.G.-P.); and the Research Services of the Charleston, SC, and Durham, NC, Veterans Affairs Medical Centers. We offer our sincere apologies to the many outstanding researchers whose work has been omitted because of space and topic constraints. There is no intent to diminish or downplay the significance of their contributions to this rapidly expanding field. NR 224 TC 181 Z9 188 U1 1 U2 12 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0031-6997 J9 PHARMACOL REV JI Pharmacol. Rev. PD JUN PY 2010 VL 62 IS 2 BP 305 EP 330 DI 10.1124/pr.109.002436 PG 26 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 596QB UT WOS:000277698900005 PM 20427692 ER PT J AU Hamblin, MR Dai, TH AF Hamblin, Michael R. Dai, Tianhong TI Can surgical site infections be treated by photodynamic therapy? SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY LA English DT Letter ID ANTIMICROBIAL PHOTOINACTIVATION; METHYLENE-BLUE; PHOTOSENSITIZER; DELIVERY; PUMPS C1 [Hamblin, Michael R.; Dai, Tianhong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Wellman Ctr Photomed, Boston, MA 02114 USA. RP Hamblin, MR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Wellman Ctr Photomed, BAR 414,40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu OI Hamblin, Michael/0000-0001-6431-4605 FU NIAID NIH HHS [R01 AI050875, R01 AI050875-07] NR 21 TC 9 Z9 9 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1572-1000 J9 PHOTODIAGN PHOTODYN JI Photodiagnosis Photodyn. Ther. PD JUN PY 2010 VL 7 IS 2 BP 134 EP 136 DI 10.1016/j.pdpdt.2010.04.004 PG 3 WC Oncology SC Oncology GA 613NR UT WOS:000278986500011 PM 20510311 ER PT J AU Ferry, AT Graves, T Theodore, GH Gill, TJ AF Ferry, Amon T. Graves, Timothy Theodore, George H. Gill, Thomas J. TI Stress Fractures in Athletes SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE stress fracture; athlete; return to play; treatment ID FEMALE ARMY RECRUITS; PNEUMATIC LEG BRACE; OVERUSE INJURIES; ELECTROMAGNETIC-FIELDS; MILITARY RECRUITS; PULSED ULTRASOUND; CONTROLLED-TRIAL; RISK-FACTORS; BONE; RUNNERS AB Stress fractures that occur in the young active population typically represent an overuse injury, and may lead to prolonged periods of restriction from play if they are not treated appropriately. Several risk factors have been identified and must be addressed when treating these patients. Low-risk stress fractures can be successfully treated with activity restriction and a stepwise return to sport. Several pharmacologic and nonoperative treatment modalities have been described. However, high-risk stress fractures are more difficult to treat because they may have an increased rate of delay and nonunion, and oft en require surgical stabilization. When treating an athlete with a stress fracture, the objective is a safe and quick return to sport; therefore, special considerations must be made in this population, particularly when dealing with the in-season athlete. C1 [Ferry, Amon T.; Graves, Timothy; Theodore, George H.; Gill, Thomas J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Sports Med Serv, Boston, MA 02114 USA. RP Gill, TJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Sports Med Serv, 175 Cambridge St, Boston, MA 02114 USA. EM tgill@partners.org NR 66 TC 3 Z9 3 U1 4 U2 14 PU JTE MULTIMEDIA PI BERWYN PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA SN 0091-3847 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PD JUN PY 2010 VL 38 IS 2 BP 109 EP 116 PG 8 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA 766SY UT WOS:000290808000020 PM 20631470 ER PT J AU Barabasi, AL AF Barabasi, Albert-Laszlo TI You're so predictable SO PHYSICS WORLD LA English DT Article C1 [Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA. [Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA. [Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Boston, MA USA. RP Barabasi, AL (reprint author), Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA. EM barabasi@gmail.com NR 0 TC 1 Z9 1 U1 0 U2 7 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0953-8585 J9 PHYS WORLD JI Phys. World PD JUN PY 2010 VL 23 IS 6 BP 22 EP 26 PG 5 WC Physics, Multidisciplinary SC Physics GA 613FY UT WOS:000278965900016 ER PT J AU Pedersen, ME Baldwin, RA Niquet, J Stafford, GI van Staden, J Wasterlain, CG Jager, AK AF Pedersen, Mikael E. Baldwin, Roger A. Niquet, Jerome Stafford, Gary I. van Staden, Johannes Wasterlain, Claude G. Jager, Anna K. TI Anticonvulsant Effects of Searsia dentata (Anacardiaceae) Leaf Extract in Rats SO PHYTOTHERAPY RESEARCH LA English DT Article DE traditional medicine; epilepsy; NMDA receptor antagonists AB Searsia species are used in South Africa to treat epilepsy. Previous studies have demonstrated an in vitro N-methyl-D-aspartic acid (NMDA) receptor antagonistic effect of the ethanolic leaf extract. The aim of this study was to evaluate the potential anticonvulsant properties of the ethanolic extract of S. dentata in various animal models of epilepsy. The extract was submitted to a screening in anticonvulsant assays including NMDA-, kainic acid (KA)-, pentylenetetrazol (PTZ)- and bicuculline (BIC)-induced seizures in rats. The extract protected 47% of the PN 18 Wistar pups (postnatal day 18, date of birth PN 0) (p < 0.05, n > 10) against NMDA-induced seizures and significantly delayed the onset of PTZ-induced seizures (p < 0.05, n > 8) at a dose of 250 mg/kg. A dose optimum was detected at 500 mg/kg for protection against KA-(63% protection, p < 0.05, n > 8) and BIC-induced seizures (50% protection, p < 0.05, n > 8) in young adult and PN 18 rats, respectively. The ethanolic extract of S. dentata showed anticonvulsive properties in several models of epilepsy. These results are compatible with previous findings of NMDA receptor antagonism. Due to the complex composition of the extract, the effect might be caused by more than one compound. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Pedersen, Mikael E.; Jager, Anna K.] Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen O, Denmark. [Pedersen, Mikael E.; Stafford, Gary I.; van Staden, Johannes] Univ KwaZulu Natal Pietermaritzburg, Sch Biol & Conservat Sci, Res Ctr Plant Growth & Dev, ZA-3209 Scottsville, South Africa. [Pedersen, Mikael E.; Baldwin, Roger A.; Niquet, Jerome; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Jager, AK (reprint author), Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, 2 Univ Pk, DK-2100 Copenhagen O, Denmark. EM ankj@farma.ku.dk RI Stafford, Gary/E-8668-2011; Pedersen, Mikael/F-9158-2011 OI Stafford, Gary/0000-0003-0198-0955; FU National Research Foundation (South Africa) FX The National Research Foundation (South Africa) is thanked for financial assistance. NR 11 TC 5 Z9 5 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0951-418X J9 PHYTOTHER RES JI Phytother. Res. PD JUN PY 2010 VL 24 IS 6 BP 924 EP 927 DI 10.1002/ptr.3016 PG 4 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 614OS UT WOS:000279070200021 PM 19953526 ER PT J AU Salvatori, R Nachtigall, LB Cook, DM Bonert, V Molitch, ME Blethen, S Chang, S AF Salvatori, Roberto Nachtigall, Lisa B. Cook, David M. Bonert, Vivien Molitch, Mark E. Blethen, Sandra Chang, Stephen CA SALSA Study Grp TI Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly SO PITUITARY LA English DT Article DE Acromegaly; Self-administration; Somatostatin analogue; Lanreotide; Octreotide ID OCTREOTIDE; THERAPY; AUTOGEL(R); MANAGEMENT; DIAGNOSIS AB Surgical resection is often not curative in patients with acromegaly and long-acting somatostatin analogues (lanreotide or octreotide) are often needed. This study assessed the efficacy and safety of self- or partner-administration of lanreotide in patients with acromegaly. This was a six-month, single-arm, open-label study conducted at 13 endocrinology clinics. Fifty-nine patients received deep subcutaneous lanreotide injections every 28 days. Twelve patients started on 120 mg lanreotide and forty-seven started on 90 mg lanreotide. At week 16, the dose was adjusted to 60, 90 or 120 mg based on insulin-like growth factor-1 (IGF-1) levels at week 12. Fifty-nine patients with acromegaly either switched from long-acting octreotide (switch; n = 33) or were somatostatin analogue treatment-na < ve or not currently taking long-acting octreotide ("other"; n = 26). The key endpoints included the percentage of patients/partners able to self- or partner-inject lanreotide and those with normal IGF-1 or growth hormone (GH) levels at week 24/early termination. 100% of patients/partners correctly self- (n = 41) or partner-injected (n = 18) lanreotide by week 4. By week 24/early termination, IGF-1 levels were controlled in 93.7% of switch and 46.2% of "other" patients, while GH levels were controlled in 76.9% and 39.1% of patients, respectively. Both IGF-1 and GH were controlled in 73.1% of switch and 30.4% of "other" patients. Most switch patients (81%) reported they preferred lanreotide over long-acting octreotide for future use (P = 0.0001). Self- or partner-administration of lanreotide is generally well tolerated and associated with IGF-1 and GH control in many lanreotide-na < ve patients with acromegaly. C1 [Salvatori, Roberto] Johns Hopkins Univ, Sch Med, Div Endocrinol, Baltimore, MD 21287 USA. [Nachtigall, Lisa B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cook, David M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bonert, Vivien] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Bonert, Vivien] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Molitch, Mark E.] Northwestern Univ, Chicago, IL 60611 USA. [Blethen, Sandra; Chang, Stephen] Tercica Inc, Brisbane, CA USA. RP Salvatori, R (reprint author), Johns Hopkins Univ, Sch Med, Div Endocrinol, 1830 E Monument St 333, Baltimore, MD 21287 USA. EM salvator@jhmi.edu FU Tercica, Inc. FX This study was sponsored by Tercica, Inc., a subsidiary of the Ipsen Group; the sponsor participated in the study design as well as the data collection, analysis and interpretation. Medical writing support for the preparation of this manuscript was provided by Jessica Mendoza, PhD, who is a full-time employee of Tercica, Inc., a subsidiary of the Ipsen Group. NR 13 TC 27 Z9 27 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1386-341X J9 PITUITARY JI Pituitary PD JUN PY 2010 VL 13 IS 2 BP 115 EP 122 DI 10.1007/s11102-009-0207-x PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 584RS UT WOS:000276770900004 PM 19898989 ER PT J AU Yueh, JH Slavin, SA Adesiyun, T Nyame, TT Gautam, S Morris, DJ Tobias, AM Lee, BT AF Yueh, Janet H. Slavin, Sumner A. Adesiyun, Tolulope Nyame, Theodore T. Gautam, Shiva Morris, Donald J. Tobias, Adam M. Lee, Bernard T. TI Patient Satisfaction in Postmastectomy Breast Reconstruction: A Comparative Evaluation of DIEP, TRAM, Latissimus Flap, and Implant Techniques SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article; Proceedings Paper CT 39th Annual Fall Scientific Symposium of the American-Society-of-Ophthalmic-Plastic-and-Reconstructive-Surgery CY NOV, 2008 CL Atlanta, GA SP Amer Soc Ophthalm Plast & Reconstruct Surg ID EPIGASTRIC PERFORATOR FLAPS; QUALITY-OF-LIFE; RETROSPECTIVE ANALYSIS; OUTCOMES; DETERMINANTS; EXPERIENCE AB Background: Despite a growing literature on patient satisfaction in breast reconstruction, few studies have compared perforator flaps with the more commonly practiced methods. The authors compared four reconstructive techniques and identified factors influencing patient satisfaction. Methods: All patients undergoing postmastectomy breast reconstruction between 1999 and 2006 at a single academic institution were included in our study. A total of 583 patients with tissue expander/implant, latissimus, pedicle transverse rectus abdominis muscle (TRAM), and deep inferior epigastric perforator (DIEP) flap reconstructions received a validated questionnaire on satisfaction, health-related quality of life, and sociodemographic data. Results: Patient response was 75 percent, with 439 completed questionnaires including 87 tissue expander/implant, 116 latissimus, and 119 pedicle TRAM and 117 DIEP flap patients. DIEP patients had the highest level of general satisfaction at 80 percent, and pedicle TRAM patients had the highest level of aesthetic satisfaction at 77 percent (p < 0.001 and p < 0.001, respectively). Health-related quality of life and length of time since surgery were identified as significant covariates influencing patient satisfaction. After logistic regression analysis, autologous reconstruction had significantly higher generalandaesthetic satisfaction than implant-based reconstruction (p = 0.017 and p < 0.001). Among the autologous reconstructions, abdominal-based flaps had significantly higher general and aesthetic satisfaction than latissimus flaps (p = 0.011 and p = 0.016). When comparing the abdominal-based reconstructions, general and aesthetic satisfaction were no longer statistically significant between pedicle TRAM and DIEP flaps (p = 0.659 and p = 0.198). Conclusions: Autologous, abdominal-based reconstructions had the highest satisfaction rates across all four groups. After logistic regression analysis, differences in patient satisfaction between pedicle TRAM and DIEP flap reconstruction were no longer observed. Discussing satisfaction outcomes with patients will help them make educated decisions about breast reconstruction. (Plast. Reconstr. Surg. 125:1585,2010.) C1 [Lee, Bernard T.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Plast & Reconstruct Surg, Dept Surg,Med Sch,Harvard Thorndike Gen Clin Res, Boston, MA 02215 USA. Harvard Univ, Beth Israel Deaconess Med Ctr, Harvard Thorndike Gen Clin Res, Sch Med,Biostat Program, Boston, MA 02215 USA. RP Lee, BT (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Plast & Reconstruct Surg, Dept Surg,Med Sch,Harvard Thorndike Gen Clin Res, 110 Francis St,Suite 5A, Boston, MA 02215 USA. EM blee3@bidmc.harvard.edu RI Lee, Bernard/K-1106-2016 OI Lee, Bernard/0000-0002-5533-3166 NR 36 TC 108 Z9 112 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD JUN PY 2010 VL 125 IS 6 BP 1585 EP 1595 DI 10.1097/PRS.0b013e3181cb6351 PG 11 WC Surgery SC Surgery GA 605XC UT WOS:000278380700001 PM 20517080 ER PT J AU Murphy, AD McCormack, MC Bichara, DA Nguyen, JT Randolph, MA Watkins, MT Lee, RC Austen, WG AF Murphy, Adrian D. McCormack, Michael C. Bichara, David A. Nguyen, John T. Randolph, Mark A. Watkins, Michael T. Lee, Raphael C. Austen, William G., Jr. TI Poloxamer 188 Protects against Ischemia-Reperfusion Injury in a Murine Hind-Limb Model SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article; Proceedings Paper CT 54th Annual Meeting of the Plastic-Surgery-Research-Council CY MAY 27-30, 2009 CL Pittsburgh, PA SP Plast Surg Res Council ID ACUTE MYOCARDIAL-INFARCTION; EXPERIMENTAL FREE FLAPS; NO-REFLOW PHENOMENON; SKELETAL-MUSCLE; ISCHEMIA/REPERFUSION INJURY; FUNCTIONAL RECOVERY; LIPID MONOLAYERS; IN-VIVO; IGM; COMPLEMENT AB Background: Ischemia-reperfusion injury can activate pathways generating reactive oxygen species, which can injure cells by creating holes in the cell membranes. Copolymer surfactants such as poloxamer 188 are capable of sealing defects in cell membranes. The authors postulated that a single-dose administration of poloxamer 188 would decrease skeletal myocyte injury and mortality following ischemia-reperfusion injury. Methods: Mice underwent normothermic hind-limb ischemia for 2 hours. Animals were treated with 150 mu l of poloxamer 188 or dextran at three time points: (1) 10 minutes before ischemia; (2) 10 minutes before reperfusion; and (3) 2 or 4 hours after reperfusion. After 24 hours of reperfusion, tissues were analyzed for myocyte injury (histology) and metabolic dysfunction (muscle adenosine 5'-triphosphate). Additional groups of mice were followed for 7 days to assess mortality. Results: When poloxamer 188 treatment was administered 10 minutes before ischemia, injury was reduced by 84 percent, from 50 percent injury in the dextran group to 8 percent injury in the poloxamer 188 group (p < 0.001). When administered 10 minutes before reperfusion, poloxamer 188 animals demonstrated a 60 percent reduction in injury compared with dextran controls (12 percent versus 29 percent). Treatment at 2 hours, but not at 4 hours, postinjury prevented substantial myocyte injury. Preservation of muscle adenosine 5'-triphosphate paralleled the decrease in myocyte injury in poloxamer 188-treated animals. Poloxamer 188 treatment significantly reduced mortality following injury (10 minutes before, 75 percent versus 25 percent survival, p = 0.0077; 2 hours after, 50 percent versus 8 percent survival, p = 0.032). Conclusion: Poloxamer 188 administered to animals decreased myocyte injury, preserved tissue adenosine 5'-triphosphate levels, and improved survival following hind-limb ischemia-reperfusion injury. (Plast. Reconstr. Surg. 125: 1651, 2010.) C1 [Austen, William G., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. Univ Chicago, Dept Surg, Comm Mol Med, Chicago, IL 60637 USA. Univ Chicago, Dept Med, Comm Mol Med, Chicago, IL 60637 USA. Univ Chicago, Dept Organismal Biol & Anat, Comm Mol Med, Chicago, IL 60637 USA. RP Austen, WG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, 15 Parkman St,Suite WAC 435, Boston, MA 02114 USA. EM wausten@partners.org FU NIGMS NIH HHS [R01 GM064757, GM 5R01GM064757-07] NR 46 TC 13 Z9 13 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD JUN PY 2010 VL 125 IS 6 BP 1651 EP 1660 DI 10.1097/PRS.0b013e3181ccdbef PG 10 WC Surgery SC Surgery GA 605XC UT WOS:000278380700010 PM 20517088 ER PT J AU Gold, MC Cerri, S Smyk-Pearson, S Cansler, ME Vogt, TM Delepine, J Winata, E Swarbrick, GM Chua, WJ Yu, YYL Lantz, O Cook, MS Null, MD Jacoby, DB Harriff, MJ Lewinsohn, DA Hansen, TH Lewinsohn, DM AF Gold, Marielle C. Cerri, Stefania Smyk-Pearson, Susan Cansler, Meghan E. Vogt, Todd M. Delepine, Jacob Winata, Ervina Swarbrick, Gwendolyn M. Chua, Wei-Jen Yu, Yik Y. L. Lantz, Olivier Cook, Matthew S. Null, Megan D. Jacoby, David B. Harriff, Melanie J. Lewinsohn, Deborah A. Hansen, Ted H. Lewinsohn, David M. TI Human Mucosal Associated Invariant T Cells Detect Bacterially Infected Cells SO PLOS BIOLOGY LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; MR1 ANTIGEN PRESENTATION; ALPHA-CHAIN; MAIT CELLS; RECOGNITION; LYMPHOCYTES; RESPONSES; RECEPTOR; PROTEIN; INNATE AB Control of infection with Mycobacterium tuberculosis (Mtb) requires Th1-type immunity, of which CD8(+) T cells play a unique role. High frequency Mtb-reactive CD8(+) T cells are present in both Mtb-infected and uninfected humans. We show by limiting dilution analysis that nonclassically restricted CD8(+) T cells are universally present, but predominate in Mtb-uninfected individuals. Interestingly, these Mtb-reactive cells expressed the V alpha 7.2 T-cell receptor (TCR), were restricted by the nonclassical MHC (HLA-Ib) molecule MR1, and were activated in a transporter associated with antigen processing and presentation (TAP) independent manner. These properties are all characteristics of mucosal associated invariant T cells (MAIT), an "innate'' T-cell population of previously unknown function. These MAIT cells also detect cells infected with other bacteria. Direct ex vivo analysis demonstrates that Mtb-reactive MAIT cells are decreased in peripheral blood mononuclear cells (PBMCs) from individuals with active tuberculosis, are enriched in human lung, and respond to Mtb-infected MR1-expressing lung epithelial cells. Overall, these findings suggest a generalized role for MAIT cells in the detection of bacterially infected cells, and potentially in the control of bacterial infection. C1 [Gold, Marielle C.; Cerri, Stefania; Smyk-Pearson, Susan; Delepine, Jacob; Winata, Ervina; Swarbrick, Gwendolyn M.; Cook, Matthew S.; Jacoby, David B.; Harriff, Melanie J.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Gold, Marielle C.; Delepine, Jacob; Swarbrick, Gwendolyn M.; Harriff, Melanie J.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR USA. [Smyk-Pearson, Susan; Cansler, Meghan E.; Vogt, Todd M.; Swarbrick, Gwendolyn M.; Cook, Matthew S.; Null, Megan D.; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Chua, Wei-Jen; Yu, Yik Y. L.; Hansen, Ted H.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA. [Lantz, Olivier] Inst Curie Paris, Inserm 932, Lab Immunol & Unite, Paris, France. [Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Gold, MC (reprint author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. EM goldm@ohsu.edu; lewinsod@ohsu.edu RI Lantz, Olivier/J-4960-2012; Cerri, Stefania/N-9701-2016; Lewinsohn, David/I-4936-2013; OI Lantz, Olivier/0000-0003-3161-7719; Cerri, Stefania/0000-0003-4612-1580; Jacoby, David/0000-0003-2195-9512; Lewinsohn, David/0000-0001-9906-9494; Gold, Marielle/0000-0003-2505-3291 FU Department of Veterans Affairs; National Institutes of Health (NIH) [AI48090, HHSN266200400081C] FX Funding was provided in part by the Department of Veterans Affairs and with resources and the use of facilities at the Portland VA Medical Center, National Institutes of Health (NIH) grant AI48090, and NIH contract HHSN266200400081C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 192 Z9 192 U1 4 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1544-9173 J9 PLOS BIOL JI PLoS. Biol. PD JUN PY 2010 VL 8 IS 6 AR e1000407 DI 10.1371/journal.pbio.1000407 PG 14 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 618LK UT WOS:000279355600019 PM 20613858 ER PT J AU Sepulcre, J Liu, HS Talukdar, T Martincorena, I Yeo, BTT Buckner, RL AF Sepulcre, Jorge Liu, Hesheng Talukdar, Tanveer Martincorena, Inigo Yeo, B. T. Thomas Buckner, Randy L. TI The Organization of Local and Distant Functional Connectivity in the Human Brain SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID DEFAULT MODE NETWORK; MEDIAL PREFRONTAL CORTEX; RESTING HUMAN BRAIN; CEREBRAL-CORTEX; WHITE-MATTER; NEUROCOGNITIVE NETWORKS; AUTOBIOGRAPHICAL MEMORY; CORTICAL CONNECTIONS; MACAQUE MONKEYS; LOW-FREQUENCY AB Information processing in the human brain arises from both interactions between adjacent areas and from distant projections that form distributed brain systems. Here we map interactions across different spatial scales by estimating the degree of intrinsic functional connectivity for the local (<= 14 mm) neighborhood directly surrounding brain regions as contrasted with distant (>14 mm) interactions. The balance between local and distant functional interactions measured at rest forms a map that separates sensorimotor cortices from heteromodal association areas and further identifies regions that possess both high local and distant cortical-cortical interactions. Map estimates of network measures demonstrate that high local connectivity is most often associated with a high clustering coefficient, long path length, and low physical cost. Task performance changed the balance between local and distant functional coupling in a subset of regions, particularly, increasing local functional coupling in regions engaged by the task. The observed properties suggest that the brain has evolved a balance that optimizes information-processing efficiency across different classes of specialized areas as well as mechanisms to modulate coupling in support of dynamically changing processing demands. We discuss the implications of these observations and applications of the present method for exploring normal and atypical brain function. C1 [Sepulcre, Jorge; Buckner, Randy L.] Howard Hughes Med Inst, Cambridge, MA USA. [Sepulcre, Jorge; Liu, Hesheng; Yeo, B. T. Thomas; Buckner, Randy L.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Sepulcre, Jorge; Liu, Hesheng; Yeo, B. T. Thomas; Buckner, Randy L.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA. [Sepulcre, Jorge; Liu, Hesheng; Talukdar, Tanveer; Yeo, B. T. Thomas; Buckner, Randy L.] Athinioula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA. [Martincorena, Inigo] Univ Cambridge, European Bioinformat Inst, Cambridge, England. [Buckner, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Buckner, Randy L.] Harvard Univ, Sch Med, Boston, MA USA. RP Sepulcre, J (reprint author), Howard Hughes Med Inst, Cambridge, MA USA. EM sepulcre@nmr.mgh.harvard.edu OI Liu, Hesheng/0000-0002-7233-1509; Yeo, B.T. Thomas/0000-0002-0119-3276 FU Howard Hughes Medical Institute; NIA [R01-AG21910] FX Grants support: Howard Hughes Medical Institute, NIA R01-AG21910 and Martinos Ctr 5R90DA023427. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 81 TC 125 Z9 129 U1 3 U2 17 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-734X J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD JUN PY 2010 VL 6 IS 6 AR e1000808 DI 10.1371/journal.pcbi.1000808 PG 15 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA 618HA UT WOS:000279341000014 PM 20548945 ER PT J AU Lim, SY Chan, T Gelman, RS Whitney, JB O'Brien, KL Barouch, DH Goldstein, DB Haynes, BF Letvin, NL AF Lim, So-Yon Chan, Tiffany Gelman, Rebecca S. Whitney, James B. O'Brien, Kara L. Barouch, Dan H. Goldstein, David B. Haynes, Barton F. Letvin, Norman L. TI Contributions of Mamu-A*01 Status and TRIM5 Allele Expression, But Not CCL3L Copy Number Variation, to the Control of SIVmac251 Replication in Indian-Origin Rhesus Monkeys SO PLOS GENETICS LA English DT Article ID SIMIAN IMMUNODEFICIENCY; HIV-1 INFECTION; SEGMENTAL DUPLICATIONS; SUSCEPTIBILITY; PROGRESSION; GENE; AIDS; GENOME; CELLS AB CCL3 is a ligand for the HIV-1 co-receptor CCR5. There have recently been conflicting reports in the literature concerning whether CCL3-like gene (CCL3L) copy number variation (CNV) is associated with resistance to HIV-1 acquisition and with both viral load and disease progression following infection with HIV-1. An association has also been reported between CCL3L CNV and clinical sequelae of the simian immunodeficiency virus (SIV) infection in vivo in rhesus monkeys. The present study was initiated to explore the possibility of an association of CCL3L CNV with the control of virus replication and AIDS progression in a carefully defined cohort of SIVmac251-infected, Indian-origin rhesus monkeys. Although we demonstrated extensive variation in copy number of CCL3L in this cohort of monkeys, CCL3L CNV was not significantly associated with either peak or set-point plasma SIV RNA levels in these monkeys when MHC class I allele Mamu-A*01 was included in the models or progression to AIDS in these monkeys. With 66 monkeys in the study, there was adequate power for these tests if the correlation of CCL3L and either peak or set-point plasma SIV RNA levels was 0.34 or 0.36, respectively. These findings call into question the premise that CCL3L CNV is important in HIV/SIV pathogenesis. C1 [Lim, So-Yon; Chan, Tiffany; Whitney, James B.; O'Brien, Kara L.; Barouch, Dan H.; Letvin, Norman L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Haynes, Barton F.] Duke Univ, Duke Human Vaccine Inst, Durham, NC USA. [Goldstein, David B.] Duke Univ, Duke Inst Genome Sci & Policy, Ctr Populat Genom & Pharmacogenet, Durham, NC USA. [Gelman, Rebecca S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA. RP Lim, SY (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. EM nletvin@bidmc.harvard.edu FU NIAID Center for HIV/AIDS Vaccine Immunology [AI067854, AI078526] FX This work was supported by the NIAID Center for HIV/AIDS Vaccine Immunology grant AI067854 (NLL) and AI078526 (DHB). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 25 Z9 26 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD JUN PY 2010 VL 6 IS 6 AR e1000997 DI 10.1371/journal.pgen.1000997 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 624GN UT WOS:000279805200026 PM 20585621 ER PT J AU Cohen, T Murray, M Wallengren, K Alvarez, GG Samuel, EY Wilson, D AF Cohen, Ted Murray, Megan Wallengren, Kristina Alvarez, Gonzalo G. Samuel, Elizabeth Y. Wilson, Douglas TI The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study SO PLOS MEDICINE LA English DT Article ID NEGATIVE PULMONARY TUBERCULOSIS; HIV-POSITIVE PATIENTS; DIAGNOSIS; AUTOPSY; SPUTUM; DEATH; MICROSCOPY; ANTIBODIES; SETTINGS; BOTSWANA AB Background: Tuberculosis is the leading cause of death in South Africa by death notification, but accurate diagnosis of tuberculosis is challenging in this setting of high HIV prevalence. We conducted limited autopsies on young adults dying in a single public hospital in the province of KwaZulu-Natal between October 2008 and August 2009 in order to estimate the magnitude of deaths attributable to tuberculosis. Methods and Findings: We studied a representative sample of 240 adult inpatients (aged 20-45 years) dying after admission to Edendale Hospital. Limited autopsies included collection of respiratory tract secretions and tissue by needle core biopsies of lung, liver, and spleen. Specimens were examined by fluorescent microscopy for acid-fast bacilli and cultured in liquid media; cultures positive for M. tuberculosis were tested for drug susceptibility to first-and second-line antibiotics. Ninety-four percent of our study cohort was HIV seropositive and 50% of decedents had culture-positive tuberculosis at the time of death. Fifty percent of the participants were on treatment for tuberculosis at the time of death and 58% of these treated individuals remained culture positive at the time of death. Of the 50% not receiving tuberculosis treatment, 42% were culture positive. Seventeen percent of all positive cultures were resistant to both isoniazid and rifampin (i.e., multidrug resistant); 16% of patients dying during the initiation phase of their first ever course of tuberculosis treatment were infected with multidrug-resistant bacilli. Conclusions: Our findings reveal the immense toll of tuberculosis among HIV-positive individuals in KwaZulu-Natal. The majority of decedents who remained culture positive despite receiving tuberculosis treatment were infected with pansusceptible M. tuberculosis, suggesting that the diagnosis of tuberculosis was made too late to alter the fatal course of the infection. There is also a significant burden of undetected multidrug-resistant tuberculosis among HIV-coinfected individuals dying in this setting. New public health approaches that improve early diagnosis of tuberculosis and accelerate the initiation of treatment are urgently needed in this setting. C1 [Cohen, Ted; Murray, Megan] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Cohen, Ted; Murray, Megan; Wallengren, Kristina] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Murray, Megan] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA. [Alvarez, Gonzalo G.] Univ Ottawa, Dept Med, Ottawa Hosp, Ottawa, ON, Canada. [Samuel, Elizabeth Y.] Inkosi Albert Luthuli Cent Hosp, Natl Hlth Lab Serv, Mayville, South Africa. [Wilson, Douglas] Univ KwaZulu Natal, Dept Med, Edendale Hosp, Durban, South Africa. RP Cohen, T (reprint author), Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA. EM tcohen@hsph.harvard.edu RI Cohen, Ted/G-8101-2011 FU Massachusetts General Hospital; BMS Secure the Future; Edendale Hospital; Harvard University CFAR; Ragon Institute; Gary and Lauren Cohen; Mark and Lisa Schwartz Foundation; Witten Family Foundation; US National Institutes Of Health [DP2OD006663]; KwaZulu-Natal Department of Health FX This work was made possible through funding provided by Massachusetts General Hospital, BMS Secure the Future, and Edendale Hospital. We also thank the Harvard University CFAR, the Ragon Institute, Gary and Lauren Cohen, the Mark and Lisa Schwartz Foundation, and the Witten Family Foundation for additional support. TC received support through Award Number DP2OD006663 from the Office of the Director, US National Institutes Of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Office of the Director of the US NIH, or the NIH. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We appreciate the contributions of Mary-Jane Khumalo, Robin Draper, Keith Rasmussen, Langa Ngubane, Stanley Carries, Shaakir Khader, Matanja Coetzee, Molly Franke, Krista Dong, Rocio Hurtado, and Bruce Walker. We acknowledge the support of the KwaZulu-Natal Department of Health. NR 37 TC 64 Z9 64 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD JUN PY 2010 VL 7 IS 6 AR e1000296 DI 10.1371/journal.pmed.1000296 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 619AV UT WOS:000279400000016 PM 20582324 ER PT J AU Figoni, SF Kunkel, CF Scremin, AME Scremin, OU Cohen, B AF Figoni, Stephen F. Kunkel, Charles F. Scremin, A. M. Erika Scremin, Oscar U. Cohen, Babak TI Ergometric Performance During Exercise Training in Men With Intermittent Claudication SO PM&R LA English DT Article AB Objective: To determine and describe changes in weekly work, power, exercise times, and recovery times during an exercise training intervention in men with peripheral arterial disease (PAD) and intermittent calf claudication. Design: Tracking of weekly exercise training parameters involved repeated measures over time in one group of participants. Other outcomes of this pilot study used a one-group, pretest-posttest design. Setting: Tertiary-care medical center. Participants: Fifteen male veterans (mean age, 69 years) with Fontaine stage ha PAD and classic intermittent calf claudication. Main Outcome Measurements: Participants completed graded treadmill exercise tests before and after intervention from which maximal walking power was calculated. Work, power, and exercise and recovery times for each exercise training session were computed and averaged for each week. Intervention: The intervention consisted of an intensive 3-month exercise training program involving walking and calf muscle exercises: 3 sessions per week at the clinic (treadmill walking and calf ergometry) and 2 sessions per week at home (free walking and standing heel raises). Results: After training, participants increased treadmill maximal walking power from 220 to 414 W (by 87%). Treadmill and calf exercise work, power, and exercise time per session increased linearly during 13 weeks of training, whereas recovery time per session of treadmill exercise decreased. During the same period, treadmill and calf exercise training power outputs increased by averages of 227% and 92%, respectively. Conclusion: Calculation of work and power during exercise training can be used to track progress quantitatively at short intervals. Weekly linear increases in training work and power per exercise session suggest that optimal intervention duration may be longer than 3 months for men with PAD and intermittent calf claudication. PM R 2010;2:528-536 C1 [Figoni, Stephen F.; Kunkel, Charles F.; Scremin, A. M. Erika; Cohen, Babak] VA Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Serv, Los Angeles, CA 90073 USA. [Kunkel, Charles F.; Scremin, A. M. Erika] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Scremin, Oscar U.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Scremin, Oscar U.; Cohen, Babak] VA Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA. RP Figoni, SF (reprint author), VA Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM sfigoni@gmail.com FU Rehabilitation Research and Development Service, Department of Veterans Affairs [B3644P] FX Disclosure: 8, Rehabilitation Research and Development Service, Department of Veterans Affairs grant #B3644P NR 18 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD JUN PY 2010 VL 2 IS 6 BP 528 EP 536 DI 10.1016/j.pmrj.2010.03.009 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA V24LQ UT WOS:000208412300008 PM 20630439 ER PT J AU Zhou, BY Xu, WH Herndon, D Tompkins, R Davis, R Xiao, WZ Wong, WH AF Zhou, Baiyu Xu, Weihong Herndon, David Tompkins, Ronald Davis, Ronald Xiao, Wenzhong Wong, Wing Hung CA Inflammation Host Response Injury TI Analysis of factorial time-course microarrays with application to a clinical study of burn injury SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE factorial design; longitudinal data; analysis of variance ID GENE-EXPRESSION DATA; IDENTIFICATION; CHILDREN; MODEL AB Time-course microarray experiments are capable of capturing dynamic gene expression profiles. It is important to study how these dynamic profiles depend on the multiple factors that characterize the experimental condition under which the time course is observed. Analytic methods are needed to simultaneously handle the time course and factorial structure in the data. We developed a method to evaluate factor effects by pooling information across the time course while accounting for multiple testing and non-normality of the microarray data. The method effectively extracts gene-specific response features and models their dependency on the experimental factors. Both longitudinal and cross-sectional time-course data can be handled by our approach. The method was used to analyze the impact of age on the temporal gene response to burn injury in a large-scale clinical study. Our analysis reveals that 21% of the genes responsive to burn are age-specific, among which expressions of mitochondria and immunoglobulin genes are differentially perturbed in pediatric and adult patients by burn injury. These new findings in the body's response to burn injury between children and adults support further investigations of therapeutic options targeting specific age groups. The methodology proposed here has been implemented in R package "TANOVA" and submitted to the Comprehensive R Archive Network at http://www.r-project.org/. It is also available for download at http://gluegrant1.stanford.edu/TANOVA/. C1 [Xu, Weihong; Davis, Ronald; Xiao, Wenzhong] Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA. [Xu, Weihong; Davis, Ronald; Xiao, Wenzhong] Stanford Univ, Dept Biochem, Palo Alto, CA 94304 USA. [Zhou, Baiyu; Wong, Wing Hung] Stanford Univ, Dept Stat, Stanford, CA 94305 USA. [Herndon, David] Univ Texas Galveston, Med Branch, Dept Surg, Galveston, TX 77550 USA. [Tompkins, Ronald; Xiao, Wenzhong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Children, Boston, MA 02114 USA. [Wong, Wing Hung] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. RP Xiao, WZ (reprint author), Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA. EM wxiao1@partners.org; whwong@stanford.edu RI Zhou, Baiyu/H-3506-2012; Xu, Weihong/C-4175-2012; OI xiao, wenzhong/0000-0003-4944-6380; Remick, Daniel/0000-0002-2615-3713 FU NIH [U54 GM-062119, SHC 86400] FX We thank Ted Anderson for helpful discussions. In particular, we wish to acknowledge the efforts of many individuals at participating institutions of the Glue Grant Program that generated the clinical and genomic data reported here. This study was supported by NIH U54 GM-062119 and SHC 86400. NR 21 TC 33 Z9 35 U1 0 U2 5 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JUN 1 PY 2010 VL 107 IS 22 BP 9923 EP 9928 DI 10.1073/pnas.1002757107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 603ZD UT WOS:000278246000005 PM 20479259 ER PT J AU Wolk, DA Dickerson, BC AF Wolk, David A. Dickerson, Bradford C. CA Alzheimer's Dis Neuroimaging TI Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE cognition; neuroimaging; dementia; cortical thickness; medial temporal lobe ID NINCDS-ADRDA CRITERIA; E EPSILON-4 ALLELE; MILD AD DEMENTIA; FRONTOTEMPORAL DEMENTIA; CORTICAL SIGNATURE; ENTORHINAL CORTEX; TRANSGENIC MICE; E POLYMORPHISM; BRAIN ATROPHY; SURFACE-AREA AB The epsilon 4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for Alzheimer's disease (AD), but limited work has suggested that APOE genotype may modulate disease phenotype. Carriers of the e4 allele have been reported to have greater medial temporal lobe (MTL) pathology and poorer memory than noncarriers. Less attention has focused on whether there are domains of cognition and neuroanatomical regions more affected in noncarriers. Further, a major potential confound of prior in vivo studies is the possibility of different rates of clinical misdiagnosis for carriers vs. noncarriers. We compared phenotypic differences in cognition and topography of regional cortical atrophy of e4 carriers (n = 67) vs. noncarriers (n = 24) with mild AD from the Alzheimer's Disease Neuroimaging Initiative, restricted to those with a cerebrospinal fluid (CSF) molecular pro. le consistent with AD. Between-group comparisons were made for psychometric tests and morphometric measures of cortical thickness and hippocampal volume. Carriers displayed significantly greater impairment on measures of memory retention, whereas noncarriers were more impaired on tests of working memory, executive control, and lexical access. Consistent with this cognitive dissociation, carriers exhibited greater MTL atrophy, whereas noncarriers had greater frontoparietal atrophy. Performance deficits in particular cognitive domains were associated with disproportionate regional brain atrophy within nodes of cortical networks thought to subserve these cognitive processes. These convergent cognitive and neuroanatomic findings in individuals with a CSF molecular pro. le consistent with AD support the hypothesis that APOE genotype modulates the clinical phenotype of AD through influence on specific large-scale brain networks. C1 [Wolk, David A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Wolk, David A.] Univ Penn, Alzheimers Dis Core Ctr, Philadelphia, PA 19104 USA. [Wolk, David A.] Univ Penn, Penn Memory Ctr, Philadelphia, PA 19104 USA. [Dickerson, Bradford C.] Massachusetts Gen Hosp, Frontotemporal Dementia Unit, Boston, MA 02115 USA. [Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. [Dickerson, Bradford C.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02115 USA. [Dickerson, Bradford C.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Wolk, DA (reprint author), Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. EM david.wolk@uphs.upenn.edu RI Scharre, Douglas/E-4030-2011; Preda, Adrian /K-8889-2013; Saykin, Andrew/A-1318-2007; Beversdorf, David/M-2786-2016 OI Preda, Adrian /0000-0003-3373-2438; Saykin, Andrew/0000-0002-1376-8532; Beversdorf, David/0000-0002-0298-0634 FU ADNI; National Institutes of Health [U01 AG024904]; National Institute on Aging (NIA); National Institute of Biomedical Imaging and Bioengineering; Northern California Institute for Research and Education; NIA [R01-AG29411, R21-AG29840, P50-AG005134, K23-AG028018, P30-AG010124]; Alzheimer's Association FX This work was primarily funded by the ADNI (Principal Investigator: Michael Weiner; National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering, and the with participation from the US Food and Drug Administration. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. This analysis was also supported by NIA Grants R01-AG29411, R21-AG29840, P50-AG005134, K23-AG028018, and P30-AG010124 and the Alzheimer's Association. NR 60 TC 89 Z9 90 U1 0 U2 8 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JUN 1 PY 2010 VL 107 IS 22 BP 10256 EP 10261 DI 10.1073/pnas.1001412107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 603ZD UT WOS:000278246000063 PM 20479234 ER PT J AU Banez, LL Loftis, RM Freedland, SJ Presti, JC Aronson, WJ Amling, CL Kane, CJ Terris, MK AF Banez, L. L. Loftis, R. M. Freedland, S. J. Presti, J. C., Jr. Aronson, W. J. Amling, C. L. Kane, C. J. Terris, M. K. TI The influence of hepatic function on prostate cancer outcomes after radical prostatectomy SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article DE prostate neoplasm; staging; pathology; PSA recurrence; radical prostatectomy; liver function tests ID HORMONE-BINDING GLOBULIN; LIVER-CIRRHOSIS; ALCOHOL-CONSUMPTION; RISK; ANTIGEN; FINASTERIDE; OBESITY; COHORT; MALES; MEN AB Prostate growth is dependent on circulating androgens, which can be influenced by hepatic function. Liver disease has been suggested to influence prostate cancer (CaP) incidence. However, the effect of hepatic function on CaP outcomes has not been investigated. A total of 1181 patients who underwent radical prostatectomy (RP) between 1988 and 2008 at four Veterans Affairs hospitals that comprise the Shared Equal Access Regional Cancer Hospital database and had available liver function test (LFT) data were included in the study. Independent associations of LFTs with unfavorable pathological features and biochemical recurrence were determined using logistic and Cox regression analyses. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were elevated in 8.2 and 4.4% of patients, respectively. After controlling for CaP features, logistic regression revealed a significant association between SGOT levels and pathological Gleason sum >= 7(4 + 3) cancer (odds ratio = 2.12; 95% confidence interval = 1.11-4.05; P = 0.02). Mild hepatic dysfunction was significantly associated with adverse CaP grade, but was not significantly associated with other adverse pathological features or biochemical recurrence in a cohort of men undergoing RP. The effect of moderate-to-severe liver disease on disease outcomes in CaP patients managed non-surgically remains to be investigated. Prostate Cancer and Prostatic Diseases (2010) 13, 173-177; doi:10.1038/pcan.2010.3; published online 2 March 2010 C1 [Banez, L. L.; Freedland, S. J.] Duke Univ, Div Urol Surg, Dept Surg, Med Ctr, Durham, NC 27710 USA. [Banez, L. L.; Freedland, S. J.] Duke Univ, Duke Prostate Ctr, Dept Surg, Med Ctr, Durham, NC 27710 USA. [Banez, L. L.; Freedland, S. J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Loftis, R. M.; Terris, M. K.] Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA. [Loftis, R. M.; Terris, M. K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Freedland, S. J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Presti, J. C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, J. C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Aronson, W. J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA. [Amling, C. L.] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR 97201 USA. [Kane, C. J.] Univ Calif San Diego, Dept Urol, San Diego, CA 92103 USA. [Kane, C. J.] Vet Affairs Med Ctr, Urol Sect, San Diego, CA 92161 USA. RP Banez, LL (reprint author), Duke Univ, Div Urol Surg, Dept Surg, Med Ctr, Box 2626,571 Res Dr, Durham, NC 27710 USA. EM lionel.banez@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU Department of Veterans Affairs; Department of Defense; Georgia Cancer Coalition; American Urological Association Foundation; National Institutes of Health [R01 CA100938, P50 CA921310-1A1] FX This study was supported by the Department of Veterans Affairs, Department of Defense Prostate Cancer Research Program, the Georgia Cancer Coalition, the American Urological Association Foundation/Astellas Rising Star in Urology Award, National Institutes of Health R01 CA100938, and National Institutes of Health Specialized Programs of Research Excellence Grant P50 CA921310-1A1. NR 24 TC 9 Z9 9 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD JUN PY 2010 VL 13 IS 2 BP 173 EP 177 DI 10.1038/pcan.2010.3 PG 5 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 595QC UT WOS:000277626300011 PM 20195294 ER PT J AU Cohen, LS Wang, B Nonacs, R Viguera, AC Lemon, EL Freeman, MP AF Cohen, Lee S. Wang, Betty Nonacs, Ruta Viguera, Adele C. Lemon, Elizabeth L. Freeman, Marlene P. TI Treatment of Mood Disorders During Pregnancy and Postpartum SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Mood disorders; Pregnancy; Postpartum ID SEROTONIN-REUPTAKE INHIBITORS; PERSISTENT PULMONARY-HYPERTENSION; IN-UTERO EXPOSURE; DEFICIT HYPERACTIVITY DISORDER; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTROPIC-DRUG USE; BIPOLAR DISORDER; PANIC DISORDER; POSTNATAL DEPRESSION; MAJOR DEPRESSION AB Studies suggest that pregnancy does not protect women from the emergence or persistence of mood disorders. Mood and anxiety disorders are prevalent in women during the childbearing years and, for many women, these mood disorders are chronic or recurrent. Maintenance antidepressant therapy is often indicated during the reproductive years and women face difficult treatment decisions regarding psychotropic medications and pregnancy. Treatment of psychiatric disorders during pregnancy involves a thoughtful weighing of the risks and benefits of proposed interventions and the documented and theoretical risks associated with untreated psychiatric disorders such as depression. Collaborative decision-making that incorporates patient treatment preferences is optimal for women trying to conceive or who are pregnant. This article reviews the diagnosis and treatment guidelines of mood disorders during pregnancy and postpartum, with specific reference to the use of psychotropic medications during this critical time. C1 [Cohen, Lee S.; Wang, Betty; Nonacs, Ruta; Viguera, Adele C.; Lemon, Elizabeth L.; Freeman, Marlene P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. RP Cohen, LS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 185 Cambridge St, Boston, MA 02114 USA. EM lcohen2@partners.org NR 138 TC 29 Z9 29 U1 6 U2 15 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD JUN PY 2010 VL 33 IS 2 BP 273 EP + DI 10.1016/j.psc.2010.02.001 PG 22 WC Psychiatry SC Psychiatry GA 591FN UT WOS:000277285300003 PM 20385337 ER PT J AU Deligiannidis, KM Freeman, MP AF Deligiannidis, Kristina M. Freeman, Marlene P. TI Complementary and Alternative Medicine for the Treatment of Depressive Disorders in Women SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Complementary/alternative treatment; S-Adenosylmethionine; Omega-3 fatty acids; St John's wort; Acupuncture; Depression; Women ID ST-JOHNS-WORT; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; ADENOSYL-L-METHIONINE; PHASE DYSPHORIC DISORDER; DECREASES PREMENSTRUAL SYMPTOMS; POLYUNSATURATED FATTY-ACIDS; POSTMENOPAUSAL HOT FLASHES; BRIGHT LIGHT TREATMENT; MIDDLE-AGED WOMEN AB Complementary and alternative medicine (CAM) therapies are commonly practiced in the United States and are used more frequently among women than men. This article reviews several CAM treatments for depressive disorders in women, with a focus on major depressive disorder across the reproductive life cycle. The CAM therapies selected for this review (ie, S-adenosylmethionine, omega-3 fatty acids, St John's wort, bright light therapy, acupuncture, and exercise) were based on their prevalence of use and the availability of randomized, placebo-controlled data. Further study is necessary to delineate the role of specific CAM therapies in premenstrual syndrome, premenstrual dysphoric disorder, antepartum and postpartum depression, lactation, and the menopausal transition. C1 [Deligiannidis, Kristina M.] Univ Massachusetts, Sch Med, Ctr Psychopharmacol Res & Treatment, Worcester, MA 01605 USA. [Deligiannidis, Kristina M.] Univ Massachusetts, Sch Med, Depress Specialty Clin, UMass Mem Med Ctr, Worcester, MA 01605 USA. [Deligiannidis, Kristina M.] Univ Massachusetts, Sch Med, Womens Mental Hlth Specialty Clin, UMass Mem Med Ctr, Worcester, MA 01605 USA. [Freeman, Marlene P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Perinatal & Reprod Psychiat Program, Boston, MA 02114 USA. RP Deligiannidis, KM (reprint author), Univ Massachusetts, Sch Med, Ctr Psychopharmacol Res & Treatment, 361 Plantat St, Worcester, MA 01605 USA. EM kristina.deligiannidis@umassmemorial.org RI Deligiannidis, Kristina/C-3654-2014 OI Deligiannidis, Kristina/0000-0001-7439-2236 NR 182 TC 17 Z9 17 U1 10 U2 23 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD JUN PY 2010 VL 33 IS 2 BP 441 EP + DI 10.1016/j.psc.2010.01.002 PG 24 WC Psychiatry SC Psychiatry GA 591FN UT WOS:000277285300012 PM 20385346 ER PT J AU Pratchett, LC Pelcovitz, MR Yehuda, R AF Pratchett, Laura C. Pelcovitz, Michelle R. Yehuda, Rachel TI Trauma and Violence: Are Women the Weaker Sex? SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Trauma; Gender; Risk; Prevalence ID POSTTRAUMATIC-STRESS-DISORDER; BORDERLINE PERSONALITY-DISORDER; NATIONAL-COMORBIDITY-SURVEY; PSYCHOLOGICAL RISK-FACTORS; GENDER-DIFFERENCES; CHILDHOOD EXPERIENCES; GENERAL-POPULATION; FEMALE-PATIENTS; MENTAL-HEALTH; LIFE EVENTS AB Posttraumatic stress disorder (PTSD) as a response to trauma is repeatedly found to be more common among women than men. This article explores prevalence rates and gender differences. Explanations for this gender bias and examined and the literature on trauma types and resulting PTSD is reviewed. Other disorders that may result from trauma that also have gender biases are considered as a potential way to understand this difference. Risk and resilience can perhaps more appropriately be considered specific to symptom picture rather than merely development of pathology. C1 [Pratchett, Laura C.; Pelcovitz, Michelle R.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Pratchett, Laura C.; Pelcovitz, Michelle R.; Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Pratchett, LC (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH 116-A,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM laura.pratchett@va.gov NR 62 TC 30 Z9 31 U1 1 U2 13 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD JUN PY 2010 VL 33 IS 2 BP 465 EP + DI 10.1016/j.psc.2010.01.010 PG 12 WC Psychiatry SC Psychiatry GA 591FN UT WOS:000277285300013 PM 20385347 ER PT J AU Kettl, P AF Kettl, Paul TI State Hospitals and Getting Stuck in a Train SO PSYCHIATRIC SERVICES LA English DT Editorial Material C1 Philadelphia Dept Vet Affairs Med Ctr, Behav Hlth Serv, Philadelphia, PA 19104 USA. RP Kettl, P (reprint author), Philadelphia Dept Vet Affairs Med Ctr, Behav Hlth Serv, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM paul.kettl@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUN PY 2010 VL 61 IS 6 BP 552 EP 553 PG 2 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 602UT UT WOS:000278165100004 PM 20513676 ER PT J AU Perron, BE Grahovac, ID Parrish, D AF Perron, Brian E. Grahovac, Ivana D. Parrish, Diana TI Students for Recovery: A Novel Way to Support Students on Campus SO PSYCHIATRIC SERVICES LA English DT Editorial Material C1 [Perron, Brian E.] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA. [Grahovac, Ivana D.] Univ Texas Austin, Ctr Students Recovery, Austin, TX 78712 USA. [Parrish, Diana] US Dept Vet Affairs, Ann Arbor, MI USA. RP Perron, BE (reprint author), Univ Michigan, Sch Social Work, 1080 S Univ Ave, Ann Arbor, MI 48109 USA. EM beperron@umich.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUN PY 2010 VL 61 IS 6 BP 633 EP 633 PG 1 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 602UT UT WOS:000278165100019 PM 20513691 ER PT J AU Moore, SA Varra, AA Michael, ST Simpson, TL AF Moore, Sally A. Varra, Alethea A. Michael, Scott T. Simpson, Tracy L. TI Stress-Related Growth, Positive Reframing, and Emotional Processing in the Prediction of Post-Trauma Functioning Among Veterans in Mental Health Treatment SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE stress-related growth; emotional processing; reappraisal; positive reframing; posttraumatic stress disorder ID BREAST-CANCER; TRAUMA; ADJUSTMENT; DEPRESSION; VALIDATION AB The role of stress related growth (SRG) in posttrauma functioning is currently uncertain and may be obscured by the overlap between SRG and key coping strategies. Utilizing a veteran sample in mental health treatment, the current study examined whether SRG accounts for unique variance in the severity of posttraumatic stress disorder (PTSD), depression, and Disorders of Extreme Stress Not Otherwise Specified (DESNOS) beyond the effects of two general coping strategies, emotional processing and positive reframing. Curvilinear relationships were evident between SRG and outcome measures, such that individuals with moderate SRG reported the greatest distress, and individuals with the lowest and highest SRG scores reported lower distress. In regression analyses. SRG accounted for significant variance in lower PTSD, depression, and DESNOS while accounting for demographics, trauma type, emotional processing, and positive reframing. The results suggest that SRG captures variance in posttrauma functioning that may be distinct from general emotional processing and positive refraining coping and provides further evidence for a curvilinear relationship between SRG and measures of psychological distress. C1 [Moore, Sally A.] Dept Vet Affairs Med Ctr, MIRECC, Seattle, WA USA. [Moore, Sally A.; Varra, Alethea A.; Michael, Scott T.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Varra, Alethea A.; Michael, Scott T.; Simpson, Tracy L.] Dept Vet Affairs Med Ctr, Mental Hlth Serv, Seattle, WA USA. RP Moore, SA (reprint author), VA Puget Sound Hlth Care Syst, Mail Stop S116-WTRC,1660 S Columbian Way, Seattle, WA 98108 USA. EM sally.moore2@va.gov NR 15 TC 6 Z9 6 U1 1 U2 2 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD JUN PY 2010 VL 2 IS 2 BP 93 EP 96 DI 10.1037/a0018975 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 742CD UT WOS:000288914800004 ER PT J AU Boscarino, JA Forsberg, CW Goldberg, J AF Boscarino, Joseph A. Forsberg, Christopher W. Goldberg, Jack TI A Twin Study of the Association Between PTSD Symptoms and Rheumatoid Arthritis SO PSYCHOSOMATIC MEDICINE LA English DT Article DE posttratimatic stress disorder; rheumatoid arthritis; autoimmune disease; inflammation; zygosity; co-twin study ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; TRADE-CENTER DISASTER; VIETNAM VETERANS; CLINICAL-RESEARCH; COMBAT EXPOSURE; CHILDHOOD ABUSE; PHYSICAL HEALTH; MORTALITY; TRAUMA AB Objectives: To assess the association between posttraumatic stress disorder (PTSD) and rheumatoid arthritis (RA) and to determine if this was due to PTSD or confounding by environmental and genetic factors. Methods: Data were obtained from 3143 twin pairs in the Vietnam Era Twin Registry, which included male twin pairs who served during the Vietnam War era (mean age, 40.6 years; standard deviation, 2.9). Measurements included a PTSD symptom scale, history of physician-diagnosed RA, sociodemographics, and health confounding factors. Co-twin control analytic methods used generalized estimating equation logistic regression to account for the paired twin data and to examine the association between PTSD symptoms and RA in all twins. Separate analyses were conducted within twin pairs. Results: The prevalence of RA among this population was 1.9% (95% confidence interval, 1.6-2.3) and the mean PTSD symptom level was 25.5 (standard deviation, 9.6). PTSD symptoms were associated with an increased likelihood of adult RA even after adjustment for confounding (p(trend) < .001). Among all twins, those in the highest PTSD symptom quartile were 3.8 times more likely (95% confidence interval, 2.1-6.1) to have RA compared with those in the lowest. These findings also persist when examined within twin pairs (p(trend) < .022). Conclusions: PTSD symptoms were associated with adult RA onset. Even after adjustment for familial/genetic factors and other confounders, an association between PTSD symptoms and RA remained. This is one of the first studies to demonstrate a link between PTSD and RA onset among a community-based population sample, independent of familial and genetic factors. C1 [Boscarino, Joseph A.] Geisinger Med Clin, Ctr Hlth Res, Danville, PA 17822 USA. [Boscarino, Joseph A.] Mt Sinai Sch Med, Dept Internal Med, New York, NY USA. [Boscarino, Joseph A.] Mt Sinai Sch Med, Dept Pediat, New York, NY USA. [Forsberg, Christopher W.; Goldberg, Jack] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Goldberg, Jack] Univ Washington, Dept Epidemiol, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA. RP Boscarino, JA (reprint author), Geisinger Med Clin, Ctr Hlth Res, 100 N Acad Ave, Danville, PA 17822 USA. EM jaboscarino@geisinger.edu FU VA Puget Sound Health Care System, Seattle, Washington; U.S. Department of Veterans Affairs FX This study was supported, in part, by the VA Puget Sound Health Care System, Seattle, Washington. The U.S. Department of Veterans Affairs provided financial support for the development and maintenance of the VET Registry. NR 49 TC 40 Z9 40 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD JUN PY 2010 VL 72 IS 5 BP 481 EP 486 DI 10.1097/PSY.0b013e3181d9a80c PG 6 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 613UB UT WOS:000279005800007 PM 20410244 ER PT J AU Schwarzschild, M AF Schwarzschild, Michael TI Targeting purines in Parkinson's: From adenosine to caffeine to urate SO PURINERGIC SIGNALLING LA English DT Meeting Abstract C1 [Schwarzschild, Michael] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1573-9538 J9 PURINERG SIGNAL JI Purinergic Signal. PD JUN PY 2010 VL 6 SU 1 BP 21 EP 21 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 630AA UT WOS:000280241700044 ER PT J AU Holden, LM Watts, DD Walker, PH AF Holden, L. M. Watts, D. D. Walker, P. H. TI Communication and collaboration: it's about the pharmacists, as well as the physicians and nurses SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID SAFETY ATTITUDES QUESTIONNAIRE; GENERAL-PRACTICE; MEDICAL ERRORS; MALPRACTICE CLAIMS; ADVERSE EVENTS; TEAMWORK; CLIMATE; CARE AB Objective Collaboration and communication as dimensions of patient safety climate have been measured in acute care hospital units, and discrepant viewpoints have been documented between different professional groups, particularly between physicians and nurses. In the ambulatory care setting, these groups often work more closely together throughout the day than in acute care settings, thereby enhancing effective collaboration and communication. This study sought to determine if the communication differences that are known to impact patient safety, which are found in acute care, also exist in ambulatory care. Methods The Safety Attitudes Questionnaire, a 77-item survey of collaboration, communication and safety attitudes, was administered to the primary care staff at four Midwestern military ambulatory care clinics. Results There were 107 participants consisting of nurses (n=46), nurse practitioners (n=12), pharmacists (n=10) and physicians (n=39), yielding an overall response rate of 65%. All groups rated their peer group higher than other professional groups. The ratings of nurses and physicians were very similar: 85.0% of nurses rated physicians, and 85.7% of physicians rated nurses as high or very high in communication and collaboration. Pharmacists were rated the lowest by each of the other professional groups. Only 60% of pharmacists rated physicians as high or very high. Conclusions Collaboration and communication ratings among physicians and nurses appear to be higher in the ambulatory care setting than in the acute care. However, interactions with pharmacists are more problematic, perceived as adversarial. Teamwork training that focuses on specific interactions among professional groups should target these concerns. C1 [Holden, L. M.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA. [Holden, L. M.] United States AF Nurse Corps, Offutt AFB, NE USA. [Watts, D. D.; Walker, P. H.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. RP Holden, LM (reprint author), Massachusetts Gen Hosp, Ctr Qual & Safety, 55 Fruit St,BUL 280, Boston, MA 02114 USA. EM LMHolden@Partners.org NR 24 TC 5 Z9 5 U1 1 U2 5 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD JUN PY 2010 VL 19 IS 3 BP 169 EP 172 DI 10.1136/qshc.2008.026435 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 618LL UT WOS:000279355700003 PM 20123760 ER PT J AU Pomerantz, SR Choy, G AF Pomerantz, Stuart R. Choy, Garry TI Net Assets: PowerPoint Pearls for Radiology Presentations. Part II SO RADIOLOGY LA English DT Editorial Material ID MOVIE CLIPS C1 [Pomerantz, Stuart R.] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA. [Choy, Garry] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Pomerantz, SR (reprint author), Massachusetts Gen Hosp, Dept Neuroradiol, 55 Fruit St,Gray 2-B285, Boston, MA 02114 USA. EM netassets@rsna.org NR 5 TC 2 Z9 2 U1 0 U2 1 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JUN PY 2010 VL 255 IS 3 BP 687 EP 691 DI 10.1148/radiol.10100479 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 601DO UT WOS:000278038500006 PM 20501709 ER PT J AU Vartanians, VM Sistrom, CL Weilburg, JB Rosenthal, DI Thrall, JH AF Vartanians, Vartan M. Sistrom, Christopher L. Weilburg, Jeffrey B. Rosenthal, Daniel I. Thrall, James H. TI Increasing the Appropriateness of Outpatient Imaging: Effects of a Barrier to Ordering Low-Yield Examinations SO RADIOLOGY LA English DT Article ID CLINICAL DECISION-SUPPORT; PATIENT OUTCOMES; CHEST PAIN; EDUCATION; PROGRAM; SYSTEMS; CARE; INTERVENTION; INFORMATION; MANAGEMENT AB Purpose: To determine the effect of a computerized radiology order entry system rule that prevented nonclinician support staff from completing orders for outpatient computed tomographic, magnetic resonance imaging, and nuclear medicine examinations that received initial low-yield decision support scores in the order entry system. Materials and Methods: This retrospective HIPAA-compliant study was approved by the institutional review board; the requirement for informed consent was waived. The control group consisted of 42 737 consecutive orders for examinations in which decision support was provided that were placed from April to December 2006. The study group consisted of 76 238 consecutive orders that were placed from April to December 2007. During the latter time period, a new rule in the order entry system was implemented: Examinations that had low-yield decision support scores could not be scheduled when the orders were placed by nonclinician support staff. To schedule the blocked examinations, the responsible clinician was required to personally log in to complete the process. System event logs and records of outpatient imaging procedures were extracted, counted, and analyzed to determine which ordering sessions resulted in examinations being scheduled and performed and which sessions resulted in modified or cancelled examinations. Results were correlated with user status and decision support scores. The Cochran-Mantel-Haenszel technique was used to control for the status of the order initiator and to allow testing for significance of the effect of the intervention on the "fate" of ordering events. Results: After the intervention, the proportion of total examination requests initiated by clinicians directly logging in almost doubled: from 11 243 (26.31%) of 42 737 to 41 450 (54.37%) of 76 238 examinations (P < .001). The fraction of low-yield (decision support score, 1-3) examinations requested through the order entry system that were later scheduled and performed decreased from 2106 (5.43%) of 38 801 to 1261 (1.92%) of 65 765 (P < .001). This is in contrast to requests for examinations with higher initial decision support scores that were not affected by the policy change and were scheduled at the same rate (relative risk, 0.988) before and after the change. Conclusion: A simple change in the business logic of the order entry system resulted in a substantially decreased rate of low-yield imaging examinations and a markedly increased percentage of tests personally ordered by clinicians. C1 [Vartanians, Vartan M.; Rosenthal, Daniel I.; Thrall, James H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Weilburg, Jeffrey B.] Harvard Univ, Sch Med, Massachusetts Gen Phys Org, Boston, MA 02114 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sistrom, Christopher L.] Univ Florida, Dept Radiol, Gainesville, FL 32610 USA. RP Vartanians, VM (reprint author), Harvard Univ, Sch Med, Dept Radiol, 25 New Chardon St,Suite 427B, Boston, MA 02114 USA. EM vvartanians@partners.org NR 21 TC 47 Z9 50 U1 1 U2 3 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JUN PY 2010 VL 255 IS 3 BP 842 EP 849 DI 10.1148/radiol.10091228 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 601DO UT WOS:000278038500023 PM 20501721 ER PT J AU Almandoz, JED Schaefer, PW Kelly, HR Lev, MH Gonzalez, RG Romero, JM AF Almandoz, Josser E. Delgado Schaefer, Pamela W. Kelly, Hillary R. Lev, Michael H. Gonzalez, R. Gilberto Romero, Javier M. TI CT Angiography in Head and Neck Trauma Response SO RADIOLOGY LA English DT Letter C1 [Almandoz, Josser E. Delgado; Schaefer, Pamela W.; Kelly, Hillary R.; Lev, Michael H.; Gonzalez, R. Gilberto; Romero, Javier M.] Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA. [Almandoz, Josser E. Delgado] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Div Neuroradiol, St Louis, MO 63110 USA. RP Almandoz, JED (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA. EM delgadoj@mir.wustl.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JUN PY 2010 VL 255 IS 3 BP 1009 EP 1009 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 601DO UT WOS:000278038500041 ER PT J AU Ling, CC Gerweck, LE Zaider, M Yorke, E AF Ling, C. Clifton Gerweck, Leo E. Zaider, Marco Yorke, Ellen TI Dose-rate effects in external beam radiotherapy redux SO RADIOTHERAPY AND ONCOLOGY LA English DT Review DE Dose-rate effect; External beam radiotherapy ID POTENTIALLY LETHAL DAMAGE; LINEAR-QUADRATIC MODEL; PLATEAU-PHASE CULTURES; CHINESE-HAMSTER CELLS; MAMMALIAN-CELLS; RADIATION-DAMAGE; SUBLETHAL DAMAGE; SPINAL-CORD; INTERFRACTION INTERVAL; CHROMOSOME-ABERRATIONS AB Recent developments in external beam radiotherapy, both in technical advances and in clinical approaches, have prompted renewed discussions on the potential influence of dose-rate on radio-response in certain treatment scenarios. We consider the multiple factors that influence the dose-rate effect, e.g. radical recombination, the kinetics of sublethal damage repair for tumors and normal tissues, the difference in alpha/beta ratio for early and late reacting tissues, and perform a comprehensive literature review. Based on radiobiological considerations and the linear-quadratic (LQ) model we estimate the influence of overall treatment time on radio-response for specific clinical situations. As the influence of dose-rate applies to both the tumor and normal tissues, in oligo-fractionated treatment using large doses per fraction, the influence of delivery prolongation is likely important, with late reacting normal tissues being generally more sensitive to the dose-rate effect than tumors and early reacting tissues. In conventional fractionated treatment using 1.8-2 Gy per fraction and treatment times of 2-10 min, the influence of dose-rate is relatively small. Lastly, the dose-rate effect in external beam radiotherapy is governed by the overall beam-on-time, not by the average linac dose-rate, nor by the instantaneous dose-rate within individual linac pulses which could be as high as 3 x 10(6) MU/min. (C) 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 95 (2010) 261-268 C1 [Ling, C. Clifton] Varian Med Syst, Palo Alto, CA USA. [Ling, C. Clifton; Zaider, Marco; Yorke, Ellen] Mem Hosp, Dept Med Phys, New York, NY USA. [Gerweck, Leo E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Ling, CC (reprint author), Varian Med Syst, Palo Alto, CA USA. EM lingc@mskcc.org; lgerweck@partners.org OI Zaider, Marco/0000-0002-5113-7862 NR 66 TC 42 Z9 43 U1 2 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD JUN PY 2010 VL 95 IS 3 BP 261 EP 268 DI 10.1016/j.radonc.2010.03.014 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 614EO UT WOS:000279038400001 PM 20363041 ER PT J AU Hurwitz, MD Kaur, P Nagaraja, GM Bausero, MA Manola, J Asea, A AF Hurwitz, Mark D. Kaur, Punit Nagaraja, Ganachari M. Bausero, Maria A. Manola, Judith Asea, Alexzander TI Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE Androgen suppressive therapy; Chaperokine; Heat shock proteins; Prostate cancer; Radiation ID HEAT-SHOCK-PROTEIN; CELL-DERIVED EXOSOMES; IMMUNE-RESPONSE; CHAPEROKINE ACTIVITY; EXTRACELLULAR HSP72; STRESS-PROTEINS; T-CELLS; IN-VIVO; HEAT-SHOCK-PROTEIN-70; PATHWAY AB Background and purpose: Hsp72 found in the extracellular milieu has been shown to play an important role in immune regulation. The impact of common cancer therapies on extracellular release of Hsp72 however, has been to date undefined. Materials and methods: Serum from 13 patients undergoing radiation therapy (XRT) for prostate cancer with or without hormonal therapy (ADT) was measured for levels of circulating serum Hsp72 and pro-inflammatory cytokines (IL-6 and TNF-alpha) using the classical sandwich ELISA technique and the relative expression of CD8(+) T lymphocytes and natural killer (NK) cells was measured using flow cytometry. Mouse orthotopic xenograft of human prostate cancer tumors (DU-145 and PC-3) were used to validate and further characterize the response noted in the clinical setting. The biological significance of tumor released Hsp72 was studied in human dendritic cells (DC) in vitro. Results: Circulating serum Hsp72 levels increased an average of 3.5-fold (median per patient 4.8-fold) with XRT but not with ADT (p = 0.0002). Increases in IL-6 (3.3-fold), TNF-alpha (1.8-fold), CD8(+) CTL (2.1-fold) and NK cells (3.2-fold) also occurred. Using PC-3 and DU-145 human prostate cancer xenograft models in mice, we confirmed that XRT induces Hsp72 release primarily from implanted tumors. In vitro studies using supernatant recovered from irradiated human prostate cancer cells point to exosomes containing Hsp72 as a possible stimulator of pro-inflammatory cytokine production and costimulatory molecules expression in human DC. Conclusions: The current study confirms for the first time in an actual clinical setting elevation of circulating serum Hsp72 with XRT. The accompanying studies in mice and in vitro identify the released exosomes containing Hsp72 as playing a pivotal role in stimulating pro-inflammatory immune responses. These findings, if validated, may lead to new treatment paradigms for common human malignancies. (C) 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 95 (2010) 350-358 C1 [Kaur, Punit; Nagaraja, Ganachari M.; Bausero, Maria A.; Asea, Alexzander] Scott & White Mem Hosp & Clin, Dept Pathol, Temple, TX 76504 USA. [Kaur, Punit; Nagaraja, Ganachari M.; Bausero, Maria A.; Asea, Alexzander] Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX 76504 USA. [Hurwitz, Mark D.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA. [Hurwitz, Mark D.; Manola, Judith] Harvard Univ, Sch Med, Boston, MA USA. [Manola, Judith] Dana Farber Brigham & Womens Canc Ctr, Dept Biostat Sci, Boston, MA USA. RP Asea, A (reprint author), Scott & White Mem Hosp & Clin, Div Investigat Pathol, 1901 S 1st St, Temple, TX 76504 USA. EM asea@medicine.tamhsc.edu RI Asea, Alexzander/I-4112-2013 OI Asea, Alexzander/0000-0003-3592-3481 FU National Institute of Health [RO1CA91889]; Scott White Clinic; Texas A&M Health Science Center, College of Medicine; Central Texas Veterans Health Administration; Cain Foundation FX Research in this study was supported in part by the National Institute of Health grant RO1CA91889, Scott & White Clinic, the Texas A&M Health Science Center, College of Medicine, the Central Texas Veterans Health Administration and an Endowment from the Cain Foundation to A.A. The authors thank Edwina E. Asea, Department of Pathology, Scott and White Hospital and Clinic, Temple, Texas, USA for expert technical assistance. NR 35 TC 27 Z9 27 U1 1 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD JUN PY 2010 VL 95 IS 3 BP 350 EP 358 DI 10.1016/j.radonc.2010.03.024 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 614EO UT WOS:000279038400017 PM 20430459 ER PT J AU Schmidt, UH Hess, DR AF Schmidt, Ulrich H. Hess, Dean R. TI Does Spontaneous Breathing Produce Harm in Patients With the Acute Respiratory Distress Syndrome? SO RESPIRATORY CARE LA English DT Editorial Material ID ACUTE LUNG INJURY; MECHANICALLY VENTILATED PATIENTS; ESOPHAGEAL PRESSURE; AIRWAY PRESSURE; TIDAL VOLUMES; CARE; FEASIBILITY; SEDATION; PROTOCOL; STRESS C1 [Schmidt, Ulrich H.; Hess, Dean R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. RP Schmidt, UH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. NR 22 TC 9 Z9 11 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD JUN PY 2010 VL 55 IS 6 BP 784 EP 786 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 616TJ UT WOS:000279232200019 PM 20507667 ER PT J AU Grudzen, CR Hoffman, JR Koenig, WJ Boscardin, J Lorenz, KA Asch, SM AF Grudzen, Corita R. Hoffman, Jerome R. Koenig, William J. Boscardin, John Lorenz, Karl A. Asch, Steven M. TI The LA story: What happened after a new policy allowing paramedics to forgo resuscitation attempts in prehospital cardiac arrest SO RESUSCITATION LA English DT Article DE Prehospital care; Cardiopulmonary resuscitation; Ethics ID EMERGENCY MEDICAL-SERVICES; OF-LIFE CARE; PATIENT PREFERENCES; DEATH; SURVIVAL; PLACE; FATES; WORSE AB Background: Despite potential harm to patients, families, and emergency personnel, a low survival rate, and high costs and intensity of care, attempting resuscitation after prehospital cardiac arrest is the norm, unless there are signs of irreversible death or the presence of a valid, state-issued DNR. Objective: To determine whether there was a change in the rate of forgoing resuscitation attempts in prehospital cardiac arrest after implementation of a new policy allowing paramedics to forgo resuscitation based on a verbal family request or the presence of certain arrest characteristics. Methods and results: All prehospital run sheets for cardiac arrest in Los Angeles County were reviewed for the first seven days of each month August 2006-January 2007 (pre-policy) and January-June 2008 (post-policy). Paramedics were more likely to forgo resuscitation attempts after the policy change (13.3% vs. 8.5%, p < 0.01). In addition, the percentage of patients with documented signs of irreversible death decreased post-policy, from 50.4% to 35.8%, p < 0.01. After adjustment for potential confounders (patient demographics, clinical characteristics and EMS factors), as well as exclusion of patients with signs of irreversible death, paramedics are significantly more likely to forgo a resuscitation, and less likely to attempt resuscitation, after the policy change (OR 1.67 [95% CI 1.07, 2.61], p = 0.024). Conclusions: Paramedics are more likely to forgo, and less likely to attempt, resuscitation in victims of cardiac arrest after implementation of a new policy. There was also an associated decrease in the percentage of patients who had signs of irreversible death, which might reflect a change in paramedic behavior. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Grudzen, Corita R.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. [Grudzen, Corita R.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Hoffman, Jerome R.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA. [Koenig, William J.] Los Angeles Cty Emergency Med Serv Agcy, Los Angeles, CA USA. [Boscardin, John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Boscardin, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Lorenz, Karl A.; Asch, Steven M.] VA Greater Los Angeles, Los Angeles, CA USA. RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, 1 Gustave L Levy Pl,Box 1620, New York, NY 10029 USA. EM corita.grudzen@mssm.edu OI Grudzen, Corita/0000-0003-3039-8497 FU California HealthCare Foundation; Los Angeles County EMS FX We would like to thank Nui Brown and Jacqueline Torres for their help collecting the data as well as Susan Mori, Richard Taddeo, Maureen Hasbrouck, and Robin Smilor at Los Angeles County EMS for support of the project and help in acquiring the run sheets.; Funding sources: This project was supported by the California HealthCare Foundation. NR 17 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD JUN PY 2010 VL 81 IS 6 BP 685 EP 690 DI 10.1016/j.resuscitation.2010.02.011 PG 6 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA 614VM UT WOS:000279087900012 PM 20236748 ER PT J AU Ceranoglu, TA AF Ceranoglu, T. Atilla TI Video Games in Psychotherapy SO REVIEW OF GENERAL PSYCHOLOGY LA English DT Article DE child and adolescent psychotherapy; video games; media ID TREASURE HUNT; CHILDREN; DISTRACTION; ADOLESCENTS; THERAPY; CANCER AB Video games have found their way into the clinical care of youth in most medical fields, and academic interest in their use is increasing steadily. The popularity of video games among youth may qualify them as a useful tool in psychotherapy tor children and adolescents. Limited literature on use of video games in mental health care suggests that they can help young patients become more cooperative and enthusiastic about psychotherapy. Recent experience suggests that video games may facilitate therapeutic relationships, complement the psychological assessment of youth by evaluating cognitive skills, and elaborate and clarify conflicts during the therapy process. Concerns about video game content, perceived effects on youth. and lack of familiarity with this medium may form a barrier in their use in therapy offices. Further research on the benefits of video game use in psychotherapy, including patient characteristics that may moderate outcomes, is needed. Finally, future collaborations between clinicians and video game developers may produce specific games to be used in psychotherapy. C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ceranoglu, TA (reprint author), Massachusetts Gen Hosp, 55 Fruit St,YAW 6A, Boston, MA 02114 USA. EM aceranoglu@partners.org NR 40 TC 29 Z9 33 U1 1 U2 22 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1089-2680 J9 REV GEN PSYCHOL JI Rev. Gen. Psychol. PD JUN PY 2010 VL 14 IS 2 SI SI BP 141 EP 146 DI 10.1037/a0019439 PG 6 WC Psychology, Multidisciplinary SC Psychology GA 612GY UT WOS:000278886000009 ER PT J AU Olson, CK AF Olson, Cheryl K. TI Children's Motivations for Video Game Play in the Context of Normal Development SO REVIEW OF GENERAL PSYCHOLOGY LA English DT Article DE video games; child development; adolescence; motivation ID VIOLENCE; PERSPECTIVES; EXPERIENCES; ENJOYMENT; BEHAVIOR; PARENTS; BOYS; FLOW; FEAR AB Electronic games are now an everyday part of childhood and adolescence. The debate has moved from whether children should play video games to how to maximize potential benefits and to identify and minimize potential harms. To do this, we must understand what motivates children to play electronic games and what needs the games meet. Drawing on a survey of 1,254 middle school children, focus groups with boys and their parents, and findings from other quantitative and qualitative research, the author describes a variety of motivations for video game play (including games with violent content) and how these may vary based on factors such as mood, environment. personality, and developmental stage. The findings are put into the context of normal development, and suggestions are given for parents, educators, and researchers. C1 Massachusetts Gen Hosp, Dept Psychiat, Ctr Mental Hlth & Media, Boston, MA 02114 USA. RP Olson, CK (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Mental Hlth & Media, Wang 812,15 Parkman St, Boston, MA 02114 USA. EM colson@hms.harvard.edu NR 57 TC 102 Z9 103 U1 4 U2 45 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1089-2680 J9 REV GEN PSYCHOL JI Rev. Gen. Psychol. PD JUN PY 2010 VL 14 IS 2 SI SI BP 180 EP 187 DI 10.1037/a0018984 PG 8 WC Psychology, Multidisciplinary SC Psychology GA 612GY UT WOS:000278886000013 ER PT J AU Waheed, S Cannon, CP AF Waheed, Salman Cannon, Christopher P. TI Cardiac Rehabilitation Reduces the Long-Term Risk of Death and Cardiovascular Complications SO REVIEWS IN CARDIOVASCULAR MEDICINE LA English DT Editorial Material ID CORONARY-ARTERY-DISEASE; PROGRAMS C1 [Waheed, Salman] UMass Mem Med Ctr, Worcester, MA USA. [Cannon, Christopher P.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. RP Waheed, S (reprint author), UMass Mem Med Ctr, Worcester, MA USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU MEDREVIEWS, LLC PI NEW YORK PA 1370 BROADWAY, STE 900, NEW YORK, NY 10018 USA SN 1530-6550 J9 REV CARDIOVASC MED JI Rev. Cardiovasc. Med. PD SUM PY 2010 VL 11 IS 3 BP E181 EP E184 DI 10.3909/ricm0543 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 690GH UT WOS:000284990000007 PM 21045772 ER PT J AU Olincy, A Braff, DL Adler, LE Cadenhead, KS Calkins, ME Dobie, DJ Green, MF Greenwood, TA Gur, RE Gur, RC Light, GA Mintz, J Nuechterlein, KH Radant, AD Schork, NJ Seidman, LJ Siever, LJ Silverman, JM Stone, WS Swerdlow, NR Tsuang, DW Tsuang, MT Turetsky, BI Wagner, BD Freedman, R AF Olincy, Ann Braff, David L. Adler, Lawrence E. Cadenhead, Kristin S. Calkins, Monica E. Dobie, Dorcas J. Green, Michael F. Greenwood, Tiffany A. Gur, Raquel E. Gur, Reuben C. Light, Gregory A. Mintz, James Nuechterlein, Keith H. Radant, Allen D. Schork, Nicholas J. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Swerdlow, Neal R. Tsuang, Debby W. Tsuang, Ming T. Turetsky, Bruce I. Wagner, Brandie D. Freedman, Robert TI Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: Results from the Consortium on Genetics of Schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Evoked potentials auditory; Inhibition; Genetics ID SENSORY-GATING DEFICIT; REM-SLEEP; HIPPOCAMPUS; SUPPRESSION; ABNORMALITIES; HERITABILITY; POLYMORPHISM; RELATIVES; P300 AB Inhibitiion of the P50 evoked electroencephalographic response to the second of paired auditory stimuli has been frequently examined as a neurophysiological deficit in schizophrenia. The Consoritum on the Genetics of Schizophrenia (COGS), a 7-site study funded by the National Institute of Mental Health, examined this endophenotype in recording from 181 probands with schizophrenia, 429 of their first degree relatives, and 333 community comparison control subjects. Most probands were treated with second generation antipsychotic medications. Highly significant differnces in P50 inhibtion, measured as either the ratio of amplitudes or their difference in response to the two stimuli, were found between the probands and the community comparison sample. There were no differences between the COGS sites for these findings. For the ratio parameter, an admixture analysis found that nearly 40% of the relatives demonstrated deficiencies in P50 inhibition that are comparable to the deficit found in the probands. These results indicate that P50 auditory evoked potentials can be recorded across multiple sites and reliably demonstrate a physiological abnormality in schizophrenia. The appearance of the physicological abnormality in a substantial proporition of clinically unaffected first degree relatives is consisten with the hypothesis that deficits in cerebral inhibition are a familial neurobiological risk factor for the illness. Published by Elsevier B.V. C1 [Olincy, Ann] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA. [Olincy, Ann; Adler, Lawrence E.; Freedman, Robert] Vet Affairs Denver Med Ctr VISN 19 MIRECC, Dept Psychiat, Denver, CO USA. [Braff, David L.; Cadenhead, Kristin S.; Greenwood, Tiffany A.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Calkins, Monica E.; Gur, Raquel E.; Gur, Reuben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Dobie, Dorcas J.; Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Green, Michael F.; Mintz, James; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Green, Michael F.; Mintz, James] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Schork, Nicholas J.] Scripps Genome Med, La Jolla, CA USA. [Schork, Nicholas J.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA. [Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med,Publ Psychiat Div,Beth Israel Deaconess M, Dept Psychiat,Massachusetts Mental Hlth Ctr, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.; Silverman, Jeremy M.] James J Peters VA Med Ctr, Bronx, NY USA. [Siever, Larry J.; Silverman, Jeremy M.] VISN 3 MIRECC, Bronx, NY USA. [Wagner, Brandie D.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA. RP Olincy, A (reprint author), Univ Colorado Denver, Dept Psychiat, Mail Stop F546,13001 E 17th Pl, Aurora, CO 80045 USA. EM Ann.olincy@ucdenver.edu RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016 OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang, Debby/0000-0002-4716-1894 FU NIMH [R01] FX Funding for this study was provided by the NIMH Collaborative R01 Grants to each of the 7 sites; the NIMH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decisiion to submit the paper for publication. NR 37 TC 48 Z9 50 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUN PY 2010 VL 119 IS 1-3 BP 175 EP 182 DI 10.1016/j.schres.2010.03.004 PG 8 WC Psychiatry SC Psychiatry GA 631JC UT WOS:000280341700026 PM 20382002 ER PT J AU Ogg, JA Brinkman, TM Dedrick, RF Carlson, JS AF Ogg, Julia A. Brinkman, Tara M. Dedrick, Robert F. Carlson, John S. TI Factor Structure and Invariance Across Gender of the Devereux Early Childhood Assessment Protective Factor Scale SO SCHOOL PSYCHOLOGY QUARTERLY LA English DT Article DE DECA; strength-based assessment; Head Start; differential item functioning ID HEAD-START; PRESCHOOL-CHILDREN; BEHAVIOR PROBLEMS; LANGUAGE DELAYS; RISK; PSYCHOPATHOLOGY; MODEL; BOYS AB Early childhood social emotional assessment has traditionally focused on risk factors or psychopathology, and has less frequently examined protective factors that may serve to promote positive developmental outcomes for children. To advance conceptual models that include protective factors as key explanatory constructs, there is a need for quantitative measures of protective factors that are psychometrically sound and function similarly across different subgroups, including gender. This study examined the factor structure and factorial invariance across gender of the Devereux Early Childhood Assessment (DECA), one of the few measures to focus on protective behaviors. A total of 1,344 parents completed the DECA for a group of developmentally and economically at-risk children ages 2 to 5 years. Results of the confirmatory factor analysis, the first to be conducted on the DECA, revealed that the factor structure proposed by the authors of the DECA was adequate with some modifications. Multigroup comparisons by gender supported the invariance of the factor pattern coefficients and 26 of the 27 item intercepts, indicating that the items were functioning similarly across boys and girls. Suggestions for improving problematic item pairs and content are provided. This study can be viewed as part of the ongoing validation of the DECA and an important contribution to the strength-based assessment literature. C1 [Ogg, Julia A.] Univ S Florida, Dept Psychol & Social Fdn, Tampa, FL 33620 USA. [Brinkman, Tara M.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA USA. [Dedrick, Robert F.] Univ S Florida, Dept Measurement & Res, Tampa, FL 33620 USA. [Carlson, John S.] Michigan State Univ, Dept Educ Psychol Counseling & Special Educ, E Lansing, MI 48824 USA. RP Ogg, JA (reprint author), 4202 E Fowler Ave,Stop EDU 105, Tampa, FL 33620 USA. EM jogg@usf.edu NR 35 TC 5 Z9 5 U1 0 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1045-3830 J9 SCHOOL PSYCHOL QUART JI Sch. Psychol. Q. PD JUN PY 2010 VL 25 IS 2 BP 107 EP 118 DI 10.1037/a0020251 PG 12 WC Psychology, Educational SC Psychology GA 629XY UT WOS:000280235700005 ER PT J AU Feramisco, JD Tsao, H Siegel, DH AF Feramisco, Jamison D. Tsao, Hensin Siegel, Dawn H. TI Genetics for the Practicing Dermatologist SO SEMINARS IN CUTANEOUS MEDICINE AND SURGERY LA English DT Article ID GENOME-WIDE ASSOCIATION; IDENTIFIES SUSCEPTIBILITY VARIANTS; FACIO-CUTANEOUS SYNDROME; MUCKLE-WELLS-SYNDROME; ATOPIC-DERMATITIS; LUPUS-ERYTHEMATOSUS; GERMLINE MUTATIONS; DNA METHYLATION; CROHNS-DISEASE; SKIN DISEASES AB In the era of robust genome sequencing, a working understanding of genetics has become important for the clinician. For the dermatologist, understanding the flow of genetic information from genotype to phenotype can aid in the delivery of effective patient care. In this article, we will review concepts in genetics and the human genome and how they contribute to clinical dermatology. Semin Cutan Med Surg 29:127-136 (C) 2010 Published by Elsevier Inc. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. RP Siegel, DH (reprint author), Oregon Hlth & Sci Univ, Dept Dermatol & Pediat, 3303 SW Bond Ave,CH16D, Portland, OR 97239 USA. EM siegeld@ohsu.edu NR 95 TC 4 Z9 4 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1085-5629 J9 SEMIN CUTAN MED SURG JI Semin. Cutan. Med. Surg. PD JUN PY 2010 VL 29 IS 2 BP 127 EP 136 DI 10.1016/j.sder.2010.04.006 PG 10 WC Dermatology; Surgery SC Dermatology; Surgery GA 619IU UT WOS:000279424600009 PM 20579602 ER PT J AU Hough, S AF Hough, Sigmund TI The Psychology of Spinal Surgery SO SEXUALITY AND DISABILITY LA English DT Book Review C1 [Hough, Sigmund] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Hough, Sigmund] Boston Sch Med, Boston, MA USA. [Hough, Sigmund] VA Boston Healthcare Syst, Spinal Cord Injury Serv, W Roxbury, MA USA. RP Hough, S (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. EM sigmund_hough@hms.harvard.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD JUN PY 2010 VL 28 IS 2 BP 141 EP 142 DI 10.1007/s11195-010-9151-y PG 2 WC Rehabilitation SC Rehabilitation GA 593JM UT WOS:000277450000007 ER PT J AU Sumi, Y Chen, Y Yao, Y Woehrle, T El Khal, A Junger, WG AF Sumi, Y. Chen, Y. Yao, Y. Woehrle, T. El Khal, A. Junger, W. G. TI PLASMA ATP CONCENTRATIONS CORRELATE WITH NEUTROPHIL ACTIVATION AFTER SEPSIS SO SHOCK LA English DT Meeting Abstract CT 33rd Annual Conference on Shock CY JUN 12-15, 2010 CL Portland, OR SP Shock Soc C1 [Sumi, Y.; Chen, Y.; Yao, Y.; Woehrle, T.; El Khal, A.; Junger, W. G.] Harvard Univ, Sch Med, Dept Surg, BIDMC, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD JUN PY 2010 VL 33 SU 1 BP 10 EP 10 PG 1 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 598IC UT WOS:000277828000034 ER PT J AU Chen, Y Yao, Y Sumi, Y Woehrle, T ElKhal, A Junger, WG AF Chen, Y. Yao, Y. Sumi, Y. Woehrle, T. ElKhal, A. Junger, W. G. TI ATP RELEASE VIA PANNEXIN 1 HEMI-CHANNELS CONTROLS NEUTROPHIL CHEMOTAXIS SO SHOCK LA English DT Meeting Abstract CT 33rd Annual Conference on Shock CY JUN 12-15, 2010 CL Portland, OR SP Shock Soc C1 [Chen, Y.; Yao, Y.; Sumi, Y.; Woehrle, T.; ElKhal, A.; Junger, W. G.] Harvard Univ, Sch Med, Dept Surg, BIDMC, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD JUN PY 2010 VL 33 SU 1 BP 27 EP 27 PG 1 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 598IC UT WOS:000277828000089 ER PT J AU Li, Y Xiang, M Wilson, M Fan, J AF Li, Y. Xiang, M. Wilson, M. Fan, J. TI TLR4-IL-1RI CROSS-TALK MEDIATES HEMORRHAGIC SHOCK-PRIMED CASPASE-1 ACTIVATION IN LUNG ENDOTHELIAL CELLS SO SHOCK LA English DT Meeting Abstract CT 33rd Annual Conference on Shock CY JUN 12-15, 2010 CL Portland, OR SP Shock Soc C1 [Li, Y.; Xiang, M.; Wilson, M.; Fan, J.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15240 USA. [Li, Y.; Xiang, M.; Wilson, M.; Fan, J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. NR 0 TC 0 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD JUN PY 2010 VL 33 SU 1 BP 36 EP 37 PG 2 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 598IC UT WOS:000277828000122 ER PT J AU Junger, WG Rhind, SG Rizoli, SB Cuschieri, J Hoyt, DB Baker, AJ Shek, PN Bulger, EM AF Junger, W. G. Rhind, S. G. Rizoli, S. B. Cuschieri, J. Hoyt, D. B. Baker, A. J. Shek, P. N. Bulger, E. M. TI HYPERTONIC RESUSCITATION OF SHOCK PATIENTS DOWNREGULATES NEUTROPHIL ACTIVATION SO SHOCK LA English DT Meeting Abstract CT 33rd Annual Conference on Shock CY JUN 12-15, 2010 CL Portland, OR SP Shock Soc C1 [Junger, W. G.; Rhind, S. G.; Rizoli, S. B.; Cuschieri, J.; Hoyt, D. B.; Baker, A. J.; Shek, P. N.; Bulger, E. M.] Harvard Univ, Sch Med, BIDMC, Dept Surg, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD JUN PY 2010 VL 33 SU 1 BP 50 EP 50 PG 1 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 598IC UT WOS:000277828000163 ER PT J AU Elkhal, A Sumi, Y Bhate, M Chen, Y Yao, Y Woehrle, T Junger, WG AF Elkhal, A. Sumi, Y. Bhate, M. Chen, Y. Yao, Y. Woehrle, T. Junger, W. G. TI TH17 TYPE CYTOKINES ARE INCREASED LOCALLY AND SYSTEMICALLY IN A MOUSE SEPSIS MODEL SO SHOCK LA English DT Meeting Abstract CT 33rd Annual Conference on Shock CY JUN 12-15, 2010 CL Portland, OR SP Shock Soc C1 [Elkhal, A.; Sumi, Y.; Bhate, M.; Chen, Y.; Yao, Y.; Woehrle, T.; Junger, W. G.] Harvard Univ, BIDMC, Sch Med, Dept Surg, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD JUN PY 2010 VL 33 SU 1 BP 80 EP 81 PG 2 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 598IC UT WOS:000277828000265 ER PT J AU Gutchess, AH Hedden, T Ketay, S Aron, A Gabrieli, JDE AF Gutchess, Angela H. Hedden, Trey Ketay, Sarah Aron, Arthur Gabrieli, John D. E. TI Neural differences in the processing of semantic relationships across cultures SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE cognition; culture; executive function; fMRI; semantic ID THEMATIC CONCEPTUAL RELATIONS; EVENT-RELATED FMRI; COGNITIVE CONTROL; CHINESE; BRAIN; CATEGORIES; OBJECT; AMERICAN; CONTEXT; WORDS AB The current study employed functional MRI to investigate the contribution of domain-general (e. g. executive functions) and domain-specific (e. g. semantic knowledge) processes to differences in semantic judgments across cultures. Previous behavioral experiments have identified cross-cultural differences in categorization, with East Asians preferring strategies involving thematic or functional relationships (e. g. cow-grass) and Americans preferring categorical relationships (e. g. cow-chicken). East Asians and American participants underwent functional imaging while alternating between categorical or thematic strategies to sort triads of words, as well as matching words on control trials. Many similarities were observed. However, across both category and relationship trials compared to match (control) trials, East Asians activated a frontal-parietal network implicated in controlled executive processes, whereas Americans engaged regions of the temporal lobes and the cingulate, possibly in response to conflict in the semantic content of information. The results suggest that cultures differ in the strategies employed to resolve conflict between competing semantic judgments. C1 [Gutchess, Angela H.] Brandeis Univ, Dept Psychol, Waltham, MA 02454 USA. [Hedden, Trey] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Hedden, Trey; Gabrieli, John D. E.] MIT, Cambridge, MA 02139 USA. [Ketay, Sarah] Mt Sinai Sch Med, New York, NY 10029 USA. [Aron, Arthur] SUNY Stony Brook, Stony Brook, NY 11794 USA. RP Gutchess, AH (reprint author), Brandeis Univ, Dept Psychol, 415 South St,MS 062, Waltham, MA 02454 USA. EM gutchess@brandeis.edu FU National Institutes of Health; McGovern Institute for Brain Research at MIT FX This work was supported by the National Institutes of Health [to J.D.E.G.] and the McGovern Institute for Brain Research at MIT. NR 48 TC 18 Z9 18 U1 3 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD JUN PY 2010 VL 5 IS 2-3 BP 254 EP 263 DI 10.1093/scan/nsp059 PG 10 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 653EU UT WOS:000282071900017 PM 20139116 ER PT J AU Kilzieh, N Rastam, S Ward, KD Maziak, W AF Kilzieh, Nael Rastam, Samer Ward, Kenneth D. Maziak, Wasim TI Gender, depression and physical impairment: an epidemiologic perspective from Aleppo, Syria SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Physical impairment; Gender; Depression; Epidemiologic studies; Syria ID GENERAL-POPULATION; MENTAL-DISORDERS; MAJOR DEPRESSION; PRIMARY-CARE; HEALTH; DISABILITY; ILLNESS; DETERMINANTS; OUTCOMES; ADHERENCE AB Examine the association of physical impairment with gender, depression, and socio-demographics in the community in Aleppo, Syria. We conducted a cross-sectional, population-based study in Aleppo on adults aged 18-65 (N = 2,038). We used a computerized interviewer-administered structured questionnaire. Physical impairment was measured via an adapted 12-item World Health Organization, Health State Description Individual Questionnaire which includes both physical and emotional items. We used physical impairment items score to classify individuals into low, middle, and high physical impairment category. Self-report of physician-diagnosed depression and chronic diseases active in the past year and their current treatment status were obtained. Sample mean age (SD) was 35.3 (12.1) years, 55% were female, and 4.5% had depression. Female gender, low socioeconomic status (SES), and depression were associated with high physical impairment. Women had more impairment (OR = 3.35, 95% CI: 2.15-5.21) with little change after controlling for depression and chronic diseases, but significantly decreased after controlling for socio-demographics (OR = 1.51, 95% CI: 0.84-2.73). The association with low (vs. high) SES was prominent (OR = 2.48, 95% CI: 1.32-4.67) after controlling for all variables. Depression's association (OR = 4.85, 95% CI: 1.93-12.15) lost significance after controlling for chronic diseases (OR = 2.81, 95% CI: 0.96-8.25), but further adjustment for socio-demographics had little effect. Women and individuals of low SES appear more vulnerable to physical impairment in the community in Aleppo. Depression's association with physical impairment may be mediated through co-existing chronic diseases. Public health planning regarding physical impairment in Syria should encompass these as putative risk factors. C1 [Kilzieh, Nael] VA Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA 98493 USA. [Kilzieh, Nael] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rastam, Samer; Maziak, Wasim] Syrian Ctr Tobacco Studies, Aleppo, Syria. [Ward, Kenneth D.; Maziak, Wasim] Univ Memphis, Dept Hlth & Sport Sci, Memphis, TN 38152 USA. [Ward, Kenneth D.; Maziak, Wasim] Univ Memphis, Ctr Community Hlth, Memphis, TN 38152 USA. RP Kilzieh, N (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div, 9600 Vet Dr,A-116, Tacoma, WA 98493 USA. EM nael.kilzieh@va.gov OI Rastam, Samer/0000-0002-4004-7773 FU US Public Health Service [R01 TW05962, R21 TW006545]; NIDA [R01DA024876-01]; Fulbright Scholar Grant, Bureau of Cultural and Educational Affairs, US Department of State; Veterans Affairs Mental Illness Research, Education, and Clinical Center (MIRECC); VISN 20 FX This work is supported by US Public Health Service grants R01 TW05962 and R21 TW006545; and NIDA grant R01DA024876-01. Nael Kilzieh is supported by The Fulbright Scholar Grant, Bureau of Cultural and Educational Affairs, US Department of State and the Veterans Affairs Mental Illness Research, Education, and Clinical Center (MIRECC), VISN 20. NR 32 TC 3 Z9 3 U1 2 U2 8 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD JUN PY 2010 VL 45 IS 6 BP 595 EP 602 DI 10.1007/s00127-009-0076-7 PG 8 WC Psychiatry SC Psychiatry GA 599VS UT WOS:000277942500001 PM 20195569 ER PT J AU Krause, JS Terza, JV Saunders, LL Dismuke, CE AF Krause, J. S. Terza, J. V. Saunders, L. L. Dismuke, C. E. TI Delayed entry into employment after spinal cord injury: factors related to time to first job SO SPINAL CORD LA English DT Article DE spinal cord injury; employment; vocational rehabilitation; participation; psychosocial ID LIFE; ADJUSTMENT; EARNINGS; RETURN; GENDER; WORK AB Study design: Data were cross-sectional and were collected by survey methodology. Objectives: To investigate factors predictive of length of time between spinal cord injury (SCI) onset and start of first post-injury employment and full-time employment. Setting: A large specialty hospital in the Southeastern United States, with additional participant samples from two hospitals in the Midwestern United States. Methods: Participants were identified from patient records at the participating hospitals. They met the following three exclusion/inclusion criteria: traumatic SCI, at least 18 years of age at time of survey, and a minimum of 1-year after SCI. Outcome measures were years from injury onset to beginning first post-injury job and years to first full-time post-injury job. Two separate models were developed for each outcome using a regression analysis. All those 10 years and more post-injury were censored (that is eliminated) in the analysis. Results: Having a higher level of education, less severe injury, being Caucasian, and returning to the pre-injury employer were associated with a shorter interval to initiation of employment with 10-year censoring. In addition to these variables, gender was associated with time to return to first full-time job. Conclusion: The findings underscore the importance of using pre-injury education and opportunities to return to the pre-injury employer to minimize the length of time until initiation of employment after SCI. Spinal Cord (2010) 48, 487-491; doi: 10.1038/sc.2009.157; published online 24 November 2009 C1 [Krause, J. S.; Saunders, L. L.; Dismuke, C. E.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. [Terza, J. V.] Univ N Carolina, Bryan Sch Business & Econ, Greensboro, NC 27412 USA. [Dismuke, C. E.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. RP Krause, JS (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA. EM krause@musc.edu FU National Institute for Disability and Rehabilitation Research (NIDRR) of the Office of Special Education and Rehabilitative Services (OSERS) [H133G020239, H133G060126]; United States Department of Education FX This research was supported by field initiated grants (H133G020239, H133G060126) from the National Institute for Disability and Rehabilitation Research (NIDRR) of the Office of Special Education and Rehabilitative Services (OSERS), the United States Department of Education. The opinions expressed here are those of the grantee and not the funding agency. We thank the following people whose contributions made completion of this article possible: Richard Aust, Dr Rickey E Carter Jennifer Coker, Karla Reed, and Yusheng Zhai, and Sarah Lottes and Christina McCleery of the Shepherd Center. NR 18 TC 18 Z9 18 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD JUN PY 2010 VL 48 IS 6 BP 487 EP 491 DI 10.1038/sc.2009.157 PG 5 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 605BI UT WOS:000278321900009 PM 19935754 ER PT J AU Yang, C Hornicek, FJ Wood, KB Schwab, JH Choy, E Iafrate, J Rosenberg, A Nielsen, GP Xavier, RJ Mankin, H Duan, ZF AF Yang, Cao Hornicek, Francis J. Wood, Kirkham B. Schwab, Joseph H. Choy, Edwin Iafrate, John Rosenberg, Andrew Nielsen, G. Petur Xavier, Ramnik J. Mankin, Henry Duan, Zhenfeng TI Characterization and Analysis of Human Chordoma Cell Lines SO SPINE LA English DT Article DE chordoma; characteristics; 3D cell culture; chemotherapy ID TUMOR-SUPPRESSOR PROTEIN; BREAST-CARCINOMA CELLS; TERM-FOLLOW-UP; PROGNOSTIC-FACTORS; MOBILE SPINE; CANCER CELLS; V COLLAGEN; I-TRIMER; HYPOXIA; GROWTH AB Study Design. An experimental study to investigate the characterization of 3 chordoma cell lines. Objective. To characterize chordoma cell lines and generate hypothesis for further chordoma studies. Summary of Background Data. Three cultured human chordoma cell lines have been successfully generated; however, their characterization is incomplete. Complete characterization of chordoma cell lines is necessary for these reagents to be a useful preclinical model. Methods. Three chordoma cell lines, CH 8, U-CH1, and GP 60, were cultured in different commercially available tissue culture media. They were also cultured in different environments, which included collagen substrate, various concentrations of glucose, and various levels of hypoxic conditions. The rate of cell proliferation was assessed by either MTT or numeration assay. A 3-dimensional (3D) cell culture model of these chordoma cell lines was also studied, and the expression of vimentin and cytokeratin was measured by immunofluorescence and Western blot. Additionally, the sensitivity of the 3 chordoma cell lines to 6 chemotherapeutic drugs was analyzed. Results. CH 8, GP 60, and U-CH1 cells proliferate more actively in Iscove Modified Dulbecco Medium or Dulbecco modified Eagle Medium and less actively in RPMI medium. All 3 chordoma cell lines universally grow better in collagen substrate and survive in hypoxic conditions, whereas glucose concentration has no significant influence on their growth properties. Chordoma cell lines grew well in 3D culture systems and formed acini-like spheroids and retained the expression of vimentin and cytokeratin. MTT analysis indicates that all 3 chordoma cell lines are sensitive to doxorubicin, yondelis, zalypsis, and cisplatin. Conclusion. We characterized 3 chordoma cell lines for differential growth properties in a variety of media and response to chemotherapeutic agents. C1 [Yang, Cao; Hornicek, Francis J.; Wood, Kirkham B.; Schwab, Joseph H.; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Yang, Cao; Hornicek, Francis J.; Schwab, Joseph H.; Choy, Edwin; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Yang, Cao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed Surg, Wuhan 430074, Peoples R China. [Choy, Edwin] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Iafrate, John; Rosenberg, Andrew; Nielsen, G. Petur; Xavier, Ramnik J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 70 Blossom St,GRJ 1115, Boston, MA 02114 USA. EM zduan@partners.org OI Choy, Edwin/0000-0001-9896-8084 FU NIDDK NIH HHS [P30 DK040561-15, P30 DK040561] NR 38 TC 17 Z9 19 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD JUN 1 PY 2010 VL 35 IS 13 BP 1257 EP 1264 DI 10.1097/BRS.0b013e3181c2a8b0 PG 8 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 602TZ UT WOS:000278163000002 PM 20461036 ER PT J AU Kim, DS Lee, JS Leem, JW Huh, YJ Kim, JY Kim, HS Park, IH Daley, GQ Hwang, DY Kim, DW AF Kim, Dae-Sung Lee, Jae Souk Leem, Joong Woo Huh, Yong Jun Kim, Ji Young Kim, Han-Soo Park, In-Hyun Daley, George Q. Hwang, Dong-Youn Kim, Dong-Wook TI Robust Enhancement of Neural Differentiation from Human ES and iPS Cells Regardless of their Innate Difference in Differentiation Propensity SO STEM CELL REVIEWS AND REPORTS LA English DT Article DE Pluripotent stem cell; Differentiation propensity; Neural induction; Cell signaling; Small molecule ID HUMAN EMBRYONIC STEM; HIGHLY EFFICIENT; GROWTH-FACTOR; PLURIPOTENCY; INDUCTION; SUPPRESSION; PRECURSORS; PATHWAYS; SIGNALS; ABSENCE AB Our analyses of three human induced pluripotent stem cell (hiPSC) and six human embryonic stem cell (hESC) lines showed marked variability in differentiation potential into specific lineages, which often hampers their differentiation into specific cell types or cell lineages of interest. Simultaneous inhibition of both Activin/Nodal and BMP pathways with small molecules, SB431542 and dorsomorphin (DM), respectively, promoted significant neural differentiation from all human pluripotent stem cell (hPSC) lines tested, regardless of their differentiation propensity. On the contrary, differentiation into other cell lineages and the number of undifferentiated cells were significantly reduced after differentiation by the dual inhibition. These results demonstrate that innate differentiation propensity of hPSCs could be overcome, at least in part, by modulation of intracellular signaling pathways, resulting in efficient generation of desirable cell types, such as neural cells. C1 [Hwang, Dong-Youn] CHA Univ, Coll Med, CHA Stem Cell Inst, Seoul, South Korea. [Kim, Dong-Wook] Yonsei Univ, Coll Med, Dept Physiol, Ctr Cell Therapy, Seoul, South Korea. [Kim, Dae-Sung; Lee, Jae Souk; Leem, Joong Woo; Huh, Yong Jun; Kim, Ji Young; Kim, Dong-Wook] Brain Korea 21 Project Med Sci, Dept Physiol, Seoul 120752, South Korea. [Kim, Han-Soo] Yonsei Univ, Coll Med, Dept Lab Med, Seoul 120752, South Korea. [Park, In-Hyun; Daley, George Q.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med,Div Pediat Hematol Oncol, Boston, MA 02115 USA. [Park, In-Hyun; Daley, George Q.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Hwang, DY (reprint author), CHA Univ, Coll Med, CHA Stem Cell Inst, 606-16 Vis Bldg,4th Floor, Seoul, South Korea. EM hdy@cha.ac.kr; dwkim2@yuhs.ac RI Kim, Dae-Sung/H-1116-2015 OI Kim, Dae-Sung/0000-0002-3835-4803 FU Ministry of Education, Science and Technology, Republic of Korea [SC1110, SC4140, SC5170] FX This research was supported by grants (code: SC1110, SC4140 and SC5170) from the Stem Cell Research Center of the 21th Century Frontier Research Program funded by the Ministry of Education, Science and Technology, Republic of Korea. NR 25 TC 111 Z9 113 U1 2 U2 26 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1550-8943 J9 STEM CELL REV REP JI Stem Cell Rev. Rep. PD JUN PY 2010 VL 6 IS 2 BP 270 EP 281 DI 10.1007/s12015-010-9138-1 PG 12 WC Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 613CG UT WOS:000278953100013 PM 20376579 ER PT J AU Sauerwein, W Wittig, A Matsumttra, A Nakagawa, Y Mauri, P Zonta, A Busse, P Moss, R AF Sauerwein, W. Wittig, A. Matsumttra, A. Nakagawa, Y. Mauri, P. Zonta, A. Busse, P. Moss, R. TI Clinical applications for Boron Neutron Capture Therapy (BNCT) SO STRAHLENTHERAPIE UND ONKOLOGIE LA English DT Meeting Abstract CT 16th Annual Meeting of the German-Society-of-Radiooncology CY JUN 03-03, 2010 CL Magdenburg, GERMANY SP German Soc Radiooncol C1 [Sauerwein, W.; Wittig, A.] Univ Duisburg Essen, Strahlen Klin, Essen, Germany. [Matsumttra, A.] Univ Tsukuba, Ibaraki, Japan. [Nakagawa, Y.] Natl Kagawa Childrens Hosp, Dept Neurosurg, Zentsuji, Japan. [Mauri, P.] CNR, Ist Tecnol Biomed, Segrate, Italy. [Zonta, A.] Univ Studi Pavia, Dept Surg Sci, Pavia, Italy. [Busse, P.] Massachusetts Gen Hosp, Head & Neck Canc Ctr, Boston, MA 02114 USA. [Moss, R.] European Commiss Joint Res Ctr, Inst Energy, Petten, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU URBAN & VOGEL PI MUNICH PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY SN 0179-7158 J9 STRAHLENTHER ONKOL JI Strahlenther. Onkol. PD JUN PY 2010 VL 186 SU 1 BP 56 EP 56 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 601OK UT WOS:000278071200145 ER PT J AU Hachinski, V Donnan, GA Gorelick, PB Hacke, W Cramer, SC Kaste, M Fisher, M Brainin, M Buchan, AM Lo, EH Skolnick, BE Furie, KL Hankey, GJ Kivipelto, M Morris, J Rothwell, PM Sacco, RL Smith, SC Wang, YL Bryer, A Ford, GA Iadecola, C Martins, SCO Saver, J Skvortsova, V Bayley, M Bednar, MM Duncan, P Enney, L Finklestein, S Jones, TA Kalra, L Kleim, J Nitkin, R Teasell, R Weiller, C Desai, B Goldberg, MP Heiss, WD Saarelma, O Schwamm, LH Shinohara, Y Trivedi, B Wahlgren, N Wong, LK Hakim, A Norrving, B Prudhomme, S Bornstein, NM Davis, SM Goldstein, LB Leys, D Tuomilehto, J AF Hachinski, Vladimir Donnan, Geoffrey A. Gorelick, Philip B. Hacke, Werner Cramer, Steven C. Kaste, Markku Fisher, Marc Brainin, Michael Buchan, Alastair M. Lo, Eng H. Skolnick, Brett E. Furie, Karen L. Hankey, Graeme J. Kivipelto, Miia Morris, John Rothwell, Peter M. Sacco, Ralph L. Smith, Sidney C., Jr. Wang, Yulun Bryer, Alan Ford, Gary A. Iadecola, Costantino Martins, Sheila C. O. Saver, Jeff Skvortsova, Veronika Bayley, Mark Bednar, Martin M. Duncan, Pamela Enney, Lori Finklestein, Seth Jones, Theresa A. Kalra, Lalit Kleim, Jeff Nitkin, Ralph Teasell, Robert Weiller, Cornelius Desai, Bhupat Goldberg, Mark P. Heiss, Wolf-Dieter Saarelma, Osmo Schwamm, Lee H. Shinohara, Yukito Trivedi, Bhargava Wahlgren, Nils Wong, Lawrence K. Hakim, Antoine Norrving, Bo Prudhomme, Stephen Bornstein, Natan M. Davis, Stephen M. Goldstein, Larry B. Leys, Didier Tuomilehto, Jaakko TI Stroke: Working Toward a Prioritized World Agenda SO STROKE LA English DT Article DE prevention; rehabilitation; stroke; translational; treatment ID VASCULAR COGNITIVE IMPAIRMENT; TISSUE-PLASMINOGEN ACTIVATOR; TRANSIENT ISCHEMIC ATTACK; HEALTHY LIFE-STYLE; PRIMARY PREVENTION; POLICY STATEMENT; CARE; RECOMMENDATIONS; PROGRESS; BRAIN AB Background and Purpose-The aim of the Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke. Methods-Preliminary work was performed by 7 working groups of stroke leaders followed by a synergium (a forum for working synergistically together) with approximately 100 additional participants. The resulting draft document had further input from contributors outside the synergium. Results-Recommendations of the Synergium are: Basic Science, Drug Development and Technology: There is a need to develop: (1) New systems of working together to break down the prevalent "silo" mentality; (2) New models of vertically integrated basic, clinical, and epidemiological disciplines; and (3) Efficient methods of identifying other relevant areas of science. Stroke Prevention: (1) Establish a global chronic disease prevention initiative with stroke as a major focus. (2) Recognize not only abrupt clinical stroke, but subtle subclinical stroke, the commonest type of cerebrovascular disease, leading to impairments of executive function. (3) Develop, implement and evaluate a population approach for stroke prevention. (4) Develop public health communication strategies using traditional and novel (eg, social media/marketing) techniques. Acute Stroke Management: Continue the establishment of stroke centers, stroke units, regional systems of emergency stroke care and telestroke networks. Brain Recovery and Rehabilitation: (1) Translate best neuroscience, including animal and human studies, into poststroke recovery research and clinical care. (2) Standardize poststroke rehabilitation based on best evidence. (3) Develop consensus on, then implementation of, standardized clinical and surrogate assessments. (4) Carry out rigorous clinical research to advance stroke recovery. Into the 21st Century: Web, Technology and Communications: (1) Work toward global unrestricted access to stroke-related information. (2) Build centralized electronic archives and registries. Foster Cooperation Among Stakeholders (large stroke organizations, nongovernmental organizations, governments, patient organizations and industry) to enhance stroke care. Educate and energize professionals, patients, the public and policy makers by using a "Brain Health" concept that enables promotion of preventive measures. Conclusions-To accelerate progress in stroke, we must reach beyond the current status scientifically, conceptually, and pragmatically. Advances can be made not only by doing, but ceasing to do. Significant savings in time, money, and effort could result from discontinuing practices driven by unsubstantiated opinion, unproven approaches, and financial gain. Systematic integration of knowledge into programs coupled with careful evaluation can speed the pace of progress. C1 [Hachinski, Vladimir] Univ Western Ontario, Dept Clin Neurol Sci, London Hlth Sci Ctr, London, ON N6A 5A5, Canada. [Donnan, Geoffrey A.] Florey Neurosci Inst, Carlton, Vic, Australia. [Gorelick, Philip B.] Univ Illinois, Chicago, IL USA. [Hacke, Werner] Univ Heidelberg, Heidelberg, Germany. [Cramer, Steven C.] Univ Calif Irvine, Orange, CA 92668 USA. [Kaste, Markku] Univ Helsinki, Helsinki Univ Cent Hosp, Helsinki, Finland. [Fisher, Marc] Univ Massachusetts, Sch Med, Worcester, MA USA. [Brainin, Michael] Univ Donau Univ Krems, Krems, Austria. [Buchan, Alastair M.] Univ Oxford, Oxford, England. [Lo, Eng H.; Furie, Karen L.; Schwamm, Lee H.] Massachusetts Gen Hosp, Charlestown, MA USA. [Skolnick, Brett E.] Novo Nordisk, Princeton, NJ USA. [Hankey, Graeme J.] Royal Perth Hosp, Perth, WA, Australia. [Kivipelto, Miia; Wahlgren, Nils] Karolinska Inst, Stockholm, Sweden. [Morris, John; Goldberg, Mark P.] Washington Univ, Sch Med, St Louis, MO USA. [Rothwell, Peter M.] John Radcliffe Hosp, Oxford OX3 9DU, England. [Sacco, Ralph L.] Univ Miami, AHA, Miami, FL USA. [Smith, Sidney C., Jr.] Univ N Carolina, Ctr Cardiovasc Sci & Med, Chapel Hill, NC USA. World Heart Federat, Geneva, Switzerland. [Wang, Yulun] InTouch Hlth, Goleta, CA USA. [Bryer, Alan] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa. [Bryer, Alan] Univ Cape Town, ZA-7925 Cape Town, South Africa. [Ford, Gary A.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Iadecola, Costantino] Weill Cornell Med Coll, New York, NY USA. [Martins, Sheila C. O.] Hosp Clin, Porto Alegre, RS, Brazil. [Saver, Jeff] Univ Calif Los Angeles, Los Angeles Stroke Ctr, Los Angeles, CA USA. [Skvortsova, Veronika] Russian State Res Stroke Inst, Moscow, Russia. [Bayley, Mark] Toronto Rehabil Inst, Toronto, ON, Canada. [Bednar, Martin M.] Pfizer Inc, Neurosci Res Unit, Groton, CT 06340 USA. [Duncan, Pamela; Goldstein, Larry B.] Duke Univ, Durham, NC USA. [Enney, Lori] GlaxoSmithKline Inc, Durham, NC USA. [Finklestein, Seth] Biotrofix Inc, Waltham, MA USA. [Jones, Theresa A.] Univ Texas Austin, Austin, TX 78712 USA. [Kalra, Lalit] Kings Coll London, London WC2R 2LS, England. [Kleim, Jeff] Univ Florida, Gainesville, FL USA. [Nitkin, Ralph] NICHHD, Natl Ctr Med Rehabil, NIH, Rockville, MD USA. [Teasell, Robert] St Josephs Healthcare London, London, ON, Canada. [Weiller, Cornelius] Univ Freiburg, Freiburg, Germany. [Desai, Bhupat] Pomona Valley Hosp Med Ctr, Pomona, CA USA. [Heiss, Wolf-Dieter] Max Planck Inst Neurol Res, Cologne, Germany. [Saarelma, Osmo] Terveystalo Med Ctr, Helsinki, Finland. [Shinohara, Yukito] Tachikawa Hosp, Tokyo, Japan. [Trivedi, Bhargava] So Illinois Healthcare, Carbondale, IL USA. [Wong, Lawrence K.] Chinese Univ Hong Kong, Sha Tin, Hong Kong, Peoples R China. [Hakim, Antoine] Univ Ottawa, Canadian Stroke Network, Ottawa, ON, Canada. Ottawa Hosp Res Inst, Ottawa, ON, Canada. [Norrving, Bo] Univ Lund Hosp, S-22185 Lund, Sweden. [Prudhomme, Stephen] Amer Heart Assoc, Dallas, TX USA. [Bornstein, Natan M.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel. [Davis, Stephen M.] Royal Melbourne Hosp, Melbourne, Vic, Australia. Univ Melbourne, Melbourne, Vic, Australia. [Goldstein, Larry B.] Durham VA Med Ctr, Durham, NC USA. [Leys, Didier] Univ Lille Nord France, Lille, France. [Tuomilehto, Jaakko] Univ Helsinki, Helsinki, Finland. RP Hachinski, V (reprint author), Univ Western Ontario, Univ Hosp, 339 Windermere Rd, London, ON N6A 5A5, Canada. EM Vladimir.Hachinski@lhsc.on.ca RI Skolnick, Brett/B-5140-2009; Buchan, Alastair/B-9095-2009; Jones, Theresa/F-1182-2010; Davis, Stephen/L-5260-2013; Wong, Ka Sing Lawrence/N-3434-2015; LEYS, Didier/G-2955-2016; OI Saver, Jeffrey/0000-0001-9141-2251; Kaste, Markku/0000-0001-6557-6412; Schwamm, Lee/0000-0003-0592-9145; Donnan, Geoffrey/0000-0001-6324-3403; Buchan, Alastair/0000-0002-2918-5200; Jones, Theresa/0000-0003-0906-6439; Davis, Stephen/0000-0003-0962-2300; Wong, Ka Sing Lawrence/0000-0002-2031-9866; LEYS, Didier/0000-0003-4408-4392; Kivipelto, Miia/0000-0003-0992-3875; Norrving, Bo/0000-0002-8024-5096 FU Medical Research Council [G0500495]; NINDS NIH HHS [P01 NS055104, RC2 NS069335] NR 83 TC 54 Z9 55 U1 2 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JUN PY 2010 VL 41 IS 6 BP 1084 EP 1099 DI 10.1161/STROKEAHA.110.586156 PG 16 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 600WK UT WOS:000278019400006 PM 20498453 ER PT J AU Anderson, CD Biffi, A Rost, NS Cortellini, L Furie, KL Rosand, J AF Anderson, Christopher D. Biffi, Alessandro Rost, Natalia S. Cortellini, Lynelle Furie, Karen L. Rosand, Jonathan TI Chromosome 9p21 in Ischemic Stroke Population Structure and Meta-Analysis SO STROKE LA English DT Article DE atherosclerosis; cardiac disease; genetics; ischemic stroke; meta-analysis; methodology ID CORONARY-ARTERY-DISEASE; HEART-DISEASE; GENOMEWIDE ASSOCIATION; MYOCARDIAL-INFARCTION; GENETIC-VARIANTS; SUSCEPTIBILITY; CHINESE; LOCUS; RISK AB Background and Purpose-Sequence variants on chromosome 9p21.3 are implicated in coronary artery disease and myocardial infarction, but studies in ischemic stroke have produced inconsistent results. We investigated whether these conflicting findings were due to false-positive studies confounded by population stratification or false-negative studies that failed to account for effects specific to certain stroke subtypes. Methods-After assessing for population stratification at 9p21.3 using genomewide data, we meta-analyzed 8 ischemic stroke studies. This analysis focused on 2 single nucleotide polymorphisms, rs1537378 and rs10757278, because these variants are in strong linkage disequilibrium with most single nucleotide polymorphisms analyzed in prior studies of the region. Results-Principal component analysis of the genomewide data showed no evidence of population stratification at that locus. Meta-analysis confirmed that both rs1537378 and rs10757278 are risk factors for ischemic stroke (ORs, 1.09 [P = 0.0014] and 1.11 [P = 0.001], respectively). Subtype analysis revealed a substantial increase in the effect of each single nucleotide polymorphism for risk of large artery stroke, achieving an effect size similar to that seen in coronary artery disease/myocardial infarction. Conclusions-Variants on 9p21.3 are associated with ischemic stroke, and restriction of analysis to large artery stroke increases effect size toward that observed in prior association studies of coronary artery disease/myocardial infarction. Previous inconsistent findings are best explained by this subtype specificity rather than any unmeasured confounding by population stratification. (Stroke. 2010; 41: 1123-1131.) C1 [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Cortellini, Lynelle; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Cortellini, Lynelle; Furie, Karen L.; Rosand, Jonathan] Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA. [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Cortellini, Lynelle; Rosand, Jonathan] Broad Inst, Cambridge, MA USA. RP Rosand, J (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA. OI Anderson, Christopher/0000-0002-0053-2002 FU American Heart Association/Bugher Foundation Centers for Stroke Prevention Research [0775010N]; Deane Institute for Integrative Study of Atrial Fibrillation and Stroke; US National Institutes of Health and National Heart, Lung, and Blood Institute [R01 HL087676]; National Center for Research [U54 RR020278] FX Supported by the American Heart Association/Bugher Foundation Centers for Stroke Prevention Research (0775010N), Deane Institute for Integrative Study of Atrial Fibrillation and Stroke, US National Institutes of Health and National Heart, Lung, and Blood Institute's STAMPEED genomics research program (R01 HL087676), and The National Center for Research (U54 RR020278). NR 20 TC 35 Z9 37 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JUN PY 2010 VL 41 IS 6 BP 1123 EP 1131 DI 10.1161/STROKEAHA.110.580589 PG 9 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 600WK UT WOS:000278019400011 PM 20395606 ER PT J AU Zhao, XH Zhao, Q Chu, BC Yang, Y Li, FY Zhou, XH Cai, JM Cai, ZL Yuan, C AF Zhao, Xihai Zhao, Qian Chu, Baocheng Yang, Yin Li, Feiyu Zhou, Xiao-Hua Cai, Jianming Cai, Zulong Yuan, Chun TI Prevalence of Compositional Features in Subclinical Carotid Atherosclerosis Determined by High-Resolution Magnetic Resonance Imaging in Chinese Patients With Coronary Artery Disease SO STROKE LA English DT Article DE carotid artery; coronary artery disease; magnetic resonance imaging; plaque composition; subclinical atherosclerosis ID TRANSIENT ISCHEMIC ATTACK; INTIMA-MEDIA THICKNESS; MYOCARDIAL-ISCHEMIA; PLAQUE COMPOSITION; MRI; CALCIFICATION; ASSOCIATION; TOMOGRAPHY; STROKE; STENOSIS AB Background and Purpose-Previous studies have reported that carotid atherosclerosis frequently can be seen in coronary artery disease (CAD) patients. This study sought to determine the prevalence of compositional features in subclinical carotid atherosclerosis by MRI in CAD patients. Methods-Ninety-six subjects with suspected CAD but free of neurological symptoms underwent coronary CT angiography and carotid MRI including 3-dimensional time-of-flight, T1-weighted, T2-weighted, and proton density-weighted sequences at 3 T within a 2-week interval. The coronary artery calcium score (CACS) and degree of stenosis were measured. Areas for carotid lumen, wall, total vessel, and percent wall volume (wall volume/total vessel volume) were measured. The prevalence of carotid calcification, lipid-rich necrotic core, intraplaque hemorrhage, and surface disruption in coronary stenosis and CACS categories were determined. Results-Carotid percent wall volume was correlated with CACS (P = 0.001). Both coronary stenosis and CACS were significantly associated with presence of carotid calcification (OR = 5.79 for 1%-49% vs 0% stenosis; OR = 10.23 for >50% vs 0% stenosis; OR = 10.65 for CACS 1-399 vs CACS 0; and OR = 20.28 for CACS >400 vs CACS 0; all P<0.05) and lipid-rich necrotic core (OR = 10.29 for 1%-49% vs 0% stenosis; OR = 4.66 for >50% vs 0% stenosis; OR = 8.23 for CACS 1-399 vs CACS 0; and OR = 11.87 for CACS >400 vs CACS 0; all P < 0.05) High prevalence of lipid-rich necrotic core was found in low-grade coronary stenosis (75.6% in 1%-49% stenosis) and CACS (73.5% in CACS 1-399). Conclusions-Carotid plaque burden and compositional features are significantly associated with CAD severity. The finding of high prevalence of lipid-rich necrotic core in patients with low-grade coronary stenosis and CACS suggests the need for early monitoring of carotid atherosclerosis in CAD patients. (Stroke. 2010; 41: 1157-1162.) C1 [Zhao, Xihai; Chu, Baocheng; Li, Feiyu; Yuan, Chun] Univ Washington, Dept Radiol, Seattle, WA 98109 USA. [Yang, Yin; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhao, Qian; Cai, Jianming; Cai, Zulong] Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA USA. RP Yuan, C (reprint author), Univ Washington, Dept Radiol, 815 Mercer St,Box 358050, Seattle, WA 98109 USA. EM cyuan@u.washington.edu FU National Institutes of Health [RO1 HL 56874] FX This study is supported in part by a grant from the National Institutes of Health (RO1 HL 56874). NR 30 TC 9 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JUN PY 2010 VL 41 IS 6 BP 1157 EP 1162 DI 10.1161/STROKEAHA.110.580027 PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 600WK UT WOS:000278019400016 PM 20395607 ER PT J AU Abou-Chebl, A Lin, R Hussain, MS Jovin, TG Levy, EI Liebeskind, DS Yoo, AJ Hsu, DP Rymer, MM Tayal, AH Zaidat, OO Natarajan, SK Nogueira, RG Nanda, A Tian, M Hao, Q Kalia, JS Nguyen, TN Chen, M Gupta, R AF Abou-Chebl, Alex Lin, Ridwan Hussain, Muhammad Shazam Jovin, Tudor G. Levy, Elad I. Liebeskind, David S. Yoo, Albert J. Hsu, Daniel P. Rymer, Marilyn M. Tayal, Ashis H. Zaidat, Osama O. Natarajan, Sabareesh K. Nogueira, Raul G. Nanda, Ashish Tian, Melissa Hao, Qing Kalia, Junaid S. Nguyen, Thanh N. Chen, Michael Gupta, Rishi TI Conscious Sedation Versus General Anesthesia During Endovascular Therapy for Acute Anterior Circulation Stroke Preliminary Results From a Retrospective, Multicenter Study SO STROKE LA English DT Article DE acute stroke; thrombolysis; endovascular therapy; intra-arterial therapy; sedation ID ACUTE ISCHEMIC-STROKE; MULTIMODAL REPERFUSION THERAPY; INTRAARTERIAL THROMBOLYSIS; PROACT II; TRIAL; RECANALIZATION; MANAGEMENT; OCCLUSION; PATIENT; SAFETY AB Background and Purpose-Patients undergoing intra-arterial therapy (IAT) for acute ischemic stroke receive either general anesthesia (GA) or conscious sedation. GA may delay time to treatment, whereas conscious sedation may result in patient movement and compromise the safety of the procedure. We sought to determine whether there were differences in safety and outcomes in GA patients before initiation of IAT. Methods-A cohort of 980 patients at 12 stroke centers underwent IAT for acute stroke between 2005 and 2009. Only patients with anterior circulation strokes due to large-vessel occlusion were included in the study. A binary logistic-regression model was used to determine independent predictors of good outcome and death. Results-The mean age was 66 +/- 15 years and median National Institutes of Health Stroke Scale score was 17 (interquartile range, 13-20). The overall recanalization rate was 68% and the symptomatic hemorrhage rate was 9.2%. GA was used in 44% of patients with no differences in intracranial hemorrhage rates when compared with the conscious sedation group. The use of GA was associated with poorer neurologic outcome at 90 days (odds ratio = 2.33; 95% CI, 1.63-3.44; P<0.0001) and higher mortality (odds ratio = 1.68; 95% CI, 1.23-2.30; P<0.0001) compared with conscious sedation. Conclusions-Patients placed under GA during IAT for anterior circulation stroke appear to have a higher chance of poor neurologic outcome and mortality. There do not appear to be differences in hemorrhagic complications between the 2 groups. Future clinical trials with IAT can help elucidate the etiology of the differences in outcomes. (Stroke. 2010; 41: 1175-1179.) C1 [Abou-Chebl, Alex] Univ Louisville, Med Ctr, Louisville, KY 40292 USA. [Lin, Ridwan; Jovin, Tudor G.] Univ Pittsburgh, Med Ctr, Stroke Inst, Pittsburgh, PA USA. [Hussain, Muhammad Shazam; Gupta, Rishi] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Levy, Elad I.; Natarajan, Sabareesh K.] SUNY Buffalo, Buffalo, NY 14260 USA. [Liebeskind, David S.; Hao, Qing] Univ Calif Los Angeles, Los Angeles, CA USA. [Yoo, Albert J.; Nogueira, Raul G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hsu, Daniel P.; Nanda, Ashish] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Rymer, Marilyn M.] St Lukes Brain & Stroke Inst, Kansas City, MO USA. [Tayal, Ashis H.; Tian, Melissa] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Zaidat, Osama O.; Kalia, Junaid S.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Nguyen, Thanh N.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Chen, Michael] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Gupta, Rishi] Vanderbilt Univ, Med Ctr, Nashville, TN USA. RP Gupta, R (reprint author), Vanderbilt Stroke Ctr, Dept Neurol, A-0118 Med Ctr N, Nashville, TN 37232 USA. EM rishi.gupta@vanderbilt.edu OI Kalia, Junaid/0000-0001-7121-8638 FU National Institutes of Health; Penumbra Corp; Boston Scientific Corp; Micrus Endovascular; Abbott Vascular; EV3 FX David Liebeskind has received significant research support from the National Institutes of Health.; Alex Abou-Chebl, MD; Ridwan Lin, MD; Muhammad Shazam Hussain, MD; Daniel P. Hsu, MD; Sabareesh K. Natarajan, MD, MS; Ashish Nanda, MD; Melissa Tian, RN; Qing Hao, MD, PhD; Junaid S. Kalia, MD; and Thanh N. Nguyen, MD, have no relevant conflicts of interest to disclose. Albert J. Yoo has research support from Penumbra Corp. Tudor G. Jovin, MD, is on the consultant/scientific advisory boards for CoAxia Medical and Concentric Medical and is a consultant for EV3. Elad I. Levy, MD, has received a research grant from Boston Scientific Corp; research support from Micrus Endovascular, Abbott Vascular, and EV3; has received honoraria from Intratech Medical Ltd; has an ownership interest in Mynx/Access Closure and TheraSyn Sensors, Inc; and is on the consultant/advisory boards for Cordis Neurovascular and Micrus Endovascular. Marilyn M. Rymer, MD, is a speaker for Concentric Medical and a consultant for Genentech. Ashis H. Tayal, MD, is a speaker for Genentech and Boehringer Ingelheim. David S. Liebskind, MD, and Raul G. Nogueira, MD, are consultants to and on the advisory boards for Concentric Medical, EV3, and CoAxia. Osama Zaidat, MD, is on the consultant/scientific advisory board for Boston Scientific Corp. Michael Chen, MD, is a speaker for Concentric Medical. Rishi Gupta, MD, is on the consultant/scientific advisory boards for Concentric Medical and CoAxia. NR 21 TC 146 Z9 147 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JUN PY 2010 VL 41 IS 6 BP 1175 EP 1179 DI 10.1161/STROKEAHA.109.574129 PG 5 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 600WK UT WOS:000278019400019 PM 20395617 ER PT J AU Uppal, R Ay, I Dai, GP Kim, YR Sorensen, AG Caravan, P AF Uppal, Ritika Ay, Ilknur Dai, Guangping Kim, Young Ro Sorensen, A. Gregory Caravan, Peter TI Molecular MRI of Intracranial Thrombus in a Rat Ischemic Stroke Model SO STROKE LA English DT Article DE fibrin; gadolinium; ischemic stroke; molecular imaging; thrombus ID MIDDLE CEREBRAL-ARTERY; TARGETED CONTRAST AGENT; TISSUE-PLASMINOGEN ACTIVATOR; IN-VIVO; SWINE MODEL; CORONARY-THROMBOSIS; PULMONARY EMBOLI; FIBRIN; SIGN; EP-2104R AB Background and Purpose-Intracranial thrombus is a principal feature in most ischemic stroke, and thrombus location and size may correlate with outcome and response to thrombolytic therapy. EP-2104R is a fibrin-specific molecular MR agent that has previously been shown to enhance extracranial and venous sinus thrombi in animal models and, recently, in clinical trials. In this study, we examined whether this fibrin-specific MR probe could noninvasively characterize intracranial arterial thrombi. Methods-Embolic stroke was induced in adult rats by occlusion of the right internal carotid artery with an aged thrombus. We used diffusion-weighted imaging, time of flight angiography, and high-resolution 3-dimensional T1-weighted MRI at 4.7 T before and after use of contrast agents EP-2104R (n = 6) and gadopentetate dimeglumine (n = 5). Results-In all animals, MR angiography revealed a flow deficit and diffusion-weighted imaging showed hyperintensity consistent with ischemia. Using EP-2104R-enhanced MRI, we saw occlusive thrombi and vessel wall enhancement in all 6 animals with high contrast to noise relative to blood, whereas gadopentetate dimeglumine-injected animals showed no occlusive thrombus or vessel wall enhancement. The concentration of gadolinium in the thrombus after EP-2104R was 18 times that in the blood pool. Conclusions-EP-2104R-enhanced MRI successfully identifies intracranial thrombus in a rat embolic stroke model. (Stroke. 2010; 41: 1271-1277.) C1 Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. Harvard Univ, Sch Med, Charlestown, MA USA. RP Ay, I (reprint author), Massachusetts Gen Hosp E, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St,Suite 2301, Charlestown, MA 02129 USA. EM iay@partners.org; caravan@nmr.mgh.harvard.edu FU National Institute of Biomedical Imaging and Bioengineering [EB009062]; Ruth L. Kirschstein National Research Service [5T32CA009502]; PHS [NS38477]; National Center for Research Resources [P41-RR14075]; MIND Institute FX This study was supported by the National Institute of Biomedical Imaging and Bioengineering (EB009062 to P. C.). I. A. was supported by a T32 Ruth L. Kirschstein National Research Service Award (5T32CA009502). A. G. S. was supported by PHS NS38477. Partial support was also provided by National Center for Research Resources (P41-RR14075) and the MIND Institute. NR 33 TC 24 Z9 26 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JUN PY 2010 VL 41 IS 6 BP 1271 EP 1277 DI 10.1161/STROKEAHA.109.575662 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 600WK UT WOS:000278019400033 PM 20395615 ER PT J AU Ziegler, PD Glotzer, TV Daoud, EG Wyse, DG Singer, DE Ezekowitz, MD AF Ziegler, Paul D. Glotzer, Taya V. Daoud, Emile G. Wyse, D. George Singer, Daniel E. Ezekowitz, Michael D. TI Incidence of Newly Detected Atrial Arrhythmias Through Implantable Devices in Patients With a History of Thromboembolic Events Response SO STROKE LA English DT Letter ID FIBRILLATION; ABLATION; CATHETER C1 [Ziegler, Paul D.] Medtronic, Mt View, MN USA. [Glotzer, Taya V.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Daoud, Emile G.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ezekowitz, Michael D.] Lankenau Inst Med Res, Wynnewood, PA USA. RP Ziegler, PD (reprint author), Medtronic, Mt View, MN USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JUN PY 2010 VL 41 IS 6 BP E453 EP E454 DI 10.1161/STROKEAHA.110.584821 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 600WK UT WOS:000278019400050 ER PT J AU Bagley, SC Munjas, B Shekelle, P AF Bagley, Steven C. Munjas, Brett Shekelle, Paul TI A Systematic Review of Suicide Prevention Programs for Military or Veterans SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID HEALTH; QUALITY; RISK; POPULATION; FORCE; ARMY; IRAQ; WAR AB Military personnel and veterans have important suicide risk factors. After a systematic review of the literature on suicide prevention, seven (five in the U.S.) studies of military personnel were identified containing interventions that may reduce the risk of suicide. The effectiveness of the individual components was not assessed, and problems in methodology or reporting of data were common. Overall, multifaceted interventions for active duty military personnel are supported by consistent evidence, although of very mixed quality, and in some cases during intervals of declines in suicide rates in the general population. There were insufficient studies of U.S. Veterans to reach conclusions. C1 [Bagley, Steven C.; Munjas, Brett; Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bagley, Steven C.; Munjas, Brett; Shekelle, Paul] So Calif RAND Evidence Based Practice Ctr, Los Angeles, CA USA. RP Bagley, SC (reprint author), Dept Vet Affairs, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM steven.bagley2@va.gov NR 27 TC 18 Z9 18 U1 1 U2 5 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0363-0234 J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD JUN PY 2010 VL 40 IS 3 BP 257 EP 265 PG 9 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 610NQ UT WOS:000278740200005 PM 20560747 ER PT J AU Conrad, C Konuk, Y Werner, P Cao, CG Warshaw, A Rattner, D Jones, DB Gee, D AF Conrad, Claudius Konuk, Yusuf Werner, Paul Cao, Caroline G. Warshaw, Andrew Rattner, David Jones, Daniel B. Gee, Denise TI The effect of defined auditory conditions versus mental loading on the laparoscopic motor skill performance of experts SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article DE Laparoscopy; Memory consolidation; Mental loading; Motor performance; Music; Stress ID NOISE-POLLUTION; MUSIC; SURGEONS; TASK AB Music and noise are frequent occurrences in the operating room. To date, the effects of these auditory conditions on the performance of laparoscopic surgery experts have not been evaluated. Eight internationally recognized experts were recruited for a crossover study. The experts were randomized to perform three simple tasks on a laparoscopic simulator, SurgicalSIM VR. The tasks were equal in difficulty and performed under the following conditions: silence, dichaotic music (auditory stress), classical music (auditory relaxation), and mental loading (mental arithmetic tasks). Permutations of the conditions were created to account for a learning effect. The tasks were performed twice to test for memory consolidation and to accommodate baseline variability. Time until task completion and task accuracy via instrument tip trajectory (path of the tip through space) were recorded. Performance was correlated with responses on the Brief Musical Experience Questionnaire (MEQ). The study demonstrated that dichaotic music has a negative impact on time until task completion but not on task accuracy. In addition, memory consolidation of accuracy is negatively influenced. Classical music has a variable effect on experts' time until task completion, yet all the experts performed the tasks more accurately. Classical music had no effect on recall of a procedure. Mental loading increased time until completion, but did not affect accuracy or recall. The experience of music varied among experts and influenced how each of the conditions affected their performance. The study demonstrated that, contrary to common belief, proficiency in surgery does not protect against stressful auditory influences or the influence of mental preoccupation. Interestingly, relaxing auditory influences such as classical music can even have a positive impact on the accuracy of experts. Previous musical experience could help to identify surgeons whose performance may be specifically affected by music or noise. C1 [Conrad, Claudius; Konuk, Yusuf; Warshaw, Andrew; Rattner, David; Gee, Denise] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Werner, Paul] Alliant Int Univ, Calif Sch Profess Psychol, San Francisco, CA USA. [Cao, Caroline G.] Tufts Univ, Dept Mech Engn, Medford, MA 02155 USA. [Jones, Daniel B.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA. RP Conrad, C (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St, Boston, MA 02114 USA. EM Cconrad1@partners.org NR 16 TC 19 Z9 19 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0930-2794 J9 SURG ENDOSC JI Surg. Endosc. PD JUN PY 2010 VL 24 IS 6 BP 1347 EP 1352 DI 10.1007/s00464-009-0772-0 PG 6 WC Surgery SC Surgery GA 596VO UT WOS:000277713800019 PM 20033720 ER PT J AU Spadea, MF Peroni, M Preve, E Riboldi, M Baroni, G Chen, GTY Sharp, GC AF Spadea, Maria Francesca Peroni, Marta Preve, Eleonora Riboldi, Marco Baroni, Guido Chen, George T. Y. Sharp, Gregory Charles TI Uncertainties in Lung Motion Prediction Relying on External Surrogate: A 4DCT Study in Regular vs. Irregular Breathers SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT LA English DT Article DE 4D-CT; Lung tumor; Prediction error ID 4-DIMENSIONAL COMPUTED-TOMOGRAPHY; TUMOR MOTION; RADIATION-THERAPY; TRACKING SYSTEM; CT; RESPIRATION; MARKERS; 4D-CT; PHASE AB This paper examines the uncertainty in estimating lung motion from external surrogates for lung cancer patients with regular and irregular breathing 4DCT data sets were analyzed using a template matching algorithm to track the spatial movement of vessel bifurcations in 12 patients The detected internal movement of features in 3D was retrospectively synchronized with the RPM surrogate signal, and the correlation index R(2) and the prediction error were computed Patients were classified into two groups depending on the presence or not of irregularities in their breathing pattern Peak-to-peak values of feature motion in the SI direction ranged from 0 8 mm (upper lung) to 25 3 mm (lower lung) Some patients exhibited large motion also in the latero-lateral (10 6 mm) and anterior-posterior (12 2 mm) directions The median +/- quartile of R(2) in SI direction was 0 89 +/- 0 09 Prediction error values were up to 4 2 mm (95(th) percentile) with a maximum value of 4 9 mm Statistical differences between regular and irregular breathers were found for R(2), while prediction error depended only on the range of motion This study is relevant for image guided radiotherapy methods that rely on external surrogates to monitor motion C1 [Spadea, Maria Francesca] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy. [Spadea, Maria Francesca; Peroni, Marta; Preve, Eleonora; Riboldi, Marco; Baroni, Guido] Politecn Milano Univ, Dept Bioengn, Milan, Italy. [Chen, George T. Y.; Sharp, Gregory Charles] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Spadea, MF (reprint author), Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy. RI Baroni, Guido/D-3012-2011; Spadea, Maria Francesca/I-2468-2012; Riboldi, Marco/I-2980-2014 OI Riboldi, Marco/0000-0002-2431-4966 FU CNAO Foundation (the Italian National Center of Oncological Hadrontherapy); "Progetto Rocca" Foundation, a collaboration program between MIT and Politecnico di Milano FX This work was supported in part by the CNAO Foundation (the Italian National Center of Oncological Hadrontherapy) and by the "Progetto Rocca" Foundation, a collaboration program between MIT and Politecnico di Milano NR 25 TC 7 Z9 8 U1 0 U2 3 PU ADENINE PRESS PI SCHENECTADY PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA SN 1533-0346 J9 TECHNOL CANCER RES T JI Technol. Cancer Res. Treat. PD JUN PY 2010 VL 9 IS 3 BP 307 EP 315 PG 9 WC Oncology SC Oncology GA 600CK UT WOS:000277961000010 PM 20441241 ER PT J AU Cho, AH Arar, NH Edelman, DE Hartwell, PH Oddone, EZ Yancy, WS AF Cho, Alex H. Arar, Nedal H. Edelman, David E. Hartwell, Patricia H. Oddone, Eugene Z. Yancy, William S., Jr. TI Do Diabetic Veterans Use the Internet? Self-Reported Usage, Skills, and Interest in Using My HealtheVet Web Portal SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Article DE veterans; medical informatics; patient preferences; diabetes; self-care; Internet ID GLUCOSE MONITORING-SYSTEM; CARE; MANAGEMENT AB Objective: The Veterans Health Administration has developed My HealtheVet (MHV), a Web-based portal that links veterans to their care in the veteran affairs (VA) system. The objective of this study was to measure diabetic veterans' access to and use of the Internet, and their interest in using MHV to help manage their diabetes. Materials and Methods: Cross-sectional mailed survey of 201 patients with type 2 diabetes and hemoglobin A(1c) > 8.0% receiving primary care at any of five primary care clinic sites affiliated with a VA tertiary care facility. Main measures included Internet usage, access, and attitudes; computer skills; interest in using the Internet; awareness of and attitudes toward MHV; demographics; and socioeconomic status. Results: A majority of respondents reported having access to the Internet at home. Nearly half of all respondents had searched online for information about diabetes, including some who did not have home Internet access. More than a third obtained "some'' or "a lot'' of their health-related information online. Forty-one percent reported being "very interested'' in using MHV to help track their home blood glucose readings, a third of whom did not have home Internet access. Factors associated with being "very interested'' were as follows: having access to the Internet at home (p < 0.001), "a lot/some'' trust in the Internet as a source of health information (p = 0.002), lower age (p = 0.03), and some college (p = 0.04). Neither race (p = 0.44) nor income (p = 0.25) was significantly associated with interest in MHV. Conclusions: This study found that a diverse sample of older VA patients with sub-optimally controlled diabetes had a level of familiarity with and access to the Internet comparable to an age-matched national sample. In addition, there was a high degree of interest in using the Internet to help manage their diabetes. C1 [Cho, Alex H.; Edelman, David E.; Oddone, Eugene Z.; Yancy, William S., Jr.] Duke Univ, Div Gen Internal Med, Durham, NC 27710 USA. [Arar, Nedal H.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Edelman, David E.; Hartwell, Patricia H.; Oddone, Eugene Z.; Yancy, William S., Jr.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. RP Cho, AH (reprint author), Duke Univ, Div Gen Internal Med, 106 Davison Bldg,DUMC Box 3701, Durham, NC 27710 USA. EM alex.cho@duke.edu OI Edelman, David/0000-0001-7112-6151 FU Agency for Healthcare Research and Quality [5T32HS00079] FX This work was supported by Grant 5T32HS00079 from Agency for Healthcare Research and Quality. NR 15 TC 20 Z9 20 U1 2 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD JUN PY 2010 VL 16 IS 5 BP 595 EP 602 DI 10.1089/tmj.2009.0164 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 615ZW UT WOS:000279178400011 PM 20575727 ER PT J AU Libby, P Nahrendorf, M Weissleder, R AF Libby, Peter Nahrendorf, Matthias Weissleder, Ralph TI Molecular Imaging of Atherosclerosis A Progress Report SO TEXAS HEART INSTITUTE JOURNAL LA English DT Article; Proceedings Paper CT 9th Texas Update in Cardiovascular Advancements CY DEC 04-05, 2009 CL Houston, TX ID IN-VIVO; PATHOPHYSIOLOGY; INFLAMMATION; MACROPHAGES; ACTIVATION; DISEASE C1 [Libby, Peter] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [Nahrendorf, Matthias; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. RP Libby, P (reprint author), Brigham & Womens Hosp, Div Cardiovasc Med, 77 Ave, Boston, MA 02115 USA. EM plibby@rics.bwh.harvard.edu FU NHLBI NIH HHS [R01 HL080472, HL080472, U01 HL080731, U01HL080731] NR 14 TC 8 Z9 8 U1 0 U2 3 PU TEXAS HEART INST PI HOUSTON PA PO BOX 20345, HOUSTON, TX 77225-0345 USA SN 0730-2347 J9 TEX HEART I J JI Tex. Heart Inst. J. PD JUN PY 2010 VL 37 IS 3 BP 324 EP 327 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 607PI UT WOS:000278517600015 PM 20548813 ER PT J AU Conesa, A Fernandez-Mestre, M Padron, D Toro, F Silva, N Tassinari, P Blanca, I Martin, MP Carrington, M Layrisse, Z AF Conesa, A. Fernandez-Mestre, M. Padron, D. Toro, F. Silva, N. Tassinari, P. Blanca, I. Martin, M. P. Carrington, M. Layrisse, Z. TI Distribution of killer cell immunoglobulin-like receptor genes in the mestizo population from Venezuela SO TISSUE ANTIGENS LA English DT Article DE KIR; mestizo Venezuelan population; natural killer cells; polymerase chain reaction-sequence-specific primers ID IG-LIKE RECEPTOR; KIR GENE; HLA-C; T-CELLS; DIVERSITY; MOLECULES; ADMIXTURE; CLUSTER; CLONES; BLOOD AB This study represents the first report on the distribution of KIR genes in 205 unrelated healthy mestizo Venezuelan individuals. Genotyping analysis showed that all KIR genes are present in this population. Frequency of inhibitory killer cell immunoglobulin-like receptors (KIRs) exceeded 0.69, except for KIR2DL2 (0.29) and 2DL5 (0.37). Activating KIRs showed low frequencies (0.11-0.29), except for KIR2DS4 (0.68). Forty-five different KIR genotypes were identified, with a predominance of three genotypes found in 50.7% of the population of which 25.9% were individuals homozygous for haplotype A. The frequencies of KIR genes reflect the ethnic admixture existing in the mestizo Venezuelan population. C1 [Fernandez-Mestre, M.; Padron, D.; Layrisse, Z.] Inst Venezolano Invest Cient, Ctr Med Expt Miguel Layrisse, Caracas 1020A, Venezuela. [Conesa, A.; Toro, F.; Silva, N.; Tassinari, P.; Blanca, I.] Cent Univ Venezuela, Fac Med, Inst Inmunol, FOCIS Ctr Excellence, Caracas, Venezuela. [Martin, M. P.; Carrington, M.] NCI, Canc & Inflammat Program, Expt Immunol Lab, SAIC Frederick Inc, Frederick, MD 21701 USA. [Carrington, M.] Massachusetts Gen Hosp, Ragon Inst, MIT, Boston, MA 02114 USA. [Carrington, M.] Harvard Univ, Boston, MA 02115 USA. RP Fernandez-Mestre, M (reprint author), Inst Venezolano Invest Cient, Ctr Med Expt Miguel Layrisse, Kilometro 11,Carretera Panamericana,Apdo 21827, Caracas 1020A, Venezuela. EM mfernand@ivic.ve FU FONACIT [G-2005000395, S1-2002000504]; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; NIH, National Cancer Institute, Center for Cancer Research FX This research was supported in part by FONACIT grants G-2005000395 and S1-2002000504. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This Research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. Our gratitude to the individuals who participated in the study and to Omar Balbas for assistance with the Phylogeny Inference Package. NR 39 TC 1 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0001-2815 J9 TISSUE ANTIGENS JI Tissue Antigens PD JUN PY 2010 VL 75 IS 6 BP 724 EP 729 DI 10.1111/j.1399-0039.2010.01446.x PG 6 WC Cell Biology; Immunology; Pathology SC Cell Biology; Immunology; Pathology GA 595KJ UT WOS:000277609000012 PM 20210918 ER PT J AU Chin, MS Ogawa, R Lancerotto, L Pietramaggiori, G Schomacker, KT Mathews, JC Scherer, SS Van Duyn, P Prsa, MJ Ottensmeyer, MP Veves, A Orgill, DP AF Chin, Michael S. Ogawa, Rei Lancerotto, Luca Pietramaggiori, Giorgio Schomacker, Kevin T. Mathews, Jasmine C. Scherer, Saja S. Van Duyn, Paul Prsa, Michael J. Ottensmeyer, Mark P. Veves, Aristidis Orgill, Dennis P. TI In Vivo Acceleration of Skin Growth Using a Servo-Controlled Stretching Device SO TISSUE ENGINEERING PART C-METHODS LA English DT Article ID HYDROSTATIC-PRESSURE; MECHANICAL STRETCH; TISSUE EXPANDER; HYPOXIA; FIBROBLASTS; PROLIFERATION; BIOREACTOR; EXPRESSION; CARTILAGE; MUSCLE AB Tension is a principal force experienced by skin and serves a critical role in growth and development. Optimal tension application regimens may be an important component for skin tissue engineering and dermatogenesis. In this study, we designed and tested a novel servo-controlled skin-stretching device to apply predetermined tension and waveforms in mice. The effects of static and cyclical stretching forces were compared in 48 mice by measuring epidermal proliferation, angiogenesis, cutaneous perfusion, and principal growth factors using immunohistochemistry, real-time reverse transcriptase-polymerase chain reaction, and hyperspectral imaging. All stretched samples had upregulated epidermal proliferation and angiogenesis. Real-time reverse transcriptase polymerase chain reaction of epidermal growth factor, transforming growth factor beta 1, and nerve growth factor demonstrated greater expression in cyclically stretched skin when compared to static stretch. Hypoxia-induced factor 1 alpha was significantly upregulated in cyclically stretched skin, but poststretch analysis demonstrated well-oxygenated tissue, collectively suggesting the presence of transient hypoxia. Waveform-specific mechanical loads may accelerate tissue growth by mechanotransduction and as a result of repeated cycles of temporary hypoxia. Further analysis of mechanotransduction signaling pathways may provide additional insight to improve skin tissue engineering methods and optimize our device. C1 [Chin, Michael S.; Ogawa, Rei; Lancerotto, Luca; Pietramaggiori, Giorgio; Mathews, Jasmine C.; Scherer, Saja S.; Orgill, Dennis P.] Harvard Univ, Brigham & Womens Hosp, Div Plast Surg, Tissue Engn & Wound Healing Lab,Sch Med, Boston, MA 02115 USA. [Chin, Michael S.; Mathews, Jasmine C.] Univ Massachusetts, Sch Med, Div Plast Surg, Worcester, MA USA. [Ogawa, Rei] Nippon Med Sch, Dept Plast Reconstruct & Aesthet Surg, Tokyo 113, Japan. [Lancerotto, Luca; Pietramaggiori, Giorgio] Univ Padua, Clin Plast Surg, I-35100 Padua, Italy. [Schomacker, Kevin T.] HyperMed Inc, Burlington, MA USA. [Van Duyn, Paul; Prsa, Michael J.] Wentworth Inst Technol, Boston, MA USA. [Ottensmeyer, Mark P.] Massachusetts Gen Hosp, CIMIT, Simulat Grp, Boston, MA 02114 USA. [Veves, Aristidis] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Joslin Beth Israel Deaconess Foot Ctr, Boston, MA 02115 USA. [Veves, Aristidis] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Microcirculat Lab, Boston, MA 02115 USA. RP Orgill, DP (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Plast Surg, Tissue Engn & Wound Healing Lab,Sch Med, 75 Francis St, Boston, MA 02115 USA. EM dorgill@partners.org RI Lancerotto, Luca/A-5745-2013; OI Lancerotto, Luca/0000-0002-2908-678X; Orgill, Dennis/0000-0002-8279-7310 FU Sean Oakes; Moore Surgical Laboratory FX The authors would like to thank George Younan, M. D. for his excellent technical assistance in the collection and preparation of the data. Additionally, the authors would like to recognize the support of Sean Oakes and the Moore Surgical Laboratory, without which this project would not have been possible. NR 37 TC 33 Z9 34 U1 0 U2 11 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3384 J9 TISSUE ENG PART C-ME JI Tissue Eng. Part C-Methods PD JUN PY 2010 VL 16 IS 3 BP 397 EP 405 DI 10.1089/ten.tec.2009.0185 PG 9 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA 601SJ UT WOS:000278083900008 PM 19601702 ER PT J AU Blake, KD Viswanath, K Blendon, RJ Vallone, D AF Blake, Kelly D. Viswanath, K. Blendon, Robert J. Vallone, Donna TI The role of reported tobacco-specific media exposure on adult attitudes towards proposed policies to limit the portrayal of smoking in movies SO TOBACCO CONTROL LA English DT Article ID ADOLESCENT SMOKING; UNITED-STATES; NEWS; INITIATION; BEHAVIOR AB Objective To assess the relative, independent contribution of reported tobacco-specific media exposure (pro-tobacco advertising, anti-tobacco advertising, and news coverage of tobacco issues) to US adults' support for policy efforts that aim to regulate the portrayal of smoking in movies. Methods Using the American Legacy Foundation's 2003 American Smoking and Health Survey (ASHES-2), multivariable logistic regression was used to model the predicted probability that US adults support movie-specific tobacco control policies, by reported exposure to tobacco-specific media messages, controlling for smoking status, education, income, race/ethnicity, age, sex, knowledge of the negative effects of tobacco and state. Results Across most outcome variables under study, findings reveal that reported exposure to tobacco-specific media messages is associated with adult attitudes towards movie-specific policy measures. Most exposure to tobacco information in the media (with the exception of pro-tobacco advertising on the internet) contributes independently to the prediction of adult support for movie-specific policies. The direction of effect follows an expected pattern, with reported exposure to anti-tobacco advertising and news coverage of tobacco predicting supportive attitudes towards movie policies, and reported exposure to pro-tobacco advertising lessening support for some movie policies, though the medium of delivery makes a difference. Conclusion Media campaigns to prevent tobacco use and exposure to secondhand smoke have had value beyond the intended impact of single-issue campaigns; exposure to anti-tobacco campaigns and public dialogue about the dangers of tobacco seem also to be associated with shaping perceptions of the social world related to norms about tobacco, and ideas about regulating the portrayal of smoking in movies. C1 [Blake, Kelly D.; Viswanath, K.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Blake, Kelly D.; Viswanath, K.] Dana Farber Canc Inst Boston, Boston, MA USA. [Blendon, Robert J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Vallone, Donna] Amer Legacy Fdn, Washington, DC USA. RP Blake, KD (reprint author), 44 Binney St,MS LW703, Boston, MA 02115 USA. EM kellyblake@post.harvard.edu FU National Cancer Institute [5R25CA057711-14]; NIH FX This study was made possible by the Harvard Education Program in Cancer Prevention and Control, Grant 5R25CA057711-14 from the National Cancer Institute. Other Funders: NIH. NR 33 TC 7 Z9 7 U1 2 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 J9 TOB CONTROL JI Tob. Control PD JUN PY 2010 VL 19 IS 3 BP 191 EP 196 DI 10.1136/tc.2009.031260 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 600QP UT WOS:000278002400013 PM 20008152 ER PT J AU Gerbino, A Debellis, L Caroppo, R Curci, S Colella, M AF Gerbino, Andrea Debellis, Lucantonio Caroppo, Rosa Curci, Silvana Colella, Matilde TI Cadmium inhibits acid secretion in stimulated frog gastric mucosa SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Cadmium; Gastric acid secretion; Short circuit current; Omeprazole; H(+)/K(+)-ATPase ID OXYNTIC CELLS; PARIETAL-CELL; SARCOPLASMIC-RETICULUM; CHLORIDE TRANSPORT; ALKALINE SECRETION; HEAVY-METAL; CYCLIC-AMP; RECEPTOR; CALCIUM; RAT AB Cadmium, a toxic environmental pollutant, affects the function of different organs such as lungs, liver and kidney. Less is known about its toxic effects on the gastric mucosa. The aim of this study was to investigate the mechanisms by which cadmium impacts on the physiology of gastric mucosa. To this end, intact amphibian mucosae were mounted in Ussing chambers and the rate of acid secretion, short circuit current (I(SC)), transepithelial potential (V(t)) and resistance (R(t)) were recorded in the continuous presence of cadmium. Addition of cadmium (20 mu M to 1 mM) on the serosal but not luminal side of the mucosae resulted in inhibition of acid secretion and increase in NPPB-sensitive, chloride-dependent short circuit current. Remarkably, cadmium exerted its effects only on histamine-stimulated tissues. Experiments with TPEN, a cell-permeant chelator for heavy metals, showed that cadmium acts from the intracellular side of the acid secreting cells. Furthermore, cadmium-induced inhibition of acid secretion and increase in I(SC) cannot be explained by an action on: 1) H(2) histamine receptor, 2) Ca(2+) signalling 3) adenylyl cyclase or 4) carbonic anhydrase. Conversely, cadmium was ineffective in the presence of the H(+)/K(+)-ATPase blocker omeprazole suggesting that the two compounds likely act on the same target. Our findings suggest that cadmium affects the functionality of histamine-stimulated gastric mucosa by inhibiting the H(+)/K(+)-ATPase from the intracellular side. These data shed new light on the toxic effect of this dangerous environmental pollutant and may result in new avenues for therapeutic intervention in acute and chronic intoxication. (C) 2010 Elsevier Inc. All rights reserved. C1 [Gerbino, Andrea; Debellis, Lucantonio; Caroppo, Rosa; Colella, Matilde] Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy. [Curci, Silvana] Harvard Univ, Sch Med, VA Boston Healthcare Syst, W Roxbury, MA 02132 USA. [Curci, Silvana] Harvard Univ, Sch Med, Dept Surg, W Roxbury, MA 02132 USA. [Curci, Silvana] Brigham & Womens Hosp, W Roxbury, MA 02132 USA. RP Gerbino, A (reprint author), Univ Bari, Dept Gen & Environm Physiol, Via Amendola 165-A, I-70126 Bari, Italy. EM gerbino@biologia.uniba.it RI Colella, Matilde/G-9246-2011; OI Colella, Matilde/0000-0002-9584-7030; Debellis, Lucantonio/0000-0002-7571-0969; CAROPPO, Rosa/0000-0002-8773-8985; Gerbino, Andrea/0000-0002-2839-0130 FU Finanziamenti di Ateneo (Bari, Italy); Fondo per gli Investimenti della Ricerca di Base (FIRB, Rome, Italy) [RBIN04PHZ7] FX This work was supported by Finanziamenti di Ateneo (Bari, Italy) and Fondo per gli Investimenti della Ricerca di Base (FIRB) grant RBIN04PHZ7 (Rome, Italy). We are grateful to Dr. Aldebaran M. Hofer (Harvard University, MA, USA) for critical reading of the manuscript. We wish to thank Claudia Carmone, Claudia Lippolis, Rosa Piazzolla and Michela Sguera for excellent assistance during experiments. NR 61 TC 2 Z9 2 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD JUN 1 PY 2010 VL 245 IS 2 BP 264 EP 271 DI 10.1016/j.taap.2010.03.010 PG 8 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 601SB UT WOS:000278083100015 PM 20307561 ER PT J AU Contreras, AM Ochoa-Jimenez, RJ Celis, A Mendez, C Olivares, L Rebolledo, CE Hernandez-Lugo, I Aguirre-Zavala, AI Jimenez-Mendez, R Chung, RT AF Contreras, Ana M. Ochoa-Jimenez, Rodolfo J. Celis, Alfredo Mendez, Claudia Olivares, Laura Rebolledo, Claudia E. Hernandez-Lugo, Isabel Aguirre-Zavala, Ana I. Jimenez-Mendez, Ricardo Chung, Raymond T. TI High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection SO TRANSFUSION LA English DT Article ID VIRUS-INFECTION; PARTIAL SEROREVERSION; COST-EFFECTIVENESS; ASSAY; LIKELIHOOD; CLEARANCE; SAMPLES; RATIOS AB BACKGROUND: The screening and diagnosis of hepatitis C virus (HCV) infection is initiated by testing for antibody to HCV (anti-HCV). A positive anti-HCV test in blood donors represents ongoing infection in only a variable proportion of individuals. Because a high anti-HCV level has been associated with viremia, a study was conducted to determine whether a high antibody level is an accurate serologic marker for viremia in asymptomatic anti-HCV-positive persons. STUDY DESIGN AND METHODS: In a diagnostic test study, we included 856 anti-HCV-positive blood donors in a blood bank at Guadalajara, Jalisco, Mexico, between 2002 and 2007. A third-generation amplified chemiluminescence assay (ChLIA HCV) was used to detect anti-HCV. A positive result of the qualitative nucleic acid test (HCV RNA) was considered the gold standard for viremia. RESULTS: By receiver operating characteristic analysis, the signal-to-cutoff (S/CO) ratio of 20 or more was chosen as optimal to identify viremia and so was defined as high anti-HCV level. There was a significant difference in the proportion of viremia between subjects with high antibody level and those with lower levels (93.7% vs. 1.8%, respectively; p < 0.001). A high antibody level showed a sensitivity for viremia of 96.6% (95% confidence interval [CI], 93.8%-98.1%), a specificity of 96.6% (95% CI, 94.8%-97.8%), and a likelihood ratio of 28.6 (95% CI, 18.4%-44.6%). CONCLUSION: A high antibody level (S/CO ratio >= 20 by ChLIA HCV) clearly divides the viremic from the nonviremic blood donors and functions as an accurate serologic marker to guide the use of routine HCV RNA testing to confirm hepatitis C infection. C1 [Contreras, Ana M.] Mexican Inst Social Secur, Hlth Res Council Jalisco State, Zapopan 45120, Jalisco, Mexico. Univ Guadalajara, Med Res Unit, Dept Internal Med, Mol Diagnost Lab, Guadalajara 44430, Jalisco, Mexico. Univ Guadalajara, Cent Blood Bank, Specialties Hosp, W Natl Med Ctr,Mexican Inst Social Secur, Guadalajara 44430, Jalisco, Mexico. Univ Guadalajara, Dept Publ Hlth, Hlth Sci Ctr, Guadalajara 44430, Jalisco, Mexico. Gen Hosp 1, Mexican Inst Social Secur, Dept Internal Med, Colima, Mexico. Reg Hosp Colima, Dept Internal Med, Colima, Mexico. Reg Hosp Colima, Clin Sexually Transmitted Dis, Colima, Mexico. Natl Politech Inst, CINVESTAV, External Sect Pharmacol, Mexico City, DF, Mexico. Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. RP Contreras, AM (reprint author), Mexican Inst Social Secur, Hlth Res Council Jalisco State, Pedro Alarcon 45-61, Zapopan 45120, Jalisco, Mexico. EM acontreras53@hotmail.com FU National Council of Science and Technology (CONACyT); Grupo Roche Syntex de Mexico; cosHCVir [SALUD-2005-01-14158] FX Partial grant support was provided by cosHCVir study, SALUD-2005-01-14158, and a scholarship (Dr Ochoa-Jimenez) by the National Council of Science and Technology (CONACyT). An unrestricted educational grant was provided from Grupo Roche Syntex de Mexico. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. NR 31 TC 14 Z9 15 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD JUN PY 2010 VL 50 IS 6 BP 1335 EP 1343 DI 10.1111/j.1537-2995.2009.02571.x PG 9 WC Hematology SC Hematology GA 604ZH UT WOS:000278316500024 PM 20088833 ER PT J AU Wang, J Pfleger, CM Friedman, L Vittorino, R Zhao, W Qian, XJ Conley, L Ho, L Pasinetti, GM AF Wang, Jun Pfleger, Cathie M. Friedman, Lauren Vittorino, Roselle Zhao, Wei Qian, Xianjuan Conley, Lindsay Ho, Lap Pasinetti, Giulio M. TI POTENTIAL APPLICATION OF GRAPE DERIVED POLYPHENOLS IN HUNTINGTON'S DISEASE SO TRANSLATIONAL NEUROSCIENCE LA English DT Article DE Neurological disorders; Motor function; Abnormal protein aggregation Huntingtin protein; Drosophila; PC-12 cell; R6/2 mouse AB Huntington's disease (HD) is a progressive neurodegenerative disorder associated with selective neuronal cell death. Abnormal aggregation of huntingtin protein with polyQ expansion has been shown to be causally linked to HD. Grape seed polyphenolic extract (GSPE) is a natural compound that has previously been shown to interfere with aggregations of proteins involved in neurological disorders, such as amyloid beta peptides (A beta) and Tau protein. In this study we found that GSPE treatment significantly inhibits polyQ aggregation in phaeochromocytoma (PC)-12 cell line containing an ecdysone-inducible protein comprising the first 17 amino acid of huntingtin plus 103 glutamines fused with enhanced GFP. In vivo feasibility studies using the Q93httexon1 drosophila model of HD, we extended our in vitro evidence and found that flies fed with GSPE had a significantly improved lifespan compared to the control flies. Using the R6/2 rodent model of HD, we found that oral administration of 100 mg/kg/day GSPE (equivalent to 500mg per day in human) significantly attenuated the motor skill decay as well as extended the lifespan in the R6/2 mice relative to vehicle-control mice. Collectively, our studies strongly suggest that GSPE might be able to modulate the onset and/or progression of HD. C1 [Wang, Jun; Friedman, Lauren; Vittorino, Roselle; Zhao, Wei; Qian, Xianjuan; Conley, Lindsay; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Zhao, Wei; Qian, Xianjuan; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Pfleger, Cathie M.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA. [Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA. RP Wang, J (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Polyphenolics, Inc. FX This work was supported by Polyphenolics, Inc. We thank Hayley Fivecoat for assistance in the preparation of the manuscript. NR 38 TC 7 Z9 7 U1 0 U2 2 PU VERSITA PI WARSAW PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND SN 2081-3856 J9 TRANSL NEUROSCI JI Transl. Neurosci. PD JUN PY 2010 VL 1 IS 2 BP 95 EP 100 DI 10.2478/v10134-010-0022-y PG 6 WC Neurosciences SC Neurosciences & Neurology GA V20PY UT WOS:000208153100001 PM 21331299 ER PT J AU Arrieta-Cruz, I Pavlides, C Pasinetti, GM AF Arrieta-Cruz, Isabel Pavlides, Constantine Pasinetti, Giulio Maria TI DEEP BRAIN STIMULATION FACILITATES MEMORY IN A MODEL OF ALZHEIMER'S DISEASE SO TRANSLATIONAL NEUROSCIENCE LA English DT Article DE Alzheimer's disease; Deep brain stimulation; Hippocampus; LTP; Neuronal transmission Synaptic plasticity; Memory; TgCRND8 mice; Thalamus AB Based on evidence suggesting that deep brain stimulation (DBS) may promote certain cognitive processes, we have been interested in developing DBS as a means of mitigating memory and learning impairments in Alzheimer's disease (AD). In this study we used an animal model of AD (TgCRND8 mice) to determine the effects of high-frequency stimulation (HFS) on non-amyloidogenic a-secretase activity and DBS in short-term memory. We tested our hypothesis using hippocampal slices (in vitro studies) from TgCRND8 mice to evaluate whether HFS increases a-secretase activity (non-amyloidogenic pathway) in the CA1 region. In a second set of experiments, we performed in vivo studies to evaluate whether DBS in midline thalamic region re-establishes hippocampal dependent short-term memory in TgCRND8 mice. The results showed that application of HFS to isolated hippocampal slices significantly increased synaptic plasticity in the CA1 region and promoted a 2-fold increase of non-amyloidogenic a-secretase activity, in comparison to low frequency stimulated controls from TgCRND8 mice. In the in vivo studies, DBS treatment facilitated acquisition memory in TgCRND8 mice, in comparison to their own baseline before treatment. These results provide evidence that DBS could enhance short-term memory in a mouse model of AD by increasing synaptic transmission and a-secretase activity in the C A1 region of hippocampus. C1 [Arrieta-Cruz, Isabel; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Pavlides, Constantine] Rockefeller Univ, Neuroendocrinol Lab, New York, NY 10065 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA. RP Arrieta-Cruz, I (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu NR 14 TC 0 Z9 0 U1 1 U2 6 PU VERSITA PI WARSAW PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND SN 2081-3856 J9 TRANSL NEUROSCI JI Transl. Neurosci. PD JUN PY 2010 VL 1 IS 2 BP 170 EP 176 DI 10.2478/v10134-010-0026-7 PG 7 WC Neurosciences SC Neurosciences & Neurology GA V20PY UT WOS:000208153100010 ER PT J AU Ahmad, M Graham, SH AF Ahmad, Muzamil Graham, Steven H. TI Inflammation After Stroke: Mechanisms and Therapeutic Approaches SO TRANSLATIONAL STROKE RESEARCH LA English DT Review DE Stroke; Ischemia; Inflammation; Inflammatory cells; Cytokines; Cell adhesion molecules; Eicosanoids AB Reperfusion of ischemic brain can reduce injury and improve outcome, but secondary injury due to inflammatory mechanisms limits the efficacy and time window of such treatments for stroke. This review summarizes the cellular and molecular basis of inflammation in ischemic injury as well as possible therapeutic strategies. C1 [Ahmad, Muzamil; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, Pittsburgh, PA 15206 USA. [Ahmad, Muzamil; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM sgra@pitt.edu FU NCATS NIH HHS [UL1 TR000005]; NINDS NIH HHS [R01 NS037459, R01 NS037459-04, R01 NS037459-11] NR 178 TC 33 Z9 40 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD JUN PY 2010 VL 1 IS 2 BP 74 EP 84 DI 10.1007/s12975-010-0023-7 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V23ER UT WOS:000208326600002 PM 20976117 ER PT J AU Zhang, F Xing, J Liou, AKF Wang, S Gan, Y Luo, YM Ji, XM Stetler, RA Chen, J Cao, GD AF Zhang, Feng Xing, Juan Liou, Anthony Kian-Fong Wang, Suping Gan, Yu Luo, Yumin Ji, Xuming Stetler, R. Anne Chen, Jun Cao, Guodong TI Enhanced Delivery of Erythropoietin Across the Blood-Brain Barrier for Neuroprotection Against Ischemic Neuronal Injury SO TRANSLATIONAL STROKE RESEARCH LA English DT Article DE Erythropoietin; Drug delivery system; HIV TAT protein; Blood-brain barrier; Neuroprotection; Ischemia/brain AB Due to limited penetration of the blood-brain barrier (BBB), many therapeutic agents in clinical use require higher doses in order to reach effective concentrations in brain. In some instances, these high doses elicit severe side effects. In the case of erythropoietin (EPO), an established neuroprotectant against ischemic brain injury, its low BBB permeability requires such a high therapeutic dose that it can induce dangerous complications such as polycythemia and secondary stroke. The purpose of this study is to generate a modified EPO that has increased facility crossing the BBB without losing its neuroprotective element. We have engineered a fusion protein (EPO-TAT) by tagging a protein transduction domain derived from HIV trans-acting activator of transcription (TAT) to the EPO protein. This sequence enhanced the capacity of EPO to cross the BBB in animals at least twofold when intraperitoneally administered and up to fivefold when intravenously administered. In vitro experiments showed that this EPO fusion protein retained all its protective properties against neuronal death elicited by oxygen-glucose deprivation and N-methyl-D-aspartate insults. The needed therapeutic dose of the EPO-TAT was decreased by similar to tenfold compared to that of regular EPO to achieve equivalent neuroprotection in terms of reducing volume of infarction induced by middle cerebral artery occlusion in mice. Our results support the approach of using a protein transduction domain coupled to therapeutic agents. In this way, not only can the therapeutic doses be lowered but also agents without BBB permeability may now be available for clinical applications. C1 [Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, BST S505, Pittsburgh, PA 15261 USA. [Zhang, Feng; Xing, Juan; Wang, Suping; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15260 USA. [Luo, Yumin; Ji, Xuming] Capital Univ Med Sci, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China. [Zhang, Feng; Xing, Juan; Liou, Anthony Kian-Fong; Wang, Suping; Gan, Yu; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Zhang, Feng; Xing, Juan; Liou, Anthony Kian-Fong; Wang, Suping; Gan, Yu; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA. RP Cao, GD (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, BST S505, 200 Lothrop St, Pittsburgh, PA 15261 USA. EM caog@upmc.edu OI Zhang, Feng/0000-0001-7275-9989 FU National Institutes of Health [NS053473, NS43802, NS45048, NS36736, NS 56118]; American Heart Association Scientist Development [06300064N]; Chinese Natural Science Foundation [30670725] FX The project was supported by National Institutes of Health Grants NS053473 (to G. C.), NS43802, NS45048, NS36736, and NS 56118 (to J.C.), and the American Heart Association Scientist Development Grant 06300064N (to G. C.). Y.L. is a recipient of the Chinese Natural Science Foundation Grant 30670725. NR 28 TC 19 Z9 22 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD JUN PY 2010 VL 1 IS 2 BP 113 EP 121 DI 10.1007/s12975-010-0019-3 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V23ER UT WOS:000208326600006 PM 20577577 ER PT J AU Avery, R Clauss, H Danziger-Isakov, L Davis, J Doucette, K van Duin, D Fishman, J Gunseren, F Humar, A Husain, S Isada, C Julian, K Kaul, D Kumar, D Martin, S Michaels, M Morris, M Silveira, F Subramanian, A AF Avery, R. Clauss, H. Danziger-Isakov, L. Davis, J. Doucette, K. van Duin, D. Fishman, J. Gunseren, F. Humar, A. Husain, S. Isada, C. Julian, K. Kaul, D. Kumar, D. Martin, S. Michaels, M. Morris, M. Silveira, F. Subramanian, A. TI Recommended curriculum for subspecialty training in transplant infectious disease on behalf of the American Society of Transplantation Infectious Diseases Community of Practice Educational Initiatives Working Group SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE curriculum; training; subspecialty; transplant infectious disease AB P>The American Society of Transplantation Infectious Diseases (ID) Community of Practice has established an education workgroup to identify core components of a curriculum for training specialists in transplant ID. Clinical, laboratory, and research training form the triad of components on which an additional year of ID training, dedicated to the care of solid organ and hematopoietic stem cell transplant recipients, should be based. The recommended training environment would have access to adequate numbers of transplant patients, along with qualified faculty committed to teaching specialized fellows in this area. The learning objectives for both inpatient and outpatient clinical training are presented. The laboratory component requires trainees to attain expertize in utilizing and interpreting cutting-edge diagnostics used in transplant medicine. The research component may involve basic science, and translational or clinical research individualized to the trainee. Finally, suggestions for evaluation of both the fellows and the training program are provided. C1 [Subramanian, A.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Avery, R.; Danziger-Isakov, L.; van Duin, D.; Isada, C.] Cleveland Clin Hosp, Cleveland, OH USA. [Clauss, H.] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA. [Davis, J.; Martin, S.] Ohio State Univ Hosp, Columbus, OH 43210 USA. [Doucette, K.; Humar, A.; Kumar, D.] Univ Alberta, Edmonton, AB, Canada. [Fishman, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gunseren, F.] Akdeni Univ, Antalya, Turkey. [Husain, S.] Toronto Gen Hosp, Toronto, ON, Canada. [Julian, K.] Penn State Univ, Coll Med, Hershey, PA USA. [Kaul, D.] Univ Michigan Hosp, Ann Arbor, MI 48109 USA. [Michaels, M.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. [Morris, M.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Silveira, F.] Univ Pittsburgh Hosp, Pittsburgh, PA USA. RP Subramanian, A (reprint author), Johns Hopkins Univ, Transplant & Oncol Ctr, Div Infect Dis, Sch Med, 1830 E Monument St,Room 463A, Baltimore, MD 21287 USA. EM asubra@jhmi.edu RI Silveira, Fernanda/K-4465-2012; Martin, Stanley/E-3600-2011; OI Doucette, Karen/0000-0002-1660-9166 NR 0 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-2273 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD JUN PY 2010 VL 12 IS 3 BP 190 EP 194 DI 10.1111/j.1399-3062.2010.00510.x PG 5 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 604YY UT WOS:000278315600002 PM 20624259 ER PT J AU Neofytos, D Fishman, JA Horn, D Anaissie, E Chang, CH Olyaei, A Pfaller, M Steinbach, WJ Webster, KM Marr, KA AF Neofytos, D. Fishman, J. A. Horn, D. Anaissie, E. Chang, C. -H. Olyaei, A. Pfaller, M. Steinbach, W. J. Webster, K. M. Marr, K. A. TI Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE invasive fungal infection; solid organ transplant; epidemiology; outcomes; Candida; Aspergillus; invasive candidiasis; invasive aspergillosis ID ORTHOTOPIC LIVER-TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; RISK-FACTORS; AMPHOTERICIN-B; ITRACONAZOLE PROPHYLAXIS; ANTIFUNGAL PROPHYLAXIS; RANDOMIZED-TRIAL; DOUBLE-BLIND; FLUCONAZOLE; CANDIDEMIA AB P>Contemporary epidemiology and outcomes of invasive fungal infections (IFIs) in solid organ transplant (SOT) recipients are not well described. From March 2004 through September 2007, proven and probable IFIs were prospectively identified in 17 transplant centers in the United States. A total 429 adult SOT recipients with 515 IFIs were identified; 362 patients received a single and 67 patients received >= 2 organs. Most IFIs were caused by Candida species (59.0%), followed by Aspergillus species (24.8%), Cryptococcus species (7.0%), and other molds (5.8%). Invasive candidiasis (IC) was the most frequently observed IFI in all groups, except for lung recipients where invasive aspergillosis (IA) was the most common IFI (P < 0.0001). Almost half of IC cases in liver, heart, and lung transplant recipients occurred during the first 100 days post transplant. Over half of IA cases in lung recipients occurred > 1 year post transplant. Overall 12-week mortality was 29.6%; liver recipients had the highest mortality (P=0.05). Organ damage, neutropenia, and administration of corticosteroids were predictors of death. These results extend our knowledge on the epidemiology of IFI in SOT recipients, emphasizing the occurrence of IC early after non-lung transplant, and late complications with molds after lung transplant. Overall survival appears to have improved compared with historical reports. C1 [Neofytos, D.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Neofytos, D.; Horn, D.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Fishman, J. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Anaissie, E.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Chang, C. -H.] Info Spectrum Incorp, Markham, ON, Canada. [Olyaei, A.] Oregon Hlth & Sci Univ, Portland, OR USA. [Pfaller, M.] Univ Iowa Hlth Care, Iowa City, IA USA. [Steinbach, W. J.] Duke Univ, Med Ctr, Durham, NC USA. [Webster, K. M.] Axiom Real Time Metr Inc, Oakville, ON, Canada. [Webster, K. M.] EBM Consulting Inc, Mississauga, ON, Canada. RP Neofytos, D (reprint author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 1830 E Monument St,Room 421, Baltimore, MD 21205 USA. EM dneofyt1@jhmi.edu FU Astellas Pharma US Inc. (APUS) FX Funding sources: We would like to acknowledge Astellas Pharma US Inc. (APUS) for their generous support, Axiom Real-Time Metrics Inc. (Axiom) for their expertise in registry management, and the many dedicated coordinators at each site. As the financial sponsor of the PATH Alliance, APUS observed, but did not influence, the design of the PATH Alliance registry by the independent Scientific Advisory Board. APUS contracts Axiom to provide overall management services for the PATH Alliance registry, comprising data management, site support, application and database hosting, administrative management, and data extraction and analysis. APUS also sponsored Axiom's services for this individual research project; these services were comprised of data extraction, facilitation of statistical analyses, preparation of figures, and manuscript review. Potential conflicts of interest: D.N. has received grant support (educational research) from Astellas and has been a consultant and/or part of advisory boards for Pfizer. J.F. has been a consultant to Merck Inc., Hoffman LaRoche, Astellas, and Primera, has received grant support (educational/research) from Astellas, and has been on the speakers' bureau for Astellas and Roche. D.H. has received recent research funding from Astellas and past funding from Pfizer; has served as a consultant or advisor to Astellas and Pfizer, has been on the speaker's bureau for Pfizer and Astellas, and has received speaking honoraria from Roche. W.S. has served as consultant to Pfizer, Astellas, and Schering-Plough and on the speakers' bureau for Astellas, Merck, Pfizer. E.A. has been a consultant to and on the speaker's bureau for Astellas, Pfizer, Gilead, Merck, and Schering-Plough. A.O. has been a speaker and served as consultant to Pfizer and Astellas. M.P. has been a consultant to and on the speakers' bureau for Pfizer, Astellas, Merck, and Schering-Plough. C.C. has served as a statistical consultant to Pharmacia, Pfizer, and Eli Lilly, marketing analytics consultant to Roche, and statistical consultant via third parties to Astellas, Topigen, and AstraZeneca. K.W. has had contract work with Astellas. K.A.M. has been a consultant and/or part of advisory boards for Astellas, Basilea, Enzon, Merck, Pfizer, and Schering Plough and received grant support from Astellas, Enzon, Merck, and Pfizer. NR 37 TC 145 Z9 156 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-2273 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD JUN PY 2010 VL 12 IS 3 BP 220 EP 229 DI 10.1111/j.1399-3062.2010.00492.x PG 10 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 604YY UT WOS:000278315600006 PM 20113459 ER PT J AU Liu, M Gu, M Xu, D Lv, Q Zhang, W Wu, Y AF Liu, M. Gu, M. Xu, D. Lv, Q. Zhang, W. Wu, Y. TI Protective Effects of Toll-like Receptor 4 Inhibitor Eritoran on Renal Ischemia-Reperfusion Injury SO TRANSPLANTATION PROCEEDINGS LA English DT Article ID INNATE IMMUNE-RESPONSE; ACUTE KIDNEY INJURY; ISCHEMIA/REPERFUSION INJURY; PRESERVATION; INFLAMMATION; E5564; HEART AB Background. Ischemia-reperfusion injury (I/R) has a negative effect on renal allograft survival. Using a rat model of kidney IR injury, we demonstrated inhibition of Toll-like receptor (TLR) 4 with erotoran may shed new light on I/R therapy. Methods. All 44 Fisher rats were anesthetized with ethrane. Animals were randomly divided into the S group (sham, n = 11) that received only right kidney nephrectomy or the I/R group of right kidney nephrectomy and ichemia for 40 minutes by clamping of left renal artery (n = 11). In addition, the E group (Eritoran, n = 11) and the V group (vehicle, n = 11) received eritoran (5 mg . kg(-1)) and vehicle pretreatment, respectively. Analysis of renal histology, function, cytokine/chemokine production, as well as animal mortality was performed in parallel groups by ribonuclease protection assay (RPA). Results. At 24 hours, the creatinine value 1.49 +/- 0.2 mg/dL in the eritoran group was significantly lower than untreated controls (2.17 +/- 0.4 mg/dL). Histological findings showed tubular loss and morphological stutus as well as animal survival post-I/R injury compared to vehicle-treated rats; the difference between the S versus E groups was significant. Eritoran administration significantly attenuated monocyte infiltration into the kidney. RPA assays showed the following fold increase over sham normalized to that of GAPDH mRNA expression of tumor necrosis factor-alpha (4.67 +/- 1.52 vs 1.37 +/- 0.05), interleukin (IL)-1 beta (5.11 +/- 1.17 vs 1.92 +/- 0.27), IL-6 (4.20 +/- 0.29 vs 1.21 +/- 0.37) and monocyte chemoattractant protein-1 (8.77 +/- 1.24 vs 2.57 +/- 1.59). GAPDH was markedly reduced by eritoran treatment (eritoran vs vehicle group). Conclusion. These data demonstrated that inhibition of TLR4 with eritoran reduced I/R-related inflammatory responses and improved the course of kidney I/R injury. C1 [Liu, M.; Gu, M.; Xu, D.; Lv, Q.; Zhang, W.] Nanjing Med Univ, Dept Urol & Kidney Transplantat, Affiliated Hosp 1, Nanjing 210029, Jiangsu Prov, Peoples R China. [Wu, Y.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Gu, M (reprint author), Nanjing Med Univ, Dept Urol & Kidney Transplantat, Affiliated Hosp 1, Nanjing 210029, Jiangsu Prov, Peoples R China. EM lancetgu@163.com OI Liu, Min/0000-0002-8117-4808 NR 20 TC 23 Z9 25 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 J9 TRANSPL P JI Transplant. Proc. PD JUN PY 2010 VL 42 IS 5 BP 1539 EP 1544 DI 10.1016/j.transproceed.2010.03.133 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 616UQ UT WOS:000279236100030 PM 20620471 ER PT J AU Geng, EH Glidden, DV Emenyonu, N Musinguzi, N Bwana, MB Neilands, TB Muyindike, W Yiannoutsos, CT Deeks, SG Bangsberg, DR Martin, JN AF Geng, Elvin H. Glidden, David V. Emenyonu, Nneka Musinguzi, Nicolas Bwana, Mwebwesa Bosco Neilands, Torsten B. Muyindike, Winnie Yiannoutsos, Constantin T. Deeks, Steven G. Bangsberg, David R. Martin, Jeffrey N. TI Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE antiretroviral scale-up strategies; losses to follow-up; determinants of mortality on antiretroviral therapy; sampling studies; monitoring and evaluation; Africa ID HIV-1-INFECTED PATIENTS; WESTERN KENYA; SCALING-UP; MORTALITY; OUTCOMES; EXPERIENCE; SETTINGS; PROGRAMS AB P>Objective To date, data regarding the determinants of mortality in HIV-infected patients starting antiretroviral therapy (ART) in Africa have been primarily derived from routine clinical care settings practicing the public health approach. Losses to follow-up, however, are high in these settings and may lead to bias in understanding the determinants of mortality. Methods We evaluated HIV-infected adults initiating ART between January 1, 2004 and September 30th, 2007 in an ART clinic in southwestern Uganda. Clinical and demographic characteristics were obtained through routine clinical care. In evaluating determinants of mortality, a 'naive' analysis used only deaths known through routine processes. A 'sample-corrected' approach incorporated, through probability weights, outcomes from a representative sample of patients lost to follow-up whose vital status was ascertained through tracking in the community. Results In 3,628 patients followed for up to 3.75 years after ART initiation, the 'naive' approach identified male sex and lower pre-ART CD4 count as independent determinants of mortality. The 'sample-corrected' approach found lower pre-ART CD4 count, older age, lower weight and calendar year of ART initiation, but not male sex, to be independent determinants of mortality. Conclusions Analyses to identify determinants of mortality in HIV-infected patients on ART in Africa that do not account for losses to follow-up can identify spurious associations and miss actual relationships - both with the potential to mislead public health efforts. A sampling-based approach to account for losses to follow-up represents a feasible and potentially scalable method to strengthen the evidence available for implementation of ART delivery in Africa. C1 [Geng, Elvin H.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, Dept Med, San Francisco, CA 94110 USA. [Glidden, David V.; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Emenyonu, Nneka; Musinguzi, Nicolas; Bwana, Mwebwesa Bosco; Muyindike, Winnie; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda. [Neilands, Torsten B.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. [Yiannoutsos, Constantin T.] Indiana Univ, Div Biostat, Dept Med, Indianapolis, IN USA. [Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Global Hlth, Boston, MA USA. RP Geng, EH (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, Dept Med, 995 Potrero Ave,Bldg 80, San Francisco, CA 94110 USA. EM genge@php.ucsf.edu FU NIAID NIH HHS [K23 AI084544, K23 AI084544-01, K23 AI084544-02, K23 AI084544-03, P30 AI027763, T32 AI060530, U01 AI069911]; NIMH NIH HHS [R01 MH054907, K24 MH087227] NR 24 TC 34 Z9 34 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD JUN PY 2010 VL 15 SU 1 BP 63 EP 69 DI 10.1111/j.1365-3156.2010.02507.x PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 590DZ UT WOS:000277205500006 PM 20586962 ER PT J AU Eisner, BH Eisenberg, ML Stoller, ML AF Eisner, Brian H. Eisenberg, Michael L. Stoller, Marshall L. TI Relationship Between Body Mass Index and Quantitative 24-Hour Urine Chemistries in Patients With Nephrolithiasis SO UROLOGY LA English DT Article ID STONE FORMERS; KIDNEY-STONES; UNITED-STATES; RISK-FACTORS; OBESITY; OVERWEIGHT; WEIGHT; UROLITHIASIS; PREVALENCE; EXCRETION AB OBJECTIVES To examine the relationship between body mass index and 24-hour urine constituents in a population of stone-forming patients. METHODS A total of 880 patients who presented to a metabolic stone clinic for initial evaluation were analyzed. Patients were stratified by gender and divided into quartiles of body mass index. Associations between body mass index (BMI) and urine parameters were explored using bivariate and multivariate linear regression. RESULTS On bivariate analysis, increasing body mass index was associated with a significant increase in sodium, calcium, citrate, uric acid, magnesium, calcium oxalate, uric acid, and a decrease in pH in men. In women, it was associated with a significant increase in sodium, uric acid, oxalate, uric acid, and decreasing pH. On multivariate analysis, BMI was associated only with increases in sodium and calcium oxalate and decrease in pH in men. In women, multivariate analysis demonstrated positive association between BMI and urine sodium, creatinine, and phosphate and a negative relationship with urine citrate and sulfate. CONCLUSIONS Increasing body mass index was related to several risk factors for urinary stone disease in this study, including increasing urine sodium and decreasing pH in men and increasing urine uric acid, sodium, and decreasing urine citrate in women. Just as general recommendations for patients with nephrolithiasis include high voided volumes, low dietary sodium, and low animal protein intake, perhaps weight reduction should be included as part of the counseling of stone-formers to optimize 24-hour urine parameters. UROLOGY 75: 1289-1293, 2010. (C) 2010 Elsevier Inc. C1 [Eisner, Brian H.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Eisner, BH (reprint author), Massachusetts Gen Hosp, Dept Urol, GRB 1102,55 Fruit St, Boston, MA 02114 USA. EM beisner@partners.org OI Eisenberg, Michael/0000-0001-5482-0141 NR 18 TC 18 Z9 21 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD JUN PY 2010 VL 75 IS 6 BP 1289 EP 1293 DI 10.1016/j.urology.2009.09.024 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 603PS UT WOS:000278221100015 PM 20018350 ER PT J AU Jahn, B Theurl, E Siebert, U Pfeiffer, KP AF Jahn, Beate Theurl, Engelbert Siebert, Uwe Pfeiffer, Karl-Peter TI Tutorial in Medical Decision Modeling Incorporating Waiting Lines and Queues Using Discrete Event Simulation SO VALUE IN HEALTH LA English DT Article DE discrete event simulation; modeling; queue; waiting time ID ECONOMIC-EVALUATION; COST-EFFECTIVENESS; HEALTH; PHARMACOECONOMICS; DISEASE; STENTS AB In most decision-analytic models in health care, it is assumed that there is treatment without delay and availability of all required resources. Therefore, waiting times caused by limited resources and their impact on treatment effects and costs often remain unconsidered. Queuing theory enables mathematical analysis and the derivation of several performance measures of queuing systems. Nevertheless, an analytical approach with closed formulas is not always possible. Therefore, simulation techniques are used to evaluate systems that include queuing or waiting, for example, discrete event simulation. To include queuing in decision-analytic models requires a basic knowledge of queuing theory and of the underlying interrelationships. This tutorial introduces queuing theory. Analysts and decision-makers get an understanding of queue characteristics, modeling features, and its strength. Conceptual issues are covered, but the emphasis is on practical issues like modeling the arrival of patients. The treatment of coronary artery disease with percutaneous coronary intervention including stent placement serves as an illustrative queuing example. Discrete event simulation is applied to explicitly model resource capacities, to incorporate waiting lines and queues in the decision-analytic modeling example.. C1 [Jahn, Beate; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Informat Syst & Hlth Technol Asses, A-6060 Hall In Tirol, IT, Austria. [Jahn, Beate; Pfeiffer, Karl-Peter] Innsbruck Med Univ, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria. [Theurl, Engelbert] Leopold Franzens Univ Innsbruck, Dept Publ Finance, Innsbruck, Austria. [Siebert, Uwe] Harvard Univ, Sch Med, Inst Technol Assessment, Cardiovasc Res Program, Boston, MA USA. [Siebert, Uwe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Pfeiffer, Karl-Peter] FH Johanneum Univ Appl Sci, Graz, Austria. RP Jahn, B (reprint author), UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Informat Syst & Hlth Technol Asses, Eduard Wallnoefer Ctr 1, A-6060 Hall In Tirol, IT, Austria. EM Beate.Jahn@umit.at FU Medical University of Innsbruck; Leopold-Franzens-University of Innsbruck; Canadian Study Centre Innsbruck; ONCOTYROL-Center for Personalized Cancer Medicine (Austria); Federal Ministry for Transport Innovation and Technology (BMVIT); Federal Ministry of Economics and Labour; Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ); Tyrolean Future Foundation (TZS); State of Styria; UMIT-University for Health Sciences, Medical Informatics and Technology; TILAK-Hospital Holding Company FX Financial support for this study was provided in part by the Medical University of Innsbruck, Leopold-Franzens-University of Innsbruck and the Canadian Study Centre Innsbruck, and ONCOTYROL-Center for Personalized Cancer Medicine (Austria). ONCOTYROL is a K1-COMET Center and funded by the Federal Ministry for Transport Innovation and Technology (BMVIT) and the Federal Ministry of Economics and Labour/the Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ), the Tyrolean Future Foundation (TZS), and the State of Styria, represented by the Styrian Business Promotion Agency (SFG), and supported by UMIT-University for Health Sciences, Medical Informatics and Technology and TILAK-Hospital Holding Company. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. NR 30 TC 6 Z9 6 U1 0 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD JUN-JUL PY 2010 VL 13 IS 4 BP 501 EP 506 DI 10.1111/j.1524-4733.2010.00707.x PG 6 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 625DD UT WOS:000279872300024 PM 20345550 ER PT J AU Liu, H Wang, C Chen, PH Zhang, BS Zheng, YL Zhang, CX Meng, HQ Wang, Y Chen, DC Xiu, MH Kosten, TR Zhang, XY AF Liu, Hong Wang, Cui Chen, Pin Hong Zhang, Ben Shu Zheng, You Lan Zhang, Chong Xi Meng, Hua Qing Wang, Yu Chen, Da Chun Xiu, Mei Hong Kosten, Thomas R. Zhang, Xiang Yang TI Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Review DE Association; Manganese superoxide dismutase; Polymorphism; Schizophrenia; Tardive dyskinesia ID ABNORMAL INVOLUNTARY MOVEMENTS; FREE-RADICAL PATHOLOGY; PARKINSONS-DISEASE; OXIDATIVE STRESS; MNSOD GENES; RISK; PHARMACOGENOMICS; METAANALYSIS; POPULATION; SOD2 AB Objective: Several recent studies that have investigated the genetic association between the manganese superoxide dismutase (MnSOD) gene Ala-9Val single-nucleotide polymorphism (SNP) and tardive dyskinesia (TD) have produced conflicting results. This study was to investigate whether this SNP was associated with clinical phenotypes and antipsychotic-induced tardive dyskinesia (TD) in schizophrenia in a genetically homogeneous Han Chinese inpatient population. Methods: Genotyping was performed for the MnSOD gene Ala-9Val SNP in Chinese schizophrenia patients with (n = 176) and without TD (n = 346). The severity of TD was assessed using the abnormal involuntary movement scale (AIMS), and psychopathology using the Positive and Negative Syndrome Scale (PANSS). Results: The frequencies of genotypes and alleles did not differ significantly between schizophrenic patients with and without TO (both p>0.05). Also, there was no significant difference in the AIMS total score between the Val/Val and Ala allele carrier groups (p>0.05). However, the PANSS negative symptom subscore was significantly higher in patients with Val/Val genotype (21.8 +/- 7.3) than those with Ala alleles (20.1 +/- 7.7) (t = 2.32, p = 0.03). Conclusion: While the MnSOD gene Ala-9Val polymorphism did not play a major role in the susceptibility to TD in schizophrenic patients, it might be associated with negative symptoms of schizophrenia. (C) 2010 Elsevier Inc. All rights reserved. C1 [Liu, Hong; Zhang, Ben Shu; Wang, Yu] Tianjin Med Univ, Gen Hosp, Dept Neurol, Tianjin 300052, Peoples R China. [Liu, Hong] Heping Hosp Affiliated, Changzhi Med Coll, Dept Neurol, Changzhi 046000, Shanxi Province, Peoples R China. [Wang, Cui; Zheng, You Lan] Jilin Agr Univ, Coll Chinese Med Mat, Changchun, Peoples R China. [Chen, Pin Hong; Meng, Hua Qing] Chongqing Med Univ, Affiliated Hosp 1, Dept Mental Hlth, Chongqing 400016, Peoples R China. [Zhang, Chong Xi] Shandong Univ Weihai, Marine Coll, Weihai, Shandong, Peoples R China. [Chen, Da Chun; Xiu, Mei Hong; Zhang, Xiang Yang] Beijing Huilongguan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China. [Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Kosten, TR (reprint author), VA Med Ctr, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA. EM kosten@bcm.edu; xyzhang@bcm.edu FU Stanley Medical Research Institute [03T-459, 05T-726]; Beijing Municipal Natural Science Foundation [ID: 7072035]; Department of Veterans Affairs FX This study was funded by the Stanley Medical Research Institute (03T-459 and 05T-726), the Beijing Municipal Natural Science Foundation (ID: 7072035), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. NR 35 TC 10 Z9 10 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD MAY 30 PY 2010 VL 34 IS 4 BP 692 EP 696 DI 10.1016/j.pnpbp.2010.03.026 PG 5 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 612GV UT WOS:000278885700021 PM 20346996 ER PT J AU Biederman, J Petty, CR Evans, M Small, J Faraone, SV AF Biederman, Joseph Petty, Carter R. Evans, Maggie Small, Jacqueline Faraone, Stephen V. TI How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD SO PSYCHIATRY RESEARCH LA English DT Article DE Longitudinal; Adult; Remission; ADHD ID ATTENTION-DEFICIT HYPERACTIVITY; AGE-DEPENDENT DECLINE; DEFICIT/HYPERACTIVITY DISORDER; SUBTHRESHOLD DIAGNOSES; PSYCHIATRIC STATUS; LATE-ONSET; CHILDREN; ADULTS; DEFINITION; PREVALENCE AB The main aim of this study was to examine the age-dependent persistence of attention-deficit hyperactivity disorder (ADHD) in boys transitioning from adolescence into early adulthood attending to different definitions of persistence. We conducted a 10-year follow-up study (mean follow-up time = 11 years) of 110 boys with ADHD and 105 non-ADHD controls. Both groups were 6-17 years of age at ascertainment. ADHD was considered persistent at follow-up if subjects met full or subthreshold (more than half of the symptoms required for a full diagnosis) Diagnostic and Statistical Manual of Mental Disorders, fourth edition. (DSM-IV) diagnostic criteria, failed to attain functional remission (Global Assessment of Functioning, GAF score <= 60) or were receiving treatment for ADHD. While 65% of children with ADHD no longer met full DSM-IV criteria for ADHD at the 10-year follow-up, 78% of subjects met at least one of our definitions of persistence. Persistence as described above was associated with more psychiatric co-morbidity, more familiality with mood disorders and higher levels of educational and interpersonal impairments than controls. This 10-year longitudinal follow-up study shows that the majority of ADHD boys experience persistent symptoms and functional impairments into early adulthood. Persistence of ADHD is associated with greater psychiatric comorbidity, familiality and functional impairments. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Biederman, Joseph] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Dept Psychiat, Boston, MA 02114 USA. [Biederman, Joseph; Petty, Carter R.; Evans, Maggie; Small, Jacqueline] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Dept Psychiat, 55 Fruit St,YAW 6A-6900, Boston, MA 02114 USA. EM jbiederman@partners.org OI Faraone, Stephen/0000-0002-9217-3982 FU National Institute of Child Health and Human Development (NICHD) [5R01HD036317-10]; Lilly Foundation; Pediatric Psychopharmacology Philanthropic Fund FX This work was supported, in part, by National Institute of Child Health and Human Development (NICHD) grant 5R01HD036317-10, the Lilly Foundation Fund, and the Pediatric Psychopharmacology Philanthropic Fund. NR 36 TC 143 Z9 145 U1 3 U2 25 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAY 30 PY 2010 VL 177 IS 3 BP 299 EP 304 DI 10.1016/j.psychres.2009.12.010 PG 6 WC Psychiatry SC Psychiatry GA 609MB UT WOS:000278659600005 PM 20452063 ER PT J AU Herzog, DB Thomas, JG Kass, AE Eddy, KT Franko, DL Lowe, MR AF Herzog, David B. Thomas, J. Graham Kass, Andrea E. Eddy, Kamryn T. Franko, Debra L. Lowe, Michael R. TI Weight suppression predicts weight change over 5 years in bulimia nervosa SO PSYCHIATRY RESEARCH LA English DT Article DE Eating disorders; BMI; Longitudinal ID BODY-WEIGHT; RESTRAINT; ANOREXIA; BEHAVIOR; GAIN AB Recent studies suggest that weight suppression (WS), defined as the discrepancy between current and highest past weight, predicts short-term weight gain in bulimia nervosa (BN) during treatment. The current study was designed to build on this preliminary work by examining the relation between WS and long-term weight change in BN. Treatment-seeking women (N=97) with DSM-IV BN participated in a naturalistic longitudinal follow-up study of eating disorders. At intake, height and weight were measured and highest past weight was assessed. Self-reported weights were collected every 6 months for 5 years. Hierarchical Linear Modeling (HLM) estimated growth curves for weight change over time. Significant inter-person variability was detected for intercepts and slopes (P<0.001) so both were treated as random effects. Participants' weights increased over the study course, moderated by baseline WS (P<0.001). such that higher WS predicted more rapid weight gain. Weight change was not associated with entry weight, height, or highest-ever weight, suggesting that WS per se predicted weight change. These findings complement previous short-term studies in BN by demonstrating that WS predicts weight gain over 5 years. Because weight gain could spur radical dieting that maintains BN, these results have important treatment implications. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Herzog, David B.; Kass, Andrea E.; Eddy, Kamryn T.; Franko, Debra L.] Massachusetts Gen Hosp, Dept Psychiat, Harris Ctr, Boston, MA 02114 USA. [Herzog, David B.; Eddy, Kamryn T.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Thomas, J. Graham; Lowe, Michael R.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA. [Franko, Debra L.] Northeastern Univ, Dept Counseling & Appl Educ Psychol, Boston, MA 02115 USA. RP Herzog, DB (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Harris Ctr, 2 Longfellow Pl,Ste 200, Boston, MA 02214 USA. EM dherzog@partners.org FU National Institute of Mental Health [5R01 MH 38333 05] FX This work was supported by the National Institute of Mental Health grant 5R01 MH 38333 05 (DBH). These data were presented in part at the Eating Disorder Research Society Annual Meeting in Montreal. Quebec (September 2008). The authors would like to thank Stephanie Ross for her assistance in editing and preparing the final version of this manuscript. NR 27 TC 21 Z9 21 U1 1 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAY 30 PY 2010 VL 177 IS 3 BP 330 EP 334 DI 10.1016/j.psychres.2010.03.002 PG 5 WC Psychiatry SC Psychiatry GA 609MB UT WOS:000278659600010 PM 20398944 ER PT J AU Saito, A Wakao, M Deguchi, H Mawatari, A Sobel, M Suda, Y AF Saito, Akihiro Wakao, Masahiro Deguchi, Hiroshi Mawatari, Aya Sobel, Michael Suda, Yasuo TI Toward the assembly of heparin and heparan sulfate oligosaccharide libraries: efficient synthesis of uronic acid and disaccharide building blocks SO TETRAHEDRON LA English DT Article DE Synthesis; Uronic acid; Glucuronic acid; Iduronic acid; Glucosamine; Heparin; Heparan sulfate ID L-IDURONIC ACID; BIOLOGICAL-ACTIVITY; PROTEIN INTERACTIONS; MODULAR SYNTHESIS; SUGAR CHIPS; GLYCOSAMINOGLYCANS; BINDING; STRATEGY; ROUTE; PENTASACCHARIDE AB The monosaccharide moieties found in heparin (HP) and heparan sulfate (HS), glucosamine and two kinds of uronic acids, glucuronic and iduronic acids, were efficiently synthesized by use of glucosamine hydrochloride and glucurono-6,3-lactone as starting compounds. In the synthesis of the disaccharide building block, the key issues of preparation of uronic acids (glucuronic acid and iduronic acid moieties) were achieved in 12 steps and 15 steps, respectively, without cumbersome C-6 oxidation. The resulting monosaccharide moieties were utilized to the syntheses of HP/HS disaccharide building blocks possessing glucosamine-glucuronic acid (GlcN-GlcA) or iduronic acid (GlcN-IdoA) sequences. The disaccharide building blocks were also suitable for further modification such as glycosylation, selective deprotection, and sulfation. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Saito, Akihiro; Wakao, Masahiro; Deguchi, Hiroshi; Mawatari, Aya; Suda, Yasuo] Kagoshima Univ, Grad Sch Sci & Engn, Dept Chem Biotechnol & Chem Engn, Kagoshima 8900065, Japan. [Sobel, Michael] VA Puget Sound Hlth Care Syst, Div Vasc Surg, Seattle, WA USA. [Sobel, Michael] Univ Washington, Sch Med, Seattle, WA USA. [Suda, Yasuo] SUDx Biotec Corp, Kagoshima 8900013, Japan. RP Wakao, M (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, Dept Chem Biotechnol & Chem Engn, 1-21-40 Kohrimoto, Kagoshima 8900065, Japan. EM wakao@eng.kagoshima-u.ac.jp; ysuda@eng.kagoshima-u.ac.jp FU Japan Science and Technology Agency [V07-05]; Japan Ministry of Health, Labour and Welfare (MHLW); National Institutes of Health, USA [RO1 HL079182] FX The present work was financially supported in part by grants from Japan Science and Technology Agency (Evolutionally-venture program V07-05 to Y.S., CREST to Y.S.), and the Japan Ministry of Health, Labour and Welfare (MHLW) (Nanomedicine program to Y.S.), and the National Institutes of Health, USA (RO1 HL079182 to M.S.). NR 55 TC 10 Z9 11 U1 2 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0040-4020 J9 TETRAHEDRON JI Tetrahedron PD MAY 29 PY 2010 VL 66 IS 22 BP 3951 EP 3962 DI 10.1016/j.tet.2010.03.077 PG 12 WC Chemistry, Organic SC Chemistry GA 603GK UT WOS:000278196500009 PM 20473366 ER PT J AU Liu, XH Manzano, G Lovett, DH Kim, HT AF Liu, Xuhui Manzano, Givenchy Lovett, David H. Kim, Hubert T. TI Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Matrix metalloproteinase-2; Muscle atrophy; Extracellular matrix; Gene expression regulation; Transcription; AP-1 ID HINDLIMB IMMOBILIZATION; EXPRESSION; RECOVERY; ISCHEMIA; CELLS; MMP-2; JUNB; YB-1; RATS; FOSB AB Previous work has suggested that an extracellular matrix degrading enzyme matrix metalloproteinase-2 (MMP-2) plays an important role in the development of muscle atrophy. However, the transcriptional regulation mechanism of MMP-2 in skeletal muscle atrophy remains largely unknown. Using transgenic MMP-2 promoter reporter mice, we have demonstrated that AP-1 and RE-1 binding sites in the MMP-2 promoter region, coupled with increased binding of Fra-1, Fra-2 and AP-2, play a critical role in MMP-2 transcriptional regulation in muscle atrophy. Novel information gained from this study has improved our understanding of in vivo transcriptional regulation of MMP-2 in skeletal muscle atrophy. Published by Elsevier Inc. C1 [Liu, Xuhui; Manzano, Givenchy; Lovett, David H.; Kim, Hubert T.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA. [Liu, Xuhui; Manzano, Givenchy; Kim, Hubert T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94122 USA. [Lovett, David H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94122 USA. RP Kim, HT (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, 4150 Clement St 112, San Francisco, CA 94121 USA. EM Kimh@orthosurg.ucsf.edu FU Orthopedic Research & Education Foundation; Illinois Bone and Joint Institute FX This work was supported by Orthopedic Research & Education Foundation and Illinois Bone and Joint Institute. NR 19 TC 5 Z9 5 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAY 28 PY 2010 VL 396 IS 2 BP 219 EP 223 DI 10.1016/j.bbrc.2010.04.067 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 609LL UT WOS:000278658000008 PM 20398633 ER PT J AU Hong, W Chen, LF Li, JA Yao, Z AF Hong, Wei Chen, Linfeng Li, Juan Yao, Zhi TI Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE MAPK; Corepressor; Nuclear hormone receptor; Tamoxifen ID BREAST-CANCER CELLS; GLUCOCORTICOID-RECEPTOR; RESPONSE ELEMENT; CROSS-TALK; TRANSCRIPTION; RESISTANCE; GROWTH; GENE; PHOSPHORYLATION; COACTIVATORS AB Estrogen receptor alpha (ER alpha), a ligand controlled transcription factor, plays an important role in breast cancer growth and endocrine therapy. Tamoxifen (TAM) antagonizes ER alpha activity and has been applied in breast cancer treatment. TAM-bound ER alpha associates with nuclear receptor-corepressors. Mitogen-activated protein kinase (MAPK) has been elucidated to result in cross-talk between growth factor and ER alpha. mediated signaling. We show that activated MAPK represses interaction of TAM-bound ER alpha with silencing mediator for retinoid and thyroid hormone receptors (SMRT) and inhibits the recruitment of SMRT by ER alpha to certain estrogen target genes. Blockade of MAPK signaling cascade with MEK inhibitor U0126 promotes the interaction and subsequently inhibits ER alpha activity via enhanced recruitment of SMRT, leading to reduced expression of ER alpha target genes. The growth rate of MCF-7 cells was decelerated when treated with both TAM and U0126. Moreover, the growth of MCF-7 cells stably expressing SMRT showed a robust repression in the presence of TAM and U0126. These results suggest that activated MAPK signaling cascade attenuates antagonist-induced recruitment of SMRT to ER alpha, suggesting corepressor mediates inhibition of ER alpha trans-activation and breast cancer cell growth by antagonist. Taken together, our finding indicates combination of antagonist and MAPK inhibitor could be a helpful approach for breast cancer therapy. (C) 2010 Elsevier Inc. All rights reserved. C1 [Hong, Wei; Yao, Zhi] Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China. [Hong, Wei; Li, Juan] Tianjin Med Univ, Dept Lab Med, Tianjin 300070, Peoples R China. [Chen, Linfeng] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Hong, W (reprint author), Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China. EM hongwei@tijmu.edu.cn FU Tianjin Medical University; National Basic Research Program [2009CB918903] FX We thank David Fisher for critically reading the manuscript. This work was supported by a grant for the "11-5" New Century Outstanding Scientist from Tianjin Medical University (W.H.) and a grant of National Basic Research Program (2009CB918903). NR 29 TC 5 Z9 5 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAY 28 PY 2010 VL 396 IS 2 BP 299 EP 303 DI 10.1016/j.bbrc.2010.04.085 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 609LL UT WOS:000278658000021 PM 20406620 ER PT J AU Bhasin, M Yuan, L Keskin, DB Otu, HH Libermann, TA Oettgen, P AF Bhasin, Manoj Yuan, Lei Keskin, Derin B. Otu, Hasan H. Libermann, Towia A. Oettgen, Peter TI Bioinformatic identification and characterization of human endothelial cell-restricted genes SO BMC GENOMICS LA English DT Article ID HUMAN PROTEIN ATLAS; LYS198ASN POLYMORPHISM; ANTIBODY PROTEOMICS; BLOOD-PRESSURE; EXPRESSION; HYPERTENSION; PROMOTER; PATHOPHYSIOLOGY; ANGIOGENESIS; SPECIFICITY AB Background: In this study, we used a systematic bioinformatics analysis approach to elucidate genes that exhibit an endothelial cell (EC) restricted expression pattern, and began to define their regulation, tissue distribution, and potential biological role. Results: Using a high throughput microarray platform, a primary set of 1,191 transcripts that are enriched in different primary ECs compared to non-ECs was identified (LCB >3, FDR <2%). Further refinement of this initial subset of transcripts, using published data, yielded 152 transcripts ( representing 109 genes) with different degrees of EC-specificity. Several interesting patterns emerged among these genes: some were expressed in all ECs and several were restricted to microvascular ECs. Pathway analysis and gene ontology demonstrated that several of the identified genes are known to be involved in vasculature development, angiogenesis, and endothelial function ( P < 0.01). These genes are enriched in cardiovascular diseases, hemorrhage and ischemia gene sets ( P < 0.001). Most of the identified genes are ubiquitously expressed in many different tissues. Analysis of the proximal promoter revealed the enrichment of conserved binding sites for 26 different transcription factors and analysis of the untranslated regions suggests that a subset of the EC-restricted genes are targets of 15 microRNAs. While many of the identified genes are known for their regulatory role in ECs, we have also identified several novel EC-restricted genes, the function of which have yet to be fully defined. Conclusion: The study provides an initial catalogue of EC-restricted genes most of which are ubiquitously expressed in different endothelial cells. C1 [Bhasin, Manoj; Yuan, Lei; Otu, Hasan H.; Libermann, Towia A.; Oettgen, Peter] Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Bhasin, Manoj; Libermann, Towia A.] Harvard Univ, Sch Med, Div Interdisciplinary Med & Biotechnol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Yuan, Lei; Oettgen, Peter] Harvard Univ, Sch Med, Div Cardiol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Yuan, Lei; Oettgen, Peter] Harvard Univ, Sch Med, Div Mol & Vasc Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Keskin, Derin B.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. RP Oettgen, P (reprint author), Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. EM joettgen@bidmc.harvard.edu OI Otu, Hasan/0000-0002-9253-8152; Libermann, Towia/0000-0002-4006-8179 FU NIH [HL-67219, P01 HL76540]; AHA [EIA0740012] FX This work was supported by NIH grants HL-67219 (PO) and P01 HL76540 (PO), and AHA award EIA0740012 (PO) NR 41 TC 19 Z9 20 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2164 J9 BMC GENOMICS JI BMC Genomics PD MAY 28 PY 2010 VL 11 AR 342 DI 10.1186/1471-2164-11-342 PG 18 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 625BR UT WOS:000279867300005 PM 20509943 ER PT J AU Lengner, CJ Gimelbrant, AA Erwin, JA Cheng, AW Guenther, MG Welstead, GG Alagappan, R Frampton, GM Xu, P Muffat, J Santagata, S Powers, D Barrett, CB Young, RA Lee, JT Jaenisch, R Mitalipova, M AF Lengner, Christopher J. Gimelbrant, Alexander A. Erwin, Jennifer A. Cheng, Albert Wu Guenther, Matthew G. Welstead, G. Grant Alagappan, Raaji Frampton, Garrett M. Xu, Ping Muffat, Julien Santagata, Sandro Powers, Doug Barrett, C. Brent Young, Richard A. Lee, Jeannie T. Jaenisch, Rudolf Mitalipova, Maisam TI Derivation of Pre-X Inactivation Human Embryonic Stem Cells under Physiological Oxygen Concentrations SO CELL LA English DT Article ID EARLY MOUSE EMBRYOS; CHROMOSOME INACTIVATION; IN-VITRO; HUMAN BLASTOCYSTS; HISTONE H3; XIST RNA; SELF-RENEWAL; LINES; DIFFERENTIATION; METHYLATION AB The presence of two active X chromosomes (XaXa) is a hallmark of the ground state of pluripotency specific to murine embryonic stem cells (ESCs). Human ESCs (hESCs) invariably exhibit signs of X chromosome inactivation (XCI) and are considered developmentally more advanced than their murine counterparts. We describe the establishment of XaXa hESCs derived under physiological oxygen concentrations. Using these cell lines, we demonstrate that (1) differentiation of hESCs induces random XCI in a manner similar to murine ESCs, (2) chronic exposure to atmospheric oxygen is sufficient to induce irreversible XCI with minor changes of the transcriptome, (3) the Xa exhibits heavy methylation of the XIST promoter region, and (4) XCI is associated with demethylation and transcriptional activation of XIST along with H3K27-me3 deposition across the Xi. These findings indicate that the human blastocyst contains pre-X-inactivation cells and that this state is preserved in vitro through culture under physiological oxygen. C1 [Lengner, Christopher J.; Cheng, Albert Wu; Guenther, Matthew G.; Welstead, G. Grant; Alagappan, Raaji; Frampton, Garrett M.; Xu, Ping; Muffat, Julien; Santagata, Sandro; Young, Richard A.; Jaenisch, Rudolf; Mitalipova, Maisam] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Frampton, Garrett M.; Young, Richard A.; Jaenisch, Rudolf] MIT, Dept Biol, Cambridge, MA 02139 USA. [Cheng, Albert Wu] MIT, Dept Computat & Syst Biol, Cambridge, MA 02139 USA. [Gimelbrant, Alexander A.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Gimelbrant, Alexander A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Erwin, Jennifer A.; Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. [Erwin, Jennifer A.; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Erwin, Jennifer A.; Lee, Jeannie T.] Howard Hughes Med Inst, Ann Arbor, MI 48108 USA. [Powers, Doug] Incept Biosyst, Ann Arbor, MI 48108 USA. [Barrett, C. Brent] Waltham Ctr, Boston IVF, Waltham, MA 02451 USA. RP Jaenisch, R (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA. EM jaenisch@wi.mit.edu; mitalipo@wi.mit.edu RI Young, Richard/F-6495-2012; OI Young, Richard/0000-0001-8855-8647; Muffat, Julien/0000-0003-1889-7023; Lengner, Christopher/0000-0002-0574-5189 FU Howard Hughes Medical Institute NR 54 TC 205 Z9 209 U1 6 U2 19 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD MAY 28 PY 2010 VL 141 IS 5 BP 872 EP 883 DI 10.1016/j.cell.2010.04.010 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 602IO UT WOS:000278132900021 PM 20471072 ER PT J AU Hur, W Sun, Z Jiang, T Mason, DE Peters, EC Zhang, DD Luesch, H Schultz, PG Gray, NS AF Hur, Wooyoung Sun, Zheng Jiang, Tao Mason, Daniel E. Peters, Eric C. Zhang, Donna D. Luesch, Hendrik Schultz, Peter G. Gray, Nathanael S. TI A Small-Molecule Inducer of the Antioxidant Response Element SO CHEMISTRY & BIOLOGY LA English DT Article ID HUMAN NEUROBLASTOMA-CELLS; SUBSTRATE ADAPTER PROTEIN; OXIDATIVE STRESS; TERT-BUTYLHYDROQUINONE; HISTONE DEACETYLASE; CYSTEINE RESIDUES; SULFHYDRYL-GROUPS; ACTIVATE NRF2; KEAP1; UBIQUITINATION AB Eukaryotic cells counteract oxidative and other environmental stress through the activation of Nrf2, the transcription factor that controls the expression of a host of protective enzymes by binding to the antioxidant response element (ARE). The electrophilic molecules that are able to activate Nrf2 and its downstream target genes have demonstrated therapeutic potential in carcinogen-induced tumor models. Using a high-throughput cellular screen, we discovered a class of ARE activator, which we named AI-1, that activates Nrf2 by covalently modifying Keap1, the negative regulator of Nrf2. Biochemical studies indicated that modification of Cys151 of Keap1 by AI-1 disrupted the ability of Keap1 to serve as an adaptor for Cul3-Keap1 ubiquitin ligase complex, thereby causing stabilization and transcriptional activation of Nrf2. Al-1 and its biotinylated derivative are useful pharmacological probes for investigating the molecular details of the cellular antioxidant response. C1 [Luesch, Hendrik] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA. [Hur, Wooyoung; Schultz, Peter G.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA. [Sun, Zheng; Jiang, Tao; Zhang, Donna D.] Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85721 USA. [Mason, Daniel E.; Peters, Eric C.; Schultz, Peter G.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA. [Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. RP Luesch, H (reprint author), Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA. EM luesch@cop.ufl.edu; schultz@scripps.edu; Nathanael_Gray@dfci.harvard.edu RI Sun, Zheng/C-1146-2012; Zhang, Donna /B-1015-2012 OI Sun, Zheng/0000-0002-6858-0633; FU Ellison Medical Foundation; American Heart Association; Evelyn F. and William L. McKnight Brain Institute of the University of Florida FX This work was supported by the Ellison Medical Foundation (P.G.S.), the American Heart Association (H.L.), and the Evelyn F. and William L. McKnight Brain Institute of the University of Florida (H.L.). We thank Jonathan Kern for assistance with the screens. The authors declare no competing financial interests. NR 43 TC 35 Z9 36 U1 0 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-5521 J9 CHEM BIOL JI Chem. Biol. PD MAY 28 PY 2010 VL 17 IS 5 BP 537 EP 547 DI 10.1016/j.chembiol.2010.03.013 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 611TE UT WOS:000278845000015 PM 20534351 ER PT J AU Cavusoglu, E Chopra, V Gupta, A Battala, VR Poludasu, S Eng, C Marmur, JD AF Cavusoglu, Erdal Chopra, Vineet Gupta, Amit Battala, Venkata R. Poludasu, Shyam Eng, Calvin Marmur, Jonathan D. TI Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE RDW; Anemia; Coronary angiography; Prognosis ID INDEPENDENT PREDICTOR; CHARM PROGRAM; HEART-FAILURE; CHEST-PAIN; ANEMIA; OUTCOMES AB Background: Red blood cell distribution width (RDW), a numerical measure of the variability in size of circulating erythrocytes, has recently been shown to be a strong predictor of adverse outcomes in patients with heart failure and in patients with prior myocardial infarction but no symptomatic heart failure at baseline, even after adjustment for hematocrit. However, there are no data in other cardiac populations, including patients with acute coronary syndromes (ACS). Methods: The present study investigated the long-term prognostic significance of baseline RDW in a well-characterized cohort of 389 male patients who were referred to coronary angiography for a variety of indications. All patients were followed prospectively for all-cause mortality, and data regarding this endpoint was available for 97% of the population at 24 months. Results: After controlling for a variety of baseline variables (including hemoglobin and the presence of heart failure), RDW (analyzed as a categorical variable comparing the upper tertile of baseline values to the lower two levels combined) was a strong and independent predictor of all-cause mortality using a Cox proportional hazards model [ hazard ratio (HR) 2.69, 95% confidence interval (CI) 1.50-4.84, p=0.0008]. In addition, baseline RDW was also an independent predictor of all-cause mortality in the non-anemic (HR 4.73, 95% CI 2.06-10.86, p=0.0003) and ACS (HR 2.90, 95% CI 1.32-6.38, p=0.0082) subpopulations of patients. Conclusions: These data demonstrate that elevated RDW is a strong and independent predictor of all-cause mortality in an unselected population of male patients across a broad spectrum of risk (including ACS) referred for coronary angiography. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Cavusoglu, Erdal; Gupta, Amit; Battala, Venkata R.; Poludasu, Shyam; Marmur, Jonathan D.] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. [Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA. RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, 450 Clarkson Ave,Box 1257, Brooklyn, NY 11203 USA. EM ECavusoglu@aol.com NR 12 TC 88 Z9 98 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD MAY 28 PY 2010 VL 141 IS 2 BP 141 EP 146 DI 10.1016/j.ijcard.2008.11.187 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 597AI UT WOS:000277727200004 PM 19144426 ER PT J AU Boucher, J Tseng, YH Kahn, CR AF Boucher, Jeremie Tseng, Yu-Hua Kahn, C. Ronald TI Insulin and Insulin-like Growth Factor-1 Receptors Act as Ligand-specific Amplitude Modulators of a Common Pathway Regulating Gene Transcription SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID IGF-I; MICROARRAY ANALYSIS; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION; GLUCOSE-METABOLISM; BROWN ADIPOCYTES; CELL-CULTURES; MUSCLE-CELLS; MICE; EXPRESSION AB Insulin and insulin-like growth factor-1 (IGF-1) act on highly homologous receptors, yet in vivo elicit distinct effects on metabolism and growth. To investigate how the insulin and IGF-1 receptors exert specificity in their biological responses, we assessed their role in the regulation of gene expression using three experimental paradigms: 1) preadipocytes before and after differentiation into adipocytes that express both receptors, but at different ratios; 2) insulin receptor (IR) or IGF1R knock-out preadipocytes that only express the complimentary receptor; and 3) IR/IGF1R double knock-out (DKO) cells reconstituted with the IR, IGF1R, or both. In wild-type preadipocytes, which express predominantly IGF1R, microarray analysis revealed similar to 500 IGF-1 regulated genes (p < 0.05). The largest of these were confirmed by quantitative PCR, which also revealed that insulin produced a similar effect, but with a smaller magnitude of response. After differentiation, when IR levels increase and IGF1R decrease, insulin became the dominant regulator of each of these genes. Measurement of the 50 most highly regulated genes by quantitative PCR did not reveal a single gene regulated uniquely via the IR or IGF1R using cells expressing exclusively IGF-1 or insulin receptors. Insulin and IGF-1 dose responses from 1 to 100 nM in WT, IRKO, IGFRKO, and DKO cells re-expressing IR, IGF1R, or both showed that insulin and IGF-1 produced effects in proportion to the concentration of ligand and the specific receptor on which they act. Thus, IR and IGF1R act as identical portals to the regulation of gene expression, with differences between insulin and IGF-1 effects due to a modulation of the amplitude of the signal created by the specific ligand-receptor interaction. C1 Joslin Diabet Ctr, Boston, MA 02215 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA 02215 USA. RP Kahn, CR (reprint author), 1 Joslin Pl, Boston, MA 02215 USA. EM c.ronald.kahn@joslin.harvard.edu FU National Institutes of Health [DK31036, DK33201, DK077097]; Diabetes Genome Anatomy Project [DK60837]; Harvard Catalyst/The Harvard Clinical and Translational Science Center [UL1 RR 025758-01] FX This work was supported, in whole or in part, by National Institutes of Health Grants DK31036, DK33201, and DK077097, Diabetes Genome Anatomy Project Grant DK60837, and Harvard Catalyst/The Harvard Clinical and Translational Science Center Grant UL1 RR 025758-01. NR 40 TC 39 Z9 40 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 28 PY 2010 VL 285 IS 22 BP 17235 EP 17245 DI 10.1074/jbc.M110.118620 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 600JS UT WOS:000277982600085 PM 20360006 ER PT J AU Choo, AY Kim, SG Heiden, MGV Mahoney, SJ Vu, H Yoon, SO Cantley, LC Blenis, J AF Choo, Andrew Y. Kim, Sang Gyun Heiden, Matthew G. Vander Mahoney, Sarah J. Vu, Hieu Yoon, Sang-Oh Cantley, Lewis C. Blenis, John TI Glucose Addiction of TSC Null Cells Is Caused by Failed mTORC1-Dependent Balancing of Metabolic Demand with Supply SO MOLECULAR CELL LA English DT Article ID TUBEROUS SCLEROSIS COMPLEX; GREEN TEA POLYPHENOLS; GROWTH; SURVIVAL; GLUTAMINE; TUMOR; ACTIVATION; APOPTOSIS; CANCER; PHOSPHORYLATION AB The mTORC1-signaling pathway integrates environmental conditions into distinct signals for cell growth by balancing anabolic and catabolic processes. Accordingly, energetic stress inhibits mTORC1 signaling predominantly through AMPK-dependent activation of TSC1/2. Thus, TSC1/2-/- cells are hypersensitive to glucose deprivation, and this has been linked to increased p53 translation and activation of apoptosis. Herein, we show that mTORC1 inhibition during glucose deprivation prevented not only the execution of death, but also induction of energetic stress. mTORC1 inhibition during glucose deprivation decreased AMPK activation and allowed ATP to remain high, which was both necessary and sufficient for protection. This effect was not due to increased catabolic activities such as autophagy, but rather exclusively due to decreased anabolic processes, reducing energy consumption. Specifically, TSC1/2-/- cells become highly dependent on glutamate dehydrogenase-dependent glutamine metabolism via the TCA cycle for survival. Therefore, mTORC1 inhibition during energetic stress is primarily to balance metabolic demand with supply. C1 [Choo, Andrew Y.; Kim, Sang Gyun; Mahoney, Sarah J.; Vu, Hieu; Yoon, Sang-Oh; Blenis, John] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Choo, Andrew Y.; Mahoney, Sarah J.] Harvard Univ, Sch Med, Program Biol, Boston, MA 02115 USA. [Choo, Andrew Y.; Mahoney, Sarah J.] Harvard Univ, Sch Med, Program Biomed Sci, Boston, MA 02115 USA. [Heiden, Matthew G. Vander; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. [Heiden, Matthew G. Vander] Dana Farber Canc Inst, Boston, MA 02115 USA. [Heiden, Matthew G. Vander; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA. RP Blenis, J (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. EM john_blenis@hms.harvard.edu RI Cantley, Lewis/D-1800-2014 OI Cantley, Lewis/0000-0002-1298-7653 FU NIH [GM51405] FX We thank members of the Blenis laboratory for critical discussions and technical assistance. We are also grateful to D. Kwiatkowski, B. Manning, J. Brugge, W. Kaelin, Jr., C. Walker, N. Mizushima, and K.L. Guan for providing reagents and to S. Soltoff for advice and discussions regarding Ne+/K+-AT-Pase assays. A.Y.C. would also like to thank J. Brugge and L. Gehrke for discussions. This work was funded-by the NIH Grant GM51405 to J.B. NR 32 TC 122 Z9 126 U1 3 U2 14 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 J9 MOL CELL JI Mol. Cell PD MAY 28 PY 2010 VL 38 IS 4 BP 487 EP 499 DI 10.1016/j.molcel.2010.05.007 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 606SQ UT WOS:000278448100005 PM 20513425 ER PT J AU Qiao, M Wang, YQ Xu, XE Lu, J Dong, YL Tao, WF Stein, J Stein, GS Iglehart, JD Shi, QA Pardee, AB AF Qiao, Meng Wang, Yaqi Xu, Xiaoen Lu, Jing Dong, Yongli Tao, Wufan Stein, Janet Stein, Gary S. Iglehart, James D. Shi, Qian Pardee, Arthur B. TI Mst1 Is an Interacting Protein that Mediates PHLPPs' Induced Apoptosis SO MOLECULAR CELL LA English DT Article ID KINASE MST1; SUPRACHIASMATIC NUCLEUS; STE20-LIKE KINASE; BREAST-CANCER; HIPPO PATHWAY; MAP KINASE; ACTIVATION; PHOSPHORYLATION; AKT; HETEROZYGOSITY AB PHLPP1 and PHLPP2 phosphatases exert their tumor-suppressing functions by dephosphorylation and inactivation of Akt in several breast cancer and glioblastoma cells. However, Akt, or other known targets of PHLPPs that include PKC and ERK, may not fully elucidate the physiological role of the multifunctional phosphatases, especially their powerful apoptosis induction function. Here, we show that PHLPPs induce apoptosis in cancer cells independent of the known targets of PHLPPs. We identified Mst1 as a binding partner that interacts with PHLPPs both in vivo and in vitro. PHLPPs dephosphorylate Mst1 on the 1387 inhibitory site, which activate Mst1 and its downstream effectors p38 and JNK to induce apoptosis. The same 1387 site can be phosphorylated by Akt. Thus, PHLPP, Akt, and Mst1 constitute an autoinhibitory triangle that controls the fine balance of apoptosis and proliferation that is cell type and context dependent. C1 [Qiao, Meng; Pardee, Arthur B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA. [Iglehart, James D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Canc Biol, Boston, MA 02115 USA. [Iglehart, James D.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Wang, Yaqi; Xu, Xiaoen; Lu, Jing] Fudan Univ, Sch Life Sci, Shanghai 200032, Peoples R China. [Wang, Yaqi; Xu, Xiaoen; Lu, Jing] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China. [Dong, Yongli; Tao, Wufan] Fudan Univ, Inst Dev Biol, Shanghai 200032, Peoples R China. [Stein, Janet; Stein, Gary S.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA. [Stein, Janet; Stein, Gary S.] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA. RP Pardee, AB (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA. EM shiqian@fudan.edu.cn; arthur_pardee@dfci.harvard.edu RI Dong, Yongli/K-1222-2016 FU Department of Defense [DAMD 17-02-1-0692]; Pu Jiang Project [07pj14011]; Shu Guang Project [05SG05]; Science and Technology Commission of Shanghai Municipality [07dz19505]; NSFC [30970653]; State Key Research Project [2008ZX10002-017, 2009ZX09301-011]; Dana-Farber/Harvard Specialized Program of Research Excellence in Breast Cancer; Dana-Farber FX This work was supported by Department of Defense grant DAMD 17-02-1-0692 to A.B.P. and J.D.I., and by Pu Jiang Project (07pj14011), Shu Guang Project (05SG05), Science and Technology Commission of Shanghai Municipality Grant (07dz19505), NSFC fund (30970653), State Key Research Project (2008ZX10002-017, 2009ZX09301-011) to Q.S. M.Q. was sponsored by a fellowship from Dana-Farber/Harvard Specialized Program of Research Excellence in Breast Cancer and the Women's Cancers Program at Dana-Farber. NR 39 TC 60 Z9 63 U1 0 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 J9 MOL CELL JI Mol. Cell PD MAY 28 PY 2010 VL 38 IS 4 BP 512 EP 523 DI 10.1016/j.molcel.2010.03.017 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 606SQ UT WOS:000278448100007 PM 20513427 ER PT J AU Sharma, R Tsuchiya, M Skobe, Z Tannous, BA Bartlett, JD AF Sharma, Ramaswamy Tsuchiya, Masahiro Skobe, Ziedonis Tannous, Bakhos A. Bartlett, John D. TI The Acid Test of Fluoride: How pH Modulates Toxicity SO PLOS ONE LA English DT Article ID RAT INCISOR ENAMEL; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; SODIUM-FLUORIDE; SECRETORY PATHWAY; DEPENDENT EVENT; MESSENGER-RNAS; ULTRASTRUCTURAL-CHANGES; DENTAL FLUOROSIS; RENAL CLEARANCE AB Background: It is not known why the ameloblasts responsible for dental enamel formation are uniquely sensitive to fluoride (F(-)). Herein, we present a novel theory with supporting data to show that the low pH environment of maturating stage ameloblasts enhances their sensitivity to a given dose of F(-). Enamel formation is initiated in a neutral pH environment (secretory stage); however, the pH can fall to below 6.0 as most of the mineral precipitates (maturation stage). Low pH can facilitate entry of F(-) into cells. Here, we asked if F(-) was more toxic at low pH, as measured by increased cell stress and decreased cell function. Methodology/Principal Findings: Treatment of ameloblast-derived LS8 cells with F(-) at low pH reduced the threshold dose of F(-) required to phosphorylate stress-related proteins, PERK, eIF2 alpha, JNK and c-jun. To assess protein secretion, LS8 cells were stably transduced with a secreted reporter, Gaussia luciferase, and secretion was quantified as a function of F(-) dose and pH. Luciferase secretion significantly decreased within 2 hr of F(-) treatment at low pH versus neutral pH, indicating increased functional toxicity. Rats given 100 ppm F(-) in their drinking water exhibited increased stress-mediated phosphorylation of eIF2 alpha in maturation stage ameloblasts (pH<6.0) as compared to secretory stage ameloblasts (pH similar to 7.2). Intriguingly, F(-)-treated rats demonstrated a striking decrease in transcripts expressed during the maturation stage of enamel development (Klk4 and Amtn). In contrast, the expression of secretory stage genes, AmelX, Ambn, Enam and Mmp20, was unaffected. Conclusions: The low pH environment of maturation stage ameloblasts facilitates the uptake of F 2, causing increased cell stress that compromises ameloblast function, resulting in dental fluorosis. C1 [Sharma, Ramaswamy; Skobe, Ziedonis; Bartlett, John D.] Harvard Univ, Sch Dent Med, Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. [Sharma, Ramaswamy; Skobe, Ziedonis; Bartlett, John D.] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA. [Tsuchiya, Masahiro] Tohoku Univ, Div Aging & Geriatr Dent, Sendai, Miyagi 980, Japan. [Tannous, Bakhos A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Tannous, Bakhos A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. [Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. RP Sharma, R (reprint author), Harvard Univ, Sch Dent Med, Forsyth Inst, Dept Cytokine Biol, 188 Longwood Ave, Boston, MA 02115 USA. EM jbartlett@forsyth.org RI Sharma, Ramaswamy/F-8401-2012; OI Tsuchiya, Masahiro/0000-0002-7000-4547 FU National Institute of Dental and Craniofacial Research [DE018106] FX This work was supported by grant DE018106 from the National Institute of Dental and Craniofacial Research (www.nidcr.nih.gov) to JDB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 80 TC 16 Z9 17 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 28 PY 2010 VL 5 IS 5 AR e10895 DI 10.1371/journal.pone.0010895 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 603QC UT WOS:000278222100024 PM 20531944 ER PT J AU Fu, J Ghali, BW Lozynsky, AJ Oral, E Muratoglu, OK AF Fu, Jun Ghali, Bassem W. Lozynsky, Andrew J. Oral, Ebru Muratoglu, Orhun K. TI Ultra high molecular weight polyethylene with improved plasticity and toughness by high temperature melting SO POLYMER LA English DT Article DE High temperature melting; Wear; Total joint implants ID UHMWPE; WEAR; RESISTANCE; DEFORMATION; DEGRADATION; OSTEOLYSIS; DEPENDENCE; COMPONENTS; POLYMERS; DENSITY AB Our goal was to improve the strength and toughness of ultra high molecular weight polyethylene (UHWMPE), which is the preferred polymeric bearing material in total joint implants. Based on accelerated diffusion of UHMWPE chains at high temperatures, our hypothesis was that high temperature melting could minimize the structural defects and thus improve the toughness of consolidated UHMWPE. Melting of consolidated medical-grade UHMWPE at 280, 300, and 320 degrees C in inert atmosphere improved the elongation at break, work-to-failure and impact strength, presumably due to chain scissioning and structural defect elimination through self-diffusion. An important finding of this study was that the gain in plasticity and toughness did not sacrifice the wear resistance under optimized melting conditions, which may be promising for next generation high performance UHMWPE materials for joint implant bearing surfaces. (c) 2010 Elsevier Ltd. All rights reserved. C1 [Fu, Jun; Ghali, Bassem W.; Lozynsky, Andrew J.; Oral, Ebru; Muratoglu, Orhun K.] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. [Fu, Jun; Oral, Ebru; Muratoglu, Orhun K.] Harvard Univ, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA. RP Oral, E (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, GRJ 1206, Boston, MA 02114 USA. EM eoral@partners.org RI Fu, Jun/C-1648-2012 OI Fu, Jun/0000-0002-8723-1439 FU laboratory funds FX The authors are grateful to Dr. Neil Hubbard, Mark Allen, and Rebecca Field of the Orthoplastics Inc., UK for assistance in the double-notched Izod impact strength measurements. This study was funded by laboratory funds. NR 28 TC 20 Z9 20 U1 2 U2 28 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0032-3861 J9 POLYMER JI Polymer PD MAY 28 PY 2010 VL 51 IS 12 BP 2721 EP 2731 DI 10.1016/j.polymer.2010.04.003 PG 11 WC Polymer Science SC Polymer Science GA 603DK UT WOS:000278188500035 ER PT J AU Allen, JD Coronado, GD Williams, RS Glenn, B Escoffery, C Fernandez, M Tuff, RA Wilson, KM Mullen, PD AF Allen, Jennifer D. Coronado, Gloria D. Williams, Rebecca S. Glenn, Beth Escoffery, Cam Fernandez, Maria Tuff, Raegan A. Wilson, Katherine M. Mullen, Patricia Dolan TI A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability SO VACCINE LA English DT Review DE Human papillomavirus; Vaccine; Measures; Methods; Systematic review ID YOUNG-ADULT MEN; CERVICAL-CANCER; PARENTAL ATTITUDES; REPRESENTATIVE SAMPLE; ADOLESCENT CHILDREN; WOMENS ATTITUDES; HEALTH-EDUCATION; COLLEGE-STUDENTS; CLINICAL-TRIALS; RISK-FACTORS AB Background: The recent proliferation of studies describing factors associated with HPV vaccine acceptability could inform health care providers in improving vaccine coverage and support future research. This review examined measures of HPV and HPV-vaccine knowledge, attitudes, beliefs and acceptability, described psychometric characteristics, and provided recommendations about their use. Methods: A systematic search of Medline, CINAHL, PsychoInfo, and ERIC through May 2008 for English language reports of quantitative data from parents, young adults or adolescents yielded 79 studies. Results: The majority of studies were cross-sectional surveys (87%), self-administered (67%), conducted before prophylactic vaccines were publicly available (67%) and utilized convenience samples (65%). Most measured knowledge (80%), general attitudes about HPV vaccination (40%), and willingness to vaccinate one's daughter (26%). Two-thirds did not report reliability or validity of measures. The majority did not specify a theoretical framework. Conclusions: Use of a theoretical framework, consistent labeling of constructs, more rigorous validation of measures, and testing of measures in more diverse samples are needed to yield measurement instruments that will produce findings to guide practitioners in developing successful community and clinical interventions. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Allen, Jennifer D.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Allen, Jennifer D.] Harvard Univ, Sch Med, Boston, MA USA. [Coronado, Gloria D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Williams, Rebecca S.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC USA. [Glenn, Beth] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Glenn, Beth] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Escoffery, Cam] Rollins Sch Publ Hlth, Atlanta, GA USA. [Fernandez, Maria; Mullen, Patricia Dolan] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Tuff, Raegan A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wilson, Katherine M.] Morehouse Sch Med, Atlanta, GA 30310 USA. RP Allen, JD (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 44 Binney St, Boston, MA 02115 USA. EM jennifer_allen@dfci.harvard.edu RI Escoffery, Cam/F-8030-2011; Allen, Jennifer/M-2113-2015 FU Centers for Disease Control and Prevention (CDC); National Cancer Institute (NCI), Cancer Prevention and Control Research Networks (CPCRN) at Emory University School of Public Health [1-U48-DP00043]; Harvard School of Public Health/Boston School of Public Health [1-U48-DP000064]; Morehouse School of Medicine, Prevention Research Center [1-U48-DP000056]; University of California at Los Angeles School of Public Health [1-U48-DP000059]; University of North Carolina at Chapel Hill, Center for Health Promotion and Disease Prevention [1-U48-DP000056]; University of Texas School of Public Health [1-U48-DP-000057]; University of Washington School of Public Health and Community Medicine/Fred Hutchinson Cancer Research Center [1-U48-DP000050] FX Research for this publication was supported by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) cooperative agreements for the Cancer Prevention and Control Research Networks (CPCRN) at Emory University School of Public Health (1-U48-DP00043); Harvard School of Public Health/Boston School of Public Health (1-U48-DP000064); Morehouse School of Medicine, Prevention Research Center (1-U48-DP000056); University of California at Los Angeles School of Public Health (1-U48-DP000059); University of North Carolina at Chapel Hill, Center for Health Promotion and Disease Prevention (1-U48-DP000056); University of Texas School of Public Health (1-U48-DP-000057); and University of Washington School of Public Health and Community Medicine/Fred Hutchinson Cancer Research Center (1-U48-DP000050). NR 117 TC 59 Z9 60 U1 3 U2 15 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 28 PY 2010 VL 28 IS 24 BP 4027 EP 4037 DI 10.1016/j.vaccine.2010.03.063 PG 11 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 614NE UT WOS:000279065400003 PM 20412875 ER PT J AU Heinrichs, S Li, C Look, AT AF Heinrichs, Stefan Li, Cheng Look, A. Thomas TI SNP array analysis in hematologic malignancies: avoiding false discoveries SO BLOOD LA English DT Article ID ACUTE MYELOID-LEUKEMIA; RISK MYELODYSPLASTIC SYNDROMES; LOSS-OF-HETEROZYGOSITY; COPY NUMBER; UNIPARENTAL DISOMY; CHROMOSOMAL LESIONS; HUMAN GENOME; GENETIC ALTERATIONS; HIGH-RESOLUTION; CYTOGENETICS AB Comprehensive analysis of the cancer genome has become a standard approach to identifying new disease loci, and ultimately will guide therapeutic decisions. A key technology in this effort, single nucleotide polymorphism arrays, has been applied in hematologic malignancies to detect deletions, amplifications, and loss of heterozygosity (LOH) at high resolution. An inherent challenge of such studies lies in correctly distinguishing somatically acquired, cancer-specific lesions from patient-specific inherited copy number variations or segments of homozygosity. Failure to include appropriate normal DNA reference samples for each patient in retrospective or prospective studies makes it difficult to identify small somatic deletions not evident by standard cytogenetic analysis. In addition, the lack of proper controls can also lead to vastly overestimated frequencies of LOH without accompanying loss of DNA copies, so-called copy-neutral LOH. Here we use examples from patients with myeloid malignancies to demonstrate the superiority of matched tumor and normal DNA samples (paired studies) over multiple unpaired samples with respect to reducing false discovery rates in high-resolution single nucleotide polymorphism array analysis. Comparisons between matched tumor and normal samples will continue to be critical as the field moves from high resolution array analysis to deep sequencing to detect abnormalities in the cancer genome. (Blood. 2010; 115(21): 4157-4161) C1 [Heinrichs, Stefan; Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Li, Cheng] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Look, AT (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Mayer Bldg,Rm 630,44 Binney St, Boston, MA 02115 USA. EM thomas_look@dfci.harvard.edu FU National Institutes of Health [CA-108631] FX The authors thank John Gilbert for editorial review and Donna S. Neuberg and David P. Steensma for helpful discussions.; This work was supported in part by the National Institutes of Health (P01 grant CA-108631). NR 25 TC 51 Z9 55 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAY 27 PY 2010 VL 115 IS 21 BP 4157 EP 4161 DI 10.1182/blood-2009-11-203182 PG 5 WC Hematology SC Hematology GA 602DE UT WOS:000278117900005 PM 20304806 ER PT J AU Weisberg, E Choi, HG Ray, A Barrett, R Zhang, JM Sim, T Zhou, WJ Seeliger, M Cameron, M Azam, M Fletcher, JA Debiec-Rychter, M Mayeda, M Moreno, D Kung, AL Janne, PA Khosravi-Far, R Melo, JV Manley, PW Adamia, S Wu, C Gray, N Griffin, JD AF Weisberg, Ellen Choi, Hwan Geun Ray, Arghya Barrett, Rosemary Zhang, Jianming Sim, Taebo Zhou, Wenjun Seeliger, Markus Cameron, Michael Azam, Mohammed Fletcher, Jonathan A. Debiec-Rychter, Maria Mayeda, Mark Moreno, Daisy Kung, Andrew L. Janne, Pasi Antero Khosravi-Far, Roya Melo, Junia V. Manley, Paul W. Adamia, Sophia Wu, Catherine Gray, Nathanael Griffin, James D. TI Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR alpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants SO BLOOD LA English DT Article ID GASTROINTESTINAL STROMAL TUMOR; MYELOID BLAST CRISIS; TYROSINE KINASE; IMATINIB MESYLATE; IN-VITRO; MYELOPROLIFERATIVE DISEASE; SELECTIVE INHIBITOR; LEUKEMIA-CELLS; T315I MUTANT; C-SRC AB Many clinically validated kinases, such as BCR-ABL, c-Kit, PDGFR, and EGFR, become resistant to adenosine triphosphate-competitive inhibitors through mutation of the so-called gatekeeper amino acid from a threonine to a large hydrophobic amino acid, such as an isoleucine or methionine. We have developed a new class of adenosine triphosphate competitive inhibitors, exemplified by HG-7-85-01, which is capable of inhibiting T315I-BCR-ABL (clinically observed in chronic myeloid leukemia), T670I-c-Kit (clinically observed in gastrointestinal stromal tumors), and T674I/M-PDGFR alpha (clinically observed in hypereosinophilic syndrome). HG-7-85-01 is unique among all currently reported kinase inhibitors in having the ability to accommodate either a gatekeeper threonine, present in the wild-type forms of these kinases, or a large hydrophobic amino acid without becoming a promiscuous kinase inhibitor. The distinctive ability of HG-7-85-01 to simultaneously inhibit both wild-type and mutant forms of several kinases of clinical relevance is an important step in the development of the next generation of tyrosine kinase inhibitors. (Blood. 2010; 115(21): 4206-4216) C1 [Weisberg, Ellen; Ray, Arghya; Barrett, Rosemary; Janne, Pasi Antero; Adamia, Sophia; Wu, Catherine; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Choi, Hwan Geun; Zhang, Jianming; Sim, Taebo; Zhou, Wenjun; Gray, Nathanael] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA USA. [Seeliger, Markus] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA. [Seeliger, Markus] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA. [Seeliger, Markus] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA. [Cameron, Michael] Scripps Florida, Translat Res Inst, Jupiter, FL USA. [Azam, Mohammed] Cincinnati Childrens Hosp & Med Ctr, Div Pathol & Expt Hematol & Canc Pathol, Cincinnati, OH USA. [Fletcher, Jonathan A.; Mayeda, Mark] Brigham & Womens Hosp, Boston, MA 02115 USA. [Debiec-Rychter, Maria] Univ Louvain, Dept Human Genet, Louvain, Belgium. [Moreno, Daisy] Dana Farber Canc Inst, Anim Resources Facil, Boston, MA 02115 USA. [Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kung, Andrew L.] Childrens Hosp, Boston, MA 02115 USA. [Khosravi-Far, Roya] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA. [Melo, Junia V.] Inst Med & Vet Sci, Dept Haematol, Adelaide, SA 5000, Australia. [Manley, Paul W.] Novartis Pharma AG, Basel, Switzerland. RP Weisberg, E (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM Ellen_Weisberg@dfci.harvard.edu; Nathanael_Gray@dfci.harvard.edu RI Seeliger, Markus/D-6409-2013 FU National Institutes of Health [5K99GM080097, CA66996, CA36167, DK50654, R01 CA130876-01A1]; Office of Science, Office of Basic Energy Sciences, US Department of Energy [DE-AC02-05CH11231]; Leukemia & Lymphoma Society FX The authors thank George Q. Daley for his development and provision of PDGFR mutant-expressing cells, Jonathan Fletcher and George Demetri for their kind development and provision of KIT mutant-expressing cell lines used for our studies, Jinyan Du for development and provision of the T670I-KIT plasmid and the T681I-PDGFR beta plasmid, Tina Davis for her help with in vivo analysis, and Jayasree Sundaram for technical assistance.; M. S. was supported by the National Institutes of Health (5K99GM080097). The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, US Department of Energy (contract DE-AC02-05CH11231). J.D.G is supported by the National Institutes of Health (grants CA66996, CA36167, and DK50654) and the Leukemia & Lymphoma Society (Specialized Center of Research Award). N.S.G. is supported by the National Institutes of Health (grant R01 CA130876-01A1). NR 43 TC 40 Z9 40 U1 0 U2 7 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAY 27 PY 2010 VL 115 IS 21 BP 4206 EP 4216 DI 10.1182/blood-2009-11-251751 PG 11 WC Hematology SC Hematology GA 602DE UT WOS:000278117900012 PM 20299508 ER PT J AU Higgins, JM Sloan, SR AF Higgins, John M. Sloan, Steven R. TI Other factors may contribute to differences between sickle cell and non-sickle cell patients Response SO BLOOD LA English DT Letter C1 [Higgins, John M.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Higgins, John M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Higgins, John M.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA. [Sloan, Steven R.] Childrens Hosp Boston, Blood Bank, Joint Program Transfus Med, Boston, MA 02115 USA. [Sloan, Steven R.] Childrens Hosp Boston, Dept Lab Med, Boston, MA 02115 USA. [Sloan, Steven R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Sloan, SR (reprint author), Childrens Hosp Boston, Blood Bank, Joint Program Transfus Med, Baden 406,300 Longwood Ave, Boston, MA 02115 USA. EM steven.sloan@childrens.harvard.edu NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAY 27 PY 2010 VL 115 IS 21 BP 4315 EP 4316 PG 3 WC Hematology SC Hematology GA 602DE UT WOS:000278117900026 ER PT J AU Frei, CR Mortensen, EM Copeland, LA Attridge, RT Pugh, MJV Restrepo, MI Anzueto, A Nakashima, B Fine, MJ AF Frei, Christopher R. Mortensen, Eric M. Copeland, Laurel A. Attridge, Russell T. Pugh, Mary Jo V. Restrepo, Marcos I. Anzueto, Antonio Nakashima, Brandy Fine, Michael J. TI Disparities of Care for African-Americans and Caucasians with Community-Acquired Pneumonia: A Retrospective Cohort Study SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID OF-VETERANS-AFFAIRS; EMPIRIC ANTIBIOTIC-THERAPY; UNITED-STATES; ANTIMICROBIAL THERAPY; ADMINISTRATIVE DATA; RACIAL-DIFFERENCES; ELDERLY-PATIENTS; HOSPITAL MORTALITY; PULMONARY-DISEASE; IMPACT AB Background: African-Americans admitted to U.S. hospitals with community-acquired pneumonia (CAP) are more likely than Caucasians to experience prolonged hospital length of stay (LOS), possibly due to either differential treatment decisions or patient characteristics. Methods: We assessed associations between race and outcomes (Intensive Care Unit [ICU] variables, LOS, 30-day mortality) for African-American or Caucasian patients over 65 years hospitalized in the Veterans Health Administration (VHA) with CAP (2002-2007). Patients admitted to the ICU were analyzed separately from those not admitted to the ICU. VHA patients who died within 30 days of discharge were excluded from all LOS analyses. We used chi-square and Fisher's exact statistics to compare dichotomous variables, the Wilcoxon Rank Sum test to compare age by race, and Cox Proportional Hazards Regression to analyze hospital LOS. We used separate generalized linear mixed-effect models, with admitting hospital as a random effect, to examine associations between patient race and the receipt of guideline-concordant antibiotics, ICU admission, use of mechanical ventilation, use of vasopressors, LOS, and 30-day mortality. We defined statistical significance as a two-tailed p <= 0.0001. Results: Of 40,878 patients, African-Americans (n = 4,936) were less likely to be married and more likely to have a substance use disorder, neoplastic disease, renal disease, or diabetes compared to Caucasians. African-Americans and Caucasians were equally likely to receive guideline-concordant antibiotics (92% versus 93%, adjusted OR = 0.99; 95% CI = 0.81 to 1.20) and experienced similar 30-day mortality when treated in medical wards (adjusted OR = 0.98; 95% CI = 0.87 to 1.10). African-Americans had a shorter adjusted hospital LOS (adjusted HR = 0.95; 95% CI = 0.92 to 0.98). When admitted to the ICU, African Americans were as likely as Caucasians to receive guideline-concordant antibiotics (76% versus 78%, adjusted OR = 0.99; 95% CI = 0.81 to 1.20), but experienced lower 30-day mortality (adjusted OR = 0.82; 95% CI = 0.68 to 0.99) and shorter hospital LOS (adjusted HR = 0.84; 95% CI = 0.76 to 0.93). Conclusions: Elderly African-American CAP patients experienced a survival advantage (i.e., lower 30-day mortality) in the ICU compared to Caucasians and shorter hospital LOS in both medical wards and ICUs, after adjusting for numerous baseline differences in patient characteristics. There were no racial differences in receipt of guideline-concordant antibiotic therapies. C1 [Frei, Christopher R.; Mortensen, Eric M.; Copeland, Laurel A.; Attridge, Russell T.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Anzueto, Antonio; Nakashima, Brandy] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Frei, Christopher R.; Attridge, Russell T.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Anzueto, Antonio; Nakashima, Brandy] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Nakashima, Brandy] S Texas Vet Hlth Care Syst, VERDICT Res Program, San Antonio, TX 78229 USA. [Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. RP Mortensen, EM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM mortensene@uthscsa.edu RI Restrepo, Marcos/H-4442-2014; OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 FU National Institute of Nursing Research [R01NR010828] FX The authors would like to thank Christine Oramasionwu and Warunee Srisupha-Olarn for their editorial review of this manuscript. The project described herein was supported by Grant Number R01NR010828 from the National Institute of Nursing Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research or the National Institutes of Health. This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System and The University of Texas at Austin. Dr. Frei is supported by a Loan Repayment award from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, salary support from The University of Texas at Austin College of Pharmacy, and research support from AstraZeneca, Elan, and Ortho-McNeil Janssen. Dr Copeland is funded by Merit Review Entry Program grant MRP-05-145 from the VA Health Services Research and Development program. Dr. Restrepo is supported by a National Institutes of Health Grant KL2 RR025766, salary support by the South Texas Veterans Health Care System Audie L. Murphy Division and The University of Texas Health Science Center at San Antonio. The funding agencies had no role in conducting the study, or role in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. This manuscript was presented, in part, at the American Thoracic Society International Conference, May 15-20, 2009, San Diego, CA. NR 60 TC 10 Z9 10 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD MAY 27 PY 2010 VL 10 AR 143 DI 10.1186/1472-6963-10-143 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 625FB UT WOS:000279878900005 PM 20507628 ER PT J AU Huang, YY Mroz, P Zhiyentayev, T Sharma, SK Balasubramanian, T Ruzie, C Krayer, M Fan, DZ Borbas, KE Yang, EY Kee, HL Kirmaier, C Diers, JR Bocian, DF Holten, D Lindsey, JS Hamblin, MR AF Huang, Ying-Ying Mroz, Pawel Zhiyentayev, Timur Sharma, Sulbha K. Balasubramanian, Thiagarajan Ruzie, Christian Krayer, Michael Fan, Dazhong Borbas, K. Eszter Yang, Eunkyung Kee, Hooi Ling Kirmaier, Christine Diers, James R. Bocian, David F. Holten, Dewey Lindsey, Jonathan S. Hamblin, Michael R. TI In Vitro Photodynamic Therapy and Quantitative Structure-Activity Relationship Studies with Stable Synthetic Near-Infrared-Absorbing Bacteriochlorin Photosensitizers SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID SUBCELLULAR-LOCALIZATION; ELECTRONIC-STRUCTURE; CELL-DEATH; MTT ASSAYS; SUBSTITUENTS; DERIVATIVES; PORPHYRINS; MOLECULES; EFFICACY; CANCER AB Photodynamic therapy (PDT) is a rapidly developing approach to treating cancer that combines harmless visible and near-infrared light with a nontoxic photoactivatable dye, which upon encounter with molecular oxygen generates the reactive oxygen species that are toxic to cancer cells. Bacteriochlorins are tetrapyrrole compounds with two reduced pyrrole rings in the macrocycle. These molecules are characterized by strong absorption features from 700 to > 800 nm, which enable deep penetration into tissue. This report describes testing of 12 new stable synthetic bacteriochlorins for PDT activity. The 12 compounds possess a variety of peripheral substituents and are very potent in killing cancer cells in vitro after illumination. Quantitative structure-activity relationships were derived, and subcellular localization was determined. The most active compounds have both low dark toxicity and high phototoxicity. This combination together with near-infrared absorption gives these bacteriochlorins great potential as photosensitizers for treatment of cancer. C1 [Huang, Ying-Ying; Mroz, Pawel; Zhiyentayev, Timur; Sharma, Sulbha K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Huang, Ying-Ying; Mroz, Pawel; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China. [Zhiyentayev, Timur] MIT, Dept Chem, Cambridge, MA 02139 USA. [Balasubramanian, Thiagarajan] NIRvana Pharmaceut Inc, Raleigh, NC USA. [Ruzie, Christian; Krayer, Michael; Fan, Dazhong; Borbas, K. Eszter; Lindsey, Jonathan S.] N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA. [Yang, Eunkyung; Kee, Hooi Ling; Kirmaier, Christine; Holten, Dewey] Washington Univ, Dept Chem, St Louis, MO 63130 USA. [Diers, James R.; Bocian, David F.] Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St,BA R414, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu RI Lindsey, Jonathan/J-7761-2012; Huang, Ying-ying/G-3153-2011; OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin, Michael/0000-0001-6431-4605 FU NIH [GM 36238, AI050875]; Burroughs-Wellcome; Jimmy V. NCSU Cancer Therapeutics; National Institute of Allergy and Infectious Diseases [R41AI072854]; Genzyme-Partners Translational Research Grant; Division of Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences of the U.S. Department of Energy [DE-FG02-05ER15660, DE-FG02-05ER15661] FX This work was supported by the NIH (Grant GM 36238 to J.S.L. and Grant AI050875 to M.R.H.), by a Burroughs-Wellcome fellowship (to M.K.), and by the Jimmy V. NCSU Cancer Therapeutics Training Program. Y.-Y.H. and T.B. were supported by Grant R41AI072854 from the National Institute of Allergy and Infectious Diseases to NIRvana Pharmaceuticals, Inc. P.M. was partially supported by Genzyme-Partners Translational Research Grant. Characterization of the photophysical and redox properties of the bacteriochlorins described herein were initially motivated by solar-energy studies and supported by grants from the Division of Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences of the U.S. Department of Energy to D.F.B. (Grant DE-FG02-05ER15660) and D.H. (Grant DE-FG02-05ER15661). NR 39 TC 59 Z9 60 U1 1 U2 27 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD MAY 27 PY 2010 VL 53 IS 10 BP 4018 EP 4027 DI 10.1021/jm901908s PG 10 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 597OF UT WOS:000277766900015 PM 20441223 ER PT J AU Baba, Y Huttenhower, C Nosho, K Tanaka, N Shima, K Hazra, A Schernhammer, ES Hunter, DJ Giovannucci, EL Fuchs, CS Ogino, S AF Baba, Yoshifumi Huttenhower, Curtis Nosho, Katsuhiko Tanaka, Noriko Shima, Kaori Hazra, Aditi Schernhammer, Eva S. Hunter, David J. Giovannucci, Edward L. Fuchs, Charles S. Ogino, Shuji TI Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors SO MOLECULAR CANCER LA English DT Article ID POPULATION-BASED SAMPLE; NORMAL COLONIC-MUCOSA; MICROSATELLITE INSTABILITY; DNA METHYLATION; PHENOTYPE CIMP; CHROMOSOMAL INSTABILITY; EPIGENETIC INSTABILITY; L1 RETROTRANSPOSON; PIK3CA MUTATION; HYPOMETHYLATION AB Background: Genome-wide DNA hypomethylation plays a role in genomic instability and carcinogenesis. LINE-1 (L1 retrotransposon) constitutes a substantial portion of the human genome, and LINE-1 methylation correlates with global DNA methylation status. LINE-1 hypomethylation in colon cancer has been strongly associated with poor prognosis. However, whether LINE-1 hypomethylators constitute a distinct cancer subtype remains uncertain. Recent evidence for concordant LINE-1 hypomethylation within synchronous colorectal cancer pairs suggests the presence of a non-stochastic mechanism influencing tumor LINE-1 methylation level. Thus, it is of particular interest to examine whether its wide variation can be attributed to clinical, pathologic or molecular features. Design: Utilizing a database of 869 colorectal cancers in two prospective cohort studies, we constructed multivariate linear and logistic regression models for LINE-1 methylation (quantified by Pyrosequencing). Variables included age, sex, body mass index, family history of colorectal cancer, smoking status, tumor location, stage, grade, mucinous component, signet ring cells, tumor infiltrating lymphocytes, CpG island methylator phenotype (CIMP), microsatellite instability, expression of TP53 (p53), CDKN1A (p21), CTNNB1 (beta-catenin), PTGS2 (cyclooxygenase-2), and FASN, and mutations in KRAS, BRAF, and PIK3CA. Results: Tumoral LINE-1 methylation ranged from 23.1 to 90.3 of 0-100 scale (mean 61.4; median 62.3; standard deviation 9.6), and distributed approximately normally except for extreme hypomethylators [LINE-1 methylation < 40; N = 22 (2.5%), which were far more than what could be expected by normal distribution]. LINE-1 extreme hypomethylators were significantly associated with younger patients (p = 0.0058). Residual plot by multivariate linear regression showed that LINE-1 extreme hypomethylators clustered as one distinct group, separate from the main tumor group. The multivariate linear regression model could explain 8.4% of the total variability of LINE-1 methylation (R-square = 0.084). Multivariate logistic regression models for binary LINE-1 hypomethylation outcomes (cutoffs of 40, 50 and 60) showed at most fair predictive ability (area under receiver operator characteristics curve < 0.63). Conclusions: LINE-1 extreme hypomethylators appear to constitute a previously-unrecognized, distinct subtype of colorectal cancers, which needs to be confirmed by additional studies. Our tumor LINE-1 methylation data indicate enormous epigenomic diversity of individual colorectal cancers. C1 [Baba, Yoshifumi; Nosho, Katsuhiko; Tanaka, Noriko; Shima, Kaori; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Baba, Yoshifumi; Nosho, Katsuhiko; Tanaka, Noriko; Shima, Kaori; Hazra, Aditi; Schernhammer, Eva S.; Hunter, David J.; Giovannucci, Edward L.; Fuchs, Charles S.; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA USA. [Huttenhower, Curtis; Tanaka, Noriko] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Hazra, Aditi; Schernhammer, Eva S.; Hunter, David J.; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Hazra, Aditi; Schernhammer, Eva S.; Hunter, David J.; Giovannucci, Edward L.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. [Schernhammer, Eva S.] Ludwig Boltzmann Inst Appl Canc Res, Vienna, Austria. [Schernhammer, Eva S.] Appl Canc Res Inst Translat Res, Vienna, Austria. [Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Ogino, S (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM shuji_ogino@dfci.harvard.edu OI Huttenhower, Curtis/0000-0002-1110-0096 FU U.S. National Institute of Health [P01 CA87969, P01 CA55075, P50 CA127003, K07 CA122826]; Bennett Family Fund for Targeted Therapies Research; Entertainment Industry Foundation National Colorectal Cancer Research Alliance; Japan Society for the Promotion of Science FX This work was supported by U.S. National Institute of Health [P01 CA87969 (to S. Hankinson), P01 CA55075 (to W. Willett), P50 CA127003 (to C.S.F.), K07 CA122826 (to S.O.)]; the Bennett Family Fund for Targeted Therapies Research; and the Entertainment Industry Foundation National Colorectal Cancer Research Alliance. K.N. was supported by a fellowship grant from the Japan Society for the Promotion of Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of NCI or NIH. Funding agencies did not have any role in the design of the study; the collection, analysis, or interpretation of the data; the decision to submit the manuscript for publication; or the writing of the manuscript. NR 69 TC 79 Z9 81 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-4598 J9 MOL CANCER JI Mol. Cancer PD MAY 27 PY 2010 VL 9 AR 125 DI 10.1186/1476-4598-9-125 PG 17 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 617KE UT WOS:000279278800002 PM 20507599 ER PT J AU Medoff, BD Abbott, GF Louissaint, A AF Medoff, Benjamin D. Abbott, Gerald F. Louissaint, Abner, Jr. TI A Man with a Cough and Pain in the Left Shoulder Langerhans'-cell histiocytosis of bone and lung. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ERDHEIM-CHESTER-DISEASE; DENDRITIC CELLS; PULMONARY; LESIONS; MANIFESTATIONS; CLASSIFICATION; MELIOIDOSIS; INVOLVEMENT; SARCOIDOSIS; TUMORS C1 [Medoff, Benjamin D.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Abbott, Gerald F.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Louissaint, Abner, Jr.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Medoff, Benjamin D.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Abbott, Gerald F.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Louissaint, Abner, Jr.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Medoff, BD (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. NR 36 TC 1 Z9 1 U1 1 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 27 PY 2010 VL 362 IS 21 BP 2013 EP 2022 DI 10.1056/NEJMcpc1002114 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 601JI UT WOS:000278054000011 PM 20505181 ER PT J AU Sloss, CM Wang, F Palladino, MA Cusack, JC AF Sloss, C. M. Wang, F. Palladino, M. A. Cusack, J. C., Jr. TI Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells SO ONCOGENE LA English DT Article DE proteasome inhibition; NPI-0052; EGFR; HB-EGF; pancreatic cancer ID EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; EXPRESSION; BORTEZOMIB; RESISTANCE; P38; CHEMOTHERAPY; CONTRIBUTES; SENSITIVITY; ERLOTINIB AB Resistance to drug treatments underlies the high lethality of pancreatic ductal adenocarcinoma. Along with others, we have recently identified that proteasome inhibition is a promising therapeutic option in this highly refractory disease. The pleiotropic effects of proteasome inhibition include the activation of apoptotic signaling pathways and also antiapoptotic signaling pathways such as EGFR, AKT and the MAP kinases that reduce the apoptotic potential of this class of drug. In this study, we sought to determine the mechanism behind the activation of EGFR in response to proteasome inhibition in pancreatic cancer cells. We found that the second-generation proteasome inhibitor NPI-0052 induced the mRNA transcription of several EGFR family ligands (EGF, HB-EGF and epiregulin), however only increases in HB-EGF were detected at the protein level. Using both pharmacological inhibitors and lentiviral-mediated shRNA knockdown of EGFR ligand expression, we discovered that ligand cleavage by MMP/ADAMs and HB-EGF expression is required for activation of EGFR in response to proteasome inhibition. Furthermore, we discover that induction of HB-EGF is dependent on reactive oxygen species and p38-MAPK signaling but not ERK and that the transcription factor SP-1 is involved in NPI-0052-induced HB-EGF transcription. Together, these results indicate that stress signaling leading to induction of HB-EGF expression and increases in MMP/ADAM-dependent HB-EGF cleavage are responsible for proteasome inhibitor-induced activation of EGFR in pancreatic cancer cells. Oncogene (2010) 29, 3146-3152; doi: 10.1038/onc.2010.52; published online 8 March 2010 C1 [Sloss, C. M.; Wang, F.; Cusack, J. C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Boston, MA 02114 USA. [Palladino, M. A.] Nereus Pharmaceut, San Diego, CA USA. RP Cusack, JC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Yawkey Bldg 7th Floor,55 Fruit St, Boston, MA 02114 USA. EM jcusack@partners.org FU NIH [CA98871] FX This study was supported by NIH Grant no. CA98871 (JC Cusack). NR 30 TC 9 Z9 11 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD MAY 27 PY 2010 VL 29 IS 21 BP 3146 EP 3152 DI 10.1038/onc.2010.52 PG 7 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 602IQ UT WOS:000278133100011 PM 20208558 ER PT J AU Porcheray, F DeVito, J Yeap, BY Xue, LJ Dargon, I Paine, R Girouard, TC Saidman, SL Colvin, RB Wong, WC Zorn, E AF Porcheray, Fabrice DeVito, Julie Yeap, Beow Y. Xue, Lijuan Dargon, Ian Paine, Rosemary Girouard, Timothy C. Saidman, Susan L. Colvin, Robert B. Wong, Waichi Zorn, Emmanuel TI Chronic Humoral Rejection of Human Kidney Allografts Associates With Broad Autoantibody Responses SO TRANSPLANTATION LA English DT Article DE Chronic humoral rejection; Autoantibodies; Human ID RENAL-TRANSPLANT RECIPIENTS; CORONARY-ARTERY DISEASE; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; CARDIAC TRANSPLANTATION; ORGAN-TRANSPLANTATION; ENDOTHELIAL-CELLS; TARGETS; SERA; CAPILLARIES AB Background. Chronic humoral rejection (CHR) is a major complication after kidney transplantation. The cause of CHR is currently unknown. Autoantibodies have often been reported in kidney transplant recipients alongside anti-donor human leukocyte antigen antibodies. Yet, the lack of comprehensive studies has limited our understanding of this autoimmune component in the pathophysiology of CHR. Methods. By using a series of ELISA and immunocytochemistry assays, we assessed the development of autoantibodies in 25 kidney transplant recipients with CHR and 25 patients with stable graft function. We also compared the reactivity of five CHR and five non-CHR patient sera with 8027 recombinant human proteins using protein microarrays. Results. We observed that a majority of CHR patients, but not non-CHR control patients, had developed antibody responses to one or several autoantigens at the time of rejection. Protein microarray assays revealed a burst of autoimmunity at the time of CHR. Remarkably, microarray analysis showed minimal overlap between profiles, indicating that each CHR patient had developed autoantibodies to a unique set of antigenic targets. Conclusion. The breadth of autoantibody responses, together with the absence of consensual targets, suggests that these antibody responses result from systemic B-cell deregulation. C1 [Porcheray, Fabrice; DeVito, Julie; Xue, Lijuan; Dargon, Ian; Paine, Rosemary; Zorn, Emmanuel] Harvard Univ, Sch Med, Dept Surg, Transplantat Biol Res Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Yeap, Beow Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA USA. [Xue, Lijuan] Jilin Univ, Hosp 1, Urol Dept 2, Changchun 130023, Jilin, Peoples R China. [Girouard, Timothy C.; Saidman, Susan L.; Colvin, Robert B.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Wong, Waichi] Harvard Univ, Sch Med, Dept Med, Renal Unit,Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Zorn, E (reprint author), MGH E, Transplantat Biol Res Ctr, Bldg 149-5102,13th St, Charlestown, MA 02129 USA. EM emmanuel.zorn@tbrc.mgh.harvard.edu RI porcheray, fabrice/B-9505-2012 FU Fahd and Nadia Alireza's Research Fund FX This work was supported by the Fahd and Nadia Alireza's Research Fund. NR 36 TC 32 Z9 34 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD MAY 27 PY 2010 VL 89 IS 10 BP 1239 EP 1246 DI 10.1097/TP.0b013e3181d72091 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 605HZ UT WOS:000278339900010 PM 20445487 ER PT J AU Hamm, JP Dyckman, KA Ethridge, LE McDowell, JE Clementz, BA AF Hamm, Jordan P. Dyckman, Kara A. Ethridge, Lauren E. McDowell, Jennifer E. Clementz, Brett A. TI Preparatory Activations across a Distributed Cortical Network Determine Production of Express Saccades in Humans SO JOURNAL OF NEUROSCIENCE LA English DT Article ID VISUALLY GUIDED SACCADES; FRONTAL EYE FIELD; SUPERIOR COLLICULUS; REACTION-TIMES; ATTENTION; EEG; MONKEY; BRAIN; OSCILLATIONS; MOVEMENTS AB Reaction time variability across trials to identical stimuli may arise from both ongoing and transient neural processes occurring before trial onset. These processes were examined with dense-array EEG as humans completed saccades in a "gap" paradigm known to elicit bimodal variability in response times, including separate populations of "express" and regular reaction time saccades. Results indicated that express reaction time trials could be differentiated from regular reaction time trials by (1) pretrial phase synchrony of occipital cortex oscillations in the 8-9 Hz (low alpha) frequency range (lower phase synchrony preceding express trials), (2) subsequent mid-and late-gap period cortical activities across a distributed occipital-parietal network (stronger activations preceding express trials), and (3) posttarget parietal activations locked to response generation (weaker preceding express trials). A post hoc path analysis suggested that the observed cortical activations leading to express saccades are best understood as an interdependent chain of events that affect express saccade production. These results highlight the importance of a distributed posterior cortical network, particularly in right hemisphere, that prepares the saccade system for rapid responding. C1 [Hamm, Jordan P.; Ethridge, Lauren E.; McDowell, Jennifer E.; Clementz, Brett A.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA. [Hamm, Jordan P.; Ethridge, Lauren E.; McDowell, Jennifer E.; Clementz, Brett A.] Univ Georgia, Dept Neurosci, BioImaging Res Ctr, Athens, GA 30602 USA. [Dyckman, Kara A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02129 USA. RP Clementz, BA (reprint author), Univ Georgia, Dept Psychol, Psychol Bldg,Baldwin St, Athens, GA 30602 USA. EM clementz@uga.edu OI Hamm, Jordan/0000-0002-9868-6121; Ethridge, Lauren/0000-0003-0601-6911 FU National Institutes of Health [MH076998, MH082514] FX This work was supported by National Institutes of Health Grants MH076998 and MH082514. We thank Noah Duncan and Emily Leonard Parks for their help with data collection. NR 58 TC 22 Z9 22 U1 0 U2 3 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAY 26 PY 2010 VL 30 IS 21 BP 7350 EP 7357 DI 10.1523/JNEUROSCI.0785-10.2010 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 601XZ UT WOS:000278102600024 PM 20505102 ER PT J AU Brown, TI Ross, RS Keller, JB Hasselmo, ME Stern, CE AF Brown, Thackery I. Ross, Robert S. Keller, Joseph B. Hasselmo, Michael E. Stern, Chantal E. TI Which Way Was I Going? Contextual Retrieval Supports the Disambiguation of Well Learned Overlapping Navigational Routes SO JOURNAL OF NEUROSCIENCE LA English DT Article ID MEDIAL TEMPORAL-LOBE; BILATERAL HIPPOCAMPAL-LESIONS; ORBITOFRONTAL CORTEX; PREFRONTAL CORTICES; SPATIAL CONTEXT; EPISODIC MEMORY; WORKING-MEMORY; SEQUENCES; PARAHIPPOCAMPAL; CONNECTIONS AB Groundbreaking research in animals has demonstrated that the hippocampus contains neurons that distinguish between overlapping navigational trajectories. These hippocampal neurons respond selectively to the context of specific episodes despite interference from overlapping memory representations. The present study used functional magnetic resonance imaging in humans to examine the role of the hippocampus and related structures when participants need to retrieve contextual information to navigate well learned spatial sequences that share common elements. Participants were trained outside the scanner to navigate through 12 virtual mazes from a ground-level first-person perspective. Six of the 12 mazes shared overlapping components. Overlapping mazes began and ended at distinct locations, but converged in the middle to share some hallways with another maze. Non-overlapping mazes did not share any hallways with any other maze. Successful navigation through the overlapping hallways required the retrieval of contextual information relevant to the current navigational episode. Results revealed greater activation during the successful navigation of the overlapping mazes compared with the non-overlapping mazes in regions typically associated with spatial and episodic memory, including the hippocampus, parahippocampal cortex, and orbitofrontal cortex. When combined with previous research, the current findings suggest that an anatomically integrated system including the hippocampus, parahippocampal cortex, and orbitofrontal cortex is critical for the contextually dependent retrieval of well learned overlapping navigational routes. C1 [Brown, Thackery I.; Ross, Robert S.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Brown, Thackery I.; Ross, Robert S.; Keller, Joseph B.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Silvio O Conte Ctr Memory & Brain, Boston, MA 02215 USA. [Brown, Thackery I.; Keller, Joseph B.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Ctr Excellence Learning Educ Sci & Technol, Boston, MA 02215 USA. [Brown, Thackery I.; Ross, Robert S.; Stern, Chantal E.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Stern, CE (reprint author), Boston Univ, Ctr Memory & Brain, 2 Cummington St, Boston, MA 02215 USA. EM chantal@bu.edu OI Ross, Robert/0000-0002-3987-881X; Hasselmo, Michael/0000-0002-9925-6377 FU Silvio O. Conte Center National Institutes of Health [P50 MH071702]; Center of Excellence for Learning in Education, Science and Technology National Science Foundation Science of Learning Center [NSF SBE-0354378]; National Center for Research Resources [P41RR14075] FX This work was supported by the Silvio O. Conte Center National Institutes of Health Grant P50 MH071702; Center of Excellence for Learning in Education, Science and Technology National Science Foundation Science of Learning Center Grant NSF SBE-0354378; and National Center for Research Resources Grant P41RR14075. Research was conducted at the Cognitive Neuroimaging Laboratory, Center for Memory and Brain, Boston University (Boston, MA), and the Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School (Charlestown, MA). We thank R. Newmark for his technical assistance during data collection. NR 56 TC 57 Z9 57 U1 1 U2 10 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAY 26 PY 2010 VL 30 IS 21 BP 7414 EP 7422 DI 10.1523/JNEUROSCI.6021-09.2010 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 601XZ UT WOS:000278102600030 PM 20505108 ER PT J AU Kim, BW Kennedy, DN Lehar, J Lee, MJ Blood, AJ Lee, S Perlis, RH Smoller, JW Morris, R Fava, M Breiter, HC AF Kim, Byoung Woo Kennedy, David N. Lehar, Joseph Lee, Myung Joo Blood, Anne J. Lee, Sang Perlis, Roy H. Smoller, Jordan W. Morris, Robert Fava, Maurizio Breiter, Hans C. CA Phenotype Genotype Project Addicti TI Recurrent, Robust and Scalable Patterns Underlie Human Approach and Avoidance SO PLOS ONE LA English DT Article ID OPPONENT-PROCESS THEORY; MEDIAL FRONTAL-CORTEX; DECISION-MAKING; PROSPECT-THEORY; NEURAL SYSTEMS; REWARD VALUE; INFORMATION-THEORY; EXPECTED VALUE; POWER FUNCTION; HUMAN BRAIN AB Background: Approach and avoidance behavior provide a means for assessing the rewarding or aversive value of stimuli, and can be quantified by a keypress procedure whereby subjects work to increase (approach), decrease (avoid), or do nothing about time of exposure to a rewarding/aversive stimulus. To investigate whether approach/avoidance behavior might be governed by quantitative principles that meet engineering criteria for lawfulness and that encode known features of reward/aversion function, we evaluated whether keypress responses toward pictures with potential motivational value produced any regular patterns, such as a trade-off between approach and avoidance, or recurrent lawful patterns as observed with prospect theory. Methodology/Principal Findings: Three sets of experiments employed this task with beautiful face images, a standardized set of affective photographs, and pictures of food during controlled states of hunger and satiety. An iterative modeling approach to data identified multiple law-like patterns, based on variables grounded in the individual. These patterns were consistent across stimulus types, robust to noise, describable by a simple power law, and scalable between individuals and groups. Patterns included: (i) a preference trade-off counterbalancing approach and avoidance, (ii) a value function linking preference intensity to uncertainty about preference, and (iii) a saturation function linking preference intensity to its standard deviation, thereby setting limits to both. Conclusions/Significance: These law-like patterns were compatible with critical features of prospect theory, the matching law, and alliesthesia. Furthermore, they appeared consistent with both mean-variance and expected utility approaches to the assessment of risk. Ordering of responses across categories of stimuli demonstrated three properties thought to be relevant for preference-based choice, suggesting these patterns might be grouped together as a relative preference theory. Since variables in these patterns have been associated with reward circuitry structure and function, they may provide a method for quantitative phenotyping of normative and pathological function (e.g., psychiatric illness). C1 [Kim, Byoung Woo; Lee, Myung Joo; Blood, Anne J.; Lee, Sang; Morris, Robert; Breiter, Hans C.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, MENC, Boston, MA 02114 USA. [Kim, Byoung Woo; Kennedy, David N.; Lee, Myung Joo; Blood, Anne J.; Lee, Sang; Perlis, Roy H.; Smoller, Jordan W.; Morris, Robert; Fava, Maurizio; Breiter, Hans C.] Harvard Univ, Sch Med, Boston, MA USA. [Kim, Byoung Woo; Lee, Myung Joo; Blood, Anne J.; Lee, Sang; Breiter, Hans C.] Massachusetts Gen Hosp, Dept Psychiat, Lab Neuroimaging & Genet, Boston, MA 02114 USA. [Kennedy, David N.] Massachusetts Gen Hosp, Dept Neurol, Ctr Morphometr Anal, Boston, MA 02114 USA. [Lehar, Joseph] Boston Univ, Dept Bioinformat, Boston, MA 02215 USA. [Blood, Anne J.; Breiter, Hans C.] Massachusetts Gen Hosp, Dept Psychiat, Mood & Motor Control Lab, Boston, MA 02114 USA. [Perlis, Roy H.; Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin, Boston, MA 02114 USA. [Perlis, Roy H.; Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Res Program, Boston, MA 02114 USA. [Perlis, Roy H.; Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. RP Kim, BW (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, MENC, Boston, MA 02114 USA. EM hbreiter@partners.org RI Kennedy, David/H-3627-2012; OI Lauwereyns, Jan/0000-0003-0551-2550 FU National Institute on Drug Abuse [14118, 026002, 026104]; Office of National Drug Control Policy - Counterdrug Technology Assessment Center, Washington, D.C.; MGH Department of Radiology; National Center for Research Resources [P41RR14075]; National Institute of Neurological Disorders and Stroke [34189, 052368]; [DABK39-03-0098]; [DABK39-03-C-0098] FX This work was supported by grants to HCB (#14118, 026002, 026104) from the National Institute on Drug Abuse, and grants (DABK39-03-0098 & DABK39-03-C-0098; The MGH Phenotype Genotype Project in Addiction and Mood Disorder) from the Office of National Drug Control Policy - Counterdrug Technology Assessment Center, Washington, D.C. Further support, in part, was provided to HCB by the MGH Department of Radiology, and the National Center for Research Resources (P41RR14075). Other support was provided to DNK by the National Institute of Neurological Disorders and Stroke (#34189), and to SJB by the National Institute of Neurological Disorders and Stroke (#052368). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 151 TC 7 Z9 7 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 26 PY 2010 VL 5 IS 5 AR e10613 DI 10.1371/journal.pone.0010613 PG 25 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 603PW UT WOS:000278221500002 PM 20532247 ER PT J AU Lewis, GD Farrell, L Wood, MJ Martinovic, M Arany, Z Rowe, GC Souza, A Cheng, S McCabe, EL Yang, E Shi, X Deo, R Roth, FP Asnani, A Rhee, EP Systrom, DM Semigran, MJ Vasan, RS Carr, SA Wang, TJ Sabatine, MS Clish, CB Gerszten, RE AF Lewis, Gregory D. Farrell, Laurie Wood, Malissa J. Martinovic, Maryann Arany, Zoltan Rowe, Glenn C. Souza, Amanda Cheng, Susan McCabe, Elizabeth L. Yang, Elaine Shi, Xu Deo, Rahul Roth, Frederick P. Asnani, Aarti Rhee, Eugene P. Systrom, David M. Semigran, Marc J. Vasan, Ramachandran S. Carr, Steven A. Wang, Thomas J. Sabatine, Marc S. Clish, Clary B. Gerszten, Robert E. TI Metabolic Signatures of Exercise in Human Plasma SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID STRENUOUS PHYSICAL-EXERCISE; ISCHEMIC-HEART-DISEASE; RAT SKELETAL-MUSCLE; CARDIOVASCULAR-DISEASE; ADIPOSE-TISSUE; RESISTANCE EXERCISE; VITAMIN-E; ACID; MORTALITY; LIPOLYSIS AB Exercise provides numerous salutary effects, but our understanding of how these occur is limited. To gain a clearer picture of exercise-induced metabolic responses, we have developed comprehensive plasma metabolite signatures by using mass spectrometry to measure >200 metabolites before and after exercise. We identified plasma indicators of glycogenolysis (glucose-6-phosphate), tricarboxylic acid cycle span 2 expansion (succinate, malate, and fumarate), and lipolysis (glycerol), as well as modulators of insulin sensitivity (niacinamide) and fatty acid oxidation (pantothenic acid). Metabolites that were highly correlated with fitness parameters were found in subjects undergoing acute exercise testing and marathon running and in 302 subjects from a longitudinal cohort study. Exercise-induced increases in glycerol were strongly related to fitness levels in normal individuals and were attenuated in subjects with myocardial ischemia. A combination of metabolites that increased in plasma in response to exercise (glycerol, niacinamide, glucose-6-phosphate, pantothenate, and succinate) up-regulated the expression of nur77, a transcriptional regulator of glucose utilization and lipid metabolism genes in skeletal muscle in vitro. Plasma metabolic profiles obtained during exercise provide signatures of exercise performance and cardiovascular disease susceptibility, in addition to highlighting molecular pathways that may modulate the salutary effects of exercise. C1 [Lewis, Gregory D.; Farrell, Laurie; Wood, Malissa J.; Martinovic, Maryann; Cheng, Susan; Deo, Rahul; Asnani, Aarti; Semigran, Marc J.; Wang, Thomas J.; Gerszten, Robert E.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Lewis, Gregory D.; Farrell, Laurie; Wood, Malissa J.; Martinovic, Maryann; Cheng, Susan; Deo, Rahul; Asnani, Aarti; Semigran, Marc J.; Wang, Thomas J.; Gerszten, Robert E.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Lewis, Gregory D.; Asnani, Aarti; Gerszten, Robert E.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. [Lewis, Gregory D.; Sabatine, Marc S.; Gerszten, Robert E.] Harvard Univ, Sch Med, Donald W Reynolds Cardiovasc Clin Res Ctr Atheros, Boston, MA 02115 USA. [Lewis, Gregory D.; Souza, Amanda; Yang, Elaine; Shi, Xu; Rhee, Eugene P.; Carr, Steven A.; Clish, Clary B.; Gerszten, Robert E.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. [Arany, Zoltan; Rowe, Glenn C.] Beth Israel Deaconess Med Ctr, Cardiovasc Inst, Boston, MA 02215 USA. [Arany, Zoltan; Rowe, Glenn C.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Cheng, Susan; McCabe, Elizabeth L.; Vasan, Ramachandran S.; Wang, Thomas J.] Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA. [Cheng, Susan; Sabatine, Marc S.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Deo, Rahul; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Rhee, Eugene P.] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. [Systrom, David M.] Massachusetts Gen Hosp, Div Pulm & Crit Care, Boston, MA 02114 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Epidemiol Sect, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Sect Prevent Med, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA. RP Lewis, GD (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. EM glewis@partners.org; rgerszten@partners.org RI Roth, Frederick/H-6308-2011; OI Systrom, David/0000-0002-9610-6330; Ramachandran, Vasan/0000-0001-7357-5970; Roth, Frederick/0000-0002-6628-649X; Rowe, Glenn/0000-0002-8195-9605 FU NIH [K23HL091106, R01 HL072872, U01HL083141, R01DK081572]; Donald W. Reynolds Foundation; Fondation Leducq; American Heart Association Fellow-to-Faculty Award; Established Investigator Award; National Heart, Lung and Blood Institute [N01-HC-25195]; Sarnoff Cardiovascular Research Foundation; NIH-National Human Genome Research Institute [HG003224, HG0017115, NS054052, HG004233]; Keck Foundation FX Funding: NIH grants K23HL091106 (G. D. L.), R01 HL072872 (R. E. G. and M. S. S.), U01HL083141 (R. E. G., M. S. S., and F. P. R.), and R01DK081572 (R. E. G.); Donald W. Reynolds Foundation (R. E. G. and M. S. S.); Fondation Leducq (R. E. G.); American Heart Association Fellow-to-Faculty Award (G. D. L.); and Established Investigator Award (R. E. G.). This work was also supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195). A. A. was supported by a predoctoral award from the Sarnoff Cardiovascular Research Foundation. F. P. R. was also supported in part by NIH-National Human Genome Research Institute grants HG003224, HG0017115, NS054052, and HG004233 and by the Keck Foundation. NR 62 TC 97 Z9 101 U1 4 U2 40 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD MAY 26 PY 2010 VL 2 IS 33 AR 33ra37 DI 10.1126/scitranslmed.3001006 PG 13 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 601SV UT WOS:000278085300003 PM 20505214 ER PT J AU Rasmussen, RA Lakhashe, SK Ruprecht, RM AF Rasmussen, Robert A. Lakhashe, Samir K. Ruprecht, Ruth M. TI Bimodal AIDS vaccine approach: Induction of cellular as well as humoral immunity can protect from systemic infection SO VACCINE LA English DT Article DE HIV clade C; Vaccine; R5 SHIV; Animal model; Protein immunization; Multimeric gp160 ID HUMAN-IMMUNODEFICIENCY-VIRUS; CLADE-C ENV; NEUTRALIZING ANTIBODIES; HIV-1 INFECTION; CORE ANTIGENS; ENVELOPE; MACAQUES; TYPE-1; IMMUNOGENICITY; IMMUNIZATION AB HIV clade C ( HIV-C) strains comprise similar to 56% of all HIV infections worldwide, and AIDS vaccines intended for global use must protect against this subtype. Our vaccine strategy has been to induce balanced antiviral immunity consisting of both neutralizing antibody and cell-mediated immune responses, an approach we tested in primates. As reported earlier, after isolating recently transmitted HIV-C strains from Zambian infants, we used env from one such virus. HIV1084i. to generate a multimeric gp160 immunogen. From another virus, isolated from a different child of the same mother-infant cohort, we cloned env to generate a recombinant simian-human immunodeficiency virus (SHIV), which was adapted to rhesus monkeys to yield SHIV-1157ip. Infant macaques were immunized with recombinant viral proteins, including multimeric HIV-C Env 1084i. To test whether cross-protection could be achieved, we mismatched HIV-C Env immunogens and challenge virus cite. All vaccinated and control monkeys were exposed orally to low-dose SHIV-1157ip. Animals with no or only transient infection were rechallenged intrarectally with a high dose of R5 SHIV-1157ipd3N4, a "late", animal-evolved variant of SHIV-1157ip. Compared to controls, the vaccinees had significantly lower peak viral RNA loads, and one vaccinee remained completely virus-free, even in lymphoid tissues. Data from our novel heterologous mucosal challenge model and our protein-only immunogens imply that significant protection against heterologous viruses circulating in the local community may be achievable with a strategy that seeks to simultaneously induce cellular immunity as well as neutralizing antibody responses. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Rasmussen, Robert A.; Lakhashe, Samir K.; Ruprecht, Ruth M.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Rasmussen, Robert A.; Lakhashe, Samir K.; Ruprecht, Ruth M.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Ruprecht, RM (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM ruth_ruprecht@dfci.harvard.edu RI Lakhashe, Samir/F-1150-2014 FU NCRR NIH HHS [RR-00165, P51 RR000165]; NIAID NIH HHS [P01 AI048240, P01 AI48240] NR 28 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 26 PY 2010 VL 28 SU 2 BP B25 EP B31 DI 10.1016/j.vaccine.2009.10.131 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 613ZI UT WOS:000279023600006 PM 20510739 ER PT J AU Kveiborg, B Hermann, TS Major-Pedersen, A Christiansen, B Rask-Madsen, C Raunso, J Kober, L Torp-Pedersen, C Dominguez, H AF Kveiborg, Britt Hermann, Thomas S. Major-Pedersen, Atheline Christiansen, Buris Rask-Madsen, Christian Raunso, Jakob Kober, Lars Torp-Pedersen, Christian Dominguez, Helena TI Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study SO CARDIOVASCULAR DIABETOLOGY LA English DT Article ID CORONARY-ARTERY-DISEASE; CHRONIC HEART-FAILURE; EUROPEAN TRIAL COMET; BETA-BLOCKING-AGENTS; OXIDATIVE STRESS; NITRIC-OXIDE; INTRAVENOUS PROPRANOLOL; HYPERTENSIVE PATIENTS; PLASMA ADIPONECTIN; MELLITUS AB Aim: Studies of beta blockade in patients with type 2 diabetes have shown inferiority of metoprolol treatment compared to carvedilol on indices of insulin resistance. The aim of this study was to examine the effect of metoprolol versus carvedilol on endothelial function and insulin-stimulated endothelial function in patients with type 2 diabetes. Method: 24 patients with type 2 diabetes were randomized to receive either 200 mg metoprolol succinate or 50 mg carvedilol daily. Endothelium-dependent vasodilation was assessed by using venous occlusion plethysmography with increasing doses of intra-arterial infusions of the agonist serotonin. Insulin-stimulated endothelial function was assessed after co-infusion of insulin for sixty minutes. Vaso-reactivity studies were done before and after the two-month treatment period. Results: Insulin-stimulated endothelial function was deteriorated after treatment with metoprolol, the percentage change in forearm blood-flow was 60.19% +/- 17.89 (at the highest serotonin dosages) before treatment and -33.80% +/- 23.38 after treatment (p = 0.007). Treatment with carvedilol did not change insulin-stimulated endothelial function. Endothelium-dependent vasodilation without insulin was not changed in either of the two treatment groups. Conclusion: This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type 2 diabetes. C1 [Kveiborg, Britt; Christiansen, Buris] Naestved Hosp, Dept Med, Naestved, Denmark. [Hermann, Thomas S.; Raunso, Jakob; Torp-Pedersen, Christian] Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark. [Rask-Madsen, Christian] Joslin Diabet Ctr, Boston, MA 02215 USA. [Kober, Lars] Rigshosp, Ctr Heart, Dept Cardiol, DK-2100 Copenhagen, Denmark. [Dominguez, Helena] Herlev Hosp, Dept Cardiol, DK-2730 Herlev, Denmark. [Major-Pedersen, Atheline] Gentofte Univ Hosp, Dept Internal Med, Hellerup, Denmark. RP Kveiborg, B (reprint author), Naestved Hosp, Dept Med, Naestved, Denmark. EM BRIKVE01@geh.regionh.dk RI Torp-Pedersen, Christian/E-5931-2013; OI DOMINGUEZ, HELENA/0000-0002-7089-2636 FU Danish Heart Foundation; Bispebjerg Hospital Research Foundation FX Grant has been provided for Britt Kveiborg from The Danish Heart Foundation and Bispebjerg Hospital Research Foundation. NR 36 TC 13 Z9 15 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2840 J9 CARDIOVASC DIABETOL JI Cardiovasc. Diabetol. PD MAY 25 PY 2010 VL 9 AR 21 DI 10.1186/1475-2840-9-21 PG 11 WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism SC Cardiovascular System & Cardiology; Endocrinology & Metabolism GA 626FF UT WOS:000279950900001 PM 20500877 ER PT J AU Katritsis, D Merchant, FM Mela, T Singh, JP Heist, EK Armoundas, AA AF Katritsis, Demosthenes Merchant, Faisal M. Mela, Theofanie Singh, Jagmeet P. Heist, E. Kevin Armoundas, Antonis A. TI Catheter Ablation of Atrial Fibrillation The Search for Substrate-Driven End Points SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Review DE atrial fibrillation; catheter ablation; substrate modification ID PULMONARY VEIN ISOLATION; DOUBLE-LASSO TECHNIQUE; LONG-TERM; CIRCUMFERENTIAL ABLATION; RADIOFREQUENCY ABLATION; GANGLIONATED PLEXI; SPECTRAL-ANALYSIS; ANATOMIC APPROACH; FOLLOW-UP; ELECTROGRAMS AB Indications for catheter ablation of atrial fibrillation (AF) have expanded to include increasingly complex cases, such as long-standing persistent AF and structural heart disease. Although pulmonary vein isolation remains essential for most ablation procedures, the role of substrate modification has taken on increasing importance. Despite the various ablation strategies available, single-procedure efficacy remains suboptimal among patients with structural heart disease or long-standing persistent AF, where recurrence rates may exceed 50% after a single procedure. These high rates of AF recurrence support the notion that currently available procedural end points are ineffective in identifying which patients are most likely to benefit from substrate modification and defining when that substrate has been sufficiently modified such that additional ablation is unnecessary. In order to improve outcomes, the next generation of procedural end points should seek to define specific properties of the underlying atrial electrical substrate and characterize the impact of catheter ablation on those electrophysiologic properties. The use of substrate-driven end points would be a major step in the process of moving from empiric ablation lesions to a customized ablation strategy based on atrial physiology. In this article, we review current approaches to catheter ablation of AF and discuss specific procedural end points as they pertain to each ablation strategy. We also provide a paradigm for the future development of novel substrate-driven procedural end points. (J Am Coll Cardiol 2010;55:2293-8) (C) 2010 by the American College of Cardiology Foundation C1 [Armoundas, Antonis A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. [Katritsis, Demosthenes] Athens Euroclin, Dept Cardiol, Athens, Greece. [Merchant, Faisal M.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA USA. [Mela, Theofanie; Singh, Jagmeet P.; Heist, E. Kevin] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA USA. RP Armoundas, AA (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA. EM aarmoundas@partners.org FU American Heart Association [0635127N]; Center for Integration of Medicine and Innovative Technology; Deane Institute for Integrative Research in Atrial Fibrillation and Stroke; Cardiovascular Research Society; Johnson Johnson; Medtronic; Boston Scientific; Biotronik; Boston Scientific, Medtronic; Sorin Group; St. Jude Medical FX From the *Department of Cardiology, Athens Euroclinic, Athens, Greece; dagger Cardiology Division and Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, Massachusetts; and the Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts. This work was supported by a Scientist Development Grant (#0635127N) from the American Heart Association and grants from the Center for Integration of Medicine and Innovative Technology, the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke, and the Cardiovascular Research Society. Dr. Katritsis has received research grants from Johnson & Johnson, Medtronic, and Boston Scientific. Dr. Mela has received lecture honoraria from Boston Scientific, Medtronic, St. Jude Medical, and Biotronik. Dr. Singh has received lecture honoraria and research grants from Biotronik, Boston Scientific, Medtronic, Sorin Group, and St. Jude Medical, and has done consulting for sanofi-aventis. Dr. Heist has received research support from and been a speaker for Biotronik, Boston Scientific, Medtronic, and Sorin/ELA and has been a consultant and speaker for and received research support from St. Jude Medical. Drs. Katritsis and Merchant contributed equally to this work. NR 64 TC 19 Z9 22 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 25 PY 2010 VL 55 IS 21 BP 2293 EP 2298 DI 10.1016/j.jacc.2010.03.016 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 598BB UT WOS:000277805800001 PM 20488298 ER PT J AU Ahmadiyeh, N Pomerantz, MM Grisanzio, C Herman, P Jia, L Almendro, V He, HH Brown, M Liu, XS Davis, M Caswell, JL Beckwith, CA Hills, A MacConaill, L Coetzee, GA Regan, MM Freedman, ML AF Ahmadiyeh, Nasim Pomerantz, Mark M. Grisanzio, Chiara Herman, Paula Jia, Li Almendro, Vanessa He, Housheng Hansen Brown, Myles Liu, X. Shirley Davis, Matt Caswell, Jennifer L. Beckwith, Christine A. Hills, Adam MacConaill, Laura Coetzee, Gerhard A. Regan, Meredith M. Freedman, Matthew L. TI 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE chromosome conformation capture; epigenetic; genetics ID GENOME-WIDE ASSOCIATION; COLORECTAL-CANCER; GENE-EXPRESSION; ACTIVE CHROMATIN; CHROMOSOME 8Q24; SUSCEPTIBILITY; ENHANCERS; VARIANT; RS6983267; SCAN AB The 8q24 gene desert contains risk loci for multiple epithelial cancers, including colon, breast, and prostate. Recent evidence suggests these risk loci contain enhancers. In this study, data are presented showing that each risk locus bears epigenetic marks consistent with enhancer elements and forms a long-range chromatin loop with the MYC proto-oncogene located several hundred kilobases telomeric and that these interactions are tissue-specific. We therefore propose that the 8q24 risk loci operate through a common mechanism-as tissue-specific enhancers of MYC. C1 [Ahmadiyeh, Nasim; Pomerantz, Mark M.; Grisanzio, Chiara; Herman, Paula; Almendro, Vanessa; He, Housheng Hansen; Brown, Myles; Liu, X. Shirley; Davis, Matt; Caswell, Jennifer L.; Beckwith, Christine A.; Hills, Adam; MacConaill, Laura; Freedman, Matthew L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [He, Housheng Hansen; Liu, X. Shirley; Regan, Meredith M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Ahmadiyeh, Nasim] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Jia, Li] Washington Univ, Sch Med, Dept Internal Med, Ctr Pharmacogenom, St Louis, MO 63110 USA. [Coetzee, Gerhard A.] Univ So Calif, Norris Canc Ctr, Dept Urol, Los Angeles, CA 90033 USA. [Freedman, Matthew L.] Eli & Edythe L Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. RP Freedman, ML (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM freedman@broadinstitute.org RI He, Housheng/G-9614-2011; Davis, Matt/F-9045-2012; OI Brown, Myles/0000-0002-8213-1658; Caswell-Jin, Jennifer/0000-0002-5711-8355 FU Doris Duke Clinical Scientist Development Award; National Institutes of Health [R01 CA129435]; Mayer Foundation; H.L. Snyder Medical Foundation; Dana-Farber/Harvard Cancer Center Prostate Cancer SPORE (National Cancer Institute) [5P50CA90381]; Emerald Foundation, Inc.; National Cancer Institute [R01 CA 109147, R01 CA 136924, CA089393]; William L. Edwards Prostate Cancer Foundation FX We thank Keluo Yao and Sarah Kehoe from Center for Cancer Genome Discovery, Dana-Farber Cancer Center, for running Sequenom Chips. M. L. F. is a Howard Hughes Medical Institute Physician-Scientist Early Career Awardee and is a recipient of a 2006 Doris Duke Clinical Scientist Development Award. This work was supported by grants from the National Institutes of Health (R01 CA129435 to M. L. F.), the Mayer Foundation (to M. L. F.), the H.L. Snyder Medical Foundation (to M. L. F.), the Dana-Farber/Harvard Cancer Center Prostate Cancer SPORE (National Cancer Institute Grant 5P50CA90381), the Emerald Foundation, Inc. (to M. L. F.), National Cancer Institute R01 CA 109147 and National Cancer Institute R01 CA 136924 (to G. A. C.), and by the Dana-Farber/Harvard SPORE in breast cancer from the National Cancer Institute (CA089393). M. P. is the recipient of the William L. Edwards Prostate Cancer Foundation Young Investigator Award. NR 30 TC 167 Z9 174 U1 1 U2 10 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 25 PY 2010 VL 107 IS 21 BP 9742 EP 9746 DI 10.1073/pnas.0910668107 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 601JP UT WOS:000278054700049 PM 20453196 ER PT J AU Tong, YR Yamaguchi, H Giaime, E Boyle, S Kopan, R Kelleher, RJ Shen, J AF Tong, Youren Yamaguchi, Hiroo Giaime, Emilie Boyle, Scott Kopan, Raphael Kelleher, Raymond J., III Shen, Jie TI Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE Parkinson's disease; knockout; autophagy; ubiquitin-proteasome system; aging ID CAUSES NEURODEGENERATIVE DISEASE; PARKINSONS-DISEASE; NEURONAL TOXICITY; TRANSGENIC MICE; AUTOPHAGY; LRRK2; MUTATIONS; GENE; EXPRESSION; SYSTEM AB Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease. LRRK2is a large protein containing a small GTPase domain and a kinase domain, but its physiological role is unknown. To identify the normal function of LRRK2 in vivo, we generated two independent linesofgerm-line deletion mice. The dopaminergic system of LRRK2(-/-) mice appears normal, and numbers of dopaminergic neurons and levels of striatal dopamine are unchanged. However, LRRK2-/- kidneys, which suffer the greatest loss of LRRK compared with other organs, develop striking accumulation and aggregation of alpha-synuclein and ubiquitinated proteins at 20 months of age. The autophagy-lysosomal pathway is also impaired in the absence of LRRK2, as indicated by accumulation of lipofuscin granules as well as altered levels of LC3-II and p62. Furthermore, loss of LRRK2 dramatically increases apoptotic cell death, inflammatory responses, and oxidative damage. Collectively, our findings show that LRRK2 plays an essential and unexpected role in the regulation of protein homeostasis during aging, and suggest that LRRK2 mutations may cause Parkinson's disease and cell death via impairment of protein degradation pathways, leading to alpha-synuclein accumulation and aggregation over time. C1 [Tong, Youren; Yamaguchi, Hiroo; Giaime, Emilie; Shen, Jie] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis,Dept Neurol,Program Neurosci, Boston, MA 02115 USA. [Boyle, Scott; Kopan, Raphael] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA. [Kelleher, Raymond J., III] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res,Dept Neurol,Program Neurosci, Boston, MA 02115 USA. RP Shen, J (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis,Dept Neurol,Program Neurosci, Boston, MA 02115 USA. EM jshen@rics.bwh.harvard.edu FU National Institute of Diabetes and Digestive and Kidney Diseases FX We thank Huailong Zhao and Lan Wang for technical assistance. This work was supported by grants from the National Institute of Neurological Disorders and Stroke and the Michael J. Fox Foundation (to J.S.) and grants from the National Institute of Diabetes and Digestive and Kidney Diseases (to R.K. and S.B.). NR 38 TC 209 Z9 210 U1 1 U2 20 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 25 PY 2010 VL 107 IS 21 BP 9879 EP 9884 DI 10.1073/pnas.1004676107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 601JP UT WOS:000278054700072 PM 20457918 ER PT J AU Poliseno, L Salmena, L Riccardi, L Fornari, A Song, MS Hobbs, RM Sportoletti, P Varmeh, S Egia, A Fedele, G Rameh, L Loda, M Pandolfi, PP AF Poliseno, Laura Salmena, Leonardo Riccardi, Luisa Fornari, Alessandro Song, Min Sup Hobbs, Robin M. Sportoletti, Paolo Varmeh, Shorheh Egia, Ainara Fedele, Giuseppe Rameh, Lucia Loda, Massimo Pandolfi, Pier Paolo TI Identification of the miR-106b similar to 25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation (vol 3, artn ra29, 2010) SO SCIENCE SIGNALING LA English DT Correction ID MAINTENANCE PROTEIN MCM7; PROSTATE-CANCER; CELLULAR-TRANSFORMATION; TUMOR SUPPRESSION; MYC PROTEIN; EXPRESSION; NEUROBLASTOMA; TUMORIGENESIS; SPECIFICITY; ACTIVATION AB PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor suppressor that antagonizes signaling through the phosphatidylinositol-3-kinase-Akt pathway. We have demonstrated that subtle decreases in PTEN abundance can have critical consequences for tumorigenesis. Here, we used a computational approach to identify miR-22, miR-25, and miR-302 as three PTEN-targeting microRNA (miRNA) families found within nine genomic loci. We showed that miR-22 and the miR-106b similar to 25 cluster are aberrantly overexpressed in human prostate cancer, correlate with abundance of the miRNA processing enzyme DICER, and potentiate cellular transformation both in vitro and in vivo. We demonstrated that the intronic miR-106b similar to 25 cluster cooperates with its host gene MCM7 in cellular transformation both in vitro and in vivo, so that the concomitant overexpression of MCM7 and the miRNA cluster triggers prostatic intraepithelial neoplasia in transgenic mice. Therefore, the MCM7 gene locus delivers two simultaneous oncogenic insults when amplified or overexpressed in human cancer. Thus, we have uncovered a proto-oncogenic miRNA-dependent network for PTEN regulation and defined the MCM7 locus as a critical factor in initiating prostate tumorigenesis. C1 [Poliseno, Laura; Salmena, Leonardo; Riccardi, Luisa; Song, Min Sup; Hobbs, Robin M.; Sportoletti, Paolo; Varmeh, Shorheh; Egia, Ainara; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA. [Fornari, Alessandro; Fedele, Giuseppe; Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Fornari, Alessandro] Univ Turin, Dept Biomed Sci & Human Oncol, Molinette Hosp, I-10126 Turin, Italy. [Fedele, Giuseppe; Loda, Massimo] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA. [Rameh, Lucia] Boston Biomed Res Inst, Watertown, MA 02472 USA. RP Pandolfi, PP (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA. EM ppandolf@bidmc.harvard.edu OI Poliseno, Laura/0000-0001-6557-955X NR 1 TC 1 Z9 1 U1 3 U2 5 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1945-0877 EI 1937-9145 J9 SCI SIGNAL JI Sci. Signal. PD MAY 25 PY 2010 VL 3 IS 123 AR er6 DI 10.1126/scisignal.3123er6 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 601BC UT WOS:000278032000006 ER PT J AU Han, LH Wu, SM Condit, JC Kemp, NJ Milner, TE Feldman, MD Chen, SC AF Han, Li-Hsin Wu, Shaomin Condit, J. Christopher Kemp, Nate J. Milner, Thomas E. Feldman, Marc D. Chen, Shaochen TI Light-powered micromotor driven by geometry-assisted, asymmetric photon-heating and subsequent gas convection SO APPLIED PHYSICS LETTERS LA English DT Article DE convection; gold; micromotors; molecular dynamics method; nanoparticles; nanoporous materials; polymers AB We report on the design, fabrication, and analysis of a light-driven micromotor. The micromotor was created from a nanoporous polymer with close-packed gold nanoparticles which generate heat by absorbing light. The blades of the micromotor were curved, forming convex and concave sides. Upon lateral irradiation, by geometric effect the convex side transfers more photon-generated heat to the surrounding gas molecules, causing a convective motion of gas and leading to the rotation of the micromotor. The light-driven motions of gas molecules were analyzed using molecular dynamics modeling. (C) 2010 American Institute of Physics. [doi:10.1063/1.3431741] C1 [Han, Li-Hsin; Wu, Shaomin; Chen, Shaochen] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Condit, J. Christopher; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Kemp, Nate J.] Volcano Corp, Billerica, MA 01821 USA. [Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Feldman, Marc D.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Chen, SC (reprint author), Univ Texas Austin, Dept Mech Engn, C2200, Austin, TX 78712 USA. EM scchen@mail.utexas.edu RI Han, Li-Hsin/C-5440-2015 OI Han, Li-Hsin/0000-0002-0135-2863 FU Office of Naval Research [N00014-07-1-0609]; National Science Foundation [CMMI 0555275] FX This work is supported by grants from the Office of Naval Research N00014-07-1-0609 and the National Science Foundation CMMI 0555275 to S.C. We appreciate the donation of the DMD tool kit from Texas Instruments. We also thank the computer support from Intel's High Education Program. NR 20 TC 7 Z9 7 U1 2 U2 11 PU AMER INST PHYSICS PI MELVILLE PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1, MELVILLE, NY 11747-4501 USA SN 0003-6951 J9 APPL PHYS LETT JI Appl. Phys. Lett. PD MAY 24 PY 2010 VL 96 IS 21 AR 213509 DI 10.1063/1.3431741 PG 3 WC Physics, Applied SC Physics GA 603BP UT WOS:000278183200085 ER PT J AU Ho, PM Zeng, C Tavel, HM Selby, JV O'Connor, PJ Margolis, KL Magid, DJ AF Ho, P. Michael Zeng, Chan Tavel, Heather M. Selby, Joe V. O'Connor, Patrick J. Margolis, Karen L. Magid, David J. TI Trends in First-line Therapy for Hypertension in the Cardiovascular Research Network Hypertension Registry, 2002-2007 SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID JOINT NATIONAL COMMITTEE; LIPID-LOWERING TREATMENT; HIGH BLOOD-PRESSURE; 7TH REPORT; PREVENTION C1 [Ho, P. Michael; Zeng, Chan; Tavel, Heather M.; Magid, David J.] Inst Hlth Res, Denver, CO USA. [Ho, P. Michael] Vet Affairs Med Ctr, Denver Dept, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Dept Med, Denver, CO USA. [Magid, David J.] Univ Colorado, Dept Emergency Med, Denver, CO 80202 USA. [Selby, Joe V.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [O'Connor, Patrick J.; Margolis, Karen L.] HealthPartners Res Fdn, Minneapolis, MN USA. RP Ho, PM (reprint author), Denver VA Med Ctr, 1055 Clermont St 111B, Denver, CO 80220 USA. FU NHLBI NIH HHS [U19HL091179] NR 6 TC 10 Z9 10 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 24 PY 2010 VL 170 IS 10 BP 912 EP 913 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 599LO UT WOS:000277914400012 PM 20498420 ER PT J AU Hellman, A Chess, A AF Hellman, Asaf Chess, Andrew TI Extensive sequence-influenced DNA methylation polymorphism in the human genome SO EPIGENETICS & CHROMATIN LA English DT Article ID INHERITANCE; LOCUS; GENE AB Background: Epigenetic polymorphisms are a potential source of human diversity, but their frequency and relationship to genetic polymorphisms are unclear. DNA methylation, an epigenetic mark that is a covalent modification of the DNA itself, plays an important role in the regulation of gene expression. Most studies of DNA methylation in mammalian cells have focused on CpG methylation present in CpG islands (areas of concentrated CpGs often found near promoters), but there are also interesting patterns of CpG methylation found outside of CpG islands. Results: We compared DNA methylation patterns on both alleles between many pairs (and larger groups) of related and unrelated individuals. Direct observation and simulation experiments revealed that around 10% of common single nucleotide polymorphisms (SNPs) reside in regions with differences in the propensity for local DNA methylation between the two alleles. We further showed that for the most common form of SNP, a polymorphism at a CpG dinucleotide, the presence of the CpG at the SNP positively affected local DNA methylation in cis. Conclusions: Taken together with the known effect of DNA methylation on mutation rate, our results suggest an interesting interdependence between genetics and epigenetics underlying diversity in the human genome. C1 [Hellman, Asaf] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel. [Chess, Andrew] Harvard Univ, Ctr Human Genet Res, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Chess, Andrew] Harvard Univ, Dept Med, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Chess, Andrew] Broad Inst, Cambridge, MA USA. RP Hellman, A (reprint author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel. EM asafh@ekmd.huji.ac.il; chess@chgr.mgh.harvard.edu FU National Institutes of Health; Simons Foundation; Israel Science Foundation FX We are grateful to H. Cedar, M. Daly, J. Hutchinson, L. Merriam, T. Mitchison, V. Mootha and R. Mostoslavsky for discussions and comments, and to A. Kirby for discussions and analyses of polymorphisms. We thank J. Smoller for DNA samples. This work was supported by the National Institutes of Health (to A.C.), the Simons Foundation (to A.C.) and from the Israel Science Foundation (to A.H). NR 14 TC 47 Z9 47 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-8935 J9 EPIGENET CHROMATIN JI Epigenetics Chromatin PD MAY 24 PY 2010 VL 3 AR 11 DI 10.1186/1756-8935-3-11 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 674UH UT WOS:000283775100001 PM 20497546 ER PT J AU Razansky, RN Rosenthal, A Mallas, G Razansky, D Jaffer, FA Ntziachristos, V AF Razansky, R. Nika Rosenthal, Amir Mallas, George Razansky, Daniel Jaffer, Farouc A. Ntziachristos, Vasilis TI Near-infrared fluorescence catheter system for two-dimensional intravascular imaging in vivo SO OPTICS EXPRESS LA English DT Article ID INDOCYANINE GREEN; VULNERABLE PLAQUE; PLASMA-VOLUME; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR-DISEASE; INFLAMMATION; TOMOGRAPHY; MODALITIES; MODEL; RISK AB Detection of high-risk coronary arterial plaques prior to rupture remains an unmet clinical challenge, in part due to the stringent resolution and sensitivity requirements for in vivo human coronary arterial imaging. To address this need, we have developed a near-infrared (NIR) fluorescence imaging catheter system for intra-vascular molecular imaging of atherosclerosis in coronary artery-sized vessels, capable of resolving two-dimensional fluorescence activity in hollow organs, such as blood vessels. Based on a rotational fiber design, the catheter system illuminates and detects perpendicular to the rotational axis, while an automated pullback mechanism enables visualization along blood vessels with a scan speed of up to 1.5 mm/sec. We demonstrate the previously undocumented capacity to produce intravascular NIR fluorescence images of hollow organs in vivo and showcase the performance metrics of the system developed using blood vessel mimicking phantoms. This imaging approach is geared toward in vivo molecular imaging of atherosclerotic biomarkers and is engineered to allow seamless integration into the cardiac catheterization laboratory. (C) 2010 Optical Society of America C1 [Razansky, R. Nika; Rosenthal, Amir; Razansky, Daniel; Ntziachristos, Vasilis] Tech Univ Munich, Chair Biol Imaging, Munich, Germany. [Razansky, R. Nika; Rosenthal, Amir; Razansky, Daniel; Ntziachristos, Vasilis] Helmholtz Zentrum Munchen, Inst Biol & Med Imaging, Munich, Germany. [Rosenthal, Amir; Mallas, George; Jaffer, Farouc A.] Harvard Univ, Sch Med, Boston, MA USA. [Rosenthal, Amir; Mallas, George; Jaffer, Farouc A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Rosenthal, Amir; Mallas, George; Jaffer, Farouc A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Razansky, RN (reprint author), Tech Univ Munich, Chair Biol Imaging, Munich, Germany. EM 1nika.razansky@tum.de RI Rosenthal, Amir/C-8650-2014; OI Jaffer, Farouc/0000-0001-7980-384X; Razansky, Daniel/0000-0001-8676-0964 FU MOBITUM project; German Federal Ministry of Education and Research (BMBF) FX This work was funded in part by the MOBITUM project, the German Federal Ministry of Education and Research (BMBF). The authors acknowledge the great help of Ion Botnar MD, Adam Mauskapf BS, and J. Luis Guerrero BS with in vivo experimentation and the help of Alexander Lang with the technical support. NR 25 TC 16 Z9 16 U1 0 U2 4 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 1094-4087 J9 OPT EXPRESS JI Opt. Express PD MAY 24 PY 2010 VL 18 IS 11 BP 11372 EP 11381 DI 10.1364/OE.18.011372 PG 10 WC Optics SC Optics GA 607OB UT WOS:000278512300052 PM 20588998 ER PT J AU Ha, JY Shishkov, M Colice, M Oh, WY Yoo, H Liu, L Tearney, GJ Bouma, BE AF Ha, J. Y. Shishkov, M. Colice, M. Oh, W. Y. Yoo, H. Liu, L. Tearney, G. J. Bouma, B. E. TI Compensation of motion artifacts in catheter-based optical frequency domain imaging SO OPTICS EXPRESS LA English DT Article ID COHERENCE TOMOGRAPHY; PERFORMANCE; MICROSCOPY AB A novel heterodyne Doppler interferometer method for compensating motion artifacts caused by cardiac motion in intracoronary optical frequency domain imaging (OFDI) is demonstrated. To track the relative motion of a catheter with regard to the vessel, a motion tracking system is incorporated with a standard OFDI system by using wavelength division multiplexing (WDM) techniques. Without affecting the imaging beam, dual WDM monochromatic beams are utilized for tracking the relative radial and longitudinal velocities of a catheter-based fiber probe. Our results demonstrate that tracking instantaneous velocity can be used to compensate for distortion in the images due to motion artifacts, thus leading to accurate reconstruction and volumetric measurements with catheter-based imaging. (C) 2010 Optical Society of America C1 [Ha, J. Y.] Harvard Univ, Sch Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Ha, JY (reprint author), Harvard Univ, Sch Med, 50 Blossom St,BAR 7, Boston, MA 02114 USA. EM bouma@helix.mgh.harvard.edu RI Oh, Wang-Yuhl/C-2055-2011; Yoo, Hongki/B-6421-2013 OI Yoo, Hongki/0000-0001-9819-3135 FU National Institutes of Health [R33 CA125560, R01 HL076398]; Terumo Medical Corporation FX This research was supported in part by the National Institutes of Health (grants R33 CA125560 and R01 HL076398), and Terumo Medical Corporation. M. Colice is currently with Hamilton Brook Smith Reynolds P. C., 530 Virginia Rd, Concord MA 01742. NR 15 TC 11 Z9 11 U1 0 U2 3 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 1094-4087 J9 OPT EXPRESS JI Opt. Express PD MAY 24 PY 2010 VL 18 IS 11 BP 11418 EP 11427 DI 10.1364/OE.18.011418 PG 10 WC Optics SC Optics GA 607OB UT WOS:000278512300056 PM 20589002 ER PT J AU Kabbarah, O Nogueira, C Feng, B Nazarian, RM Bosenberg, M Wu, M Scott, KL Kwong, LN Xiao, YH Cordon-Cardo, C Granter, SR Ramaswamy, S Golub, T Duncan, LM Wagner, SN Brennan, C Chin, L AF Kabbarah, Omar Nogueira, Cristina Feng, Bin Nazarian, Rosalynn M. Bosenberg, Marcus Wu, Min Scott, Kenneth L. Kwong, Lawrence N. Xiao, Yonghong Cordon-Cardo, Carlos Granter, Scott R. Ramaswamy, Sridhar Golub, Todd Duncan, Lyn M. Wagner, Stephan N. Brennan, Cameron Chin, Lynda TI Integrative Genome Comparison of Primary and Metastatic Melanomas SO PLOS ONE LA English DT Article ID NUCLEOTIDE POLYMORPHISM ARRAYS; HUMAN HEPATOCELLULAR-CARCINOMA; PROTEIN-KINASE PATHWAY; COPY NUMBER ANALYSIS; MALIGNANT-MELANOMA; CELL CARCINOMAS; CUTANEOUS MELANOMA; UVEAL MELANOMA; BREAST-CANCER; LUNG-CANCER AB A cardinal feature of malignant melanoma is its metastatic propensity. An incomplete view of the genetic events driving metastatic progression has been a major barrier to rational development of effective therapeutics and prognostic diagnostics for melanoma patients. In this study, we conducted global genomic characterization of primary and metastatic melanomas to examine the genomic landscape associated with metastatic progression. In addition to uncovering three genomic subclasses of metastastic melanomas, we delineated 39 focal and recurrent regions of amplification and deletions, many of which encompassed resident genes that have not been implicated in cancer or metastasis. To identify progressionassociated metastasis gene candidates, we applied a statistical approach, Integrative Genome Comparison (IGC), to define 32 genomic regions of interest that were significantly altered in metastatic relative to primary melanomas, encompassing 30 resident genes with statistically significant expression deregulation. Functional assays on a subset of these candidates, including MET, ASPM, AKAP9, IMP3, PRKCA, RPA3, and SCAP2, validated their pro-invasion activities in human melanoma cells. Validity of the IGC approach was further reinforced by tissue microarray analysis of Survivin showing significant increased protein expression in thick versus thin primary cutaneous melanomas, and a progression correlation with lymph node metastases. Together, these functional validation results and correlative analysis of human tissues support the thesis that integrated genomic and pathological analyses of staged melanomas provide a productive entry point for discovery of melanoma metastases genes. C1 [Kabbarah, Omar; Nogueira, Cristina; Wu, Min; Scott, Kenneth L.; Kwong, Lawrence N.; Golub, Todd; Chin, Lynda] Dana Faber Canc Inst, Dept Med Oncol, Boston, MA USA. [Kabbarah, Omar; Nogueira, Cristina; Wu, Min; Scott, Kenneth L.; Kwong, Lawrence N.; Golub, Todd; Chin, Lynda] Harvard Med Sch, Boston, MA USA. [Nogueira, Cristina; Xiao, Yonghong] Univ Porto, Inst Mol Pathol & Immunol, Oporto, Portugal. [Feng, Bin; Xiao, Yonghong; Chin, Lynda] Dana Faber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA. [Nazarian, Rosalynn M.; Duncan, Lyn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol,Dermatopathol Unit, Boston, MA USA. [Bosenberg, Marcus] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT USA. [Cordon-Cardo, Carlos] Columbia Univ, Dept Pathol, New York, NY USA. [Granter, Scott R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA. [Ramaswamy, Sridhar] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA. [Golub, Todd] MIT, Braod Inst, Boston, MA USA. [Wagner, Stephan N.] Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria. [Wagner, Stephan N.] Austrian Acad Sci, Ctr Mol Med, Vienna, Austria. [Brennan, Cameron] Memorial Sloan Kettering Canc Ctr, Dept Neurosurg, HOPP, New York, NY USA. [Chin, Lynda] Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA. RP Kabbarah, O (reprint author), Dana Faber Canc Inst, Dept Med Oncol, Boston, MA USA. EM cbrennan@mskcc.org; lynda_chin@dfci.harvard.edu RI Nogueira, Cristina/N-4574-2015; OI Nogueira, Cristina/0000-0002-0853-5304; Brennan, Cameron/0000-0003-4064-8891; Wagner, Stephan/0000-0003-4941-7029; Nazarian, Rosalynn/0000-0003-4003-7193 FU National Institutes of Health [T32 AR07098, UO1 CA84313, RO1 CA93947, P50 CA93683]; Foundation for Science and Technology [PRAXIS/BD/21794/99] FX National Institutes of Health training grant (T32 AR07098) to O. K. Fellowship from the Foundation for Science and Technology (Fundacao para a Ciencia e Tecnologia , PRAXIS/BD/21794/99) to C. N. National Institutes of Health grants UO1 CA84313, RO1 CA93947, and P50 CA93683 to L. C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript NR 55 TC 61 Z9 61 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 24 PY 2010 VL 5 IS 5 AR e10770 DI 10.1371/journal.pone.0010770 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 601CC UT WOS:000278034600003 PM 20520718 ER PT J AU Nitta, M Kozono, D Kennedy, R Stommel, J Ng, K Zinn, PO Kushwaha, D Kesari, S Furnari, F Hoadley, KA Chin, L DePinho, RA Cavenne, WK D'Andrea, A Chen, CC AF Nitta, Masayuki Kozono, David Kennedy, Richard Stommel, Jayne Ng, Kimberly Zinn, Pascal O. Kushwaha, Deepa Kesari, Santosh Furnari, Frank Hoadley, Katherine A. Chin, Lynda DePinho, Ronald A. Cavenee, Webster K. D'Andrea, Alan Chen, Clark C. TI Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy SO PLOS ONE LA English DT Article ID GROWTH-FACTOR RECEPTOR; DNA-DAMAGE RESPONSE; INTEGRATED GENOMIC ANALYSIS; ERROR-PRONE REPAIR; REACTIVE OXYGEN; HUMAN CANCERS; POLY(ADP-RIBOSE) POLYMERASE; RAS ONCOGENE; CELLS; INSTABILITY AB Despite the critical role of Epidermal Growth Factor Receptor (EGFR) in glioblastoma pathogenesis [1,2], EGFR targeted therapies have achieved limited clinical efficacy [3]. Here we propose an alternate therapeutic strategy based on the conceptual framework of non-oncogene addiction [4,5]. A directed RNAi screen revealed that glioblastoma cells overexpressing EGFRvIII [6], an oncogenic variant of EGFR, become hyper-dependent on a variety of DNA repair genes. Among these, there was an enrichment of Base Excision Repair (BER) genes required for the repair of Reactive Oxygen Species (ROS)-induced DNA damage, including poly-ADP ribose polymerase 1 (PARP1). Subsequent studies revealed that EGFRvIII overexpression in glioblastoma cells caused increased levels of ROS, DNA strand break accumulation, and genome instability. In a panel of primary glioblastoma lines, sensitivity to PARP1 inhibition correlated with the levels of EGFR activation and oxidative stress. Gene expression analysis indicated that reduced expression of BER genes in glioblastomas with high EGFR expression correlated with improved patient survival. These observations suggest that oxidative stress secondary to EGFR hyperactivation necessitates increased cellular reliance on PARP1 mediated BER, and offer critical insights into clinical trial design. C1 [Nitta, Masayuki; Kozono, David; Ng, Kimberly; Zinn, Pascal O.; Kushwaha, Deepa; D'Andrea, Alan; Chen, Clark C.] Dana-Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. [Kozono, David] Harvard Radiat Oncol Program, Boston, MA USA. [Kennedy, Richard] Almac Diagnost, Craigavon, North Ireland. [Stommel, Jayne; Chin, Lynda; DePinho, Ronald A.] Dana-Farber Canc Inst, Belfer Inst Appl Canc Sci, Dept Med Oncol, Boston, MA USA. [Kesari, Santosh] Univ Calif San Diego, Dept Neurol, Moores UCSD Canc Ctr, La Jolla, CA USA. [Furnari, Frank; Cavenee, Webster K.] Ludwig Inst Canc Res, La Jolla, CA USA. [Hoadley, Katherine A.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Chen, Clark C.] Beth Israel Deaconess Med Ctr, Div Neurosurg, Boston, MA USA. RP Nitta, M (reprint author), Dana-Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. EM clark_chen@dfci.harvard.edu RI Chen, Clark/C-8714-2013; Kesari, Santosh/E-8461-2013 OI Chen, Clark/0000-0001-6258-9277; FU Burroughs Wellcome Fund [CAMS 1006775.01]; National Brain Tumor Foundation; ABC2 Foundation FX CCC was supported by an award from the Burroughs Wellcome Fund (CAMS 1006775.01), National Brain Tumor Foundation, and ABC2 Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 34 Z9 36 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 24 PY 2010 VL 5 IS 5 AR e10767 DI 10.1371/journal.pone.0010767 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 601CC UT WOS:000278034600002 PM 20532243 ER PT J AU Susa, M Iyer, AK Ryu, K Choy, E Hornicek, FJ Mankin, H Milane, L Amiji, MM Duan, Z AF Susa, Michiro Iyer, Arun K. Ryu, Keinosuke Choy, Edwin Hornicek, Francis J. Mankin, Henry Milane, Lara Amiji, Mansoor M. Duan, Zhenfeng TI Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma SO PLOS ONE LA English DT Article ID P-GLYCOPROTEIN EXPRESSION; MULTIDRUG-RESISTANCE; OVARIAN-CARCINOMA; CYCLOSPORINE-A; CANCER CELLS; SOLID TUMOR; STEM-CELLS; REVERSAL; DOXORUBICIN; GENE AB Background: The use of neo-adjuvant chemotherapy in treating osteosarcoma has improved patients' average 5 year survival rate from 20% to 70% in the past 30 years. However, for patients who progress after chemotherapy, its effectiveness diminishes due to the emergence of multi-drug resistance (MDR) after prolonged therapy. Methodology/Principal Findings: In order to overcome both the dose-limiting side effects of conventional chemotherapeutic agents and the therapeutic failure resulting from MDR, we designed and evaluated a novel drug delivery system for MDR1 siRNA delivery. Novel biocompatible, lipid-modified dextran-based polymeric nanoparticles were used as the platform for MDR1 siRNA delivery; and the efficacy of combination therapy with this system was evaluated. In this study, multi-drug resistant osteosarcoma cell lines (KHOS(R2) and U-2OS(R2)) were treated with the MDR1 siRNA nanocarriers and MDR1 protein (P-gp) expression, drug retention, and immunofluoresence were analyzed. Combination therapy of the MDR1 siRNA loaded nanocarriers with increasing concentrations of doxorubicin was also analyzed. We observed that MDR1 siRNA loaded dextran nanoparticles efficiently suppresses P-gp expression in the drug resistant osteosarcoma cell lines. The results also demonstrated that this approach may be capable of reversing drug resistance by increasing the amount of drug accumulation in MDR cell lines. Conclusions/Significance: Lipid-modified dextran-based polymeric nanoparticles are a promising platform for siRNA delivery. Nanocarriers loaded with MDR1 siRNA are a potential treatment strategy for reversing MDR in osteosarcoma. C1 [Susa, Michiro; Ryu, Keinosuke; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA USA. [Susa, Michiro; Ryu, Keinosuke; Choy, Edwin; Hornicek, Francis J.; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA USA. [Iyer, Arun K.; Milane, Lara; Amiji, Mansoor M.] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA USA. RP Susa, M (reprint author), Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA USA. EM zduan@partners.org RI Susa, Michiro/L-2291-2013; Amiji, Mansoor/A-4365-2014; OI Amiji, Mansoor/0000-0001-6170-881X; Choy, Edwin/0000-0001-9896-8084; Iyer, Arun/0000-0002-4428-0222 FU National Cancer Institute, National Institutes of Health (Nanotechnology Platform Partnership) [R01-CA119617]; Sarcoma Foundation of America; Gattegno and Wechsler funds FX This project was supported, in part, by a grant from the National Cancer Institute, National Institutes of Health (Nanotechnology Platform Partnership), R01-CA119617. Dr. Duan is supported, in part, through a grant from Sarcoma Foundation of America. Support has also been provided by the Gattegno and Wechsler funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 70 Z9 77 U1 5 U2 36 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 24 PY 2010 VL 5 IS 5 AR e10764 DI 10.1371/journal.pone.0010764 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 601CC UT WOS:000278034600001 PM 20520719 ER PT J AU Jespersen, S Sogaard, OS Schonheyder, HC Fine, MJ Ostergaard, L AF Jespersen, Sanne Sogaard, Ole S. Schonheyder, Henrik C. Fine, Michael J. Ostergaard, Lars TI Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: A Danish historical cohort study SO BMC INFECTIOUS DISEASES LA English DT Article ID LEGIONNAIRES-DISEASE; PROGNOSTIC-FACTORS; PNEUMONIA; VALIDATION; MORBIDITY; THERAPY; TRENDS AB Background: Legionella is a common cause of bacterial pneumonia. Community-acquired [CAL] and hospital-acquired legionellosis [HAL] may have different presentations and outcome. We aimed to compare clinical characteristics and examine predictors of mortality for CAL and HAL. Methods: We identified hospitalized cases of legionellosis in 4 Danish counties from January 1995 to December 2005 using the Danish national surveillance system and databases at departments of clinical microbiology. Clinical and laboratory data were retrieved from medical records; vital status was obtained from the Danish Civil Registration System. We calculated 30- and 90-day case fatality rates and identified independent predictors of mortality using logistic regression analyses. Results: We included 272 cases of CAL and 60 cases of HAL. Signs and symptoms of HAL were less pronounced than for CAL and time from in-hospital symptoms to legionellosis diagnosis was shorter for CAL than for HAL (5.5 days vs. 12 days p < 0.001). Thirty-day case fatality was 12.9% for CAL and 33.3% for HAL; similarly 90-day case fatalities in the two groups were 15.8% and 55.0%, respectively. In a logistic regression analysis (excluding symptoms and laboratory tests) age > 65 years (OR = 2.6, 95% CI: 1.1-5.9) and Charlson comorbidty index = 2 (OR = 2.7, 95% CI: 1.1-6.5) were associated with an increased risk of death in CAL. We identified no statistically significant predictors of 30-day mortality in HAL. Conclusions: Signs and symptoms were less pronounced in HAL compared to CAL. Conversely, 30-day case fatality was almost 3 times higher. Clinical awareness is important for the timely diagnosis and treatment especially of HAL. There is a need for further studies of prognostic factors in order to improve the therapeutic approach to legionellosis and potentially reduce mortality. C1 [Jespersen, Sanne; Sogaard, Ole S.; Ostergaard, Lars] Aarhus Univ Hosp, Dept Infect Dis, DK-8200 Aarhus N, Denmark. [Schonheyder, Henrik C.] Aarhus Univ Hosp, Dept Clin Microbiol, DK-9000 Aalborg, Denmark. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Med, UPMC Montefiore Hosp, Pittsburgh, PA 15213 USA. RP Jespersen, S (reprint author), Aarhus Univ Hosp, Dept Infect Dis, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. EM sanne.jespersen@ki.au.dk RI Sogaard, Ole/P-6058-2016 FU Beckett-fonden FX We would like to acknowledge Statens Serum Institut for making the microbiological data available to us and Beckett-fonden for financial support. NR 20 TC 12 Z9 14 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD MAY 21 PY 2010 VL 10 AR 124 DI 10.1186/1471-2334-10-124 PG 12 WC Infectious Diseases SC Infectious Diseases GA 605XP UT WOS:000278382100001 PM 20492639 ER PT J AU Owens, RM Gu, XL Shin, MR Springer, TA Jin, MM AF Owens, Roisin M. Gu, Xiaoling Shin, Miran Springer, Timothy A. Jin, Moonsoo M. TI Engineering of Single Ig Superfamily Domain of Intercellular Adhesion Molecule 1 (ICAM-1) for Native Fold and Function SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID HUMAN RHINOVIRUS; CRYSTAL-STRUCTURE; CELL-SURFACE; TRANSENDOTHELIAL MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; DIRECTED EVOLUTION; COXSACKIEVIRUS A21; RECEPTOR MOLECULE; ANTIGEN-1 LFA-1; IN-VIVO AB The immunoglobulin (Ig) superfamily is one of the largest families in the vertebrate genome, found most frequently in cell surface molecules. Intercellular adhesion molecule-1 (ICAM-1) contains five extracellular Ig superfamily domains (D1-D5) of which the first domain, D1, is the binding site for the integrin lymphocyte function-associated antigen-1 (LFA-1) and human rhinovirus. Despite the modular nature of many Ig superfamily domains with respect to domain folding and ligand recognition, D1 does not fold on its own due to the loss of its interaction with the second domain. The goal of this study was to engineer ICAM-1D1 by introducing mutations that would stabilize the Ig superfamily domain fold while retaining its ability to bind to LFA-1 and rhinovirus. First, with a directed evolution approach, we isolated mutations in D1 that showed binding to conformation-specific antibodies and the ligand binding domain of LFA-1 called the inserted, or I, domain. Then, with a rational design approach we introduced mutations that contributed to the stability of ICAM-1 D1 in solution. The mutations that restored native folding of D1 in isolation were those that would convert hydrogen bond networks in buried regions into hydrophobic contacts. Notably, for most mutations, identical or similar types of substitutions were found in ICAM-1 molecules of different species and other ICAM family members. The systematic approach demonstrated in this study to engineer a single Ig superfamily fold in ICAM-1 can be broadly applicable to the engineering of modular Ig superfamily domains in other cell surface molecules. C1 [Springer, Timothy A.; Jin, Moonsoo M.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Owens, Roisin M.; Gu, Xiaoling; Shin, Miran; Jin, Moonsoo M.] Cornell Univ, Dept Biomed Engn, Ithaca, NY 14853 USA. RP Springer, TA (reprint author), Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. EM springer@idi.harvard.edu; mj227@cornell.edu RI Jin, Moonsoo/D-6128-2011; OI Owens, Roisin/0000-0001-7856-2108 FU National Institutes of Health [CA31798, AI079532] FX This work was supported, in whole or in part, by National Institutes of Health Grants CA31798 and AI079532. NR 50 TC 7 Z9 7 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 21 PY 2010 VL 285 IS 21 BP 15906 EP 15915 DI 10.1074/jbc.M110.104349 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 596WJ UT WOS:000277715900028 PM 20304924 ER PT J AU Smith, KJ Twal, WO Soodavar, F Virella, G Lopes-Virella, MF Hammad, SM AF Smith, Kent J. Twal, Waleed O. Soodavar, Farzan Virella, Gabriel Lopes-Virella, Maria F. Hammad, Samar M. TI Heat Shock Protein 70B ' (HSP70B ') Expression and Release in Response to Human Oxidized Low Density Lipoprotein Immune Complexes in Macrophages SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID U937 MONOCYTIC CELLS; SPHINGOSINE KINASE; CYTOKINE PRODUCTION; PLASMA-MEMBRANE; STRESS-PROTEINS; LDL; HEAT-SHOCK-PROTEIN-70; SURVIVAL; PATHWAY; ATHEROSCLEROSIS AB Heat shock proteins (HSPs) have been implicated in the activation and survival of macrophages. This study examined the role of HSP70B', a poorly characterized member of the HSP70 family, in response to oxidatively modified LDL (oxLDL) and immune complexes prepared with human oxLDL and purified human antibodies to oxLDL (oxLDL-IC) in monocytic and macrophage cell lines. Immunoblot analysis of cell lysates and conditioned medium from U937 cells treated with oxLDL alone revealed an increase in intracellular HSP70B' protein levels accompanied by a concomitant increase in HSP70B' extracellular levels. Fluorescence immunohistochemistry and confocal microscopy, however, demonstrated that oxLDL-IC stimulated the release of HSP70B', which co-localized with cell-associated oxLDL-IC. In HSP70B'-green fluorescent protein-transfected mouse RAW 264.7 cells, oxLDL-IC-induced HSP70B' co-localized with membrane-associated oxLDL-IC as well as the lipid moiety of internalized oxLDL-IC. Furthermore, the data demonstrated that HSP70B' is involved in cell survival, and this effect could be mediated by sphingosine kinase 1 (SK1) activation. An examination of regularly implicated cytokines revealed a significant relationship between HSP70B' and the release of the anti-inflammatory cytokine interleukin-10 (IL-10). Small interfering RNA knockdown of HSP70B' resulted in a corresponding decrease in SK1 mRNA levels and SK1 phosphorylation as well as increased release of IL-10. In conclusion, these findings suggest that oxLDL-IC induce the synthesis and release of HSP70B', and once stimulated, HSP70B' binds to the cell-associated and internalized lipid moiety of oxLDL-IC. The data also implicate HSP70B' in key cellular functions, such as regulation of SK1 activity and release of IL-10, which influence macrophage activation and survival. C1 [Smith, Kent J.; Twal, Waleed O.; Soodavar, Farzan; Hammad, Samar M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, 114 Doughty St,630B,POB 250776, Charleston, SC 29425 USA. EM hammadsm@musc.edu FU National Institutes of Health (NIH) [HL079274]; NIH (American Recovery and Investment Act (ARRA)) [R01 HL079274-04S1]; NIH (National Center for Research Resources) [P20 RR17677]; NIH [P01 HL55782, R01 DK081352, R01 DK081352-02S1]; Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health (NIH) Grant HL079274 and NIH (American Recovery and Investment Act (ARRA)) Grant R01 HL079274-04S1 (to S. M. H.); NIH (National Center for Research Resources) Grant P20 RR17677 (South Carolina Center of Biomedical Research Excellence in Lipidomics and Pathobiology) (to S. M. H.); and NIH Grants P01 HL55782, R01 DK081352, and R01 DK081352-02S1 (ARRA) (to M. F. L.-V.). This work was also supported by funding from the Department of Veterans Affairs (to M. F. L.-V.). NR 58 TC 14 Z9 14 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 21 PY 2010 VL 285 IS 21 BP 15985 EP 15993 DI 10.1074/jbc.M110.113605 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 596WJ UT WOS:000277715900036 PM 20348092 ER PT J AU Okuhira, K Fitzgerald, ML Tamehiro, N Ohoka, N Suzuki, K Sawada, J Naito, M Nishimaki-Mogami, T AF Okuhira, Keiichiro Fitzgerald, Michael L. Tamehiro, Norimasa Ohoka, Nobumichi Suzuki, Kazuhiro Sawada, Jun-ichi Naito, Mikihiko Nishimaki-Mogami, Tomoko TI Binding of PDZ-RhoGEF to ATP-binding Cassette Transporter A1 (ABCA1) Induces Cholesterol Efflux through RhoA Activation and Prevention of Transporter Degradation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NUCLEOTIDE EXCHANGE FACTOR; HIGH-DENSITY-LIPOPROTEIN; LEUKEMIA-ASSOCIATED RHO; HETEROTRIMERIC G-PROTEINS; TANGIER-DISEASE; APOA-I; CELLULAR CHOLESTEROL; ABCA1-DEFICIENT MACROPHAGES; P115 RHOGEF; RECEPTOR AB ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux to apolipoprotein A1 (apoA-I) initiates the biogenesis of high density lipoprotein. Here we show that the Rho guanine nucleotide exchange factors PDZ-RhoGEF and LARG bind to the C terminus of ABCA1 by a PDZ-PDZ interaction and prevent ABCA1 protein degradation by activating RhoA. ABCA1 is a protein with a short half-life, and apoA-I stabilizes ABCA1 protein; however, depletion of PDZ-RhoGEF/LARG by RNA interference suppressed the apoA-I stabilization of ABCA1 protein in human primary fibroblasts. Exogenous PDZ-RhoGEF expression activated RhoA and increased ABCA1 protein levels and cholesterol efflux activity. Likewise, forced expression of a constitutively active RhoA mutant significantly increased ABCA1 protein levels, whereas a dominant negative RhoA mutant decreased them. The constitutively active RhoA retarded ABCA1 degradation, thus accounting for its ability to increase ABCA1 protein. Moreover, stimulation with apoA-I transiently activated RhoA, and the pharmacological inhibition of RhoA or the dominant negative RhoA blocked the ability of apoA-I to stabilize ABCA1. Finally, depletion of RhoA or RhoGEFs/RhoA reduces the cholesterol efflux when transcriptional regulation via PPAR gamma is eliminated. Taken together, our results have identified a novel physical and functional interaction between ABCA1 and PDZ-RhoGEF/LARG, which activates RhoA, resulting in ABCA1 stabilization and cholesterol efflux activity. C1 [Okuhira, Keiichiro; Ohoka, Nobumichi; Suzuki, Kazuhiro; Sawada, Jun-ichi; Naito, Mikihiko; Nishimaki-Mogami, Tomoko] Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588511, Japan. [Fitzgerald, Michael L.; Tamehiro, Norimasa] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, Boston, MA 02114 USA. [Fitzgerald, Michael L.; Tamehiro, Norimasa] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. RP Okuhira, K (reprint author), Natl Inst Hlth Sci, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588511, Japan. EM okuhira@nihs.go.jp FU National Institutes of Health [HL-074136]; Japan Society for the Promotion of Science; Japan Health Sciences Foundation; Takeda Science Foundation; American Heart Association [09GRNT2260352] FX This work was supported by National Institutes of Health Grant HL-074136 (to M. L. F.). This work was also supported by grants-in-aid for scientific research from the Japan Society for the Promotion of Science, by a research fund from Japan Health Sciences Foundation, by a Takeda Science Foundation grant (to K. O.), and by American Heart Association Grant 09GRNT2260352 (to M. L. F.). NR 55 TC 24 Z9 25 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 21 PY 2010 VL 285 IS 21 BP 16369 EP 16377 DI 10.1074/jbc.M109.061424 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 596WJ UT WOS:000277715900073 PM 20348106 ER PT J AU Athar, BS Bednarz, B Seco, J Hancox, C Paganetti, H AF Athar, Basit S. Bednarz, Bryan Seco, Joao Hancox, Cindy Paganetti, Harald TI Comparison of out-of-field photon doses in 6 MV IMRT and neutron doses in proton therapy for adult and pediatric patients SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID MODULATED RADIATION-THERAPY; MONTE-CARLO SIMULATIONS; 2ND CANCERS; RISK; IRRADIATION; PHANTOMS; BEAMS; MODEL AB The purpose of this study was to assess lateral out-of-field doses in 6MV IMRT (intensity modulated radiation therapy) and compare them with secondary neutron equivalent dose contributions in proton therapy. We simulated out-of-field photon doses to various organs as a function of distance, patient's age, gender and treatment volumes based on 3, 6, 9 cm field diameters in the head and neck and spine region. The out-of-field photon doses to organs near the field edge were found to be in the range of 2, 5 and 10 mSv Gy(-1) for 3 cm, 6 cm and 9 cm diameter IMRT fields, respectively, within 5 cm of the field edge. Statistical uncertainties calculated in organ doses vary from 0.2% to 40% depending on the organ location and the organ volume. Next, a comparison was made with previously calculated neutron equivalent doses from proton therapy using identical field arrangements. For example, out-of-field doses for IMRT to lung and uterus (organs close to the 3 cm diameter spinal field) were computed to be 0.63 and 0.62 mSv Gy(-1), respectively. These numbers are found to be a factor of 2 smaller than the corresponding out-of-field doses for proton therapy, which were estimated to be 1.6 and 1.7 mSv Gy(-1) (RBE), respectively. However, as the distance to the field edge increases beyond approximately 25 cm the neutron equivalent dose from proton therapy was found to be a factor of 2-3 smaller than the out-of-field photon dose from IMRT. We have also analyzed the neutron equivalent doses from an ideal scanned proton therapy (assuming not significant amount of absorbers in the treatment head). Out-of-field doses were found to be an order of magnitude smaller compared to out-of-field doses in IMRT or passive scattered proton therapy. In conclusion, there seem to be three geometrical areas when comparing the out-of-target dose from IMRT and (passive scattered) proton treatments. Close to the target (in-field, not analyzed here) protons offer a distinct advantage due to the lower integral dose. Out-of-field, but within approximately 25 cm from the field edge, the scattered photon dose in IMRT turned out to be roughly a factor of 2 lower than the neutron equivalent dose from proton therapy for the fields considered in this study. At larger distances to the field (beyond similar to 25 cm), protons offer an advantage, resulting in doses that are roughly a factor of 2-3 lower. C1 [Athar, Basit S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Athar, BS (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM bathar@partners.org; bbednarz@partners.org; jseco@partners.org; chancox@partners.org; hpaganetti@partners.org RI Seco, Joao/J-4451-2012 FU Department of Radiation Oncology at Massachusetts General Hospital (MGH); NIH/NCI [CO6-CA059267] FX This work was supported by institutional funds (ECOR award by Partners Health Care Inc., Ira Spiro award for translational research by the Department of Radiation Oncology at Massachusetts General Hospital (MGH)) and an NIH/NCI grant (CO6-CA059267). NR 21 TC 24 Z9 24 U1 1 U2 8 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD MAY 21 PY 2010 VL 55 IS 10 BP 2879 EP 2891 DI 10.1088/0031-9155/55/10/006 PG 13 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 590HI UT WOS:000277215700006 PM 20427856 ER PT J AU Nickerson, ML Kostiha, BN Brandt, W Fredericks, W Xu, KP Yu, FS Gold, B Chodosh, J Goldberg, M Lu, DW Yamada, M Tervo, TM Grutzmacher, R Croasdale, C Hoeltzenbein, M Sutphin, J Malkowicz, SB Wessjohann, L Kruth, HS Dean, M Weiss, JS AF Nickerson, Michael L. Kostiha, Brittany N. Brandt, Wolfgang Fredericks, William Xu, Ke-Ping Yu, Fu-Shin Gold, Bert Chodosh, James Goldberg, Marc Lu, Da Wen Yamada, Masakazu Tervo, Timo M. Grutzmacher, Richard Croasdale, Chris Hoeltzenbein, Maria Sutphin, John Malkowicz, S. Bruce Wessjohann, Ludger Kruth, Howard S. Dean, Michael Weiss, Jayne S. TI UBIAD1 Mutation Alters a Mitochondrial Prenyltransferase to Cause Schnyder Corneal Dystrophy SO PLOS ONE LA English DT Article ID ESCHERICHIA-COLI; CRYSTALLINE DYSTROPHY; TOPOLOGY PREDICTION; PROTEIN STRUCTURES; CHOLESTEROL; GENE; MEMBRANE; TRANSFERASE; METABOLISM; BLADDER AB Background: Mutations in a novel gene, UBIAD1, were recently found to cause the autosomal dominant eye disease Schnyder corneal dystrophy (SCD). SCD is characterized by an abnormal deposition of cholesterol and phospholipids in the cornea resulting in progressive corneal opacification and visual loss. We characterized lesions in the UBIAD1 gene in new SCD families and examined protein homology, localization, and structure. Methodology/Principal Findings: We characterized five novel mutations in the UBIAD1 gene in ten SCD families, including a first SCD family of Native American ethnicity. Examination of protein homology revealed that SCD altered amino acids which were highly conserved across species. Cell lines were established from patients including keratocytes obtained after corneal transplant surgery and lymphoblastoid cell lines from Epstein-Barr virus immortalized peripheral blood mononuclear cells. These were used to determine the subcellular localization of mutant and wild type protein, and to examine cholesterol metabolite ratios. Immunohistochemistry using antibodies specific for UBIAD1 protein in keratocytes revealed that both wild type and N102S protein were localized sub-cellularly to mitochondria. Analysis of cholesterol metabolites in patient cell line extracts showed no significant alteration in the presence of mutant protein indicating a potentially novel function of the UBIAD1 protein in cholesterol biochemistry. Molecular modeling was used to develop a model of human UBIAD1 protein in a membrane and revealed potentially critical roles for amino acids mutated in SCD. Potential primary and secondary substrate binding sites were identified and docking simulations indicated likely substrates including prenyl and phenolic molecules. Conclusions/Significance: Accumulating evidence from the SCD familial mutation spectrum, protein homology across species, and molecular modeling suggest that protein function is likely down-regulated by SCD mutations. Mitochondrial UBIAD1 protein appears to have a highly conserved function that, at least in humans, is involved in cholesterol metabolism in a novel manner. C1 [Nickerson, Michael L.; Kostiha, Brittany N.; Gold, Bert; Dean, Michael] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA. [Nickerson, Michael L.] NIH, Grad Partnership Program, Bethesda, MD 20892 USA. [Nickerson, Michael L.] George Washington Univ, Inst Biomed Sci, Program Mol Med, Washington, DC USA. [Kostiha, Brittany N.] Hood Coll, Biomed Sci Grad Program, Frederick, MD 21701 USA. [Brandt, Wolfgang; Wessjohann, Ludger] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Halle, Saale, Germany. [Fredericks, William; Malkowicz, S. Bruce] Univ Penn, Dept Surg, Div Urol, Philadelphia, PA 19104 USA. [Fredericks, William; Malkowicz, S. Bruce] Vet Affairs Med Ctr, Philadelphia, PA USA. [Xu, Ke-Ping; Yu, Fu-Shin; Weiss, Jayne S.] Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA. [Xu, Ke-Ping; Yu, Fu-Shin; Weiss, Jayne S.] Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA. [Chodosh, James] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Howe Lab, Cambridge, MA 02138 USA. [Goldberg, Marc] Inst Eye, Tulsa, OK USA. [Lu, Da Wen] Triserv Gen Hosp, Taipei, Taiwan. [Yamada, Masakazu] Natl Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo, Japan. [Tervo, Timo M.] Univ Helsinki, Hosp Eye, Helsinki, Finland. [Grutzmacher, Richard] Grutzmacher Lewis & Sierra, Sacramento, CA USA. [Croasdale, Chris] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA. [Hoeltzenbein, Maria] Max Planck Inst Mol Genet, Berlin, Germany. [Sutphin, John] Univ Kansas, Med Ctr, Dept Ophthalmol, Prairie Village, KS USA. [Kruth, Howard S.] NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA. [Weiss, Jayne S.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA. RP Nickerson, ML (reprint author), NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA. EM nickersonml@mail.nih.gov; jweiss@med.wayne.edu RI Dean, Michael/G-8172-2012; Hoeltzenbein, Maria/B-1134-2016 OI Dean, Michael/0000-0003-2234-0631; Hoeltzenbein, Maria/0000-0002-2451-4247 FU National Eye Institute [EY12972]; Eye Bank Association of America (JSW); Midwest Eye Banks; National Cancer Institute, National Institutes of Health [HHSN261200800001E] FX This work was supported in part by a grant from the National Eye Institute (grant EY12972 to J.S.W.) and by funding from the Eye Bank Association of America (JSW), and the Midwest Eye Banks (J.S.W. and K.-P.X.). This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 29 Z9 32 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 21 PY 2010 VL 5 IS 5 AR e10760 DI 10.1371/journal.pone.0010760 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 600VQ UT WOS:000278017400016 PM 20505825 ER PT J AU Roccaro, AM Sacco, A Aujay, M Ngo, HT Azab, AK Azab, F Quang, P Maiso, P Runnels, J Anderson, KC Demo, S Ghobrial, IM AF Roccaro, Aldo M. Sacco, Antonio Aujay, Monette Ngo, Hai T. Azab, Abdel Kareem Azab, Feda Quang, Phong Maiso, Patricia Runnels, Judith Anderson, Kenneth C. Demo, Susan Ghobrial, Irene M. TI Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia SO BLOOD LA English DT Article ID MULTIPLE-MYELOMA CELLS; ENDOPLASMIC-RETICULUM STRESS; IN-VITRO; KAPPA-B; PATHWAY; BORTEZOMIB; TARGET; CYTOTOXICITY; SURVIVAL; THERAPY AB Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has been successfully tested in clinical trials. Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects. Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteasome 20S (c20S) and immunoproteasome 20S (i20S) represents a sufficient and successful strategy to induce antineoplastic effect in hematologic tumors. We therefore studied ONX0912, a novel selective, irreversible inhibitor of the CT-L activity of i20S and c20S. Primary WM cells express higher level of i20S compared with c20S, and that ONX0912 inhibited the CT-L activity of both i20S and c20S, leading to induction of toxicity in primary WM cells, as well as of apoptosis through c-Jun N-terminal kinase activation, nuclear factor kappa B (NF-kappa B) inhibition, caspase cleavage, and initiation of the unfolded protein response. Importantly, ONX0912 exerted toxicity in WM cells, by reducing bone marrow (BM)derived interleukin-6 (IL-6) and insulinlike growth factor 1 (IGF-1) secretion, thus inhibiting BM-induced p-Akt and phosphorylated extracellular signal-related kinase (p-ERK) activation in WM cells. These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM. (Blood. 2010; 115(20): 4051-4060) C1 [Roccaro, Aldo M.; Sacco, Antonio; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Roccaro, Aldo M.; Sacco, Antonio; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA USA. [Aujay, Monette; Demo, Susan] Onyx Pharmaceut, Emeryville, CA USA. RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, 44 Binney St,Mayer 548A, Boston, MA 02115 USA. EM irene_ghobrial@dfci.harvard.edu RI Sacco, Antonio/K-4681-2016; OI Sacco, Antonio/0000-0003-2945-9416; Maiso, Patricia/0000-0003-3745-1924; Roccaro, Aldo/0000-0002-1872-5128 FU International Waldenstrom Macroglobulinemia Foundation (IWMF); [R21 1R21CA126119-01] FX This study was supported in part by R21 1R21CA126119-01 and the International Waldenstrom Macroglobulinemia Foundation (IWMF). This work was supported by the Michelle and Steven Kirsch laboratory for Waldenstrom and the Heje fellowship for Waldenstrom. NR 32 TC 44 Z9 45 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAY 20 PY 2010 VL 115 IS 20 BP 4051 EP 4060 DI 10.1182/blood-2009-09-243402 PG 10 WC Hematology SC Hematology GA 599OS UT WOS:000277923600010 PM 20110419 ER PT J AU Schulz, C Leuschen, NV Frohlich, T Lorenz, M Pfeiler, S Gleissner, CA Kremmer, E Kessler, M Khandoga, AG Engelmann, B Ley, K Massberg, S Arnold, GJ AF Schulz, Christian Leuschen, Nina V. Froehlich, Thomas Lorenz, Michael Pfeiler, Susanne Gleissner, Christian A. Kremmer, Elisabeth Kessler, Mirjam Khandoga, Alexander G. Engelmann, Bernd Ley, Klaus Massberg, Steffen Arnold, Georg J. TI Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation SO BLOOD LA English DT Article ID ALDOSE REDUCTASE INHIBITOR; ACTIN-RELATED PROTEIN; RECEPTOR GAMMA-CHAIN; COLLAGEN RECEPTOR; DISULFIDE-ISOMERASE; GEL-ELECTROPHORESIS; ENDOTHELIAL-CELLS; IN-VIVO; PHOSPHORYLATION; AGGREGATION AB Platelets play a key role in hemostasis and various diseases including arterial thrombosis. Glycoprotein VI (GPVI) mediates adhesion to collagen structures exposed at sites of vascular injury and subsequent platelet activation. We determined the effects of specific activation of GPVI on the human platelet proteome. Isolated human platelets were stimulated with an activating monoclonal antibody specific for GPVI. Platelet proteins were analyzed by 2-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry. We identified 8 differentially abundant proteins associated with cell signaling, metabolism, organization and rearrangement of the cytoskeleton, and membrane trafficking. Differentially abundant proteins included aldose reductase (AR), beta-centractin, charged multivesicular body protein 3, Src substrate cortactin, ERp57, and pleckstrin. Importantly, GPVI-modulated protein abundance was functionally relevant. Correspondingly, AR enzyme activity significantly increased upon GPVI activation and inhibition of AR resulted in reduced platelet aggregation. Furthermore, ERp57 was re-leased upon ligation of platelet GPVI and increased the activity of tissue factor, a major initiator of blood coagulation. In summary, GPVI activation results in differential changes in abundance of platelet proteins, including AR and ERp57, which support platelet aggregation and platelet-dependent coagulation. These results provide further insight into the mechanisms that underlie platelet activation through the GPVI receptor and may help to identify novel pharmacologic targets. (Blood. 2010; 115(20): 4102-4110) C1 [Schulz, Christian; Leuschen, Nina V.; Lorenz, Michael; Kessler, Mirjam; Khandoga, Alexander G.; Massberg, Steffen] Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany. [Leuschen, Nina V.] Univ Cologne, Inst Genet, Dept Mouse Genet & Metab, D-5000 Cologne, Germany. [Froehlich, Thomas; Arnold, Georg J.] Univ Munich, LAFUGA, Gene Ctr, Munich, Germany. [Pfeiler, Susanne; Engelmann, Bernd] Univ Munich, Inst Klin Chem, Munich, Germany. [Gleissner, Christian A.; Ley, Klaus] La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA USA. [Gleissner, Christian A.] Heidelberg Univ, Dept Cardiol Angiol & Pneumonol, Heidelberg, Germany. [Kremmer, Elisabeth] Helmholtz Zentrum Munchen, Inst Mol Immunol, Munich, Germany. [Massberg, Steffen] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. [Massberg, Steffen] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Schulz, C (reprint author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany. EM schulz@dhm.mhn.de RI Schulz, Christian/J-8545-2012; Frohlich, Thomas/C-6735-2011 OI Schulz, Christian/0000-0003-3878-7833; FU German Foundation of Heart Research; Dr Helmut Legerlotz-Stiftung; Deutsche Forschungsgemeinschaft (DFG) [Ma2186-3/1, Ma2186-4/1] FX This study was supported by grants of the German Foundation of Heart Research and the Dr Helmut Legerlotz-Stiftung (C. S.), and grants from the Deutsche Forschungsgemeinschaft (DFG; Ma2186-3/1 and Ma2186-4/1; S. M.). S. M. is a Heisenberg fellow of the DFG. NR 52 TC 33 Z9 35 U1 1 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAY 20 PY 2010 VL 115 IS 20 BP 4102 EP 4110 DI 10.1182/blood-2009-07-230268 PG 9 WC Hematology SC Hematology GA 599OS UT WOS:000277923600015 PM 20107233 ER PT J AU Brown, JA Stevenson, K Kim, HT Cutler, C Ballen, K McDonough, S Reynolds, C Herrera, M Liney, D Ho, V Kao, G Armand, P Koreth, J Alyea, E McAfee, S Attar, E Dey, B Spitzer, T Soiffer, R Ritz, J Antin, JH Boussiotis, VA AF Brown, Julia A. Stevenson, Kristen Kim, Haesook T. Cutler, Corey Ballen, Karen McDonough, Sean Reynolds, Carol Herrera, Maria Liney, Deborah Ho, Vincent Kao, Grace Armand, Philippe Koreth, John Alyea, Edwin McAfee, Steve Attar, Eyal Dey, Bimalangshu Spitzer, Thomas Soiffer, Robert Ritz, Jerome Antin, Joseph H. Boussiotis, Vassiliki A. TI Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis SO BLOOD LA English DT Article ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; IMMUNE RECONSTITUTION; UNRELATED DONORS; T-LYMPHOCYTES; PERIPHERAL-BLOOD; CYTOMEGALOVIRUS-INFECTION; HEMATOLOGIC MALIGNANCIES; THYMIC FUNCTION; RECIPIENTS AB Umbilical cord blood grafts are increasingly used as sources of hematopoietic stem cells in adults. Data regarding the outcome of this approach in adults are consistent with delayed and insufficient immune reconstitution resulting in high infection-related morbidity and mortality. Using cytomegalovirus (CMV)-specific immunity as a paradigm, we evaluated the status, mechanism, and clinical implications of immune reconstitution in adults with hematologic malignancies undergoing unrelated double unit cord blood transplantation. Our data indicate that CD8(_) T cells capable of secreting interferon-gamma (IFN-gamma) in a CMV-specific enzyme-linked immunosorbent spot (ELISpot) assay are detectable at 8 weeks after transplantation, before reconstitution of thymopoiesis, but fail to clear CMV viremia. Clearance of CMV viremia occurs later and depends on the recovery of CD4(+)CD45RA(+) T cells, reconstitution of thymopoiesis, and attainment of T-cell receptor rearrangement excision circle (TREC) levels of 2000 or more copies/mu g DNA. In addition, overall survival was significantly higher in patients who displayed thymic regeneration and attainment of TREC levels of 2000 or more copies/mu g DNA (P = .005). These results indicate that reconstitution of thymopoiesis is critical for long-term clinical outcome in adult recipients of umbilical cord blood transplant. The trial was prospectively registered at http://www.clinicaltrials.gov (NCT00133367). (Blood. 2010; 115(20): 4111-4119) C1 [Brown, Julia A.; Boussiotis, Vassiliki A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol & Canc Biol, Boston, MA 02215 USA. [Stevenson, Kristen; Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Stevenson, Kristen; Kim, Haesook T.] Dana Farber Canc Inst, Dept Computat Biol, Boston, MA 02115 USA. [Cutler, Corey; McDonough, Sean; Reynolds, Carol; Herrera, Maria; Liney, Deborah; Ho, Vincent; Kao, Grace; Armand, Philippe; Koreth, John; Alyea, Edwin; Soiffer, Robert; Ritz, Jerome; Antin, Joseph H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ballen, Karen; McAfee, Steve; Attar, Eyal; Dey, Bimalangshu; Spitzer, Thomas] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. RP Boussiotis, VA (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol & Canc Biol, 330 Brookline Ave, Boston, MA 02215 USA. EM vboussio@bidmc.harvard.edu OI Ritz, Jerome/0000-0001-5526-4669 FU National Institutes of Health [CA123855, AI43552, CA104596, HL087870, T32CA081156, AI029530, CA142106] FX This work was supported by grants from the National Institutes of Health: CA123855, AI43552, CA104596, HL087870 (V. A. B.), T32CA081156 (J.B.), AI029530 and CA142106 (H. T. K., K. S.), and CA142106 (J.H.A.). NR 49 TC 52 Z9 52 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAY 20 PY 2010 VL 115 IS 20 BP 4111 EP 4119 DI 10.1182/blood-2009-09-244145 PG 9 WC Hematology SC Hematology GA 599OS UT WOS:000277923600016 PM 20107229 ER PT J AU Cheung, WY Neville, BA Earle, CC AF Cheung, Winson Y. Neville, Bridget A. Earle, Craig C. TI Associations Among Cancer Survivorship Discussions, Patient and Physician Expectations, and Receipt of Follow-Up Care SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; BREAST-CANCER; HEALTH; OUTCOMES; OLDER; SATISFACTION; TRENDS AB Purpose To explore the associations among cancer survivorship discussions, patient-physician expectations, and receipt of follow-up care in cancer survivors. Patients and Methods We surveyed cancer survivors about various aspects of their care, including expectations of their providers' roles, whether discussions with a physician had occurred, and self-reported patterns of follow-up. Primary care providers (PCPs) and oncologists were also surveyed for their own perceived roles. We developed a scoring system to evaluate the level of agreement in expectations between patients and physicians and between PCPs and oncologists (where 0 = most discordant and 4 = most concordant). Regression and stratified analyses were conducted to examine the relationships among expectations, discussions, and follow-up. Results In total, 535 patients (54%) and 378 physicians (62%) responded. Survivorship care expectations were most discrepant between PCPs and oncologists (mean score, 1.78), moderate between patients and oncologists (mean score, 1.97), and most similar between patients and PCPs (mean score, 2.82). Having a conversation specifically about cancer follow-up was associated with better concordance between patients and oncologists, but not for patients and their PCPs or between physicians. Better concordance in patient-oncologist expectations also correlated with greater odds of receiving certain aspects of follow-up care, such as influenza vaccinations and physical examinations, but only if a discussion about cancer follow-up had occurred. Conclusion A discussion about cancer follow-up may affect survivorship care through its primary influence on patient-oncologist expectations. Further work is required to clarify the aspects of survivorship discussions that are important for optimal cancer survivorship care planning. C1 [Earle, Craig C.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada. British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA. RP Earle, CC (reprint author), Inst Clin Evaluat Sci, 2075 Bayview Ave,Rm G-106, Toronto, ON M4N 3M5, Canada. EM craig.earle@ices.on.ca FU Perini Family Cancer Survivors' Center; Canadian Association of Medical Oncologists; National Cancer Institute of Canada FX Supported by funds from the Perini Family Cancer Survivors' Center, an award from the Canadian Association of Medical Oncologists, and a grant from the National Cancer Institute of Canada. NR 22 TC 27 Z9 27 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 BP 2577 EP 2583 DI 10.1200/JCO.2009.26.4549 PG 7 WC Oncology SC Oncology GA 598JO UT WOS:000277832400014 PM 20406932 ER PT J AU Peppercorn, J Shapira, I Collyar, D Deshields, T Lin, N Krop, I Grunwald, H Friedman, P Partridge, AH Schilsky, RL Bertagnolli, MM AF Peppercorn, Jeffrey Shapira, Iuliana Collyar, Deborah Deshields, Teresa Lin, Nancy Krop, Ian Grunwald, Hans Friedman, Paula Partridge, Ann H. Schilsky, Richard L. Bertagnolli, Monica M. TI Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CHRONIC MYELOID-LEUKEMIA; LOW-DOSE CYTARABINE; CELL LUNG-CANCER; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; MOLECULAR SUBTYPES; ANTICANCER AGENTS; PROSTATE-CANCER; GENE-MUTATIONS AB Clinical investigators in oncology are increasingly interested in using molecular analysis of cancer tissue to understand the biologic bases of response or resistance to novel interventions and to develop prognostic and predictive biomarkers that will guide clinical decision making. Some scientific questions of this nature can only be addressed, or may best be addressed, through the conduct of a clinical trial in which research biopsies are obtained from all participants. However, trial designs with mandatory research biopsies have raised ethical concerns related to the risk of harm to participants, the adequacy of voluntary informed consent, and the potential for misunderstanding among research participants when access to an experimental intervention is linked to the requirement to undergo a research biopsy. In consideration of the ethical and scientific issues at stake in this debate, the Cancer and Leukemia Group B Ethics Committee proposes guidelines for clinical trials involving mandatory research biopsies. Any cancer clinical trial that requires research biopsies of participants must be well designed to address the scientific question, obtain the biopsy in a way that minimizes risk, and ensure that research participants are fully informed of the risks, rationale, and requirements of the study, as well as of treatment alternatives. Further guidelines and discussions of this issue are specified in this position paper. We feel that if these principles are respected, an informed adult with cancer can both understand and voluntarily consent to participation in a clinical trial involving mandatory research biopsy for scientific end points. C1 [Peppercorn, Jeffrey] Duke Univ, Med Ctr, Div Med Oncol, Duke Comprehens Canc Ctr, Durham, NC 27710 USA. N Shore Univ Hosp, Manhasset, NY USA. Mt Sinai Queens Hosp Ctr, Jamaica, NY USA. Patient Advocates Res, Danville, CA USA. Washington Univ, Sch Med, St Louis, MO USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. Canc & Leukemia Grp B Cent Off, Chicago, IL USA. RP Peppercorn, J (reprint author), Duke Univ, Med Ctr, Div Med Oncol, Duke Comprehens Canc Ctr, Box 3446, Durham, NC 27710 USA. EM jeffrey.peppercorn@duke.edu FU American Society of Clinical Oncology Foundation; Breast Cancer Research Foundation; Greenwall Foundation FX Supported by the American Society of Clinical Oncology Foundation (J.P.), Breast Cancer Research Foundation (J.P.), and the Greenwall Foundation Faculty Scholars Program in Bioethics (J.P.). NR 46 TC 33 Z9 33 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 BP 2635 EP 2640 DI 10.1200/JCO.2009.27.2443 PG 6 WC Oncology SC Oncology GA 598JO UT WOS:000277832400021 PM 20406927 ER PT J AU Abel, GA Neville, BA Weeks, JC Stone, RM AF Abel, G. A. Neville, B. A. Weeks, J. C. Stone, R. M. TI Assessment of performance measures for patients with the myclodysplastic syndrome (MDS) in the United States SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Abel, G. A.; Neville, B. A.; Weeks, J. C.; Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6002 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004281 ER PT J AU Abou-Nassar, K Stevenson, K Antin, JH Freedman, A AF Abou-Nassar, K. Stevenson, K. Antin, J. H. Freedman, A. TI (90)y-ibritumomab tiuxetan followed by reduced-intensity conditioning (RIC) and allogeneic stem-cell transplantation (SCT) in patients with high-risk relapsed, refractory, or transformed follicular lymphoma (FL). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Partners Canc Care, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6538 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004474 ER PT J AU Alsina, M Lonial, S Weber, DM Coutre, SE Kang, BP Glynos, T Warsi, G Snodgrass, SM Richardson, PG AF Alsina, M. Lonial, S. Weber, D. M. Coutre, S. E. Kang, B. P. Glynos, T. Warsi, G. Snodgrass, S. M. Richardson, P. G. TI PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. Novartis Pharmaceut, E Hanover, NJ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS308 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002308 ER PT J AU Anand, A Scher, HI Beer, TM Higano, CE Danila, DC Taplin, M Efstathiou, E Hirmand, M Sawyers, CL Heller, G AF Anand, A. Scher, H. I. Beer, T. M. Higano, C. E. Danila, D. C. Taplin, M. Efstathiou, E. Hirmand, M. Sawyers, C. L. Heller, G. CA Prostate Canc Clin Trials TI Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naive patients with progressive castration-resistant prostate cancer(CRPC) treated with MDV3100. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Univ Washington, Sch Med, Seattle, WA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Medivation Inc, San Francisco, CA USA. RI Anand, Aseem/P-1214-2014; Sawyers, Charles/G-5327-2016 OI Anand, Aseem/0000-0002-3606-540X; NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4546 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003669 ER PT J AU Anaya, DA Richardson, PA Albo, D Artinyan, A Petersen, NJ Awad, SS Berger, DH Cormier, JN AF Anaya, D. A. Richardson, P. A. Albo, D. Artinyan, A. Petersen, N. J. Awad, S. S. Berger, D. H. Cormier, J. N. TI Treatment patterns in patients with colorectal liver metastasis: A cohort study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3628 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003440 ER PT J AU Anderson, KC Weller, E Lonial, S Jakubowiak, AJ Jagannath, S Raje, NS Avigan, D Knight, RD Esseltine, D Richardson, PG AF Anderson, K. C. Weller, E. Lonial, S. Jakubowiak, A. J. Jagannath, S. Raje, N. S. Avigan, D. Knight, R. D. Esseltine, D. Richardson, P. G. TI Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Univ Michigan, Ann Arbor, MI 48109 USA. St Vincent Catholic Med Ctr, New York, NY USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Celgene Corp, Summit, NJ USA. Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8016 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852005036 ER PT J AU Anderson, KS Wong, J Posner, MR Riemer, AB Lorch, JH Haddad, RI Bryan, J Mclean, M Kelsey, K AF Anderson, K. S. Wong, J. Posner, M. R. Riemer, A. B. Lorch, J. H. Haddad, R. I. Bryan, J. Mclean, M. Kelsey, K. TI Detection of antibodies to the HPV16 proteome in head and neck cancer patient sera SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Merck & Co Inc, West Point, PA USA. Boston Univ, Sch Publ Hlth, Boston, MA USA. Brown Univ, Providence, RI 02912 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5545 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004222 ER PT J AU Avigan, D Rosenblatt, J Vasir, B Atkins, MB McDermott, DF Somaiya, P Mills, H Fitzgerald, D Dombagoda, D Kufe, DW AF Avigan, D. Rosenblatt, J. Vasir, B. Atkins, M. B. McDermott, D. F. Somaiya, P. Mills, H. Fitzgerald, D. Dombagoda, D. Kufe, D. W. TI Vaccination with DC/RCC fusions following cytoreductive nophrectomy SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2511 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003103 ER PT J AU Azzi, GR Schutz, FA Je, Y Choueiri, TK AF Azzi, G. R. Schutz, F. A. Je, Y. Choueiri, T. K. TI Bevacizumab (BEV) and the risk of arterial thromboembolic evets (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4609 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003732 ER PT J AU Baer, MR George, SL Sanford, BL Stone, RM Marcucci, G Mayer, RJ Larson, RA AF Baer, M. R. George, S. L. Sanford, B. L. Stone, R. M. Marcucci, G. Mayer, R. J. Larson, R. A. TI Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA. Canc & Leukemia Grp B, Chicago, IL USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6531 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004468 ER PT J AU Balboni, TA Paulk, ME Balboni, MJ Phelps, AC Vanderweele, T Wright, AA Block, S Prigerson, HG AF Balboni, T. A. Paulk, M. E. Balboni, M. J. Phelps, A. C. Vanderweele, T. Wright, A. A. Block, S. Prigerson, H. G. TI Contrasting effects of religious/spiritual support front religious communities versus medical teams on advanced cancer patient end-of-life care SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9012 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005279 ER PT J AU Bardia, A Huang, P Zhang, Z Sokoll, L Ingle, JN Carey, LA Lin, NU Nanda, R Viswanathan, K Wolff, AC AF Bardia, A. Huang, P. Zhang, Z. Sokoll, L. Ingle, J. N. Carey, L. A. Lin, N. U. Nanda, R. Viswanathan, K. Wolff, A. C. CA Translational Breast Canc Res Cons TI Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. Mayo Clin Rochester, Rochester, MN USA. Univ N Carolina, Chapel Hill, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1001 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002520 ER PT J AU Bartolomeo, J Norden, AD Drappatz, J Ciampa, AS Doherty, LM LaFrankie, DC Quant, EC Beroukhim, R Wen, PY AF Bartolomeo, J. Norden, A. D. Drappatz, J. Ciampa, A. S. Doherty, L. M. LaFrankie, D. C. Quant, E. C. Beroukhim, R. Wen, P. Y. TI Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Bartolomeo, J.; Norden, A. D.; Drappatz, J.; Ciampa, A. S.; Doherty, L. M.; LaFrankie, D. C.; Quant, E. C.; Beroukhim, R.; Wen, P. Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2043 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003038 ER PT J AU Basch, EM Reeve, BB Cleeland, CS Sloan, JA Mendoza, TR Abemethy, AP Bruner, D Minasian, LM Burke, LB Schrag, D AF Basch, E. M. Reeve, B. B. Cleeland, C. S. Sloan, J. A. Mendoza, T. R. Abemethy, A. P. Bruner, D. Minasian, L. M. Burke, L. B. Schrag, D. CA PRO-CTCAE Investigators TI Development of the patient-reported version of the common terminology criteria for adverse events (PRO-CTCAE) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NCI, Bethesda, MD 20892 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Mayo Clin Rochester, Rochester, MN USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. US FDA, Silver Spring, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e19605 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001668 ER PT J AU Batchu, RB Semaan, A Seward, SM Qazi, A Chamala, S Bryant, CS Steffes, C Kumar, S Shammas, MA Weaver, DW AF Batchu, R. B. Semaan, A. Seward, S. M. Qazi, A. Chamala, S. Bryant, C. S. Steffes, C. Kumar, S. Shammas, M. A. Weaver, D. W. TI Relationship of miR-101 and targeted epigenetic silencing of EzH2 on cell growth and invasiveness in ovarian cancer cells. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Wayne State Univ, Dept Surg, Detroit, MI USA. Wayne State Univ, Detroit, MI USA. Detroit Med Ctr, Detroit, MI USA. Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e15538 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001189 ER PT J AU Beadling, C Heinrich, MC Schuff, K Druker, BJ Corless, CL AF Beadling, C. Heinrich, M. C. Schuff, K. Druker, B. J. Corless, C. L. TI Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10503 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005611 ER PT J AU Beer, TM Rademacher, BL Geng, H Pittsenbarger, J Garzotto, M Nelson, P Higano, CS Qian, DZ AF Beer, T. M. Rademacher, B. L. Geng, H. Pittsenbarger, J. Garzotto, M. Nelson, P. Higano, C. S. Qian, D. Z. TI Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Washington, Sch Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4548 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003671 ER PT J AU Berlin, J Catalano, PJ Feng, Y Lowy, AM Blackstock, AW Philip, PA McWilliams, RR Abbruzzese, JL Benson, AB AF Berlin, J. Catalano, P. J. Feng, Y. Lowy, A. M. Blackstock, A. W. Philip, P. A. McWilliams, R. R. Abbruzzese, J. L. Benson, A. B. TI ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Diego, San Diego Moores Canc Ctr, San Diego, CA 92103 USA. Wake Forest Univ, Winston Salem, NC 27109 USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Mayo Clin, Rochester, MN USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 1 Z9 1 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4034 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003500 ER PT J AU Bhowmik, S Lu, W Rosenthal, DS AF Bhowmik, S. Lu, W. Rosenthal, D. S. TI Effects of Chinese herbal medicine on cytochrome P450, a systematic review SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Osher Res Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e13150 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000364 ER PT J AU Blakeley, JO Ye, X Grossman, SA Mikkelsen, T Rosenfeld, MR Bradley, CR Eichler, AF Nabors, LB Desideri, S Supko, JG AF Blakeley, J. O. Ye, X. Grossman, S. A. Mikkelsen, T. Rosenfeld, M. R. Bradley, C. R. Eichler, A. F. Nabors, L. B. Desideri, S. Supko, J. G. CA Adult Brain Tumor Consortium TI Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Johns Hopkins Univ, Baltimore, MD USA. Johns Hopkins Comprehens Canc Ctr, Baltimore, MD USA. Henry Ford Hlth Syst, Detroit, MI USA. Univ Penn, Philadelphia, PA 19104 USA. BiPar Sci, San Francisco, CA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Univ Alabama Birmingham, Birmingham, AL USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2012 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852003007 ER PT J AU Blaszkowsky, LS Abrams, TA Miksad, RA Zheng, H Meyerhardt, JA Schrag, D Kwak, EL Fuchs, C Ryan, DP Zhu, AX AF Blaszkowsky, L. S. Abrams, T. A. Miksad, R. A. Zheng, H. Meyerhardt, J. A. Schrag, D. Kwak, E. L. Fuchs, C. Ryan, D. P. Zhu, A. X. TI Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e14542 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000673 ER PT J AU Bradbury, AR Patrick-Miller, LJ Tuchman, L Moore, C Rauch, P Sands, CB Schmidheiser, H Daly, MB AF Bradbury, A. R. Patrick-Miller, L. J. Tuchman, L. Moore, C. Rauch, P. Sands, C. B. Schmidheiser, H. Daly, M. B. TI Knowledge and perceptions of breast cancer risk in adolescent girls at high risk and population risk for breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Canc Inst New Jersey, New Brunswick, NJ USA. Childrens Natl Med Ctr, Washington, DC 20010 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e12037 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000165 ER PT J AU Brawer, MK Smith, MR Malkowicz, SB Hancock, ML Morton, RA Steiner, MS AF Brawer, M. K. Smith, M. R. Malkowicz, S. B. Hancock, M. L. Morton, R. A. Steiner, M. S. TI Effect of toremifene on fracture risk in men younger than age 80 on androgen-deprivation therapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 GTx Inc, Memphis, TN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Hosp Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4676 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004045 ER PT J AU Buckle, GC Werner, L Oh, WK Bubley, G Hayes, JH Weckstein, D Elfiky, A Sims, DM Kantoff, P Taplin, M AF Buckle, G. C. Werner, L. Oh, W. K. Bubley, G. Hayes, J. H. Weckstein, D. Elfiky, A. Sims, D. M. Kantoff, P. Taplin, M. TI Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat & Computat Blol, Boston, MA 02115 USA. Mt Sinai Sch Med, New York, NY USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. New Hampshre Oncol Hematol PA, Hooksett, NH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4660 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004029 ER PT J AU Bullock, AJ Zhang, L O'Neill, AM Percy, A Sukhatme, V Mier, JW Atkins, MB Bhatt, RS AF Bullock, A. J. Zhang, L. O'Neill, A. M. Percy, A. Sukhatme, V. Mier, J. W. Atkins, M. B. Bhatt, R. S. TI Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 9 Z9 9 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4630 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003753 ER PT J AU Campbell, A Reckamp, KL Camidge, DR Giaccone, G Gadgeel, SM Khuri, FR Engelman, JA Denis, LJ O'Connell, JP Janne, PA AF Campbell, A. Reckamp, K. L. Camidge, D. R. Giaccone, G. Gadgeel, S. M. Khuri, F. R. Engelman, J. A. Denis, L. J. O'Connell, J. P. Janne, P. A. TI PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Pfizer Inc, New London, CT USA. City Hope Natl Med Ctr, Duarte, CA USA. Univ Colorado Denver, Aurora, CO USA. NCI, Bethesda, MD 20892 USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 20 Z9 20 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7596 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004729 ER PT J AU Capelletti, M Wang, XF Gu, L Graziano, SL Kratzke, RA Strauss, GM Maddaus, M Green, MR Vokes, EE Janne, PA AF Capelletti, M. Wang, X. F. Gu, L. Graziano, S. L. Kratzke, R. A. Strauss, G. M. Maddaus, M. Green, M. R. Vokes, E. E. Janne, P. A. TI Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Canc & Leukemia Grp B Stat Ctr, Durham, NC USA. SUNY Upstate Med Univ, Syracuse, NY 13210 USA. Univ Minnesota, Minneapolis, MN USA. Tufts Med Ctr, Boston, MA USA. Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA. Xcenda, Palm Harbor, FL USA. Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 1 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7008 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004552 ER PT J AU Cassier, PA Stacchiotti, S Gelderblom, H Thomas, DM Van der Graaf, W Seddon, BM Julien, D Wagner, AJ Blay, J AF Cassier, P. A. Stacchiotti, S. Gelderblom, H. Thomas, D. M. Van der Graaf, W. Seddon, B. M. Julien, D. Wagner, A. J. Blay, J. TI Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Hop Edouard Herriot, Lyon, France. Ist Nazl Tumori, I-20133 Milan, Italy. Leiden Univ, Dept Clin Oncol, Med Ctr, Leiden, Netherlands. Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. Univ Coll London Hosp, London, England. Inst Gustave Roussy, Villejuif, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Lyon 1, F-69365 Lyon, France. RI van der Graaf, Winette/A-5006-2014; Blay, Jean-Yves/N-3966-2016 OI Blay, Jean-Yves/0000-0001-7190-120X NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10012 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005521 ER PT J AU Cercek, A Weiser, MR Goodman, KA Reidy, DL Wong, WD Guillem, JG Temple, LK Schrag, D Paty, P Saltz, L AF Cercek, A. Weiser, M. R. Goodman, K. A. Reidy, D. L. Wong, W. D. Guillem, J. G. Temple, L. K. Schrag, D. Paty, P. Saltz, L. TI Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003460 ER PT J AU Chan, JA Mayer, RJ Jackson, N Malinowski, P Regan, E Kulke, M AF Chan, J. A. Mayer, R. J. Jackson, N. Malinowski, P. Regan, E. Kulke, M. TI Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Chan, J. A.; Mayer, R. J.; Jackson, N.; Malinowski, P.; Regan, E.; Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e14597 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000720 ER PT J AU Chen, AB Neville, BA Schrag, D AF Chen, A. B. Neville, B. A. Schrag, D. TI Adoption of CT-based simulation and outcomes following radiation for stage III non-small cell lung cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Chen, A. B.; Neville, B. A.; Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6007 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004286 ER PT J AU Chen, Y Kolesar, J Huang, W DiPaola, RS Pins, M Carducci, MA Stein, MN Bubiey, G Wilding, G Liu, G AF Chen, Y. Kolesar, J. Huang, W. DiPaola, R. S. Pins, M. Carducci, M. A. Stein, M. N. Bubiey, G. Wilding, G. Liu, G. TI Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803): Effect of Kras and EGFR status on clinical outcome SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. Canc Inst New Jersey, New Brunswick, NJ USA. Univ Illinois, Coll Med, Chicago, IL USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4668 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004037 ER PT J AU Chiorean, EG Matei, D Younger, A Funke, JM Waddell, MJ Jones, DR Hahn, NM Perkins, SM Sandrasegaran, K Sweeney, C AF Chiorean, E. G. Matei, D. Younger, A. Funke, J. M. Waddell, M. J. Jones, D. R. Hahn, N. M. Perkins, S. M. Sandrasegaran, K. Sweeney, C. TI Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. Hoosier Oncol Grp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3043 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003248 ER PT J AU Choueiri, TK Xie, W Kollmannsberger, CK Rini, BI McDermott, DF Knox, JJ Heng, DY AF Choueiri, T. K. Xie, W. Kollmannsberger, C. K. Rini, B. I. McDermott, D. F. Knox, J. J. Heng, D. Y. TI The impact of body mass index (HMI) and body surface area (RSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada. Cleveland Clin, Cleveland, OH 44106 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4524 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003647 ER PT J AU Choy, E Cao, Y Hornicek, F Wood, KB Schwab, JH Liu, X Mankin, H Duan, Z AF Choy, E. Cao, Y. Hornicek, F. Wood, K. B. Schwab, J. H. Liu, X. Mankin, H. Duan, Z. TI Effect of histone deacetylase inhibitor (HDACI) PCI-24781 on chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Choy, E.; Cao, Y.; Hornicek, F.; Wood, K. B.; Schwab, J. H.; Liu, X.; Mankin, H.; Duan, Z.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10089 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005598 ER PT J AU Clancy, MS Cleary, JM Mani, S Choy, E Wolf, M Silverman, MH Gad, SC Parkman, MH Shapiro, G Dezube, BJ AF Clancy, M. S. Cleary, J. M. Mani, S. Choy, E. Wolf, M. Silverman, M. H. Gad, S. C. Parkman, M. H. Shapiro, G. Dezube, B. J. TI Novel tubulin inhibitors ALB 109564(a) in patients with solid tumurs: A phase I trail SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Montefiore Med Ctr, Bronx, NY 10467 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Albany Mol Res Inc, Albany, NY USA. Aptuit Consulting Inc, Lexington, MA USA. Gad Consulting Serv, Cary, NC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e13119 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000338 ER PT J AU Cleary, JM Heath, EI Kwak, EL Dezube, BJ Gandhi, L Zack, C Bradley, R Vukovic, VM Shapiro, G LoRusso, P AF Cleary, J. M. Heath, E. I. Kwak, E. L. Dezube, B. J. Gandhi, L. Zack, C. Bradley, R. Vukovic, V. M. Shapiro, G. LoRusso, P. TI A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Karmanos Canc Inst, Detroit, MI USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Synta Pharmaceut Corp, Lexington, MA USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3083 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003288 ER PT J AU Cohen, RB Janne, PA Engelman, JA Martinez, P Nishida, Y Gendreau, S Wu, B Felip, E AF Cohen, R. B. Janne, P. A. Engelman, J. A. Martinez, P. Nishida, Y. Gendreau, S. Wu, B. Felip, E. TI A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid fumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Vall dHebron Univ Hosp, Barcelona, Spain. Exelixis, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3015 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003220 ER PT J AU Corless, CL Ballman, KV Antonescu, C Blanke, CD Blackstein, ME Demetri, GD von Mehren, M Maki, RG Pisters, PW DeMatteo, RP AF Corless, C. L. Ballman, K. V. Antonescu, C. Blanke, C. D. Blackstein, M. E. Demetri, G. D. von Mehren, M. Maki, R. G. Pisters, P. W. DeMatteo, R. P. CA Amer Coll Surg Oncology Grp TI Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Mayo Clin Rochester, Rochester, MN USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada. Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. Harvard Canc Ctr, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA. Sarcoma Ctr, Boston, MA USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 16 Z9 19 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10006 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005515 ER PT J AU Cranmer, LD Chawla, SP Rushing, DA Butrynski, JE Okuno, SH Adkins, D Langmuir, VK Lorente, GA Kroll, S Ganjoo, KN AF Cranmer, L. D. Chawla, S. P. Rushing, D. A. Butrynski, J. E. Okuno, S. H. Adkins, D. Langmuir, V. K. Lorente, G. A. Kroll, S. Ganjoo, K. N. TI Phase I/III study of TH-302 combined with doxorubicin in soft tissue sarcoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA. Sarcoma Oncol Ctr, Santa Monica, CA USA. Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin, Rochester, MN USA. Washington Univ, Sch Med, St Louis, MO USA. Threshold Pharmaceut, Redwood City, CA USA. Stanford Univ, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10036 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005545 ER PT J AU Da Grace, DI Yellapragada, S Yasin, Z Arce-Lara, CE AF Da Grace, D. I. Yellapragada, S. Yasin, Z. Arce-Lara, C. E. TI Retrospective analysis of multiple myeloma survival outcomes in veterans: Focus on racial differences, age, and novel therapies SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Da Grace, D. I.; Yellapragada, S.; Yasin, Z.; Arce-Lara, C. E.] Baylor Coll Med, Dan L Duncan Canc Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8127 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005147 ER PT J AU Dandamudi, UB Ghebremichael, MS Sosman, JA Regan, MM Atkins, MB Clark, J Dutcher, JP Curti, BD Vaishampayan, UN Ernstoff, MS AF Dandamudi, U. B. Ghebremichael, M. S. Sosman, J. A. Regan, M. M. Atkins, M. B. Clark, J. Dutcher, J. P. Curti, B. D. Vaishampayan, U. N. Ernstoff, M. S. CA Cytokine Working Grp TI A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Montefiore Med Ctr, North Div, New York, NY USA. Earle A Chiles Res Inst, Portland, OR USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4530 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003653 ER PT J AU DeAngelo, DJ Tefferi, A Mesa, RA Paley, CS Wadleigh, M Snyder, D Ondovik, MS Rine, J Bhalla, KN AF DeAngelo, D. J. Tefferi, A. Mesa, R. A. Paley, C. S. Wadleigh, M. Snyder, D. Ondovik, M. S. Rine, J. Bhalla, K. N. TI A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin Rochester, Rochester, MN USA. Mayo Clin Arizona, Scottsdale, AZ USA. Novartis Pharmaceut, E Hanover, NJ USA. City Hope Natl Med Ctr, Duarte, CA USA. Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS283 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002283 ER PT J AU del Campo, J Ciuleanu, T Sessa, C Westermann, AM Roszak, A Chan, S Hogberg, T Zintl, P Park, YC Krasner, CN AF del Campo, J. Ciuleanu, T. Sessa, C. Westermann, A. M. Roszak, A. Chan, S. Hogberg, T. Zintl, P. Park, Y. C. Krasner, C. N. TI Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC) patients (pts) with a platinum-free interval (PFI) of 6 to 12 months SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Vall dHebron Hosp, Barcelona, Spain. Inst Oncol 1 Chiricuta, Cluj Napoca, Romania. Osped Reg Bellinzona & Valli, Oncol Inst Southern Switzerland, Bellinzona, Switzerland. Ctr Dept Med Oncol, Amsterdam, Zuidoost, Netherlands. Wielkopolsica Ctr Oncol, Poznan, Poland. Univ Nottingham Hosp, Nottingham NG7 2UH, England. Nord Soc Gynaecol Oncol, Lund, Sweden. PharmaMar, Colmenar Vlejo, Madrid, Spain. Johnson & Johnson Pharmaceut Res & Dev, Titusville, NJ USA. Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5060 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004116 ER PT J AU Demetri, GD Blay, J Schoffski, P Maki, RG Yovine, AJ Judson, IR Casali, PG Gomez, J Bayever, E Le Cesne, A AF Demetri, G. D. Blay, J. Schoffski, P. Maki, R. G. Yovine, A. J. Judson, I. R. Casali, P. G. Gomez, J. Bayever, E. Le Cesne, A. TI Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Ludwig Ctr, Harvard Canc Ctr, Boston, MA 02115 USA. Sarcoma Ctr, Boston, MA USA. Univ Lyon 1, F-69365 Lyon, France. Catholic Univ Louvain, Leuven Canc Inst, B-3000 Louvain, Belgium. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. PharmaMar, Madrid, Spain. Canc Res UK Ctr Canc Therapeut, London, England. Ist Nazl Tumori, I-20133 Milan, Italy. Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA. Inst Gustave Roussy, Villejuif, France. RI Blay, Jean-Yves/N-3966-2016 OI Blay, Jean-Yves/0000-0001-7190-120X NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10029 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852005538 ER PT J AU Dodgion, CM Neville, BA Lipsitz, SR Schrag, D Greenberg, CC AF Dodgion, C. M. Neville, B. A. Lipsitz, S. R. Schrag, D. Greenberg, C. C. TI Do older Americans tindrgo stoma reversal following low anterior resection for rectal cancer? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3656 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003467 ER PT J AU Dolly, S Wagner, AJ Bendell, JC Yan, Y Ware, JA Mazina, KE Holden, SN Derynck, MK De Bono, JS Burris, HA AF Dolly, S. Wagner, A. J. Bendell, J. C. Yan, Y. Ware, J. A. Mazina, K. E. Holden, S. N. Derynck, M. K. De Bono, J. S. Burris, H. A., III TI A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Royal Marsden Hosp, London SW3 6JJ, England. Dana Farber Canc Inst, Boston, MA 02115 USA. Sarah Cannon Res Inst, Nashville, TN USA. Genentech Inc, San Francisco, CA 94080 USA. Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton, Surrey, England. Inst Canc Res, Sutton, Surrey, England. Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA. NR 0 TC 11 Z9 11 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3079 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003284 ER PT J AU Drappatz, J Brenner, AJ Rosenfeld, S Groves, MD Mikkelsen, T Schiff, D Sarantopoulos, J Wong, E Wen, PY Castaigne, J AF Drappatz, J. Brenner, A. J. Rosenfeld, S. Groves, M. D. Mikkelsen, T. Schiff, D. Sarantopoulos, J. Wong, E. Wen, P. Y. Castaigne, J. TI ANG1005: Results of a phase I study in patients with recurrent malignant glioma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA. Columbia Univ, Med Ctr, New York, NY USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Henry Ford Hlth Syst, Detroit, MI USA. Univ Virginia, Med Ctr, Charlottesville, VA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Angiochem Inc, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2009 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003004 ER PT J AU Drouin, MA Kollmannsberger, CK Uronis, HE Martell, RE Wang, J Dubay, M Dupont, I Besterman, JM Hurwitz, H Shapiro, G AF Drouin, M. A. Kollmannsberger, C. K. Uronis, H. E. Martell, R. E. Wang, J. Dubay, M. Dupont, I. Besterman, J. M. Hurwitz, H. Shapiro, G. TI Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase 1 study (study 265-101) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 MethylGene Inc, Montreal, PQ, Canada. BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada. Duke Univ, Med Ctr, Durham, NC USA. Tufts Med Ctr, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3106 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003311 ER PT J AU Duda, GD Ancukiewicz, M Clark, JW Miksad, RA Fuchs, C Ryan, DP Jain, RK Zhu, AX AF Duda, G. D. Ancukiewicz, M. Clark, J. W. Miksad, R. A. Fuchs, C. Ryan, D. P. Jain, R. K. Zhu, A. X. TI Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4081 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003546 ER PT J AU Dumont, AG Rink, L Miettinen, M Joensuu, H Strosberg, JR Gronchi, A Corless, CL Lazar, AJ Lev, D von Mehren, M AF Dumont, A. G. Rink, L. Miettinen, M. Joensuu, H. Strosberg, J. R. Gronchi, A. Corless, C. L. Lazar, A. J. Lev, D. von Mehren, M. TI Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor (DT): Case series of 22 patients SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Armed Forces Inst Pathol, Washington, DC 20306 USA. Helsinki Univ Cent Hosp, Helsinki, Finland. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Ist Nazl Tumori, I-20133 Milan, Italy. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10052 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005561 ER PT J AU Edelman, G Bedell, C Shapiro, G Pandya, SS Kwak, EL Scheffold, C Nguyen, LT Laird, A Baselga, J Rodon, J AF Edelman, G. Bedell, C. Shapiro, G. Pandya, S. S. Kwak, E. L. Scheffold, C. Nguyen, L. T. Laird, A. Baselga, J. Rodon, J. TI A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Texas Oncol, Irving, TX USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Exelixis, San Francisco, CA USA. Vall dHebron Univ Hosp, Barcelona, Spain. NR 0 TC 18 Z9 18 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3004 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003209 ER PT J AU Egloff, AM Lee, J Vaezi, AE Langer, CJ Forastiere, AA Quon, H Burtness, B Grandis, JR AF Egloff, A. M. Lee, J. Vaezi, A. E. Langer, C. J. Forastiere, A. A. Quon, H. Burtness, B. Grandis, J. R. TI Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Penn, Philadelphia, PA 19104 USA. Johns Hopkins Univ, Baltimore, MD USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Pittsburgh, Inst Eye & Ear, Pittsburgh, PA 15213 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5537 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004214 ER PT J AU Eichler, AF Kahle, KT Wang, DL Joshi, VA Engelman, JA Sequist, LV AF Eichler, A. F. Kahle, K. T. Wang, D. L. Joshi, V. A. Engelman, J. A. Sequist, L. V. TI EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp Canc Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7542 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004675 ER PT J AU Eichler, AF Shih, HA Sequist, LV Wen, PY Jain, RK Sorensen, AG Batchelor, T AF Eichler, A. F. Shih, H. A. Sequist, L. V. Wen, P. Y. Jain, R. K. Sorensen, A. G. Batchelor, T. TI A phase I study of cediranib plus whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp Canc Ctr, Boston, MA USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS177 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002179 ER PT J AU Engelstaedter, V Cristea, MC Garber, JE Neuhausen, SL Frankel, PH Sand, S Steele, L Matulonis, U Liu, J Weitzel, J AF Engelstaedter, V. Cristea, M. C. Garber, J. E. Neuhausen, S. L. Frankel, P. H. Sand, S. Steele, L. Matulonis, U. Liu, J. Weitzel, J. TI Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. City Hope Natl Med Ctr, Duarte, CA USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5017 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004075 ER PT J AU Enzinger, PC Burtness, B Hollis, D Niedzwiecki, D Ilson, D Benson, AB Mayer, RJ Goldberg, RM AF Enzinger, P. C. Burtness, B. Hollis, D. Niedzwiecki, D. Ilson, D. Benson, A. B. Mayer, R. J. Goldberg, R. M. TI A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. CALGB Stat Ctr, Durham, NC USA. Duke Univ, Durham, NC USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4006 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852003476 ER PT J AU Esserman, L Chu, B Chung, R Ozanne, E Yau, C Tsing, P Baehner, FL Tutt, AN Moore, DH Benz, C AF Esserman, L. Chu, B. Chung, R. Ozanne, E. Yau, C. Tsing, P. Baehner, F. L. Tutt, A. N. Moore, D. H. Benz, C. TI Risk partitioning model shows need to address time dependence of breast cancer recurrence. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Buck Inst Age Res, Novato, CA USA. Guys Hosp, London SE1 9RT, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10605 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005711 ER PT J AU Ewer, M Suter, TM Lenihan, DJ Niculescu, L Breazna, A Motzer, RJ Demetri, GD AF Ewer, M. Suter, T. M. Lenihan, D. J. Niculescu, L. Breazna, A. Motzer, R. J. Demetri, G. D. TI Sunitinib (SU)-related hypertension in a randomieed placebo (P)-controlled trial of GIST patients (pts) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Hosp Bern, CH-3010 Bern, Switzerland. Vanderbilt Heart, Nashville, TN USA. Pfizer Inc, New York, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Ludwig Ctr, Harvard Canc Ctr, Boston, MA 02115 USA. Sarcoma Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10059 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852005568 ER PT J AU Fink, K Mikkelsen, T Nabors, LE Ravin, P Plotkin, SR Schiff, D Hicking, C Picard, M Reardon, DA AF Fink, K. Mikkelsen, T. Nabors, L. E. Ravin, P. Plotkin, S. R. Schiff, D. Hicking, C. Picard, M. Reardon, D. A. TI Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Baylor Res Inst, Dallas, TX USA. Henry Ford Hlth Syst, Detroit, MI USA. Univ Alabama Birmingham, Birmingham, AL USA. Univ Massachusetts, Dept Neurol, Worcester, MA 01605 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Virginia, Med Ctr, Charlottesville, VA USA. Merck KGaA, Darmstadt, Germany. Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2010 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003005 ER PT J AU Fisch, M Lee, J Chang, VT Wagner, LI Cella, D Minasian, LM McCaskill-Stevens, WJ Weiss, M Smith, M Cleeland, CS AF Fisch, M. Lee, J. Chang, V. T. Wagner, L. I. Cella, D. Minasian, L. M. McCaskill-Stevens, W. J. Weiss, M. Smith, M. Cleeland, C. S. TI A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. VA New Jersey Hlth Care Syst, E Orange, NJ USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Northwestern Univ, Chicago, IL 60611 USA. NCI, Bethesda, MD 20892 USA. Minocqua Ctr, Marshfield Clin, Minocqua, WI USA. Res Advocacy Network, Naperville, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9120 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005385 ER PT J AU Flaherty, KT Lee, SJ Schuchter, LM Flaherty, LE Wright, JJ Leming, PD Kirkwood, JM AF Flaherty, K. T. Lee, S. J. Schuchter, L. M. Flaherty, L. E. Wright, J. J. Leming, P. D. Kirkwood, J. M. TI Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Penn, Philadelphia, PA 19104 USA. Wayne State Univ, Detroit, MI USA. NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. Cincinnati Hematol Oncol Inc, Cincinnati, OH USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. NR 0 TC 5 Z9 5 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8511 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005182 ER PT J AU Foss, FM Sjak-Shie, NN Goy, A Advani, R Jacobsen, ED AF Foss, F. M. Sjak-Shie, N. N. Goy, A. Advani, R. Jacobsen, E. D. TI Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Yale Canc Ctr, New Haven, CT USA. Ctr Canc Care & Res, St Louis, MO USA. Hackensack Univ, Med Ctr, Hackensack, NJ USA. Stanford Univ, Med Ctr, Stanford, CA 94305 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8045 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005065 ER PT J AU Freedman, RA Virgo, KS He, Y Pavluck, A Winer, EP Ward, EM Keating, NL AF Freedman, R. A. Virgo, K. S. He, Y. Pavluck, A. Winer, E. P. Ward, E. M. Keating, N. L. TI Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Amer Canc Soc, Atlanta, GA 30329 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 574 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002408 ER PT J AU Furman, RR Byrd, JC Flinn, IW Coutre, SE Benson, DM Brown, JR Kahl, BS WagnerJohnston, ND Giese, NA Yu, AS AF Furman, R. R. Byrd, J. C. Flinn, I. W. Coutre, S. E. Benson, D. M., Jr. Brown, J. R. Kahl, B. S. WagnerJohnston, N. D. Giese, N. A. Yu, A. S. TI Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Weill Cornell Med Coll, New York, NY USA. Ohio State Univ, Columbus, OH 43210 USA. Sarah Cannon Res Inst, Nashville, TN USA. Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Wisconsin, Madison, WI USA. Washington Univ, Sch Med, St Louis, MO USA. Calistoga Pharmaceut Inc, Seattle, WA USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3032 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003237 ER PT J AU Garzotto, M Hung, A Beer, TM Farris, PE AF Garzotto, M. Hung, A. Beer, T. M. Farris, P. E. TI Phase I/II study of preoperative intensity-modulated radiation therapy (IMRT) and docetaxel for high-risk prostate cancer: A platform for radiosensitizer development SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS250 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002250 ER PT J AU Geoerger, B Kieran, MW Grupp, S Blaney, S Perek, D Clancy, J Krygowski, M Boni, J Berkenblit, A Spunt, SL AF Geoerger, B. Kieran, M. W. Grupp, S. Blaney, S. Perek, D. Clancy, J. Krygowski, M. Boni, J. Berkenblit, A. Spunt, S. L. TI Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Inst Gustave Roussy, Villejuif, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp, Philadelphia, PA 19104 USA. Texas Childrens Canc Ctr, Houston, TX USA. Ctr Zdowia Dziecka, Inst Pomnik, Warsaw, Poland. Pfizer Inc, Cambridge, MA USA. Pfizer Inc, Collegeville, PA USA. St Jude Childrens Res Hosp, Memphis, TN 38105 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9541 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005470 ER PT J AU Gerstner, ER Chen, Q Batchelor, T Sorensen, AG AF Gerstner, E. R. Chen, Q. Batchelor, T. Sorensen, A. G. TI Use of FLAIR MRI in determining glioblastoma response to cediranib SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Martinos Ctr Biomed Res, Charlestown, MA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2063 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003058 ER PT J AU Gibney, G Eifiky, A Bussom, S Hoimes, CJ Burns, A McDonough, JA Rowen, E Cheng, YC Kelly, WK AF Gibney, G. Eifiky, A. Bussom, S. Hoimes, C. J. Burns, A. McDonough, J. A. Rowen, E. Cheng, Y. C. Kelly, W. K. TI A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Yale Univ, Sch Med, New Haven, CT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Yale Canc Ctr, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4661 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004030 ER PT J AU Gibney, G Elfiky, A Holmes, CJ Burns, A Rowen, E McDonough, JA Lampert, R Gross, C Kelly, WK AF Gibney, G. Elfiky, A. Holmes, C. J. Burns, A. Rowen, E. McDonough, J. A. Lampert, R. Gross, C. Kelly, W. K. TI Assessing cardiae risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Yale Univ, Sch Med, New Haven, CT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Yale Canc Ctr, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS244 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002244 ER PT J AU Gibson, MK Catalano, PJ Kleinberg, L Staley, CA Montgomery, E Song, W Mulcahy, MF Leichman, LP Benson, AB AF Gibson, M. K. Catalano, P. J. Kleinberg, L. Staley, C. A. Montgomery, E. Song, W. Mulcahy, M. F. Leichman, L. P. Benson, A. B. TI E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins Univ, Baltimore, MD USA. Emory Clin, Atlanta, GA 30322 USA. Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA. Pottstown Canc Ctr, Pottstown, PA USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Desert Reg Med Ctr, Ctr Comprehens Canc, Palm Springs, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4064 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003530 ER PT J AU Gollob, J Infante, JR Shapiro, G LoRusso, P Dezube, BJ Heymach, J Cehelsky, J Falzone, R Vaishnaw, A Burris, HA AF Gollob, J. Infante, J. R. Shapiro, G. LoRusso, P. Dezube, B. J. Heymach, J. Cehelsky, J. Falzone, R. Vaishnaw, A. Burris, H. A., III TI Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Alnylam Pharmaceut, Cambridge, MA USA. Sarah Cannon Res Inst, Nashville, TN USA. Tennessee Oncol, Nashville, TN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3042 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003247 ER PT J AU Gramza, AW Patterson, J Peters, J Kaufman, M Wise, S Flynn, D AF Gramza, A. W. Patterson, J. Peters, J. Kaufman, M. Wise, S. Flynn, D. TI Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Deciphera Pharmaceut, Lawrence, KS USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5559 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004236 ER PT J AU Guo, J Si, L Kong, Y Xu, XW Flaherty, KT Corless, CL Zhu, YY Li, L Li, HF AF Guo, J. Si, L. Kong, Y. Xu, X. W. Flaherty, K. T. Corless, C. L. Zhu, Y. Y. Li, L. Li, H. F. TI A phase II study of imatinib for advanced melanoma patients with KIT aberrations SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Beijing Canc Hosp, Beijing, Peoples R China. Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8527 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005197 ER PT J AU Haddad, RI Tishler, RB Adkins, D Khuri, FR Clark, J Lorch, JH Wirth, LJ Sarlis, NJ Jaffa, Z Posner, MR AF Haddad, R. I. Tishler, R. B. Adkins, D. Khuri, F. R. Clark, J. Lorch, J. H. Wirth, L. J. Sarlis, N. J. Jaffa, Z. Posner, M. R. CA Paradigm Study Grp TI The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. Washington Univ, Sch Med, St Louis, MO USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Sanofi Aventis US, Bridgewater, NJ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5563 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004240 ER PT J AU Hahn, NM Stadler, WM Zon, R Waterhouse, DM Picus, J Nattam, SR Johnson, CS Perkins, SM Waddell, MJ Sweeney, C AF Hahn, N. M. Stadler, W. M. Zon, R. Waterhouse, D. M. Picus, J. Nattam, S. R. Johnson, C. S. Perkins, S. M. Waddell, M. J. Sweeney, C. TI Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. Univ Chicago, Chicago, IL 60637 USA. Michiana Hematol Oncol PC, South Bend, IN USA. Oncol Hematol Care Inc, Cincinnati, OH USA. Washington Univ, Sch Med, St Louis, MO USA. Ft Wayne Med Oncol & Hematol, Ft Wayne, IN USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. Hoosier Oncol Grp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4541 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003664 ER PT J AU Hamann, HA Lee, J Schiller, JH Horn, L Cleeland, CS Manola, J Wagner, LI Chang, VT Fisch, M AF Hamann, H. A. Lee, J. Schiller, J. H. Horn, L. Cleeland, C. S. Manola, J. Wagner, L. I. Chang, V. T. Fisch, M. TI Clinician perceptions of care difficulty and quality of life for lung cancer patients: Results from the ECOG SOAP? study (E2Z02) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. VA New Jersey Hlth Care Syst, E Orange, NJ USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9102 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005367 ER PT J AU Hassett, MJ Niland, JC Hughes, ME Theriault, RL Blayney, DW Wong, Y Hudis, C Marcom, PK Laronga, C Weeks, JC AF Hassett, M. J. Niland, J. C. Hughes, M. E. Theriault, R. L. Blayney, D. W. Wong, Y. Hudis, C. Marcom, P. K. Laronga, C. Weeks, J. C. TI Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. City Hope Natl Med Ctr, Duarte, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Duke Univ, Med Ctr, Durham, NC USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 566 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002400 ER PT J AU Hay, J Atkinson, TM Mendoza, TR Reeve, BB Willis, G Gagne, JJ Abernethy, AP Cleeland, CS Schrag, D Basch, EM AF Hay, J. Atkinson, T. M. Mendoza, T. R. Reeve, B. B. Willis, G. Gagne, J. J. Abernethy, A. P. Cleeland, C. S. Schrag, D. Basch, E. M. TI Refinement of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) via cognitive interviewing. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NCI, Bethesda, MD 20892 USA. Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. Duke Univ, Med Ctr, Durham, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9060 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005326 ER PT J AU Hayes, JH Ollendorf, DA Barry, MJ Pearson, SD McMahon, PM AF Hayes, J. H. Ollendorf, D. A. Barry, M. J. Pearson, S. D. McMahon, P. M. TI Therapeutic options for low-risk prostate cancer: A cost-effectiveness analysis SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Inst Clin & Econ Review, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6012 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004291 ER PT J AU Heinrich, MC Wise, S Hood, M Smith, B Kaufman, M Lu, W Wang, Y Griffith, D Flynn, D Fletcher, JA AF Heinrich, M. C. Wise, S. Hood, M. Smith, B. Kaufman, M. Lu, W. Wang, Y. Griffith, D. Flynn, D. Fletcher, J. A. TI In vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Deciphera Pharmaceut, Lawrence, KS USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10007 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005516 ER PT J AU Heist, RS Duda, GD Sahani, D Pennell, NA Neal, JW Ancukiewicz, M Engelman, JA Lynch, TJ Jain, RK AF Heist, R. S. Duda, G. D. Sahani, D. Pennell, N. A. Neal, J. W. Ancukiewicz, M. Engelman, J. A. Lynch, T. J. Jain, R. K. TI In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Cleveland Clin, Cleveland, OH 44106 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Yale Canc Ctr, New Haven, CT USA. Smilow Canc Hosp, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7612 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004744 ER PT J AU Henderson, TO Whitton, J Leisenring, W Neglia, JP Meadows, AT Oeffinger, KC Diller, L Armstrong, GT Robison, LL Nathan, PC AF Henderson, T. O. Whitton, J. Leisenring, W. Neglia, J. P. Meadows, A. T. Oeffinger, K. C. Diller, L. Armstrong, G. T. Robison, L. L. Nathan, P. C. TI Gastrointestinal malignancies as a subsequent malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Minnesota, Minneapolis, MN USA. Childrens Hosp, Philadelphia, PA 19104 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. St Jude Childrens Res Hosp, Memphis, TN 38105 USA. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9520 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005449 ER PT J AU Heng, DY Xie, W Bjarnason, GA Vaishampayan, UN Donskov, F Wood, L Knox, JJ Tan, M Kollmannsberger, CK Rini, BI Choueiri, TK AF Heng, D. Y. Xie, W. Bjarnason, G. A. Vaishampayan, U. N. Donskov, F. Wood, L. Knox, J. J. Tan, M. Kollmannsberger, C. K. Rini, B. I. Choueiri, T. K. TI A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark. Queen Elizabeth II Heath Sci Ctr, Halifax, NS, Canada. Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. Natl Canc Ctr Singapore, Singapore, Singapore. BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada. Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4523 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003646 ER PT J AU Hensley, ML Wathen, K Maki, RG Araujo, DM Sutton, G Priebat, DA George, S Baker, LH AF Hensley, M. L. Wathen, K. Maki, R. G. Araujo, D. M. Sutton, G. Priebat, D. A. George, S. Baker, L. H. TI Adjuvant treatment of high-risk primary uterine Ieiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. St Vincents Hosp & Hlth Serv, Indianapolis, IN USA. Washington Hosp Ctr, Washington, DC 20010 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10021 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005530 ER PT J AU Heon, S Yeap, BY Britt, GJ Rabin, MS Jackman, DM Johnson, BE AF Heon, S. Yeap, B. Y. Britt, G. J. Rabin, M. S. Jackman, D. M. Johnson, B. E. TI Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7543 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004676 ER PT J AU Higano, CS Small, EJ Schellhammer, PF Kantoff, P Redfern, CH Nemunaitis, JJ Nabhan, C Xu, Y Whitmore, JB Frohlich, MW AF Higano, C. S. Small, E. J. Schellhammer, P. F. Kantoff, P. Redfern, C. H. Nemunaitis, J. J. Nabhan, C. Xu, Y. Whitmore, J. B. Frohlich, M. W. TI Predictors of outcome and subgroup results from the integrated analysis of sipulencel-T trials in metastatic castration-resistant prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Washington, Sch Med, Seattle, WA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Urol Virginia, Norfolk, VA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Oncol Associates San Diego, San Diego, CA USA. Mary Crowley Canc Res Ctr, Dallas, TX USA. Oncol Specialists SC, Park Ridge, IL USA. Dendreon Corp, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4550 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003673 ER PT J AU Higgins, MJ Prowell, TM Blackford, A Slater, S Argani, P Green, H Khouri, N Blumenthal, R Garber, JE Stearns, V AF Higgins, M. J. Prowell, T. M. Blackford, A. Slater, S. Argani, P. Green, H. Khouri, N. Blumenthal, R. Garber, J. E. Stearns, V. TI A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. US FDA, Silver Spring, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins Sch Med, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1505 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002678 ER PT J AU Hirte, HW McGuire, WP Edwards, RP Husain, A Hoskins, P Michels, JE Matulonis, U Sexton, C Fox, JA Michelson, G AF Hirte, H. W. McGuire, W. P., III Edwards, R. P. Husain, A. Hoskins, P. Michels, J. E. Matulonis, U. Sexton, C. Fox, J. A. Michelson, G. TI Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Juravinski Canc Ctr, Hamilton, ON, Canada. Franklin Sq Hosp Ctr, Harry & Jeanette Weinberg Canc Inst, Baltimore, MD USA. Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Pittsburgh, PA 15213 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. BC Canc Agcy, Vancouver, BC, Canada. BC Canc Agcy, Vancouver Isl Ctr, Victoria, BC, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Sunesis Pharmaceut Inc, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5002 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004062 ER PT J AU Hodi, FS O'Day, S McDermott, DF Haanen, JB Robert, C Zhu, X Yellin, MJ Ibrahim, RA Hoos, A Wolchok, JD AF Hodi, F. S. O'Day, S. McDermott, D. F. Haanen, J. B. Robert, C. Zhu, X. Yellin, M. J. Ibrahim, R. A. Hoos, A. Wolchok, J. D. TI Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Angeles Clin & Res Inst, Los Angeles, CA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands. Inst Gustave Roussy, Villejuif, France. Medarex Inc, Bloomsbury, NJ USA. Bristol Myers Squibb Co, Wallingford, CT 06492 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8509 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852005180 ER PT J AU Holloway, RW Roche, M DeMars, L Williams, JA Enke, A Klein, A Linke, RG Krasner, CN AF Holloway, R. W. Roche, M. DeMars, L. Williams, J. A., Jr. Enke, A. Klein, A. Linke, R. G. Krasner, C. N. TI Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Florida Hosp Canc Inst, Orlando, FL USA. Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. South Carolina Oncol Associates, Columbia, SC USA. Fresenius Biotech N Amer, Waltham, MA USA. Fresenius Biotech GmbH, Munich, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5015 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004073 ER PT J AU Hong, TS Tsai, HK Coen, J Blaszkowsky, LS Hartshorn, KL Kwak, EL Willins, J Ryan, DP Kachnic, LA AF Hong, T. S. Tsai, H. K. Coen, J. Blaszkowsky, L. S. Hartshorn, K. L. Kwak, E. L. Willins, J. Ryan, D. P. Kachnic, L. A. TI Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Harvard Radiat Oncol Program, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Boston Univ, Sch Med, Boston, MA 02118 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Boston Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4144 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003609 ER PT J AU Hu, Y Weeks, CM In, H Dodgion, CM Golshan, M Chun, YS Hassett, MJ Gu, X Lipsitz, SR Greenberg, CC AF Hu, Y. Weeks, C. M. In, H. Dodgion, C. M. Golshan, M. Chun, Y. S. Hassett, M. J. Gu, X. Lipsitz, S. R. Greenberg, C. C. TI Impact of neoadjuvant chemotherapy on breast reconstruction. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6135 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004414 ER PT J AU Hughes, KS Schnaper, LA Cirrincione, C Berry, DA McCormick, B Muss, HB Shank, B Hudis, C Winer, EP Smith, BL AF Hughes, K. S. Schnaper, L. A. Cirrincione, C. Berry, D. A. McCormick, B. Muss, H. B. Shank, B. Hudis, C. Winer, E. P. Smith, B. L. CA CALGB ECOG RTOG TI Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Greater Baltimore Med Ctr, Baltimore, MD USA. Duke Univ, Durham, NC USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. Doctors Med Ctr, San Pablo, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 25 Z9 25 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 507 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002347 ER PT J AU Hunter, ZR Yang, G Ioakimidis, LI Hanzis, CA Manning, RJ Patterson, CJ Sheehy, PS Gong, P Xu, L Treon, SP AF Hunter, Z. R. Yang, G. Ioakimidis, L. I. Hanzis, C. A. Manning, R. J. Patterson, C. J. Sheehy, P. S. Gong, P. Xu, L. Treon, S. P. TI Association of CR/VGPR with progression-free survival in rituximab-naive WM patients undergoing rituximab-based therapy, as predicted by polymorphisms in Fc gamma RIIIA-158 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Hunter, Z. R.; Yang, G.; Ioakimidis, L. I.; Hanzis, C. A.; Manning, R. J.; Patterson, C. J.; Sheehy, P. S.; Gong, P.; Xu, L.; Treon, S. P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8108 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005128 ER PT J AU Huober, JB Gelber, S Thurlimann, E Regan, MM Price, KN Goldhirsch, A Coates, AS Viale, G Oehischiegei, C AF Huober, J. B. Gelber, S. Thuerlimann, El. Regan, M. M. Price, K. N. Goldhirsch, A. Coates, A. S. Viale, G. Oehischiegei, C. TI Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Int Breast Canc Study Grp, Bern, Switzerland. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 630 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002464 ER PT J AU Infante, JR Fecher, LA Nallapareddy, S Gordon, MS Flaherty, KT Cox, DS DeMarini, DJ Morris, SR Burris, HA Messersmith, WA AF Infante, J. R. Fecher, L. A. Nallapareddy, S. Gordon, M. S. Flaherty, K. T. Cox, D. S. DeMarini, D. J. Morris, S. R. Burris, H. A. Messersmith, W. A. TI Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Sarah Cannon Res Inst, Nashville, TN USA. Tennessee Oncol, Nashville, TN USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Premiere Oncol Arizona, Scottsdale, AZ USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC USA. NR 0 TC 30 Z9 32 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2503 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003095 ER PT J AU Ioakimidis, LI Hanzis, CA Manning, RJ Patterson, CJ Soumerai, JD Hunter, ZR Brodsky, PS Sheehy, PS Turnbull, B Treon, SP AF Ioakimidis, L. I. Hanzis, C. A. Manning, R. J. Patterson, C. J. Soumerai, J. D. Hunter, Z. R. Brodsky, P. S. Sheehy, P. S. Turnbull, B. Treon, S. P. TI Association of maintenance rituximab with clinical outcome in rituximab-naive patients with Waldenstrom's macroglobulinemia (WM) who respond to a rituximab containing regimen SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Biobridges, Needham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8107 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005127 ER PT J AU Isakoff, SJ Overmoyer, B Tung, NM Gelman, RS Giranda, VL Bernhard, KM Habin, KR Ellisen, LW Winer, EP Goss, PE AF Isakoff, S. J. Overmoyer, B. Tung, N. M. Gelman, R. S. Giranda, V. L. Bernhard, K. M. Habin, K. R. Ellisen, L. W. Winer, E. P. Goss, P. E. TI A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Abbott Labs, Abbott Pk, IL 60064 USA. NR 0 TC 9 Z9 9 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1019 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002534 ER PT J AU Jacobus, SJ Van Wier, SA Ahmann, GJ Henderson, KJ Callander, NS Williams, ME Siegel, DS Greipp, PR Rajkumar, SV Fonseca, R AF Jacobus, S. J. Van Wier, S. A. Ahmann, G. J. Henderson, K. J. Callander, N. S. Williams, M. E. Siegel, D. S. Greipp, P. R. Rajkumar, S. V. Fonseca, R. TI Impact high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin Scottsdale, Scottsdale, AZ USA. Mayo Clin, Rochester, MN USA. Univ Wisconsin, Madison, WI USA. Univ Virginia, Med Ctr, Charlottesville, VA USA. Hackensack Univ, Med Ctr, Hackensack, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10546 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005654 ER PT J AU Jagannath, S Siegel, DS Hajek, R Dimopoulos, MA Yoon, S Lonial, S Graef, T Lupinacci, L Reiser, D Anderson, KC AF Jagannath, S. Siegel, D. S. Hajek, R. Dimopoulos, M. A. Yoon, S. Lonial, S. Graef, T. Lupinacci, L. Reiser, D. Anderson, K. C. TI Update on vantage program to assess combined vorinostol (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 St Vincent Catholic Med Ctr, New York, NY USA. Hackensack Univ Med Ctr, Hackensack, NJ USA. Fac Med MU, Brno, Czech Republic. Univ Hosp Brno, Brno, Czech Republic. Univ Athens, Sch Med, Dept Therapeut, GR-11527 Athens, Greece. Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Merck & Co Inc, Upper Gwynedd, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8133 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852005153 ER PT J AU Jakubowiak, AJ Benson, DM Bensinger, W Siegel, DS Zimmerman, TM Mohrbacher, A Richardson, PG Afar, D Singhal, AK Anderson, KC AF Jakubowiak, A. J. Benson, D. M., Jr. Bensinger, W. Siegel, D. S. Zimmerman, T. M. Mohrbacher, A. Richardson, P. G. Afar, D. Singhal, A. K. Anderson, K. C. CA Multiple Myeloma Res Consortium TI Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Michigan, Ann Arbor, MI 48109 USA. Ohio State Univ, Columbus, OH 43210 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Hackensack Univ, Med Ctr, Hackensack, NJ USA. Univ Chicago, Chicago, IL 60637 USA. Univ So Calif, Los Angeles, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Facet Biotech Inc, Redwood City, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8003 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005023 ER PT J AU James, DF Brown, JR Werner, L Wierda, WG Rai, KR Gould, J Castro, JE Rassenti, L Neuberg, DS Kipps, TJ AF James, D. F. Brown, J. R. Werner, L. Wierda, W. G. Rai, K. R. Gould, J. Castro, J. E. Rassenti, L. Neuberg, D. S. Kipps, T. J. TI Lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia: Report of an ongoing study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif San Diego, Chron Lymphocyt Leukemia Res Consortium, Moores Canc Ctr, La Jolla, CA 92093 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA. Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6583 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004519 ER PT J AU Janeway, KA Kim, S Lodish, M Nose, V Dahia, P Rustin, P Demetri, GD Fletcher, JA Helman, LJ Stratakis, CA AF Janeway, K. A. Kim, S. Lodish, M. Nose, V. Dahia, P. Rustin, P. Demetri, G. D. Fletcher, J. A. Helman, L. J. Stratakis, C. A. CA Consortium Pediat Wildtype GIST TI Succinate dehydrogenase in KIT/PDGFRA wild-type gastrointestinal stromal tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. NCI, Bethesda, MD 20892 USA. NIH, Bethesda, MD 20892 USA. Univ Miami, Sch Med, Miami, FL USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. Hop Robert Debre, F-75019 Paris, France. Harvard Canc Ctr, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA. Sarcoma Ctr, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10008 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005517 ER PT J AU Janne, PA Wang, XF Socinski, MA Crawford, J Capelletti, M Edelman, MJ Villalona-Calero, MA Kratzke, RA Vokes, EE Miller, VA AF Janne, P. A. Wang, X. F. Socinski, M. A. Crawford, J. Capelletti, M. Edelman, M. J. Villalona-Calero, M. A. Kratzke, R. A. Vokes, E. E. Miller, V. A. TI Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/parclitaxel (CP) in never or light former smokers with advanced lung adenocarinoma: CALGB 30406 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA. Univ N Carolina, Chapel Hill, NC USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. Univ Minnesota, Minneapolis, MN USA. Univ Chicago, Chicago, IL 60637 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 9 Z9 13 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7503 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004643 ER PT J AU Johnson, BE Ryan, AJ Heymach, J Stephens, C Kennedy, SJ Langmuir, PB Herbst, RS AF Johnson, B. E. Ryan, A. J. Heymach, J. Stephens, C. Kennedy, S. J. Langmuir, P. B. Herbst, R. S. TI Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. AstraZeneca, Macclesfield, Cheshire, England. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. AstraZeneca, Wilmington, DE USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7516 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004652 ER PT J AU Judson, IR Blay, J Chawla, SP Radford, JA Le Cesne, A Verweij, J von Mehren, M Pontes, J Bayever, E Demetri, GD AF Judson, I. R. Blay, J. Chawla, S. P. Radford, J. A. Le Cesne, A. Verweij, J. von Mehren, M. Pontes, J. Bayever, E. Demetri, G. D. TI Trabecteding (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Canc Res UK Ctr Canc Therapeut, London, England. Univ Lyon 1, F-69365 Lyon, France. Sarcoma Oncol Ctr, Santa Monica, CA USA. Univ Manchester, Manchester, Lancs, England. Christie NHS Fdn Trust, Manchester, Lancs, England. Inst Gustave Roussy, Villejuif, France. Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Rotterdam, Netherlands. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. PharmaMar, Madrid, Spain. Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA. Dana Farber Canc Inst, Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA. Sarcoma Ctr, Boston, MA USA. RI Radford, John/N-1331-2015; Blay, Jean-Yves/N-3966-2016 OI Radford, John/0000-0001-7898-2786; Blay, Jean-Yves/0000-0001-7190-120X NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10028 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005537 ER PT J AU Kabbinavar, FF Miller, VA Johnson, BE O'Connor, PG Soh, C AF Kabbinavar, F. F. Miller, V. A. Johnson, B. E. O'Connor, P. G. Soh, C. CA ATLAS Investigators TI Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Genentech Inc, San Francisco, CA 94080 USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7526 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004661 ER PT J AU Kalinsky, K Lee, SJ Lawrence, DP Kirkwood, JM AF Kalinsky, K. Lee, S. J. Lawrence, D. P. Kirkwood, J. M. TI A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Columbia Univ, Med Ctr, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS312 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002312 ER PT J AU Kantoff, P Petrylak, DP Pomerantz, M Israel, RJ Olson, WC Ramakrishna, T Morris, S AF Kantoff, P. Petrylak, D. P. Pomerantz, M. Israel, R. J. Olson, W. C. Ramakrishna, T. Morris, S. TI First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Columbia Univ, Med Ctr, New York, NY USA. Progen Pharmaceut Inc, Tarrytown, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS245 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002245 ER PT J AU Katz, ML Archer, L Peppercorn, JM Kereakoglow, S Collyar, D Burstein, HJ Schilsky, RL Partridge, AH AF Katz, M. L. Archer, L. Peppercorn, J. M. Kereakoglow, S. Collyar, D. Burstein, H. J. Schilsky, R. L. Partridge, A. H. TI The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Ohio State Univ, Columbus, OH 43210 USA. Canc & Leukemia Grp B, Ctr Stat, Durham, NC USA. Duke Univ, Med Ctr, Durham, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Canc & Leukemia Grp B, Daville, CA USA. Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6148 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004427 ER PT J AU Keefe, SM Moyneur, E Meyers, S Barghout, V Flaherty, KT AF Keefe, S. M. Moyneur, E. Meyers, S. Barghout, V. Flaherty, K. T. TI Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two large US health care claims databases SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Hosp Univ Penn, Philadelphia, PA 19104 USA. StatLog Consulting Inc, Lange Gardien, PQ, Canada. Bayer Healthcare Pharmaceut, Wayne, NJ USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6090 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004369 ER PT J AU Kelly, K Hwang, JJ Shapiro, G Mani, S Cotreau, MM Credi, M Al-Adhami, M Bhargava, P AF Kelly, K. Hwang, J. J. Shapiro, G. Mani, S. Cotreau, M. M. Credi, M. Al-Adhami, M. Bhargava, P. TI Phase I study of AV-412, a novel, irreversible EGER inhibitor, administered intermittently in patients with advanced solid tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Kansas, Med Ctr, Westwood, KS USA. Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Montefiore Med Ctr, Bronx, NY 10467 USA. AVEO Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3103 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003308 ER PT J AU Khan, N Dicker, D Flaherty, KT Lerner, J El-Deiry, W AF Khan, N. Dicker, D. Flaherty, K. T. Lerner, J. El-Deiry, W. TI Hyperspectral imaging: A noninvasive in vivo method of imaging melanoma lesions in a patient being treated with a novel B-RAF inhibitor SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. LightForm Inc, Hillsborough, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e19019 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001557 ER PT J AU Kim, E Sharko, J Drohan, B Roche, C Specht, M Gadd, M Smith, BL Hughes, KS AF Kim, E. Sharko, J. Drohan, B. Roche, C. Specht, M. Gadd, M. Smith, B. L. Hughes, K. S. TI Breast cancer and high-risk diagnosis in core biopsies stratified by ethnicity SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Kim, E.; Sharko, J.; Drohan, B.; Roche, C.; Specht, M.; Gadd, M.; Smith, B. L.; Hughes, K. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1584 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002751 ER PT J AU Kindelberger, D Daniels, K Kantoff, E Atkinson, T Liu, J Campos, SM Berlin, ST Cibas, E Matulonis, U AF Kindelberger, D. Daniels, K. Kantoff, E. Atkinson, T. Liu, J. Campos, S. M. Berlin, S. T. Cibas, E. Matulonis, U. TI Predictive value of circulating tumor cells for response to therapy in women with recurrent epithelial ovarian cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5111 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004166 ER PT J AU Kindler, HL Richards, DA Stephenson, J Garbo, LE Lima, CSR Safran, H Wiezorek, JS Feigal, EG Bray, S Fuchs, C AF Kindler, H. L. Richards, D. A. Stephenson, J. Garbo, L. E. Lima, C. S. Rocha Safran, H. Wiezorek, J. S. Feigal, E. G. Bray, S. Fuchs, C. TI A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Chicago, Chicago, IL 60637 USA. Texas Oncol, Tyler, TX USA. Oncol Res Inst, Greenville, SC USA. Canc Treatment Ctr, Greenville, SC USA. New York Oncol Hematol, Albany, NY USA. Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA. Brown Univ, Oncol Grp, Providence, RI 02912 USA. Amgen Inc, Thousand Oaks, CA USA. Amgen Inc, Cambridge, England. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4035 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852003501 ER PT J AU Kozyreva, ON Chi, D Theall, KP Zhu, AX AF Kozyreva, O. N. Chi, D. Theall, K. P. Zhu, A. X. TI A multicenter retrospective study on clinical features and outcome in elderly patients with hepatocellular carcinoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Tufts Med Ctr, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e14569 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000696 ER PT J AU Krajewski, KM Heng, DY Pedrosa, I Ramaiya, NH Jagannathan, JP Van den Abbeeie, AD Atkins, MB McDermott, DF Schutz, FA Choueiri, TK AF Krajewski, K. M. Heng, D. Y. Pedrosa, I. Ramaiya, N. H. Jagannathan, J. P. Van den Abbeeie, A. D. Atkins, M. B. McDermott, D. F. Schutz, F. A. Choueiri, T. K. TI Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4526 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003649 ER PT J AU Krasner, CN Seiden, M Roche, M Morgan, MA Matulonis, U Wolf, J Drescher, C Alvarez, RD Armstrong, DK Supko, JG AF Krasner, C. N. Seiden, M. Roche, M. Morgan, M. A. Matulonis, U. Wolf, J. Drescher, C. Alvarez, R. D. Armstrong, D. K. Supko, J. G. TI Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Alabama Birmingham, Birmingham, AL USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5037 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004093 ER PT J AU Kraveka, JM Weitzman, SS Smith, L Lynch, JC Chang, M Kinney, M Perkins, SL Laver, JH Gross, TG Weinstein, HJ AF Kraveka, J. M. Weitzman, S. S. Smith, L. Lynch, J. C. Chang, M. Kinney, M. Perkins, S. L. Laver, J. H. Gross, T. G. Weinstein, H. J. CA Children's Oncology Grp TI Advanced-stage anaplastic large-cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trail with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: A report from the Children's Oncology Group SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Med Univ S Carolina, Hollings Canc Ctr, Div Pediat Hematol Oncol, Charleston, SC 29425 USA. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. COG Stat & Data Ctr, Omaha, NE USA. Univ Nebraska Med Ctr, Omaha, NE USA. COG Stat & Data Ctr, Gainesville, FL USA. Univ Florida, Gainesville, FL USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. Univ Utah Hlth Sci, Dept Pathol, Salt Lake City, UT USA. ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA. St Jude Childrens Res Hosp, Memphis, TN 38105 USA. Nationwide Childrens Hosp, Dept Pediat Hematol Oncol, Columbus, OH USA. Massachusetts Gen Hosp, Div Pediat Hematol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9511 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005440 ER PT J AU Kroetz, DL Baldwin, RM Owzar, K Jiang, C Zembutsu, H Kubo, M Nakamura, Y Shulman, LN Retain, MJ AF Kroetz, D. L. Baldwin, R. M. Owzar, K. Jiang, C. Zembutsu, H. Kubo, M. Nakamura, Y. Shulman, L. N. Retain, M. J. CA Canc Leukemia Grp B TI Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Tokyo, Tokyo, Japan. RIKEN, Ctr Genom Med, Yokohama, Kanagawa, Japan. Univ Tokyo, Inst Med Sci, Tokyo, Japan. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Chicago, Chicago, IL 60637 USA. RI Kubo, Michiaki/N-7947-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3021 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003226 ER PT J AU Krop, IE Flores, L Tuck, DP Ryan, PD Partridge, AH Morganstern, D Najita, J Iezon-Geyda, K Winer, EP Harris, L AF Krop, I. E. Flores, L. Tuck, D. P. Ryan, P. D. Partridge, A. H. Morganstern, D. Najita, J. Iezon-Geyda, K. Winer, E. P. Harris, L. TI Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Faulkner Hosp, Dana Farber Canc Inst, Boston, MA USA. Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 549 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002383 ER PT J AU Kumar, S Crowley, J Klein, SK Lahuerta, JJ Lee, J Moreau, P Morgan, G Richardson, PG Siegel, DS Durie, BG AF Kumar, S. Crowley, J. Klein, S. K. Lahuerta, J. J. Lee, J. Moreau, P. Morgan, G. Richardson, P. G. Siegel, D. S. Durie, B. G. CA IMWG TI Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mayo Clin, Rochester, MN USA. Canc Res & Biostat, Seattle, WA USA. Erasmus Univ, Med Ctr, Rotterdam, Netherlands. Hosp Univ 12 Octubre, Madrid, Spain. Gachon Univ Gil Hosp, Inchon, South Korea. Univ Hosp, Nantes, France. Royal Marsden Hosp, London SW3 6JJ, England. Royal Marsden Hosp, Surrey, England. Dana Farber Canc Inst, Boston, MA 02115 USA. Hackensack Univ, Med Ctr, Hackensack, NJ USA. Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA. RI Kumar, Shaji/A-9853-2008; richard, chrystelle/K-8595-2015 OI Kumar, Shaji/0000-0001-5392-9284; NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8125 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005145 ER PT J AU Lacouture, ME McArthur, GA Chapman, PB Ribas, A Flaherty, KT Lee, RJ Nolop, KB Kim, KB Duvic, M Sosman, JA AF Lacouture, M. E. McArthur, G. A. Chapman, P. B. Ribas, A. Flaherty, K. T. Lee, R. J. Nolop, K. B. Kim, K. B. Duvic, M. Sosman, J. A. CA Dermatology Working Grp TI PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. Univ Calif Los Angeles, Los Angeles, CA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Roche, Nutley, NJ USA. Plexxikon Inc, Berkeley, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8592 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005262 ER PT J AU Lawrence, DP Hamid, O McDermott, DF Puzanov, I Sznol, M Clark, J Logan, T Hodi, FS Heller, KN Margolin, KA AF Lawrence, D. P. Hamid, O. McDermott, D. F. Puzanov, I. Sznol, M. Clark, J. Logan, T. Hodi, F. S. Heller, K. N. Margolin, K. A. TI Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Angeles Clin & Res Inst, Santa Monica, CA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Yale Canc Ctr, New Haven, CT USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Bristol Myers Squibb Co, Plainsboro, NJ USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8523 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005193 ER PT J AU Lawson, DH Lee, SJ Tarhini, AA Margolin, KA Ernstoff, MS Kirkwood, JM AF Lawson, D. H. Lee, S. J. Tarhini, A. A. Margolin, K. A. Ernstoff, M. S. Kirkwood, J. M. TI E4697: Phase III cooperative group studt of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. Univ Washington, Seattle, WA 98195 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8504 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005176 ER PT J AU Leavey, P Bender, JLG Mascarenhas, L Granowetter, L Anderson, M Krailo, MD Gorlick, RG Marina, N AF Leavey, P. Bender, J. L. Glade Mascarenhas, L. Granowetter, L. Anderson, M. Krailo, M. D. Gorlick, R. G. Marina, N. TI Feasibility of bevacizumab (NSC 704865, BB-IN D# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): A Children's Oncology Group (COG) study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Columbia Univ, New York, NY USA. Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA. Columbia Univ, CHONY, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. Childrens Oncol Grp, Arcadia, CA USA. Childrens Hosp, Bronx, NY USA. Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9552 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005481 ER PT J AU Leighl, NB Soria, J Bennouna, J Blais, N Traynor, AM Papadimitrakopoulou, V Klimovsky, J Jappe, A Jehl, V Johnson, BE AF Leighl, N. B. Soria, J. Bennouna, J. Blais, N. Traynor, A. M. Papadimitrakopoulou, V. Klimovsky, J. Jappe, A. Jehl, V. Johnson, B. E. TI Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada. Inst Gustave Roussy, Villejuif, France. Ctr Rene Gauducheau, F-44035 Nantes, France. CHUM Hop Notre Dame, Montreal, PQ, Canada. Univ Wisconsin Carbone Canc Ctr, Madison, WI USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Novartis Oncol, E Hanover, NJ USA. Novartis Pharma AG, Basel, Switzerland. Dana Farber Canc Inst, Boston, MA 02115 USA. RI bennouna, jaafar/K-9350-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7524 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004659 ER PT J AU Leijen, S Schellens, JH Shapiro, G Pavlick, AC Tibes, R Demuth, T Viscusi, J Cheng, JD Xu, Y Oza, AM AF Leijen, S. Schellens, J. H. Shapiro, G. Pavlick, A. C. Tibes, R. Demuth, T. Viscusi, J. Cheng, J. D. Xu, Y. Oza, A. M. TI A phase I pharmacological and pharmacodynamic study of MK-1775, a Weel tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Netherlands Canc Inst, Amsterdam, Netherlands. Univ Utrecht, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands. Dana Farber Canc Inst, Boston, MA 02115 USA. NYU, Med Ctr, New York, NY 10016 USA. Scottsdale Healthcare & TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ USA. Merck & Co Inc, N Wales, PA USA. Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3067 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003272 ER PT J AU Lennes, IT Temel, JS Hoedt, C Saylor, PJ Ortiz, TM Admane, S Lamont, EB AF Lennes, I. T. Temel, J. S. Hoedt, C. Saylor, P. J. Ortiz, T. M. Admane, S. Lamont, E. B. TI Predictors of patient misunderstanding of the goals of care at initiation of chemotheraphy SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. SUNY Buffalo, Buffalo, NY 14260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9038 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005304 ER PT J AU Li, J Liu, R Wang, J Rabkin, SD AF Li, J. Liu, R. Wang, J. Rabkin, S. D. TI Cytotoxicity of oncolytic herpes simplex virus vector of breast cancer stem cells. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Sun Yat Sen Univ, Affiliated Hosp 3, Breast Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China. Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurosurg Lab, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e13637 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000487 ER PT J AU Lim, ZD Choueiri, TK Hirsch, MS Jonasch, E Vaishampayan, UN Tamboli, P Corn, PG Hang, DY Tannir, NM AF Lim, Z. Dubauskas Choueiri, T. K. Hirsch, M. S. Jonasch, E. Vaishampayan, U. N. Tamboli, P. Corn, P. G. Hang, D. Y. Tannir, N. M. TI Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4606 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003729 ER PT J AU Lin, NU Ramakrishna, N Younger, WJ Storniolo, AM Come, SE Gelman, RS Eisenberg, E Winer, EP AF Lin, N. U. Ramakrishna, N. Younger, W. J. Storniolo, A. M. Come, S. E. Gelman, R. S. Eisenberg, E. Winer, E. P. TI Phase I study of lapatinib(L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. MD Anderson Canc Ctr Orlando, Orlando, FL USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Indiana Univ Simon Canc Ctr, Indianapolis, IN USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1154 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002669 ER PT J AU Lin, NU Mayer, IA Hobday, TJ Falkson, CI Dees, EC Nanda, R Krop, IE Rimawi, MF Wolff, AC Winer, EP AF Lin, N. U. Mayer, I. A. Hobday, T. J. Falkson, C. I. Dees, E. C. Nanda, R. Krop, I. E. Rimawi, M. F. Wolff, A. C. Winer, E. P. CA TBCRC TI TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Mayo Clin, Rochester, MN USA. Univ Alabama Birmingham, Birmingham, AL USA. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. Univ Chicago, Chicago, IL 60637 USA. Baylor Coll Med, Houston, TX 77030 USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS132 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002135 ER PT J AU Lipshultz, SE Lipsitz, SR Miller, TL Neuberg, DS Dahlberg, SE Colan, SD Silverman, LB Cushman, LL Henkel, JM Sallan, SE AF Lipshultz, S. E. Lipsitz, S. R. Miller, T. L. Neuberg, D. S. Dahlberg, S. E. Colan, S. D. Silverman, L. B. Cushman, L. L. Henkel, J. M. Sallan, S. E. CA Acute Lymphoblastic Leukemia TI Late cardiac status in long-term survivors of childhood high-risk ALL 8 years after continuous or bolus infusion of doxorubicin: The DFCI Childhood ALL 91-01 randomized trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9513 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005442 ER PT J AU Liu, R Wang, J Li, J Rabkin, SD AF Liu, R. Wang, J. Li, J. Rabkin, S. D. TI Treatment of human breast tumors by oncolytic herpes simplex virus. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China. Sun Yat Sen Univ, Affiliated Hosp 3, Breast Canc Ctr, Guangzhou 510275, Guangdong, Peoples R China. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurosurg Lab, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e13605 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000459 ER PT J AU Loggers, ET Soto, E Desanto-Madeya, S Wright, AA Stieglitz, H Paulk, ME Prigerson, HG AF Loggers, E. T. Soto, E. Desanto-Madeya, S. Wright, A. A. Stieglitz, H. Paulk, M. E. Prigerson, H. G. TI The role of acculturation in end-of-life outcomes for Latino advanced cancer patients SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Harvard Univ, Sch Med, Mt Auburn Hosp, Dept Med, Cambridge, MA 02138 USA. Univ Massachusetts, Boston, MA 02125 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas Southwestern, Dallas, TX USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6117 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004396 ER PT J AU Lorch, JH Posner, MR Goloubeva, O Cullen, KJ Sarlis, NJ Tishler, RB Haddad, RI AF Lorch, J. H. Posner, M. R. Goloubeva, O. Cullen, K. J. Sarlis, N. J. Tishler, R. B. Haddad, R. I. CA TAX 324 Study Grp TI Long-term results from TAX324: A phase III trial of sequential therapy comparing TPF to PF in locally advanced (LA) squamous cell cancer of the head and neck (HNC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA. Sanofi Aventis, Bridgewater, NJ USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5512 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004189 ER PT J AU LoRusso, P Krop, IE Burris, HA Vukelja, SJ Miller, K Zheng, M Chu, Y Lu, M Amler, LC Rugo, HS AF LoRusso, P. Krop, I. E. Burris, H. A., III Vukelja, S. J. Miller, K. Zheng, M. Chu, Y. Lu, M. Amler, L. C. Rugo, H. S. TI Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cannon Res Inst Tennessee Oncol, Nashville, TN USA. Texas Oncol, Tyler, TX USA. Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. Genentech Inc, San Francisco, CA 94080 USA. Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1016 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852002532 ER PT J AU Lu, KH Skates, S Bevers, TB Newland, W Moore, RG Leeds, L Harris, S Adeyinka, OW Fritsche, HA Bast, RC AF Lu, K. H. Skates, S. Bevers, T. B. Newland, W. Moore, R. G. Leeds, L. Harris, S. Adeyinka, O. W. Fritsche, H. A. Bast, R. C. TI A prospective US ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Iowa Clin, Des Moines, IA USA. Brown Univ, Women & Infants Hosp, Providence, RI USA. Obstet & Gynecol Associates, Houston, TX USA. Baylor Sammons Breast Ctr, Dallas, TX USA. Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. RI Bast, Robert/E-6585-2011 OI Bast, Robert/0000-0003-4621-8462 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5003 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004063 ER PT J AU Lu, W Lorch, JH Balboni, TA Sher, DJ Goguen, LA Norris, CM Tishler, RB Posner, MR Rosenthal, DS Haddad, RI AF Lu, W. Lorch, J. H. Balboni, T. A. Sher, D. J. Goguen, L. A. Norris, C. M., Jr. Tishler, R. B. Posner, M. R. Rosenthal, D. S. Haddad, R. I. TI Acupuncture for dysphagia after chemoradialion therapy in head and neck cancer: An ongoing pilot, randomized, sham-controlled trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Osher Res Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Surg, Div Otolaryngol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS270 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002270 ER PT J AU Lu-Emerson, C Norden, AD Drappatz, J Quant, EC Ciampa, AS Doherty, LM LaFrankie, DC Wen, PY AF Lu-Emerson, C. Norden, A. D. Drappatz, J. Quant, E. C. Ciampa, A. S. Doherty, L. M. LaFrankie, D. C. Wen, P. Y. TI Retrospective study of dasatinib in recurrent high-grade glioma (HGG) patients who failed bevacizumab. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Lu-Emerson, C.; Norden, A. D.; Drappatz, J.; Quant, E. C.; Ciampa, A. S.; Doherty, L. M.; LaFrankie, D. C.; Wen, P. Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e12525 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000214 ER PT J AU Mahindra, AK Richardson, PG Hari, P Laubach, J Ghobrial, IM Schlossman, RL Weller, E Munshi, NC Anderson, KC Raje, NS AF Mahindra, A. K. Richardson, P. G. Hari, P. Laubach, J. Ghobrial, I. M. Schlossman, R. L. Weller, E. Munshi, N. C. Anderson, K. C. Raje, N. S. TI Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple mycloma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8032 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005052 ER PT J AU Mak, RH Doran, E Muzikansky, A Kang, J Choi, NC Willers, H Jackman, DM Sequist, LV AF Mak, R. H. Doran, E. Muzikansky, A. Kang, J. Choi, N. C. Willers, H. Jackman, D. M. Sequist, L. V. TI Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Radiat Oncol Program, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7016 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004560 ER PT J AU Margalit, DN Heckman, K Chen, Y Catalano, PJ Vivenzio, T Nissen, K Mauch, P Ng, AK AF Margalit, D. N. Heckman, K. Chen, Y. Catalano, P. J. Vivenzio, T. Nissen, K. Mauch, P. Ng, A. K. TI Technologic advancements and error rates in ratiation therapy (RT) delivery. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Canc Consortium, Harvard Radiat Oncol Program, Boston, MA USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Dept Radiat Oncol, Sch Med, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6141 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004420 ER PT J AU Matulonis, U Pereira, L Lee, H Campos, SM Liu, J Lee, J Whalen, C Atkinson, T Hill, M Berlin, ST AF Matulonis, U. Pereira, L. Lee, H. Campos, S. M. Liu, J. Lee, J. Whalen, C. Atkinson, T. Hill, M. Berlin, S. T. TI Sequential angiogenic blockade for the treatment of recurrent ovarian cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5083 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004138 ER PT J AU Mayer, EL Nohria, A Miller, K Rugo, HS Carey, LA Ryabin, N Gelman, RS Winer, EP Burstein, HJ AF Mayer, E. L. Nohria, A. Miller, K. Rugo, H. S. Carey, L. A. Ryabin, N. Gelman, R. S. Winer, E. P. Burstein, H. J. TI Cardiovascular safety of adjuvant bevacizumab for breast cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA. Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 571 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002405 ER PT J AU Mayer, EL Ligibel, JA Burstein, HJ Miller, K Carey, LA Rugo, HS Ryabin, N Gelman, RS Winer, EP Wolff, AC AF Mayer, E. L. Ligibel, J. A. Burstein, H. J. Miller, K. Carey, L. A. Rugo, H. S. Ryabin, N. Gelman, R. S. Winer, E. P. Wolff, A. C. TI TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. Univ N Carolina, Chapel Hill, NC USA. Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS103 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002106 ER PT J AU McArthur, GA Puzanov, I Ribas, A Chapman, PB Kim, KB Sosman, JA Lee, RJ Nolop, KB Flaherty, KT Hicks, R AF McArthur, G. A. Puzanov, I. Ribas, A. Chapman, P. B. Kim, K. B. Sosman, J. A. Lee, R. J. Nolop, K. B. Flaherty, K. T. Hicks, R. TI Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Univ Calif Los Angeles, Los Angeles, CA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Roche, Nutley, NJ USA. Plexxikon Inc, Berkeley, CA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Canc Trials Australia, Melbourne, Vic, Australia. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8529 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005199 ER PT J AU McCarthy, PL Owzar, K Anderson, KC Hofmeister, CC Hassoun, H Hurd, DD Stadtmauer, EA Giralt, S Hars, V Linker, CA AF McCarthy, P. L. Owzar, K. Anderson, K. C. Hofmeister, C. C. Hassoun, H. Hurd, D. D. Stadtmauer, E. A. Giralt, S. Hars, V. Linker, C. A. CA CALGB ECOG BMT-CTN TI Phase III intergroup study of lenalfdomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Duke Univ, Med Ctr, Durham, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Ohio State Univ, Columbus, OH 43210 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Wake Forest Univ, Winston Salem, NC 27109 USA. Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8017 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005037 ER PT J AU McDermott, DF Hebremichael, MS Signoretti, S Margolin, KA Clark, J Sosman, JA Dutcher, JP Logan, T Figlin, RA Atkins, MB AF McDermott, D. F. Hebremichael, M. S. Signoretti, S. Margolin, K. A. Clark, J. Sosman, J. A. Dutcher, J. P. Logan, T. Figlin, R. A. Atkins, M. B. CA Cytokine Working Grp TI The high-dose aldesleukin (HD IL-2) 'SELECT" trial in patients with metastatic renal cell carcinoma (mRCC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Washington, Seattle, WA 98195 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Monash Med Ctr, North Div, New York, NY USA. Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. NR 0 TC 16 Z9 16 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4514 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003640 ER PT J AU McMillin, DW Hunter, ZR Delmore, J Smith, P Birner, A Richardson, PG Anderson, KC Treon, SP Mitsiades, CS AF McMillin, D. W. Hunter, Z. R. Delmore, J. Smith, P. Birner, A. Richardson, P. G. Anderson, K. C. Treon, S. P. Mitsiades, C. S. TI Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenstrom's macroglobulinemia, and effect on miRNA expression SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Takeda Oncol Co, Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8110 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005130 ER PT J AU Meier, FE Beck, D Niessner, H Flaherty, KT Sinnberg, T Schadendorf, D Kulms, D Garbe, C AF Meier, F. E. Beck, D. Niessner, H. Flaherty, K. T. Sinnberg, T. Schadendorf, D. Kulms, D. Garbe, C. TI Effect of mTOR inhibitors on sorafenib-induced endoplasnic reticulum stress and apoptosis in melanoma cells SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Tubingen, Dept Dermatol & Oncol, Tubingen, Germany. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Univ Hosp Essen, Essen, Germany. Univ Stuttgart, Inst Cell Biol & Immunol, D-70174 Stuttgart, Germany. Univ Tubingen, Dept Dermatol, Tubingen, Germany. RI Kulms, Dagmar/H-1653-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e19027 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001565 ER PT J AU Mercado, RC Hempel, H Mopala, R Kastrinos, F Steyerberg, EW Balmana, J Cohn, DE Backes, FJ De La Chapelle, A Syngal, S AF Mercado, R. C. Hempel, H. Mopala, R. Kastrinos, F. Steyerberg, E. W. Balmana, J. Cohn, D. E. Backes, F. J. De La Chapelle, A. Syngal, S. CA CCFR TI Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA. Ohio State Univ, Div Human Genet, Columbus, OH 43210 USA. Columbia Univ, Herbert Irving Comprehens Canc Ctr, Div Digest & Liver Dis, Med Ctr, New York, NY USA. Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. Univ Autonoma Barcelona, Hosp Vall dHebron, Dept Med, E-08193 Barcelona, Spain. Ohio State Univ, Div Gynecol Oncol, Columbus, OH 43210 USA. Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA. Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5024 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004081 ER PT J AU Meyerhardt, JA Schrag, D Kulke, M Enzinger, PC Chan, JA Blaszkowsky, LS Goldstein, M Allen, B Regan, E Abrams, TA AF Meyerhardt, J. A. Schrag, D. Kulke, M. Enzinger, P. C. Chan, J. A. Blaszkowsky, L. S. Goldstein, M. Allen, B. Regan, E. Abrams, T. A. TI Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) in previously treated metastatic colorectal cancer (mCRC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e14055 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000563 ER PT J AU Michaelson, D McDermott, DF Atkins, MB Cho, DC Olivier, KM Schwarzberg, AB Choueiri, TK AF Michaelson, D. McDermott, D. F. Atkins, M. B. Cho, D. C. Olivier, K. M. Schwarzberg, A. B. Choueiri, T. K. TI Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Canc Ctr South Florida, Lake Worth, FL USA. Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e15076 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001084 ER PT J AU Millenson, MM Lee, J Hanna, NH Langer, CJ Hoang, T Graham, DL Okuno, SH Schiller, JH AF Millenson, M. M. Lee, J. Hanna, N. H. Langer, C. J. Hoang, T. Graham, D. L. Okuno, S. H. Schiller, J. H. TI Pemetrexed (Pem) plus gemcitabine (Gem) or carboplatin (Carbo) in patients (pts) with advanced malignant mesothelioma (MPM): A randomized phase II trial, E1B03 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Indiana Univ, Indianapolis, IN 46204 USA. Univ Penn, Philadelphia, PA 19104 USA. Univ Wisconsin, Madison, WI USA. Carle Clin Associates, Urbana, IL USA. Mayo Clin Rochester, Rochester, MN USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e18053 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001391 ER PT J AU Mita, AC Heist, RS Aren, O Mainwaring, PN Bazhenova, L Gadgeel, SM Blum, RH Polikoff, J Biswas, J Spear, MA AF Mita, A. C. Heist, R. S. Aren, O. Mainwaring, P. N. Bazhenova, L. Gadgeel, S. M. Blum, R. H. Polikoff, J. Biswas, J. Spear, M. A. TI Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Inst Nacl Canc Oncol, Santiago, Chile. Mater Misericordiae Adult Hosp, Brisbane, Australia. Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Bendigo Hlth Care Grp, Bendigo, Australia. Kaiser Hosp San Diego, San Diego, CA USA. Chittaranjan Natl Canc Inst, Kolkata, India. Nereus Pharmaceut, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7592 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004725 ER PT J AU Mok, T Spigel, DR Park, K Socinski, MA Tung, SY Kim, D Borzillo, G Zhang, H O'Connell, JP Janne, PA AF Mok, T. Spigel, D. R. Park, K. Socinski, M. A. Tung, S. Y. Kim, D. Borzillo, G. Zhang, H. O'Connell, J. P. Janne, P. A. TI Efficacy and safety of PF-00299804 (PF299). an oral, irreversible, part-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA. Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea. Univ N Carolina, Chapel Hill, NC USA. Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China. Seoul Natl Univ Hosp, Seoul 110744, South Korea. Pfizer Inc, New London, CT USA. Pfizer Res & Dev Co Ltd, Shanghai, Peoples R China. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 10 Z9 10 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7537 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004670 ER PT J AU Morrow, PH Wulf, GM Booser, DJ Moore, JA Flores, PR Krop, IE Winer, EP Hortobagyi, GN Yu, D Esteva, FJ AF Morrow, P. H. Wulf, G. M. Booser, D. J. Moore, J. A. Flores, P. R. Krop, I. E. Winer, E. P. Hortobagyi, G. N. Yu, D. Esteva, F. J. TI Phase I/II trail of everoiimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1014 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002530 ER PT J AU Mullen, JT Kobayashi, W Harmon, DC Choy, E Hornicek, F Gebhardt, MC Springfield, DS Rosenberg, AE Spiro, IJ DeLaney, TF AF Mullen, J. T. Kobayashi, W. Harmon, D. C. Choy, E. Hornicek, F. Gebhardt, M. C. Springfield, D. S. Rosenberg, A. E. Spiro, I. J. DeLaney, T. F. TI Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large extremity soft tissue sarcomas. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10022 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005531 ER PT J AU Munshi, NC Lee, S Roodman, GD Behler, C Kambhampati, S Rose, MG Brophy, MT Houranieh, A Esseltine, D Lichtenstein, A AF Munshi, N. C. Lee, S. Roodman, G. D. Behler, C. Kambhampati, S. Rose, M. G. Brophy, M. T. Houranieh, A. Esseltine, D. Lichtenstein, A. TI Phase II multisite study to evaluate efficacy and safety of single weekly administration of bortezomib (BZ) and dexmethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Boston VA Healthcare Syst, West Roxbury, MA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. San Francisco VA Med Ctr, San Francisco, CA USA. Kansas City Vet Affairs Med Ctr, Kansas City, MO USA. VA Connecticut Healthcare Syst, West Haven, CT USA. Millennium Pharmaceut Inc, Cambridge, MA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS307 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002307 ER PT J AU Nakabayashi, M Oh, WK Werner, L Xie, W Regan, MM McKearn, TJ Kantoff, P Pomerantz, M AF Nakabayashi, M. Oh, W. K. Werner, L. Xie, W. Regan, M. M. McKearn, T. J. Kantoff, P. Pomerantz, M. TI Association of genetic polymorphisms in ERCC1 gene with PSA response to carboplatin chemotherapy in men with metastatic castration-resistant prostate cancer (CRPC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mt Sinai Sch Med, New York, NY USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Agennix Inc, Princeton, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4639 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004009 ER PT J AU Nannini, M Pantaleo, MA Astolfi, A Maleddu, A Heinrich, MC Corless, CL di Battista, M Catena, F Santini, D Biasco, G AF Nannini, M. Pantaleo, M. A. Astolfi, A. Maleddu, A. Heinrich, M. C. Corless, C. L. di Battista, M. Catena, F. Santini, D. Biasco, G. TI Identification of oncogenic events in gastrointestinal stromal tumors (GISTs) by combined gene expression and copy number analysis. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Bologna, Bologna, Italy. Univ Bologna, Seragnoli Dept, Bologna, Italy. Univ Bologna, GIST Study Grp, Bologna, Italy. Interdept Ctr Canc Res, Bologna, Italy. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Univ Bologna, S Orsola Malpighi Hosp, Emergency Surg & Transplant Dept, Bologna, Italy. St Orsola Marcello Malpighi Hosp, Pathol Unit, Bologna, Italy. RI nannini, margherita/J-9866-2016 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10039 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005548 ER PT J AU Neal, JW Pennell, NA Goodgame, BW Lanuti, M Heist, RS Shaw, AT Temel, JS Janne, PA Azzoli, CG Sequist, LV AF Neal, J. W. Pennell, N. A. Goodgame, B. W. Lanuti, M. Heist, R. S. Shaw, A. T. Temel, J. S. Janne, P. A. Azzoli, C. G. Sequist, L. V. TI A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Cleveland Clin, Cleveland, OH 44106 USA. Washington Univ, St Louis, MO USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7078 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004621 ER PT J AU Nghiemphu, PL Omuro, AM Cloughesy, T Mellinghoff, IK Norden, AG Nguyen, LT Rajangam, K Wen, PY AF Nghiemphu, P. L. Omuro, A. M. Cloughesy, T. Mellinghoff, I. K. Norden, A. G. Nguyen, L. T. Rajangam, K. Wen, P. Y. TI A Phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Neurooncol Program, Los Angeles, CA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Exelixis, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3085 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003290 ER PT J AU O'Regan, KN Ramaiya, NH Jagannathan, JP Dipiro, P Van den Abbeele, AD Hodi, FS AF O'Regan, K. N. Ramaiya, N. H. Jagannathan, J. P. Dipiro, P. Van den Abbeele, A. D. Hodi, F. S. TI Patterns of disease spread in metastatic mucosal melanoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [O'Regan, K. N.; Ramaiya, N. H.; Jagannathan, J. P.; Dipiro, P.; Van den Abbeele, A. D.; Hodi, F. S.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8583 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005253 ER PT J AU O'Shaughnessy, J Miles, D Gray, RJ Dieras, V Perez, EA Zon, R Cortes, J Zhou, X Phan, S Miller, K AF O'Shaughnessy, J. Miles, D. Gray, R. J. Dieras, V. Perez, E. A. Zon, R. Cortes, J. Zhou, X. Phan, S. Miller, K. TI A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Baylor Sammons Canc Ctr, Dallas, TX USA. Mt Vernon Canc Ctr, Northwood, Middx, England. Dana Farber Canc Inst, Boston, MA 02115 USA. Inst Curie, Paris, France. Mayo Clin Florida, Jacksonville, FL USA. Michiana Hematol Oncol PC, South Bend, IN USA. Vall dHebron Univ Hosp, Barcelona, Spain. Genentech Inc, San Francisco, CA 94080 USA. Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. NR 0 TC 16 Z9 16 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1005 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002523 ER PT J AU Ottmann, OG Fenaux, P Lubbert, M DeAngelo, DJ Garcia-Manero, G Bhalla, KN Sekeres, MA Ludicke, F Weber, HJ Winiger, IJ AF Ottmann, O. G. Fenaux, P. Luebbert, M. DeAngelo, D. J. Garcia-Manero, G. Bhalla, K. N. Sekeres, M. A. Luedicke, F. Weber, H. J. Winiger, I. J. TI A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myeloid leukemia (AML) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Hosp Frankfurt, Frankfurt, Germany. Hop Avicenne, F-93009 Bobigny, France. Univ Hosp Freiburg, Freiburg, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA. Cleveland Clin, Taussig Canc Inst, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA. Novertis Pharma AG, Basel, Switzerland. RI Ottmann, Oliver/D-5007-2016 OI Ottmann, Oliver/0000-0001-9559-1330 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS282 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002282 ER PT J AU Pandalai, PK Hornick, JL Wang, Q Morgan, JA George, S Baldini, EH Devlin, PM Raut, CP AF Pandalai, P. K. Hornick, J. L. Wang, Q. Morgan, J. A. George, S. Baldini, E. H. Devlin, P. M. Raut, C. P. TI Cutaneous angiosarcoma of the head and neck. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10067 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005576 ER PT J AU Partridge, AH Hughes, ME Wong, Y Edge, SB Theriault, RL Blayney, DW Niland, JC Winer, EP Weeks, JC Tamimi, RM AF Partridge, A. H. Hughes, M. E. Wong, Y. Edge, S. B. Theriault, R. L. Blayney, D. W. Niland, J. C. Winer, E. P. Weeks, J. C. Tamimi, R. M. TI The effect of age on delay in diagnosis and stage of breast cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Michigan, Ann Arbor, MI 48109 USA. City Hope Natl Med Ctr, Duarte, CA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1580 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002747 ER PT J AU Patil, S Figlin, RA Hutson, TE Michaelson, D Negrier, S Kim, ST Huang, X Motzer, RJ AF Patil, S. Figlin, R. A. Hutson, T. E. Michaelson, D. Negrier, S. Kim, S. T. Huang, X. Motzer, R. J. TI TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-alpha) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. City Hope Natl Med Ctr, Duarte, CA USA. Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Ctr Leon Berard, Serv Cancerol Med, F-69373 Lyon, France. Pfizer Inc, La Jolla, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4594 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003717 ER PT J AU Peled, N Hakim, M Haick, H Bunn, PA Miller, YE Kennedy, TC Mitchell, JD Weyant, MJ Hirsch, FR AF Peled, N. Hakim, M. Haick, H. Bunn, P. A. Miller, Y. E. Kennedy, T. C. Mitchell, J. D. Weyant, M. J. Hirsch, F. R. TI Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Colorado Denver Canc Ctr, Aurora, CO USA. Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel. Russell Berrie Nanotechnol Inst, Haifa, Israel. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado Denver, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10521 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005629 ER PT J AU Petricoin, E Ross, MM Zhou, W Tamburro, D Luchini, A Liotta, LA Scully, RE Miller, TL Sallan, SE Lipshultz, SE AF Petricoin, E. Ross, M. M. Zhou, W. Tamburro, D. Luchini, A. Liotta, L. A. Scully, R. E. Miller, T. L. Sallan, S. E. Lipshultz, S. E. TI Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanopartice-capture mass spectrometry. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 George Mason Univ, Manassas, VA USA. George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA. Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy. Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA. Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA. Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RI Luchini, Alessandra/M-5340-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9528 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005457 ER PT J AU Phan, AT Yao, JC Fogelman, DR Hess, KR Ng, CS Bullock, SA Malinowski, P Regan, E Kulke, M AF Phan, A. T. Yao, J. C. Fogelman, D. R. Hess, K. R. Ng, C. S. Bullock, S. A. Malinowski, P. Regan, E. Kulke, M. TI A prospective, multi-institutional phase II study of GW786034 (pozopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 22 Z9 22 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4001 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003471 ER PT J AU Pindyck, T Spurgeon, SE Okada, CY Epner, EE AF Pindyck, T. Spurgeon, S. E. Okada, C. Y. Epner, E. E. TI Cladribine plus rituximab for the initial treatment of mantle cell lymphoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Penn State Hershey Canc Inst, Hershey, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8099 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005119 ER PT J AU Pirl, WF Greer, J Bemis, H Heist, RS Gallagher, E Sequist, LV Engelman, JA Traeger, L Lennes, IT Temel, JS AF Pirl, W. F. Greer, J. Bemis, H. Heist, R. S. Gallagher, E. Sequist, L. V. Engelman, J. A. Traeger, L. Lennes, I. T. Temel, J. S. TI Depression and EGFR mutation status in stage IV non-small cell lung cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9086 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005351 ER PT J AU Pishvalan, MJ Cotarla, I Wagner, AJ Deeken, JF He, AR Hwang, JJ Demetri, GD Halim, A Copigneaux, C Marshall, J AF Pishvalan, M. J. Cotarla, I. Wagner, A. J. Deeken, J. F. He, A. R. Hwang, J. J. Demetri, G. D. Halim, A. Copigneaux, C. Marshall, J. TI Final reporting of a phase I clinical trial of the oral PPAR-gamma against, CS-7017, in patients with advanced malignancies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Georgetown Univ, Med Ctr, Washington, DC 20007 USA. Harvard Canc Ctr, Dana Farber Canc Inst, Ludwig Ctr, Boston, MA USA. Sarcoma Ctr, Boston, MA USA. Daiichi Sankyo Pharma Dev, Edison, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2526 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003118 ER PT J AU Posner, MR Lorch, JH Goloubeva, O Tan, M Schumaker, L Sartis, NJ Haddad, RI Cullen, KJ AF Posner, M. R. Lorch, J. H. Goloubeva, O. Tan, M. Schumaker, L. Sartis, N. J. Haddad, R. I. Cullen, K. J. TI Oropharyax cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Univ Maryland, Marlene & Stewart Greertebaum Canc Ctr, Baltimore, MD 21201 USA. Sanofi Eventis US, Bridgewater, NJ USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5525 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004202 ER PT J AU Pulsifer, MB Delgado, I Tarbell, N Kuhlthau, K MacDonald, SM Yock, TI AF Pulsifer, M. B. Delgado, I. Tarbell, N. Kuhlthau, K. MacDonald, S. M. Yock, T. I. TI Neurocognitive outcomes after proton radiation for pediatric brain tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9508 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005437 ER PT J AU Punglia, RS Wong, JS Burstein, HJ Weeks, JC AF Punglia, R. S. Wong, J. S. Burstein, H. J. Weeks, J. C. TI Decision analysis: Excision alone versus excision plus radiation therapy for ductal carcinoma in situ SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Punglia, R. S.; Wong, J. S.; Burstein, H. J.; Weeks, J. C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 577 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002411 ER PT J AU Quek, RH Morgan, JA Shapiro, G Butrynski, JE Wang, Q Huftalen, T Jederlinic, N Wagner, AJ Demetri, GD George, S AF Quek, R. H. Morgan, J. A. Shapiro, G. Butrynski, J. E. Wang, Q. Huftalen, T. Jederlinic, N. Wagner, A. J. Demetri, G. D. George, S. TI Combination mTOR plus IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Canc Ctr, Dana Farber Canc Inst, Ludwig Ctr, Boston, MA USA. Sarcoma Ctr, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10002 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005511 ER PT J AU Raje, NS Munshi, NC Mahindra, AK Pozzi, S Richardson, PG Laubach, J Ghobrial, IM Schlossman, RL Anderson, KC AF Raje, N. S. Munshi, N. C. Mahindra, A. K. Pozzi, S. Richardson, P. G. Laubach, J. Ghobrial, I. M. Schlossman, R. L. Anderson, K. C. TI Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8140 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005160 ER PT J AU Ramalingam, SS Lee, J Belani, CP Aisner, SC Kolesar, J Howe, CW Velasco, MR Schiller, JH AF Ramalingam, S. S. Lee, J. Belani, C. P. Aisner, S. C. Kolesar, J. Howe, C. W. Velasco, M. R. Schiller, J. H. TI Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Penn State Hershey Canc Inst, Hershey, PA USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. Univ Wisconsin Carbone Canc Ctr, Madison, WI USA. Minnesota Oncol Hematol PA, St Paul, MN USA. Canc Care Specialists, Decatur, GA USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7522 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004658 ER PT J AU Ramanathan, RK Rosen, PJ Wagner, AJ Sahasrabudhe, S Weiss, GJ Lee, P Fuerst, M Robbins, P Litka, P Von Hoff, DD AF Ramanathan, R. K. Rosen, P. J. Wagner, A. J. Sahasrabudhe, S. Weiss, G. J. Lee, P. Fuerst, M. Robbins, P. Litka, P. Von Hoff, D. D. TI A phase I pharmacodynamic and pharmacokinetic study of a Ras inhibitor, PRLX 93936, in patients with advanced solid tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Virginia G Piper Canc Ctr, Scottsdale, AZ USA. TGen, Scottsdale, AZ USA. Tower Canc Res Fdn, Beverly Hills, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Prolexys Pharmaceut Inc, Salt Lake City, UT USA. Scottsdale Healthcare, Virginia G Piper Canc Ctr, Scottsdale, AZ USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e13042 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000279 ER PT J AU Raut, CP Morgan, JA Quek, RH Boucher, Y Duda, GD Lahdenranta, J Ancukiewicz, M Eder, JP Jain, RK Demetri, GD AF Raut, C. P. Morgan, J. A. Quek, R. H. Boucher, Y. Duda, G. D. Lahdenranta, J. Ancukiewicz, M. Eder, J. P. Jain, R. K. Demetri, G. D. TI Measurement of interstitial fluid pressure (IF P) and circulating biomarkers in soft tissue sarcoma (STS): An exploratory phase II clinical and correlative study of sorafenib (SOR) in patients with refractory STS (NCI Protocol 6948). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. AstraZeneca, Waltham, MA USA. Harvard Canc Ctr, Dana Farber Canc Inst, Ludwig Ctr, Boston, MA USA. Sarcoma Ctr, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10091 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005600 ER PT J AU Reichardt, P Blay, J Gelderblom, H Schlemmer, M Demetri, GD Bin Bui, N McArthur, GA Yazji, S Hsu, Y Rutkowski, P AF Reichardt, P. Blay, J. Gelderblom, H. Schlemmer, M. Demetri, G. D. Bin Bui, N. McArthur, G. A. Yazji, S. Hsu, Y. Rutkowski, P. TI Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 HELIOS Klinikum Bad Saarow, Berlin, Germany. Univ Lyon 1, F-69365 Lyon, France. Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands. Univ Munich, Univ Hosp Grosshadem, Dept Internal Med 3, Munich, Germany. Dana Farber Canc Inst, Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA. Sarcoma Ctr, Boston, MA USA. Inst Bergonie, Bordeaux, France. Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. Novartis Pharmaceut, Florham Pk, NJ USA. M Sklodowska Curie Mem Canc Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland. Inst Oncol, Warsaw, Poland. RI Blay, Jean-Yves/N-3966-2016 OI Blay, Jean-Yves/0000-0001-7190-120X NR 0 TC 8 Z9 9 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10017 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852005526 ER PT J AU Ribi, K Aldridge, J Phillips, K Sun, Z Thompson, AM Harvey, VJ Thurlimann, B Cardoso, F Coates, AS Bernhard, J AF Ribi, K. Aldridge, J. Phillips, K. Sun, Z. Thompson, A. M. Harvey, V. J. Thuerlimann, B. Cardoso, F. Coates, A. S. Bernhard, J. TI Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Int Beast Canc Study Grp, Bern, Switzerland. Dana Farber Canc Inst, Int Beast Canc Study Grp Stat Ctr, Boston, MA 02115 USA. Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. Univ Dundee, Dundee, Scotland. Auckland Hosp, Auckland, New Zealand. Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland. Inst Jules Bordet, B-1000 Brussels, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 527 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002363 ER PT J AU Richardson, PG Weber, DM Mitsiades, CS Dimopoulos, MA Harousseau, J Howe, J Graef, T Byrne, C Anderson, KC Siegel, DS AF Richardson, P. G. Weber, D. M. Mitsiades, C. S. Dimopoulos, M. A. Harousseau, J. Howe, J. Graef, T. Byrne, C. Anderson, K. C. Siegel, D. S. TI Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Athens, Sch Med, Dept Therapeut, GR-11527 Athens, Greece. Ctr Rene Gauducheau, St Herblain, France. Merck & Co Inc, Upper Gwynedd, PA USA. Celgene Corp, Summit, NJ USA. Hackensack Univ, Med Ctr, Hackensack, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8031 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852005051 ER PT J AU Rosenberg, JE Drabkin, HA Lara, P Harzstark, AL Figlin, RA Smith, GW Erlandsson, F Laber, DA AF Rosenberg, J. E. Drabkin, H. A. Lara, P., Jr. Harzstark, A. L. Figlin, R. A. Smith, G. W. Erlandsson, F. Laber, D. A. TI A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Med Univ S Carolina, Charleston, SC 29425 USA. Univ Calif Davis, Sacramento, CA 95817 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. City Hope Natl Med Ctr, Duarte, CA USA. St Francis Hosp, Beech Grove, IN USA. Antisoma Res Ltd, London, England. Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4590 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003713 ER PT J AU Rosenzweig, MQ Giblin, JM Mickle, M Morse, A Sheehy, PS Sommer, V AF Rosenzweig, M. Q. Giblin, J. M. Mickle, M. Morse, A. Sheehy, P. S. Sommer, V. TI Knowledge needs of nurse practitioners new to oncology care. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. Emory Clin, Atlanta, GA 30322 USA. Northwestern Mem Fac Fdn, Chicago, IL USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Kansas City Canc Ctr, Kansas City, KS USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e16532 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001274 ER PT J AU Ruddy, KJ Gelber, S Tamimi, RM Schapira, L Come, SE Meyer, ME Winer, EP Partridge, AH AF Ruddy, K. J. Gelber, S. Tamimi, R. M. Schapira, L. Come, S. E. Meyer, M. E. Winer, E. P. Partridge, A. H. TI Coping strategies in young women with breast cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9159 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005423 ER PT J AU Rudin, CM Oliveira, MR Garon, EB Bonomi, P Camidge, DR Nolan, C Busman, T Krivoshik, A Humerickhouse, R Gandhi, L AF Rudin, C. M. Oliveira, M. R. Garon, E. B. Bonomi, P. Camidge, D. R. Nolan, C. Busman, T. Krivoshik, A. Humerickhouse, R. Gandhi, L. TI A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. NorthWest Med Specia, Tacoma, WA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Rush Univ, Med Ctr, Chicago, IL 60612 USA. Univ Colorado Denver, Aurora, CO USA. Abbott Labs, Abbott Pk, IL 60064 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7046 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004590 ER PT J AU Rueda, BR McCann, C Growdon, WB Foster, R Curley, MD Ross, RW Proctor, J MacDougall, J AF Rueda, B. R. McCann, C. Growdon, W. B. Foster, R. Curley, M. D. Ross, R. W. Proctor, J. MacDougall, J. TI Significance of the hedgehog (Hh) pathway in ovarian cancer xenograft growth. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Infin Pharmaceut, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5058 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004114 ER PT J AU Ryan, CJ Smith, MR Logothetis, C Koepfgen, K Taplin, M Harzstark, AL Kantoff, P Khooh, TS Molina, A Small, EJ AF Ryan, C. J. Smith, M. R. Logothetis, C. Koepfgen, K. Taplin, M. Harzstark, A. L. Kantoff, P. Khooh, T. S. Molina, A. Small, E. J. TI Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone at and low-dose prednisone (Pred). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cougar Biotechnol, Los Angeles, CA USA. Ortho Biotech Oncol Res & Dev, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4671 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004040 ER PT J AU Samuel, TA Sessa, C Britten, C Milligan, KS Mita, MM Banerji, U Pluard, TJ Stiegler, P Quad, C Shapiro, G AF Samuel, T. A. Sessa, C. Britten, C. Milligan, K. S. Mita, M. M. Banerji, U. Pluard, T. J. Stiegler, P. Quad, C. Shapiro, G. TI AUY922, a novel HSP90 inhibitor: Final results of a First-in-human study in patients with advanced solid malignancies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Med Coll Georgia, Augusta, GA 30912 USA. Osped Reg Bellinzona & Valli, Oncol Inst Southern Switzerland, Bellinzona, Switzerland. Univ Calif Los Angeles, Clin Res Unit, Los Angeles, CA USA. Nevada Canc Inst, Las Vegas, NV USA. Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA. Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England. Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA. Novartis Pharmaceut, E Hanover, NJ USA. Novartis Pharmaceut, Basel, Switzerland. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2528 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003119 ER PT J AU Samuels, BL Tap, WD Patel, S von Mehren, M Hamm, JT Kaiser, PE Schuetze, S Li, J Bayever, E Demetri, GD AF Samuels, B. L. Tap, W. D. Patel, S. von Mehren, M. Hamm, J. T. Kaiser, P. E. Schuetze, S. Li, J. Bayever, E. Demetri, G. D. TI Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Kootenai Canc Ctr, Post Falls, ID USA. Univ Calif Los Angeles, Santa Monica, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Norton Hlth Care, Louisville, KY USA. Oncol Specialists, Niles, IL USA. Univ Michigan, Ann Arbor, MI 48109 USA. Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA. Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA. Dana Farber Canc Inst, Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA. Sarcoma Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10027 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005536 ER PT J AU San-Miguel, JF Sezer, O Siegel, DS Guenther, A Blade, J Prosser, IW Bengoudifa, B Klebsattel, M Bourquelot, PM Anderson, KC AF San-Miguel, J. F. Sezer, O. Siegel, D. S. Guenther, A. Blade, J. Prosser, I. W. Bengoudifa, B. Klebsattel, M. Bourquelot, P. M. Anderson, K. C. TI Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Hosp Univ Salamanca, Salamanca, Spain. Wuerzburg Univ Hosp, Wurzburg, Germany. Hackensack Univ, Med Ctr, Hackensack, NJ USA. Univ Kiel, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany. Hosp Clin Barcelona, Barcelona, Spain. Canberra Hosp, Canberra, ACT, Australia. Novartis Pharma AG, Basel, Switzerland. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8001 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852005021 ER PT J AU Schiff, D Reardon, DA Kesari, S Mikkelsen, T De Groot, JF Fichtel, L Coyle, TE Wong, E Eaton, C Silver, B AF Schiff, D. Reardon, D. A. Kesari, S. Mikkelsen, T. De Groot, J. F. Fichtel, L. Coyle, T. E. Wong, E. Eaton, C. Silver, B. TI Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Virginia, Med Ctr, Charlottesville, VA USA. Duke Univ, Med Ctr, Durham, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Henry Ford Hlth Syst, Detroit, MI USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. South Texas Oncol & Hematol, San Antonio, TX USA. SUNY Upstate Med Univ, Syracuse, NY 13210 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Adnexus, Waltham, MA USA. RI Kesari, Santosh/E-8461-2013 NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2011 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003006 ER PT J AU Schoenfeld, A Nielsen, GP Hornicek, F Duan, Z Ferrone, S Schwab, JH AF Schoenfeld, A. Nielsen, G. P. Hornicek, F. Duan, Z. Ferrone, S. Schwab, J. H. TI CSPG4 and B7-H3 as prognostic biomarkers in chordonta SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10050 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005559 ER PT J AU Schrag, D Weiser, MR Goodman, KA Gonen, M Cercek, A Reidy, DL Temple, LK Wong, WD Paty, P Saltz, L AF Schrag, D. Weiser, M. R. Goodman, K. A. Gonen, M. Cercek, A. Reidy, D. L. Temple, L. K. Wong, W. D. Paty, P. Saltz, L. TI Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 17 Z9 17 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3511 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003323 ER PT J AU Schuetze, S Wathen, K Choy, E Samuels, BL Ganjoo, KN Staddon, AP von Mehren, M Chow, WA Trent, JC Baker, LH AF Schuetze, S. Wathen, K. Choy, E. Samuels, B. L. Ganjoo, K. N. Staddon, A. P. von Mehren, M. Chow, W. A. Trent, J. C. Baker, L. H. TI Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Michigan, Ann Arbor, MI 48109 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Kootenai Canc Ctr, Post Falls, ID USA. Stanford Univ, Palo Alto, CA 94304 USA. Univ Penn, Philadelphia, PA 19104 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. City Hope Natl Med Ctr, Duarte, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10009 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005518 ER PT J AU Schutz, FA Je, Y Azzi, GR Choueiri, TK AF Schutz, F. A. Je, Y. Azzi, G. R. Choueiri, T. K. TI Risk of congestive heart failure with VEGF-targeted therapy. A systematic review and meta-analysis of clinical trials. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4602 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003725 ER PT J AU Sequist, LV Natale, RB Senzer, NN Martins, R Lilenbaum, R Gray, JE Borger, DR Paez, G Grayzel, DS Gettinger, SN AF Sequist, L. V. Natale, R. B. Senzer, N. N. Martins, R. Lilenbaum, R. Gray, J. E. Borger, D. R. Paez, G. Grayzel, D. S. Gettinger, S. N. TI Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp Canc Ctr, Boston, MA USA. Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA. Mary Crowley Canc Res Ctr, Dallas, TX USA. Seattle Canc Care Alliance, Seattle, WA USA. Mt Sinai Comprehens Canc Ctr, Miami Beach, FL USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA. Infin Pharmaceut, Cambridge, MA USA. Yale Univ Sch Med, New Haven, CT USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7517 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004653 ER PT J AU Shannon, J Lieberman, S Maxcy, C Thuillier, P Peters, L Garzotto, M AF Shannon, J. Lieberman, S. Maxcy, C. Thuillier, P. Peters, L. Garzotto, M. TI Fish oil, green tea, and prostate cancer prevention SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Kaiser Permanente Northwest, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS140 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002143 ER PT J AU Shapiro, G Kwak, EL Dezube, BJ Lawrence, DP Cleary, JM Lewis, S Squires, M Lock, V Lyons, JF Yule, M AF Shapiro, G. Kwak, E. L. Dezube, B. J. Lawrence, D. P. Cleary, J. M. Lewis, S. Squires, M. Lock, V. Lyons, J. F. Yule, M. TI Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Astex Therapeut, Cambridge, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3069 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003274 ER PT J AU Shaw, AT Yeap, B Costa, DB Solomon, BJ Kwak, EL Nguyen, AT Bergethon, K Engelman, JA Iafrate, AJ AF Shaw, A. T. Yeap, B. Costa, D. B. Solomon, B. J. Kwak, E. L. Nguyen, A. T. Bergethon, K. Engelman, J. A. Iafrate, A. J. TI Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. Canc Trials Australia, Melbourne, Vic, Australia. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA. NR 0 TC 5 Z9 6 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7606 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004739 ER PT J AU Sher, DJ Neville, BA Tishler, RB Schrag, D AF Sher, D. J. Neville, B. A. Tishler, R. B. Schrag, D. TI Changing rates of organ-preservation therapy over time for head and neck cancer: A SEER-Medicare analysis SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6063 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004342 ER PT J AU Shonka, NA Gilbert, MR Yung, WA Paio, Y Liu, J Bekele, BN Wen, PY Chen, AP Heymach, J De Groot, JF AF Shonka, N. A. Gilbert, M. R. Yung, W. A. Paio, Y. Liu, J. Bekele, B. N. Wen, P. Y. Chen, A. P. Heymach, J. De Groot, J. F. TI Use of cytokines to predict on-target in patients with recurrent glioblastoma treated with aflibercept SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NCI, Bethesda, MD 20892 USA. RI Gilbert, Mark/J-7494-2016 OI Gilbert, Mark/0000-0003-2556-9722 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e12507 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000199 ER PT J AU Shustov, AR Pro, B Horwitz, SM Jacobsen, ED Boyd, A Fruchtman, SM O'Connor, O AF Shustov, A. R. Pro, B. Horwitz, S. M. Jacobsen, E. D. Boyd, A. Fruchtman, S. M. O'Connor, O. TI Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Seattle Canc Care Alliance, Seattle, WA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Alios Therapeut, Westminster, CO USA. Alios Therapeut, Princeton, NJ USA. NYU, Inst Canc, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8054 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005074 ER PT J AU Sikov, WM Perou, CM Golshan, M Collyar, D Berry, DA Hahn, OM Singh, B Hudis, C Winer, EP AF Sikov, W. M. Perou, C. M. Golshan, M. Collyar, D. Berry, D. A. Hahn, O. M. Singh, B. Hudis, C. Winer, E. P. CA Canc Leukemia Grp B North Amer Intergrp TI Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Canc & Leukemia Grp B, Daville, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Chicago, Chicago, IL 60637 USA. NYU Med Ctr, Tisch Hosp, New York, NY 10016 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS110 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002113 ER PT J AU Slingluff, CL Lee, SJ Chianese-Bullock, KA Olson, WC Butterfield, LH Leming, PD Kirkwood, JM AF Slingluff, C. L. Lee, S. J. Chianese-Bullock, K. A. Olson, W. C. Butterfield, L. H. Leming, P. D. Kirkwood, J. M. TI First report of a randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells in patients with metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1602) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Virginia, Charlottesville, VA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Pittsburgh, Pittsburgh, PA USA. Cincinnati Hematol Oncol Inc, Cincinnati, OH USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8508 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005179 ER PT J AU Small, EJ Beer, TM Weinberg, VK Higano, CS Nordquist, LT Rosenberg, JE Alumkal, JJ Yu, EY Sun, J Lin, AM AF Small, E. J. Beer, T. M. Weinberg, V. K. Higano, C. S. Nordquist, L. T. Rosenberg, J. E. Alumkal, J. J. Yu, E. Y. Sun, J. Lin, A. M. TI Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Univ Washington, Sch Med, Seattle, WA USA. Oncol Hematol West PC, Omaha, NE USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4684 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004053 ER PT J AU Smith, MR Cook, RJ Nelson, JB AF Smith, M. R. Cook, R. J. Nelson, J. B. TI Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Waterloo, Waterloo, ON N2L 3G1, Canada. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4653 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004022 ER PT J AU Soumerai, JD Hunter, LR Boxer, M Kahl, BS Ioakimidis, LI Patterson, CJ Treon, SP AF Soumerai, J. D. Hunter, L. R. Boxer, M. Kahl, B. S. Ioakimidis, L. I. Patterson, C. J. Treon, S. P. TI Long-term follow-up of patients with lymphoplasmacylic lymphoma (Waldenstronls macroglobulinemia) who were treated with alemtuzumab SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Arizona Oncol Associates, Tucson, AZ USA. Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8109 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005129 ER PT J AU Sperduto, PW Xu, Z Sneed, P Luo, X Roberge, D Bhatt, AK Jensen, AW Shih, HA Kirkpatrick, J Gaspar, LE AF Sperduto, P. W. Xu, Z. Sneed, P. Luo, X. Roberge, D. Bhatt, A. K. Jensen, A. W. Shih, H. A. Kirkpatrick, J. Gaspar, L. E. CA Graded Prognostic Assessment GPA TI A graded prognostic assessment (GPA) for women with breast cancer and brain metastases. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Minnesota, Gamma Knife Ctr, Waconia, MN USA. Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Minnesota, Div Biostat, Minneapolis, MN USA. McGill Univ, Dept Radiat Oncol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada. Univ Wisconsin Hosp, Dept Radiat Oncol, Madison, WI USA. Mayo Clin, Dept Radiat Oncol, Rochester, MN USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Colorado Denver, Aurora, CO USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 1028 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002543 ER PT J AU Spurgeon, SE Okada, CY Huang, J Phillips, J Epner, EE AF Spurgeon, S. E. Okada, C. Y. Huang, J. Phillips, J. Epner, E. E. TI Targeting the epigenome: A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab in relapsed B-cell malignancies SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Univ Utah, Salt Lake City, UT USA. Penn State Hershey Canc Inst, Hershey, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS301 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002301 ER PT J AU Stein, MN Chen, Y Hudes, GR Carducci, MA Tan, W DiPaola, RS AF Stein, M. N. Chen, Y. Hudes, G. R. Carducci, M. A. Tan, W. DiPaola, R. S. TI ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Canc Inst New Jersey, New Brunswick, NJ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Mayo Clin Jacksonville, Jacksonville, FL 32224 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4556 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003679 ER PT J AU Stuart, RK Kashani, FR Cripe, LD Maris, MB Cooper, MA Dakhil, SR Stone, RM Turturro, F Fox, JA Michelson, G AF Stuart, R. K. Kashani, F. Ravandi Cripe, L. D. Maris, M. B. Cooper, M. A. Dakhil, S. R. Stone, R. M. Turturro, F. Fox, J. A. Michelson, G. TI Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA. Rocky Mt Blood & Marrow Transplant Program, Denver, CO USA. St Francis Hosp, Indianapolis, IN USA. Canc Ctr Kansas, Wichita, KS USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA. Sunesis Pharmaceut Inc, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6525 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004462 ER PT J AU Sullivan, RJ Frankenthaler, A Wang, W Seery, VJ Lee, M Koon, HB Atkins, MB AF Sullivan, R. J. Frankenthaler, A. Wang, W. Seery, V. J. Lee, M. Koon, H. B. Atkins, M. B. TI A retrospective comparison of 12 weeks versus 52 weeks of adjuvant interferon for patients with stage HB, HC, and IHA (IIB-IIA) melanoma (Mel) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Hosp Case Med Ctr, Cleveland, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 19013 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001551 ER PT J AU Sweeney, C Dugan, WM Dreicer, R Chu, F Parks, G Baker, K Reed, D Jansz, K Zadra, J Yiannoutsos, CT AF Sweeney, C. Dugan, W. M., II Dreicer, R. Chu, F. Parks, G. Baker, K. Reed, D. Jansz, K. Zadra, J. Yiannoutsos, C. T. TI A randomized placebo-controlled trial of daily high-dose oral risedronate in men with metastatic prostate cancer commencing androgen deprivation therapy (ADT) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Hoosier Oncol Grp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Community Canc Care, Indianapolis, IN USA. Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. San Bernadino Urol Associates, San Bernardino, CA USA. Kansas City Urol Care, Overland Pk, KS USA. Madigan Army Med Ctr, Urol Serv, Tacoma, WA 98431 USA. David Reed, Seattle, WA USA. Burlington Profess Ctr, Burlington, ON, Canada. Male Female Hlth & Res, Barrie, ON, Canada. Indiana Univ, Hoosier Oncol Grp, Indianapolis, IN 46204 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e15000 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852001017 ER PT J AU Sznol, M Powderly, JD Smith, DC Brahmer, JR Drake, CG McDermott, DF Lawrence, DP Wolchok, JD Topalian, SL Lowy, I AF Sznol, M. Powderly, J. D. Smith, D. C. Brahmer, J. R. Drake, C. G. McDermott, D. F. Lawrence, D. P. Wolchok, J. D. Topalian, S. L. Lowy, I. TI Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Yale Canc Ctr, New Haven, CT USA. Carolina BioOnco Inst, Huntersville, NC USA. Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA. Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Medarex Inc, Bloomsbury, NJ USA. NR 0 TC 30 Z9 32 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2506 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003098 ER PT J AU Tai, WD Phoon, HP Tan, S Koo, Y Quek, RH Tao, M Lim, S AF Tai, W. D. Phoon, H. P. Tan, S. Koo, Y. Quek, R. H. Tao, M. Lim, S. TI Primary mediastinal large B-cell lymphoma: Otimal therapy and prognostic factors in 40 consecutive Asian patients SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Natl Canc Ctr Singapore, Singapore, Singapore. Natl Canc Ctr, Singapore, Singapore. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8074 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005094 ER PT J AU Tan, W Wilner, KD Bang, Y Kwak, EL Maki, RG Camidge, DR Solomon, BJ Ou, SI Salgia, R Clark, JW AF Tan, W. Wilner, K. D. Bang, Y. Kwak, E. L. Maki, R. G. Camidge, D. R. Solomon, B. J. Ou, S. I. Salgia, R. Clark, J. W. TI Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Pfizer Inc, San Diego, CA USA. Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Colorado Denver, Aurora, CO USA. Peter MacCallum Canc Ctr & Canc Trials Australia, Melbourne, Vic, Australia. Univ Calif Irvine, Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA USA. Univ Chicago, Dept Med, Chicago, IL 60637 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 18 Z9 19 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2596 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003187 ER PT J AU Tannir, NM Wong, Y Kollmannsberger, CK Ernstoff, MS Perry, DJ Appleman, LJ Posadas, EM Qian, J Ricker, JL Michaelson, D AF Tannir, N. M. Wong, Y. Kollmannsberger, C. K. Ernstoff, M. S. Perry, D. J. Appleman, L. J. Posadas, E. M. Qian, J. Ricker, J. L. Michaelson, D. TI Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Washington Hosp Ctr, Washington, DC 20010 USA. Univ Pittsburgh, Pittsburgh, PA USA. Univ Chicago, Chicago, IL 60637 USA. Abbott Labs, Abbott Pk, IL 60064 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4527 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003650 ER PT J AU Tap, WD Demetri, GD Barnette, P Desai, J Kavan, P Tozer, R Friberg, GR Deng, H McCaffery, I Tolcher, AW AF Tap, W. D. Demetri, G. D. Barnette, P. Desai, J. Kavan, P. Tozer, R. Friberg, G. R. Deng, H. McCaffery, I. Tolcher, A. W. TI AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif, Los Angeles Med Hematol Oncol, Santa Monica, CA USA. Harvard Canc Ctr, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA. Sarcoma Ctr, Boston, MA USA. Primary Childrens Med Ctr, Salt Lake City, UT 84103 USA. Royal Melbourne Hosp, Parkville, Vic 3050, Australia. McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada. Juravinski Canc Ctr, Hamilton, ON, Canada. Amgen Inc, Thousand Oaks, CA USA. START Ctr Canc Care, San Antonio, TX USA. NR 0 TC 4 Z9 5 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10001 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005510 ER PT J AU Taplin, M Nakabayashi, A Werner, L Yang, M Xie, W Sun, T Pomerantz, M Freedman, M Lee, GM Kantoff, P AF Taplin, M. Nakabayashi, A. Werner, L. Yang, M. Xie, W. Sun, T. Pomerantz, M. Freedman, M. Lee, G. M. Kantoff, P. TI Association between genetic polymorphisms in SLCO1B3 gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4557 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003680 ER PT J AU Temel, JS Greer, J Gallagher, E Admane, S Pirl, WF Jackson, V Dahlin, C Muzikansky, A Jacobsen, J Lynch, TJ AF Temel, J. S. Greer, J. Gallagher, E. Admane, S. Pirl, W. F. Jackson, V. Dahlin, C. Muzikansky, A. Jacobsen, J. Lynch, T. J. TI Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. SUNY Buffalo, Buffalo, NY 14260 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Yale Canc Ctr, New Haven, CT USA. Smilow Canc Hosp, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7509 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004648 ER PT J AU Temple, LK Patil, S Paty, P Weiser, MR Nash, G Guillem, JG Goodman, KA Wong, WD Schrag, D AF Temple, L. K. Patil, S. Paty, P. Weiser, M. R. Nash, G. Guillem, J. G. Goodman, K. A. Wong, W. D. Schrag, D. TI Bowel dysfunction after sphincter-preserving surgery SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3657 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003468 ER PT J AU Ter-Minassian, M Frauenhoffer, CS Hooshmand, SM Asomaning, K Lin, X Chan, JA Christiani, DC Kulke, M AF Ter-Minassian, M. Frauenhoffer, C. S. Hooshmand, S. M. Asomaning, K. Lin, X. Chan, J. A. Christiani, D. C. Kulke, M. TI Prospective analysis of clinical outcomes and prognostic factors in patients with ne 11 neuroendocrine tumors (NETs) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4044 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003510 ER PT J AU Tevaarwerk, A Lee, J Sesto, MC Buhr, KA Cleeland, CS Manola, J Wagner, LI Chang, VT Fisch, M AF Tevaarwerk, A. Lee, J. Sesto, M. C. Buhr, K. A. Cleeland, C. S. Manola, J. Wagner, L. I. Chang, V. T. Fisch, M. TI Predictors of employment (empl) outcomes in outpatients (pts) with common solid tumors: A secondary analysis from E2Z02 (ECOG's SOAPP study) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Wisconsin, Madison, WI USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. VA New Jersey Hlth Care Syst, E Orange, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 9118 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005383 ER PT J AU Tolcher, AW Mikulski, SM Messersmith, WA Kwak, EL Gibbon, D Boylan, J Xu, ZX DeMario, M Wheler, JJ AF Tolcher, A. W. Mikulski, S. M. Messersmith, W. A. Kwak, E. L. Gibbon, D. Boylan, J. Xu, Z. X. DeMario, M. Wheler, J. J. TI A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 START Ctr Canc Care, San Antonio, TX USA. Hoffmann La Roche, Nutley, NJ USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Canc Inst New Jersey, New Brunswick, NJ USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2502 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003094 ER PT J AU Treon, SP Hanzis, CA Ioakimidis, LI Patterson, CJ Hunter, ZR Brodsky, PS Sheehy, PS Manning, RJ AF Treon, S. P. Hanzis, C. A. Ioakimidis, L. I. Patterson, C. J. Hunter, Z. R. Brodsky, P. S. Sheehy, P. S. Manning, R. J. TI Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstom's macroglobulinemia (WM) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Treon, S. P.; Hanzis, C. A.; Ioakimidis, L. I.; Patterson, C. J.; Hunter, Z. R.; Brodsky, P. S.; Sheehy, P. S.; Manning, R. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8114 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005134 ER PT J AU Vaezi, AE Wang, X Buch, SC Farrow, D Weaver, DT D'Andrea, AD Seethala, RR Romkes, M Niedernhofer, LJ Grandis, JR AF Vaezi, A. E. Wang, X. Buch, S. C. Farrow, D. Weaver, D. T. D'Andrea, A. D. Seethala, R. R. Romkes, M. Niedernhofer, L. J. Grandis, J. R. TI Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Pittsburgh, Pittsburgh, PA USA. On Q Ity, Waltham, MA USA. Univ Pittsburgh, Div Clin Pharmacol, Pittsburgh, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Pittsburgh, Inst Eye & Ear, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5520 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004197 ER PT J AU Vandergrift, JL Mamet, R Zornosa, C Reid, ME Rabin, MS Ettinger, DS Kalemkerian, GP Otterson, GA Niland, JC Pisters, K AF Vandergrift, J. L. Mamet, R. Zornosa, C. Reid, M. E. Rabin, M. S. Ettinger, D. S. Kalemkerian, G. P. Otterson, G. A. Niland, J. C. Pisters, K. CA NCCN Oncology Outcomes Database TI First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Natl Comprehens Canc Network, Ft Washington, PA USA. City Hope Natl Med Ctr, Duarte, CA USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. Arthur G James Canc Hosp, Columbus, OH USA. Solove Res Inst, Columbus, OH USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7634 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005014 ER PT J AU Von Hoff, DD LoRusso, P Tibes, R Shapiro, G Weiss, GJ Ware, JA Fredrickson, J Mazina, KE Levy, GG Wagner, AJ AF Von Hoff, D. D. LoRusso, P. Tibes, R. Shapiro, G. Weiss, G. J. Ware, J. A. Fredrickson, J. Mazina, K. E. Levy, G. G. Wagner, A. J. TI A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Virginia G Piper Canc Ctr, Scottsdale, AZ USA. TGen, Scottsdale, AZ USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Scottsdale Healthcare, Virginia G Piper Canc Ctr, Scottsdale, AZ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Genentech Inc, San Francisco, CA 94080 USA. NR 0 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2541 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003132 ER PT J AU Wakelee, HA Gettinger, SN Engelman, JA Janne, PA West, HJ Subramaniam, DS Leach, JW Wax, MB Yaron, Y Lara, P AF Wakelee, H. A. Gettinger, S. N. Engelman, J. A. Janne, P. A. West, H. J. Subramaniam, D. S. Leach, J. W. Wax, M. B. Yaron, Y. Lara, P., Jr. TI A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Stanford Univ, Sch Med, Stanford, CA 94305 USA. Yale Univ, Sch Med, New Haven, CT USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Swedish Canc Inst, Seattle, WA USA. Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. Pk Nicollet Inst, St Louis Pk, MN USA. Summit Med Grp, Summit, NJ USA. Exelixis, San Francisco, CA USA. Univ Calif Davis, Sacramento, CA 95817 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 3017 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003222 ER PT J AU Waltman, BA Dias-Santagata, D Cosper, AK Mino-Kenudson, M Borger, DR Fidias, P Shaw, AT Iafrate, AJ Engelman, JA Sequist, LV AF Waltman, B. A. Dias-Santagata, D. Cosper, A. K. Mino-Kenudson, M. Borger, D. R. Fidias, P. Shaw, A. T. Iafrate, A. J. Engelman, J. A. Sequist, L. V. TI SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7554 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004687 ER PT J AU Wanebo, HJ Ghebremichael, MS Burtness, B Ridge, JA Spencer, S Rosen, FR Hancock, MR Tolba, KA Forastiere, AA AF Wanebo, H. J. Ghebremichael, M. S. Burtness, B. Ridge, J. A. Spencer, S. Rosen, F. R. Hancock, M. R. Tolba, K. A. Forastiere, A. A. TI Phase II induction cetuximab (C25), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C255, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Landmark Med Ctr, Woonsocket, RI USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Alabama Birmingham, Birmingham, AL USA. John H Stroger Jr Hosp Cook Cty, Chicago, IL USA. St Mary Canc Ctr, Grand Junction, CO USA. Univ Miami, Sch Med, Miami, FL USA. Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5513 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004190 ER PT J AU Wang, J Dang, P Pandalai, PK Raut, CP Maduekwe, UN Yoon, SS AF Wang, J. Dang, P. Pandalai, P. K. Raut, C. P. Maduekwe, U. N. Yoon, S. S. TI Comparison of the 2010 AJCC TNM staging system with a modified lymph node ratio staging system in 7,233 gastric cancer patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4023 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003489 ER PT J AU Wen, PY Prados, M Schiff, D Reardon, DA Cloughesy, T Mikkelsen, T Batchelor, T Drappatz, J Chamberlain, MC De Groot, JF AF Wen, P. Y. Prados, M. Schiff, D. Reardon, D. A. Cloughesy, T. Mikkelsen, T. Batchelor, T. Drappatz, J. Chamberlain, M. C. De Groot, J. F. TI Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Virginia, Med Ctr, Charlottesville, VA USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Henry Ford Hlth Syst, Detroit, MI USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Seattle Canc Care Alliance, Seattle, WA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 2006 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003002 ER PT J AU Wood, ME Kingsley, F Ellerton, JA Atkins, JN Grubbs, SS Muss, HB Garber, JE AF Wood, M. E. Kingsley, F. Ellerton, J. A. Atkins, J. N. Grubbs, S. S. Muss, H. B. Garber, J. E. TI A randomized trial of atorvastatin versus placebo in women at high risk for breast cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Vermont, Coll Med, Fletcher Allen Hlth Care, Burlington, VT USA. Univ Vermont, Coll Med, Burlington, VT USA. Canc Consultants, Las Vegas, NV USA. Southeastern Med Ctr, Winston Salem, NC USA. Med Oncol Hematol Consultants PA, Newark, DE USA. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA TPS141 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852002144 ER PT J AU Wright, AA Pereira, L Nilsson, ME Gibson, C Campos, SM Roche, M Berlin, ST Krasner, CN Penson, RT Matulonis, U AF Wright, A. A. Pereira, L. Nilsson, M. E. Gibson, C. Campos, S. M. Roche, M. Berlin, S. T. Krasner, C. N. Penson, R. T. Matulonis, U. TI Associations between age and quality of life in advanced ovarian cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 5085 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004140 ER PT J AU Yang, G Gong, P Xu, L Hunter, ZR Zhou, Y Liu, X Cao, Y Ciccarelli, B Patterson, CJ Treon, SP AF Yang, G. Gong, P. Xu, L. Hunter, Z. R. Zhou, Y. Liu, X. Cao, Y. Ciccarelli, B. Patterson, C. J. Treon, S. P. TI Activity of the CD20-directed monoclonal antibody GA101 relative to rituximab in Waldenstrom's macroglobulinemia (WM), and applicability to patients expressing Fc gamma RIIIA-158 F/F SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Yang, G.; Gong, P.; Xu, L.; Hunter, Z. R.; Zhou, Y.; Liu, X.; Cao, Y.; Ciccarelli, B.; Patterson, C. J.; Treon, S. P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 8112 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005132 ER PT J AU Yeo, W Riely, GJ Yeap, B Lau, MW Warner, J Bodio, KA Kris, MG Pao, W Kobayashi, S Costa, DB AF Yeo, W. Riely, G. J. Yeap, B. Lau, M. W. Warner, J. Bodio, K. A. Kris, M. G. Pao, W. Kobayashi, S. Costa, D. B. TI Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Natl Univ Singapore Hosp, Singapore 117548, Singapore. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7572 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004705 ER PT J AU Yonesaka, K Okamoto, I Satoh, T Takeda, K Takada, M Nishio, K Fukuoka, M Saijo, N Janne, PA Nakagawa, K AF Yonesaka, K. Okamoto, I. Satoh, T. Takeda, K. Takada, M. Nishio, K. Fukuoka, M. Saijo, N. Janne, P. A. Nakagawa, K. TI Heregulin as a novel cetuximab-resistace factor in colorectal cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Kinki Univ, Sch Med, Osaka 589, Japan. Osaka City Gen Hosp, Osaka, Japan. Kinki Univ, Sch Med, Sakai Hosp, Osaka 589, Japan. Dana Farber Canc Inst, Boston, MA 02115 USA. Kinki Univ Hosp, Osaka, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA e14044 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852000554 ER PT J AU Yoon, SS Chen, Y Karl, D Choy, E Harmon, DC Kambadakone, A Sahani, D Duda, DG Jain, RK DeLaney, TF AF Yoon, S. S. Chen, Y. Karl, D. Choy, E. Harmon, D. C. Kambadakone, A. Sahani, D. Duda, D. G. Jain, R. K. DeLaney, T. F. TI A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Yoon, S. S.; Chen, Y.; Karl, D.; Choy, E.; Harmon, D. C.; Kambadakone, A.; Sahani, D.; Duda, D. G.; Jain, R. K.; DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 10023 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852005532 ER PT J AU Zeliadt, SB Sekaran, NK Slatore, CG Au, DH Wu, DY Crawford, J Lyman, GH Dale, DC AF Zeliadt, S. B. Sekaran, N. K. Slatore, C. G. Au, D. H. Wu, D. Y. Crawford, J. Lyman, G. H. Dale, D. C. TI Comparison of the Veterans Affairs Oncology Registry and the SEER Cancer Registry among patients with lung cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 VA Puget Sound Healthcare Syst, HSR&D Northwest Ctr Excellence, Seattle, WA USA. VA Puget Sound, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA USA. Portland VAMC Hlth Serv Res & Dev, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. Duke Univ, Med Ctr, Durham, NC USA. Duke Univ, Durham, NC USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 6056 PG 2 WC Oncology SC Oncology GA V30YT UT WOS:000208852004335 ER PT J AU Zhang, W Lee, J Schiller, JH Carbone, DP Chung, CH Lenz, H AF Zhang, W. Lee, J. Schiller, J. H. Carbone, D. P. Chung, C. H. Lenz, H. TI Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Vanderbilt Univ, Nashville, TN 37235 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7607 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004740 ER PT J AU Zhu, AX Finn, RS Mulcahy, MF Gurtler, JS Sun, W Schwartz, JD Rojas, P Dontabhaktuni, A Youssoufian, H Stuart, KE AF Zhu, A. X. Finn, R. S. Mulcahy, M. F. Gurtler, J. S. Sun, W. Schwartz, J. D. Rojas, P. Dontabhaktuni, A. Youssoufian, H. Stuart, K. E. TI A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. East Jefferson Gen Hosp, Metairie, LA USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. ImClone Syst, Branchburg, NJ USA. Tufts Univ, Sch Med, Lahey Clin Med Ctr, Burlington, MA USA. NR 0 TC 8 Z9 10 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 4083 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852003548 ER PT J AU Zornosa, C Mamet, R Reid, ME Ettinger, DS Otterson, GA Rabin, MS Hayman, J Niland, JC Pisters, K AF Zornosa, C. Mamet, R. Reid, M. E. Ettinger, D. S. Otterson, G. A. Rabin, M. S. Hayman, J. Niland, J. C. Pisters, K. CA NCCN Oncology Outcomes Database TI Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Natl Comprehens Canc Network, Ft Washington, PA USA. City Hope Natl Med Ctr, Duarte, CA USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. Arthur G James Canc Hosp, Columbus, OH USA. Sotove Res Inst, Columbus, OH USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2010 VL 28 IS 15 SU S MA 7017 PG 1 WC Oncology SC Oncology GA V30YT UT WOS:000208852004561 ER PT J AU Guiguemde, WA Shelat, AA Bouck, D Duffy, S Crowther, GJ Davis, PH Smithson, DC Connelly, M Clark, J Zhu, FY Jimenez-Diaz, MB Martinez, MS Wilson, EB Tripathi, AK Gut, J Sharlow, ER Bathurst, I El Mazouni, F Fowble, JW Forquer, I McGinley, PL Castro, S Angulo-Barturen, I Ferrer, S Rosenthal, PJ DeRisi, JL Sullivan, DJ Lazo, JS Roos, DS Riscoe, MK Phillips, MA Rathod, PK Van Voorhis, WC Avery, VM Guy, RK AF Guiguemde, W. Armand Shelat, Anang A. Bouck, David Duffy, Sandra Crowther, Gregory J. Davis, Paul H. Smithson, David C. Connelly, Michele Clark, Julie Zhu, Fangyi Jimenez-Diaz, Maria B. Martinez, Maria S. Wilson, Emily B. Tripathi, Abhai K. Gut, Jiri Sharlow, Elizabeth R. Bathurst, Ian El Mazouni, Farah Fowble, Joseph W. Forquer, Isaac McGinley, Paula L. Castro, Steve Angulo-Barturen, Inigo Ferrer, Santiago Rosenthal, Philip J. DeRisi, Joseph L. Sullivan, David J., Jr. Lazo, John S. Roos, David S. Riscoe, Michael K. Phillips, Margaret A. Rathod, Pradipsinh K. Van Voorhis, Wesley C. Avery, Vicky M. Guy, R. Kiplin TI Chemical genetics of Plasmodium falciparum SO NATURE LA English DT Article ID DIHYDROOROTATE DEHYDROGENASE; SCREENING LIBRARIES; DRUG DISCOVERY; MALARIA; IDENTIFICATION; DISRUPTION; RESISTANCE; SURVIVAL; GROWTH AB Malaria caused by Plasmodium falciparum is a disease that is responsible for 880,000 deaths per year worldwide. Vaccine development has proved difficult and resistance has emerged for most antimalarial drugs. To discover new antimalarial chemotypes, we have used a phenotypic forward chemical genetic approach to assay 309,474 chemicals. Here we disclose structures and biological activity of the entire library-many of which showed potent in vitro activity against drug-resistant P. falciparum strains-and detailed profiling of 172 representative candidates. A reverse chemical genetic study identified 19 new inhibitors of 4 validated drug targets and 15 novel binders among 61 malarial proteins. Phylochemogenetic profiling in several organisms revealed similarities between Toxoplasma gondii and mammalian cell lines and dissimilarities between P. falciparum and related protozoans. One exemplar compound displayed efficacy in a murine model. Our findings provide the scientific community with new starting points for malaria drug discovery. C1 [Guiguemde, W. Armand; Shelat, Anang A.; Bouck, David; Smithson, David C.; Connelly, Michele; Clark, Julie; Zhu, Fangyi; Guy, R. Kiplin] St Jude Childrens Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA. [Duffy, Sandra; Avery, Vicky M.] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Brisbane, Qld 4111, Australia. [Crowther, Gregory J.; Van Voorhis, Wesley C.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Davis, Paul H.; Roos, David S.] Univ Penn, Penn Genome Frontiers Inst, Philadelphia, PA 19104 USA. [Davis, Paul H.; Roos, David S.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA. [Jimenez-Diaz, Maria B.; Martinez, Maria S.; Angulo-Barturen, Inigo; Ferrer, Santiago] GlaxoSmithKline Inc, Dis Developing World, Tres Cantos 28760, Spain. [Wilson, Emily B.; DeRisi, Joseph L.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA. [Tripathi, Abhai K.; Sullivan, David J., Jr.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA. [Gut, Jiri; Rosenthal, Philip J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA. [Sharlow, Elizabeth R.; Lazo, John S.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA. [Bathurst, Ian] Med Malaria Venture, CH-1215 Geneva, Switzerland. [El Mazouni, Farah; Phillips, Margaret A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA. [Fowble, Joseph W.; Rathod, Pradipsinh K.] Univ Washington, Dept Chem, Seattle, WA 98195 USA. [Forquer, Isaac; Riscoe, Michael K.] Portland VA Med Ctr, Expt Chemotherapy Lab, Portland, OR 97239 USA. [McGinley, Paula L.; Castro, Steve] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA. RP Guy, RK (reprint author), St Jude Childrens Hosp, Dept Chem Biol & Therapeut, 332 N Lauderdale St, Memphis, TN 38105 USA. EM kip.guy@stjude.org RI Avery, Vicky/A-5449-2010; Davis, Paul/J-6141-2012; Shelat, Anang /J-4995-2013; Guy, Rodney/J-7107-2013; duffy, sandra/B-8479-2017; OI Davis, Paul/0000-0002-0526-3841; Guy, Rodney/0000-0002-9638-2060; duffy, sandra/0000-0002-2814-1193; Crowther, Gregory/0000-0003-0530-9130 FU American Lebanese Syrian Associated Charities (ALSAC); St Jude Children's Research Hospital (SJCRH); Medicines for Malaria Venture; National Institute of Allergy and Infectious Diseases [AI772682, AI075517, AI067921, AI080625, AI28724, AI53862, AI35707, AI053680, AI075594, AI082617, AI045774]; National Cancer Institute [CA78039]; Welch Foundation [I-1257]; Doris Duke Charitable Foundation; Ellison Medical Foundation FX This work was supported by the American Lebanese Syrian Associated Charities (ALSAC) and St Jude Children's Research Hospital (SJCRH, R. K. G.), the Medicines for Malaria Venture (W. C. V. V. and V. M. A.), National Institute of Allergy and Infectious Diseases (AI772682 (P. H. D.), AI075517 (R. K. G.), AI067921 (W. C. V. V.) and AI080625 (W. C. V. V.), AI28724 (D. S. R.), AI53862 (J.L.D.), AI35707 (P.J.R.), AI053680 (M. A. P. and P. K. R.), AI075594 (M. A. P., P. K. R. and I. B.), AI082617 (P. K. R.) and AI045774 (D.J.S.)), the National Cancer Institute (CA78039 (J.S.L.)), the Welch Foundation (I-1257 (M. A. P.)), the Doris Duke Charitable Foundation (P.J.R.), and the Ellison Medical Foundation (D. S. R.). We acknowledge A. B. Vaidya for providing the parasite strain D10_yDHOD. We acknowledge M. Sigal for assistance in the early leads project coordination, the SJCRH High Throughput Screening Center, particularly J. Cui; the SJCRH Lead Discovery Informatics Center, and the SJCRH High Throughput Analytical Chemistry Center, particularly C. Nelson and A. Lemoff; at UW, F. Buckner, W. Hol and A. Napuli (AI067921, W. Hol); S. Wei and W. Hao in the UT Southwestern HTS Center; and the Australian Red Cross Blood Service for the provision of O+ erythrocytes to Griffith University. NR 27 TC 286 Z9 289 U1 2 U2 55 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD MAY 20 PY 2010 VL 465 IS 7296 BP 311 EP 315 DI 10.1038/nature09099 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 598IO UT WOS:000277829200032 PM 20485428 ER PT J AU Wu, XW Nguyen, BC Dziunycz, P Chang, S Brooks, Y Lefort, K Hofbauer, GFL Dotto, GP AF Wu, Xunwei Nguyen, Bach-Cuc Dziunycz, Piotr Chang, Sungeun Brooks, Yang Lefort, Karine Hofbauer, Guenther F. L. Dotto, G. Paolo TI Opposing roles for calcineurin and ATF3 in squamous skin cancer SO NATURE LA English DT Article ID TRANSFORMED PHENOTYPE; CELLULAR SENESCENCE; TUMOR SUPPRESSION; INHIBITOR DSCR1; STEM-CELLS; C-MYC; GROWTH; DIFFERENTIATION; PROLIFERATION; CARCINOMA AB Calcineurin inhibitors such as cyclosporin A (CsA) are the mainstay of immunosuppressive treatment for organ transplant recipients. Squamous cell carcinoma (SCC) of the skin is a major complication of treatment with these drugs, with a 65 to 100-fold higher risk than in the normal population(1). By contrast, the incidence of basal cell carcinoma (BCC), the other major keratinocyte-derived tumour of the skin, of melanoma and of internal malignancies increases to a significantly lesser extent(1). Here we report that genetic and pharmacological suppression of calcineurin/nuclear factor of activated T cells (NFAT) function promotes tumour formation in mouse skin and in xenografts, in immune compromised mice, of H-ras(V12) (also known as Hras1)-expressing primary human keratinocytes or keratinocyte-derived SCC cells. Calcineurin/NFAT inhibition counteracts p53 (also known as TRP53)-dependent cancer cell senescence, thereby increasing tumorigenic potential. ATF3, a member of the 'enlarged' AP-1 family, is selectively induced by calcineurin/NFAT inhibition, both under experimental conditions and in clinically occurring tumours, and increased ATF3 expression accounts for suppression of p53-dependent senescence and enhanced tumorigenic potential. Thus, intact calcineurin/NFAT signalling is critically required for p53 and senescence-associated mechanisms that protect against skin squamous cancer development. C1 [Wu, Xunwei; Nguyen, Bach-Cuc; Chang, Sungeun; Brooks, Yang; Dotto, G. Paolo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. [Dziunycz, Piotr; Hofbauer, Guenther F. L.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland. [Lefort, Karine; Dotto, G. Paolo] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland. RP Dotto, GP (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. EM gian-paolo.dotto@unil.ch RI Hofbauer, Gunther/B-2671-2010 OI Hofbauer, Gunther/0000-0003-0542-7989 FU NIH [AR054856, AR39190]; Swiss National Foundation [311003A-122281/1]; Oncosuisse [OCS-02361-02-2009]; European Union [LSHB-CT-2005-019067]; Korean Government Foundation [KRF-2007-013-E00044]; Olga-Mayenfisch-Stiftung FX We thank P. Khavari, S. Kitajima, N. Clipstone and G. Crabtree for gift of retroviruses, W. Austen for human skin material, C. Brisken and C. Missero for careful reading of the manuscript, and E. Castillo for sequencing of the ras and p53 genes. This work was supported by grants from NIH (AR054856 and AR39190), the Swiss National Foundation (311003A-122281/1), Oncosuisse (OCS-02361-02-2009), the European Union (Epistem, Sixth Framework Program, LSHB-CT-2005-019067) and, in part, by a grant to S. C. by the Korean Government Foundation (KRF-2007-013-E00044) and to G. F. L. H. by the Olga-Mayenfisch-Stiftung. NR 37 TC 111 Z9 111 U1 0 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD MAY 20 PY 2010 VL 465 IS 7296 BP 368 EP U130 DI 10.1038/nature08996 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 598IO UT WOS:000277829200045 PM 20485437 ER PT J AU D'Andrea, AD AF D'Andrea, Alan D. TI MECHANISMS OF DISEASE Susceptibility Pathways in Fanconi's Anemia and Breast Cancer SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Review ID DNA-DAMAGE RESPONSE; CROSS-LINK REPAIR; ACUTE MYELOID-LEUKEMIA; HOMOLOGOUS RECOMBINATION REPAIR; SHARED GENETIC SUSCEPTIBILITY; PANCREATIC-CANCER; POLY(ADP-RIBOSE) POLYMERASE; CORE COMPLEX; BRCA PATHWAY; GERMLINE MUTATIONS C1 [D'Andrea, Alan D.] Childrens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. [D'Andrea, Alan D.] Childrens Hosp, Dept Pediat, Dana Farber Canc Inst, Boston, MA 02115 USA. [D'Andrea, Alan D.] Harvard Univ, Sch Med, Boston, MA USA. RP D'Andrea, AD (reprint author), Childrens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM alan_dandrea@dfci.harvard.edu FU National Institutes of Health [RO1DK43889, R01HL52725, PO1CA092584, U19A1067751] FX Supported by grants (RO1DK43889, R01HL52725, PO1CA092584, and U19A1067751) from the National Institutes of Health. NR 117 TC 156 Z9 158 U1 1 U2 21 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 20 PY 2010 VL 362 IS 20 BP 1909 EP 1919 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 598EI UT WOS:000277815600009 PM 20484397 ER PT J AU Muss, HB D'Alessandro, HA Brachtel, EF AF Muss, Hyman B. D'Alessandro, Helen Anne Brachtel, Elena F. TI A Woman with Mammographically Detected Early Breast Cancer Invasive ductal carcinoma of the breast, grade 3 of 3, positive for estrogen receptors, progesterone receptors, and HER2 SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIALS; GERIATRIC ASSESSMENT; AMERICAN-SOCIETY; 15-YEAR SURVIVAL; PROGNOSTIC INDEX; OLDER WOMEN; AGE; TRASTUZUMAB; COMORBIDITY C1 [Muss, Hyman B.] Univ N Carolina, Dept Med, Div Hematol & Oncol, Chapel Hill, NC 27515 USA. [Muss, Hyman B.] Univ N Carolina, Dept Med, Coll Med, Chapel Hill, NC USA. [D'Alessandro, Helen Anne] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Brachtel, Elena F.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [D'Alessandro, Helen Anne] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Brachtel, Elena F.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Muss, HB (reprint author), Univ N Carolina, Dept Med, Div Hematol & Oncol, Chapel Hill, NC 27515 USA. NR 40 TC 1 Z9 1 U1 0 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 20 PY 2010 VL 362 IS 20 BP 1921 EP 1928 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 598EI UT WOS:000277815600013 PM 20484399 ER PT J AU Isselbacher, EM AF Isselbacher, Eric M. TI A Man with Abdominal and Flank Pain REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID DISEASE C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Isselbacher, EM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 20 PY 2010 VL 362 IS 20 BP 1944 EP 1945 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 598EI UT WOS:000277815600034 ER PT J AU Moncaster, JA Pineda, R Moir, RD Lu, SQ Burton, MA Ghosh, JG Ericsson, M Soscia, SJ Mocofanescu, A Folkerth, RD Robb, RM Kuszak, JR Clark, JI Tanzi, RE Hunter, DG Goldstein, LE AF Moncaster, Juliet A. Pineda, Roberto Moir, Robert D. Lu, Suqian Burton, Mark A. Ghosh, Joy G. Ericsson, Maria Soscia, Stephanie J. Mocofanescu, Anca Folkerth, Rebecca D. Robb, Richard M. Kuszak, Jer R. Clark, John I. Tanzi, Rudolph E. Hunter, David G. Goldstein, Lee E. TI Alzheimer's Disease Amyloid-beta Links Lens and Brain Pathology in Down Syndrome SO PLOS ONE LA English DT Article ID PROTEIN-PRECURSOR; EXPRESSION; DEPOSITION; DEMENTIA; LOCUS; HYPOTHESIS; CRYSTALLIN; CATARACTS; PEOPLE; CDNA AB Down syndrome (DS, trisomy 21) is the most common chromosomal disorder and the leading genetic cause of intellectual disability in humans. In DS, triplication of chromosome 21 invariably includes the APP gene (21q21) encoding the Alzheimer's disease (AD) amyloid precursor protein (APP). Triplication of the APP gene accelerates APP expression leading to cerebral accumulation of APP-derived amyloid-beta peptides (A beta), early-onset AD neuropathology, and age-dependent cognitive sequelae. The DS phenotype complex also includes distinctive early-onset cerulean cataracts of unknown etiology. Previously, we reported increased A beta accumulation, co-localizing amyloid pathology, and disease-linked supranuclear cataracts in the ocular lenses of subjects with AD. Here, we investigate the hypothesis that related AD-linked A beta pathology underlies the distinctive lens phenotype associated with DS. Ophthalmological examinations of DS subjects were correlated with phenotypic, histochemical, and biochemical analyses of lenses obtained from DS, AD, and normal control subjects. Evaluation of DS lenses revealed a characteristic pattern of supranuclear opacification accompanied by accelerated supranuclear A beta accumulation, co-localizing amyloid pathology, and fiber cell cytoplasmic A beta aggregates (similar to 5 to 50 nm) identical to the lens pathology identified in AD. Peptide sequencing, immunoblot analysis, and ELISA confirmed the identity and increased accumulation of A beta in DS lenses. Incubation of synthetic A beta with human lens protein promoted protein aggregation, amyloid formation, and light scattering that recapitulated the molecular pathology and clinical features observed in DS lenses. These results establish the genetic etiology of the distinctive lens phenotype in DS and identify the molecular origin and pathogenic mechanism by which lens pathology is expressed in this common chromosomal disorder. Moreover, these findings confirm increased A beta accumulation as a key pathogenic determinant linking lens and brain pathology in both DS and AD. C1 [Moncaster, Juliet A.; Lu, Suqian; Burton, Mark A.; Ghosh, Joy G.; Mocofanescu, Anca; Goldstein, Lee E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Mol Aging & Dev Lab,Dept Surg, Boston, MA 02115 USA. [Pineda, Roberto] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. [Moir, Robert D.; Soscia, Stephanie J.; Tanzi, Rudolph E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit,Dept Neurol, Charlestown, MA USA. [Ericsson, Maria] Harvard Univ, Dept Cell Biol, Sch Med, Elect Microscopy Facil, Boston, MA USA. [Folkerth, Rebecca D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Robb, Richard M.; Hunter, David G.] Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA. [Kuszak, Jer R.] Rush Univ, Med Ctr, Dept Ophthalmol, Chicago, IL 60612 USA. [Kuszak, Jer R.] Rush Univ, Dept Pathol, Med Ctr, Chicago, IL 60612 USA. [Clark, John I.] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA. [Clark, John I.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA. RP Moncaster, JA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Mol Aging & Dev Lab,Dept Surg, Boston, MA 02115 USA. EM LGOLD@BU.EDU OI Moncaster, Juliet/0000-0002-7849-4325; Hunter, David/0000-0002-4587-4794; Goldstein, Lee/0000-0001-8419-9800 FU National Institutes of Health, Bethesda, MD [R01GM75986, K23AG024792]; American Federation for Aging Research, New York, NY; Alzheimer's Association, Chicago, IL; American Health Assistance Foundation, Clarksburg, MD; Cure Alzheimer's Fund, Wellesley Hills, MA; Boston University School of Medicine, Boston, MA; Boston University Alzheimer's Disease Center, Boston, MA (NIH ADCC) [P30AG13846] FX Funding: National Institutes of Health, Bethesda, MD (R01GM75986 and K23AG024792, LEG); American Federation for Aging Research, New York, NY (LEG); Alzheimer's Association, Chicago, IL (LEG); American Health Assistance Foundation, Clarksburg, MD (LEG); Anonymous Foundation (LEG); Cure Alzheimer's Fund, Wellesley Hills, MA (RDM); Boston University School of Medicine, Boston, MA (LEG); and Boston University Alzheimer's Disease Center, Boston, MA (NIH ADCC grant P30AG13846). The funding sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The senior corresponding author (LEG) has full access to all study data and takes final responsibility for the decision to submit the results of the study for publication. NR 50 TC 49 Z9 50 U1 2 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 20 PY 2010 VL 5 IS 5 AR e10659 DI 10.1371/journal.pone.0010659 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 600VP UT WOS:000278017300002 PM 20502642 ER PT J AU Van Cleave, J Gortmaker, SL Perrin, JM AF Van Cleave, Jeanne Gortmaker, Steven L. Perrin, James M. TI Chronic Health Conditions and Obesity Among Children and Youth Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Van Cleave, Jeanne; Perrin, James M.] MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA USA. [Gortmaker, Steven L.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. RP Van Cleave, J (reprint author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA USA. NR 4 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 19 PY 2010 VL 303 IS 19 BP 1915 EP 1916 DI 10.1001/jama.2010.586 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 597NJ UT WOS:000277764500012 ER PT J AU Piacentini, J Woods, DW Scahill, L Wilhelm, S Peterson, AL Chang, S Ginsburg, GS Deckersbach, T Dziura, J Levi-Pearl, S Walkup, JT AF Piacentini, John Woods, Douglas W. Scahill, Lawrence Wilhelm, Sabine Peterson, Alan L. Chang, Susanna Ginsburg, Golda S. Deckersbach, Thilo Dziura, James Levi-Pearl, Sue Walkup, John T. TI Behavior Therapy for Children With Tourette Disorder A Randomized Controlled Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID TIC DISORDERS; HABIT REVERSAL; RISPERIDONE; SEVERITY; ADOLESCENTS; PREVALENCE; REDUCTION; PIMOZIDE; MODEL; SCALE AB Context Tourette disorder is a chronic and typically impairing childhood-onset neurologic condition. Antipsychotic medications, the first-line treatments for moderate to severe tics, are often associated with adverse effects. Behavioral interventions, although promising, have not been evaluated in large-scale controlled trials. Objective To determine the efficacy of a comprehensive behavioral intervention for reducing tic severity in children and adolescents. Design, Setting, and Participants Randomized, observer-blind, controlled trial of 126 children recruited from December 2004 through May 2007 and aged 9 through 17 years, with impairing Tourette or chronic tic disorder as a primary diagnosis, randomly assigned to 8 sessions during 10 weeks of behavior therapy (n=61) or a control treatment consisting of supportive therapy and education (n=65). Responders received 3 monthly booster treatment sessions and were reassessed at 3 and 6 months following treatment. Intervention Comprehensive behavioral intervention. Main Outcome Measures Yale Global Tic Severity Scale (range 0-50, score >15 indicating clinically significant tics) and Clinical Global Impressions-Improvement Scale (range 1 [very much improved] to 8 [very much worse]). Results Behavioral intervention led to a significantly greater decrease on the Yale Global Tic Severity Scale (24.7 [95% confidence interval {CI}, 23.1-26.3] to 17.1 [95% CI, 15.1-19.1]) from baseline to end point compared with the control treatment (24.6 [95% CI, 23.2-26.0] to 21.1 [95% CI, 19.2-23.0]) (P<.001; difference between groups, 4.1; 95% CI, 2.0-6.2) (effect size=0.68). Significantly more children receiving behavioral intervention compared with those in the control group were rated as being very much improved or much improved on the Clinical Global Impressions-Improvement scale (52.5% vs 18.5%, respectively; P<.001; number needed to treat=3). Attrition was low (12/126, or 9.5%); tic worsening was reported by 4% of children (5/126). Treatment gains were durable, with 87% of available responders to behavior therapy exhibiting continued benefit 6 months following treatment. Conclusion A comprehensive behavioral intervention, compared with supportive therapy and education, resulted in greater improvement in symptom severity among children with Tourette and chronic tic disorder. C1 [Piacentini, John] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Woods, Douglas W.] Univ Wisconsin, Milwaukee, WI 53201 USA. [Scahill, Lawrence; Dziura, James] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA. [Wilhelm, Sabine; Deckersbach, Thilo] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ginsburg, Golda S.; Walkup, John T.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Levi-Pearl, Sue] Tourette Syndrome Assoc, Bayside, NY USA. RP Piacentini, J (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,Room 68-251, Los Angeles, CA 90024 USA. EM jpiacentini@mednet.ucla.edu RI Piacentini, John/C-4645-2011; OI Scahill, Lawrence/0000-0001-5073-1707 FU NIMH; Seaside Therapeutics; Shire Pharmaceuticals; National Institutes of Health (NIH); Janssen; Forest Research Institute; Shire Development Inc; Medtronic; Cyberonics; Northstar; Eli Lilly; JAZZ Pharmaceuticals; CMP Media; Medical Education Reviews; McMahon Group; DiMedix; Tourette Syndrome Association; National Institute of Mental Health [R01MH070802]; National Center for Research Resources, NIH [UL1 RR024139] FX Drs Piacentini, Woods, Scahill, Wilhelm, Peterson, Chang, Ginsburg, Deckersbach, and Walkup report receiving royalties from Oxford University Press for treatment manuals on tic disorders. Drs Piacentini, Woods, Scahill, Wilhelm, Peterson, Chang, and Walkup report receiving honoraria for CME presentations from the Tourette Syndrome Association. Drs Piacentini, Woods, and Walkup receive royalties from Guilford Press for a book on Tourette disorder. Dr Piacentini reports receiving royalties from Oxford University Press for treatment manuals on child obsessive-compulsive disorder and APA Books for other books on child mental health, speaking honoraria from Janssen-Cilag, and support in the form of free medication and matching placebo from Pfizer for clinical trials funded by NIMH. Dr Woods reports receiving book royalties from New Harbinger and Springer Publications. Dr Scahill reports receiving royalties from Oxford University Press for a textbook on pediatric psychopharmacology; serving as a consultant for Janssen Pharmaceuticals, Bristol-Myers Squibb, Neuropharm, Supernus, and Shire Pharmaceuticals; receiving research support from Seaside Therapeutics and Shire Pharmaceuticals; and receiving support in the form of free medication and matching placebo from Janssen Pharmaceuticals and Shire Pharmaceuticals for clinical trials funded by NIMH. Dr Wilhelm reports receiving support in the form of free medication and matching placebo from Forest Laboratories for clinical trials funded by the National Institutes of Health (NIH) and receiving book royalties from Guilford Publications, New Harbinger Publications, and Oxford University Press and speaking honoraria from PRIMEDIA Healthcare, a publicly traded company working as a logistics collaborator for the MGH Psychiatry Academy (the education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education grants from pharmaceutical companies cosupporting the overall program, along with participant tuition). Dr Deckersbach reports receiving consulting fees from the Constella Group for serving as a reviewer for the Congressionally Directed Medical Research Program. He also reports receiving honoraria, consulting fees, and/or royalties from Medacorp, MGH Psychiatry Academy, BrainCells Inc, Systems Research and Applications Corp, Boston University, the Catalan Agency for Health Technology Assessment and Research, and National Association of Social Workers-Massachusetts. He reports participating in research funded by Janssen, Forest Research Institute, Shire Development Inc, Medtronic, Cyberonics, and Northstar. Dr Walkup reports receiving consulting fees from Eli Lilly and JAZZ Pharmaceuticals and lecture fees from CMP Media, Medical Education Reviews, McMahon Group, DiMedix, and the Tourette Syndrome Association. He reports receiving free drug and matching placebo from Pfizer and Lilly and free drugs from Abbott for NIMH-funded clinical trials. He reports receiving fees for consultation with defense counsel and submission of written reports in litigation involving GlaxoSmithKline. No other disclosures relevant to this article were reported.; Funding/Support: This work was supported by grant R01MH070802 from the National Institute of Mental Health to Dr Piacentini, with subcontracts to Drs Woods, Scahill, Wilhelm, Peterson, and Walkup. Drs Scahill and Dziura receive support from the Yale University Clinical and Translational Sciences Award grant UL1 RR024139 from the National Center for Research Resources, NIH. NR 49 TC 192 Z9 195 U1 8 U2 31 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 19 PY 2010 VL 303 IS 19 BP 1929 EP 1937 DI 10.1001/jama.2010.607 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 597NJ UT WOS:000277764500019 PM 20483969 ER PT J AU Al-Swailem, AM Shehata, MM Abu-Duhier, FM Al-Yamani, EJ Al-Busadah, KA Al-Arawi, MS Al-Khider, AY Al-Muhaimeed, AN Al-Qahtani, FH Manee, MM Al-Shomrani, BM Al-Qhtani, SM Al-Harthi, AS Akdemir, KC Inan, MS Otu, HH AF Al-Swailem, Abdulaziz M. Shehata, Maher M. Abu-Duhier, Faisel M. Al-Yamani, Essam J. Al-Busadah, Khalid A. Al-Arawi, Mohammed S. Al-Khider, Ali Y. Al-Muhaimeed, Abdullah N. Al-Qahtani, Fahad H. Manee, Manee M. Al-Shomrani, Badr M. Al-Qhtani, Saad M. Al-Harthi, Amer S. Akdemir, Kadir C. Inan, Mehmet S. Otu, Hasan H. TI Sequencing, Analysis, and Annotation of Expressed Sequence Tags for Camelus dromedarius SO PLOS ONE LA English DT Article ID IMMUNOGLOBULIN HEAVY-CHAIN; FATTY-ACID COMPOSITION; CONSTANT-REGION GENES; ALPHA-GENES; STRESS; ORGANIZATION; P27(KIP1); ALIGNMENT; GLUCOSE; BLOOD AB Despite its economical, cultural, and biological importance, there has not been a large scale sequencing project to date for Camelus dromedarius. With the goal of sequencing complete DNA of the organism, we first established and sequenced camel EST libraries, generating 70,272 reads. Following trimming, chimera check, repeat masking, cluster and assembly, we obtained 23,602 putative gene sequences, out of which over 4,500 potentially novel or fast evolving gene sequences do not carry any homology to other available genomes. Functional annotation of sequences with similarities in nucleotide and protein databases has been obtained using Gene Ontology classification. Comparison to available full length cDNA sequences and Open Reading Frame (ORF) analysis of camel sequences that exhibit homology to known genes show more than 80% of the contigs with an ORF>300 bp and similar to 40% hits extending to the start codons of full length cDNAs suggesting successful characterization of camel genes. Similarity analyses are done separately for different organisms including human, mouse, bovine, and rat. Accompanying web portal, CAGBASE (http://camel.kacst.edu.sa/), hosts a relational database containing annotated EST sequences and analysis tools with possibility to add sequences from public domain. We anticipate our results to provide a home base for genomic studies of camel and other comparative studies enabling a starting point for whole genome sequencing of the organism. C1 [Al-Swailem, Abdulaziz M.; Shehata, Maher M.; Abu-Duhier, Faisel M.; Al-Yamani, Essam J.; Al-Arawi, Mohammed S.; Al-Khider, Ali Y.; Al-Muhaimeed, Abdullah N.; Al-Qahtani, Fahad H.; Manee, Manee M.; Al-Shomrani, Badr M.; Al-Qhtani, Saad M.; Al-Harthi, Amer S.; Inan, Mehmet S.; Otu, Hasan H.] King Abdulaziz City Sci & Technol, Biotechnol Res Ctr, Nat Resources & Environm Res Inst, Riyadh, Saudi Arabia. [Al-Busadah, Khalid A.] King Faisal Univ, Fac Vet Med & Anim Resources, Al Hasa, Saudi Arabia. [Akdemir, Kadir C.; Otu, Hasan H.] Harvard Univ, Sch Med, Dept Med, BIDMC Genom Ctr, Boston, MA USA. RP Al-Swailem, AM (reprint author), King Abdulaziz City Sci & Technol, Biotechnol Res Ctr, Nat Resources & Environm Res Inst, Riyadh, Saudi Arabia. EM hotu@bidmc.harvard.edu FU King Abdulaziz City for Science and Technology (KACST); Natural Resources and Environment Research Institute (NRERI), Riyadh, Saudi Arabia; Dubai-Harvard Foundation for Medical Research FX This project was supported by a grant from King Abdulaziz City for Science and Technology (KACST), Natural Resources and Environment Research Institute (NRERI), Riyadh, Saudi Arabia (http://www.kacst.edu.sa). HHO is partially supported by Dubai-Harvard Foundation for Medical Research (http://www.dhfmr.hms.harvard.edu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 14 Z9 14 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 19 PY 2010 VL 5 IS 5 AR e10720 DI 10.1371/journal.pone.0010720 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 598NT UT WOS:000277845400022 PM 20502665 ER PT J AU Sykiotis, GP Pitteloud, N Seminara, SB Kaiser, UB Crowley, WF AF Sykiotis, Gerasimos P. Pitteloud, Nelly Seminara, Stephanie B. Kaiser, Ursula B. Crowley, William F., Jr. TI Deciphering Genetic Disease in the Genomic Era: The Model of GnRH Deficiency SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Review ID IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; GONADOTROPIN-RELEASING-HORMONE; ADRENAL HYPOPLASIA CONGENITA; KALLMANN-SYNDROME; OLFACTORY-BULB; CANDIDATE GENE; MUTATIONS; RECEPTOR; DIAGNOSIS; OBESITY AB Isolated gonadotropin-releasing hormone (GnRH) deficiency is a treatable albeit rare form of reproductive failure that has revealed physiological mechanisms controlling human reproduction, but despite substantial progress in discovering pathogenic single-gene defects, most of the genetic basis of GnRH deficiency remains uncharted. Although unbiased genetic investigations of affected families have identified mutations in previously unsuspected genes as causes of this disease in some cases, their application has been severely limited because of the negative effect of GnRH deficiency on fertility; moreover, relatively few of the many candidate genes nominated because of biological plausibility from in vitro or animal model experiments were subsequently validated in patients. With the advent of exciting technological platforms for sequencing, homozygosity mapping, and detection of structural variation at the whole-genome level, human investigations are again assuming the leading role for gene discovery. Using human GnRH deficiency as a paradigm and presenting original data from the screening of numerous candidate genes, we discuss the emerging model of patient-focused clinical genetic research and its complementarities with basic approaches in the near future. C1 [Sykiotis, Gerasimos P.; Pitteloud, Nelly; Seminara, Stephanie B.; Kaiser, Ursula B.; Crowley, William F., Jr.] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA. [Sykiotis, Gerasimos P.; Pitteloud, Nelly; Seminara, Stephanie B.; Crowley, William F., Jr.] Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA. [Kaiser, Ursula B.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. RP Crowley, WF (reprint author), Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA. EM crowley.william@mgh.harvard.edu RI PITTELOUD, Nelly/K-2709-2014; OI Sykiotis, Gerasimos/0000-0002-9565-4941 FU NICHD NIH HHS [U54 HD028138-19S1, HD056264-02S1, R01 HD015788, R01 HD015788-23, R01 HD043341, R01 HD056264, U54 HD028138] NR 58 TC 13 Z9 13 U1 0 U2 2 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD MAY 19 PY 2010 VL 2 IS 32 AR 32rv2 DI 10.1126/scitranslmed.3000288 PG 10 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 598KK UT WOS:000277835400005 PM 20484732 ER PT J AU Parker, BD Schurgers, LJ Brandenburg, VM Christenson, RH Vermeer, C Ketteler, M Shlipak, MG Whooley, MA Ix, JH AF Parker, Benjamin D. Schurgers, Leon J. Brandenburg, Vincent M. Christenson, Robert H. Vermeer, Cees Ketteler, Markus Shlipak, Michael G. Whooley, Mary A. Ix, Joachim H. TI The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CHRONIC KIDNEY-DISEASE; FETUIN-A LEVELS; CARDIOVASCULAR MORTALITY; SERUM PHOSPHORUS; MYOCARDIAL-INFARCTION; DIALYSIS PATIENTS; VASCULAR CALCIFICATION; GLYCOPROTEIN/FETUIN-A; PHOSPHATE LEVELS; RISK AB Background: Fibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. Whether circulating levels of each are associated with cardiovascular disease (CVD) events or mortality in populations without end-stage renal disease is unknown. Objective: To evaluate the associations of FGF23, ucMGP, and fetuin-A with mortality and CVD events. Design: Observational study. Setting: 12 outpatient clinics in the San Francisco Bay area. Patients: 833 outpatients with stable coronary artery disease (CAD), recruited from 11 September 2000 to 20 December 2002. Measurements: Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline. Participants were followed until 1 December 2008 for mortality and CVD events. Results: During a median follow-up of 6.0 years, 220 participants died and 182 had CVD events. Compared with participants with FGF-23 levels in the lowest tertile, those in the highest tertile had 2-fold greater risk for mortality (hazard ratio [HR], 2.15 [95% CI, 1.43 to 3.24]) and CVD events (HR, 1.83 [CI, 1.15 to 2.91]) after adjustment for traditional CVD risk factors, C-reactive protein levels, and kidney function. The highest ucMGP tertile was associated with lower mortality risk (HR, 0.48 [CI, 0.31 to 0.75]) and showed a nonsignificant trend toward lower CVD event risk by tertile analysis (HR, 0.65 [CI, 0.40 to 1.05])-an association that was significant when modeled continuously (P = 0.029). No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or CVD events (HR, 0.99 [CI, 0.64 to 1.55]) was observed. Limitation: Participants had prevalent CAD. Conclusion: In outpatients with stable CAD, higher FGF23 and lower ucMGP levels are independently associated with mortality and CVD events. C1 [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA. Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Maastricht Univ, Cardiovasc Res Inst, Maastricht, Netherlands. VitaK, Maastricht, Netherlands. Rhein Westfal TH Aachen, Univ Hosp, Aachen, Germany. Klinikum Coburg, Coburg, Germany. Univ Maryland, Baltimore, MD 21201 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu OI Vermeer, Cees/0000-0002-2300-8561 FU National Heart, Lung, and Blood Institute (NHLBI) [T32 HL007261, R01HL096851, R01 HL079235]; American Heart Association; Department of Veterans Epidemiology Merit Review Program; Department of Veterans Affairs Health Services Research and Development service; American Federation for Aging Research; Robert Wood Johnson Foundation; Ischemia Research and Education Foundation FX Grant Support: By a Hypertension Training Grant (T32 HL007261) through the National Heart, Lung, and Blood Institute (NHLBI) (Dr. Parker), an American Heart Association Fellow-to-Faculty transition grant, and the NHLBI (grant R01HL096851, Dr. Ix). The Heart and Soul Study was supported by the Department of Veterans Epidemiology Merit Review Program; the Department of Veterans Affairs Health Services Research and Development service; the NHLBI (grant R01 HL079235); the American Federation for Aging Research (Paul Beeson Scholars Program); the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); and the Ischemia Research and Education Foundation. Dr. Ix had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 56 TC 234 Z9 242 U1 0 U2 14 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 18 PY 2010 VL 152 IS 10 BP 640 EP + DI 10.1059/0003-4819-152-10-201005180-00004 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 598RJ UT WOS:000277855500003 PM 20479029 ER PT J AU Drews, RE Shulman, LN AF Drews, Reed E. Shulman, Lawrence N. TI Update in Hematology and Oncology SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID CHRONIC KIDNEY-DISEASE; ANEMIA; CANCER C1 [Drews, Reed E.] Harvard Univ, Div Hematol Oncol, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. RP Drews, RE (reprint author), Harvard Univ, Div Hematol Oncol, Beth Israel Deaconess Med Ctr, Sch Med, E-RA-430,330 Brookline Ave, Boston, MA 02215 USA. EM rdrews@bidmc.harvard.edu NR 5 TC 4 Z9 4 U1 1 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 18 PY 2010 VL 152 IS 10 BP 655 EP W229 DI 10.1059/0003-4819-152-10-201005180-00244 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 598RJ UT WOS:000277855500005 PM 20410447 ER PT J AU Zhang, B Strauss, AC Chu, S Li, M Ho, YW Shiang, KD Snyder, DS Huettner, CS Shultz, L Holyoake, T Bhatia, R AF Zhang, Bin Strauss, Adam C. Chu, Su Li, Min Ho, Yinwei Shiang, Keh-Dong Snyder, David S. Huettner, Claudia S. Shultz, Leonard Holyoake, Tessa Bhatia, Ravi TI Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate SO CANCER CELL LA English DT Article ID CHRONIC MYELOID-LEUKEMIA; COMPLETE CYTOGENETIC REMISSION; BCR-ABL; TYROSINE KINASE; CD34(+) CELLS; BLAST-CRISIS; HEMATOPOIETIC PROGENITORS; DASATINIB BMS-354825; CHRONIC-PHASE; PRIMARY CML AB Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients but does not eliminate leukemia stem cells (LSCs), which remain a potential source of relapse. Here we investigated the ability of HDAC inhibitors (HDACis) to target CML stem cells. Treatment with HDACis combined with IM effectively induced apoptosis in quiescent CML progenitors resistant to elimination by IM alone, and eliminated CML stem cells capable of engrafting immunodeficient mice. In vivo administration of HDACis with IM markedly diminished LSCs in a transgenic mouse model of CML. The interaction of IM and HDACis inhibited genes regulating hematopoietic stem cell maintenance and survival. HDACi treatment represents an effective strategy to target LSCs in CML patients receiving tyrosine kinase inhibitors. C1 [Zhang, Bin; Strauss, Adam C.; Chu, Su; Ho, Yinwei; Shiang, Keh-Dong; Bhatia, Ravi] City Hope Natl Med Ctr, Div Hematopoiet Stem Cell & Leukemia Res, Duarte, CA 91010 USA. [Li, Min; Shiang, Keh-Dong] City Hope Natl Med Ctr, Dept Informat Sci, Duarte, CA 91010 USA. [Snyder, David S.] City Hope Natl Med Ctr, Dept Hematol & HCT, Duarte, CA 91010 USA. [Huettner, Claudia S.] Dana Farber Canc Inst, Beffer Inst Appl Canc Sci, Boston, MA 02445 USA. [Shultz, Leonard] Jackson Lab, Bar Harbor, ME 04609 USA. [Holyoake, Tessa] Univ Glasgow, Canc Div, Sect Expt Haematol, Glasgow G12 OYN, Lanark, Scotland. RP Bhatia, R (reprint author), City Hope Natl Med Ctr, Div Hematopoiet Stem Cell & Leukemia Res, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM rbhatia@coh.org OI holyoake, tessa/0000-0002-0608-6066 FU National Institutes of Health [R01 CA95684, R01 HL77847, CA34196]; Leukemia and Lymphoma Society; General clinical Research Center [5M01 RR00043]; Novartis FX This work was supported by the National Institutes of Health (grants R01 CA95684 and R01 HL77847, and grant CA34196 to the Jackson Laboratory), the Leukemia and Lymphoma Society (Translational research Grant to R.B.), and the General clinical Research Center (grant #5M01 RR00043). We acknoweldge the excellent technical support of the COHNMC Analytical Cytometry, Functional Genomics and Bioinformatics cores, and the Animal Resources Center. We thank Allen Lin and UK Hematologies for assistance with obtaining samples, StemCyte for their generous gift of CB samples, Elisabeth Buchdunger and Peter Atadja from Novartis Pharmaceuticals for supplying IM, LAQ, and Jeff Taur for assistance with NSG mouse studies. R.B. is a Novartis advisory board member. T.H. is a Novartis advisory board member and has received research funding form Novartis. NR 44 TC 130 Z9 137 U1 1 U2 11 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD MAY 18 PY 2010 VL 17 IS 5 BP 427 EP 442 DI 10.1016/j.ccr.2010.03.011 PG 16 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 598UC UT WOS:000277863300006 PM 20478526 ER PT J AU Zheng, HW Ying, HQ Wiedemeyer, R Yan, HY Quayle, SN Ivanova, EV Paik, JH Zhang, HL Xiao, YH Perry, SR Hu, J Vinjamoori, A Gan, BY Sahin, E Chheda, MG Brennan, C Wang, YA Hahn, WC Chin, L DePinho, RA AF Zheng, Hongwu Ying, Haoqiang Wiedemeyer, Ruprecht Yan, Haiyan Quayle, Steven N. Ivanova, Elena V. Paik, Ji-Hye Zhang, Hailei Xiao, Yonghong Perry, Samuel R. Hu, Jian Vinjamoori, Anant Gan, Boyi Sahin, Ergun Chheda, Milan G. Brennan, Cameron Wang, Y. Alan Hahn, William C. Chin, Lynda DePinho, Ronald A. TI PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas SO CANCER CELL LA English DT Article ID TUMOR-INITIATING CELLS; BETA-CATENIN; HUMAN GLIOBLASTOMA; SELF-RENEWAL; SPORADIC MEDULLOBLASTOMAS; PATHWAY ACTIVATION; PROGENITOR CELLS; BRAIN-TUMORS; CANCER-CELLS; DISEASE AB A hallmark feature of glioblastoma is its strong self-renewal potential and immature differentiation state, which contributes to its plasticity and therapeutic resistance. Here, integrated genomic and biological analyses identified PLAGL2 as a potent protooncogene targeted for amplification/gain in malignant gliomas. Enhanced PLAGL2 expression strongly suppresses neural stem cell (NSC) and glioma-initiating cell differentiation while promoting their self-renewal capacity upon differentiation induction. Transcriptome analysis revealed that these differentiation-suppressive activities are attributable in part to PLAGL2 modulation of Wnt/beta-catenin signaling. Inhibition of Wnt signaling partially restores PLAGL2-expressing NSC differentiation capacity. The identification of PLAGL2 as a glioma oncogene highlights the importance of a growing class of cancer genes functioning to impart stem cell-like characteristics in malignant cells. C1 [Zheng, Hongwu; Ying, Haoqiang; Wiedemeyer, Ruprecht; Yan, Haiyan; Quayle, Steven N.; Ivanova, Elena V.; Paik, Ji-Hye; Zhang, Hailei; Xiao, Yonghong; Perry, Samuel R.; Hu, Jian; Gan, Boyi; Sahin, Ergun; Wang, Y. Alan; Chin, Lynda; DePinho, Ronald A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. [Zheng, Hongwu; Ying, Haoqiang; Wiedemeyer, Ruprecht; Yan, Haiyan; Quayle, Steven N.; Ivanova, Elena V.; Paik, Ji-Hye; Zhang, Hailei; Xiao, Yonghong; Perry, Samuel R.; Hu, Jian; Vinjamoori, Anant; Gan, Boyi; Sahin, Ergun; Chheda, Milan G.; Wang, Y. Alan; Hahn, William C.; Chin, Lynda; DePinho, Ronald A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Zheng, Hongwu; Ying, Haoqiang; Quayle, Steven N.; Paik, Ji-Hye; Hu, Jian; Gan, Boyi; Sahin, Ergun; Chheda, Milan G.; Hahn, William C.; Chin, Lynda; DePinho, Ronald A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Zheng, Hongwu; Ying, Haoqiang; Quayle, Steven N.; Paik, Ji-Hye; Hu, Jian; Gan, Boyi; Sahin, Ergun; Chin, Lynda; DePinho, Ronald A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Chin, Lynda] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Chheda, Milan G.] Massachusetts Gen Hosp, Dept Neurooncol, Boston, MA 02129 USA. [Chheda, Milan G.; Hahn, William C.; Chin, Lynda] Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA 02142 USA. [Brennan, Cameron] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA. [Brennan, Cameron] Weill Cornell Med Coll, Dept Neurosurg, New York, NY 10065 USA. RP DePinho, RA (reprint author), Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. EM ron_depinho@dfci.harvard.edu OI Zheng, Hongwu/0000-0002-5823-4913; Brennan, Cameron/0000-0003-4064-8891 FU Helen Hay Whitney Foundation; American Brain Tumor Association; Damon Runyon Cancer Research Foundation; Mildred Scheel Fellowship (Deutsche Krebshilfe); Canadian Institutes of Health Research; Goldhirsh Foundation; Multiple Myeloma Research Foundation; National Institutes of Health [RO1CA99041, 5P01CA95616, 1RC2CA148268-01, 1RC2CA148222-01]; Renee E. Belfer Foundation for Innovative Cancer Science; Ben and Catherine Ivy Foundation FX We thank S. Zhou and S. Jiang for excellent mouse husbandry and care. H.Z. was supported by the Helen Hay Whitney Foundation. H.Y. is supported by the American Brain Tumor Association. J.H.P was supported by the Damon Runyon Cancer Research Foundation. R.W. is supported by a Mildred Scheel Fellowship (Deutsche Krebshilfe), and S.N.Q. is supported by a fellowship from the Canadian Institutes of Health Research. Grant support comes from the Goldhirsh Foundation (R.A.D.), the Ben and Catherine Ivy Foundation (W.C.H., L.C., and R.A.D.), the Multiple Myeloma Research Foundation (YAW.), and National Institutes of Health grants RO1CA99041 (L.C.), 5P01CA95616 (W.C.H., L.C., and R.A.D.), 1RC2CA148268-01 (W.C.H., L.C., and R.A.D.), and 1RC2CA148222-01 (BAD.). R.A.D. is an American Cancer Society Research Professor and is supported by the Robert A. and Renee E. Belfer Foundation for Innovative Cancer Science. NR 69 TC 98 Z9 101 U1 0 U2 7 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD MAY 18 PY 2010 VL 17 IS 5 BP 497 EP 509 DI 10.1016/j.ccr.2010.03.020 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 598UC UT WOS:000277863300011 PM 20478531 ER PT J AU Noushmehr, H Weisenberger, DJ Diefes, K Phillips, HS Pujara, K Berman, BP Pan, F Pelloski, CE Sulman, EP Bhat, KP Verhaak, RGW Hoadley, KA Hayes, DN Perou, CM Schmidt, HK Ding, L Wilson, RK Van Den Berg, D Shen, H Bengtsson, H Neuvial, P Cope, LM Buckley, J Herman, JG Baylin, SB Laird, PW Aldape, K AF Noushmehr, Houtan Weisenberger, Daniel J. Diefes, Kristin Phillips, Heidi S. Pujara, Kanan Berman, Benjamin P. Pan, Fei Pelloski, Christopher E. Sulman, Erik P. Bhat, Krishna P. Verhaak, Roel G. W. Hoadley, Katherine A. Hayes, D. Neil Perou, Charles M. Schmidt, Heather K. Ding, Li Wilson, Richard K. Van Den Berg, David Shen, Hui Bengtsson, Henrik Neuvial, Pierre Cope, Leslie M. Buckley, Jonathan Herman, James G. Baylin, Stephen B. Laird, Peter W. Aldape, Kenneth CA Canc Genome Atlas Res Network TI Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma SO CANCER CELL LA English DT Article ID INTEGRATED GENOMIC ANALYSIS; CODON 132 MUTATION; HIGH-GRADE GLIOMA; DNA METHYLATION; GLIOBLASTOMA-MULTIFORME; PROSTATE-CANCER; RETINOIC ACID; COLORECTAL-CANCER; PROMOTER HYPERMETHYLATION; PROFILING REVEALS AB We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples displays concerted hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island methylator phenotype (G-CIMP). We validated G-CIMP in a set of non-TCGA glioblastomas and low-grade gliomas. G-CIMP tumors belong to the proneural subgroup, are more prevalent among lower-grade gliomas, display distinct copy-number alterations, and are tightly associated with IDH1 somatic mutations. Patients with G-CIMP tumors are younger at the time of diagnosis and experience significantly improved outcome. These findings identify G-CIMP as a distinct subset of human gliomas on molecular and clinical grounds. C1 [Noushmehr, Houtan; Weisenberger, Daniel J.; Berman, Benjamin P.; Pan, Fei; Van Den Berg, David; Shen, Hui; Buckley, Jonathan; Laird, Peter W.] Univ So Calif, USC Epigenome Ctr, Los Angeles, CA 90033 USA. [Diefes, Kristin; Bhat, Krishna P.; Aldape, Kenneth] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Phillips, Heidi S.; Pujara, Kanan] Genentech Inc, Dept Tumor Biol & Angiogenesis, San Francisco, CA 94080 USA. [Pelloski, Christopher E.; Sulman, Erik P.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Verhaak, Roel G. W.] MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02142 USA. [Verhaak, Roel G. W.] Harvard Univ, Cambridge, MA 02142 USA. [Verhaak, Roel G. W.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hoadley, Katherine A.; Hayes, D. Neil; Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA. [Hoadley, Katherine A.; Hayes, D. Neil; Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Schmidt, Heather K.; Ding, Li; Wilson, Richard K.] Washington Univ, Sch Med, Genome Ctr, Dept Genet, St Louis, MO 63108 USA. [Bengtsson, Henrik; Neuvial, Pierre] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA. [Cope, Leslie M.; Herman, James G.; Baylin, Stephen B.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21231 USA. [Buckley, Jonathan] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. RP Laird, PW (reprint author), Univ So Calif, USC Epigenome Ctr, Los Angeles, CA 90033 USA. EM plaird@usc.edu RI Noushmehr, Houtan/C-9692-2013; Berman, Benjamin/D-5942-2014; Waha, Andreas/J-2950-2014; Laird, Peter/G-8683-2012; OI Noushmehr, Houtan/0000-0003-4051-8114; Hayes, D. Neil/0000-0001-6203-7771; Perou, Charles/0000-0001-9827-2247 FU NIH/NCI [U24 CA126561, U24 CA143882-01, P50CA127001]; M.D. Anderson Center for Cancer Epigenetics; Brain Tumor Funders' Collaborative; V Foundation; Rose Foundation FX This work was supported by NIH/NCI grants U24 CA126561 and U24 CA143882-01 (P.W.L. and S.B.B.), grants from the M.D. Anderson Center for Cancer Epigenetics, the Brain Tumor Funders' Collaborative, the V Foundation, and the Rose Foundation, and SPORE grant P50CA127001 from NIH/NCI (K.A.). We thank Dennis Maglinte and members of the USC Epigenome Center for helpful discussions, Andreana Rivera for technical assistance, and Marisol Guerrero for editorial assistance. P.W.L. is a shareholder, consultant, and scientific advisory board member of Epigenomics, AG, which has a commercial interest in DNA methylation markers. This work was not supported by Epigenomics, AG. K.A. is a consultant and scientific advisory board member for Castle Biosciences, which has a commercial interest in molecular diagnostics. This work was not supported by Castle Biosciences. NR 64 TC 867 Z9 890 U1 6 U2 71 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD MAY 18 PY 2010 VL 17 IS 5 BP 510 EP 522 DI 10.1016/j.ccr.2010.03.017 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 598UC UT WOS:000277863300012 PM 20399149 ER PT J AU Enhorning, S Wang, TJ Nilsson, PM Almgren, P Hedblad, B Berglund, G Struck, J Morgenthaler, NG Bergmann, A Lindholm, E Groop, L Lyssenko, V Orho-Melander, M Newton-Cheh, C Melander, O AF Enhorning, Sofia Wang, Thomas J. Nilsson, Peter M. Almgren, Peter Hedblad, Bo Berglund, Goran Struck, Joachim Morgenthaler, Nils G. Bergmann, Andreas Lindholm, Eero Groop, Leif Lyssenko, Valeria Orho-Melander, Marju Newton-Cheh, Christopher Melander, Olle TI Plasma Copeptin and the Risk of Diabetes Mellitus SO CIRCULATION LA English DT Article DE arginine vasopressin; copeptin; diabetes mellitus; epidemiology; risk factors ID TERMINAL PROVASOPRESSIN COPEPTIN; ACUTE MYOCARDIAL-INFARCTION; VASOPRESSIN RECEPTOR; ARGININE-VASOPRESSIN; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; HEART-FAILURE; ANTAGONIST; CLONING AB Background-Animal studies suggest that the arginine vasopressin system may play a role in glucose metabolism, but data from humans are limited. Methods and Results-We analyzed plasma copeptin (copeptin), a stable C-terminal fragment of the arginine vasopressin prohormone. Using baseline and longitudinal data from a Swedish population-based sample (n=4742; mean age, 58 years; 60% women) and multivariable logistic regression, we examined the association of increasing quartiles of copeptin (lowest quartile as reference) with prevalent diabetes mellitus at baseline, insulin resistance (top quartile of fasting plasma insulin among nondiabetic subjects), and incident diabetes mellitus on long-term follow-up. New-onset diabetes mellitus was ascertained through 3 national and regional registers. All models were adjusted for clinical and anthropometric risk factors, cystatin C, and C-reactive protein. In cross-sectional analyses, increasing copeptin was associated with prevalent diabetes mellitus (P=0.04) and insulin resistance (P < 0.001). During 12.6 years of follow-up, 174 subjects (4%) developed new-onset diabetes mellitus. The odds of developing diabetes mellitus increased across increasing quartiles of copeptin, even after additional adjustment for baseline fasting glucose and insulin (adjusted odds ratios, 1.0, 1.37, 1.79, and 2.09; P for trend=0.004). The association with incident diabetes mellitus remained significant in analyses restricted to subjects with fasting whole blood glucose < 5.4 mmol/L at baseline (adjusted odds ratios, 1.0, 1.80, 1.92, and 3.48; P=0.001). Conclusions-Elevated copeptin predicts increased risk for diabetes mellitus independently of established clinical risk factors, including fasting glucose and insulin. These findings could have implications for risk assessment, novel antidiabetic treatments, and metabolic side effects from arginine vasopressin system modulation. (Circulation. 2010; 121: 2102-2108.) C1 [Enhorning, Sofia; Nilsson, Peter M.; Almgren, Peter; Hedblad, Bo; Berglund, Goran; Lindholm, Eero; Groop, Leif; Lyssenko, Valeria; Orho-Melander, Marju; Melander, Olle] Lund Univ, Dept Clin Sci, SE-20502 Malmo, Sweden. [Enhorning, Sofia; Nilsson, Peter M.; Melander, Olle] Malmo Univ Hosp, Dept Internal Med, Malmo, Sweden. [Newton-Cheh, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA. [Wang, Thomas J.; Newton-Cheh, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA USA. [Newton-Cheh, Christopher] Harvard & MIT, Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Struck, Joachim; Morgenthaler, Nils G.; Bergmann, Andreas] BRAHMS AG, Res Dept, Hennigsdorf, Germany. [Wang, Thomas J.; Newton-Cheh, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. RP Melander, O (reprint author), Lund Univ, Dept Clin Sci, Clin Res Ctr, Malmo Univ Hosp, Entrance 72,Bldg 91,Floor 12, SE-20502 Malmo, Sweden. EM olle.melander@med.lu.se FU Swedish Medical Research Council; Swedish Heart and Lung Foundation; Medical Faculty of Lund University; Malmo University Hospital; Albert Pahlsson Research Foundation; Crafoord Foundation; Ernhold Lundstroms Research Foundation; Region Skane; Hulda and Conrad Mossfelt Foundation; King Gustaf V and Queen Victoria Foundation; Lennart Hanssons Memorial Fund; Wallenberg Foundation; NIH [K23-HL-080025, R01-HL-086875, R01-HL-083197, R01-DK-081572]; Doris Duke Charitable Foundation; Burroughs Wellcome Fund; American Heart Association FX Drs Enhorning and Melander were supported by grants from the Swedish Medical Research Council, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University, Malmo University Hospital, the Albert Pahlsson Research Foundation, the Crafoord Foundation, the Ernhold Lundstroms Research Foundation, the Region Skane, the Hulda and Conrad Mossfelt Foundation, the King Gustaf V and Queen Victoria Foundation, the Lennart Hanssons Memorial Fund, and the Wallenberg Foundation. Dr Newton-Cheh was supported by NIH K23-HL-080025, a Doris Duke Charitable Foundation Clinical Scientist Development Award, and a Burroughs Wellcome Fund Career Award for Medical Scientists. Dr Wang was supported by NIH grants R01-HL-086875, R01-HL-083197, and R01-DK-081572 and a grant from the American Heart Association. We also thank Brahms and Dade-Behring for their support of assay measurements. NR 37 TC 93 Z9 97 U1 5 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 18 PY 2010 VL 121 IS 19 BP 2102 EP U51 DI 10.1161/CIRCULATIONAHA.109.909663 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 597PF UT WOS:000277769900004 PM 20439785 ER PT J AU Stewart, RA Sanda, T Widlund, HR Zhu, SZ Swanson, KD Hurley, AD Bentires-Alj, M Fisher, DE Kontaridis, MI Look, AT Neel, BG AF Stewart, Rodney A. Sanda, Takaomi Widlund, Hans R. Zhu, Shizhen Swanson, Kenneth D. Hurley, Aeron D. Bentires-Alj, Mohamed Fisher, David E. Kontaridis, Maria I. Look, A. Thomas Neel, Benjamin G. TI Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome Pathogenesis SO DEVELOPMENTAL CELL LA English DT Article ID PROTEIN-TYROSINE-PHOSPHATASE; CAUSE NOONAN-SYNDROME; MUTATIONS CAUSE NOONAN; OF-FUNCTION MUTATIONS; DNA-DAMAGE; STEM-CELLS; ZEBRAFISH; PTPN11; GERMLINE; DIFFERENTIATION AB The tyrosine phosphatase SHP2 (PTPN11) regulates cellular proliferation, survival, migration, and differentiation during development. Germ line mutations in PTPN11 cause Noonan and LEOPARD syndromes, which have overlapping clinical features. Paradoxically, Noonan syndrome mutations increase SHP2 phosphatase activity, while LEOPARD syndrome mutants are catalytically impaired, raising the possibility that SHP2 has phosphatase-independent roles. By comparing shp2-deficient zebrafish embryos with those injected with mRNA encoding LEOPARD syndrome point mutations, we identify a phosphatase- and Erk-dependent role for Shp2 in neural crest specification and migration. We also identify an unexpected phosphatase- and Erk-independent function, mediated through its SH2 domains, which is evolutionarily conserved and prevents p53-mediated apoptosis in the brain and neural crest. Our results indicate that previously enigmatic aspects of LEOPARD syndrome pathogenesis can be explained by the combined effects of loss of Shp2 catalytic function and retention of an SH2 domain-mediated role that is essential for neural crest cell survival. C1 [Stewart, Rodney A.; Sanda, Takaomi; Zhu, Shizhen; Hurley, Aeron D.; Fisher, David E.; Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Stewart, Rodney A.] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA. [Widlund, Hans R.; Hurley, Aeron D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Swanson, Kenneth D.; Bentires-Alj, Mohamed; Kontaridis, Maria I.; Neel, Benjamin G.] Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02115 USA. RP Stewart, RA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM rodney.stewart@hci.utah.edu; thomas_look@dfci.harvard.edu; bneel@uhnres.utoronto.ca RI Mohamed, Bentires-Alj/F-4484-2015; OI Mohamed, Bentires-Alj/0000-0001-6344-1127; Stewart, Rodney/0000-0003-1220-1830 FU NIH/NINDS [R00 NS058608]; Friends for Life, DFCI; Children's Leukemia Research Association research; NIH/NHLBI [R00 HL088514]; [R01 HL083271]; [R37 CA49152]; [R01 CA104605] FX We thank P. Henion, J. Amatruda, R. Halaban, R. George, and C. Levi for reagents; T. Buyal, R. Solovyev and Y. Ahn for technical assistance; K. Kotredes, J. Kanki, and B. Baker for zebrafish maintenance; and C. Jette and members of the Look and Neel labs for helpful discussions. This work was supported by grants R01 HL083271 and R37 CA49152 (B.G.N) and R01 CA104605 (A.T.L.). R.A.S is supported by NIH/NINDS award R00 NS058608. S.Z. is supported by a fellowship from Friends for Life, DFCI. T.S. is supported by Children's Leukemia Research Association research grant. M.K. is supported by NIH/NHLBI grant R00 HL088514. NR 50 TC 50 Z9 50 U1 0 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1534-5807 J9 DEV CELL JI Dev. Cell PD MAY 18 PY 2010 VL 18 IS 5 BP 750 EP 762 DI 10.1016/j.devcel.2010.03.009 PG 13 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 602CI UT WOS:000278115500011 PM 20493809 ER PT J AU Scharf, JM Mathews, CA AF Scharf, Jeremiah M. Mathews, Carol A. TI Copy number variation in Tourette syndrome Another case of neurodevelopmental generalist genes? SO NEUROLOGY LA English DT Editorial Material ID DISEASE C1 [Scharf, Jeremiah M.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Dept Neurol, Boston, MA 02114 USA. [Scharf, Jeremiah M.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Dept Psychiat, Boston, MA 02114 USA. [Scharf, Jeremiah M.] Brigham & Womens Hosp, Div Cognit & Behav Neurol, Dept Neurol, Boston, MA 02115 USA. [Mathews, Carol A.] Univ Calif San Francisco, Langley Porter Psychiat Inst, Dept Psychiat, San Francisco, CA 94143 USA. RP Scharf, JM (reprint author), Massachusetts Gen Hosp, Psychiat Neurodev Genet Unit, Ctr Human Genet Res, 185 Cambridge St,6th Floor, Boston, MA 02114 USA. EM jscharf@partners.org FU NIMH NIH HHS [K23 MH085057, K23 MH085057-02, K23 MH085057-03, R25 MH060482]; NINDS NIH HHS [R01 NS037484, R01 NS048376, U01 NS040024] NR 10 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 18 PY 2010 VL 74 IS 20 BP 1564 EP 1565 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 597OG UT WOS:000277767000002 PM 20427746 ER PT J AU Frohlich, LF Mrakovcic, M Steinborn, R Chung, UI Bastepe, M Juppner, H AF Froehlich, Leopold F. Mrakovcic, Maria Steinborn, Ralf Chung, Ung-Il Bastepe, Murat Jueppner, Harald TI Targeted deletion of the Nesp55 DMR defines another Gnas imprinting control region and provides a mouse model of autosomal dominant PHP-Ib SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE genomic imprinting; Gsa; pseudohypoparathyroidism; parathyroid hormone; hormonal resistance ID PSEUDOHYPOPARATHYROIDISM-TYPE-IB; HORMONE RESISTANCE; EPIGENETIC CHANGES; CONTROL ELEMENT; ALPHA-SUBUNIT; G-PROTEINS; LOCUS; METHYLATION; GENE; IDENTIFICATION AB Approximately 100 genes undergo genomic imprinting. Mutations in fewer than 10 imprinted genetic loci, including GNAS, are associated with complex human diseases that differ phenotypically based on the parent transmitting the mutation. Besides the ubiquitously expressed Gsa, which is of broad biological importance, GNAS gives rise to an antisense transcript and to several Gsa variants that are transcribed from the nonmethylated parental allele. We previously identified two almost identical GNAS microdeletions extending from exon NESP55 to antisense (AS) exon 3 (delNESP55/delAS3-4). When inherited maternally, both deletions are associated with erasure of all maternal GNAS methylation imprints and autosomal-dominant pseudohypoparathyroidism type Ib, a disorder characterized by parathyroid hormone-resistant hypocalcemia and hyperphosphatemia. As for other imprinting disorders, the mechanisms resulting in abnormal GNAS methylation are largely unknown, in part because of a paucity of suitable animal models. We now showed in mice that deletion of the region equivalent to delNESP55/delAS3-4 on the paternal allele (Delta Nesp55(p)) leads to healthy animals without Gnas methylation changes. In contrast, mice carrying the deletion on the maternal allele (Delta Nesp55(m)) showed loss of all maternal Gnas methylation imprints, leading in kidney to increased 1A transcription and decreased Gsa mRNA levels, and to associated hypocalcemia, hyperphosphatemia, and secondary hyperparathyroidism. Besides representing a murine autosomal-dominant pseudohypoparathyroidism type Ib model and one of only few animal models for imprinted human disorders, our findings suggest that the Nesp55 differentially methylated region is an additional principal imprinting control region, which directs Gnas methylation and thereby affects expression of all maternal Gnas-derived transcripts. C1 [Froehlich, Leopold F.; Chung, Ung-Il; Bastepe, Murat; Jueppner, Harald] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. [Froehlich, Leopold F.; Chung, Ung-Il; Bastepe, Murat; Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Froehlich, Leopold F.; Mrakovcic, Maria] Univ Vet Med, Inst Pathophysiol, A-1210 Vienna, Austria. [Froehlich, Leopold F.] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria. [Steinborn, Ralf] Univ Vet Med, VetOMICS Ctr, A-1210 Vienna, Austria. [Chung, Ung-Il] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Tokyo 1130033, Japan. [Chung, Ung-Il] Univ Tokyo, Grad Sch Med, Dept Bioengn, Tokyo 1130033, Japan. [Jueppner, Harald] Massachusetts Gen Hosp, Dept Pediat, Pediat Nephrol Unit, Boston, MA 02114 USA. RP Juppner, H (reprint author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. EM jueppner@helix.mgh.harvard.edu FU National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health [R01DK46718, R01DK073911] FX We thank Dr. En Li (Massachusetts General Hospital) for J1 ES cells; G. Bounoutas for help with the electroporation of ES cells; T. Doetschman for the 129Sv library; K.R. Thomas for the pACN vector; M. Stuerzl for the pAL41 plasmid; and I.H. Maxwell for the DT-A cassette. This work was supported by grants from National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health Grants R01DK46718 (to H.J.) and R01DK073911 (to M.B.). NR 34 TC 32 Z9 35 U1 1 U2 5 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 18 PY 2010 VL 107 IS 20 BP 9275 EP 9280 DI 10.1073/pnas.0910224107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 598GH UT WOS:000277822600047 PM 20427744 ER PT J AU Suwanai, H Wilcox, MA Mathis, D Benoist, C AF Suwanai, Hirotsugu Wilcox, Martha Angela Mathis, Diane Benoist, Christophe TI A defective Il15 allele underlies the deficiency in natural killer cell activity in nonobese diabetic mice SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE type 1 diabetes; gene mapping; cytotoxicity; genetic variation ID NOD MICE; IN-VIVO; NK; IL-15; MOUSE; ASSOCIATION; COMPLEX; CLUSTER; BETA AB The nonobese diabetic (NOD) mouse strain has a genetic deficiency in natural killer (NK) cells. This defect underlies this strain's utility in several experimental settings; in particular, it promotes engraftment of human tissue in NOD hosts during the generation of "humanized" mouse models. We have mapped the major NK-cell defect in the NOD vs. C57BL/6 (B6) strain to an inadequately expressed Il15 allele. Treatment of NOD mice with a reagent that specifically enhances interleukin (IL)-15 bioavailability normalized NK-cell numbers and activity in the absence of nonspecific stimulation. These findings raise the possibility of exploiting reagents that impact the IL-15 receptor pathway to facilitate construction of humanized mouse models on non-NOD genetic backgrounds. C1 [Suwanai, Hirotsugu; Wilcox, Martha Angela; Mathis, Diane; Benoist, Christophe] Joslin Diabet Ctr, Sect Immunol & Immunogenet, Boston, MA 02215 USA. [Wilcox, Martha Angela; Mathis, Diane; Benoist, Christophe] Harvard Univ, Dept Pathol, Sch Med, Broad Inst, Boston, MA 02115 USA. [Wilcox, Martha Angela; Mathis, Diane; Benoist, Christophe] Harvard Stem Cell Inst, Boston, MA 02115 USA. RP Benoist, C (reprint author), Joslin Diabet Ctr, Sect Immunol & Immunogenet, Boston, MA 02215 USA. EM cbdm@hms.harvard.edu FU Alexander and Margaret Stewart Trust; National Institutes of Health [R01 DK59658]; American Diabetes Association FX We thank Dr. A. Goldrath for advice on IL-15 complexes, K. Hattori and J. Pagan for assistance with mice, and J. LaVecchio and G. Buruzula for help with flow cytometry. This work was supported by grants from the Alexander and Margaret Stewart Trust and from the National Institutes of Health (R01 DK59658). H.S. was supported by a mentor-based postdoctoral fellowship from the American Diabetes Association. NR 23 TC 15 Z9 16 U1 0 U2 0 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 18 PY 2010 VL 107 IS 20 BP 9305 EP 9310 DI 10.1073/pnas.1004492107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 598GH UT WOS:000277822600052 PM 20439722 ER PT J AU Biller, BMK Colao, A Petersenn, S Bonert, VS Boscaro, M AF Biller, Beverly M. K. Colao, Annamaria Petersenn, Stephan Bonert, Vivien S. Boscaro, Marco TI Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas SO BMC ENDOCRINE DISORDERS LA English DT Review ID ACTING SOMATOSTATIN ANALOG; CARDIAC-VALVE REGURGITATION; GAMMA-KNIFE RADIOSURGERY; VALVULAR HEART-DISEASE; LONG-TERM TREATMENT; HORMONE-RECEPTOR ANTAGONIST; GROWTH-FACTOR-I; OCTREOTIDE-LAR; DOPAMINE AGONISTS; TUMOR SHRINKAGE AB Pituitary adenomas are associated with a variety of clinical manifestations resulting from excessive hormone secretion and tumor mass effects, and require a multidisciplinary management approach. This article discusses the treatment modalities for the management of patients with a prolactinoma, Cushing's disease and acromegaly, and summarizes the options for medical therapy in these patients. First-line treatment of prolactinomas is pharmacotherapy with dopamine agonists; recent reports of cardiac valve abnormalities associated with this class of medication in Parkinson's disease has prompted study in hyperprolactinemic populations. Patients with resistance to dopamine agonists may require other treatment. First-line treatment of Cushing's disease is pituitary surgery by a surgeon with experience in this condition. Current medical options for Cushing's disease block adrenal cortisol production, but do not treat the underlying disease. Pituitary-directed medical therapies are now being explored. In several small studies, the dopamine agonist cabergoline normalized urinary free cortisol in some patients. The multi-receptor targeted somatostatin analogue pasireotide (SOM230) shows promise as a pituitary-directed medical therapy in Cushing's disease; further studies will determine its efficacy and safety. Radiation therapy, with medical adrenal blockade while awaiting the effects of radiation, and bilateral adrenalectomy remain standard treatment options for patients not cured with pituitary surgery. In patients with acromegaly, surgery remains the first-line treatment option when the tumor is likely to be completely resected, or for debulking, especially when the tumor is compressing neurovisual structures. Primary therapy with somatostatin analogues has been used in some patients with large extrasellar tumors not amenable to surgical cure, patients at high surgical risk and patients who decline surgery. Pegvisomant is indicated in patients who have not responded to surgery and other medical therapy, although there are regional differences in when it is prescribed. In conclusion, the treatment of patients with pituitary adenomas requires a multidisciplinary approach. Dopamine agonists are an effective first-line medical therapy in most patients with a prolactinoma, and somatostatin analogues can be used as first-line therapy in selected patients with acromegaly. Current medical therapies for Cushing's disease primarily focus on adrenal blockade of cortisol production, although pasireotide and cabergoline show promise as pituitary-directed medical therapy for Cushing's disease; further long-term evaluation of efficacy and safety is important. C1 [Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Clin Ctr, Boston, MA 02114 USA. [Colao, Annamaria] Univ Naples Federico II, Dipartimento Endocrinol & Oncol Mol & Clin, Naples, Italy. [Petersenn, Stephan] Univ Duisburg Essen, Div Endocrinol, Essen, Germany. [Bonert, Vivien S.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90095 USA. [Boscaro, Marco] Polytech Univ Marche, Inst Internal Med, Div Endocrinol, Ancona, Italy. RP Biller, BMK (reprint author), Massachusetts Gen Hosp, Neuroendocrine Clin Ctr, Boston, MA 02114 USA. EM bbiller@partners.org OI BOSCARO, MARCO/0000-0003-2596-1652 FU Novartis; Ipsen; Italfarmaco; Pfizer; Novartis Pharmaceuticals Corporation FX MB declares no competing interests. VB has research studies ongoing with support from Novartis, and speaker honoraria also from Novartis. BMKB has received research grants and/or consulting honoraria from Ipsen, Novartis and Pfizer. AC has received unrestricted grants by Ipsen, Italfarmaco, Novartis, and Pfizer for research programs in acromegaly, received lectures fees by Ipsen, Italfarmaco, Novartis, and Pfizer and has been a member of the Scientific Boards of Novartis and Ipsen. SP has received consulting fees from Novartis, and lecture honoraria from Novartis and Ipsen.; The authors thank Keri Wellington, PhD, Mudskipper Bioscience, for medical editorial assistance with this manuscript. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. The content of this review was not influenced by the pharmaceutical industry, and represents the content of an independent CME symposium at the 89th Annual Meeting of the Endocrine Society. NR 128 TC 28 Z9 28 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6823 J9 BMC ENDOCR DISORD JI BMC Endocr. Disord. PD MAY 17 PY 2010 VL 10 AR 10 DI 10.1186/1472-6823-10-10 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 851LS UT WOS:000297272300002 PM 20478050 ER PT J AU Rugge, M de Boni, M Pennelli, G de Bona, M Giacomelli, L Fassan, M Basso, D Plebani, M Graham, DY AF Rugge, M. de Boni, M. Pennelli, G. de Bona, M. Giacomelli, L. Fassan, M. Basso, D. Plebani, M. Graham, D. Y. TI Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID HELICOBACTER-PYLORI ERADICATION; RANDOMIZED CONTROLLED-TRIAL; ATROPHIC GASTRITIS; INTESTINAL METAPLASIA; SERUM PEPSINOGEN; CLASSIFICATION; SYSTEM; PATHOGENESIS; METAANALYSIS; POPULATION AB P>Background Intestinal-type gastric cancer (GC) still ranks among the high-incidence, highly lethal malignancies. Atrophic gastritis is the cancerization field in which GC develops. The current histological reporting formats for gastritis do not include any (atrophy-based) ranking of GC risk. Aim To test the gastritis OLGA-staging (Operative Link for Gastritis Assessment) in prognosticating neoplastic progression. Methods Ninety-three Italian patients were followed up for more than 12 years (range: 144-204 months). Clinical examinations, pepsinogen serology, endoscopy and histology (also assessing Helicobacter pylori status) were performed both at enrolment (T1) and at the end of the follow-up (T2). Results All invasive or intra-epithelial gastric neoplasia were consistently associated with high-risk (III/IV) OLGA stages. There was a significant inverse correlation between the mean pepsinogen ratio and the OLGA stage (test for trend; P < 0.001). OLGA-staging at T1 predicted both the OLGA stage (Kaplan-Maier log-rank test, P = 0.001) and the neoplasia at T2 (Kaplan-Maier log-rank test, P = 0.001). Conclusions This long-term follow-up study provides the first evidence that gastritis OLGA-staging conveys relevant information on the clinico-pathological outcome of gastritis and therefore for patient management. According to OLGA-staging and H. pylori-status, gastritis patients could be confidently stratified and managed according to their different cancer risks. C1 [Rugge, M.] Univ Padua, Cattedra Anat Patol, Ist Oncol Veneto IOV IRCCS, I-35121 Padua, Italy. [Rugge, M.; Pennelli, G.; Fassan, M.] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Pathol Unit, I-35121 Padua, Italy. [de Boni, M.; de Bona, M.] Feltre Hosp, Dept Gastroenterol, Feltre, Italy. [Giacomelli, L.] Azienda Osped Padova, Dept Pathol, Padua, Italy. [Basso, D.; Plebani, M.] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Clin Biochem Unit, I-35121 Padua, Italy. [Graham, D. Y.] Baylor Coll Med, Vet Adm Hosp, Div Digest Dis, Houston, TX 77030 USA. RP Rugge, M (reprint author), Univ Padua, Cattedra Anat Patol, Ist Oncol Veneto IOV IRCCS, Via Aristide Gabelli 61, I-35121 Padua, Italy. EM massimo.rugge@unipd.it RI Fassan, Matteo/F-5152-2012; Basso, Daniela/J-7855-2016; Rugge, Massimo/K-7525-2016; OI Fassan, Matteo/0000-0001-6515-5482; Basso, Daniela/0000-0001-8745-6171; PENNELLI, GIANMARIA/0000-0003-0210-165X FU Office of Research and Development Medical Research Service, Department of Veterans Affairs; Public Health Service [DK56338]; Texas Medical Center Digestive Diseases Center [R01 CA116845]; 'Arianna' Association ONLUS (Feltre); AIRC; 'Guido Berlucchi' Foundation; 'Morgagni' Association for Oncological Research (Padova) FX Declaration of personal interests: Guarantor of the article: Dr Rugge had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Specific author contributions: Massimo Rugge - Pathological assessment and clinico-pathological correlations. Michele de Boni - Patient recruitment, clinical examination and endoscopy assessment. Gianmaria Pennelli and Matteo Fassan - Pathological assessment. Manuela de Bona - patient recruitment. Luciano Giacomelli - Biostatistician. Daniela Basso and Mario Plebani - Serology study. David Y Graham - Clinico-pathological correlations. All authors have read and approved the final manuscript draft submitted. The authors would like to thank G. Bonet, MD, general practitioner of the Vanoi valley residents: without his enthusiastic, highly professional and dedicated co-operation, the present study would not have been possible. Special thanks to the Head of the Department of Pathology at Feltre Hospital, Dr. R. Barbazza, who kindly provided the histological material for this study. The authors are indebted to A. Bellumat, MD and F. Valiante, MD (of the Gastroenterology Department at Feltre Hospital), who were involved in the endoscopic procedures, to M. Tollardo, MD, who helped in preliminary data collection, and to Dr. M. Guido, MD, for her critical review of the manuscript. Dr. Graham is supported in part by the Office of Research and Development Medical Research Service, Department of Veterans Affairs, and by a Public Health Service grant (DK56338), which funds the Texas Medical Center Digestive Diseases Center, and R01 CA116845. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the VA or NIH. In the last 2 years, Dr. Graham has received small sums as grants from Meretek and BioHit for investigator-initiated and completely investigator-controlled research. Dr. Graham is also a paid consultant for Otsuka Pharmaceuticals (a manufacturer of the 13C-urea breath test). None of the other authors have any potential conflicts of interest. Declaration of funding interests: This research was supported in part by the 'Arianna' Association ONLUS (Feltre); the AIRC grant Veneto Region, 2009; the 'Guido Berlucchi' Foundation and the 'Morgagni' Association for Oncological Research (Padova). The funding agencies had no role in the design and conduct of the study. NR 37 TC 89 Z9 93 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD MAY 15 PY 2010 VL 31 IS 10 BP 1104 EP 1111 DI 10.1111/j.1365-2036.2010.04277.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 586NL UT WOS:000276917100006 PM 20180784 ER PT J AU Gebregziabher, M Egede, LE Lynch, CP Echols, C Zhao, YM AF Gebregziabher, Mulugeta Egede, Leonard E. Lynch, Cheryl P. Echols, Carrae Zhao, Yumin TI Effect of Trajectories of Glycemic Control on Mortality in Type 2 Diabetes: A Semiparametric Joint Modeling Approach SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE cohort studies; diabetes mellitus; type 2; hemoglobin A; glycosylated; mortality; retrospective studies; veterans ID OF-VETERANS-AFFAIRS; EVENT TIME DATA; CARDIOVASCULAR MORTALITY; MEDICATION ADHERENCE; HEMOGLOBIN A(1C); GLUCOSE CONTROL; ALL-CAUSE; ASSOCIATION; DISEASE; POPULATION AB Data on the effect of trajectories in long-term glycemia and all-cause mortality are lacking. The authors studied the effect of trajectories in long-term glycemic control on all-cause mortality in patients with type 2 diabetes. A cohort of 8,812 veterans with type 2 diabetes was assembled retrospectively using Veterans Affairs registry data. For each veteran in the cohort, a 3-month person-period data set was created from April 1997 to May 2006. The average duration of follow-up was 4.5 years. The overall mortality rate was 15.3%. Using a novel approach for joint modeling of time to death and longitudinal measurements of hemoglobin A1c (HbA1c) level, after adjustment for all significant baseline covariates, baseline HbA1c was found to be significantly associated with mortality (hazard ratio = 2.1, 95% confidence interval: 1.3, 3.6) (i.e., a 1% increase in baseline HbA1c level was associated with an average 2-fold increase in mortality risk). Similarly, the slope of the HbA1c trajectory was marginally significantly associated with mortality (hazard ratio = 7.3, 95% confidence interval: 0.9, 57.1) after adjustment for baseline covariates (i.e., a 1% increase in HbA1c level over 3 months was associated with a 22% increase in mortality risk). The authors conclude that a positive trajectory of long-term hyperglycemia is associated with increased mortality. C1 [Egede, Leonard E.; Lynch, Cheryl P.; Zhao, Yumin] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Egede, Leonard E.; Lynch, Cheryl P.; Echols, Carrae] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Egede, Leonard E.; Lynch, Cheryl P.; Zhao, Yumin] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU Center for Disease Prevention and Health Interventions for Diverse Populations [REA 08-261]; Department of Veterans Affairs Health Services Research and Development Service FX This study was supported by grant REA 08-261 from the Center for Disease Prevention and Health Interventions for Diverse Populations, which is funded by the Department of Veterans Affairs Health Services Research and Development Service (Principal Investigator, Leonard E. Egede). NR 38 TC 8 Z9 8 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAY 15 PY 2010 VL 171 IS 10 BP 1090 EP 1098 DI 10.1093/aje/kwq070 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 597AU UT WOS:000277728400005 PM 20427326 ER PT J AU Spragg, RG Bernard, GR Checkley, W Curtis, JR Gajic, O Guyatt, G Hall, J Israel, E Jain, M Needham, DM Randolph, AG Rubenfeld, GD Schoenfeld, D Thompson, BT Ware, LB Young, D Harabin, AL AF Spragg, Roger G. Bernard, Gordon R. Checkley, William Curtis, J. Randall Gajic, Ognjen Guyatt, Gordon Hall, Jesse Israel, Elliott Jain, Manu Needham, Dale M. Randolph, Adrienne G. Rubenfeld, Gordon D. Schoenfeld, David Thompson, B. Taylor Ware, Lorraine B. Young, Duncan Harabin, Andrea L. TI Beyond Mortality Future Clinical Research in Acute Lung Injury SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE clinical trials; acute respiratory distress syndrome; pulmonary diseases; edema; inflammation ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; PULMONARY-ARTERY; MECHANICAL VENTILATION; OUTCOMES; ARDS; SURVIVORS; RISK; INFLAMMATION AB Mortality in National Heart, Lung and Blood Institute sponsored clinical trials of treatments for acute lung injury (ALI) has decreased dramatically during the past two decades. As a consequence, design of such trials based on a mortality outcome requires ever-increasing numbers of patients. Recognizing that advances in clinical trial design might be applicable to these trials and might allow trials with fewer patients, the National Heart, Lung and Blood Institute convened a workshop of extramural experts from several disciplines. The workshop assessed the current state of clinical research addressing ALI, identified research needs, and recommended: (1) continued performance of trials evaluating treatments of patients with ALI; (2) development of strategies to perform ALI prevention trials; (3) observational studies of patients without ALI undergoing prolonged mechanical ventilation; and (4) development of a standardized format for reporting methods, endpoints, and results of ALI trials. C1 [Harabin, Andrea L.] NHLBI, Div Lung Dis, NIH, Bethesda, MD 20892 USA. [Spragg, Roger G.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Bernard, Gordon R.; Ware, Lorraine B.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Checkley, William; Needham, Dale M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA. [Curtis, J. Randall] Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA. [Gajic, Ognjen] Mayo Clin, Div Pulm & Crit Care, Rochester, MN USA. [Guyatt, Gordon] McMaster Univ, Dept Epidemiol & Biostat, Hamilton, ON, Canada. [Guyatt, Gordon] McMaster Univ, Dept Med, Hamilton, ON, Canada. [Hall, Jesse] Univ Chicago, Med Ctr, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA. [Israel, Elliott] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Jain, Manu] Northwestern Univ, Div Pulm & Crit Care Med, Chicago, IL 60611 USA. [Randolph, Adrienne G.] Childrens Hosp Boston, Boston, MA USA. [Rubenfeld, Gordon D.] Univ Toronto, Dept Med, Toronto, ON, Canada. [Schoenfeld, David] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Young, Duncan] John Radcliffe Hosp, Oxford OX3 9DU, England. RP Harabin, AL (reprint author), NHLBI, Div Lung Dis, NIH, 6701 Rockledge Dr, Bethesda, MD 20892 USA. EM Harabin@nih.gov OI Randolph, Adrienne/0000-0002-3084-3071 FU National Heart, Lung and Blood Institute, National Institutes of Health FX Supported by National Heart, Lung and Blood Institute, National Institutes of Health. NR 53 TC 122 Z9 126 U1 1 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAY 15 PY 2010 VL 181 IS 10 BP 1121 EP 1127 DI 10.1164/rccm.201001-0024WS PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 596ME UT WOS:000277688400016 PM 20224063 ER PT J AU Banerjee, I Maiti, S Parashurama, N Yarmush, M AF Banerjee, Ipsita Maiti, Spandan Parashurama, Natesh Yarmush, Martin TI An integer programming formulation to identify the sparse network architecture governing differentiation of embryonic stem cells SO BIOINFORMATICS LA English DT Article ID TRANSCRIPTIONAL REGULATORY NETWORKS; ENGINEERING GENE NETWORKS; PANCREATIC DEVELOPMENT; EXPRESSION; PERTURBATIONS; SPECIFICATION; NEUROGENIN3; CORTEX AB Motivation: Primary purpose of modeling gene regulatory networks for developmental process is to reveal pathways governing the cellular differentiation to specific phenotypes. Knowledge of differentiation network will enable generation of desired cell fates by careful alteration of the governing network by adequate manipulation of cellular environment. Results: We have developed a novel integer programming-based approach to reconstruct the underlying regulatory architecture of differentiating embryonic stem cells from discrete temporal gene expression data. The network reconstruction problem is formulated using inherent features of biological networks: (i) that of cascade architecture which enables treatment of the entire complex network as a set of interconnected modules and (ii) that of sparsity of interconnection between the transcription factors. The developed framework is applied to the system of embryonic stem cells differentiating towards pancreatic lineage. Experimentally determined expression pro. le dynamics of relevant transcription factors serve as the input to the network identification algorithm. The developed formulation accurately captures many of the known regulatory modes involved in pancreatic differentiation. The predictive capacity of the model is tested by simulating an in silico potential pathway of subsequent differentiation. The predicted pathway is experimentally verified by concurrent differentiation experiments. Experimental results agree well with model predictions, thereby illustrating the predictive accuracy of the proposed algorithm. Contact: ipb1@pitt.edu Supplementary information: Supplementary data are available at Bioinformatics online. C1 [Banerjee, Ipsita; Parashurama, Natesh; Yarmush, Martin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Children,Ctr Engn Med, Boston, MA 02114 USA. [Banerjee, Ipsita] Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA. [Maiti, Spandan] Michigan Technol Univ, Dept Mech Engn Engn Mech, Houghton, MI 49931 USA. RP Banerjee, I (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Children,Ctr Engn Med, 51 Blossom St, Boston, MA 02114 USA. EM ipb1@pitt.edu FU NIH [DP2-116520]; University of Pittsburgh FX This work was partly supported by NIH (DP2-116520) and start-up funds from University of Pittsburgh to IB. NR 31 TC 6 Z9 6 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1367-4803 J9 BIOINFORMATICS JI Bioinformatics PD MAY 15 PY 2010 VL 26 IS 10 BP 1332 EP 1339 DI 10.1093/bioinformatics/btq139 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics GA 593IP UT WOS:000277447500008 PM 20363729 ER PT J AU Wynn, JK Sugar, C Horan, WP Kern, R Green, MF AF Wynn, Jonathan K. Sugar, Catherine Horan, William P. Kern, Robert Green, Michael F. TI Mismatch Negativity, Social Cognition, and Functioning in Schizophrenia Patients SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Functioning; mismatch negativity; schizophrenia; social cognition ID EVENT-RELATED POTENTIALS; NEUROCOGNITIVE DEFICITS; PERCEPTION; REDUCTION; MATRICS; MEMORY; ERP AB Background: Cognition and social cognition have been found to influence functional outcome in schizophrenia patients. However, little is known about the underlying neural substrates that are associated with social cognition or daily functioning. Prior studies found associations between mismatch negativity (MMN), an event-related potential response indexing early auditory processing, and functioning in schizophrenia patients. Methods: In this study, we examined MMN, social cognition (social perception and theory of mind), and four domains of functioning (work, independent living, social networks, and family networks) in 33 schizophrenia patients and 42 demographically comparable healthy control subjects. Results: Schizophrenia patients exhibited reduced MMN activity at frontocentral electrode sites compared with healthy control subjects. Within the schizophrenia sample, greater MMN activity at frontocentral sites correlated with better work and independent living (but not social or family networks) and with better social perception. Conclusions: These results suggest that MMN activity is more closely tied to some outcome domains (work and independent living) than others. Mismatch negativity has been previously shown to be associated with basic cognition and functional outcome in schizophrenia, but these findings are the first, to our knowledge, to show MMN associations with social cognition. These results are consistent with cascade models of information processing in which deficits in early perceptual processing have a downstream impact on higher order social cognition and community functioning. C1 [Wynn, Jonathan K.] Univ Calif Los Angeles, Los Angeles & VA Greater Los Angeles Healthcare S, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Sugar, Catherine] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90073 USA. [Wynn, Jonathan K.; Horan, William P.; Kern, Robert; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. RP Wynn, JK (reprint author), Univ Calif Los Angeles, Los Angeles & VA Greater Los Angeles Healthcare S, Dept Psychiat & Biobehav Sci, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkwynn@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU National Institutes of Mental Health [MH-43292]; Veterans Affairs Career Development Award FX This work was supported by a National Alliance fir Research on Schizophrenia and Depression Young Investigator Award to JKW and Grant MH-43292 from the National Institutes of Mental Health to MFG. JKW was supported by a Veterans Affairs Career Development Award while preparing the manuscript for publication. NR 45 TC 58 Z9 58 U1 2 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 15 PY 2010 VL 67 IS 10 BP 940 EP 947 DI 10.1016/j.biopsych.2009.11.024 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 595RK UT WOS:000277629900007 PM 20074704 ER PT J AU Schonberger, M Leggett, C Kim, SW Hooker, JM AF Schoenberger, Matthias Leggett, Carmine Kim, Sung Won Hooker, Jacob M. TI Synthesis of [C-11]SSR149415 and preliminary imaging studies using positron emission tomography SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Positron emission tomography; Vasopressin; SSR149415; Carbon-11 ID V-1B RECEPTOR ANTAGONIST; STRESS-RELATED DISORDERS; VASOPRESSIN ANTAGONISTS; ANXIOLYTIC-LIKE; V1B RECEPTOR; SSR149415; RODENT; SYSTEM; RAT AB SSR149415 was the first non-peptide vasopressin-(V-1b) receptor antagonist reported. It has been used to probe the role of V-1b receptors in animal models of depression, aggression, and stress-anxiety, and was progressed to clinical trials for the treatment of depression. Due to the interest in V-1b receptors as a therapeutic target and the growing use of SSR149415 in preclinical research, we developed a method to label SSR145419 with carbon-11 and have studied its pharmacokinetics in non-human primates using positron emission tomography. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Schoenberger, Matthias; Kim, Sung Won; Hooker, Jacob M.] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA. [Schoenberger, Matthias] Johannes Gutenberg Univ Mainz, Dept Nucl Chem, D-55128 Mainz, Germany. [Leggett, Carmine] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA. [Hooker, Jacob M.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Hooker, Jacob M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. RP Hooker, JM (reprint author), Brookhaven Natl Lab, Dept Med, Bldg 555, Upton, NY 11973 USA. EM hooker@nmr.mgh.harvard.edu OI Hooker, Jacob/0000-0002-9394-7708 FU Brookhaven National Laboratory with the U. S. Department of Energy [DE-AC02-98CH10886]; Study Foundation of the German People FX This study was supported by Brookhaven National Laboratory under contract DE-AC02-98CH10886 with the U. S. Department of Energy, supported by its Office of Biological and Environmental Research. Funding for M. S. was provided by the Study Foundation of the German People. The authors are grateful to Dr. Michael Schueller for cyclotron operation and the PET radiochemistry, the imaging team at BNL (Youwen Xu, Colleen Shea, Lisa Muench, David Alexoff, Pauline Carter, Payton King, and Don Warner) for carrying out primate imaging experiments, and to Dr. Joanna Fowler for scientific input and guidance. M. S. acknowledges Prof. Dr. Frank Rosch for advice and support during this work. NR 24 TC 14 Z9 14 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD MAY 15 PY 2010 VL 20 IS 10 BP 3103 EP 3106 DI 10.1016/j.bmcl.2010.03.108 PG 4 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA 590RY UT WOS:000277246300018 PM 20400305 ER PT J AU Weingart, SN Toro, J Spencer, J Duncombe, D Gross, A Bartel, S Miransky, J Partridge, A Shulman, LN Connor, M AF Weingart, Saul N. Toro, Julio Spencer, Justin Duncombe, Deborah Gross, Anne Bartel, Sylvia Miransky, Jeremy Partridge, Ann Shulman, Lawrence N. Connor, Maureen TI Medication Errors Involving Oral Chemotherapy SO CANCER LA English DT Article DE oral chemotherapy; incident reports; medication errors; adverse drug events ID ADVERSE DRUG EVENTS; REPORTING SYSTEM; BREAST-CANCER; INPATIENTS; ATTITUDES; CHILDREN; THERAPY; WOMEN; US AB BACKGROUND: Given the expanding use of oral chemotherapies, the authors set out to examine errors in the prescribing, dispensing, administration, and monitoring of these drugs. METHODS: Reports were collected of oral chemotherapy-associated medication errors from a medical literature and Internet search and review of reports to the Medication Errors Reporting Program and MEDMARX The authors solicited incident reports from 14 comprehensive cancer centers, and also collected incident reports, pharmacy interventions, and prompted clinician reports from their own center They classified the type of incident, severity, stage in the medication use process, and type of medication error They examined the yield of the various reporting methods to identify oral chemotherapy-related medication errors RESULTS: The authors identified 99 adverse drug events, 322 near misses, and 87 medical errors with low risk of harm Of the 99 adverse drug events, 20 were serious or life-threatening, 52 were significant, and 25 were minor The most common medication errors involved wrong dose (38 8%), wrong drug (13 6%), wrong number of days supplied (11 0%), and missed dose (10 0%) The majority of errors resulted in a near miss, however, 39 3% of reports involving the wrong number of days supplied resulted in adverse drug events Incidents derived from the literature search and hospital incident reporting system included a larger percentage of adverse drug events (731% and 58 8%, respectively) compared with other sources CONCLUSIONS: Ensuring oral chemotherapy safety requires improvements in the way these drugs are ordered, dispensed, administered, and monitored Cancer 2010;116:2455-64. (C) 2010 American Cancer Society C1 [Weingart, Saul N.; Spencer, Justin; Duncombe, Deborah; Gross, Anne; Bartel, Sylvia; Partridge, Ann; Shulman, Lawrence N.; Connor, Maureen] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA. [Weingart, Saul N.; Partridge, Ann; Shulman, Lawrence N.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Toro, Julio; Gross, Anne] Brigham & Womens Hosp, Dept Nursing, Boston, MA 02115 USA. [Toro, Julio; Gross, Anne] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA. [Miransky, Jeremy] Mem Sloan Kettering Canc Ctr, Dept Qual Assessment, New York, NY 10021 USA. RP Weingart, SN (reprint author), Dana Farber Canc Inst, Ctr Patient Safety, 44 Binney St, Boston, MA 02115 USA. FU US Agency for Healthcare Research and Quality [P20 HS17123-01] FX This study was funded by the US Agency for Healthcare Research and Quality, grant P20 HS17123-01 NR 27 TC 25 Z9 25 U1 0 U2 10 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD MAY 15 PY 2010 VL 116 IS 10 BP 2455 EP 2464 DI 10.1002/cncr.25027 PG 10 WC Oncology SC Oncology GA 588ZC UT WOS:000277112300023 PM 20225328 ER PT J AU Passer, BJ Cheema, T Zhou, BS Wakimoto, H Zaupa, C Razmjoo, M Sarte, J Wu, SL Wu, CL Noah, JW Li, QJ Buolamwini, JK Yen, Y Rabkin, SD Martuza, RL AF Passer, Brent J. Cheema, Tooba Zhou, Bingsen Wakimoto, Hiroaki Zaupa, Cecile Razmjoo, Mani Sarte, Jason Wu, Shulin Wu, Chin-Lee Noah, James W. Li, Qianjun Buolamwini, John K. Yen, Yun Rabkin, Samuel D. Martuza, Robert L. TI Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication SO CANCER RESEARCH LA English DT Article ID RIBONUCLEOTIDE REDUCTASE; MITOMYCIN; VECTORS; GLIOMA; CELLS AB Oncolytic herpes simplex virus-1 (oHSV) vectors selectively replicate in tumor cells, where they kill through oncolysis while sparing normal cells. One of the drawbacks of oHSV vectors is their limited replication and spread to neighboring cancer cells. Here, we report the outcome of a high-throughput chemical library screen to identify small-molecule compounds that augment the replication of oHSV G47 Delta. Of the 2,640-screened bioactives, 6 compounds were identified and subsequently validated for enhanced G47 Delta replication. Two of these compounds, dipyridamole and dilazep, interfered with nucleotide metabolism by potently and directly inhibiting the equilibrative nucleoside transporter-1 (ENT1). Replicative amplification promoted by dipyridamole and dilazep were dependent on HSV mutations in ICP6, the large subunit of ribonucleotide reductase. Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity. Cancer Res; 70(10); 3890-5. (C) 2010 AACR. C1 [Passer, Brent J.] Massachusetts Gen Hosp, Dept Neurosurg, Brain Tumor Res Ctr, Boston, MA 02114 USA. [Wu, Shulin; Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Zhou, Bingsen; Yen, Yun] City Hope Natl Med Ctr, Dept Clin & Mol Pharmacol, Duarte, CA 91010 USA. [Noah, James W.; Li, Qianjun] So Res Inst, Birmingham, AL 35255 USA. [Buolamwini, John K.] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN USA. RP Passer, BJ (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Brain Tumor Res Ctr, Simches Res Bldg,CRPZN 3800,185 Cambridge St, Boston, MA 02114 USA. EM bpasser@partners.org RI rabkin, samuel/C-2443-2012 OI rabkin, samuel/0000-0003-2344-2795 FU [R01 CA10139]; [NS032677]; [R03 MH083258]; [P30 NS045776] FX Grant Support; Grants R01 CA10139 and NS032677 (R. L. Martuza), R03 MH083258 (B.J. Passer), and P30 NS045776 (S. D. Rabkin) for the real-time PCR core. NR 20 TC 17 Z9 18 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2010 VL 70 IS 10 BP 3890 EP 3895 DI 10.1158/0008-5472.CAN-10-0155 PG 6 WC Oncology SC Oncology GA 607GE UT WOS:000278486300006 PM 20424118 ER PT J AU Davies, JK Singh, H Huls, H Yuk, D Lee, DA Kebriaei, P Champlin, RE Nadler, LM Guinan, EC Cooper, LJN AF Davies, Jeff K. Singh, Harjeet Huls, Helen Yuk, Dongin Lee, Dean A. Kebriaei, Partow Champlin, Richard E. Nadler, Lee M. Guinan, Eva C. Cooper, Laurence J. N. TI Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies SO CANCER RESEARCH LA English DT Article ID BONE-MARROW-TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO PERSISTENCE; ADOPTIVE IMMUNOTHERAPY; CYTOMEGALOVIRUS-INFECTION; IMMUNE RECONSTITUTION; ANTITUMOR-ACTIVITY; CENTRAL MEMORY; LYMPHOCYTES; RECEPTOR AB Allogeneic hematopoietic stem-cell transplantation can cure some patients with high-risk B-cell malignancies, but disease relapse following transplantation remains a significant problem. One approach that could be used to augment the donor T-cell-mediated antitumor effect is the infusion of allogeneic donor-derived T cells expressing a chimeric antibody receptor (CAR) specific to the B-cell antigen CD19. However, the use of such cells might result in toxicity in the form of graft-versus-host disease mediated by CD19-specific (CD19-CAR) T cells possessing alloreactive endogenous T-cell receptors. We therefore investigated whether nonalloreactive tumor-specific human T cells could be generated from peripheral blood mononuclear cells of healthy donors by the combination of CD19 redirection via CAR expression and subsequent alloanergization by allostimulation and concomitant blockade of CD28-mediated costimulation. Alloanergization of CD19-CAR T cells resulted in efficient and selective reduction of alloresponses in both CD4(+) and CD8(+) T cells, including allospecific proliferation and cytokine secretion. Importantly, T-cell effector functions including CAR-dependent proliferation and specific target cytolysis and cytokine production were retained after alloanergization. Our data support the application of CD19 redirection and subsequent alloanergization to generate allogeneic donor T cells for clinical use possessing increased antitumor activity but limited capacity to mediate graft-versus-host disease. Immunotherapy with such cells could potentially reduce disease relapse after allogeneic transplantation without increasing toxicity, thereby improving the outcome of patients undergoing allogeneic transplantation for high-risk B-cell malignancies. Cancer Res; 70(10); 3915-24. (C) 2010 AACR. C1 [Cooper, Laurence J. N.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Unit 907, Houston, TX 77030 USA. [Davies, Jeff K.; Yuk, Dongin; Nadler, Lee M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Guinan, Eva C.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Guinan, Eva C.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Lee, Dean A.; Cooper, Laurence J. N.] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA. RP Cooper, LJN (reprint author), Univ Texas MD Anderson Canc Ctr, Div Pediat, Unit 907, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM ljncooper@mdanderson.org OI Lee, Dean/0000-0001-6693-5392 FU DOD [PR064229]; Alex Lemonade Stand Foundation; Alliance for Cancer Gene Therapy; Burroughs Wellcome Fund; Department of Veterans Affairs; Gillson Longenbaugh Foundation; Leukemia and Lymphoma Society; Lymphoma Research Foundation; Miller Foundation; National Foundation for Cancer Research; Pediatric Cancer Research Foundation; National Marrow Donor Program; William Lawrence and Blanche Hughes Foundation; [CA100265]; [CA16672]; [CA124782]; [CA120956]; [CA129390]; [CA116127]; [CA137645] FX Grant Support; PO1 (CA100265), CCSG (CA16672), RO1s (CA124782, CA120956), R21s (CA129390, CA116127, CA137645), DOD (PR064229), Alex Lemonade Stand Foundation, Alliance for Cancer Gene Therapy, Burroughs Wellcome Fund, Department of Veterans Affairs, Gillson Longenbaugh Foundation, Leukemia and Lymphoma Society, Lymphoma Research Foundation, Miller Foundation, National Foundation for Cancer Research, Pediatric Cancer Research Foundation, National Marrow Donor Program, and William Lawrence and Blanche Hughes Foundation. NR 48 TC 24 Z9 26 U1 0 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2010 VL 70 IS 10 BP 3915 EP 3924 DI 10.1158/0008-5472.CAN-09-3845 PG 10 WC Oncology SC Oncology GA 607GE UT WOS:000278486300009 PM 20424114 ER PT J AU Hernandez, L Hsu, SC Davidson, B Birrer, MJ Kohn, EC Annunziata, CM AF Hernandez, Lidia Hsu, Sarah C. Davidson, Ben Birrer, Michael J. Kohn, Elise C. Annunziata, Christina M. TI Activation of NF-KB Signaling by Inhibitor of NF-KB Kinase beta Increases Aggressiveness of Ovarian Cancer SO CANCER RESEARCH LA English DT Article ID KAPPA-B; IKK-BETA; CARCINOMA; GROWTH; MANAGEMENT; ONCOGENE; INVASION; SYSTEM AB The NF-kappa B family of transcription factors has been implicated in the propagation of ovarian cancer, but the significance of constitutive NF-kappa B signaling in ovarian cancer is unknown. We hypothesized that constitutive NF-kappa B signaling defines a subset of ovarian cancer susceptible to therapeutic targeting of this pathway. We investigated the biological relevance of NF-kappa B in ovarian cancer using a small-molecule inhibitor of inhibitor of NF-kappa B kinase beta (IKK beta) and confirmed with RNA interference toward IKK beta. We developed a gene expression signature of IKK beta signaling in ovarian cancer using both pharmacologic and genetic manipulation of IKK beta. The expression of IKK beta protein itself and the nine-gene ovarian cancer-specific IKK beta signature were related to poor outcome in independently collected sets of primary ovarian cancers (P = 0.02). IKK beta signaling in ovarian cancer regulated the transcription of genes involved in a wide range of cellular effects known to increase the aggressive nature of the cells. We functionally validated the effect of IKK beta signaling on proliferation, invasion, and adhesion. Downregulating IKK beta activity, either by a small-molecule kinase inhibitor or by short hairpin RNA depletion of IKK beta, blocked all of these cellular functions, reflecting the negative regulation of the target genes identified. The diversity of functions controlled by IKK beta in ovarian cancer suggests that therapeutic blockade of this pathway could be efficacious if specific IKK beta inhibitor therapy is focused to patients whose tumors express a molecular profile suggestive of dependence on IKK beta activity. Cancer Res; 70(10); 4005-14. (C) 2010 AACR. C1 [Hernandez, Lidia; Hsu, Sarah C.; Kohn, Elise C.; Annunziata, Christina M.] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Davidson, Ben] Univ Oslo, Fac Med, Oslo Univ Hosp, Fac Div,Radiumhosp,Norwegian Radium Hosp,Div Path, Oslo, Norway. [Birrer, Michael J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Annunziata, CM (reprint author), NCI, Med Oncol Branch, Ctr Canc Res, 10 Ctr Dr,Room 12N226, Bethesda, MD 20892 USA. EM annunzic@mail.nih.gov RI Annunziata, Christina/L-3219-2016 OI Annunziata, Christina/0000-0003-2033-6532 FU Center for Cancer Research, NCI; Marsha Rivkin Foundation for Ovarian Cancer Research; Norwegian Cancer Society and Health Region of South-Eastern Norway FX Grant Support; Intramural Program of the Center for Cancer Research, NCI (C. M. Annunziata and E. C. Kohn); Marsha Rivkin Foundation for Ovarian Cancer Research (C. M. Annunziata); and Norwegian Cancer Society and Health Region of South-Eastern Norway (B. Davidson). NR 26 TC 60 Z9 62 U1 2 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2010 VL 70 IS 10 BP 4005 EP 4014 DI 10.1158/0008-5472.CAN-09-3912 PG 10 WC Oncology SC Oncology GA 607GE UT WOS:000278486300018 PM 20424119 ER PT J AU Torres-Arzayus, MI Zhao, J Bronson, R Brown, M AF Torres-Arzayus, Maria I. Zhao, Jin Bronson, Roderick Brown, Myles TI Estrogen-Dependent and Estrogen-Independent Mechanisms Contribute to AIB1-Mediated Tumor Formation SO CANCER RESEARCH LA English DT Article ID MAMMARY-GLAND DEVELOPMENT; RECEPTOR-ALPHA; OVARIECTOMIZED RATS; COACTIVATOR; MICE; AIB1; 17-BETA-ESTRADIOL; AROMATASE; ONCOGENE; IMPLANTS AB We have previously reported the oncogenic properties of the gene amplified in breast cancer 1 (AIB1), a member of the p160 family of hormone receptor coactivators. In a transgenic mouse model, AIB1 overexpression resulted in a high incidence of tumors in various tissues, including mammary gland, uterus, lung, and pituitary. To determine whether the AIB1 oncogenicity in this model depended on its function as an estrogen receptor ( ER) coactivator, we abolished ER signaling through two independent approaches, by performing ovariectomy on AIB1 transgenic (AIB1-tg) mice to prevent gonadal estrogen production and by crossing AIB1-tg mice with ER alpha-null mutant mice. Ovariectomized (ovx) mice, but not AIB1 x ER alpha-/- mice, still developed mammary gland hyperplasia and ductal carcinoma in situ. Both approaches, however, completely prevented the development of invasive mammary tumors, indicating that invasive mammary tumor formation is strictly estrogen dependent. Once developed, AIB1-induced mammary tumors can subsequently lose their dependence on estrogen: Injection of ER alpha(+)tumor cell lines derived from such tumors into ovx or untreated wild-type mice resulted in a similar rate of tumor growth in both groups. Surprisingly, however, ovx mice had an similar to 4-fold higher rate of metastasis formation, suggesting that estrogen provided some protection from metastasis formation. Lastly, our experiments identified oncogenic functions of AIB1 that are independent of its ER coactivation, as both approaches, ovariectomy and ER-/- crosses, still resulted in a high incidence of tumors in the lung and pituitary. We therefore conclude that AIB1 can exert its oncogenicity through tissue-specific estrogen-dependent and estrogen-independent functions. Cancer Res; 70(10); 4102-11. (C) 2010 AACR. C1 [Torres-Arzayus, Maria I.; Zhao, Jin; Brown, Myles] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Dept Med Oncol, Boston, MA 02115 USA. [Bronson, Roderick] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Brown, M (reprint author), Dana Farber Canc Inst, Div Mol & Cellular Oncol, Dept Med Oncol, 44 Binney St,D730, Boston, MA 02115 USA. EM myles_brown@dfci.harvard.edu OI Brown, Myles/0000-0002-8213-1658 FU NIH [P01 CA8011105, P50C89393]; DF/HCC Breast Cancer Spore; National Institute of Mental Health, the National Institute of Allergy and Infectious Diseases, the National Institute of Child Health and Human Development, and the National Institutes of Health Office of the Director [K12 HD051959] FX NIH grants P01 CA8011105 and P50C89393 and the DF/HCC Breast Cancer Spore grant. M.I. Torres-Arzayus received research funding from the Building Interdisciplinary Research in Women's Health (K12 HD051959, supported by the National Institute of Mental Health, the National Institute of Allergy and Infectious Diseases, the National Institute of Child Health and Human Development, and the National Institutes of Health Office of the Director). NR 33 TC 26 Z9 28 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2010 VL 70 IS 10 BP 4102 EP 4111 DI 10.1158/0008-5472.CAN-09-4080 PG 10 WC Oncology SC Oncology GA 607GE UT WOS:000278486300028 PM 20442283 ER PT J AU Mostoslavsky, R Esteller, M Vaquero, A AF Mostoslavsky, Raul Esteller, Manel Vaquero, Alejandro TI At the crossroad of lifespan, calorie restriction, chromatin and disease Meeting on sirtuins SO CELL CYCLE LA English DT Article DE sirtuins; NAD(+) deacetylases; chromatin; metabolism; cancer; aging ID SMALL-MOLECULE INHIBITOR; REMODELING COMPLEX NORC; DNA METHYLTRANSFERASE-1; GENOMIC STABILITY; HUMAN CANCER; HUMAN SIRT1; IN-VIVO; HISTONE; ACETYLATION; RNA AB Longevity, lifespan, cancer, cellular transformation, energy, calorie restriction, diabetes. what can tie together such a diversity of hot topics in biomedical research? Emerging findings suggest that the answer lies in understanding the functions of the recently discovered family of proteins known as Sirtuins. Barcelona hosted the first scientific meeting completely focused on these evolutionary conserved protein deacetylases, bringing together experts in the biochemistry to cellular biology, mice models, drug targeting and pathophysiology of these molecules. Their work, summarized here, establishes the Sirtuins as major players in cellular homeostasis and human diseases that act through a whole range of biochemical substrates and physiological processes. Undoubtedly, this is an increasingly expanding field that it is here to stay and growth. C1 [Mostoslavsky, Raul] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA. [Esteller, Manel] Canc Epigenet Grp, Barcelona, Catalonia, Spain. [Esteller, Manel; Vaquero, Alejandro] ICREA, Barcelona, Catalonia, Spain. [Vaquero, Alejandro] Bellvitge Biomed Res Inst IDIBELL, Chromatin Biol Grp, PEBC, Barcelona, Catalonia, Spain. RP Mostoslavsky, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA. EM rmostoslavsky@mgh.harvard.edu; mes-teller@iconcologia.net; avaquero@idibell.cat RI Vaquero, Alejandro/I-9845-2014; Esteller, Manel/L-5956-2014 OI Vaquero, Alejandro/0000-0002-8735-4156; Esteller, Manel/0000-0003-4490-6093 FU Sidney Kimmel Research Foundation; V Foundation; AFAR; Massachusetts Life Sciences Center; NIH; European Union [HEALTH-F2-2007-200620, LSHG-CT-2006-037415]; Health Department of the Catalan Government (Generalitat); Spanish Ministry of Science and Innovation (MICINN); ICREA; Institut Catala d'Oncologia (ICO); Generalitat de Catalunya; Fundacion Sandra Ibarra; [FIS PI08 1345]; [Consolider MEC09-05] FX We apologize to the colleagues whose work could not be cited in this review due to space limitations. We thank Nabeel Bardeesy for critically reading the manuscript. R. M. work is supported by the Sidney Kimmel Research Foundation, the V Foundation, AFAR, The Massachusetts Life Sciences Center and NIH. M. E. work is supported by the European Union Grants FP7 CANCERDIP (HEALTH-F2-2007-200620) and SMARTER (LSHG-CT-2006-037415), the FIS PI08 1345 and Consolider MEC09-05 Spanish Grants and the Health Department of the Catalan Government (Generalitat). M. E. is an Institucio Catalana de Recerca i Estudis Avancats (ICREA) Research Professor. A. V. work is supported by the Spanish Ministry of Science and Innovation (MICINN), ICREA, the Institut Catala d'Oncologia (ICO), The Generalitat de Catalunya and the Fundacion Sandra Ibarra. NR 38 TC 13 Z9 13 U1 0 U2 2 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD MAY 15 PY 2010 VL 9 IS 10 BP 1907 EP 1912 PG 6 WC Cell Biology SC Cell Biology GA 600VB UT WOS:000278015900017 PM 20458180 ER PT J AU Xu, L Czito, BG Willett, CG AF Xu, Lei Czito, Brian G. Willett, Christopher G. TI Epigenetic Markers in Rectal Cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID DNA METHYLATION; IRRADIATED PATIENTS; RADIOTHERAPY; CARCINOMA AB DNA methylation changes in rectal cancer may serve as a new screening marker and a tool for monitoring recurrence. Importantly, these changes may also function as a predictive marker to allow appropriate exclusion of (neo)adjuvant therapies in patients at low risk for disease recurrence, sparing them from potential treatment-related morbidities. Clin Cancer Res; 16(10); 2699-701. (C) 2010 AACR. C1 [Czito, Brian G.; Willett, Christopher G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA. [Xu, Lei] Massachusetts Gen Hosp, Steele Lab, Boston, MA 02114 USA. RP Willett, CG (reprint author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA. EM christopher.willett@duke.edu NR 12 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2010 VL 16 IS 10 BP 2699 EP 2701 DI 10.1158/1078-0432.CCR-10-0559 PG 3 WC Oncology SC Oncology GA 608PH UT WOS:000278597600001 PM 20460492 ER PT J AU Zhang, WD Choi, J Zeng, WY Rogers, SA Alyea, EP Rheinwald, JG Canning, CM Brusic, V Sasada, T Reinherz, EL Ritz, J Soiffer, RJ Wu, CJ AF Zhang, Wandi Choi, Jaewon Zeng, Wanyong Rogers, Shelby A. Alyea, Edwin P. Rheinwald, James G. Canning, Christine M. Brusic, Vladimir Sasada, Tetsuro Reinherz, Ellis L. Ritz, Jerome Soiffer, Robert J. Wu, Catherine J. TI Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion SO CLINICAL CANCER RESEARCH LA English DT Article ID CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW-TRANSPLANTATION; MULTIPLE-MYELOMA; DENDRITIC CELLS; TUMOR-IMMUNITY; MEMORY; RESPONSES; IMMUNOTHERAPY; PEPTIDE; CANCER AB Purpose: The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized. Experimental Design: We examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI). Results: From this patient, CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403-restricted epitope (HDVDALLW). Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI. However, by 1 month after DLI, CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow. Subsequently, plasma antibody to CML66 developed in association with disease remission. Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor. Conclusions: CD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donor CD8+ T cells, followed by a cascade of antigen-specific immune responses detectable in blood. Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed leukemia antigens that elicit coordinated cellular and humoral immunity. Clin Cancer Res; 16(10); 2729-39. (C) 2010 AACR. C1 [Wu, Catherine J.] Harvard Inst Med, Dana Farber Canc Inst, Cancer Vaccine Ctr, Boston, MA 02115 USA. [Rogers, Shelby A.; Alyea, Edwin P.; Canning, Christine M.; Sasada, Tetsuro; Reinherz, Ellis L.; Ritz, Jerome; Soiffer, Robert J.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Rheinwald, James G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Harvard Skin Dis Res Ctr, Boston, MA USA. [Alyea, Edwin P.; Sasada, Tetsuro; Reinherz, Ellis L.; Ritz, Jerome; Soiffer, Robert J.; Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. RP Wu, CJ (reprint author), Harvard Inst Med, Dana Farber Canc Inst, Cancer Vaccine Ctr, Room 416B,77 Ave Louis Pasteur, Boston, MA 02115 USA. EM cwu@partners.org FU Dana-Farber Cancer Institute Pasquarello Tissue Bank; Dana-Farber Cancer Institute (Boston); NIAMS [P30 AR42689]; Department of Defense [W81XWH-07-1-0080]; NCI [5R21CA115043-2]; Howard Hughes Medical Institute; Damon-Runyon Cancer Research Foundation [CI-38-07] FX We thank the Dana-Farber Cancer Institute Pasquarello Tissue Bank and the clinical transplant teams at Dana-Farber Cancer Institute (Boston) for their generous support; Linyun Chen, Sean McDonough, and Patricia Barron for excellent technical help; and Zach Herbert, Alicja Piechoka-Trocha, and Dr. Christian Brander for invaluable advice and assistance.; J.G. Rheinwald and Cell Culture Core of Harvard Skin Disease Research Center were supported by NIAMS grant P30 AR42689. C.J. Wu was supported by Department of Defense grant W81XWH-07-1-0080, Miles and Eleanor Shore Award, NCI grant 5R21CA115043-2, and Early Career Physician-Scientist Award of the Howard Hughes Medical Institute and is a Damon-Runyon Clinical Investigator supported in part by Damon-Runyon Cancer Research Foundation grant CI-38-07. NR 44 TC 17 Z9 18 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2010 VL 16 IS 10 BP 2729 EP 2739 DI 10.1158/1078-0432.CCR-10-0415 PG 11 WC Oncology SC Oncology GA 608PH UT WOS:000278597600005 PM 20460482 ER PT J AU Chi, RC Rock, MT Neuzil, KM AF Chi, Ru-Chien Rock, Michael T. Neuzil, Kathleen M. TI Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID CELLULAR IMMUNE-RESPONSES; RANDOMIZED CONTROLLED-TRIAL; ANTIBODY-RESPONSES; ELDERLY-PEOPLE; MORTALITY BENEFITS; SEASONAL INFLUENZA; T-CELLS; EFFICACY; IMMUNIZATION; PROTECTION AB Background. Influenza vaccine immunogenicity is suboptimal in older persons. Intradermal (ID) vaccination may be a promising alternative to intramuscular (IM) vaccination. Methods. This randomized trial compared the immunogenicity of 60% dose ID influenza vaccination to standard IM vaccination of full-dose or 60% dose vaccine. Pre- and postvaccination measurements in the hemagglutination inhibition antibody titer were compared. Participants who received reduced-dose vaccine were revaccinated with full-dose IM vaccine. Results. 257 healthy adults aged >= 65 years received 1 of the following trivalent inactivated influenza vaccines: standard-dose (15 mu g each of 3 hemagglutinin vaccine antigens in 0.5 mL) IM injection, reduced-dose (9 mu g, 0.3 mL) IM injection, reduced-dose ( 9 mu g, 0.3 mL) ID injection, or 2 reduced-dose (4.5 mu g, 0.15 mL) ID injections. Respective seroprotection rates were 65.6%, 57.8%, 68.9%, and 67.2% against A/H1N1; 76.6%, 75.0%, 75.4%, and 75.0% against A/H3N2; and 26.6%, 17.2%, 16.4%, and 25.0% against influenza B. Subsequent full-dose IM vaccination of participants randomized to reduced-dose vaccine by either IM or ID routes did not improve seroprotection rates. Local reactions of redness, swelling, and itching were significantly more frequent among recipients of ID injections. Conclusion. Influenza vaccine at 60% dose by either IM or ID route elicited antibody responses generally similar to full-dose IM vaccination among healthy elderly persons (ClinicalTrials. gov identifier: NCT00504231). C1 [Chi, Ru-Chien] Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Neuzil, Kathleen M.] Univ Washington, Dept Global Hlth, Seattle, WA 98108 USA. [Chi, Ru-Chien] Univ Washington, Dept Med, Seattle, WA 98108 USA. [Neuzil, Kathleen M.] PATH, Seattle, WA USA. [Rock, Michael T.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. RP Chi, RC (reprint author), Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-182, Seattle, WA 98108 USA. EM rchi@u.washington.edu FU Research and Development Medical Research Service, Department of Veterans Affairs; World Health Organization; Fondation Merieux entitled "Intradermal Immunization: An Alternative Route for Vaccine Administration" in Annecy, France FX This material is based on work supported by the Research and Development Medical Research Service, Department of Veterans Affairs. The views in this article do not necessarily represent the views of the Department of Veterans Affairs.; Presented in part: a conference sponsored by the World Health Organization and Fondation Merieux entitled "Intradermal Immunization: An Alternative Route for Vaccine Administration" in Annecy, France, 8 April 2008, and 2 American Geriatrics Society annual meetings, 2 May 2008 and 30 April 2009. NR 43 TC 24 Z9 24 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2010 VL 50 IS 10 BP 1331 EP 1338 DI 10.1086/652144 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 584PO UT WOS:000276764900001 PM 20377407 ER PT J AU Bassett, IV Walensky, RP AF Bassett, Ingrid V. Walensky, Rochelle P. TI Integrating HIV Screening into Routine Health Care in Resource-Limited Settings SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID TO-CHILD TRANSMISSION; TESTING OPT-OUT; SOUTH-AFRICA; ANTIRETROVIRAL THERAPY; MISSED OPPORTUNITIES; SEXUAL-BEHAVIOR; DEVELOPING-COUNTRIES; DISCORDANT COUPLES; RANDOMIZED-TRIAL; ANTENATAL CARE AB United Nations is committed to achieving universal access to human immunodeficiency virus (HIV) care, treatment, and prevention. Although the gateway to HIV care and secondary prevention is knowledge of serostatus, use of voluntary counseling and testing in resource-limited settings with the highest burden of HIV infection and AIDS has been limited. On the basis of evidence of increased patient uptake and the opportunity to avoid missed HIV testing opportunities in health care facilities, in 2007, the World Health Organization recommended provider-initiated HIV testing as a standard part of medical care in settings with generalized HIV epidemics. Although provider-initiated testing has shown promise, optimal implementation strategies that ensure broad coverage, while preserving human rights, remain an active area of research. We review the benefits of knowledge of HIV serostatus and evidence from multiple countries surrounding the successes and pitfalls of provider-initiated testing in health care and home-based settings. C1 [Bassett, Ingrid V.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Bassett, Ingrid V.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Walensky, Rochelle P.] Harvard Ctr AIDS Res, Boston, MA USA. RP Bassett, IV (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,9th Fl, Boston, MA 02114 USA. EM ibassett@partners.org OI Walensky, Rochelle P./0000-0002-8795-379X FU National Institute of Allergy and Infectious Disease [K23AI068458]; National Institute of Mental Health [R01 MH073445, R01 MH65869]; Doris Duke Charitable Foundation; Center for Global Health Policy; Infectious Diseases Society of America; HIV Medicine Association, through the Bill & Melinda Gates Foundation FX Financial support. National Institute of Allergy and Infectious Disease (K23AI068458 to I. V. B.), National Institute of Mental Health (R01 MH073445 to R. P. W. and R01 MH65869 to R. P. W.), and the Doris Duke Charitable Foundation, Clinical Scientist Development Award (to R. P. W.).; Supplement sponsorship. This article is part of a supplement entitled "Synergistic Pandemics: Confronting the Global HIV and Tuberculosis Epidemics," which was sponsored by the Center for Global Health Policy, a project of the Infectious Diseases Society of America and the HIV Medicine Association, through a grant from the Bill & Melinda Gates Foundation. NR 81 TC 36 Z9 36 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2010 VL 50 SU 3 BP S77 EP S84 DI 10.1086/651477 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 584PV UT WOS:000276765600003 PM 20397960 ER EF